<SEC-DOCUMENT>0001459839-21-000012.txt : 20210310
<SEC-HEADER>0001459839-21-000012.hdr.sgml : 20210310
<ACCEPTANCE-DATETIME>20210310160326
ACCESSION NUMBER:		0001459839-21-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210310
DATE AS OF CHANGE:		20210310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SI-BONE, Inc.
		CENTRAL INDEX KEY:			0001459839
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262216351
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38701
		FILM NUMBER:		21729668

	BUSINESS ADDRESS:	
		STREET 1:		471 EL CAMINO REAL, SUITE 101
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050
		BUSINESS PHONE:		4082070700

	MAIL ADDRESS:	
		STREET 1:		471 EL CAMINO REAL, SUITE 101
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SI-Bone Inc.
		DATE OF NAME CHANGE:	20090326
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sibn-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:84ec410f-3815-4763-9bc2-b77d68e36727,g:546a3c6e-3b19-4bdc-9aac-42f0e40439c5,d:c5af433463274989b3f39da4377b2b55--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:sibn="http://si-bone.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sibn-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF84LTEtMS0xLTA_d7057714-94ff-4142-88e5-ea0693836023">0001459839</ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF8xMC0xLTEtMS00MzI0_fc0bb83b-86a3-43ff-8178-a6e38f39dd81">2020</ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF8xMS0xLTEtMS00MzI0_dc277d22-f5ec-4be6-b077-157a223f598a">FY</ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF8xMi0xLTEtMS00MzI0_30424d79-d8ba-4d4c-89d0-09ee3ddb628c">false</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzIvZnJhZzowNzJiMmRmNTM3ZjU0ZTkwOGUxMWFmNmY3ZTAzY2I5OS90YWJsZTo3ODJiNzE0YzdhYTE0ZDVhOTNhODQ3ZTg3MTc3ZWQ3NC90YWJsZXJhbmdlOjc4MmI3MTRjN2FhMTRkNWE5M2E4NDdlODcxNzdlZDc0XzItMS0xLTEtMA_ad6ecbc7-6328-44ad-9f87-701728e1dd1e">1</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzIvZnJhZzowNzJiMmRmNTM3ZjU0ZTkwOGUxMWFmNmY3ZTAzY2I5OS90YWJsZTo3ODJiNzE0YzdhYTE0ZDVhOTNhODQ3ZTg3MTc3ZWQ3NC90YWJsZXJhbmdlOjc4MmI3MTRjN2FhMTRkNWE5M2E4NDdlODcxNzdlZDc0XzMtMS0xLTEtMA_e69ac7fe-921b-4695-9c75-f018ca5165e7">1</ix:nonFraction><ix:nonNumeric contextRef="i0e3d05c378a547599cd9b6952a3c1c80_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1ODU_7bd59b98-57a3-4657-978b-3cc5ffa4e420">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i7fcd62c3950d4b03b74e4c0cf4d1a7cb_D20200101-20200430" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1MjI_0f5ed571-a69d-4bc7-b68e-654ed23d7077">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sibn-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i723b611d0707480481c85096cc3174e1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3e43846424574f4d99b00787ea404847_I20210305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic35d9503efb0484a818b49ffdb765d03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66d822de1dc49998b0d0dbd86b96408_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dff6565556f4ea180e9d4dc002bcc73_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b4c997fd0c473da8c08fde9e5c65d4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5589745a4b4e59be2fa5da9fc96faa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida53b01638da4d37aab2d0e74319d0d8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5678948a03bf48b99de61934b25d458e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffbce40da8154d0ebfd353ebc4ecfc66_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04fe10a38bbc4b9b992c2d00521e3926_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985109e7c07a47caa2b5f16db86a7f92_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b107ede87a64e409d8ea0d6c15db765_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic26490e07c24473bb2dfc03fc2377ce8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d1708678a945beac3f5189fa6daf27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic133b244626b43a18e2c5235832641ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a1c74b555a4f0aba5275ea8e0f0cdc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic95beb3614404efb8439b54564decf04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida15542c93ec4747869dcb494008d0f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a37168d69c463082d9d5b20b3a2f88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f72f3efd8214401a36fbcad6478c88c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23626475cd542f79e54023f0ce2273b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2d90a648464b458060488f94c81ad8_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc263e01aa24b63bfcb6b7c3ca255eb_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i181125cf82924e5b9581883ff443cf53_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3655a0a0a14ac1b122bcd81866b549_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingAndSecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5bdb3241a241cab56395a180519bf7_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0448433af0a48b1a3ca65d600cf995e_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70eea66b474641c1ad7620f47edb01b0_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5492ced8113d48a1af6af8e02eeb934e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833840966f0446599fbe1ac28b5fc775_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie94283009e404d94a4b0dc42119c45bd_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondFollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bccb8eb33f2419aa52d19db5810f680_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6592020c6d484bdca8308d69ae2e0cb8_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondFollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic82e690a259f4746a1c2de4c43841af5_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f59add943494c479a4150b168d4d73c_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee17cf0cfb74aaeba258351d3587116_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0e792c3dd245b38bfa934064b7a5f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a304c056a549c6910518b3e4157eef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i682d696ec5a64a2d895607c7e0be6d52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id046e7c696d34711b1333b15ed30b43c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e08d78c5ce4da8999df030e046372b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82073020dafa4bcc906a6b84e0f4ae90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08bbaa69d9864797b540f323ef6f6cbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab58f80617694d75bb76bca801a8396f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392839ad6d6e43ad9f50d6687b0aca2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sibn:segment</xbrli:measure></xbrli:unit><xbrli:context id="if9de17fd42404f5ab8f65ff659295c6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38adcbbef7041a5be7d1fff795cb320_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica653fed6bb2408599a2f19e331e9a09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia745aebd92ac40369a143cd547cfe75a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2561190905814081bc53ffa2be1dab5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18fdea8ce7124059abdb38fb9a56c535_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c018ede41124dcb9546a1dc0d2be832_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3540e490fa3e40728018f6cb6e927d47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25fc95b9ce164bc0840b48602420b3c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd8bd8bffe9546e6a44571d468e8e8a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21a7585b0b64bb1a4690ee991cf5d88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549ddb0f7656451894dc614cf8d2a488_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30be08150494e1ebf7f499accad38f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a5a80e24444a2997770162f3127340_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6781f723ffcc40caaeb825c9755676eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60e4a56a8df4e8692eaec00e452ea3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c39428374148bda44abdf22ebd5a95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c3186e6d7b427ebbbff1f0dbd4c8c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b326db53886469788a4a2d43dfa03b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21dfcac734f47f6957fcca7f72cdc88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29460ed74a94fa4ab322cb274b491e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034bc01ef48b4d4a8bf1bb1de85b0868_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a4613e4687843f8a379ce7c10a467e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d4c9f2c6ba40f3828a4aa2b86a45a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i193aaa31e9c44a1e82bffc909a360749_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i657bb6e3a8a046f28bfa284cf457e36f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ee32c33d8748298bb8a2da1f87d7ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53b1d8bd84944b9a5118a390e4915d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1873024e2f49b98f313c5e06a689bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7740378444747719a5eb6065629a5ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9109fa397bd4ab896aee4f1166409ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c36deb7f9274663a77e895314cda704_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if595c9553f034555b84ce4f3992ef574_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2978c44e2ebc42e5bfd593b3bd9ec954_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i959e6655c905432b8c65682560f0dd19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f5dc8e414e04b1c913f494f9f5332ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie229939d8dc74c648e87a676c60fecd4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if504c2f11d744b658048ae59b90b89ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60aa93fd86be47a69cae67136a4bf322_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae975a338844ef786881ecd9e3b9cd1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5e61b93a3f4b598884410e09cd44de_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3deabe50cd3e469793cfee5e9e7b0957_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64bda2b4edb482eb14a53a12c4bef2d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c484252700460b89333bc846225d68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5113c368e6d84d078690ec4a2dcdac26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf10733689d841b993c15e2c32cb214e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebcd89814b67470fb88261e8811fe67c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7de72341f3240d6bca072b0cf1a49d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4199c211590a43da89a234cf0e6582df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7599f342c11d4e80a1f135e9a39b17ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85cfa5d73e404d39a22111bbd6758462_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77b43286347d44ef87b90ebfe3ab45f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a04be12804c4f369306f503b36bee55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3566041ec40442cda4e388d38876c815_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2410d914e44ed9a27cd8b177231d10_D20190206-20190206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">sibn:LitigationStatutoryDamagesPerViolationOfTCPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f51810588c413195ac60a540302861_D20190206-20190206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">sibn:LitigationTrebleDamagesPerViolationOfTCPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9154de9e205d4bde873fb87f0044bdc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59004ae255bc408fbcc9c0c0bfeb19e6_D20200622-20200622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-22</xbrli:startDate><xbrli:endDate>2020-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ae02ed248d4976a0b8c92bb1c51665_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b018196eca491f8a64402c1d9c1b33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc4cef314e248258972c3adbdc0456e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fc4f2f95ee4c97adad0fe62fb8956b_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icc5dfa6f48e44ef7ad7fdc85379acfe1_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c8f148cb4c45afa01a41eb83479fbc_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtPrepaymentPenaltyPeriodAxis">sibn:PrepaymentPenalty3148MonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f9e992b05a4a77b99d38cb277c0cc2_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtPrepaymentPenaltyPeriodAxis">sibn:PrepaymentPenalty4960MonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3171054c28c94e37a7274d5bfc3fb4de_D20200529-20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">sibn:VariableOptionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a2c5d839d54923994ecdd79255d137_D20200529-20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91447b8f2dee4d7fb7da16614ef2b263_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d91ea98cc44ed2ac071a60da01b6e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd440735cdc43f5a01ccd66c2e7e22a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37605fc017f54b699b34d502dfd83f5d_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia465af5919b8475cb3625c7d3c4c60b9_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efb63d3047f421990b618ba7b240282_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c56822bb4854a00aa2c71b72d285850_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22adc896d58943239a8a55e36b35c2ff_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0893e94d84ab4ef180a7082801b17e87_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0029f543a0b44f28883347fcd2bda900_D20200421-20200421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PayrollProtectionProgramLoanCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-21</xbrli:startDate><xbrli:endDate>2020-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1857c35e4ee46f3a5e3dd78d3069507_D20200429-20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PayrollProtectionProgramLoanCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib50689df2cf5465fbcc3d49d82ce6fe0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb5133b5829435487b6826f9ee05e8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4270a5f8e26b45ef92ae241f823a5c92_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia711fb7cbd244135958a45b84e252b9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7925565e8c4323a6a9a220d817cd1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyTwentySecondTwentyThirteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba592ea26314e52a133b56ede4ac0c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyTwentySecondTwentyThirteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774bf9ebb0d849c383fd489468d870df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d677b2975b845e383359e9465b1c838_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7696c119674041ff8d5a58e5158f8c52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41018904b5854d86b3a31ec29a88bfb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b01ed73e9446848e40e7b7b997079a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6525e11de664dcc8219a14e1805fe4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i139f7071f8c84f08bbe6dceaf889a5c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd0d0bfaa8049db933a2450c31775e0_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb403ea911274bf7b259455db756d709_D20190101-20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2709796b037485da5c45a10ab0c0d2a_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaca040e3897460d8726cb690a290765_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:IncentiveStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ac410f45b545f6a9b196945613148b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:NonqualifiedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3d05c378a547599cd9b6952a3c1c80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3fc6a89c574e28830c17f1f39ec06b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43d91cf37b340449447358d82ccd92a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385b1bffbd6844aa86634798c26f1bcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f6cd8ef95b04649a99031341fddf8ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1227fe8e7ba44a1bde242290ec79931_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3ffdb1efa44a3a807c3bb0733bd89f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d34965263684d8a827e3b511ef07bf7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0283a6f15aee4e39bd5b62b008d5658f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe7e4f5c282479c9dd4b63577d53724_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c1abe777aa459288707c7d8ba52b51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82add15eb7894a888a8e8a9ba05ff086_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fcd62c3950d4b03b74e4c0cf4d1a7cb_D20200101-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2931999815684f1992182b9f6d12780e_D20200501-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="purchase_period"><xbrli:measure>sibn:purchase_period</xbrli:measure></xbrli:unit><xbrli:context id="i7ce9444b0b5849639bc0b7f620058c77_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf669f97771460fb006978ac53fcd89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474b61edbbc14b8d94e1ce0729536585_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i297b39b995a14cdebf1cfa2c3d3fc236_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie584850230f64839b9c46ed2b0b8f3a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cb20fa436042dbb60426290872da75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde4a023409a47be91b9ea5231045908_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i410806cbbdc746209446c410c6341047_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a0c0dce9584a3eb98f59092edd33c5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4055a0636841d992ed275f0ce24c78_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70af4b35e0d415a8450cc48c58a228a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5cfba54d8644e33a6243d800d6a11c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00219ae7e63c44d783f827759951eaaa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ce6cefcf474ade882fc1adc72c8eb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95838768b71a4d678805680c3b4e0eea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sibn:Company401KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3946e536ed904059b0b93a4cf16adf9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sibn:Company401KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ea822832f34b5cae2305c150d8cd7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4b044fdf884181b597402c0cfa5a59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6934a8f368ab4d9494b07c7ddfe7de0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c03f872c9a9488c981785d7b2746aa4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58413a7253e4f4d8190a06a75631d77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:ShareSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b75f3d79804b4face844493077ae7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:ShareSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc544ac398ba485a8fc4c71db95233b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:EmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06ea8c038f64be2b2835e0ef0d248f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:EmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d3b6b03018480f8f30f7f6f385c670_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696aeae988714665861bf927c6df4e88_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia344c14925fb435996aff0ac207bae68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd326d4dba048b1a3b67d4854664c94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd127df2c1c4983bc79d5cb10d32b12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:DevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i193e00bc574d4629ac04368864c1127a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:DevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20be3b85bd54fcd9fcf877450d0dd25_D20200224-20200224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:DevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-24</xbrli:startDate><xbrli:endDate>2020-02-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic5af433463274989b3f39da4377b2b55_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MTIz_d16ec913-1826-493b-afcd-2969cacd0fd3">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark&#160;One)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.560%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6OTE3NmNjNzNkMWQwNGU0NzlkMDFjYjFmOGQ4NGNjNTAvdGFibGVyYW5nZTo5MTc2Y2M3M2QxZDA0ZTQ3OWQwMWNiMWY4ZDg0Y2M1MF8wLTAtMS0xLTQwODc_44eee814-b6ea-478e-9b28-3e39525cc673">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr></table></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal&#160;year ended <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MTQ0_3d97437e-5235-4143-9b4b-788d0f002a1b"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MTQ0_b841ca86-e206-4cbe-9d57-8221ac908439">December 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.560%"><tr><td style="width:1.0%"></td><td style="width:2.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ZWYxMTI0ZjU5ZDNlNDJkMWExN2NjYTZmYzQ0MzdmZWEvdGFibGVyYW5nZTplZjExMjRmNTlkM2U0MmQxYTE3Y2NhNmZjNDQzN2ZlYV8wLTAtMS0xLTQwODk_fa4f7cd2-bfaa-4286-b861-edf197fc1b51">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO</span></div></td></tr></table></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcx_5912fd9f-a04e-43af-9130-af1fc4ca776e">001-38701</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcw_b9a93861-943e-4da4-b5c7-68e32b87504d">SI-BONE,&#160;Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.560%"><tr><td style="width:1.0%"></td><td style="width:50.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6YmE0MTY2YmUyNDNjNDlhYjk5ODgzMzRiOGQxODEyNDcvdGFibGVyYW5nZTpiYTQxNjZiZTI0M2M0OWFiOTk4ODMzNGI4ZDE4MTI0N18wLTAtMS0xLTQxMDM_1ba3f37e-ed63-49e0-ae54-41da5402f38b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6YmE0MTY2YmUyNDNjNDlhYjk5ODgzMzRiOGQxODEyNDcvdGFibGVyYW5nZTpiYTQxNjZiZTI0M2M0OWFiOTk4ODMzNGI4ZDE4MTI0N18wLTEtMS0xLTQxMDU_e3c5390b-bdff-4c65-b7be-c2ebf3f6c950">26-2216351</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction <br/>of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer <br/>Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcy_b16b02c1-2cb0-4b6d-9958-48ee89ae69e6">471 El Camino Real</ix:nonNumeric>, <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcz_f2181bff-cc93-42aa-9479-3de13c5122f7">Suite 101</ix:nonNumeric>, <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTc0_1c6e1bf3-866e-4d44-90f9-5b65620c4492">Santa Clara</ix:nonNumeric>, <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTc1_d5d1c2e6-c553-49b8-979a-31e90413b841">California</ix:nonNumeric> <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTc3_e8399b90-2837-437b-99a7-53e8aafbf608">95050</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTkx_fc126e39-a09d-4021-9ebc-5749fa363b40">408</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAw_baadd03b-8811-4498-b28d-3a4af39d0468">207-0700</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.352%"><tr><td style="width:1.0%"></td><td style="width:38.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ODdkZTRkYjczYzRkNGZlMDg4MTA2MTY0YjE0NDdmZGUvdGFibGVyYW5nZTo4N2RlNGRiNzNjNGQ0ZmUwODgxMDYxNjRiMTQ0N2ZkZV8xLTAtMS0xLTQxNTE_ced5497d-23ed-454c-be72-8bb012819da7">Common Stock, par value $0.0001&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ODdkZTRkYjczYzRkNGZlMDg4MTA2MTY0YjE0NDdmZGUvdGFibGVyYW5nZTo4N2RlNGRiNzNjNGQ0ZmUwODgxMDYxNjRiMTQ0N2ZkZV8xLTEtMS0xLTQxNTM_457bf2be-8ce7-410f-8cb8-94c2f6677428">SIBN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ODdkZTRkYjczYzRkNGZlMDg4MTA2MTY0YjE0NDdmZGUvdGFibGVyYW5nZTo4N2RlNGRiNzNjNGQ0ZmUwODgxMDYxNjRiMTQ0N2ZkZV8xLTItMS0xLTQxNTU_5cb73e93-b2a5-4c03-8f42-f7b0d49a68ec">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> None</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAx_9fc6f937-a2e5-4e38-a1dc-e0c01e2516bb">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAy_4ba5fe28-1c0a-438b-ab43-5f9f90784c50">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAz_a0a2cdee-fc4a-44c9-af1f-f91d1b97efe8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:4pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDA0_f3f76607-868b-4af5-b849-4783bc8d7a81">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.991%"><tr><td style="width:1.0%"></td><td style="width:28.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6MTQ4ZmQ2ZGU4ZThhNGI2N2FkYTMwZmM2NjM5ZGFmMDQvdGFibGVyYW5nZToxNDhmZDZkZThlOGE0YjY3YWRhMzBmYzY2MzlkYWYwNF8wLTQtMS0xLTQyMzM_bbc1b623-9595-4c57-bce4-7fdd0ca927b8">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6MTQ4ZmQ2ZGU4ZThhNGI2N2FkYTMwZmM2NjM5ZGFmMDQvdGFibGVyYW5nZToxNDhmZDZkZThlOGE0YjY3YWRhMzBmYzY2MzlkYWYwNF8xLTEtMS0xLTQyMjk_4ec84c8e-f797-4f42-adaa-01ff4f5d666e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6MTQ4ZmQ2ZGU4ZThhNGI2N2FkYTMwZmM2NjM5ZGFmMDQvdGFibGVyYW5nZToxNDhmZDZkZThlOGE0YjY3YWRhMzBmYzY2MzlkYWYwNF8xLTMtMS0xLTQyMzE_c44b8452-a692-4c6b-b885-91f40b862a12">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;<ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDcw_34aca053-5166-49cb-b95f-efcf844035ea">&#9744;</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDA5_d0de5862-4357-44a9-a37a-397aaf145d3b">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b&#8209;2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDA4_622b63f4-fa21-4bea-a488-63e5049c8806">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the shares of common stock held by non-affiliates of the registrant as of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i723b611d0707480481c85096cc3174e1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDU0_e4b93e55-998c-46cd-b519-f423dca305ea">394.1</ix:nonFraction> million, calculated based on the closing price of the registrant&#8217;s common stock as reported by the Nasdaq Global Market. Shares of common stock held by each officer and director, and each entity affiliated with a director, have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not a conclusive determination for other purposes.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s Common Stock outstanding as of March&#160;5, 2021 was <ix:nonFraction unitRef="shares" contextRef="i3e43846424574f4d99b00787ea404847_I20210305" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8yOTMw_041cc06b-a3a7-439d-b0c9-99d45035c781">32,727,666</ix:nonFraction> shares.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:4pt;text-align:center"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDE0_cbdf0eae-898f-44f6-9c19-96a78b974b77" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#8217;s fiscal&#160;year ended December 31, 2020, are incorporated by reference into Part&#160;III of this Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:8.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_16">Item 1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_70">Item 1A</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_70">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_70">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_73">Item 1B</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_73">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_73">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_76">Item 2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_76">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_76">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_79">Item 3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_79">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_79">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_82">Item 4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_82">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_82">64</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_88">Item 5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_88">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_88">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_91">Item 6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_91">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_91">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_94">Item 7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_94">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_136">Item 7A</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_136">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_136">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_139">Item 8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_139">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_139">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_229">Item 9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_229">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_229">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_232">Item 9A</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_232">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_232">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_235">Item 9B</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_235">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_235">108</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_241">Item 10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_241">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_241">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_244">Item 11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_244">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_244">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_247">Item 12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_247">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_247">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_250">Item 13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_250">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_250">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_253">Item 14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_253">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_253">108</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_259">Item 15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_259">Exhibits</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_259"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_259"> Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_259">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_262">Item 16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_262">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_262">111</a></span></div></td></tr><tr style="height:18pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_265">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_265">112</a></span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;SI-BONE,&#8221; and &#8220;the Company&#8221; refer to SI-BONE, Inc. and its consolidated subsidiaries. The SI-BONE logo and other trade names, trademarks or service marks of SI-BONE are the property of SI-BONE, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">This Annual Report on Form&#160;10&#8209;K contains forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These forward-looking statements include, but are not limited to, statements about the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact the COVID-19 pandemic and governmental actions taken to combat the COVID-19 pandemic will have on us, including our operations, financial results, liquidity and capital resources, the existence and duration of state and local orders temporarily prohibiting elective procedures including procedures using the iFuse Implant System, the ability and desire of patients and physicians to undergo and perform such procedures, the duration and any potential resurgence of the COVID-19 pandemic, and whether the COVID-19 pandemic will recur in the future;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain a healthy workforce in light of the ongoing COVID-19 pandemic;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that a significant portion of our revenues will be derived from sales of the iFuse Implant System, or iFuse;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop additional revenue opportunities, including new indications for use and new devices;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain and grow our sales team based on the demand for our products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, train, and retain surgeons to perform procedures using our products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain favorable coverage and reimbursement determinations from third-party payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of our market opportunity;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the scope of protection from intellectual property rights covering our products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of and results from clinical and other trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing clearances and authorization from the FDA and regulators in other jurisdictions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of regulatory filings and feedback;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in the markets we serve;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations of the reliability and performance of our products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations of the benefits to patients, providers, and payors of our products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on a limited number of suppliers, including sole source suppliers, which may impact the availability of instruments and materials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to sustain or increase demand for our products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding our costs and risks associated with our international operations and expansion;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to retain and recruit key personnel;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding acquisitions and strategic operations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to fund our working capital requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our compliance with, and the cost of, federal, state, and foreign regulatory requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the factors that may impact our financial results; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated trends and challenges in our business and the markets in which we operate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts, and projections about our business and the industry in which we operate, and management&#8217;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors&#8221; and elsewhere in this report. These statements, like all statements in this report, speak only as of their date. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future, except as may be required by law.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:center;text-indent:27pt"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">PART I</span></div><div id="ic5af433463274989b3f39da4377b2b55_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item 1. Business.</span></div><div id="ic5af433463274989b3f39da4377b2b55_19"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy. We have pioneered a proprietary minimally invasive surgical implant system, which we call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. As of December 31, 2020, more than 53,000 procedures implanting iFuse have been performed by over 2,300 surgeons in the United States and more than 35 other countries since we introduced iFuse in 2009. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sacroiliac joint, which is the largest joint in the human body, can cause debilitating pain. Clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the sacroiliac joint. Studies have also shown that the disability that results from disease of the sacroiliac joint is comparable to the disability associated with a number of other serious orthopedic conditions, such as knee and hip arthritis and degenerative disc disease, each of which has surgical solutions in which an implant is used and a multi-billion dollar market exists. We believe iFuse is currently the market leading implantable device used in minimally invasive surgical fusions of the sacroiliac joint in the United States.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our iFuse Implant System includes a series of patented triangular titanium implants and the instruments we have developed to enable surgeons to perform the procedure. Surgeons place our implants across the sacroiliac joint, either from a lateral approach through the iliac, or hip, bones into the sacrum, or from a posterior approach through the sacrum and into the iliac bones. Surgeons typically use three iFuse implants to fuse a sacroiliac joint in the lateral procedure, and one iFuse implant in each sacroiliac joint, typically alongside another device crossing the joint and joining to the spinal construct in the Bedrock technique.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our iFuse implants have a triangular cross section that resists twisting or rotation of the implant within the bone within which it is implanted, regardless of the surgical approach and technique used to place the implants. The triangular shape of our implants helps stabilize the joint, and the implants&#8217; porous surface facilitates biologic fixation of the bone onto the implant, or bony ongrowth and ingrowth, that results in fusion. We hold issued patents on implants with cross-sections of many non-round shapes, including the triangular shape of the iFuse implant. We also hold issued patents for the method of placing those implants across the sacroiliac joint, as well as other parts of the spine and pelvis. Each titanium iFuse implant has at least three times the strength of a typical eight-millimeter cannulated surgical screw, and the large porous surface area of our implants allows for bony ingrowth. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We introduced iFuse-3D, our second-generation implant, in 2017. This patented titanium implant combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and a fenestrated design.  This design also allows the surgeon to fill the implant with ground-up bone before implantation, which some surgeons believe accelerates bone through-growth and biological fixation. iFuse-3D implants have shown positive bony ingrowth, ongrowth and through-growth in cell culture and animal studies, whether or not ground-up bone is used. We hold issued patents on 3D-printed triangular implants with fenestrations, or holes, which allow bone to grow into and through the implants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we received clearance from the United States Food and Drug Administration, or FDA, to promote the use of our iFuse Implant System for fusion of the sacroiliac joint in conjunction with multi-level spinal fusion procedures to provide further stabilization and immobilization of the sacroiliac joint.  For this indication, surgeons typically use the posterior approach, through the sacrum and into the iliac bones, which we call the Bedrock technique. We received CE marking and began marketing our iFuse Implant System for this indication and surgical technique in Europe in December 2019. In March 2020, we received FDA 510(k) clearance for an expanded indication for the iFuse Implant System to support our trauma program. In January 2021, we received CE marking for a similarly expanded indication for use to support our trauma program in Europe.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our products primarily with a direct sales force as well as a number of distributors in the United States, and with a combination of a direct sales force and distributors in other countries. We generate substantially all of our revenues from sales of the iFuse Implant system.  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, we generated revenue of $73.4 million and $67.3 million, respectively, a growth rate of 9%, and incurred net losses of $43.7 million and $38.4 million, respectively. Our gross margins were 88% and 90% for 2020 and 2019, respectively. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2018, we completed our initial public offering (&#8220;IPO&#8221;) with net proceeds to us of $113.4&#160;million. In January and February 2020, we received a total of $63.0&#160;million of net proceeds from our first follow-on public offering of our common stock. In October 2020, we received a total of $71.6&#160;million of net proceeds from our second follow-on offering of our common stock. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Opportunity </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over 30 million American adults are estimated to have chronic lower back pain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our experience in both clinical trials and commercial settings indicates that at least 30% of patients whose chronic lower back pain stems from the sacroiliac joint may be candidates for surgery with iFuse. Based on our market experience and internal estimates, and the assumption that the average person suffering from sacroiliac joint dysfunction has been in pain for five years, we estimate that the potential market for iFuse in the United States could be</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 279,000 p</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atients annually, for a potential annual market in the United States of approximately $2.5 billion. While we have made significant progress in penetrating this market, U.S. patients received approximately 7,500 and 6,400 iFuse procedures in 2020 and 2019, respectively. Globally, the number of iFuse procedures performed in 2020 and 2019 was approximately 8,900 and 8,000, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Americans spend approximately $85.9 billion per year on spine problems and that approximately 65% of people who suffer from sacroiliac pain are women. Sacroiliac joint patients may have experienced one or more of the following events that have contributed to disruption and/or degeneration of the sacroiliac joint: pregnancy, falls, previous lumbar surgery, automobile accidents, and aging, which may cause degeneration of the cushioning in the joint much like other joints. In patients with traumatic injury to the sacroiliac joint, surgeons are increasingly using iFuse for treatment of the initial traumatic injury, rather than using it to treat chronic sacroiliac joint dysfunction and the pain that it causes as the disease and pain progresses. We recently received FDA clearance for expanded indications for the use of iFuse in the treatment of pelvic trauma, including for stabilization of the sacroiliac joint in conjunction with the treatment of fractures involving the sacroiliac joint. We continue to invest in the development of products and techniques to help surgeons improve the treatment of these patients, and anticipate continuing to build products and pursue indications that can be used to treat pelvic trauma patients.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diagnosis </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is often difficult to identify the source of lower back pain. As a result, some surgical procedures performed on the spine have a sub-optimal success rate. For example, published studies of lumbar fusion have shown success rates of only approximately 60%. Unsuccessful spine surgery may result in failed back surgery syndrome, which has been shown to result in high healthcare costs with poor overall relief of pain. Published studies have shown that the sacroiliac joint is a cause of the pain in 32% to 43% of patients who have previously had lumbar fusion surgery and are experiencing recurrent low back pain. We believe low success rates of lumbar fusion are likely related, in many cases, to failure to diagnose the sacroiliac joint as the correct cause of pain. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we launched iFuse, we have made considerable investments in teaching healthcare professionals to accurately diagnose sacroiliac joint disorders. We provide instruction and training on how to perform the provocative maneuvers in a physician&#8217;s office that can help establish the sacroiliac joint as the source of pain. If provocative tests are positive, surgeons confirm the diagnosis by injecting a small amount of local anesthetic into the joint under fluoroscopic guidance. The sacroiliac joint is confirmed as a pain source if the local anesthetic produces immediate and significant pain reduction. In addition to the differentiated characteristics of our iFuse procedure and triangular iFuse implants, we believe that more accurate diagnosis is part of the reason for the high success and patient satisfaction rates of the iFuse procedure. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surgical Treatment of Sacroiliac Joint Disease </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with sacroiliac joint dysfunction frequently experience significant pain simply from sitting, standing, or rolling over in bed. These activities result in small movements of the sacroiliac joints and pressure transferred across the joints. The pain can be exacerbated with activity - when a patient walks or runs, for example, the shock from each step is transmitted up the leg, through the iliac bones of the pelvis to the sacroiliac joint. The initial goal in fusion of the sacroiliac joint is to immediately stabilize the joint which rapidly reduces the pain. Following initial stabilization of the sacroiliac joint, the goal is to permanently fuse the joint. We believe our proprietary triangular implants stabilize the joint better and more quickly than competing technologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical fusion of the sacroiliac joint with an open surgical technique was first reported in 1908, with further reports in the 1920s. The open procedure uses plates and screws, requires a 6- to 12-inch incision and is extremely invasive. The iFuse procedure involves a 1- to 2-inch incision and is much less invasive.  Due to its infrequent use and invasive nature, resulting in post-operative pain and lengthy recovery, the open sacroiliac joint fusion procedure was rarely taught in medical school or residency programs. Prior to our launch of iFuse, most spine surgeons were unfamiliar with the sacroiliac joint and had never performed a sacroiliac joint fusion. As a result, when patients presented with lower back pain, spine surgeons often did not include evaluation of the sacroiliac joint in their diagnostic work-up. Surgeons who did recognize the condition typically told their patients they had nothing to offer surgically. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Surgical Treatment of Sacroiliac Joint Disease </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a number of non-surgical treatments exist for sacroiliac joint pain, they did not provide the level of pain or disability relief seen with the iFuse procedure for the patients participating in our randomized controlled clinical trials. Non-surgical treatments include: </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical therapy, including opiates and non-steroidal anti-inflammatory medications. </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Physical therapy, which can involve exercises as well as massage. </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intra-articular injections of steroid medications, which are typically performed by physicians who specialize in pain treatment or anesthesia. </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Radiofrequency ablation, or the cauterizing, of the lateral branches of the sacral nerve roots. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Solution - The iFuse Implant System </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our iFuse system, which includes our implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. As shown in the graphic below, our iFuse implants are triangular, and three implants are typically used in each procedure. Our implants are made of titanium and have a porous surface. Each iFuse implant is at least three times the strength of a typical eight-millimeter surgical screw, and the large porous surface area allows adherence of the bone to the implants. We introduced the original iFuse implants in 2009, and our second-generation iFuse-3D implants in 2017. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:22.5pt"><img src="sibn-20201231_g1.jpg" alt="sibn-20201231_g1.jpg" style="height:149px;margin-bottom:5pt;vertical-align:text-bottom;width:445px"/></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The iFuse procedure is typically performed under general anesthesia. The surgeon uses a custom instrument set we provide to prepare a triangular channel for each implant through the ilium, across the sacroiliac joint, and into the sacrum. An iFuse implant is then pressed into the triangular channel, which is slightly smaller than the implant, creating what is known as an interference fit. The triangular cross section of our iFuse implants, as shown below, prevents them from rotating. Our triangular iFuse implants cross the sacroiliac joint and provide immediate joint stability, which is why we believe pain diminishes soon after the iFuse procedure. Over time, bone grows onto, and in the case of iFuse-3D into, the implants and across the joint, permanently stabilizing or fusing the joint. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By contrast, open and other techniques for sacroiliac joint fusion typically use screws, plates and/or bone graft for fixation. When placed across the sacroiliac joint, standard orthopedic screws, which lack features to encourage biologic fixation, tend to rotate and loosen over time. Because of the triangular shape, porous surface, strength, and other differentiating factors of our iFuse implants, we believe that our published clinical data do not apply to other minimally invasive solutions. Little published evidence of safety, clinical effectiveness, durability, or economic utility currently exists for sacroiliac fusion devices other than iFuse. We are unaware of any data to show that our competitors&#8217; sacroiliac joint screws, with features allowing biologic fixation, have a lower rate of loosening than standard orthopedic screws. In addition, placement of plates for open fusion procedures typically requires larger incisions and more invasive dissection, which results in longer recovery times and increased morbidity. We believe that the differences between iFuse and other products, as well as the substantial published clinical evidence showing the safety and effectiveness of iFuse, are the reason why a growing number of payors have recommended that iFuse be reimbursed for sacroiliac surgery to the exclusion of other technologies that are designed for the procedure. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, surgeons recommend protected weight-bearing for three weeks. However, post-operative instructions are patient-specific and some patients are allowed to perform weight-bearing activities sooner. Follow-up studies have shown that bony bridging across the sacroiliac joint is present in the majority of cases five years after the iFuse procedure. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three implants are used in most lateral iFuse procedures. Each implant crosses the joint from the iliac bone into the sacrum. Placing each implant requires four basic steps: </span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The surgeon inserts a guide pin through the iliac bone, across the sacroiliac joint and into the sacrum. </span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Drill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Surgeons drill over the guide pin, through the iliac bone, across the sacroiliac joint and just into the sacrum. </span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Broach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The surgeon impacts a triangular broach over the pin which prepares a triangular channel that is slightly smaller than the iFuse implant. </span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Implant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The surgeon impacts the implant into the triangular channel thereby spanning the sacroiliac joint and docking the implant in the sacrum. The channel is slightly smaller than the implant, which produces an interference fit. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iFuse is a cannulated system, which means that the drill, broach and implants have hollow channels which fit over the pin for guidance purposes. As is typical in many orthopedic procedures, a member of our team is normally present in the operating suite during surgery to provide technical assistance for the use of iFuse. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer three custom instrument sets for surgical placement of iFuse implants in the body. The standard set comprises largely stainless steel materials; the XL (Extra Long) set is the same as the standard set but most instruments are elongated by three inches for treatment of larger patients; and the radiolucent set comprises instruments made with more radiolucent (transparent to X-rays) materials, such as PEEK and aluminum, to improve visualization under fluoroscopy during an iFuse procedure. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our iFuse and iFuse-3D platform technologies, we also provide enabling technologies for our surgeons.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We introduced an instrument set that is cleared for use with Medtronic&#8217;s surgical navigation system, allowing the surgeon to visualize the 3D positioning of certain instruments intra-operatively. In March 2018, we introduced surgical pins cleared for use with the Mazor surgical robot, allowing the surgeon to robotically place the guide pin according to a computer-generated surgical plan. In early 2019, we introduced our Decortication and Graft Delivery Systems that allow surgeons to remove intra-articular cartilage and deliver flowable bone graft materials. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we received clearance from the United States Food and Drug Administration, or FDA, to promote the use of our iFuse Implant System for fusion of the sacroiliac joint in conjunction with multi-level spinal fusion procedures to provide further stabilization and immobilization of the sacroiliac joint. For this indication, surgeons typically use the posterior approach, through the sacrum and into the iliac bones, which we call the Bedrock technique. We received CE marking and began marketing our iFuse Implant System for this indication and surgical technique in Europe in December 2019. In March 2020, we received FDA 510(k) clearance for an expanded indication for the iFuse Implant System to support our trauma program. The Bedrock technique utilizes our proprietary iFuse implants, with one implant placed across each sacroiliac joint (for a total of two implants per case) using a posterior approach, through the sacrum, across the sacroiliac joint, and into the ilium. The Bedrock technique differs from our traditional iFuse procedure, in which three iFuse implants are placed across one sacroiliac joint via a lateral transarticular approach through the ilium and into the sacrum. The Bedrock technique is performed to increase the overall strength and stability at the base of a long construct for multilevel spinal fusion. Biomechanical testing has shown that iFuse implants placed in this position reduce sacroiliac joint motion by approximately 30% in conjunction with a long construct.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to our iFuse and iFuse-3D platform technologies, we also provide enabling technologies for our surgeons.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We introduced an instrument set that is cleared for use with Medtronic&#8217;s surgical navigation system, allowing the surgeon to visualize the 3D positioning of certain instruments intra-operatively. In March 2018, we introduced surgical pins cleared for use with the Mazor surgical robot, allowing the surgeon to robotically place the guide pin according to a computer-generated surgical plan. In early 2019, we introduced our Decortication and Graft Delivery Systems that allow surgeons to remove intra-articular cartilage and deliver flowable bone graft materials. In mid-2019, we introduced the iFuse Bedrock technique that supplements pelvic fixation in deformity and degeneration cases and provides enhanced initial stabilization and long-term SI joint fusion. In late-2019, we introduced iFuse Bone, an implantable bone product manufactured from sterilized recovered cadaveric bone tissue, to meet the demand of some of our surgeon customers to use implantable bone products to support and augment the patient's own bone tissue in orthopedic procedures.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Published Studies </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iFuse is the only minimally invasive product for sacroiliac joint fusion commercially available in the United States that, to our knowledge, is supported by substantial high-quality published evidence of safety, clinical effectiveness, durability, and economic utility. Our implants have a triangular cross section, which resists rotation of the implant within the bone in which it is implanted, helping stabilize the joint even before fixation of the bone onto the implant, or bony ingrowth, which results in fusion. Products from our competitors use screws to treat the sacroiliac joint, which we believe do not resist rotation within the bone as effectively as our patented triangular implants. A study we performed showed that our iFuse implants have more than six times the rotation resistance of a screw designed for sacroiliac joint fusion. We hold issued patents on implants with cross-sections of many non-round shapes, including the triangular shape we use for iFuse. We also hold issued patents for the method of placing those implants across the sacroiliac joint, as well as other parts of the spine and pelvis. Each titanium iFuse implant is at least three times the strength of a typical eight-millimeter surgical screw and the larger porous surface area of our implants allows for bony ingrowth. Three of our implants are typically used in each procedure. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety, durable effectiveness and cost effectiveness of iFuse are all supported by a large number of studies that have resulted in more than 90 published papers. Several of these papers publish results from five prospective multi-center studies (INSITE, iMIA, SIFI, LOIS and SALLY) that we sponsored, two of which were randomized controlled clinical trials. LOIS provided long-term (5-year) data to support sustained improvements in pain, disability and quality of life, as well as radiographic evidence of progressive fusion of the joint. Additionally, there have been several studies showing longer-term follow-up of up to six years. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INSITE Clinical Trial</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSITE is a randomized controlled study conducted in the United States. Positive 24-month follow-up results were published in August 2016 in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Journal of Spine Surgery </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">showing statistically significant and clinically important reduction in pain and disability after sacroiliac joint fusion but very little response to maximal non-surgical treatment. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The INSITE clinical trial included 148 subjects treated at 19 centers in the United States, with subjects randomized in a two-to-one ratio to either immediate sacroiliac joint fusion with iFuse or non-surgical management. The study design allowed subjects in the non-surgical management group to cross over and have surgery after six months. By 24 months after the start of the clinical trial, 89% of the non-surgical management group subjects still participating in the trial had elected to cross over to have the iFuse procedure, primarily because they derived little clinical benefit from non-surgical treatments. The study&#8217;s results can be summarized as follows: </span></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Reduction in Pain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There was statistically significant and clinically important pain reduction in subjects treated with iFuse as compared to very small responses in the same measures in those treated with non-surgical management. Subjects surgically treated with iFuse had mean 52- 54- and 55-point reductions in sacroiliac joint pain at 6, 12 and 24 months, respectively, as measured by the Visual Analog Scale (&#8220;VAS&#8221;). By contrast, subjects in the non-surgical management group had only a mean 12-point reduction (p&lt;0.0001) at six months. 12 points is below the commonly accepted 20-point threshold for clinically important improvement. In addition, the non-surgical management group subjects who elected after six months to cross over to have the iFuse procedure had pain reduction similar to that seen in subjects originally assigned to sacroiliac joint fusion with iFuse. At 24 months, the proportion of subjects with a reduction in VAS sacroiliac joint pain of 20 or more points due to the assigned treatment only was 83% in the iFuse group and 10% in the non-surgical management group. </span></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Reduction in Disability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There was a statistically significant and clinically important reduction in disability in subjects treated with iFuse as compared to very little response in those treated with non-surgical management. Subjects surgically treated with iFuse had a mean 27-point reduction in disability at six months, on the 0&#8211;100 Oswestry Disability Index (&#8220;ODI&#8221;), while subjects in the non-surgical management group had only a mean five-point reduction (p&lt;0.0001). Five points is less than the commonly accepted 15-point threshold to denote a clinically important response. At 24 months, the iFuse group had a mean 28-point reduction in ODI. At six months, the proportion of subjects with ODI improvements of at least 15 points was 72.5% with iFuse treatment and only 13.0% in those undergoing non-surgical management (p&lt;0.0001 for difference in response rate). In addition, the subjects who elected after six months to cross over to have the iFuse procedure had similar reduction in disability as the subjects originally assigned to sacroiliac joint fusion with iFuse. At 24 months, the proportion of subjects with an ODI improvement of at least 15 points with the assigned treatment only was 68.2% and 7.5% in the iFuse and non-surgical management groups, respectively (p&lt;0.0001 for difference in response rate).</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iMIA European Clinical Trial</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iFuse Implant System Minimally Invasive Arthrodesis ("iMIA") is a second prospective, randomized clinical trial of sacroiliac joint fusion using iFuse compared to non-surgical management with a design very similar to that of INSITE. iMIA is a randomized controlled study conducted in Europe. Positive 24-month results were published in March 2019 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Journal of Bone and Joint Surgery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Like INSITE, results from iMIA show statistically significant and clinically profound reduction in pain and disability after SI joint fusion but little improvement after non-surgical treatment. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">SIFI Clinical Trial</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sacroiliac Joint Fusion with iFuse Implant System (&#8220;SIFI&#8221;), is a prospective, multicenter single-arm clinical trial. Eligibility criteria and endpoints were identical to INSITE. SIFI is a single-arm study conducted in the United States. Positive 24-month follow-up results were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Journal of Spine Surgery </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in April 2016, showing substantial and sustained reduction in pain and disability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LOIS Clinical Trial</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term follow-up in INSITE/SIFI ("LOIS") is a prospective follow-on study, enrolling subjects at a subset of INSITE and SIFI sites treated with iFuse. Study outcomes at four years were published in July 2018 in the medical journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices: Evidence and Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2019, we announced the publication of the 5-year results, which showed excellent durability of clinical responses and positive radiographic outcomes for SI joint fusion using triangular titanium implants. Among 103 enrolled subjects, mean sacroiliac joint pain scores decreased 54 points from baseline prior to surgery. Disability scores decreased 26 points and quality of life improved 0.29 points, all of which are statistically significant, clinically meaningful and consistent with previously published LOIS 4-year results. The 5-year results from LOIS demonstrated that improvements in pain, patient function and quality of life demonstrated at two years in INSITE and SIFI were durable and sustained at five years.&#160;Independent radiographic analysis of CT scans at five years showed a high rate of bony apposition to implants on both the sacral and iliac sides (98%) as well as a high rate of SI joint fusion (88% bridging bone). Patient satisfaction remained high for patients treated with the iFuse Implant.&#160;There were no reported adverse events related to the study device or procedure at five years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SALLY Clinical Trial</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery with Titanium Implants ("SALLY") is a prospective single-arm multicenter trial of iFuse-3D for the treatment of sacroiliac joint dysfunction. The enrolled patient population was very similar to that of INSITE, SIFI and iMIA. A one-year manuscript, published in early 2020, showed improvements in pain, disability and quality of life similar to prior studies as well as CT evidence of earlier fusion of the SI joint. The study also showed marked reduction in opioid use and improvement in objective functional tests. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SILVIA Clinical Trial</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently enrolling subjects in SI Joint Stabilization in Long Fusion to the Pelvis: Randomized Controlled Trial ("SILVIA"), a prospective, single-blinded international multicenter randomized controlled trial of use of iFuse during multilevel spine fusions with fixation to the pelvis. This patient population is distinct from prior studies in the following ways: 1) the patients have degenerative scoliosis of the spine and are in need of complex spine surgery to correct spine malalignment, which is associated with substantial low back symptoms and disability; 2) all are undergoing pelvic fixation, meaning anchoring of the spine constructs into the pelvis; and 3) some, but not all, have diagnosed SI joint pain. The goal of this study is to show that placement of iFuse in the Bedrock configuration reduces the rate of postoperative SI joint pain and improves the longevity of pelvic fixation hardware, failures of which are fairly common. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Published Clinical Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, several studies, some of which we did not sponsor, have been published on the safety and effectiveness of sacroiliac joint fusion using iFuse. These are prospective or retrospective, single site or multi-site, and U.S. or Europe-based. These clinical studies demonstrate the iFuse procedure to be safe and effective. These studies demonstrate pain reduction and/or ODI improvement that is statistically significant and clinically important. These additional studies are consistent with the results of INSITE, iMIA, and SIFI, including the types and rates of adverse events observed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurosurgery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> published in April 2017 showed similar improvements in pain and disability in patients followed for up to six years. The study also showed a substantial reduction in the number of subjects using opioids in patients treated with iFuse at their last follow-up visit. At the last follow-up visit, 84% of patients who received non-surgical management were using opioids, while only 7% of patients treated with iFuse were using opioids. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to clinical evidence, a number of economic publications we financially supported, including those in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicoEconomics and Outcomes Research, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demonstrate that the iFuse procedure provides a cost savings to the healthcare system when compared to non-surgical management over time. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_28"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement for iFuse products and related procedures vary by setting of care, payor type and region. In the United States, healthcare providers that purchase iFuse products look to various third-party payors, such as Medicare, Medicaid, private commercial insurance companies, health maintenance organizations, accountable care organizations, and other healthcare-related organizations, to cover and pay for all or part of the costs of these procedures. These providers bill patients for any applicable deductibles or co-payments. Sales volumes and prices of company products will continue to depend in large part on the availability of coverage and reimbursement from such third-party payors for both the surgeon's professional fee and the facility fee which covers, among other things, the cost of implants used in iFuse procedures. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare program is commonly used as a model for how private payors and other governmental payors develop their coverage and reimbursement policies for healthcare items and services, including iFuse procedures. Unless a national coverage policy exists for a particular technology, each of the Medicare Administrative Contractors is permitted to make its own determination of whether that item or service is covered by Medicare. Medicare&#8217;s reimbursement rates for the iFuse procedure vary due to geographic location, the nature of facility in which the procedure is performed (i.e., hospital inpatient department, hospital outpatient department, or ambulatory surgical center) and other factors. Medicare reviews and updates its payment rates and methodologies for these settings of care annually, and rates can change from year to year. In addition, Congress can alter reimbursement rates at any time by mandating changes to Medicare&#8217;s payment methodologies. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, private payor coverage policies and reimbursement rates tend to vary across payors and settings of care. Payors continually review the clinical evidence for new technologies and can change their coverage policies without notice or deny payment if the product was not used in accordance with the payor&#8217;s coverage policy. Payors also review and challenge the prices charged for products and procedures. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the American Medical Association (&#8220;AMA&#8221;), generally creates specific billing codes for surgical procedures under a coding system known as Current Procedural Terminology (&#8220;CPT&#8221;), which surgeons must use to bill and receive reimbursement for our iFuse procedure. Once a CPT code is established, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), typically establishes payment levels under Medicare while private payors establish rates and coverage rules independently. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our launch of iFuse, Medicare and most private insurance companies reimbursed surgeons for sacroiliac joint fusions using either an established Category I CPT code or an unlisted code. A Category I CPT code is typically assigned to procedures that are consistent with contemporary medical practice and are widely performed. Procedures with a longstanding Category I CPT code are usually reimbursed. However, effective July 1, 2013, the AMA&#8217;s CPT Editorial Panel created a new Category III CPT code for fusion of the sacroiliac joint using a minimally invasive or percutaneous approach. Category III CPT codes are used for new and emerging technologies and are reimbursed sporadically. This new code functionally redefined coding for sacroiliac joint fusions because it meant that minimally invasive or percutaneous fusion procedures should not be billed by the surgeon using the general Category I CPT code for sacroiliac fusion surgery. This coding change was accompanied by the establishment of a Medicare hospital outpatient prospective payment rate for facilities to bill for procedures with the new code. Following the creation of the new Category III CPT code, a number of papers demonstrating the clinical success of the iFuse procedure were published. As a result of these studies, along with the support of several professional medical specialty societies and leading academic surgeons, the AMA CPT Editorial Panel established a new Category I CPT code specifically for sacroiliac joint fusion surgery using a minimally invasive or percutaneous approach. This new Category I CPT code became effective on January 1, 2015. However, the new code did not immediately lead to positive coverage decisions by payors. In many cases, the payors wanted additional published evidence before deciding to cover the procedure. As a result, positive reimbursement decisions covering the procedure have occurred over the last few years, and some payors are still in the process of making decisions based on the most recent evidence. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, six-month follow-up results from our INSITE randomized controlled clinical trial were published. In June 2015, the largest spine society in the world, the North American Spine Society (&#8220;NASS&#8221;), published a positive coverage recommendation, based on the clinical evidence, signaling to insurance companies and Medicare Administrative Contractors that sacroiliac joint fusion using a minimally invasive surgical approach should be routinely reimbursed. In March 2015, the International Society for Advancement of Spine Surgery (&#8220;ISASS&#8221;), also published a similar, updated positive coverage document signaling to insurance companies in the U.S. that evidence supports reimbursement for the procedure. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage decisions for this code are made independently by each private insurance company and each of the Medicare Administrative Contractors that help manage Medicare. Around the second quarter of 2016, because of the iFuse clinical evidence, all Medicare Administrative Contractors were covering the procedure. At the time, very few private payors were covering. As of December 31, 2020 and 2019, U.S. payors covering 311.6 million and 282.7 million lives, respectively, regularly reimbursed for the iFuse procedures.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party payors, whether governmental or commercial, are also developing increasingly sophisticated methods of controlling healthcare costs. No uniform policy of coverage and reimbursement for medical device products and services exists among third-</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">party payors in the United States. Therefore, coverage and reimbursement for medical device products and services can differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny coverage for these products and procedures. As a result, the coverage determination process is often a time-consuming and costly process that requires us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained or maintained if obtained. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement. Third-party payors regularly update reimbursement amounts and sometimes revise the methodologies used to determine reimbursement amounts. This includes annual updates to payments to physicians, hospitals, and ambulatory surgical centers for procedures during which our products are used. For example, the Medicare program updates hospital and physician payments annually pursuant to applicable law and regulations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty benefit managers and companies which perform healthcare technology assessments have significant influence on coverage decisions. In May 2016, the ECRI Institute Health Technology Assessment Information Service published a positive review of the iFuse Implant System, citing our clinical evidence. In January 2018, the Blue Cross Blue Shield Association, the licensor to all 36 Blue Cross and Blue Shield insurers across the United States, wrote a favorable review of the clinical evidence conferring a positive coverage recommendation for minimally invasive sacroiliac fusion, but only when performed with iFuse. In February 2018, Milliman Care Guidelines, a Hearst Company publication, also recommended coverage and in May 2018, AIM Specialty Health, owned by Anthem, established coverage for only iFuse and none of our competitors. In October 2018, eviCore recommended our iFuse system exclusively for sacroiliac joint fusion or stabilization. In 2020, Magellan Healthcare issued surgery guidelines for percutaneous sacroiliac joint fusion, which requires case-by-case review of authorization requests and follows NASS guidelines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Private Payors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Private payors decide whether to cover and how much to pay on an individual basis. We target and track 65 of the largest U.S. private payors. As of December 31, 2020, of the targeted and tracked U.S. private payors, 56 were covering regularly, or had announced coverage for, the iFuse procedure, while the remaining U.S. private payors were reevaluating their coverage policies. As of December 31, 2020, of the U.S. private payors covering regularly, 35 have issued positive coverage policies exclusive to iFuse for sacroiliac joint fusion and 21 U.S. private payors are covering iFuse and other sacroiliac joint fusion products.</span></div><div style="margin-bottom:3pt;padding-left:45pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the total covered lives with access to minimally invasive SI joint fusion and those with coverage exclusive to iFuse as of December 31, 2020: </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.448%"><tr><td style="width:1.0%"></td><td style="width:61.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covered lives (in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total  coverage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exclusive iFuse  coverage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military/Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note that because many individuals are covered by more than one health insurance plan or may switch plans during the year, the total number of covered lives reported by the payors represented above may be larger than the number of individuals who have access to the iFuse procedure through their health insurance provider at any given time. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, CIGNA established a positive coverage policy for minimally invasive SI joint fusion using the iFuse Implant System. CIGNA is the fourth largest commercial health plan in&#160;the United States&#160;with approximately 14.6 million members. In May 2020, Aetna adopted a new coverage policy for minimally invasive arthrodesis of the sacroiliac joint for sacroiliac joint syndrome and sacroiliac joint pain. Aetna is the third largest commercial health plan in the United States with over 22 million members. Currently, covered lives counts do not include Anthem, which covers minimally invasive sacroiliac fusion procedures in the event of pelvic girdle trauma only. On October 1, 2020, Anthem published an update to its sacroiliac joint fusion medical policy. This update retained policy language limiting indications for iFuse to cases involving a history of pelvic girdle trauma, similar to earlier versions of the policy, and did not reflect the feedback from specialists Anthem received in mid-2020, or other substantive updates to the evidence base. Anthem has communicated to us that this feedback and additional evidence may be taken into consideration in future policy updates in 2021. In December 2020, Humana adopted a new coverage policy for minimally invasive arthrodesis of the sacroiliac joint exclusively when using titanium triangular implants (e.g., iFuse). </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other large and small private payors that have not published positive coverage policies for the procedure. Some of these non-covering payors are reevaluating coverage given the latest data, but there can be no assurance they will reach positive coverage decisions. In most cases, the payors who are not covering are reevaluating coverage. Many payors will only review their coverage policies for a procedure on a scheduled basis, which can be every few months or as infrequently as once per year. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to payor coverage, surgeons have been reluctant to get trained on a procedure for which they could not reliably be reimbursed. While we believe the increased coverage described above will have a positive effect on the number of iFuse procedures and our associated revenue in the future, the effect likely will happen with a lag time because, after a positive coverage decision is made, a number of months may pass before it impacts the number of procedures and associated revenue, since the surgeons have to be made aware of the coverage decision, in some cases attend one of our training courses to learn the surgical technique, schedule re-examinations of patients who were candidates for surgery, and then schedule surgeries for the patients who are still candidates. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that it generally takes between six and 24 months for a surgeon to fully incorporate iFuse into his or her practice after payors initiate coverage and the surgeon is trained. Further, the administrative burden on surgical practices can be substantial for patients where reimbursement coverage is new, and some surgeons do not believe that the current average surgeon reimbursement is yet adequate to compensate them. However, as reimbursement coverage has improved, surgeon interest in learning to diagnose the sacroiliac joint and perform iFuse procedures has been increasing. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage Outside the United States </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, reimbursement levels vary significantly by country, and by region within some countries. Reimbursement is obtained from a variety of sources, including government-sponsored and private health insurance plans, and combinations of both. Some countries will require us to gather additional clinical data before recognizing and granting broader coverage and reimbursement for our products. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Technology Assessment (&#8220;HTA&#8221;) of medical devices is, however, becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including the United Kingdom, France, Germany, Ireland, Italy, Spain and Sweden. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medical device in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, and cost&#8209;effectiveness of individual products as well as their potential implications for the healthcare system. Those elements of medical devices are compared with other treatment options available on the market. The outcome of HTA regarding specific medical devices will often influence the pricing and reimbursement status granted to these products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medical device varies between EU Member States. In addition, pursuant to Directive 2011/24/EU on the application of patients&#8217; rights in cross&#8209;border healthcare, a voluntary network of national authorities or bodies responsible for HTA in the individual EU Member States was established. The purpose of the network is to facilitate and support the exchange of scientific information concerning HTAs. This may lead to harmonization of the criteria taken into account in the conduct of HTAs between EU Member States and in pricing and reimbursement decisions and may negatively affect price in at least some EU Member States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a further step in this direction, on January 31, 2018, the European Commission adopted a proposal for a regulation on HTA. This legislative proposal is intended to increase cooperation among EU Member States in assessing health technologies, including new medical devices, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The proposal would permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. The European Commission has stated that the role of the draft HTA regulation is not to influence pricing and reimbursement decisions in the individual EU Member States. However, this consequence cannot be excluded.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, the UK&#8217;s National Institute for Health and Care Excellence (&#8220;NICE&#8221;), published guidance on minimally invasive sacroiliac joint fusion, recommending that the procedure be available to properly diagnosed patients in the UK National Health System. NICE develops guidance and quality standards in health and social care and is a worldwide leader in technology evaluations. The recommendation states that the safety and efficacy of minimally invasive sacroiliac joint fusion surgery is adequate provided that standard arrangements are in place. Use with standard arrangements is the most positive recommendation that NICE can make for an interventional procedure such as minimally invasive SI joint fusion. In October 2018, NICE published medical technology guidance specific to the iFuse Implant System, recommending that it be used in the National Health System because of the evidence demonstrating that treatment with iFuse improves pain, quality of life, and disability in properly selected patients. The continued relevance of the NICE guidance following the departure of the UK from the EU on January 31, 2020 is yet to be determined. Additionally, in August 2018, the public hospital system in France announced it would initiate coverage for iFuse exclusively beginning September 6, 2018. Some countries will require us to gather additional clinical data before recognizing and granting broader coverage and reimbursement for our products. It is our intent to complete the requisite clinical studies and obtain coverage and reimbursement approval beyond what we have today in countries where it makes economic sense to do so. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Affairs and Education </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical affairs team provides high quality educational programs internally and externally. Internally, specialized medical knowledge, and practical experience with iFuse are used to help educate our sales, marketing, quality, reimbursement, clinical, regulatory, engineering, and product development teams. This same specialized medical knowledge and practical iFuse experience provides the foundation for a wide variety of educational programs provided to both surgeons who will perform the iFuse procedure and the broader medical community that see and treat these patients. The medical affairs team is led by a fellowship trained orthopedic spine surgeon. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we contracted with over 300 healthcare practitioners in various medical specialties, such as surgeons, pain management physicians, nurse practitioners/physician&#8217;s assistants and physical therapists, to help educate healthcare professionals about the sacroiliac joint as a component of lower back pain, proper diagnosis of SI joint dysfunction, non-surgical treatment options and surgical treatment with iFuse.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our surgeon training programs are for orthopedic spine surgeons, neurosurgeons, general orthopedic surgeons, and orthopedic trauma surgeons. Since we began training surgeons, over 2,300 surgeons have treated patients with iFuse. We grew our active surgeon base to 588 surgeons as of December 31, 2020, compared to 539 active surgeons as of December 31, 2019. We define an active surgeon to be a surgeon who has performed at least one iFuse case in the last three months. The increase in active surgeons is primarily due to training of additional surgeons throughout the year. We will continue to pursue the remainder of the approximately 7,500 target surgeons in the United States, as well as international surgeons for training in the future. The COVID-19 outbreak challenged our traditional method of hands-on cadaveric and dry-lab training. In early 2020, the medical affairs team implemented a virtual education series for surgeons and mid-level practitioners. In July 2020, we began using an innovative, fully portable surgeon training simulator. This training platform allows us to train surgeons without need for an operating room or a fluoroscope.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computer-based surgeon training simulator provides quality haptics, or the realistic feel during the surgeon&#8217;s use of the instruments, and the training is performed without any radiation. One</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key advantage of this surgeon training simulator is that the surgeon can now be trained locally in their office or a hospital conference room in 2 to 3 hours, and the surgeon does not need to travel to a cadaver lab, which sometimes requires being away from their practice for as much as a day and a half. The simulator uses the same instruments and implants as those that are used during surgery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The simulator is used to train surgeons to perform SI joint injections and iFuse  sacroiliac joint fusions, as well as the iFuse Bedrock procedure. We plan to expand the use of simulators for training purposes both in the United States and internationally. We will utilize the simulators and our existing programs to train new surgeons, increase the knowledge and proficiency of existing iFuse surgeons, and re-engage inactive surgeons.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a large number of educational programs for the broader medical community including primary care physicians, pain management physicians and other healthcare practitioners that may manage a sacroiliac joint patient non-surgically, such as physical therapists and chiropractors. In addition to these general educational programs, we provide continuing education programs focused on SI joint diagnosis and treatment to physical therapists and case managers. We are able to provide these programs for both groups in all 50 states and the District of Columbia. We have trained over 6,600 physical therapists through our continuing education program as of December 31, 2020. Case managers, who typically are nurses, work in facilities where the iFuse procedure is performed, such as hospitals, or for payors or health plans. Case managers help patients navigate the healthcare system so that they receive the most appropriate treatment. As of December 31, 2020, we have trained over</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1,300 case m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anagers in the United States through our continuing education program. Our medical affairs team works with leading spine surgeons to educate other orthopedic and neurosurgeons on the differential diagnosis of sacroiliac joint disorders and the use of iFuse. We also work closely with medical specialty societies to raise the awareness of and teach the appropriate diagnosis of sacroiliac joint dysfunction and the associated treatment options. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell iFuse primarily through a direct sales force and a small number of third-party distributors. Our target customer base includes approximately 7,500 surgeons who perform spine and/or pelvic surgery, including orthopedic spine surgeons, neurosurgeons, general orthopedic surgeons, and orthopedic trauma surgeons. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct sales organization in the United States covered </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">twelve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales regions as of December 31, 2020. In each region, a number of territory sales managers act as the primary customer contact. Our territory sales managers have extensive training and experience selling medical devices for spine problems and pain management, generally focusing on emerging technologies and markets. For large and/or high volume territories, we also employ territory associate representatives who cover cases. As of December 31, 2020, our U.S. sales force consisted of 64 territory sales managers and 58 clinical specialists directly employed by us, and 41 third-party distributors. As of December 31, 2020, we had 39 employees working in our European operations, and have established operations in Italy (2010), Germany (2014), the United Kingdom (2015) and France (2019). As of December 31, 2020, our international sales force consisted of 20 sales representatives directly employed by us and 31 exclusive third-party distributors, which together had sales in 35 countries through December 31, 2020. As of December 31, 2020, beyond Europe and the U.S., surgeons had performed the first iFuse procedures in Australia, Bahrain, Canada, Cayman Islands, Hong Kong, Israel, Japan, Kuwait, New Zealand, Saudi Arabia, South Africa, and Turkey. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have made significant investments in our sales force since our initial public offering in 2018. We have built a valuable sales team, and we believe they are the key to the recovery we expect following the pandemic. As such, we have made it a top priority to support and retain our sales force through this challenging period. We limited new sales force hiring in the second and third quarter of 2020 due to uncertainty from the COVID-19 pandemic and focused on sales force productivity during this period, but resumed hiring of salespeople in the fourth quarter of 2020 based upon our favorable financial position and opportunity for future revenue growth. Our sales and marketing spending reflected normal business activities into mid-March 2020. Due to the COVID-19 pandemic, we focused on protecting key investments in our field force while curtailing most other areas of sales and marketing spend during the second and third quarter of 2020. For example, we guaranteed certain levels of incentive compensation to members of our field sales organization in order to retain these employees and partially mitigate the impact of the pandemic to their compensation. In contrast, we reduced certain other spending during the COVID-19 pandemic, such as travel and related expenses, regional surgeon training, trade shows, and discretionary marketing. As revenue growth returned to the levels that we were experiencing prior to the pandemic, we increased our sales and marketing expense accordingly in the third and fourth quarters of 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to grow our specialized sales force to foster relationships with surgeons and support revenue growth. Our territory sales managers are senior representatives who educate surgeons on the sacroiliac joint as a primary cause of lower back pain. The territory sales manager identifies new surgeons who are interested in learning more about the sacroiliac joint and the iFuse procedure and/or the Bedrock technique. The sales representative works closely with our medical affairs team to train surgeons on the anatomy, diagnosis, and surgical technique. Once trained, the sales representative works with the surgeon to incorporate into their practices the diagnosis of sacroiliac joint pain and the iFuse procedure to treat patients suffering from sacroiliac joint pain. Our clinical support specialists assist the territory sales managers to identify surgeons interested in training. The clinical support specialists also regularly cover cases, bringing our implants and instrument trays into the operating room for use by surgeons.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over 30 million American adults are estimated to have chronic lower back pain. It is often difficult to identify the source of the pain and traditional methods of spine surgery do not have high success rates. We believe it is essential to raise awareness among lower back pain sufferers that their symptoms may be the result of sacroiliac joint disorders and that minimally invasive surgical treatments are available. We have implemented targeted marketing, education and direct outreach programs. We continually update our social media initiatives and post content to educate and engage patients who may be candidates for the iFuse procedure. We plan to make additional investments to further increase patient awareness, primarily through digital and broadcast marketing, including TV and radio ads, paid search, display advertising, social media and public relations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is affected by seasonal variations. For instance, we have historically experienced lower sales in the summer months and higher sales in the last quarter of the fiscal year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as patients have more time in the winter months to have the procedure completed or want to take advantage of their annual insurance coverage limits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, taken as a whole, seasonality does not have a material impact on our financial results.</span></div><div id="ic5af433463274989b3f39da4377b2b55_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our initial launch of the iFuse Implant System, we have introduced a number of new product and procedure enhancements. An example is the iFuse-3D implant, which we developed over several years and launched in 2017. The most notable instrument enhancement was the release of the revamped instrument set that included a number of radiolucent instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we also introduced an instrument set that is cleared for use with Medtronic&#8217;s surgical navigation system, allowing the surgeon to visualize the 3D positioning of certain instruments intra-operatively.&#160;In March 2018, we introduced surgical pins which may be used with the Mazor surgical robot, allowing the surgeon to robotically place the guide pin according to a computer-generated surgical plan. In early 2019, we introduced our Decortication and Graft Delivery Systems that allow surgeons to remove intra-articular cartilage and deliver flowable bone graft materials.&#160;In mid-2019, we introduced the iFuse Bedrock technique that supplements pelvic fixation in deformity and degeneration cases and provides enhanced initial stabilization and long-term SI joint fusion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue developing enhancements to iFuse to meet our customers&#8217; changing needs and improve the surgery&#8217;s effectiveness. For example, we know that some surgeons use iFuse to treat trauma patients post-stabilization.&#160;We are developing products and techniques to help surgeons improve the treatment of these patients. We may seek regulatory clearances for additional indications as required. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued our research and development activities during the COVID-19 pandemic. Clinical study expenses declined during mid-March through April due to hospital postponement of trials as a result of the COVID-19 pandemic. However, most hospitals allowed the resumption of clinical trials starting in May 2020. As such, we anticipate that research and development expenses will continue to increase in the future. </span></div><div id="ic5af433463274989b3f39da4377b2b55_40"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we were the first company to develop, manufacture, and market a minimally invasive implant cleared by the FDA expressly for sacroiliac joint fusion other than a modified screw. Over the past several years, other companies have subsequently recognized the opportunity and have entered the minimally invasive sacroiliac joint fusion market. We expect more competitors to enter into the market and an increased number of new product introductions by existing competitors. Many of our competitors are large, publicly traded companies that can dedicate far greater resources to the minimally invasive sacroiliac joint market than we can. These companies often have wide product offerings for spine and orthopedic surgery, which allow them to bundle products in order to win large hospital group contracts and can create a barrier to entry for us. For example, some of our competitors offer sacroiliac joint fusion products which integrate with their surgical navigation and robotics platforms, enabling navigation of their procedures or performance of aspects of these procedures by surgical robots. Many of these companies also have much larger sales forces than ours, which allow them to reach more surgeons. We also expect there to be a continued push for non-surgical alternatives. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we believe that our primary competitors currently are Globus Medical, Inc. and Medtronic plc. Our primary competitors in Europe are Globus Medical and SIGNUS Medizintechnik GmbH.&#160;However, these competitors sell screw-based products, which we believe to be weaker and less able to resist rotation than our triangular iFuse implants. We also compete against non-hardware products, such as allograft bone implants. These allograft products comprise human cells or tissues and are generally regulated by the FDA differently from implantable medical devices made of metallic or other non-tissue based materials, unless these competitors' allograft products fail to meet the FDA's criteria for regulation as a human cell or tissue product. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our commercial experience and market research, we believe iFuse is currently used in the majority of minimally invasive surgical fusions of the sacroiliac joint in the United States. Our triangular titanium implant is differentiated from other screw-based technologies on the market. iFuse is the only minimally invasive product for sacroiliac joint fusion commercially available in the United States that, to our knowledge, is supported by published clinical evidence including randomized controlled studies that demonstrate the safety, clinical effectiveness, durability, and economic utility. These benefits are supported by more than 90 published papers. We have received exclusive reimbursement coverage in the United States by certain payors based upon our differentiated product and quality of our evidence. We believe these factors provide competitive advantages to us in the market. The following are the primary competitive factors on which companies compete in our industry: </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product and clinical procedure effectiveness;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ease of surgical technique and use of associated instruments;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">published clinical outcomes and evidence;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales force knowledge;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product support and service, and customer service;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comprehensive training, including disease, anatomy, diagnosis and treatment;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product innovation and the speed of innovation;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accountability and responsiveness to customers&#8217; demands; </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and reimbursement;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific (biomechanics) data; and</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting and retaining key personnel.</span></div><div id="ic5af433463274989b3f39da4377b2b55_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We protect our intellectual property through our pending patent applications and issued patents. As of December 31, 2020, we had been issued 40 patents in the United States, and 14 patents outside of the United States. Also, as of December 31, 2020, we have 29 pending patent applications in the United States and six pending patent applications outside of the United States. We have focused the majority of our foreign patent efforts in China, Europe, and Japan. Our current U.S. patents on iFuse, including the triangular shape, expire in November 2024. Competitors may market similar triangular shaped devices upon the expiration of the patents in late 2024. Our current U.S. patents on iFuse-3D, including the fenestrated design, expire in September 2035. Our foreign patents will expire between August 2025 and October 2031.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have 13 registered trademarks in the United States and have filed for 16 more. In other countries, we have focused on registering three primary trademarks: &#8220;iFuse Implant System,&#8221; &#8220;SI-BONE,&#8221; and the SI-BONE logo. As of December 31, 2020, we have sought protection for at least two of these trademarks in 60 countries including the 27 European member countries of the Madrid Protocol. The trademarks registered in the EU are also now protected by &#8220;clone&#8221; registrations in the U.K. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon trade secrets, know-how and continuing technological innovation, and may rely upon licensing opportunities in the future, to develop and maintain our competitive position. We may seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their agreements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. There can be no assurance that patents will be issued from any of our pending applications or that, if patents are issued, they will be of sufficient scope or strength to provide meaningful protection for our technology. Notwithstanding the scope of the patent protection available to us, a competitor could develop treatment methods or devices that are not covered by our patents but that compete with our proprietary technology and products. Furthermore, numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing products. Because patent applications can take many years to issue, there may be applications currently unknown to us, which may later result in issued patents that our existing or future products or proprietary technologies may be alleged and/or found to infringe. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or know-how and brands, to defend against claims of infringement of the rights of others or to determine the scope and validity of the proprietary rights of others. Litigation could be costly and could divert our attention from other functions and responsibilities. Adverse determinations in litigation could reduce the barriers to entry that we have established for iFuse, or subject us to significant liabilities to third parties, require us to seek licenses from third parties or prevent us from manufacturing, selling or using iFuse, any of which could severely harm our business. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Domestic Regulation of Our Products and Business </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in the United States and other countries. Most notably, all of our products sold in the United States are subject to the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) as implemented and enforced by the FDA. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. The FDA governs the following activities that we perform or that are performed on our behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses: </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product design, research, development, and manufacture;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product safety, testing, labeling, and storage;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">record keeping procedures;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product marketing, promotion, advertising, sales, distribution, export, and import; and</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing surveillance, complaint handling, medical device reporting, reporting of deaths, serious injuries or device malfunctions, and repair or recall of products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous FDA regulatory requirements governing the clearance or approval and marketing of our products. These include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigational device exemptions to conduct premarket clinical trials, which include extensive monitoring, recordkeeping, and reporting requirements;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality System Regulation (&#8220;QSR&#8221;), which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clearance of product modifications that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of product modifications that affect the safety or effectiveness of one of our approved devices;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-approval restrictions or conditions, including post-approval study commitments;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations; </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulations pertaining to voluntary recalls; and</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">notices of corrections or removals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">FDA Premarket Clearance and Approval Requirements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, each medical device we wish to commercially distribute in the United States will require either premarket notification, or 510(k), clearance or approval of a pre-market approval (&#8220;PMA&#8221;) from the FDA. The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either Class I or II, which typically requires the manufacturer to submit to the FDA a premarket notification requesting permission to commercially distribute the device. This process is generally known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III, requiring a PMA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I devices are those for which safety and effectiveness can be assured by adherence to FDA&#8217;s &#8220;general controls&#8221; for medical devices, which include compliance with the applicable portions of the FDA&#8217;s Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II devices are subject to FDA&#8217;s general controls, and any other &#8220;special controls&#8221; deemed necessary by FDA to ensure the safety and effectiveness of the device, such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification procedure, though certain Class II devices are exempt from this premarket review process. When a 510(k) is required, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally marketed device, which in some cases may require submission of clinical data. Unless a specific exemption applies, 510(k) premarket notification submissions are subject to user fees. If the FDA determines that the device, or its intended use, is not substantially equivalent to a legally marketed device, the FDA may place the device, or the particular use of the device, into Class III, and the device sponsor must then fulfill much more rigorous premarketing requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device. The safety and effectiveness of Class III devices cannot be assured solely by general or special controls. Submission and FDA approval of a premarket approval, or PMA, application is required before marketing of a Class III device can proceed. As with 510(k) submissions, unless subject to an exemption, PMA submissions are subject to user fees. The PMA process is much more demanding than the 510(k) premarket notification process. A PMA application, which is intended to demonstrate that the device is safe and effective, must be supported by extensive data, typically including data from preclinical studies and human clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">510(k) Clearance</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain 510(k) clearance for a medical device, an applicant must submit to the FDA a premarket notification submission demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a legally marketed device, known as a &#8220;predicate device.&#8221; A legally marketed predicate device may include a device that was legally marketed prior to May 28, 1976 for which a PMA is not required (known as a &#8220;pre-amendments device&#8221; based on the date of enactment of the Medical Device Amendments of 1976), a device that has been reclassified from Class III to Class II or Class I, or a device that was found substantially equivalent through the 510(k) process. A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics, or (ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise new questions of safety and effectiveness and is at least as safe and effective as the predicate device. A showing of substantial equivalence sometimes, but not always, requires clinical data. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before the FDA will accept a 510(k) submission for substantive review, the FDA will first assess whether the submission satisfies a minimum threshold of acceptability. If the FDA determines that the 510(k) submission is incomplete, the FDA will issue a &#8220;Refuse to Accept&#8221; letter which generally outlines the information the FDA believes is necessary to permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information before the FDA will proceed with additional review of the submission. By regulation, the FDA has 90 days from acceptance of the 510(k) submission for review to review and issue a determination. As a practical matter, clearance often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) marketing clearance or, if the modification changes the classification of the product to Class III, PMA approval. The determination as to whether or not a modification could significantly affect the device&#8217;s safety or effectiveness is initially left to the manufacturer using available FDA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guidance. Many minor modifications today are accomplished by a &#8220;letter to file&#8221; in which the manufacturer documents the rationale for the change and why a new 510(k) is not required. However, the FDA may review such letters to file to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PMA Approval</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PMA must be submitted to the FDA for any device that is classified in Class III or otherwise cannot be cleared through the 510(k) process (although the FDA has discretion to continue to allow certain pre-amendment Class III devices to use the 510(k) process). PMA applications must be supported by, among other things, valid scientific evidence demonstrating the safety and effectiveness of the device, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling. Following receipt of a PMA application, once the FDA determines that the application is sufficiently complete to permit a substantive review, the FDA will formally accept the application for review. The FDA, by statute and by regulation, has 180 days to review an &#8220;accepted&#8221; PMA application, although the review of an application more often occurs over a significantly longer period of time, and can take up to several years. During the review period, the FDA will typically request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA will generally conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the QSR. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. In approving a PMA the FDA may also require some form of post-market surveillance when necessary to protect the public health or to provide additional safety and effectiveness data for the device. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New PMAs or PMA supplements are required for modifications that affect the safety or effectiveness of a PMA-approved device, including, for example, certain types of modifications to the device&#8217;s indication for use, manufacturing process, labeling and design. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">De Novo Classification</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Manufacturers may request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. The FDA is required to classify the device within 120 days following receipt of the de novo application. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Regulation of Human Cell and Tissue Based Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our iFuse Bone products are derived from human tissue (demineralized bone tissue). The FDA has specific regulations governing human cells, tissues, and cellular and tissue-based products ("HCT/Ps"). HCT/Ps regulated by the FDA under the authority of section 361 of the Public Health service Act must be not more than minimally manipulated and be for homologous use. They are subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility, Good Tissue Practice when processing, storing, labeling and distributing HCT/Ps, including required labeling information, stringent record keeping and adverse event reporting. Our bone tissue products are regulated as 361 HCT/Ps. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AATB has issued operating standards for tissue banking. Accreditation is voluntary, but compliance with these standards is a requirement to become an AATB-accredited tissue establishment. In addition, some states have their own tissue banking regulations. We are licensed or have permits for tissue banking in California, Florida, New York, Maryland, and other states that require specific licensing or registration.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Procurement of certain human organs and tissue for transplantation is subject to the restrictions of the National Organ Transplant Act (NOTA), which prohibits the transfer of certain human organs, including bone tissue for valuable consideration, but permits reasonable payments associated with  removal, transportation, implantation, processing, preservation, quality control and storage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Trials </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) clearance. Such trials for implanted devices such as iFuse generally require an investigational device exemption application (&#8220;IDE&#8221;), approved in advance by the FDA for a specified number of subjects and study sites, unless the product is deemed a nonsignificant risk device eligible for more abbreviated IDE requirements. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements. Clinical trials must be conducted under the oversight of an institutional review board (&#8220;IRB&#8221;), and the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. To conduct a clinical trial, we also are required to obtain the subjects&#8217; informed consent in form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. We, the FDA, or the IRB, could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and effectiveness of the device or may otherwise not be sufficient to obtain FDA clearance or approval to market the product in the United States. Similarly, in Europe the clinical study must be approved by a local ethics committee and in some cases, including studies with high- risk devices, by the ministry of health in the applicable country. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pervasive and Continuing Regulation </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is placed on the market, numerous regulatory requirements continue to apply. These include: </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the manufacturing process;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indications;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clearance of product modifications that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of product modifications that affect the safety or effectiveness of one of our approved devices;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-approval restrictions or conditions, including post-approval study commitments;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations; </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulations pertaining to voluntary recalls; and </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">notices of corrections or removals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered our facility with the FDA as a medical device manufacturer. The FDA has broad post-market and regulatory enforcement powers. We are subject to announced and unannounced inspections by the FDA to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of some of our subcontractors. Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other regulatory authorities, which may result in sanctions including, but not limited to: </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">untitled letters, warning letters, fines, injunctions, consent decrees, and civil penalties;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenditures to address or defend such actions;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer notifications for repair, replacement, refunds;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, detention or seizure of our products;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusing or delaying our requests for 510(k) clearance or PMA approval of new products or modified products;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to grant export approval for our products; or</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA inspected our facilities again in December 2016. No findings were noted. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promotional Materials - &#8220;Off-Label&#8221; Promotion </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. If the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine, or criminal penalties. It is also possible that other federal, state, or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, we could be subject to additional significant penalties, such as exclusion from participation in federal healthcare programs, and our reputation could be damaged and adoption of the products would be impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the federal Lanham Act and similar state laws, competitors, and others can initiate litigation relating to advertising claims. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation of Our Products</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in other countries. For example, in the European Economic Area (&#8220;EEA&#8221;) our devices are currently required to comply with the Essential Requirements concerning medical devices that are imposed by the Medical Device Directive (Council Directive 93/42/EEC) and the related national implementing legislation of individual EU member states as well as related guidance. Demonstration of compliance with these requirements entitles us to affix the CE mark to our medical devices, without which they cannot be commercialized in the EEA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To demonstrate compliance with the Essential Requirements, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low risk medical devices, a conformity assessment procedure requires a Notified Body to conduct conformity assessments. The Notified Body typically audits and examines products&#8217; Technical File and the quality system for the manufacture, clinical evaluation report, design and final inspection of our devices before issuing a CE Certificate of Conformity. Following the issuance of this CE Certificate of Conformity, we can draw up an EC Declaration of Conformity and affix the CE mark to the products covered by this CE Certificate of Conformity and the EC Declaration of Conformity. We have successfully completed several Notified Body audits since our original certification in November 2010. Following these audits, our Notified Body issued International Standards Organization Certificates and CE Certificates of Conformity allowing us to draw up an EC Declaration of Conformity and affix the CE mark to certain of our devices.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the product has been CE marked and placed on the market in the EEA, we must comply with a number of regulatory requirements relating to:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">registration of medical devices in individual EEA countries;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and reimbursement of medical devices;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of post-marketing surveillance and adverse event reporting procedures;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Field Safety Corrective Actions, including product recalls and withdrawals; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interactions with physicians.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these requirements may result in enforcement measures being taken against us by the competent authorities of the EEA countries. These can include fines, administrative penalties, compulsory product withdraws, injunctions, and criminal prosecution. Such enforcement measures would have an adverse effect on our capacity to market our products in the EEA and, consequently, on our business and financial position.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From May 26, 2021, the Medical Device Regulation (Regulations 2017/745) will repeal and replace the Medical Device Directive and the Active Implantable Medical Device Directive and will apply in the EU Member States, Iceland, Lichtenstein and Norway. The Medical Device Regulation is, among other things, intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. Once applicable, the Medical Device Regulation will, among other things: </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthen the rules on placing medical devices on the market and reinforce surveillance once they are available; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthen the rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Device Regulation substantially augments those aspects of the Medical Device Directive governing clinical investigations of medical devices. In addition to detailed provisions concerning the authorization and conduct of clinical investigations, the Regulation imposes on non-EU sponsors a responsibility to appoint a legal representative established in the EU and an obligation on EU Member States to ensure that systems exist to compensate clinical investigation participants who are harmed in that jurisdiction due to their participation. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once applicable, the Medical Device Regulation will impose increased compliance obligations, which we must respect if we wish to continue to access the EU market. This includes the up-classification of some of our devices. Moreover, the scrutiny imposed by Notified Bodies for the technical documentation related these devices will increase considerably.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the advertising and promotion of our products in the EEA is currently subject to the provisions of the Medical Devices Directive, Directive 2006/114/EC concerning misleading and comparative advertising, Directive 2005/29/EC on unfair commercial practices, and from 26 May 2020, the Medical Device Regulation, as well as other national legislation in the EEA countries governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Status</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2008, we received 510(k) clearance to market our first generation iFuse implant from the FDA. Since 2008, we have received additional FDA 510(k) clearances for new instruments, additional implant sizes and labeling changes. In the United States, the iFuse Implant System is intended for sacroiliac fusion for the following conditions: sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruptions and degenerative sacroiliitis, which includes conditions where symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months; to augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion; and acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.  In the future, we plan to pursue additional 510(k) clearances for new products and changes to the current indication for iFuse.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2010, we obtained a CE Certificate of Conformity and affixed a CE mark to our iFuse Implant System to allow commercialization of iFuse in the EEA. In the EEA and Switzerland, iFuse is intended for sacroiliac joint fusion, including use in high and low energy fractures of the pelvic ring. Since 2010, we have added additional instruments, implant sizes and labeling updates and iFuse-3D, our second generation iFuse implant, to our product offerings in Europe. We plan to continue to work with our Notified Body to incorporate new products and labeling updates in our Technical Files for CE marking in Europe. Current delays in the revisions to the current bilateral agreement between the EU and Switzerland necessary to ensure the ongoing supply of our CE marked medical devices in Switzerland following entry into application of the Medical Device Regulation may, however, affect this plan.  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2013, we have obtained approval for iFuse in regions beyond the United States and the EEA, including Australia, Canada, Hong Kong, Israel, Malaysia, New Zealand, Saudi Arabia, Singapore and Taiwan. We are currently collecting information to determine our regulatory strategy in Japan.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Regulations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource substantially all the manufacturing of our products, therefore we have not incurred significant expenses relating to our compliance with federal, state, or local environmental laws and do not expect to incur significant expenses in the foreseeable future. However, due to the nature of our operations and the frequently changing nature of environmental compliance standards and technology, we cannot predict with any certainty that future material capital or operating expenditures will not be required in order to comply with applicable environmental laws and regulations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Fraud and Abuse</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governmental agencies and equivalent foreign authorities subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. These laws constrain the sales, marketing and other promotional activities of medical device manufacturers by limiting the kinds of financial arrangements we may have with hospitals, physicians and other potential purchasers and prescribers of our products. Federal healthcare fraud and abuse laws apply to our business when a customer submits a claim for an item or service that is reimbursable under Medicare, Medicaid, or other federally funded healthcare programs. The laws that may affect our ability to operate include:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, arrangement for, or recommendation of, items or services for which payment may be made, in whole or in part, under federal healthcare programs, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of, or a specific intent to violate, the law;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment of government funds; knowingly making, using, or causing to be made or used, a false record or statement to get a false claim paid or to avoid, decrease, or conceal an obligation to pay money to the federal government. A claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Actions under the False Claims Act may be brought by the government or as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action by a private individual in the name of the government and to share in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any monetary recovery.  There are also criminal penalties for making or presenting a false or fictitious or fraudulent claim to the federal government;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, which imposes criminal and civil liability for, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program including private third-party payors, or knowingly and willfully falsifying, concealing, or covering up a material fact or making a materially false, fictitious, or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, implemented by CMS as the Open Payments program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the CMS, information related to payments and other &#8220;transfers of value&#8221; made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers to report annually to CMS ownership and investment interests held by physicians and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided (beginning in 2021) to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, and certified nurse-midwives; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers and patients; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state beneficiary inducement laws, and state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our employees are found to have violated any of the above laws we may be subject to administrative, civil and criminal penalties, including imprisonment, exclusion from participation in federal health care programs, such as Medicare and Medicaid, significant fines, monetary penalties and damages, the restructuring or curtailment of our operations, imposition of compliance obligations and monitoring, and damage to our reputation.  For a more detailed description of the federal and state health care fraud and abuse laws, see the risk factor &#8220;We and our sales representatives must comply with U.S. federal and state fraud and abuse laws, including those relating to healthcare provider kickbacks and false claims for reimbursement, and other applicable federal and state healthcare laws, as well as equivalent foreign laws, and failure to comply could negatively affect our business&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Risks Related to Our Legal and Regulatory Environment section of Item 1A of this Annual Report on Form 10-K.  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar anti-bribery laws in other countries, such as the United Kingdom Bribery Act (&#8220;UKBA&#8221;), generally prohibit companies and their intermediaries from making improper payments to government officials and/or other persons for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Data Privacy and Security Laws</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various federal, state and foreign laws that protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information by healthcare providers, such as the Health Insurance Portability and Accountability Act, and its implementing regulations, as amended by Health Information Technology for Economic and Clinical Health Act enacted under the American Recovery and Reinvestment Act 2009 (&#8220;ARRA&#8221;) (collectively, &#8220;HIPAA&#8221;), in the United States.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA imposes obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HIPAA also requires the notification of patients, reporting to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), and other compliance actions, in the event of a breach of unsecured Protected Health Information (&#8220;PHI&#8221;). Required notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach, under HIPAA. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, HHS would post the notification on its website, and we may be required to notify the media. Failure to comply with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA privacy and security standards can result in significant civil monetary penalties, and, in certain circumstances, criminal penalties, including imprisonment.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even when HIPAA does not apply other federal and state laws impose security obligations.  For example, according to the Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (&#8220;EU&#8221;), we are subject to laws relating to our collection, control, processing and other use of personal data (i.e. data relating to an identifiable living individual). We process personal data in relation to our operations. We process data of our employees, consultants, certain individuals who may be affiliated with our customers, including physician users of our products and, in the context of clinical investigations, patients. The personal data may include sensitive personal data including health information.  The data privacy regime in the EU includes the EU General Data Protection Regulation, or the GDPR, effective on May 25, 2018 and the E-Privacy Directive 2002/58/EC and the national laws implementing it. Each EU Member State may adopt additional legislation implementing these regulations into its own national data privacy regime and therefore the laws may differ by jurisdiction, sometimes significantly. We need to ensure compliance with the rules in each jurisdiction where we are established or are otherwise subject to local privacy laws.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR is directly applicable in each EU Member State. This should, in principle, result in a more uniform application of data privacy laws across the EU. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. It requires data controllers to be transparent and to disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of information, increases requirements pertaining to pseudonymized (i.e., key-coded) data, introduces mandatory data breach notification requirements and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. Fines for non-compliance with the GDPR will be significant-the greater of &#8364; 20 million or 4% of global turnover. The GDPR provides that EU Member States may introduce further conditions, including limitations, to the processing of genetic, biometric, or health data, which could limit our ability to collect, use and share personal data, or could cause our compliance costs to increase, ultimately having an adverse impact on our business. Each EU Member State may also adopt additional related legislation and guidance in its own national data privacy regime and therefore the laws may differ by jurisdiction, sometimes significantly. We need to ensure compliance with the rules in each jurisdiction where we are established or are otherwise subject to local privacy laws.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the supervision of local data protection authorities in those jurisdictions where we are established or otherwise subject to applicable law. We depend on a number of third parties in relation to our provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions and applicable laws, and that they have sufficient technical and organizational security measures in place to fulfil their related obligations. Where we transfer personal data outside the EEA, we do so in compliance with the relevant data export requirements. We take our data protection obligations seriously, as any improper disclosure, particularly with regard to our customers&#8217; sensitive personal data, could negatively impact our business and/or our reputation. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_49"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party manufacturers to produce our implants and instruments. Our primary supplier for implants is rms Company (&#8220;RMS&#8221;) for iFuse-3D.  To mitigate supply risk, we use a rolling twelve month forecast and take into consideration production lead times to maintain adequate levels of inventory for both our iFuse-3D and iFuse. Most of our instruments have secondary manufacturing suppliers and we continually work with additional manufacturers as our secondary suppliers. Substantially all of our products, including all of our implants, are manufactured in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a non-exclusive Manufacturing, Quality and Supply Agreement with RMS in January 2017, which was amended in July 2020. Pursuant to such agreement, RMS manufactures certain of our implants in accordance with our specifications, including both purchased and sterilized iFuse-3D implants, as well as uncoated machined implants which are subsequently coated to become our finished first generation iFuse implants. While the agreement provides that we are required to purchase the amounts forecasted in a blanket purchase order, we are not required to purchase product in excess of such forecasted amounts. The prices we pay for products are fixed under the agreement provided that if order volumes deviate from forecasted amounts beyond certain thresholds, we or RMS may request to negotiate further price changes. The agreement automatically renews for successive one-year periods; provided, however, the agreement may be terminated early by either party, as specified in the agreement. RMS is currently our only supplier of iFuse-3D implants. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our manufacturing operations, and those of our suppliers, comply with regulations mandated by the FDA, as well as Medical Devices Directive regulations in the EEA. Manufacturing facilities that produce medical devices or component parts intended for distribution world-wide are subject to regulation and periodic planned and unannounced inspection by the FDA and other domestic and international regulatory agencies. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, products we sell are required to be manufactured in compliance with the FDA's Quality System Regulation, codified at 21 CFR Part 820, which covers the methods used in, and the facilities used for, the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage, and shipping. In international markets, we are required to obtain and maintain various quality assurance and quality management certifications, including those issued by DEKRA Certification, B.V., our notified body. DEKRA has issued the following international certifications: Quality Management System ISO13485:2016 for our locations in Santa Clara, California, and Gallarate Italy; Full Quality Assurance Certification for the design and manufacture of iFuse; and a Design Examination certificate for iFuse. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate continuing compliance with applicable regulatory requirements to maintain these certifications and will continue to be periodically inspected by international regulatory authorities for certification purposes. Further, we and certain of our suppliers are required to comply with all applicable regulations and current good manufacturing practices. As set forth above, these FDA and international regulations cover, among other things, the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage, and shipping of our products. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections. If we or our manufacturers fail to adhere to current good manufacturing practice requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory approvals, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations ran at suboptimal capacity as a result of decreased iFuse demand from worldwide restrictions on elective procedures due to the COVID-19 pandemic during the second quarter of 2020. Accordingly, in the second quarter of 2020, we expensed certain labor and overhead costs as incurred which impacted our gross profit and gross margin. We saw a more normalized operations capacity during the second half of 2020 as case volumes began to recover. We may experience similar issues in future quarters due to the COVID-19 pandemic. </span></div><div id="ic5af433463274989b3f39da4377b2b55_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability and Insurance </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture and sale of our products subjects us to the risk of financial exposure to product liability claims. Our products are used in situations in which there is a risk of serious injury or death. We carry insurance policies which we believe to be customary for similar companies in our industry. We cannot assure you that these policies will be sufficient to cover all or substantially all losses that we experience. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We endeavor to maintain executive and organization liability insurance in a form and with aggregate coverage limits that we believe are adequate for our business purposes, but our coverage limits may prove not to be adequate in some circumstances. </span></div><div id="ic5af433463274989b3f39da4377b2b55_2341"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining a sufficient number of skilled employees in each respective department is a key focus of our human capital efforts. Our ability to recruit, develop and retain highly skilled talent is a significant determinant of our success. To facilitate talent attraction, retention, and development, we strive to make SI-BONE an inclusive, diverse, and safe workplace with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits, and health and wellness programs, as well as by programs that build connections between our employees and the communities in which they live and work.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, we had 295 employees, including sales and marketing, product development, general administrative and accounting, both domestically and internationally. As of December 31, 2020, we had a direct field sales organization of 122 in the United States and 20 in Europe. During 2020, our turnover rate was less than 10%.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to realize our mission and vision, we are committed to actively fostering workforce diversity and an environment of cultural inclusion throughout the company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we adopted a Diversity and Inclusion Plan, overseen by our Nominating and Corporate Governance Committee.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our program goal is to increase gender and ethnic diversity in our workforce and leadership over three years, while continuing to provide equal employment opportunities to all candidates and employees without regard to any protected status.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we track gender diversity among our global and U.S. workforce, the percentage of employees above director level who are female, the representation of women and underrepresented communities on our Board of Directors and the diversity of our U.S. workforce.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to maintain a mix of backgrounds, skills and experiences in our board composition to understand and reflect the needs of our diverse stakeholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, three of our nine board members are women and one of our board members self-identifies as Asian American.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety, and Wellness</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health, safety, and wellness of our employees is a priority in which we have always invested and intend to continue to do. We provide our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs. These benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being. Additionally, we offer programs to help support employee physical and mental health by providing tools and resources to help them improve or maintain their health status, encourage engagement in healthy behaviors, and offer choices where possible so they are customized to meet their needs and the needs of their families.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the COVID-19 pandemic, the prioritization of employee health, safety, and wellness took on particular significance in 2020. We implemented significant changes that we determined were in the best interest of our employees, as well as the communities in which we operate, in compliance with government regulations. This includes having the majority of our office-based employees work from home, while implementing additional safety measures for employees continuing critical on-site work or work at customer facilities. A number of employees critical to maintaining our essential operating functions have continued to work from our office in Santa Clara, California. To protect and support our essential team members, we have implemented health and safety measures that include maximizing personal workspaces, adopting shift-based schedules to mitigate contagion risk, providing personal protective equipment (PPE), and instituting mandatory screening before accessing our offices. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide compensation and benefits programs to help meet the needs of our employees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base compensation, these programs, which vary by country, include annual bonuses, restricted stock unit awards, an Employee Stock Purchase Plan, 401(k), healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and flexible work schedules, among many others.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a response to the COVID-19 pandemic, we supported employees with standard merit increases, paid full-time wages to hourly employees when they were not able to access our facilities, and guaranteed certain commissions to our salespeople.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not furlough or terminate any of our employees due to economic concerns arising from COVID-19 in 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring fair and equitable pay is integral to our commitment to our employees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive team and Board of Directors strongly support this commitment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we conducted our first pay equity review with the assistance of an independent consulting firm. The consultant reviewed our employee compensation to determine whether any statistically significant pay differences existed between women and men and between minorities and non-minorities performing similar job functions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The review provided </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information to help us understand whether our compensation structure was appropriate and to identify what improvements can be made. In areas where pay disparities were identified, we conducted further evaluation to determine where adjustments were appropriate.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our Diversity and Inclusion Program, we implemented an applicant tracking system in 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to automating our recruiting and onboarding processes, the applicant tracking system also helps us determine whether there is a mix of new hire candidates in the system from different genders and ethnicities for open positions.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Development</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our employees and the passion, commitment, and professional depth they provide. To enhance employee retention and job satisfaction, we offer ongoing learning and leadership training opportunities that support growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human resources and sales enablement teams transitioned much of our leadership training from in-person sessions to remote learning with the emergence of COVID-19 in 2020. Our scaled learning platforms of on-demand and virtual classroom learning eliminates travel and allows employees to access development at their convenience.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have robust annual performance review processes for reviewing employees&#8217; performance and pay. To support our managers, we train them on conducting effective performance reviews and making compensation recommendations, which take into consideration market pay data and performance, as well as experience in an employee&#8217;s respective role.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that building connections between our employees, their families, and our communities creates a more meaningful, fulfilling, and enjoyable workplace. Through our engagement programs, our employees can pursue their interests and hobbies, connect to volunteering and giving opportunities, and enjoy unique recreational experiences with family members.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees engage in a variety of activities to support their local communities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acknowledge that community involvement is important to our employees and we support their interests in the communities in which they live.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to COVID-19, we hosted events at our corporate campus, including food, clothing, and toy drives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we organized employee cash donations to food banks to support the neediest individuals in San Francisco Bay Area communities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage you to review our ESG Shareholder Letter in the Governance Documents of the Corporate Governance section of our Investor website for more detailed information regarding our human capital programs and initiatives. Nothing on our website, including our ESG Shareholder Letter, shall be deemed part of or incorporated by reference into this Annual Report. </span></div><div id="ic5af433463274989b3f39da4377b2b55_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an &#8220;emerging growth company&#8221; as defined in Section 101 of the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). We will continue to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if our total annual gross revenues are $1.07 billion or more; or (ii) if we issued more than $1.0 billion in non-convertible debt in the past three years;&#160;or (iii) if we become a &#8220;large accelerated filer,&#8221; as defined in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As an emerging growth company under the JOBS Act, we can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company, we are also exempt from Section 404(b) of the Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the Exchange Act. Section 404(b) of the Sarbanes-Oxley Act of 2002 requires a public company&#8217;s auditor to attest to, and report on, management&#8217;s assessment of its internal controls. Sections 14A(a) and (b) of the Exchange Act, implemented by Section 951 of the Dodd-Frank Act, require companies to hold shareholder advisory votes on executive compensation and golden parachute compensation. As long as we qualify as an emerging growth company, we will not be required to comply with the requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the Exchange Act.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_61"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as a &#8220;smaller reporting company&#8221; as defined under Rule&#160;12b&#8209;2 of the Exchange Act. We will continue to qualify as a smaller reporting company if: (i) our public float is less than $250.0 million; or (ii) our annual revenues is less than $100.0 million and our public float is less than $700.0 million. As per guidance, we determine whether we qualify as a smaller reporting company annually as of the last business day of our second fiscal quarter. As a smaller reporting company, we may use the smaller reporting company scaled disclosure accommodations of Regulation S-K and S-X in our filings, including among others:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">two years of income statements rather than three years as required by Rule 8-02 of Regulation S-X;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">two-year management discussions and analysis comparison rather than three-year comparison as required by Item 303 of Regulation S-K;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no requirement to provide selected financial data table required by Item 301 of Regulation S-K;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no requirement to provide market risk disclosures required by Item 305 of Regulation S-K; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no requirement to provide supplemental financial information required by Item 302 of Regulation S-K; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">less extensive narrative disclosure than required of other reporting companies, particularly in the description of executive compensation as required by Item 402 of Regulation S-K.</span></div><div id="ic5af433463274989b3f39da4377b2b55_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company History </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE was founded in 2008 by the main inventor of iFuse, orthopedist Mark A. Reiley, M.D., our President, Chief Executive Officer, and Chairman, Jeffrey W. Dunn, and orthopedic surgeon Leonard Rudolf, M.D. Dr. Reiley previously invented balloon kyphoplasty and founded Kyphon Inc., which was sold to Medtronic plc in 2007. Dr. Reiley also invented the INBONE total ankle replacement system, which was sold to Wright Medical Technology, Inc. in 2008. </span></div><div id="ic5af433463274989b3f39da4377b2b55_67"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We were incorporated in March 2008 in Delaware. Our principal executive offices are located at 471 El Camino Real, Suite 101, Santa Clara, California 95050 and our telephone number is (408)&#160;207-0700.&#160;Our website address is&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline">www.si-bone.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.&#160;We completed our initial public offering in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">October&#160;2018, and our common stock is listed on the Nasdaq Global Market under the symbol &#8220;SIBN.&#8221;  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our Annual Report on Form 10-K, Quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website. The information contained on or that can be accessed through our website is not incorporated by reference into this report, and you should not consider information on our website to be part of this report. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="ic5af433463274989b3f39da4377b2b55_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Investors should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and our stockholders may lose all or part of their investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risk Factor Summary</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have incurred significant operating losses since inception, we expect to continue to incur operating losses in the future and we may not be able to achieve or sustain future profitability;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Epidemic diseases, or the perception of their effects, or extreme weather events have had and could have (or, in the case of the COVID-19 pandemic, will continue to have during its duration) a material adverse effect on our business, financial condition, results of operations, or cash flows;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If hospitals, surgeons, and other healthcare providers are unable to obtain and maintain coverage and reimbursement from third-party payors for procedures performed using our products, adoption of our products may be delayed, and it is unlikely that they will gain further acceptance;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If healthcare payors reverse decisions to cover minimally invasive sacroiliac joint fusion exclusively when performed with iFuse and choose to reimburse for procedures performed with competitive products, our market share could decline, adversely affecting our revenues;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not be able to demonstrate to physicians that iFuse is an attractive alternative to our competitors&#8217; products and that our procedure is an attractive alternative to existing surgical and non-surgical treatments of the sacroiliac joint; </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Surgeons and payors may not find our clinical evidence to be compelling, which could limit our sales and revenue, and ongoing and future research may prove our products to be less safe and effective than currently thought;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Pricing pressure from our competitors, changes in third-party coverage and reimbursement, healthcare provider consolidation, payor consolidation and the presence of &#8220;physician-owned distributorships&#8221; may impact our ability to sell our product at prices necessary to support our current business strategies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Practice trends or other factors, including the COVID-19 pandemic, may cause procedures to shift from the hospital environment to ambulatory surgical centers, or ASCs, where pressure on the prices of our products is generally more acute;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales and operating results may be adversely affected;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We currently manufacture and sell a single family of products focused on procedures, the goal of which is to stabilize and fuse the sacroiliac joint. Reliance on a single family of products and single procedure could negatively affect our results of operations and financial condition;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If clinical experience with our iFuse Bedrock technique does not result in positive outcomes for patients, or if clinical trials involving the use of iFuse Bedrock fail to show meaningful patient benefit, sales of our iFuse implants could be adversely impacted;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to maintain our network of direct sales representatives and third-party distributors, we may not be able to generate anticipated sales;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are dependent on a limited number of third-party suppliers, some of them single-source and some of them in single locations, for most of our products and components, and the loss of any of these suppliers, or their inability to provide us with an adequate supply of materials in a timely and cost-effective manner, could materially adversely affect our business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We, our suppliers, and our third-party manufacturers are subject to extensive governmental regulation both in the U.S. and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">abroad, and failure to comply with applicable requirements could cause our business to suffer;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We and our sales representatives must comply with U.S. federal and state fraud and abuse laws, including those relating to healthcare provider kickbacks and false claims for reimbursement, and other applicable federal and state healthcare laws, as well as equivalent foreign laws, and failure to comply could negatively affect our business; and</span></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be impaired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Our Industry</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, we expect to continue to incur operating losses in the future, and we may not be able to achieve or sustain future profitability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception in 2008. For the years ended December 31, 2020 and 2019, we had net losses of $43.7 million and $38.4 million, respectively. As of December 31, 2020, we had an accumulated deficit of $239.3 million. We have financed our operations primarily through the net proceeds of our public offerings of our common stock, private placements of equity securities, certain debt-related financing arrangements, and from sales of our products. We have devoted substantially all of our resources to research and development of our products, sales and marketing activities, investments in training and educating surgeons and other healthcare providers, and clinical and regulatory matters for our products. There can be no assurances that we will be able to generate sufficient revenue from our existing products or from any of our product candidates in development, and to transition to profitability and generate consistent positive cash flows, and even if we are able to do so, our ability to do so has been delayed by the COVID-19 pandemic. As COVID-19-related restrictions are lifted and as we are able to resume more normalized levels of operations, we expect that our operating expenses will continue to increase as we continue to build our commercial infrastructure, develop, enhance, and commercialize our existing and new products. As a result, we expect to continue to incur operating losses for the foreseeable future and may never achieve profitability. Furthermore, even if we do achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis. If we do not achieve profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our expected future capital requirements may depend on many factors including expanding our surgeon base, the expansion of our sales force, and the timing and extent of spending on the development of our technology to increase our product offerings. We may need additional funding to fund our operations but additional funds may not be available to us on acceptable terms on a timely basis, if at all. We may seek funds through borrowings or through additional rounds of financing, including private or public equity or debt offerings. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments, and engage in certain merger, consolidation or asset sale transactions. Any future debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Furthermore, we cannot be certain that additional funding will be available on acceptable terms, if at all. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to curtail planned activities to reduce costs, which will likely harm our ability to execute on our business plan and continue operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Epidemic diseases, or the perception of their effects, or extreme weather events have had and could have (or, in the case of the COVID-19 pandemic, will continue to have during its duration) a material adverse effect on our business, financial condition, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outbreaks of infectious diseases, such as COVID-19, and historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, or the H1N1 influenza virus, could divert medical resources and priorities towards the treatment of that disease. An outbreak of an infectious disease, or continued escalation of the outbreak of COVID-19 could also negatively affect hospital admission rates and the decision by patients to undergo elective surgery, which could decrease demand for procedures using our iFuse implants and cause other disruptions to our business. Business disruptions could include disruptions or restrictions on our ability to travel or to distribute our products, government orders suspending the performance of elective surgical procedures such as the iFuse procedure, inability of our customers to meet their financial commitments due to strain on the healthcare system, as well as temporary closures of our facilities or the facilities of our suppliers and their contract manufacturers, and a reduction in the business hours of hospitals and ambulatory surgery centers. Any disruption of our suppliers and their contract manufacturers or our customers would likely impact our sales and operating results. In addition, a significant outbreak of an infectious disease in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our products. Any of these events could negatively impact the number of procedures using our iFuse implants that are performed and have a material adverse effect on our business, financial condition, results of operations, or cash flows.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, COVID-19 has had, and we expect will continue to have, an adverse impact on our operations as a result of preventive and precautionary measures that we, other businesses, health systems and governments are taking. Due to these impacts and measures, we have experienced and expect to continue to experience significant and unpredictable reductions in the demand for our products, negatively impacted hospital admission rates and the decision by patients to undergo elective surgery, each of which has decreased and may continue to impact the demand for procedures using our iFuse implants. These developments and effects are expected to continue and may also significantly affect our business across the United States and other countries where COVID-19 has spread and may continue to spread. There are numerous uncertainties associated with this COVID-19 outbreak, including the number of individuals who will become infected, when vaccines or one or more therapies that mitigate the effect of the virus will be widely available, the extent of the protective and preventative measures that have been put in place by both governmental entities and other businesses and those that may be put in place in the future, the effect that testing for COVID-19 and antibodies will enable relaxation of protective measures for a subset of the population, and numerous other uncertainties. We intend to continue to execute on our strategic plans and operational initiatives during the COVID-19 outbreak. However, the aforementioned uncertainties may result in delays or modifications to these plans and initiatives.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing travel restrictions, and the risk that countries may continue to close borders, impose prolonged quarantines, and further restrict travel, limit our ability to reach surgeons with our goal of increasing surgeon activity by educating them to include the sacroiliac joint in their differential diagnosis of lower back pain and to regularly perform the iFuse procedure for patients for whom the procedure is indicated. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the COVID-19 pandemic has adversely affected, and may continue to adversely affect, the economies and financial markets of many countries, which may result in a period of regional, national, and global economic slowdown or regional, national, or global recessions that could curtail or delay spending by hospitals and affect demand for our products as well as increased risk of customer defaults or delays in payments. These market disruptions could impair our ability to raise capital, should our business experience a prolonged period of reduced revenue requiring additional capital to sustain the business. COVID-19 and the current financial, economic, and capital markets environment, and future developments in these and other areas present material uncertainty and risk with respect to our performance, financial condition, results of operations, and cash flows. Due to the uncertain scope and duration of the pandemic and uncertain timing of global recovery and economic normalization, we are unable to estimate the long-term impacts on our operations and financial results. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The existence and further duration of the COVID-19 pandemic may also further exacerbate certain of the risks described below.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If hospitals, surgeons, and other healthcare providers are unable to obtain and maintain coverage and reimbursement from third-party payors for procedures performed using our products, adoption of our products may be delayed, and it is unlikely that they will gain further acceptance.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maintaining and growing sales of our products depends on the availability of adequate coverage and reimbursement from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans, and managed care programs. Hospitals, surgeons, and other healthcare providers that purchase or use medical devices generally rely on third-party payors to pay for all or part of the costs and fees associated with the procedures performed with these devices.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adequate coverage and reimbursement for procedures performed with our products is central to the acceptance of our current and future products. We may be unable to sell our products on a profitable basis if third-party payors deny coverage or reduce their current levels of payment, or if reimbursement levels are insufficient to support use of our products or compensate surgeons for their time spent diagnosing patients and performing procedures using our products. For example, our sales decreased significantly after minimally invasive sacroiliac joint fusion was assigned to a Category III Current Procedural Terminology (&#8220;CPT&#8221;) code effective July&#160;1, 2013. After implementation of this Category III CPT Code, surgeons were no longer able to consistently obtain reimbursement for procedures performed using our products. However, effective January&#160;1, 2015, minimally invasive sacroiliac joint fusion was assigned to a Category I CPT Code.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many private payors refer to coverage decisions and payment amounts determined by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), which administers the Medicare program, as guidelines for setting their coverage and reimbursement policies. By December&#160;31, 2016, all Medicare Administrative Contractors were regularly reimbursing for minimally invasive sacroiliac joint fusion. Private payors that do not follow the Medicare guidelines may adopt different coverage and reimbursement policies for procedures performed with our products. Private commercial payors have been slower to adopt positive coverage policies for minimally invasive sacroiliac joint fusion, and some private payors still have policies that treat the procedure as experimental or investigational and do not regularly reimburse for the procedure. Future action by CMS or third-party payors may further reduce the availability of payments to physicians, outpatient surgery centers, and/or hospitals for procedures using our products.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The healthcare industry in the United States has experienced a trend toward cost containment as government and private insurers seek to control healthcare costs. Payors are imposing lower payment rates and negotiating reduced contract rates with service providers and being increasingly selective about the technologies and procedures they chose to cover. For example, several Blue Cross Blue Shield payors have adopted policies that treat 3D-printed orthopedic implants that come in standard sizes, rather than customized to the patient&#8217;s anatomy, such as our iFuse-3D implant, as experimental and investigational and therefore not eligible for reimbursement. There can be no guarantee that we will be able to provide the scientific and clinical data necessary to overcome these policies. Such policies may contribute to a decrease in sales of our iFuse-3D implants. Payors may adopt policies in the future restricting access to medical technologies like ours and/or the procedures performed using such technologies. Therefore, we cannot be certain that the procedures performed with each of our products will be reimbursed. There can be no guarantee that, should we introduce additional products in the future, payors will cover those products or the procedures in which they are used.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Market acceptance of our products in foreign markets may depend, in part, upon the availability of coverage and reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment systems in international markets vary significantly by country and include both government-sponsored healthcare and private insurance. We may not obtain additional international coverage and reimbursement approvals in a timely manner, if at all. Our failure to receive such approvals would negatively impact market acceptance of our products in the international markets in which those approvals are sought.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the reimbursement provided by third-party payors to hospitals, surgeons, and other healthcare providers for procedures performed using our products is insufficient, adoption and use of our products and the prices paid for our implants may decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The sales of our products depend in part on the availability of coverage and reimbursement from third-party payors such as government health administration authorities, private health insurers, health maintenance organizations, and other healthcare-related organizations. When an iFuse procedure is performed, both the surgeon and the healthcare facility, either a hospital or ambulatory surgical center, submit claims for reimbursement to the healthcare payor. Generally, the facility obtains a lump sum payment, or facility fee, for minimally invasive sacroiliac joint fusions. Our products are purchased by the facility, along with other supplies used in the procedure. The facility must also pay for its own fixed costs of operation, including certain operating room personnel involved in the procedure. If these costs exceed the facility fee reimbursement, the facility&#8217;s managers may discourage or restrict surgeons from performing the procedure in the facility or using certain technologies, such as our iFuse implants, to perform the procedure.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2021, the national average Medicare payment to hospital outpatient departments is $15,868 and the Medicare payment to an ambulatory surgery center for a sacroiliac joint fusion is $12,974. We believe that payments to facilities are generally adequate for these facilities to offer the iFuse procedure. However, there can be no guarantee that these facility fee payments will not decline in the future. The number of iFuse procedures performed and the prices paid for our implants may in the future decline if payments to facilities for minimally invasive sacroiliac joint fusions decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Surgeons are reimbursed separately for their professional time and effort to perform a surgical procedure. Prior to reassignment of minimally invasive sacroiliac joint fusion to a Category III CPT Code, the national average Medicare physician fee schedule payment to surgeons for CPT codes commonly used to submit claims for reimbursement for the iFuse procedure was approximately $1,000 and the procedure was commonly covered by both government and private commercial payors in the United States. Effective January 1, 2021, the average Medicare payment for the Category I CPT code for minimally invasive SI joint fusion is $888. Many private payors set their payment amounts with reference to the Medicare payment, often approximately 10% to 33% higher than the Medicare payment for a procedure. For some governmental programs, such as Medicaid, coverage and reimbursement differ from state to state, and some state Medicaid programs may not pay an adequate amount for the procedures performed with our products, if any payment is made at all.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that some surgeons may continue to view the Medicare and commercial reimbursement amounts as insufficient for the procedure, given the work effort involved with the procedure, including the time to diagnose the patient and obtain prior authorization from the patient&#8217;s health insurer if necessary. Many private payors require extensive documentation of a multi-step diagnosis before authorizing minimally invasive sacroiliac joint fusion for a patient. We believe that some private payors apply their own coverage policies and criteria inconsistently, and surgeons may not be able to consistently have minimally invasive sacroiliac fusions approved and covered. The perception by physicians that the reimbursement for minimally invasive sacroiliac joint fusion is insufficient to compensate them for the work required, including diagnosis, documentation, obtaining payor approval for the procedure, and burden on their office staff, may negatively affect the number of procedures performed and may therefore adversely affect our revenues.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recent political, economic, and regulatory influences are subjecting the healthcare industry to fundamental changes that can impact coverage and reimbursement from third-party payors. For example, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2011, or collectively, the Affordable Care Act, among other things, reduced and/or limited Medicare reimbursement to certain providers. Legislative changes to the Affordable Care Act remain possible. We expect that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our existing products. There have been executive, legislative and judicial challenges to the Affordable Care Act. For example, the United States Supreme Court is currently reviewing the constitutionality of the Affordable Care Act, but it is unclear when a decision will be made. Other federal laws further reduce Medicare&#8217;s payments to providers by two percent through 2030. However, COVID-19 relief support legislation suspended the 2% Medicare reductions from May 1, 2020 through March 31, 2021. These reductions may reduce reimbursement for procedures performed using our products, which could potentially negatively impact our revenue, and may reduce providers&#8217; revenues or profits, which could affect their ability to purchase new technologies. Both the federal and state governments in the U.S. and foreign governments continue to propose and pass new legislation and regulations designed to contain or reduce the cost of healthcare. Such legislation and regulations may result in decreased reimbursement for medical devices, which may further exacerbate industry-wide pressure to reduce the prices charged for medical devices. This could harm our ability to market our products and generate sales, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If healthcare payors reverse decisions to cover minimally invasive sacroiliac joint fusion exclusively when performed with iFuse and choose to reimburse for procedures performed with competitive products, our market share could decline, adversely affecting our revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, 37 of the largest 65 U.S. payors that we track and target have issued positive coverage policies covering the patented triangular design of our iFuse implants and excluding coverage of other products that are intended to fuse the sacroiliac joint because of the clinical evidence supporting the use of iFuse and the lack of clinical evidence supporting the use of other products. Additionally, the public hospital system in France initiated coverage for iFuse exclusively beginning September&#160;6, 2018. We believe that payors have adopted these exclusive coverage decisions due to the strength of our clinical evidence and in part due to recommendations of specialty benefit managers and healthcare technology assessment organizations. In 2018, AIM Specialty Health, Blue Cross Blue Shield Association Evidence Street, and eviCore Healthcare published positive coverage recommendations to their constituents and payor customers, recommending that iFuse be covered exclusively. Clinical trials of the type and size necessary to offer evidence of the safety and efficacy of competing products could be performed and could show that other products for sacroiliac joint fusion are as effective as, or more effective than, iFuse. Payors could also abandon their decisions to cover iFuse exclusively for other reasons.  If healthcare payors covering a significant number of covered lives reverse their policies of covering minimally invasive sacroiliac joint fusion exclusively when performed with the iFuse system, sales of our iFuse implants could decline or fail to grow, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to demonstrate to physicians that iFuse is an attractive alternative to our competitors&#8217; products and that our procedure is an attractive alternative to existing surgical and non-surgical treatments of the sacroiliac joint.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Surgeons, in consultation with their patients, play the primary role in determining the course of treatment and, ultimately, any product that will be used in treatment. In order for us to sell our iFuse system successfully, we must demonstrate to surgeons through education and training that treatment with iFuse is beneficial, safe, and cost-effective for patients as compared to our competitors&#8217; products. If we are not successful in demonstrating the merits of iFuse to surgeons, their use of our products may decline, adversely affecting our revenues and profitability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Historically, most spine surgeons did not include an evaluation of the sacroiliac joint in their diagnostic work-up because they did not have an adequate surgical procedure to perform for patients diagnosed with sacroiliac joint dysfunction. As a result, some patients with lower back pain resulting from sacroiliac joint dysfunction have been misdiagnosed. We believe that educating surgeons and other healthcare professionals about the clinical merits and patient benefits of iFuse is an important element of building our business. If we fail to effectively educate surgeons and other medical professionals, they may not include a sacroiliac joint evaluation as part of their diagnosis and, as a result, those patients may continue to receive unnecessary surgical procedures or only non-surgical treatment.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Surgeons may also hesitate to change their medical treatment practices for other reasons, including the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;lack of experience with minimally invasive procedures;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;perceived liability risks generally associated with the use of new products and procedures;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;costs associated with the purchase of new products; and </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;time commitment that may be required for training.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, we believe surgeons will not widely use iFuse unless they determine, based on experience, clinical data, and published peer-reviewed publications, that surgical intervention provides benefits or is an attractive alternative to non-surgical treatments of sacroiliac joint dysfunction. In addition, we believe support of our products relies heavily on long-term data showing their benefits. If we are unable to provide that data, surgeons may not use our products. In such circumstances, we may not achieve expected sales and may be unable to achieve profitability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many patients with sacroiliac joint dysfunction are cared for by pain physicians, who are generally trained as anesthesiologists or physical medicine and rehabilitation specialists. Pain physicians often offer a variety of non-surgical and surgical interventions to sacroiliac joint dysfunction patients, including, but not limited to, steroid injections, radiofrequency ablation of the nerves serving the sacroiliac joint and implantation of neurostimulation devices and other products intended to treat the sacroiliac joint or the pain it can cause. Our professional education program seeks to teach pain physicians, and other health care providers, about the benefits of iFuse, in order to prompt these providers to refer their patients with sacroiliac joint dysfunction to surgeons who have been trained to perform the iFuse procedure. These providers may, however, prefer to continue to treat these patients with the interventions they offer. If we are unable to demonstrate to potential referring health care providers of the comparative benefits of iFuse, and we are therefore unable to prompt sufficient numbers of these providers to refer their patients with sacroiliac joint dysfunction for treatment by surgeons trained to perform the iFuse procedure, sales of our iFuse implants could decline or fail to grow, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Surgeons and payors may not find our clinical evidence to be compelling, which could limit our sales and revenue, and ongoing and future research may prove our products to be less safe and effective than currently thought.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The products we currently market in the United States have either received premarket clearance under Section&#160;510(k) of the United States. Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), or are exempt from premarket review. Those marketed in the European Union (&#8220;EU&#8221;) have been the subject of a CE Certificate of Conformity. The 510(k) clearance process of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) requires us to document that our product is &#8220;substantially equivalent&#8221; to another 510(k)-cleared product. The 510(k) process is shorter and typically requires the submission of less supporting documentation than other FDA approval processes, such as a premarket approval (&#8220;PMA&#8221;), and does not usually require pre-clinical or clinical studies. Additionally, to date, we have not been required to complete clinical studies in connection with the sale of our products outside the United States. As a result, while there are a number of published studies relating to iFuse and minimally invasive sacroiliac joint surgery that support the safety and effectiveness of our products and the benefits they offer, our clinical studies may lack the size and scope of randomized controlled clinical trials required to support approval of a PMA. For these reasons, surgeons may be slow to adopt our products, third-party payors may be slow to provide coverage, and we may be subject to greater regulatory and product liability risks. Further, future patient studies or clinical experience may indicate that treatment with our products does not improve patient outcomes. Such results would slow the adoption of our products by surgeons, significantly reduce our ability to achieve expected sales, and could prevent us from achieving profitability. Moreover, if future results and experience indicate that our products cause unexpected or serious complications or other unforeseen negative effects, we could be subject to mandatory product recalls, suspension, or withdrawal of FDA clearance, and suspension, variation, or withdrawal of our CE Certificates of Conformity, significant legal liability or harm to our business reputation, which could have a material adverse effect on our results or operations and financial condition. Similar risks apply to product approvals and registrations in other countries outside the Unites States and the EU as well.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pricing pressure from our competitors, changes in third-party coverage and reimbursement, healthcare provider consolidation, payor consolidation and the presence of &#8220;physician-owned distributorships&#8221; may impact our ability to sell our product at prices necessary to support our current business strategies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If competitive forces drive down the prices we are able to charge for our product, our profit margins will shrink, which will adversely affect our ability to invest in and maintain and grow our market share. The sacroiliac joint fusion market has attracted numerous new companies and technologies. As a result of this increased competition, we believe there will be continuing increased pricing pressure, resulting in lower gross margins, with respect to our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even to the extent our product and procedures using our product are currently covered and reimbursed by third-party private and public payors, adverse changes in coverage and reimbursement policies that affect our products, discounts, and number of implants used may also drive our prices down and harm our ability to market and sell our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are unable to predict what changes will be made to the reimbursement methodologies used by third-party payors. We cannot be certain that under current and future payment systems, in which healthcare providers may be reimbursed a set amount based on the type of procedure performed, such as those utilized by Medicare and in many privately managed care systems, the cost of our products will be justified and incorporated into the overall cost of the procedure. In addition, to the extent there is a shift from inpatient setting to outpatient settings, we may experience increased pricing pressure.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidation in the healthcare industry, including both third-party payors and healthcare providers, could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, results of operations, or financial condition. Because healthcare costs have risen significantly over the past several years, numerous initiatives and reforms initiated by legislators, regulators, and third-party payors to curb these costs have resulted in a consolidation trend in the healthcare industry to aggregate purchasing power. As the healthcare industry consolidates, competition to provide products and services to industry participants has become and will continue to become more intense. This in turn has resulted and will likely continue to result in greater pricing pressures and the exclusion of certain suppliers from important market segments as group purchasing organizations, independent delivery networks, and large single accounts continue to use their market power to consolidate purchasing decisions for hospitals. We expect that market demand, government regulation, third-party coverage, and reimbursement policies and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may reduce competition, exert further downward pressure on the prices of our products, and adversely impact our business, results of operations, or financial condition. As we continue to expand into international markets, we will face similar risks relating to adverse changes in coverage and reimbursement procedures and policies in those markets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Physician-owned distributorships (&#8220;POD&#8221;), are medical device distributors that are owned, directly or indirectly, by physicians. These physicians profit from selling or arranging the sale of medical devices for use in procedures they perform on their own patients at hospitals that purchase the devices from the POD. We do not engage with PODs. The proliferation of PODs could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships and therefore choose to use competing products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Practice trends or other factors, including the COVID-19 pandemic, may cause procedures to shift from the hospital environment to ambulatory surgical centers, or ASCs, where pressure on the prices of our products is generally more acute.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To protect health care professionals involved in surgical care and their patients, we anticipate that more outpatient eligible procedures will be performed in ASCs during the COVID-19 pandemic, and as its acuity declines and the healthcare system returns to a more normalized state. Since patients do not stay overnight in ASCs and COVID-19 patients would not otherwise be treated in ASCs, it is likely that the ASC will be viewed as a safer site of service for patients and health care providers, where the risk of transmission of the novel coronavirus can be more effectively controlled. Because ASC facility fee reimbursement is typically less than facility fee reimbursement for hospitals, we typically experience more pressure on the pricing of our products by ASCs than by hospitals, and the average price for which we sell our products to ASCs is less than the average prices we charge to hospitals. An accelerated shift of procedures using our products to ASCs as a result of the COVID-19 pandemic could adversely impact the average selling prices of our products and our revenues could suffer as a result.  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales and operating results may be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our currently marketed products are, and any future products we commercialize will likely be, subject to intense competition. Our field is subject to rapid change and highly sensitive to the introduction of new products or other market activities of industry participants. Our ability to compete successfully will depend on our ability to develop proprietary products that reach the market in a timely manner, receive adequate coverage and reimbursement from third-party payors, and are safer, less invasive, and more effective than alternatives available for similar purposes as demonstrated in peer-reviewed clinical publications. Because of the size of the potential market, we anticipate that other companies will dedicate significant resources to developing competing products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The number of competitors that we are aware of marketing sacroiliac joint fusion products in the Unites States has grown from zero to more than 20 since 2008. Some of our current and potential competitors are major medical device companies that have substantially greater financial, technical, and marketing resources than we do, and they may succeed in developing products that would render our products obsolete or noncompetitive. In addition, many of these competitors have significantly longer operating history and more established reputations than we do. Some of these companies sell a broad suite of products that can be used together in the operating room in order to facilitate surgery, such as surgical imaging, navigation and robotic systems, or a large number of implants intended to treat different conditions affecting the spine and pelvis.  The ability of these competitors to sell these products together or as part of larger purchasing arrangements may put us at a disadvantage.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the Unites States, we believe that our primary competitors currently are Medtronic plc and Globus Medical, Inc. Our primary competitors in Europe are Globus Medical, Inc. and SIGNUS Medizintechnik GmbH. At any time, these or other industry participants may develop alternative treatments, products or procedures for the treatment of the sacroiliac joint that compete directly or indirectly with our products. The may also develop and patent processes or products earlier than we can, or obtain domestic and international regulatory clearances or approvals and CE Certificates of Conformity for competing products in the European Economic Area (&#8220;EEA&#8221;), more rapidly than we can, which could impair our ability to develop and commercialize similar processes or products. If alternative treatments are, or are perceived to be, superior to our products, sales of our products and our results of operations could be negatively affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of our competitors are considerably larger than us, or are subsidiaries of larger companies. These competitors may enjoy several competitive advantages over us, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;greater financial, human, and other resources for product research and development, sales and marketing, and legal matters;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;significantly greater name recognition;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;established relationships with surgeons, hospitals, and other healthcare providers;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;large and established sales and marketing and distribution networks;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;greater experience in obtaining and maintaining domestic and international regulatory clearances or approvals, or CE Certificates of Conformity for products and product enhancements;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;more expansive portfolios of intellectual property rights; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;greater ability to cross-sell their products or to incentivize hospitals or surgeons to use their products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New participants have increasingly entered the medical device industry. Many of these new competitors specialize in a specific product or focus on a particular market segment, making it more difficult for us to increase our overall market position. The frequent introduction by competitors of products that are or claim to be superior to our current or planned future products may make it difficult to differentiate the benefits of our products over competing products. In addition, the entry of multiple new products and competitors may lead some of our competitors to employ pricing strategies that could adversely affect the pricing of our products and pricing in the market generally.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, without the timely introduction of new products and enhancements, our products may become obsolete over time. If we are unable to develop innovative new products, maintain competitive pricing, and offer products that surgeons and other physicians perceive to be as reliable as those of our competitors, our market share or product margins could decrease, thereby harming our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We currently manufacture and sell a single family of products focused on procedures, the goal of which is to stabilize and fuse the sacroiliac joint. Reliance on a single family of products and single procedure could negatively affect our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of our revenue comes from the sale of iFuse-3D and iFuse implants, and related tools and instruments. Therefore, we are dependent on widespread market adoption of iFuse and we will continue to be dependent on the success of this single product family for some time. There can be no assurance that iFuse will maintain a substantial degree of market acceptance among surgeons, patients or healthcare providers. Our failure to successfully grow the market for iFuse and increase our share within that market or any other event impeding our ability to sell iFuse, could adversely affect our results of operations, financial condition and continuing operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If clinical experience with our iFuse Bedrock technique does not result in positive outcomes for patients, or if clinical trials involving the use of iFuse Bedrock fail to show meaningful patient benefit, sales of our iFuse implants could be adversely impacted.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2018, we introduced our iFuse Bedrock technique, in which spine surgeons place iFuse implants across the sacroiliac joint using a different surgical approach to treat sacroiliac joint dysfunction at the same time they are fusing multiple levels of the spine above and affixing those spinal fusion devices to the pelvis.  In April 2019, the FDA cleared promotion of iFuse Bedrock for a broader and more general purpose, to provide additional stability and immobilization of the sacroiliac joint in connection with a thoracolumbar fusion procedure.  To date, clinical experience with the iFuse Bedrock technique is limited and we have yet to complete a clinical trial to evaluate the iFuse Bedrock technique.  Surgeons do not know if the addition of iFuse implants to the implants used to fuse multiple levels of the lumbar spine will result in patient benefit.  If surgeons' clinical experience with iFuse Bedrock is not positive, or if our clinical trials do not show meaningful benefits to the patients undergoing this procedure, sale of our iFuse implants for this indication could be adversely impacted, which could negatively affect our operations and financial condition.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain our network of direct sales representatives and third-party distributors, we may not be able to generate anticipated sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our U.S. sales force consisted of 64 territory sales managers and 58 clinical support specialists directly employed by us and 41 third-party distributors. As of December 31, 2020, our international sales force consisted of 20 sales representatives directly employed by us and 31 exclusive third-party distributors, which together have had sales in 35 countries through December 31, 2020. Our operating results are directly dependent upon the sales and marketing efforts of both our direct sales force and of our third-party distributors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we launch new products and increase our marketing efforts with respect to existing products, we will need to expand the reach of our marketing and sales networks. Our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled direct sales representatives and third-party distributors with significant technical knowledge in various areas, such as spine health and treatment. New hires require training and take time to achieve full productivity. If we fail to train new hires adequately, or if we experience high turnover in our sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. Our intention is for our direct sales representatives and third-party distributors to develop long-lasting relationships with the surgeons they serve. If our direct sales representatives or third-party distributors fail to adequately promote, market and sell our products or decide to leave or cease to do business with us, our sales could significantly decrease.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face significant challenges and risks in managing our geographically dispersed distribution network and retaining the individuals who make up that network. Some of our international third-party distributors account for a significant portion of our international sales volume, and if any such third-party distributor were to cease to distribute our products, our sales could be adversely affected. In such a situation, we may need to seek alternative third-party distributors or increase our reliance on our direct sales representatives, which may not prevent our sales from being adversely affected. If a direct sales representative or third-party distributor were to depart and be retained by one of our competitors, we may be unable to prevent them from helping competitors solicit business from our existing customers, which could further adversely affect our sales. Because of the intense competition for their services, we may be unable to recruit or retain additional qualified third-party distributors or to hire additional direct sales representatives to work with us. Furthermore, we may not be able to enter into agreements with them on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified direct sales representatives or third-party distributors would prevent us from expanding our business and generating sales.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to expand our sales and marketing capabilities domestically and internationally, we may not be able to effectively commercialize our products, which would adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are dependent upon the continued services of key members of our senior management and a limited number of key advisors and personnel. The loss of members of our senior management team, key advisors or personnel, or our inability to attract or retain other qualified personnel or advisors, could have a material adverse effect on our business, results of operations, and financial condition. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees. In addition, several of the members of our executive management team are not subject to non-competition agreements that restrict their ability to compete with us. Accordingly, the adverse effect resulting from the loss of certain executives could be compounded by our inability to prevent them from competing with us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our products may have undesirable side effects which may require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unforeseen adverse events related to our products could arise either during clinical development or, if cleared, approved, or subject to CE Certificate of Conformity, after the product has been marketed. In clinical research, the most common adverse event related to our implant was leg pain resulting from misplacement. The most common adverse event for our implant procedure has been minor wound infections. Additional adverse effects from iFuse or any of our other products could arise either during clinical development or, if approved, cleared, or subject to CE Certificate of Conformity, after the product has been marketed.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or others later identify adverse events caused by our products:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;sales of the product may decrease significantly, and we may not achieve the anticipated market share;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;regulatory authorities or our Notified Body may require changes to the labeling of our product. This may include the addition of labeling statements, specific warnings, and contraindications and issuing field alerts to physicians and patients;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may be required to change instructions regarding the way the product is implanted or conduct additional clinical trials;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may be subject to limitations on how we may promote the product;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;regulatory authorities may require us to temporarily or permanently take our approved product off the market or to conduct other field safety corrective actions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may be required to modify our product;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may be subject to litigation fines or product liability claims; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our reputation may suffer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unfavorable media reports or other negative publicity concerning both alleged improper methods of tissue recovery from donors and disease transmission from donated tissue could limit widespread acceptance of some of our products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In late-2019, we introduced iFuse Bone, an implantable bone product manufactured from sterilized recovered cadaveric bone tissue, to meet the demand of some of our surgeon customers to use implantable bone products to support and augment the patient's own bone tissue in orthopedic procedures. Unfavorable reports of improper or illegal tissue recovery practices, both in the United States and internationally, as well as incidents of improperly processed tissue leading to the transmission of disease, may affect the rate of future tissue donation and market acceptance of technologies incorporating human tissue. In addition, negative publicity could cause the families of potential donors to become reluctant to donate tissue to for-profit tissue processors. For example, the media has reported examples of alleged illegal harvesting of body parts from cadavers and resulting recalls conducted by certain companies selling human tissue-based products affected by the alleged illegal harvesting. These reports and others could have a negative effect on sales of iFuse Bone.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Various factors outside our direct control may adversely affect manufacturing, sterilization, and distribution of our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacture, sterilization, and distribution of our products is challenging. Changes that our suppliers may make outside the purview of our direct control can have an impact on our processes, quality of our products, and the successful delivery of products to our customers. Mistakes and mishandling are not uncommon and can affect supply and delivery. Some of these risks include:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;failure to complete sterilization on time or in compliance with the required regulatory standards;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;transportation and import and export risk;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;delays in analytical results or failure of analytical techniques that we will depend on for quality control and release of products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;large-scale epidemics of communicable diseases such as COVID-19;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;natural disasters, labor disputes, financial distress, raw material availability, issues with facilities and equipment, or other forms of disruption to business operations affecting our manufacturers or suppliers; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;latent defects that may become apparent after products have been released and that may result in a recall or field safety corrective action with respect to such products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks were to materialize, our ability to provide our products to customers on a timely basis could be adversely impacted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are dependent on a limited number of third-party suppliers, some of them single-source and some of them in single locations, for most of our products and components, and the loss of any of these suppliers, or their inability to provide us with an adequate supply of materials in a timely and cost-effective manner, could materially adversely affect our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on third-party suppliers to manufacture and supply substantially all of our products. For us to be successful, our suppliers must be able to provide us with products and components in substantial quantities, in compliance with regulatory requirements, in accordance with agreed upon specifications, at acceptable prices, and on a timely basis. We do not have long-term supply contracts for some of our suppliers, and in some cases, even where we do have agreements in place, we purchase important parts of the iFuse Implant System from a single supplier. Therefore, we cannot assure investors that we will be able to obtain sufficient quantities of product in the future.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, future growth could strain the ability of our suppliers to deliver an increasingly large supply of products, materials, and components. Suppliers often experience difficulties in scaling up production, including financial issues, or problems with production yields and quality control and assurance. For example, from time to time, we have experienced certain delays and may experience delays from our suppliers in the future.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We generally use a small number of suppliers for our instruments and currently rely on RMS for iFuse-3D implants and Orchid for iFuse implants. Our dependence on such a limited number of suppliers exposes us to risks, including, among other things:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;third-party contract manufacturers or suppliers may fail to comply with regulatory requirements or make errors in manufacturing that could negatively affect the safety or effectiveness of our products or cause delays in shipments of our products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;third-party contract manufacturers or suppliers may fail to maintain good manufacturing practices, leading to quality control problems or regulatory findings that could cause disruptions in their manufacturing processes and lead to delays in shipments of our products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we or our third-party manufacturers and suppliers may not be able to respond to unanticipated changes in customer orders, and if orders do not match forecasts, we or our suppliers may have excess or inadequate inventory of materials and components;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we or our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we or our third-party manufacturers and suppliers may be subject to price fluctuations due to a lack of long-term supply arrangements for key components;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we or our third-party manufacturers and suppliers may lose access to critical services and components, resulting in an interruption in the manufacture, assembly and shipment of our systems;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we or our third-party manufacturers could experience plant closures due to local epidemics of communicable diseases, such as COVID-19, or local outbreaks of such diseases among their workforce, thereby shuttering a plant in which our products are manufactured;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may experience delays in delivery by our third-party manufacturers and suppliers due to changes in demand from us or their other customers;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;fluctuations in demand for products that our third-party manufacturers and suppliers manufacture for others may affect their ability or willingness to deliver components to us in a timely manner;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our third-party manufacturers and suppliers may wish to discontinue supplying components or services to us for risk management reasons;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may not be able to find new or alternative components or reconfigure our system and manufacturing processes in a timely manner if the necessary components become unavailable; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our third-party manufacturers and suppliers may encounter financial hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any one or more of these risks materialize, it could significantly increase our costs and impact our ability to meet demand for our products. If we are unable to satisfy commercial demand for our system in a timely manner, our ability to generate revenue would be impaired, market acceptance of our products could be adversely affected, and customers may instead purchase or use our competitors&#8217; products. Additionally, we could be forced to seek alternative sources of supply.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, most of our supply and manufacturing agreements do not have minimum manufacturing or purchase obligations. As such, with many of our suppliers, we have no obligation to buy any given quantity of products, and the suppliers have no obligation to sell us or to manufacture for us any given quantity of components or products. As a result, our ability to purchase adequate quantities of components or our products may be limited and we may not be able to convince suppliers to make components and products available to us in some instances. Our suppliers may also encounter problems that limit their ability to supply components or manufacture products for us, including financial difficulties, damage to their manufacturing equipment or facilities, product discontinuations or adverse findings in quality audits. As a result, there is a risk that certain components could be discontinued and no longer available to us. We may be required to make significant &#8220;last time&#8221; purchases of component inventory that is being discontinued by the supplier to ensure supply continuity. If we fail to obtain sufficient quantities of high quality components to meet demand for our products in a timely manner or on terms acceptable to us, we would have to seek alternative sources of supply. Securing a replacement third-party manufacturer or supplier could be difficult. The introduction of new or alternative manufacturers or suppliers also may require design changes to our iFuse system that are subject to domestic and international regulatory clearances or approvals and the review of our Notified Body.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the nature of our internal quality control requirements, regulatory requirements, and the custom and proprietary nature of the parts, we may not be able to quickly engage additional or replacement suppliers for many of our critical components. We may also be required to assess any potential new manufacturer&#8217;s compliance with all applicable regulations and guidelines, which could further impede our ability to manufacture our products in a timely manner. As a result, we could incur increased production costs, experience delays in deliveries of our products, suffer damage to our reputation, and experience an adverse effect on our business and financial results. Failure of any of our third-party suppliers to meet our product demand level would limit our ability to meet our sales commitments to our customers and could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA, our Notified Body and the competent authorities in the countries of the EEA, or other foreign regulatory authorities, and the failure of our suppliers to comply with strictly enforced regulatory requirements could expose us to delays in obtaining clearances or approvals, regulatory action including warning letters, product recalls, termination of distribution, product seizures, civil, administrative, or criminal penalties and the suspension, variation, or withdrawal of our CE Certificates of Conformity. We could incur delays while we locate and engage qualified alternative suppliers, and we may be unable to engage alternative suppliers on favorable terms or at all. Any such disruption or increased expenses could harm our commercialization efforts and adversely affect our ability to generate sales.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, each of our third-party suppliers operates at a facility in a single location and substantially all of our inventory of component supplies and finished goods is held at these locations. We, and our suppliers, take precautions to safeguard facilities, including acquiring insurance, employing back-up generators, adopting health and safety protocols, and utilizing off-site storage of computer data. However, a local outbreak of COVID-19 cases, vandalism, terrorism, or a natural or other disaster, such as an earthquake, fire, or flood, could damage or destroy equipment or our inventory of component supplies or finished products, cause substantial delays in our operations, result in the loss of key information, and cause us to incur additional expenses. Our insurance may not cover our losses in any particular case. In addition, regardless of the level of insurance coverage, damage to our or our suppliers&#8217; facilities could harm our business, financial condition, and operating results.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may encounter problems or delays in the assembly of our products or fail to meet certain regulatory requirements which could result in an adverse effect on our business and financial results.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To become profitable, we must assemble our products in adequate quantities in compliance with regulatory requirements and at an acceptable cost. Increasing our capacity to assemble and test our products will require us to improve internal efficiencies. We may encounter a number of difficulties in increasing our assembly and testing capacity, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;managing production yields;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;maintaining quality control and assurance;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;providing component and service availability;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;maintaining adequate control policies and procedures;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;hiring and retaining qualified personnel; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;complying with state, federal, and foreign regulations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to satisfy commercial demand for our iFuse system due to our inability to assemble and test, our ability to generate revenue would be impaired, market acceptance of our products could be adversely affected and customers may instead purchase or use our competitors&#8217; products.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not enhance and broaden our product offerings through our research and development efforts, we may be unable to compete effectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to increase our market share in the sacroiliac joint fusion and related markets, we must enhance and broaden our product offerings in response to changing customer demands and competitive pressures and technologies. We might not be able to successfully develop, obtain domestic and international regulatory clearances or approvals, or CE Certificates of Conformity for, or market new products, and our future products might not be accepted by the surgeons or the third-party payors who reimburse for many of the procedures performed with our products. The success of any new product offering or enhancement to an existing product will depend on numerous factors, including our ability to:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;properly identify and anticipate surgeon and patient needs;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;develop and introduce new products or product enhancements in a timely manner;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third parties;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;demonstrate the safety and effectiveness of new products; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;obtain the necessary domestic and international regulatory clearances or approvals and CE Certificates of Conformity for new products or product enhancements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we do not develop and obtain domestic and international regulatory clearances or approvals and CE Certificates of Conformity for new products or product enhancements in time to meet market demand, or if there is insufficient demand for these products or enhancements, our business could be adversely affected. Our research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material, or other innovation.  In some cases, following a successful product development effort, we may need to invest substantial resources in surgical instrumentation and implant inventory, prior to launch of the product, and before we understand the demand for such product.  If we overestimate the demand for such products and invest too heavily in inventory to support the product line, the additional revenue and product margins may not produce a positive return on such investments, which could cause our financial results to suffer. In addition, even if we are able to successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not produce sales in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are required to maintain adequate levels of inventory, the failure of which could consume our resources and reduce our cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the need to maintain adequate levels of inventory, we are subject to the risk of inventory obsolescence. Many of our products come in sets, which feature components in a variety of sizes so that the implant or device may be chosen for size based on the patient&#8217;s needs. In order to market our products effectively, we often maintain and provide surgeons and hospitals with back-up products and products of different sizes. For each surgery, fewer than all of the components of the set are used, and therefore certain portions of the set may become obsolete before they can be used. In addition, as we introduce new implants and instruments with the same intended uses as existing products, the older products may fall out of favor with our customers, causing them to become obsolete. In the event that a substantial portion of our inventory becomes obsolete, it could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The size and future growth in the market for iFuse has not been established with precision and may be smaller than we estimate, possibly materially. In addition, we estimate cost savings to the economy and healthcare system as a result of the iFuse procedure based on our market research. If our estimates and projections overestimate the size of this market or these benefits and cost savings, our sales growth may be adversely affected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not aware of an independent third-party study that reliably reports the potential market size for iFuse or cost savings as a result of the iFuse procedure. Therefore, our estimates of the size and potential for future growth in the market for our iFuse products, cost savings to patients, the healthcare system and the economy overall from its use, and the number of people currently suffering from lower back pain who may benefit from and be amenable to our iFuse procedure, is based on a number of internal and third-party studies, surveys, reports, and estimates. While we believe these factors have historically provided and may continue to provide us with effective tools in estimating the total market for our iFuse products and procedures and health cost savings, these estimates may not be correct and the conditions supporting our estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. The actual incidence of lower back pain, and the actual demand for our products or competitive products, could differ materially from our projections if our assumptions and estimates are incorrect. As a result, our estimates of the size and future growth in the market for our iFuse products may prove to be incorrect. In addition, actual health cost savings to the healthcare system as a result of the iFuse procedure may materially differ from those we expect. If the actual number of people with lower back pain who would benefit from our iFuse products and the size and future growth in the market for iFuse products and related costs savings to the healthcare system is smaller than we have estimated, it may impair our projected sales growth and have an adverse impact on our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our results of operations could suffer if we are unable to manage our international business effectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expansion into international markets is an element of our business strategy and involves risk. The sale and shipment of our products across international borders, as well as the purchase of components and products from international sources, subject us to extensive U.S. and foreign governmental trade, import, and export and customs regulations and laws. Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly affect us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), and the United Kingdom Bribery Act (&#8220;UKBA&#8221;), anti-boycott laws, anti-money laundering laws, and regulations relating to economic sanctions imposed by the U.S., including the Office of Foreign Asset Control of the U.S. Treasury. Any failure to comply with applicable legal and regulatory obligations in the U.S. or abroad could adversely affect us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments and restrictions on certain business activities. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our distribution and sales activities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, some of the countries in which we sell or plan to sell our products are, to some degree, subject to various risks, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;exposure to different legal and regulatory standards;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;lack of stringent protection of intellectual property;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;obstacles to obtaining domestic and foreign export, import, and other governmental approvals, permits, and licenses and compliance with foreign laws;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;potentially adverse tax consequences and the complexities of foreign value-added tax systems;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;adverse changes in tariffs and trade restrictions;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;limitations on the repatriation of earnings;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;difficulties in staffing and managing foreign operations;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;transportation delays and difficulties of managing international distribution channels;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;longer collection periods and difficulties in collecting receivables from foreign entities;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;increased financing costs;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;currency risks; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;political, social, and economic instability and increased security concerns.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These risks may limit or disrupt our expansion, restrict the movement of funds or result in the deprivation of contractual rights or the taking of property by nationalization or expropriation without fair compensation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our successful conduct of our international business depends, in part, on our ability to develop and implement policies and strategies that are effective in anticipating and managing these and other risks in the countries in which we plan to do business. Failure to manage these and other risks may have a material adverse effect on our operations in any particular country and on our business as a whole.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In the future our products may become obsolete, which would negatively affect operations and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The medical device industry is characterized by rapid and significant change. There can be no assurance that other companies will not succeed in developing or marketing devices, and products that are more effective than our iFuse system or that would render the iFuse system obsolete or noncompetitive. Additionally, new surgical procedures, medications and other therapies could be developed that replace or reduce the importance of our product. Accordingly, our success will depend in part on our ability to respond quickly to changes in technology and the practice of medicine through the development and introduction of new products. Product development involves a high degree of risk and there can be no assurance that our new product development efforts will result in any commercially successful products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we experience significant disruptions in our information technology systems, our business, results of operations, and financial condition could be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The efficient operation of our business depends on our information technology systems. We rely on our information technology systems to effectively manage:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;sales and marketing, accounting, and financial functions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;inventory management;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;engineering and product development tasks; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our research and development data.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our information technology systems are vulnerable to damage or interruption from:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;earthquakes, fires, floods, and other natural disasters;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;terrorist attacks and attacks by computer viruses or hackers or breach of our cybersecurity;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;power losses; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;computer systems, or Internet, telecommunications, or data network failures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The failure of our information technology systems to perform as we anticipate or our failure to effectively implement new systems could disrupt our entire operation and could result in decreased sales, increased overhead costs, excess inventory and product shortages, and legal liability issues, all of which could have a material adverse effect on our reputation, business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we accept payments for many of our sales through credit card transactions, which are handled through a third-party payment processor. As a result, we are subject to a number of risks related to credit card payments. As a result of these transactions, we pay interchange and other fees, which may increase over time and could require us to either increase the prices we charge for our products or experience an increase in our costs and expenses. In addition, as part of the payment processing process, we transmit our customers&#8217; credit card information to our third-party payment processor. We may in the future become subject to lawsuits or other proceedings for purportedly fraudulent transactions arising out of the actual or alleged theft of our customers&#8217; credit card information if the security of our third-party credit card payment processor is breached. We and our third-party credit card payment processor are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers, which could change or be reinterpreted to make it difficult or impossible for us to comply. If we or our third-party credit card payment processor fail to comply with these rules or requirements, we may be subject to fines and higher transaction fees and lose our ability to accept credit card payments from our customers, and there may be an adverse impact on our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may seek to grow our business through acquisitions of or investments in new or complementary businesses, products or technologies, and the failure to manage acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we expect to consider opportunities to acquire or make investments in other technologies, products, and businesses that may enhance our capabilities, complement our current products, or expand the breadth of our markets or customer base. Potential and completed acquisitions and strategic investments involve numerous risks, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;problems assimilating the purchased technologies, products, or business operations;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;issues maintaining uniform standards, procedures, controls, and policies;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;unanticipated costs and liabilities associated with acquisitions;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;diversion of management&#8217;s attention from our core business;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;adverse effects on existing business relationships with suppliers and customers;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;risks associated with entering new markets in which we have limited or no experience;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;potential loss of key employees of acquired businesses; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;increased legal and accounting compliance costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no current commitments with respect to any acquisition or investment. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired business, product, or technology into our business or retain any key personnel, suppliers, or distributors. Our ability to successfully grow through acquisitions depends upon our ability to identify, negotiate, complete, and integrate suitable target businesses and to obtain any necessary financing. These efforts could be expensive and time consuming, and may disrupt our ongoing business and prevent management from focusing on our operations. If we are unable to successfully integrate any acquired businesses, products, or technologies effectively, our business, results of operations, and financial condition will be materially adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships with third-parties that may not result in the development of commercially viable products or the generation of significant future revenue.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships, or other arrangements to develop products and to pursue new markets. Proposing, negotiating, and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenue and could be terminated prior to developing any products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any future collaborators, they may act in their self- interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any future collaborators devote to our or their future products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence, commercialization, royalty, or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our term loan contains covenants that may restrict our business and financing activities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 29, 2020, we entered into a Loan and Security Agreement with Solar Capital Ltd. (&#8220;Solar&#8221;), pursuant to which we borrowed $40.0 million pursuant to a term loan (the &#8220;Solar Term Loan&#8221;). The Loan and Security Agreement with Solar contains customary events of default, including bankruptcy, the failure to make payments when due, the occurrence of a material impairment on the lenders&#8217; security interest over the collateral, a material adverse change, the occurrence of a default under certain other indebtedness of us or our subsidiaries, the rendering of certain types of judgments against us or our subsidiaries, the revocation of certain government approvals, violation of covenants, and incorrectness of representations and warranties in any material respect. The Loan and Security Agreement with Solar also contains certain restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions, as well as financial reporting requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Solar Term Loan is secured by substantially all of our assets. The Loan and Security Agreement with Solar also contains a financial covenant related to our liquidity based on our trailing twelve-month net product revenues. We are required to hold at least $15.0 million in cash and cash equivalents so long as trailing twelve-month net product revenues are less than $75.0 million and at least $7.5 million in cash and cash equivalents so long as trailing twelve-month net product revenues are greater than or equal to $75.0 million but less than $100.0 million (collectively &#8220;Minimum Liquidity Requirements&#8221;). We are not subject to a Minimum Liquidity Requirement when trailing twelve-month net product revenues exceeds $100.0 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The covenants in the Solar Term Loan, as well as any future financing agreements that we may enter into, may restrict our ability to finance our operations, engage in, expand, or otherwise pursue our business activities and strategies. Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a default under our credit facility agreements. Due to uncertainties surrounding the impact of COVID-19 pandemic, there is a substantial risk that we may not meet the minimum trailing 12-month product revenue in future period. If not waived, future defaults could cause all of the outstanding indebtedness under our Loan and Security Agreement to become immediately due and payable.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Legal and Regulatory Environment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We, our suppliers, and our third-party manufacturers are subject to extensive governmental regulation both in the U.S. and abroad, and failure to comply with applicable requirements could cause our business to suffer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The medical device industry is regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;design, development, and manufacturing;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;testing, labeling, content, and language of instructions for use and storage;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;product safety;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;marketing, sales, and distribution;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;premarket clearance and approval;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;conformity assessment procedures;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;record keeping procedures;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;advertising and promotion;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;compliance with good manufacturing practices requirements;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;recalls and field safety corrective actions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;post-market approval studies; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;product import and export.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, difficulties achieving new product clearances, higher than anticipated costs or lower than anticipated sales.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before we can market or sell a new regulated product or make a significant modification to an existing product in the U.S., with only limited exceptions, we must obtain either clearance under Section&#160;510(k) of the FDCA for Class&#160;II devices or approval of a PMA application from the FDA for a Class&#160;III device. Both the 510(k) and PMA processes can be expensive and lengthy and require the payment of significant fees, unless exempt. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but may last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is submitted to the FDA until an approval is obtained. The process of obtaining domestic and international regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., our currently commercialized products have either received premarket clearance under Section&#160;510(k) of the FDCA or are exempt from premarket review. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline. In addition, the FDA may determine that future products will require the more costly, lengthy, and uncertain PMA process. Although we do not currently market any devices under PMA, the FDA may demand that we obtain a PMA prior to marketing certain of our future products. In addition, if the FDA disagrees with our determination that a product we currently market is subject to an exemption from premarket review, the FDA may require us to submit a 510(k) or PMA in order to continue marketing the product. Further, even with respect to those future products where a PMA is not required, we cannot assure investors that we will be able to obtain the 510(k) clearances with respect to those products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;we may not be able to demonstrate to the FDA&#8217;s satisfaction that our products are safe and effective for their intended uses;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the manufacturing process or facilities we use may not meet applicable requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay clearance or approval of our products under development or impact our ability to modify our currently approved or cleared products on a timely basis.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any delay in, or failure to receive or maintain, clearance or approval for our products under development could prevent us from generating revenue from these products or achieving profitability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, even after we have obtained the proper regulatory clearance or approval to market a product, the FDA has the power to require us to conduct post-marketing studies. These studies can be very expensive and time consuming to conduct. Failure to comply with those studies in a timely manner could result in the revocation of the 510(k) clearance for a product that is subject to such a 522 Order and the recall or withdrawal of the product, which could prevent us from generating sales from that product in the U.S.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EEA, our medical devices must currently comply with the Essential Requirements set forth in Annex I to the EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with these requirements is a prerequisite to being able to affix the CE mark to our medical devices, without which they cannot be marketed or sold in the EEA. Compliance with the Essential Requirements is confirmed by a Notified Body, a third party organization designated by the competent authorities of a EEA country to conduct conformity assessments. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the conformity assessment process, medical device manufacturers must carry out a clinical evaluation of their medical devices to verify that they comply with the relevant Essential Requirements covering safety and performance. A clinical evaluation includes an assessment of whether a medical device&#8217;s performance is in accordance with its intended use and that the known and foreseeable risks linked to the use of the device under normal conditions are minimized and acceptable when weighed against the benefits of its intended purpose. The clinical evaluation conducted by the manufacturer must also address any clinical claims, the adequacy of the device labeling and information (particularly claims, contraindications, precautions/ warnings) and the suitability of related Instructions for Use. This assessment must be based on clinical data, which can be obtained from (i)&#160;clinical studies conducted on the devices being assessed; (ii)&#160;scientific literature from similar devices whose equivalence with the assessed device can be demonstrated; or (iii)&#160;both clinical studies and scientific literature. With respect to implantable devices, or devices classified as Class&#160;III in the EU, the manufacturer must conduct clinical studies to obtain the required clinical data, unless the relying on existing clinical data from similar devices can be justified. As part of the conformity assessment procedure, depending on the type of devices, the Notified Body will review the manufacturer&#8217;s clinical evaluation for the medical device. The conduct of clinical studies to obtain clinical data that might be required as part of the described clinical evaluation process can be expensive and time consuming.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the EU Medical Device Regulation, (Regulation 2017/745) was adopted, as described in &#8220;Item 1. Business - Regulation - International Regulation of Our Products.&#8221; </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA and other regulatory authorities, including foreign authorities, have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some surgeons from using our products and adversely affect our reputation and the perceived safety and effectiveness of our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;warning letters;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;fines;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;injunctions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;civil penalties;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;termination of distribution;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;recalls or seizures of products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;delays in the introduction of products into the market;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;total or partial suspension of production;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;facility closures;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;refusal of the FDA or our Notified Body or other regulator to grant future clearances or approvals or to issue CE Certificates of Conformity;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;withdrawals, variation, or suspensions of current clearances or approvals and CE Certificates of Conformity, resulting in prohibitions on sales of our products; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;in the most serious cases, criminal penalties.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adverse action by an applicable regulatory agency, our Notified Body or the FDA could result in inability to produce our products in a cost-effective and timely manner, or at all, decreased sales, higher prices, lower margins, additional unplanned costs or actions, damage to our reputation, and could have material adverse effect on our reputation, business, results of operations, and financial condition. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We and our sales representatives must comply with U.S. federal and state fraud and abuse laws, including those relating to healthcare provider kickbacks and false claims for reimbursement, and other applicable federal and state healthcare laws, as well as equivalent foreign laws, and failure to comply could negatively affect our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Healthcare providers, distributors and third-party payors play a primary role in the distribution, recommendation, ordering, and purchasing of any implant or other medical device for which we have or obtain marketing clearance or approval. Through our arrangements with customers and third-party payors, we are exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, or third-party distributors may engage in fraudulent or other illegal activity. Misconduct by these parties could include, among other infractions or violations, intentional, reckless and/or negligent conduct or unauthorized activity that violates FDA regulations, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, laws that require the true, complete, and accurate reporting of financial information or data, other commercial or regulatory laws or requirements, and equivalent foreign rules. We have a compliance program, Code of Conduct, and associated policies and procedures, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations, and government authorities may conclude that our business practices do not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance despite our good faith efforts to comply.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback and false claims laws. Our relationships and our distributors&#8217; relationships with surgeons, other healthcare professionals, and hospitals are subject to scrutiny under these laws. For example, we are subject to the federal health care Anti-Kickback Statute, the federal civil False Claims Act, the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) and the federal Physician Payment Sunshine Act, each of which is described in detail in Item 1 Business - Healthcare Fraud and Abuse&#8221; and &#8220;-Data Privacy and Security Laws&#8221;.&#160; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain states also mandate implementation of corporate compliance programs, require compliance with the industry&#8217;s voluntary compliance guidelines, impose restrictions on device manufacturer marketing practices, and/or require tracking and reporting of gifts, compensation, and other remuneration to healthcare professionals and entities. analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers and patients; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state beneficiary inducement laws, and state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or our employees are found to have violated any of the above laws we may be subject to significant administrative, civil and criminal penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare, Medicaid, and equivalent foreign programs, significant fines, monetary penalties and damages, imposition of compliance obligations and monitoring, the curtailment or restructuring of our operations, and damage to our reputation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into consulting agreements and royalty agreements with surgeons, including some who are customers. We also engage in co-marketing arrangements with certain surgeons who use our products. In addition, prior to our IPO, a small number of our current customer surgeons acquired from us less than 1.0% of our current outstanding common stock, which they either purchased in an arm&#8217;s length transaction on terms identical to those offered to others or received from us as fair market value consideration for consulting services performed. While all of these transactions were structured with the intention of complying with all applicable laws, including the federal Anti-Kickback Statute, state anti-kickback laws and other applicable laws, it is possible that regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to significant penalties and criminal, civil and administrative liability. We would be materially and adversely affected if regulatory agencies interpret our financial relationships with surgeons who order our products to be in violation of applicable laws and we were unable to comply with such laws, which could subject us to, among other things, monetary penalties for non-compliance, the cost of which could be substantial.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In certain cases, federal, state and foreign authorities pursue actions for false claims on the basis that manufacturers and distributors are promoting unapproved, or &#8220;off-label&#8221; uses of their products. Pursuant to FDA regulations, we can only market our products for cleared or approved uses. Although surgeons are permitted, in their independent medical judgement, to use medical devices for indications other than those cleared or approved by the FDA, we are prohibited from promoting products for &#8220;off-label&#8221; uses. We market our products and provide promotional materials and training programs to surgeons regarding the use of our products. If it is determined that our marketing, promotional materials or training programs constitute promotion of unapproved uses, we could be subject to significant fines in addition to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, criminal penalty, and damage to our reputation. Federal, state and foreign authorities also pursue actions for false claims based upon improper billing and coding advice or recommendations, as well as decisions related to the medical necessity of procedures, including the site-of-service where procedures are performed, which could result in significant penalties.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Various state and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and the U.S. Congress continues to strengthen the arsenal of enforcement tools. The Bipartisan Budget Act of 2018 increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the federal Anti- Kickback Statute. To enforce compliance with the federal laws, the U.S. Department of Justice has continued its scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations can be time- and resource-consuming and can divert management&#8217;s attention from the business. Additionally, if a healthcare company settles an investigation with the Department of Justice or other law enforcement agencies, it may need to agree to additional onerous compliance and reporting requirements as part of a consent decree, deferred or non-prosecution agreement, or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert resources and the attention of our management from operating our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The scope and enforcement of these laws is uncertain and subject to rapid change. The shifting compliance environment and the need to build and maintain robust and expandable systems and processes to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that we may run afoul of one or more of the requirements or that federal or state regulatory authorities might challenge our current or future activities under these laws. Additionally, we cannot predict the impact of any changes in these laws, whether or not retroactive.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to adequately protect personal information in compliance with evolving legal requirements could harm our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including legally protected personally identifiable information. We collect this kind of information during the course of clinical trials and for post-marketing safety vigilance, helping enable surgeons and their patients to pursue claims for reimbursement for procedures using iFuse and servicing potential warranty claims. In doing so, we are subject to various federal, state and foreign laws that protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information by healthcare providers, such as HIPAA, in the U.S. and regulations in the European Union (&#8220;EU&#8221;), which are described in detail in Item 1 Business - Data Privacy and Security Laws&#8221;.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2018, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;). The CCPA, which became effective on January 1, 2020, requires a broad range of businesses to honor the requests of California residents to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used and shared. The CCPA provides for civil penalties of up to $7,500 for intentional violations, and a private right of action for data breaches that allows private plaintiffs to seek the greater of actual damages or statutory damages of up to $750 per consumer per data breach.  These remedies are expected to increase data breach litigation. Although the CCPA includes exemptions for certain clinical trials data, and protected health information governed by HIPAA, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to comply with applicable laws and regulations, or to protect such data, could result in enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by end-customers, and other affected individuals, and the imposition of integrity obligations and agency oversight, damage to our reputation, and loss of goodwill, any of which could harm our operations, financial performance, and business. Evolving and changing definitions of personal data and personal information, within the European Union, the U.S., and elsewhere, may limit or inhibit our ability to operate or expand our business, including limiting strategic partnerships that may involve the sharing of data. Moreover, if the relevant laws and regulations change, or are interpreted and applied in a manner that is inconsistent with our data practices or the operation of our products, or if we expand into new regions and are required to comply with new requirements, we may need to expend resources in order to change our business operations, data practices, or the manner in which our products operate. Even the perception of privacy concerns, whether or not valid, may harm our reputation and inhibit adoption of our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to risks associated with our non-U.S. operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FCPA prohibits companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business. Other anti-corruption or anti-bribery laws, such as the UKBA, prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business in foreign countries. The FCPA also imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of slush funds from which such improper payments can be made. Because of the predominance of government-sponsored healthcare systems around the world, many of our customer relationships outside of the U.S. are with governmental entities and are therefore subject to such anti-bribery laws. Our internal control policies and procedures may not always protect us from reckless or criminal acts committed by our employees or agents. Violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, and result in a material adverse effect on our business, results of operations, and financial condition. We also could suffer severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures, including further changes or enhancements to our procedures, policies, and controls, as well as potential personnel changes and disciplinary actions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, we are subject to anti-boycott laws, anti-money laundering laws, and the export controls and economic embargo rules and regulations of the U.S., including, but not limited to, the Export Administration Regulations and trade sanctions against embargoed countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as the laws and regulations administered by the Department of Commerce. These regulations limit our ability to market, sell, distribute, or otherwise transfer our products or technology to prohibited countries or persons. A determination that we have failed to comply, whether knowingly or inadvertently, may result in substantial penalties, including fines and enforcement actions and civil and/or criminal sanctions, the disgorgement of profits, and the imposition of a court-appointed monitor, as well as the denial of export privileges, and may have an adverse effect on our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if our products are approved by regulatory authorities or CE marked, if we, our contractors, or our suppliers fail to comply with ongoing FDA or other foreign regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any product for which we obtain regulatory clearance or approval, or a CE Certificate of Conformity, and the manufacturing processes, reporting requirements, post-approval clinical data, and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA, our Notified Body and other domestic and foreign regulatory bodies. In particular, we and our suppliers are required to comply with FDA&#8217;s Quality System Regulations (&#8220;QSR&#8221;), and International Standards Organization, regulations for the manufacture of our products and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage, and shipping of any product for which we obtain regulatory clearance or approval, or a CE Certificate of Conformity.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The failure by us or one of our suppliers to comply with applicable statutes and regulations, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;untitled letters, warning letters, fines, injunctions, consent, and civil penalties;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;unanticipated expenditures to address or defend such actions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;customer notifications for repair, replacement, refunds;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;recall, detention, or seizure of our products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;operating restrictions or partial suspension or total shutdown of production;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;refusing or delaying our requests for 510(k) clearance or premarket approval and conformity assessments of new products or modified products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;limitations on the intended uses for which the product may be marketed;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;operating restrictions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;suspension, variation or withdrawal of CE Certificates of Conformity;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;refusal to grant export approval for our products; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;criminal prosecution.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace, or refund the cost of any medical device we manufacture or distribute, fines, suspension, variation, or withdrawal of regulatory approvals or CE Certificates of Conformity, product seizures, injunctions, or the imposition of civil, administrative, or criminal penalties which would adversely affect our business, operating results, and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false or fraudulent claims for payment of government funds. Any of these actions would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our employees, independent contractors, consultants, manufacturers, and third-party distributors may engage in misconduct or other improper activities, relating to regulatory standards and requirements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the risk that our employees, independent contractors, consultants, manufacturers, and third-party distributors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal, state and foreign healthcare laws and regulations, data privacy laws and laws that require the true, complete and accurate reporting of financial information or data. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have a compliance program, code of conduct and associated policies and procedures, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, disgorgement of profits, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to enforcement action, including fines, penalties or injunctions, if we are determined to be engaging in the off-label promotion of our products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our promotional materials and training methods must comply with FDA and other applicable national and foreign laws and regulations, including the prohibition of the promotion of off-label use. Physicians may use our products off-label, as the FDA and equivalent third country authorities do not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. In the U.S., the full indication for the iFuse Implant System is: &#8220;The iFuse Implant System is intended for sacroiliac fusion for the following conditions: (i) Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. (ii) To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. (iii) Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.&#8221; In the U.S., our marketing strategies must adhere to the above statements. In all other countries, the indication statement for the iFuse Implant System (including iFuse-3D) more broadly indicates that the device is indicated for sacroiliac joint fusion. The above-described potential limitation in indication statements in the U.S. does not apply in other geographies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the specific surgical procedures for which our products are marketed fall within the scope of the surgical applications that have been cleared by the FDA and our notified body. However, if the FDA or an equivalent third country authority determines that our promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials, require us to stop promoting our products for those specific procedures until we obtain FDA or third country authority clearance or approval for them, or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fines, and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false or fraudulent claims for payment of government fund. In that event, our reputation could be damaged and adoption of the products would be impaired. Although our policy is to refrain from statements that could be considered off-label promotion of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. In addition, the off-label use of our products may increase the risk of injury to patients, and, in turn, the risk of product liability claims. Product liability claims are expensive to defend and could divert our management&#8217;s attention, result in substantial damage awards against us and harm our reputation.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are required to report certain malfunctions, deaths, and serious injuries associated with our products, which can result in voluntary corrective actions or agency enforcement actions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the FDA&#8217;s medical device reporting, regulations, and equivalent rules of other countries we are required to report to the FDA or a similar authority in such other country, any information that our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. If we fail to report these events to the FDA or applicable authority in another country within the required timeframes, or at all, FDA, or the applicable authority in the other country could take enforcement action against us. Any such adverse event involving our products or repeated product malfunctions may result in voluntary or involuntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and timely manner, and have an adverse effect on our reputation, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EEA, we must comply with the EU Medical Device Vigilance System. Under this system, incidents must be reported to the relevant authorities of the Member States of the EEA, and manufacturers are required to take Field Safety Corrective Actions (&#8220;FSCAs&#8221;), to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons, or to a serious deterioration in their state of health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. The entry into application in May 2021 of the Medical Device Regulation will increase the obligation that we must fulfill in relation to vigilance and post-market surveillance obligations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any adverse event involving our products, whether in the U.S. or abroad could result in future voluntary corrective actions, such as recalls, including corrections, or customer notifications, or agency action, such as inspection or enforcement actions. If malfunctions do occur, we may be unable to correct the malfunctions adequately or prevent further malfunctions, in which case we may need to cease manufacture and distribution of the affected products, initiate voluntary recalls, and redesign the products. Regulatory authorities may also take actions against us, such as ordering recalls, imposing fines, or seizing the affected products. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, including foreign governmental authorities, or the discovery of serious safety issues or malfunctions with our products, can result in voluntary corrective actions or agency enforcement actions, which could have a significant adverse impact on us.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is an unreasonable risk of substantial public harm. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. A government-mandated or voluntary recall by us or one of our third-party distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our reputation, results of operations, and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted. Equivalent procedures and penalties have been established in other countries including EU Member States.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Modifications to our products may require new 510(k) clearances or premarket approvals and new conformity assessment by our Notified Body, or may require us to cease marketing or recall the modified products until clearances, approvals, or CE Certificates of Conformity are obtained.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires a new 510(k) clearance or, possibly, a PMA. The FDA requires every manufacturer to make and document this determination in the first instance. A manufacturer may determine that a modification could not significantly affect safety or effectiveness and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. FDA may review any manufacturer&#8217;s decision and may not agree with our decisions regarding whether new clearances or approvals are necessary. The FDA may also on its own initiative determine that a new clearance or approval is required.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have modified some of our 510(k) cleared products and have determined based on our review of the applicable FDA guidance that in certain instances new 510(k) clearances or PMAs are not required. If the FDA disagrees with our determination and requires us to submit new 510(k) clearances or PMAs for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval. In these circumstances, we may be subject to significant enforcement actions, regulatory fines, or penalties, which could require us to redesign our products and harm our operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket approval application. Where we determine that modifications to our products require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. FDA&#8217;s ongoing review of the 510(k) program may make it more difficult for us to make modifications to our previously cleared products, either by imposing more strict requirements on when a new 510(k) for a modification to a previously cleared product must be submitted, or applying more onerous review criteria to such submissions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EEA, we must inform the Notified Body that carried out the conformity assessment of the medical devices we market or sell in the EEA of any planned substantial changes to our quality system, manufacturing process, or changes to our devices which could affect compliance with the essential requirements or the devices&#8217; intended use. The Notified Body will then assess the changes and verify whether they affect the products&#8217; conformity with Essential Requirements and related applicable laws. There can be no assurances that the assessment will be favorable and that the Notified Body will attest to our compliance with the essential requirements, which will prevent us from selling our products in the EEA. Moreover, any substantial changes that take place in the coming years may impact the continuing effectiveness of our CE Certificates of Conformity that were issued on the basis of the Medical Device Directive.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There is no guarantee that the FDA will grant 510(k) clearance or premarket approval of our future products or that our Notified Body will issue the required CE Certificate of Conformity, and failure to obtain necessary clearances or approvals for our future products would adversely affect our business prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the process of developing our regulatory strategies for obtaining clearance or approval for future products. Some of them may require 510(k) clearance by the FDA or a new CE Certificate of Conformity. Other future products may require premarket approval. In addition, some of our new products may require clinical trials or significant clinical evidence to support regulatory approval and we may not successfully complete these clinical trials. Obtaining regulatory clearances or approvals and CE Certificates of Conformity can be a time-consuming process, and delays in obtaining required future regulatory clearances or approvals, and CE Certificates of Conformity would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would adversely affect our business prospects. The FDA may not approve or clear these products or our Notified Body may not issue CE Certificate of Conformity for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or premarket approval of new products, new intended uses, or modifications to existing products and our Notified Body may refuse to issue new CE Certificates of Conformity. Failure to receive clearance, approval, or Certificates of Conformity for our new products would have an adverse effect on our ability to expand our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may fail to obtain or maintain foreign regulatory approvals to market our products in other countries.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market our products in a number of jurisdictions internationally. International jurisdictions require separate regulatory approvals and compliance with numerous and varying regulatory requirements. The approval procedures vary among countries and may involve requirements for substantial additional testing, and the time required to obtain approval may differ from country to country and from that required to obtain FDA clearance or approval or to obtain CE Certificates of Conformity.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearance or approval by the FDA or obtaining a CE Certificate of Conformity does not ensure approval or certification by regulatory authorities in other countries or jurisdictions, and approval or certification by one foreign regulatory authority does not ensure approval or certification by regulatory authorities in other foreign countries or by the FDA, and the CE marking of our products in the EEA. The foreign regulatory approval or certification process may include all of the risks associated with obtaining FDA </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">clearance or approval, or a CE Certificate of Conformity for a medical device in the EEA in addition to other risks. In addition, the time required to obtain foreign approval may differ from that required to obtain FDA clearance or approval, or a CE Certificate of Conformity in the EEA and we may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals or certifications and may not receive necessary approvals to commercialize our products in any market. If we fail to receive necessary approvals or certifications to commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, results of operations, and financial condition could be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trials necessary to support a De Novo 510(k) or PMA application or a conformity assessment procedure will be expensive and may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new products, or new indications for use for existing products, and will adversely affect our business, operating results and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiating and completing clinical trials necessary to support a De Novo 510(k) or PMA application for our future products and additional safety and effectiveness data beyond that typically required for a 510(k) clearance for iFuse, as well as other possible future product candidates, and to support a conformity assessment procedure to support a new CE Certificate of Conformity, would be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product, or new indication for use, we advance into clinical trials may not have favorable results in later clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity to clinical sites, and the ability to comply with the inclusion and exclusion criteria for participation in the clinical trial and patient compliance. Development of sufficient and appropriate clinical protocols to demonstrate safety and effectiveness are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA or our Notified Body may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. For example, the COVID-19 pandemic has caused substantial delays in site initiation and patient enrollment in our SILVIA trial designed to assess the safety and efficacy of our Bedrock technique. In addition, despite considerable time and expense invested in our clinical trials, the FDA or our Notified Body may not consider our data adequate to demonstrate safety and effectiveness. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our facility and our clinical investigational sites operate under procedures that govern the conduct and management of FDA-regulated clinical studies under 21 CFR Parts 50 and 812, and Good Clinical Practices. The FDA may conduct Bioresearch Monitoring inspections of us and/or our clinical sites to assess compliance with 21 CFR Parts 50 and 812, our procedures, and the clinical protocol. If the FDA were to find that we or our clinical investigators are not operating in compliance with applicable regulations, we could be subject to the above FDA enforcement action, as well as refusal to accept all or part of our data in support of our 510(k) or PMA, or we may need to conduct additional studies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if our clinical trials are completed as planned, or on a delayed basis, we cannot be certain that their results will support our product candidate claims or that the FDA, foreign authorities, or our Notified Body will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenue. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate&#8217;s profile.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">U.S. legislative or FDA or foreign regulatory reforms may make it more difficult and costly for us to obtain regulatory clearances or approvals, or CE Certificates of Conformity for our product candidates and to manufacture, market, and distribute our products after approval is obtained.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, Congress introduces legislation that could significantly change the statutory provisions governing the regulatory approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Moreover, the new Medical Device Regulation will enter into application on May 26, 2021. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance, or interpretations changed, and what the impact of such changes, if any, may be.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leadership, personnel and structural changes within the FDA as well as recent federal election outcomes could result in significant legislative and regulatory reforms impacting the FDA's regulation of our products. Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Another example can be found in the EEA. The Medical Devices Regulation became effective on May 25, 2017. Following its entry into application on May 26, 2021, the Medical Devices Regulation will introduce substantial changes to the obligations with which medical device manufacturers must comply in the EEA. High risk medical devices will be subject to additional scrutiny during the conformity assessment procedure. Specifically, the Medical Devices Regulation repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA Member States, regulations are directly applicable, i.e., without the need for adoption of national legislation in EEA Member States implementing them. The purpose of regulations is to eliminate current differences in regulation of medical devices among EEA Member States. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices to ensure a high level of safety and health while supporting innovation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These regulations will substantially impact medical devices manufacturers. Examples of the changes which will be introduced by these regulations include the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;additional scrutiny during the conformity assessment procedure for high risk medical devices;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;strengthening of the clinical data requirements related to medical devices;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;strengthening of the designation and monitoring processes governing notified bodies;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the obligation for manufacturers and authorized representative to have a person responsible for regulatory compliance continuously at their disposal;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;authorized representatives would be held legally responsible and liable for defective products placed on the EU market;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;increased traceability of medical devices following the introduction of a Unique Device Identification (&#8220;UDI&#8221;), system;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;new rules governing the reprocessing of medical devices; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;increased transparency with the establishment of European database on medical devices (&#8220;EUDAMED&#8221;) III as information from several databases concerning economic operators, CE Certificates of Conformity, conformity assessment, clinical investigations, the UDI system, adverse event reporting and market surveillance would be available to the public.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medical Device Regulation substantially augments the provisions of the Medical Device Directive governing clinical investigations of medical devices. Among other things, it imposes specific obligations concerning incapacitated subjects, minors, pregnant or breastfeeding women and clinical investigations in emergency situations. In addition to detailed provisions concerning the authorization and conduct of clinical investigations, the Regulation imposes on non-EU sponsors a responsibility to appoint a legal representative established in the EU and an obligation on EU Member States to ensure that systems for compensation for any damage suffered by a subject resulting from participation in a clinical investigation conducted on their territory are in place and places on sponsors and investigators the obligation to ensure they make use of these systems.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Transition from the regulation of our products under the current Medical Device Directive, and implementing legislation in each EU Member State, to regulation under the Medical Devices Regulation may require a substantial transition effort by us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, detail as to how certain aspects of the Medical Devices Regulation will be applied remains unclear. Failure to update our quality system and regulatory documentation could delay our transition to compliance with the Medical Devices Regulation and delay or prevent us from obtaining new CE Certificates of Conformity under the Regulation. Transition from compliance with the Medical Device Directive to the Medical Devices Regulation could result in disruption to our business in the EEA which could adversely affect our business, results of operation and financial condition. In addition, any changes to the membership of the European Union, such as the departure of the United Kingdom from the EU, may impact the regulatory requirements for the impacted countries and impair our business operations and our ability to market products in such countries.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business exposes us to potential product liability claims that are inherent in the testing, design, manufacture, and sale of surgical devices. Sacroiliac joint and other orthopedic spine surgeries involve significant risk of serious complications, including bleeding, nerve injury, paralysis, and even death. Surgeons may misuse or ineffectively use our products, which may result in unsatisfactory patient outcomes or patient injury. In addition, if longer-term patient results and experience indicate that our products or any component of a product cause tissue damage, motor impairment, or other adverse effects, we could be subject to significant liability. We could become the subject of product liability lawsuits alleging that component failures, manufacturing flaws, design defects, or inadequate disclosure of product-related risks or product-related information resulted in an unsafe condition or injury to patients. Product liability lawsuits and claims, safety alerts, or product recalls, regardless of their ultimate outcome, could have a material adverse effect on our business and reputation, our ability to attract and retain customers and our results of operations or financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we maintain third-party product liability insurance coverage, it is possible that claims against us may exceed the coverage limits of our insurance policies or cause us to record a self-insured loss. Even if any product liability loss is covered by an insurance policy, these policies typically have substantial retentions or deductibles that we are responsible for. Product liability claims in excess of applicable insurance coverage could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, any product liability claim brought against us, with or without merit, could result in an increase of our product liability insurance rates. Insurance coverage varies in cost and can be difficult to obtain, and we cannot guarantee that we will be able to obtain insurance coverage in the future on terms acceptable to us or at all.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to environmental laws and regulations that can impose significant costs and expose us to potential financial liabilities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacture of certain of our products, including our implants and products, and the handling of materials used in the product testing process involve the use of biological, hazardous and/or radioactive materials and wastes. Our business and facilities and those of our suppliers are subject to foreign, federal, state, and local laws and regulations relating to the protection of human health and the environment, including those governing the use, manufacture, storage, handling, and disposal of, and exposure to, such materials and wastes. We own and operate certain x-ray equipment at our facilities which requires adoption of a radiation safety plan.  Our failure to follow such safety plan or otherwise use this equipment properly could be hazardous to our employees and expose us to liability as the employer. In addition, under some environmental laws and regulations, we could be held responsible for costs relating to any contamination at our past or present facilities and at third-party waste disposal sites even if such contamination was not caused by us. A failure to comply with current or future environmental laws and regulations could result in severe fines or penalties. Any such expenses or liability could have a significant negative impact on our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Certain of our products are derived from human tissue and are or could be subject to additional regulations and requirements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our iFuse Bone product is derived from human bone tissue, and as a result is subject to FDA and certain state regulations regarding human cells, tissues and cellular or tissue-based products, or HCT/Ps. To date, iFuse Bone is our only HCT/P product, and as a product regulated under Section 361 of the Public Health Service Act, we have not been required to file a 510(k) with respect to iFuse Bone. However, the FDA could require us to obtain a 510(k) clearance for future tissue products not regulated as 361 HCT/Ps. The process of obtaining a 510(k) clearance could take time and consume resources, and failing to receive such a clearance would render us unable to market and sell such products, which could have a material and adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, procurement of certain human organs and tissue for transplantation is subject to the National Organ Transplant Act, or NOTA, which prohibits the transfer of certain human organs, including skin and related tissue, for valuable consideration, but permits the reasonable payment for costs associated with the removal, transportation, implantation, processing, preservation, quality control and storage of human tissue and skin. We reimburse tissue banks for their expenses associated with the recovery, storage and transportation of donated human tissue they provide to us for processing. We include in our pricing structure amounts paid to tissue banks to reimburse them for their expenses associated with the recovery and transportation of the tissue, in addition to certain costs </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">associated with processing, preservation, quality control and storage of the tissue, marketing and medical education expenses and costs associated with development of tissue processing technologies. NOTA payment allowances may be interpreted to limit the amount of costs and expenses we can recover in our pricing for our products, thereby reducing our future revenue and profitability. If we were to be found to have violated NOTA&#8217;s prohibition on the sale or transfer of human tissue for valuable consideration, we would potentially be subject to criminal enforcement sanctions, which could materially and adversely affect our results of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The UK&#8217;s withdrawal from the EU and uncertainty regarding tariffs affecting U.S. imports and exports may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 31, 2020, the UK withdrew from the EU. The UK&#8217;s withdrawal from the EU is commonly referred to as Brexit. From that date until December 2020 the UK and the EU negotiated an agreement as to the future customs and trading relationship between the UK and the EU; however, as this agreement was reached in December 2020, it is unclear whether the provisions set forth in the agreement will work as expected and how well the relationship between the UK and the EU will continue in practical terms. Brexit has created significant uncertainty concerning the future relationship between the UK and the EU. In light of the fact that a significant portion of the regulatory framework in the UK is derived from EU laws, the real world effects of Brexit under the new agreement could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product in the UK or the EU.  Any changes in our manufacturing or commercialization activities as a result of Brexit, could increase our costs and otherwise adversely affect our business. In addition, currency exchange rates for the British Pound and the euro with respect to each other and to the U.S. dollar have already been, and may continue to be, negatively affected by Brexit, which could cause volatility in our financial results.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not know to what extent, or when, the UK&#8217;s withdrawal from the EU or any other future changes to membership in the EU will impact our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The UK could lose the benefits of global trade agreements negotiated by the EU on behalf of its members, possibly resulting in increased trade barriers, which could make doing business in the UK more difficult and/or costly.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, in the U.S., tariffs on certain U.S. imports have recently been imposed, and the EU and other countries have responded with retaliatory tariffs on certain U.S. exports.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict what effects these and potential additional tariffs will have on our business, including in the context of escalating global trade and political tensions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, these tariffs and other trade restrictions, whether resulting from the UK&#8217;s withdrawal from the EU or otherwise, could increase our cost of doing business, reduce our gross margins or otherwise negatively impact our business and our financial results.</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be impaired.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely primarily on patent, copyright, trademark and trade secret laws, as well as confidentiality and non- disclosure agreements and other methods, to protect our proprietary technologies and know-how. As of December 31, 2020, we owned 40 issued U.S. patents and had 29 pending U.S. patent applications, and we owned 14 issued foreign patents and had 6 pending foreign patent applications. We have focused the majority of our foreign patent efforts in China, Europe, and Japan. Our current U.S. patents on iFuse, including the triangular shape, expire in November 2024. Competitors may market similar triangular shaped devices upon the expiration of the patents in late 2024. Our current U.S. patents on iFuse-3D, including the fenestrated design, expire in September 2035. Our foreign patents will expire between August 2025 and October 2031.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December 31, 2020, we have 13 registered trademarks in the U.S. and have filed for 16 more. We have sought protection for at least 2 of these trademarks in 60 countries including the 27 European member countries of the Madrid Protocol.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have applied for patent protection relating to certain existing and proposed products and processes. While we generally apply for patents in those countries where we intend to make, have made, use, or sell our products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. Furthermore, we cannot assure investors that any of our patent applications will be approved. The rights granted to us under our patents, including prospective rights sought in our pending patent applications, may not be meaningful or provide us with any commercial advantage. In addition, those rights could be opposed, contested, or circumvented by our competitors or be declared invalid or unenforceable in judicial or administrative proceedings. The failure of our patents to adequately protect our technology might make it easier for our competitors to offer the same or similar products or technologies. Competitors may be able to design around our patents or develop products that provide outcomes that are comparable to ours without infringing on our intellectual property rights. Due to differences between foreign and U.S. patent laws, our patented intellectual property rights may not receive the same degree of protection in foreign countries as they would in the U.S. Even if patents are granted outside the U.S., effective enforcement in those countries may not be available. Since most of our issued patents are for the U.S. only, we lack a corresponding scope of patent protection in other countries. In countries where we do not have significant patent protection, we may not be able to stop a competitor from marketing products in such countries that are the same as or similar to our products.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on our trademarks, trade names and brand names to distinguish our products from the products of our competitors and have registered or applied to register many of these trademarks. We cannot assure investors that our trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. Further, we cannot assure investors that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also rely on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. We try to protect this information by entering into confidentiality and intellectual property assignment agreements with parties that develop intellectual property for us and/or have access to it, such as our officers, employees, consultants, and advisors. However, in the event of unauthorized use or disclosure or other breaches of such agreements, we may not be provided with meaningful protection for our trade secrets or other proprietary information. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If any of our trade secrets, know-how or other technologies not protected by a patent were to be disclosed to or independently developed by a competitor, our business, financial condition, and results of operations could be materially adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the future, we may enter into licensing agreements to maintain our competitive position. If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence, commercialization, royalty, or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek damages or to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a competitor infringes upon one of our patents, trademarks, or other intellectual property rights, enforcing those patents, trademarks, and other rights may be difficult and time consuming. Even if successful, litigation to defend our patents and trademarks against challenges or to enforce our intellectual property rights could be expensive and time consuming and could divert management&#8217;s attention from managing our business. Moreover, we may not have sufficient resources to defend our patents or trademarks against challenges or to enforce our intellectual property rights. In addition, if third parties infringe any intellectual property that is not material to the products that we make, have made, use, or sell, it may be impractical for us to enforce this intellectual property against those third parties.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to damages resulting from claims that we, our employees, or our third-party distributors have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our employees were previously employed at other medical device companies, including our competitors or potential competitors, in some cases until recently. Some of our third-party distributors sell, or in the past have sold, products of our competitors. We may be subject to claims that we, our employees, or our third-party distributors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of these former employers or competitors. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Even if we are successful in defending against these claims, litigation could result in substantial costs, divert the attention of management from our core business and harm our reputation. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There can be no assurance that this type of litigation will not occur, and any future litigation or the threat thereof may adversely affect our ability to hire additional direct sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations, and financial condition.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The medical device industry is characterized by patent litigation and we could become subject to litigation that could be costly, result in the diversion of management&#8217;s time and efforts, require us to pay damages, and/or prevent us from developing or marketing our existing or future products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success will depend in part on not infringing the patents or violating the other proprietary rights of third parties. Significant litigation regarding patent rights exists in our industry. Our competitors in both the U.S. and abroad, many of which have substantially greater resources and have made substantial investments in competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit, or otherwise interfere with our ability to make and sell our products. We have conducted a limited review of patents issued to third parties. The large number of patents, the rapid rate of new patent issuances, the complexities of the technology involved, and the uncertainty of litigation increase the risk of management&#8217;s attention being diverted to patent litigation. Any litigation or claim against us, even those without merit, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business, and harm our reputation. Further, as the number of participants in the medical device industry grows, the possibility of intellectual property infringement claims against us increases. If we are found to infringe the intellectual property rights of third parties, we could be required to pay substantial damages, including treble, or triple, damages if an infringement is found to be willful, and/or royalties and could be prevented from selling our products unless we obtain a license or are able to redesign our products to avoid infringement. Any such license may not be available on reasonable terms, if at all, and there can be no assurance that we would be able to redesign our products in a way that would not infringe the intellectual property rights of others. If we fail to obtain any required licenses or make any necessary changes to our products or technologies, we may have to withdraw existing products from the market or may be unable to commercialize one or more of our products, all of which could have a material adverse effect on our business, results of operations, and financial condition. If passed into law, patent reform legislation currently pending in the U.S. Congress could significantly change the risks associated with bringing or defending a patent infringement lawsuit. For example, fee shifting legislation could require a non-prevailing party to pay the attorney fees of the prevailing party in some circumstances.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we generally indemnify our customers and third-party distributors with respect to infringement by our products of the proprietary rights of third parties. Third parties may assert infringement claims against our customers or third-party distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or third-party distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers or third-party distributors or may be required to obtain licenses to intellectual property owned by such third parties. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers and third-party distributors may be forced to stop using or selling our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The price of our common stock may be volatile, and the value of an investment in our common stock could decline.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medical device stocks have historically experienced volatility, and the trading price of our common stock may fluctuate substantially. These fluctuations could cause our stockholders to lose all or part of their investment in our common stock. Factors that could cause fluctuations in the trading price of our common stock include the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the impact that the COVID-19 pandemic has on our business;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">actual or anticipated changes or fluctuations in our results of operations;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;results of our clinical trials and that of our competitors&#8217; products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;regulatory actions with respect to our products or our competitor&#8217;s products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;announcements of new offerings, products, services or technologies, commercial relationships, acquisitions, or other events by us or our competitors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;price and volume fluctuations in the overall stock market from time to time; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;significant volatility in the market price and trading volume of healthcare companies, in general, and of companies in the medical device industry in particular;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;fluctuations in the trading volume of our shares or the size of our public float;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;negative publicity;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;whether our results of operations meet the expectations of securities analysts or investors or those expectations change;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;litigation involving us, our industry, or both;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;regulatory developments in the U.S., foreign countries, or both;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;lock-up releases and sales of large blocks of our common stock;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;additions or departures of key employees or scientific personnel; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;general economic conditions and trends.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if the market for healthcare stocks or the stock market, in general, experience a further loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, results of operations, or financial condition. The trading price of our common stock might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. If our stock price is volatile, we may become the target of securities litigation. Securities litigation could result in substantial costs and divert our management&#8217;s attention and resources from our business. This could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our sales volumes and our operating results may fluctuate over the course of the year, which could affect the price of our common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have experienced and continue to experience meaningful variability in our sales and gross profit from quarter to quarter, as well as within each quarter. Our sales and results of operations will be affected by numerous factors, including, among other things:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the impact that the COVID-19 pandemic has on our business;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">payor coverage and reimbursement;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the number of products sold in the quarter and our ability to drive increased sales of our products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our ability to establish and maintain an effective and dedicated sales force;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">pricing pressure applicable to our products, including adverse third-party coverage and reimbursement outcomes;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">results of clinical research and trials on our existing products and products in development;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the mix of our products sold because profit margins differ amongst our products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the ability of our suppliers to timely provide us with an adequate supply of materials and components;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the evolving product offerings of our competitors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the demand for, and pricing of, our products and the products of our competitors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">factors that may affect the sale of our products, including seasonality and budgets of our customers;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">domestic and international regulatory clearances or approvals, or CE Certificates of Conformity, and legislative changes affecting the products we may offer or those of our competitors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">interruption in the manufacturing or distribution of our products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the effect of competing technological, industry and market developments;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our ability to expand the geographic reach of our sales and marketing efforts;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the costs of maintaining adequate insurance coverage, including product liability insurance;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the availability and cost of components and materials;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the number of selling days in the quarter;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">fluctuation in foreign currency exchange rates; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">impairment and other special charges.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the products we may seek to develop and introduce in the future will require FDA clearance or approval before commercialization in the U.S., and commercialization of such products outside of the U.S. would likely require additional regulatory </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approvals, or Certificates of Conformity and import licenses. As a result, it will be difficult for us to forecast demand for these products with any degree of certainty. In addition, we will be increasing our operating expenses as we expand our commercial capabilities. Accordingly, we may experience significant, unanticipated losses. If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. Quarterly comparisons of our financial results may not always be meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to utilize our net operating loss carryforwards to reduce our income taxes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had net operating loss (&#8220;NOL&#8221;) carryforwards of $200.5 million and $165.0 million available to reduce future taxable income, if any, for U.S. federal income tax and state income tax purposes, respectively. If not utilized, our federal and state NOL carryforwards begin to expire in 2028 and 2021, respectively, subject to the recent California franchise tax law change affecting California state NOLs mentioned below. Portions of these NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under legislation enacted in 2017, as modified by legislation enacted in 2020, unused U.S. federal NOLs generated in tax years beginning after December 31, 2017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not expire and may be carried forward indefinitely, but the deductibility of such federal NOLs in taxable years beginning after December 31, 2020, is limited to 80% of taxable income. At the state level, there may be periods during which the use of NOLs is suspended or otherwise limited. In addition, under Section&#160;382 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We updated our Section 382 ownership change analysis through December 31, 2020. The analysis determined that we have experienced Section&#160;382 ownership changes in 2010 and 2020. A total of $1.4 million of our NOLs and tax credit carryforwards are subject to limitation as a result of the ownership change. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The California Assembly Bill 85 (AB 85) was signed into law by Governor Gavin Newsom on June 29, 2020. The legislation suspends the California NOL deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California Tax Credits for 2020, 2021, and 2022. The legislation disallows the use of California NOL deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1.0 million. The carryover periods for NOL deductions disallowed by this provision will be extended. Given that we expect to be at a loss position in the current year, the new legislation will not impact our current year provision. We will continue to monitor the possible California NOLs and credit limitation in future periods.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our charter documents and Delaware law could discourage takeover attempts and lead to management entrenchment.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors that are not nominated by the current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions include:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors, or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the requirement for the affirmative vote of holders of at least 66&#160;2/3% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquiror to effect such amendments to facilitate an unsolicited takeover attempt; and</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as a Delaware corporation, we are subject to Section&#160;203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of, and do not currently intend to opt out of, this provision.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer, or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for our stockholders to realize value in a corporate transaction.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the U.S. federal district courts are the exclusive forums for substantially all disputes between us and our stockholders, which restricts our stockholders&#8217; ability to bring a lawsuit against us or our directors, officers, or employees in jurisdictions other than Delaware and federal district courts.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for these types of disputes with us or our directors, officers, or other employees.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation also provides that the U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. </span></div><div id="ic5af433463274989b3f39da4377b2b55_73"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">None.</span></div><div id="ic5af433463274989b3f39da4377b2b55_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Properties.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leased headquarters in Santa Clara, California, comprises approximately 21,848 square feet. Our headquarters houses our research, product development, marketing, finance, education, and administration functions. We believe our facilities are adequate and suitable for our current needs but in the future we may need additional space. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease office spaces in Gallarate, Italy, Mannheim, Germany and Knaresborough, United Kingdom to accommodate our European sales and marketing team.</span></div><div id="ic5af433463274989b3f39da4377b2b55_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to other legal proceedings and claims in the ordinary course of business. We have received, and may from time to time receive, letters from third parties alleging patent infringement, violation of employment practices or trademark infringement, and we may in the future participate in litigation to defend ourselves. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us due to diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div id="ic5af433463274989b3f39da4377b2b55_82"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">PART II</span></div><div id="ic5af433463274989b3f39da4377b2b55_88"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Market Price of Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;SIBN&#8221;.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Holders of Record</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As of March&#160;5, 2021, we had 173 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Dividend Policy</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Recent Sales of Unregistered Securities</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of unregistered equity securities during the three months ended&#160;December 31, 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no repurchases of shares or equity securities during the three months ended&#160;December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from our Initial Public Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;16, 2018, our registration statement on Form S-1 (File No.&#160;333-227445) relating to our initial public offering (&#8220;IPO&#8221;) of common stock became effective. The IPO closed on October&#160;16, 2018 at which time we issued 8,280,000 shares of our common stock at an initial offering price of $15.00 per share for gross proceeds of $124.2 million. We received net proceeds from the IPO of approximately $113.4 million, after deducting the underwriting discount of $8.7 million and other offering-related expenses of $2.1 million. None of the expenses associated with our IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates,&#160;or to our affiliates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on October&#160;16, 2018. As of December 31, 2020, approximately $72.7 million of the net proceeds had been used for general corporate purposes including cash used in operations and capital expenditures.</span></div><div id="ic5af433463274989b3f39da4377b2b55_91"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;6. Selected Financial Data.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company&#8221;, we are not required to provide the information otherwise required by this Item.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those set forth in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied, by these forward-looking statements.</span></div><div id="ic5af433463274989b3f39da4377b2b55_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy. We have pioneered a proprietary minimally invasive surgical implant system, which we call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction, which often causes severe lower back pain. Since we introduced iFuse in 2009, as of December 31, 2020, more than 53,000 procedures have been performed by over 2,300 surgeons, in the U.S. and 35 other countries. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We introduced our second-generation implant, the iFuse-3D, in 2017. This patented titanium implant combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we received clearance from the United States Food and Drug Administration, or FDA, to promote the use of our iFuse Implant System for fusion of the sacroiliac joint in conjunction with multi-level spinal fusion procedures to provide further stabilization and immobilization of the sacroiliac joint. For this indication, surgeons typically use the posterior approach, through the sacrum and into the iliac bones, which we call the Bedrock technique. We received CE marking and began marketing our iFuse Implant System for this indication and surgical technique in Europe in December 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received FDA 510(k) clearance for an expanded indication for the iFuse Implant System to support our trauma program.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our products primarily with a direct sales force as well as a number of distributors in the U.S., and with a combination of a direct sales force and distributors in other countries. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2018, we completed our initial public offering (&#8220;IPO&#8221;) resulting in net proceeds of $113.4 million after deducting underwriting discounts and commissions and offering expenses. In January and February 2020, we received a total of $63.0 million of net proceeds, after deducting the underwriting discounts, commissions and offering expenses, from our first follow-on public offering of our common stock. In October 2020, we received a total of $71.6 million of net proceeds, after deducting underwriting discounts and commissions and offering expenses, from our second follow-on offering of our common stock. </span></div><div id="ic5af433463274989b3f39da4377b2b55_2285"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the resulting economic downturn are affecting business conditions in our industry. The overall demand for our products decreased at certain points during the year as a result of the pandemic, which impacted our operating results for the year ended December 31, 2020. Many state and local governments in the U.S. and foreign governments issued orders that temporarily precluded elective procedures in order to conserve scarce health system resources in view of the pandemic. The decrease in hospital admission rates and elective surgeries decreased the demand for elective procedures using our iFuse implants. Prior to the COVID-19 pandemic, we experienced case growth trends consistent with those experienced in the fourth quarter of 2019. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning at the end of February 2020, we began to see an impact on case volumes in Northern Italy due to the spread of the virus in the Lombardy region, the location of our operation in Gallarate, Italy. Overall, the disruption was not significant through the middle of March 2020, as Italy represents a small portion of our worldwide sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in mid-March 2020 through April 2020, we saw a substantial worldwide reduction in global case volumes due to deferral of elective surgeries as a result of the COVID-19 pandemic in the U.S. and across Europe. In May 2020, case volumes began to recover as hospitals and medical centers across the U.S. and Europe resumed performance of elective surgical procedures. In November and December 2020, we again began to see the deferral of elective surgeries by hospitals, surgeons, and patients in the U.S. and across Europe. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have taken what we believe are all necessary precautions to safeguard our employees, patients, customers, and other stakeholders from the COVID-19 pandemic. We are following the Centers for Disease Control and Prevention&#8217;s guidance and state and local restrictions. We modified operations and clinical support starting in March 2020, maintaining streamlined assembly, distribution and related processes in order to continue providing products to our customers. Specific protocols were designed and implemented to minimize contact time among employees working on site. We restricted non-essential travel to protect the health and safety of our employees, patients, and customers. Where healthcare operations were impacted, we supported healthcare providers via telephone and online technologies. We also continued to focus on increasing surgeon activity by utilizing a virtual education series for surgeons and mid-level practitioners to continue our training activities.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Starting in May 2020, we began to return to more normalized operations and clinical support as local restrictions were reduced, but tightened them again with the resurgence of COVID-19 in November 2020. The majority of our employees who are not related to manufacturing and order fulfillment are currently on a telecommunication work arrangement and have generally been able to successfully work remotely.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2020, we curtailed certain operating expense due to limited visibility on the extent and duration of the impact from COVID-19. We took preemptive steps to manage spending, including implementing hiring restrictions, eliminating discretionary spending, reducing executive salaries, reducing capital expenditures, reducing non-essential marketing expenses, and delaying clinical research projects. We returned to more normalized spending levels in the fourth quarter with returning revenue growth, refinancing of our debt, and raising of additional equity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing, extent and continuation of any further increase in procedures, and any corresponding increase in sales of our products, and whether there could be a future decrease in the current level of procedures as a result of the COVID-19 pandemic or otherwise, remain uncertain and are subject to a variety of factors, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Further increases in COVID-19 cases in various locations that would result in more hospitalizations and a corresponding decrease in elective procedures in such impacted locations. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Surgeons and hospitals postponing elective procedures as a result of reduced availability of physicians or space to treat patients, different treatment prioritizations, increased cost pressures and burdens on the overall healthcare infrastructure. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Patients electing to defer or avoid elective procedures due to concerns about being exposed to COVID-19 in hospital settings, loss of employer-sponsored health insurance related to the high levels of unemployment in the U.S. or other reasons. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Hospitals reserving more space for potential COVID-19 patients, especially as the number of COVID-19 cases spikes, limiting the space allocated to inpatient and outpatient elective procedures. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additional restrictions on access to customers, hospitals, labs and other medical facilities for sales activities, physician training and case support if they have been deemed to be &#8220;non-essential&#8221; personnel by those facilities or applicable local regulations. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The existence and further duration of the COVID-19 pandemic may also further exacerbate certain risks as described in &#8220;Item 1A - Risk Factors&#8221;. Recently, the U.S. and many other countries have experienced increasing trends of COVID-19 infections and hospitalizations.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic is continuing globally, and we are unable to predict how the COVID-19 pandemic will impact procedure volumes or product sales in the future, or the extent, duration or recurrence of the COVID-19 pandemic in any location. We are, therefore, unable to predict the impact of the COVID-19 pandemic, and such could have a material adverse effect on our results of operations, financial condition and capital resources. </span></div><div id="ic5af433463274989b3f39da4377b2b55_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Results of Operations and Key Performance Indicators</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor certain key performance indicators that we believe provide us and our investors indications of conditions that may affect results of our operations. Our revenue growth rate and commercial progress is impacted by, among other things, our key performance indicators, including our ability to leverage our sales force, increase surgeon activity and training, engage key opinion leaders, and leverage broad coverage.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leverage our sales force </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made significant investments in our sales force since our initial public offering in 2018. We have built a valuable sales team, and we believe they are the key to the recovery that follows the pandemic. As such, we have made it a top priority to support and retain our sales force through this challenging period. We limited new sales force hiring in the second and third quarter of 2020 due to uncertainty from the COVID-19 pandemic and focused on sales force productivity during this period, but resumed hiring of salespeople in the fourth quarter of 2020 based upon our favorable financial position and opportunity for future revenue growth. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our U.S. sales force consisted of 64 territory sales managers and 58 clinical support specialists directly employed by us and 41 third-party distributors, compared to 56 territory sales managers and 51 clinical support specialists directly employed by us and 37 third-party distributors as of December 31, 2019. As of December 31, 2020, our international sales force consisted of 20 sales representatives directly employed by us and 31 exclusive third-party distributors, compared to 19 sales representatives directly employed by us and 27 exclusive third-party distributors as of December 31, 2019. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increase surgeon activity and training</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical affairs team works closely with our sales team to increase surgeon activity and training. Surgeon activity includes both the number of surgeons performing iFuse procedures as well as the number of procedures performed per surgeon.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, in the U.S., more than 1,600 surgeon and 1,400 surgeons, respectively, have been trained on iFuse and have treated at least one patient. Outside the U.S., as of December 31, 2020, more than 600 surgeons have been trained on iFuse and have treated at least one patient. We grew our active surgeon base to 588 surgeons as of December 31, 2020, compared to 539 active surgeons as of December 31, 2019.  We define an active surgeon to be a surgeon who has performed at least one case in the last three months. We will continue to pursue the remainder of the approximately 7,500 target surgeons in the U.S., as well as international surgeons, for training in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak challenged our traditional method of hands-on cadaveric and dry-lab training. Therefore, in addition to utilizing a virtual education series for surgeons and mid-level practitioners for training activities, we began using the SI-BONE SImulator; a portable, radiation-free, haptics and computer-based simulator for training purposes. Starting in July 2020, we deployed four SImulators in the U.S. and one in Europe.  The SImulators were used in approximately 45% of new surgeon training courses in the second half of 2020. We have placed an order for 20 additional SImulators to increase the percentage and number of surgeons trained and retrained using the SImulator in the U.S. and Europe.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engage key opinion leaders</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bedrock technique is used in the treatment of adult spinal deformity. We introduced this technique in June 2019 for use in the fusion of the sacroiliac joints in conjunction with a multi-segment spinal fusion, or long construct, procedure. The Bedrock technique utilizes our proprietary iFuse Implants, with one implant placed across each sacroiliac joint (for a total of two implants per case) using a posterior approach, through the sacrum, across the sacroiliac joint, and into the ilium. The Bedrock technique differs from our traditional iFuse procedure, whereby three iFuse implants are placed across one sacroiliac joint via a lateral transarticular approach through the ilium and into the sacrum. The Bedrock technique is performed to increase stability at the base of a long construct. Biomechanical testing has shown that iFuse Implants placed in this position reduce sacroiliac joint motion by approximately 30% in conjunction with a long construct. We received CE mark clearance for the promotion of the Bedrock technique in Europe and we launched the promotion of this technique in select European markets. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct training courses in several academic centers in the U.S. and engage key opinion leaders to support our development efforts. Interest in the Bedrock technique among deformity surgeons, including many key opinion leaders, has provided our sales representatives with access to important academic medical centers in the U.S. This enables our representatives to train a broader group of spine surgeons, including residents and fellows at these centers, on both the Bedrock technique and minimally invasive sacroiliac fusion. In 2020, we have conducted training courses at over 50 academic centers in the U.S., where more than 200 surgical residents and fellows have been trained. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leverage broad coverage</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made significant progress in both the number of covered lives and the Medicare physician fee for surgeons performing minimally invasive sacroiliac fusion in the U.S. As of December 31, 2020, U.S. payors that account for 311.6 million U.S. covered lives reimburse for iFuse, with private payors accounting for 195.8 million of these covered lives. As of December 31, 2019, U.S. payors covering 282.7 million lives reimbursed for iFuse, of which 147.9 million were covered by private payors. As of December 31, 2020, 37 U.S. payors have issued positive coverage policies exclusive to iFuse for sacroiliac joint fusion because of the clinical evidence, compared to 32 exclusive coverage policies as of December 31, 2019. Further, as of December 31, 2020 and 2019, an additional 21 and 20, respectively, private payors cover iFuse and other products for sacroiliac joint fusion. The 2020 covered lives include Humana, the fifth largest commercial health plan in the U.S. with over 12 million members, which adopted an exclusive coverage policy in December and Aetna, the third largest commercial health plan in the U.S. with over 22 million members, which adopted a coverage policy in May 2020. Currently, covered lives counts do not include Anthem, which covers minimally invasive sacroiliac fusion procedures in the event of pelvic girdle trauma only. We track the number of U.S. covered lives, or individuals whose healthcare is paid for by a private commercial or governmental payor that routinely reimburses for minimally invasive sacroiliac fusion, as a proxy for availability of the procedure within the U.S. healthcare payment system. We believe that the full impact of each coverage decision grows over time as surgeons gain confidence that they will receive reimbursement for the majority of their diagnosed patients.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_103"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate most of our revenue from sales of iFuse. Revenue from sales of iFuse fluctuate based on volume of cases (procedures performed), discounts, mix of international and U.S. sales, and the number of implants used for a particular patient. Similar to other orthopedic companies, our case volume can vary from quarter to quarter due to a variety of factors including reimbursement, sales force changes, physician activities, and seasonality.  In addition, our revenue is impacted by changes in average selling price as we respond to the competitive landscape and price differences at different medical facilities, such as hospitals and ASCs. Further, revenue results can differ based upon the mix of business between U.S. and international sales and mix of our products either delivered at the point of implantation at the hospital or other medical facilities or delivered through distributors or to hospitals where the products were ordered in advance of the procedure. Our revenue from international sales is impacted by fluctuations in foreign currency exchange rates between the U.S. dollar (our reporting currency) and the local currency.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic reduced our expected number of cases. As the pandemic continued in the U.S. and Europe, it had a significant impact on our case volumes beginning mid-March 2020. The largest impact was felt in April 2020, where revenue declined by 84% from the prior year. Given the s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ituation, a considerable number of cases were deferred from mid-March through the end of April 2020. Starting in May 2020, case volumes began to recover as hospitals and medical centers across the U.S. and Europe resumed performance of elective surgery procedures. In the third quarter of 2020, we saw a more normalized revenue growth resulting in a 26% increase compared to the prior year. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2020, we again began to see the deferral of elective surgeries by hospitals, surgeons, and patients in the U.S. and across Europe. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the potential impact of COVID-19 to our product sales in the U.S. and international markets.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Goods Sold, Gross Profit, and Gross Margin</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize third-party manufacturers for production of iFuse implants and instrument sets. Cost of goods sold consists primarily of costs of the components of iFuse implants and instruments, instrument set depreciation, scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. Our cost of goods sold has historically increased as case levels increase. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit and gross margin are affected by factors impacting revenue and cost of goods sold. In addition, our gross margins are typically higher on products we sell directly as compared to products we sell through third-party distributors. As a result, changes in the mix of direct versus distributor sales can directly influence our gross margins. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations ran at suboptimal capacity as a result of decreased iFuse demand from worldwide restrictions on elective procedures during the second quarter of 2020. Accordingly, in the second quarter of 2020, certain labor and overhead costs were expensed as incurred which impacted our gross profit and gross margin. We saw a more normalized operations capacity during the second half of 2020 as case volumes began to recover. We may experience similar issues in future quarters due to the COVID-19 pandemic. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses consist of sales and marketing, research and development, and general and administrative expenses. Personnel costs are the most significant component of operating expenses and consist of salaries, sales commissions and other cash and stock-based compensation related expenses. We anticipate operating expenses will continue to increase to support our employees.  During the second quarter, we took steps to reduce variable expenses that were ineffective and slowed down hiring due to the impact to our revenue from COVID-19. We continue to monitor the rapidly evolving situation, but as operations returned to more normalized levels, we made additional investments to execute our strategic plans and operational initiatives.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses primarily consist of salaries, stock-based compensation expense, and other compensation related costs, for personnel employed in sales, marketing, medical affairs, reimbursement and professional education departments. In addition, our sales and marketing expenses include commissions and bonuses, generally based on a percentage of sales, to our senior sales management, direct territory sales managers, territory associate representatives and third-party distributors. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our sales and marketing spending reflected normal business activities into mid-March 2020. Due to the COVID-19 pandemic, we focused on protecting key investments in our field force while curtailing most other areas of sales and marketing spend during the second and third quarter of 2020. For example, we guaranteed certain levels of incentive compensation to members of our field sales organization in order to retain these employees and partially mitigate the impact of the pandemic to their compensation. In contrast, we reduced certain other spending during the COVID-19 pandemic, such as travel and related expenses, regional surgeon training, trade shows, and discretionary marketing. As revenue growth returned to the levels that we were experiencing prior to the pandemic, we increased our sales and marketing expense accordingly in the third and fourth quarters of 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to increase investments in our sales force and surgeon training to capture future revenue growth opportunities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses primarily consist of engineering, product development, clinical and regulatory expenses (including clinical study expenses), consulting services, outside prototyping services, outside research activities, materials, depreciation, and other costs associated with development of our products. Research and development expenses also include related personnel compensation and stock-based compensation expense. We expense research and development costs as they are incurred. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for engineering projects fluctuate with project timing. Based upon our broader set of product development initiatives and the stage of the underlying projects, we expect to continue to make investments in research and development. Clinical study expenses declined during mid-March through April due to hospital postponement of trials as a result of the COVID-19 pandemic. However, most hospitals allowed the resumption of clinical trials starting in May 2020. As such, we anticipate that research and development expenses will continue to increase in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily consist of salaries, stock-based compensation expense, and other costs for finance, accounting, legal, compliance, and administrative matters. We took measures during most of the year to control discretionary items classified as general and administrative expenses due to the COVID-19 pandemic, but expect our general and administrative expenses to return to normal levels as the acuity of the COVID-19 pandemic recedes. General and administrative activities that sustain our business and support our operations as a public company, include but are not limited to: expenses related to compliance with the rules and regulations of the Securities and Exchange Commission and those of the Nasdaq Global Market on which our securities are traded; additional insurance expenses; investor relations activities; and other administrative and professional services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income is primarily related to our investments of excess cash in money market funds and marketable securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is primarily related to borrowings, amortization of debt issuance costs and accretion of a final fee on our Solar Term Loan. Following the refinancing of our term loan, interest expense also includes the loss on debt extinguishment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of net foreign exchange gains and losses on foreign transactions.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="ic5af433463274989b3f39da4377b2b55_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage and operate as one reportable segment. The table below summarizes our results of operations for the periods presented (percentages are amounts as a percentage of revenue), which we derived from the accompanying consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.611%"><tr><td style="width:1.0%"></td><td style="width:48.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,052&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,514&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,949)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,697)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,403)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive the majority of our revenue from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. The table below summarizes our revenue by geography:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.888%"><tr><td style="width:1.0%"></td><td style="width:48.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the years ended December 31, 2020 and 2019 </span></div><div style="margin-top:12pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:48.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue for the year ended December 31, 2020 compared to the year ended December 31, 2019 comprised a $6.3 million increase in our U.S. revenue, partly offset by a decrease of $0.2 million in our international revenue. The increase in U.S. revenue was attributable to an increase in case volumes, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partly offset by lower average selling prices resulting from procedures performed at different medical facilities and cases using fewer implants in certain procedures. The increasing growth trend of our U.S. case count prior to the impact of COVID-19 was partly offset by the decline in U.S. case vol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">umes specifically during mid-March through April 2020 due to COVID-19. Prior to the impact of COVID-19, we experienced case growth trends consistent with those experienced in the fourth quarter of 2019. The case growth we experienced prior to the impact of COVID-19 we attribute to higher sales force productivity, higher numbers of sales personnel, and increased active surgeons due to improving U.S. reimbursement coverage. The decrease in our international revenue we believe was primarily due to the effects of COVID-19.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit and Gross Margin.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross profit increased $4.0 million for the year ended December 31, 2020 compared to the year ended December 31, 2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily driven by higher revenue, partly offset by higher cost of goods sold. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ross margin decreased to 88% for the year ended December 31, 2020 as compared to 90% the year ended December 31, 2019 primarily due to certain period costs of $0.2 million charged directly to cost of operations and increases in inventory write-downs of $0.8 million. Certain period costs were expensed as incurred during the second quarter of 2020 because our operations ran at suboptimal capacity due to lower case volumes as a result of the COVID-19 pandemic. Gross margin was also impacted by higher employee related costs and inventory management to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support the growth of the business. </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:48.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,052&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,514&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in sales and marketing expenses for the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to an increase of $9.7&#160;million in employee related costs and stock-based compensation expense driven by increased headcount. The increase was partly offset by decreases in travel and other sales and marketing related expenses of $4.2 million due to the COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to increases in employee related costs and stock-based compensation expense of $1.7 million driven by increased headcount, as well as increases in other research and development expenses of $0.5 million primarily due to clinical study and research and development activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in general and administrative expenses for the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to $2.5 million of accrued litigation expense recorded in the third quarter of 2019, the reversal of excess accrued litigation expense of $0.6&#160;million in the second quarter of 2020 following the final settlement of our TCPA class action lawsuit, and decreases in other general and administrative expenses of $0.6 million as a result of curtailment of discretionary spending in response to the COVID-19 pandemic. These decreases were partly offset by an increase of $2.3 million in employee related costs and stock-based compensation expense driven by increased headcount and $0.2 million public offering costs that were expensed associated with the follow-on offering in the first quarter of 2020.</span></div><div style="margin-top:12pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income (Expense), Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:48.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.878%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,949)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other expense, net</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,130)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*not meaningful</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in interest income for the year ended December 31, 2020 as compared to the year ended December 31, 2019 was mainly due to lower interest earned on our investments in marketable securities. Although the average investments balances were higher for the year ended December 31, 2020, interest rates earned were lower.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in interest expense for the year ended December 31, 2020 as compared to the year ended December 31, 2019 was mainly due to the loss on extinguishment of our Pharmakon Term Loan of $1.5&#160;million, partly offset by lower interest associated with our Solar Term Loan. See "-Liquidity and Capital Resources-Term Loan."</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, increased for the year ended December 31, 2020 as compared to the year ended December 31, 2019 due to higher foreign currency exchange losses. </span></div><div id="ic5af433463274989b3f39da4377b2b55_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had cash and marketable securities of $196.4 million compared to $93.1 million as of December 31, 2019. We have financed our operations through our public offerings, debt financing arrangements, and the sale of our products. As of December 31, 2020 and 2019 we had $39.5 million and $39.2 million outstanding debt, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had an accumulated deficit of $239.3 million. During the years ended December 31, 2020 and 2019, we incurred a net loss of $43.7 million and $38.4 million, respectively, and expect to incur additional losses in the future. We have not achieved positive cash flow from operations to date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our current operating plan, we believe that our existing cash and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months. However, the economic impact of the duration and severity of the COVID-19 pandemic, and our responses thereto (including such actions we have taken or may take in the future as disclosed elsewhere in this Report) pose risks and uncertainties in our future available capital resources. Further, we may face challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to, but not limited to, the following as a result of the COVID-19 pandemic or otherwise: (a)&#160;decreases in sales of our products and the uncertainty of future revenues from new products; (b)&#160;changes we may make to the business that affect ongoing operating expenses; (c)&#160;changes we may make in our business strategy; (d)&#160;regulatory developments affecting our existing products; (e)&#160;changes we may make in our research and development spending plans; and (f)&#160;other items affecting our forecasted level of expenditures and use of cash resources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding debt as of December 31, 2020 is related to a term loan pursuant to the Loan and Security Agreement dated May 29, 2020, entered into by us with Solar Capital Partners (&#8220;Solar&#8221;). Pursuant to the Loan and Security Agreement, Solar provided an aggregate principal amount of $40.0&#160;million term loan to us (the &#8220;Solar Term Loan&#8221;). Prior to Solar Term Loan, our outstanding debt was related to a $40.0 million Term Loan with Biopharma Credit Investments IV Sub LP (&#8220;Pharmakon&#8221;) entered in October 2017 (the &#8220;Pharmakon Term Loan&#8221;). In accordance with the Loan and Security Agreement with Solar, we paid in full and terminated the Pharmakon Term Loan, which we accounted for as debt extinguishment in accordance with the accounting standards. As of December 31, 2020 and 2019, there was no amount available that could be borrowed under the credit facilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Pharmakon Term Loan included an interest-only period for 35 months through September 2020 and equal quarterly principal payments plus interest through December 2022. The Pharmakon Term Loan carried a fixed interest rate of 11.5% and allowed for early prepayment. The prepayment penalty was equal to the remaining interest due if prepaid within the first 30 months, a 2% penalty for months 31-48, and a 1% penalty for months 49-60. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solar Term Loan bears interest at a rate per annum equal to 9.40% plus London Interbank Offered Rate (&#8220;LIBOR&#8221;), payable monthly in arrears. LIBOR means the greater of (i) 0.33% or (ii) one-month LIBOR (or a comparable replacement rate to be determined by the collateral agent if the LIBOR is no longer available), which rate shall reset monthly. The Solar Term Loan matures in 60 months on June 1, 2025 (&#8220;Maturity Date&#8221;), with an interest-only period of 36 months through June 2023, and then repaid in equal monthly principal payments plus interest through maturity date. Pursuant to the Loan and Security Agreement, we may voluntarily prepay the Solar Term Loan, in full or in part, in increments of $10.0&#160;million, for a prepayment premium in an amount equal to 3.00% of the principal if prepaid in year one, 1.25% of the principal if prepaid in year two, and 0.50% of the principal if prepaid in year three or later. The prepayment premium will be waived if we voluntarily prepay and refinance the outstanding balance with Solar. The Solar Term Loan is secured by substantially all of our assets. We are also obligated to pay a final fee equal to $1.0&#160;million or 2.5% of the aggregate principal amount of the Solar Term Loan. This final fee shall be due and payable on the earliest of (i) the maturity date, (ii) the acceleration of the loan balance, or (iii) the full prepayment, refinancing, substitution or replacement of Solar Term Loan. The final fee was included within the long-term borrowings and is accreted to interest expense using straight-line method over the life of the term loan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2017, the head of the United Kingdom Financial Conduct Authority announced the desire to phase out the use of LIBOR by the end of 2021. In addition, the U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee composed of large U.S. financial institutions, is considering replacing U.S. dollar LIBOR with the Secured Overnight Financing Rate (&#8220;SOFR&#8221;), a new index calculated by short-term repurchase agreements, backed by Treasury securities. Although there have been a few issuances utilizing SOFR or the Sterling Over Night Index Average, an alternative reference rate that is based on transactions, it is unknown whether these alternative reference rates will attain market acceptance as replacements for LIBOR. There is currently no definitive information regarding the future utilization of LIBOR or of any particular replacement rate. As such, the potential effect of any replacement of the LIBOR could have on our business and financial condition cannot yet be determined.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to other customary covenants set forth in the Loan and Security Agreement, we are required to maintain unrestricted cash and cash equivalents based on the trailing 12-month net products revenues tested on a monthly basis as follows: (a) $15.0&#160;million if net product revenue is less than $75.0&#160;million; or (b) $7.5&#160;million if net product revenue is greater than or equal to $75.0&#160;million, but less than $100.0&#160;million (the &#8220;minimum liquidity requirement&#8221;). We are not subject to minimum liquidity requirement when trailing twelve-month net product revenues exceed $100.0&#160;million. Upon the occurrence of an event of default of certain customary covenants, including the minimum liquidity requirement, as specified in the Loan and Security Agreement, subject to specified cure periods, all amounts owed by us would begin to bear interest at a rate that is 5.0% above the rate effective immediately before the event of default and may be declared immediately due and payable by Solar. As of December 31, 2020, we were in compliance with all debt covenants. Though there are uncertainties surrounding the impact of the COVID-19 pandemic that may impact our future revenue, we believe that we have sufficient cash and cash equivalents to meet the minimum liquidity requirements in the foreseeable succeeding period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contractual Obligations</span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of&#160;December 31, 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.750%"><tr><td style="width:1.0%"></td><td style="width:38.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due By Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1-3 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4-5 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal obligations and final fee on long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,644&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.305%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the principal obligations and the final fee at maturities of our Solar Term Loan.</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the future interest obligations on our Solar Term Loan estimated using the fixed interest rate of 9.40% plus LIBOR held constant as of December 31, 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash for each of the periods presented below:  </span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.972%"><tr><td style="width:1.0%"></td><td style="width:56.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.624%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$&#160;Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,916)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,407)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,685)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities  </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December 31, 2020 of $30.7 million resulted from cash outflows due to net loss of $43.7 million, adjusted for $15.6 million of non-cash items and cash outflows from changes in operating assets and liabilities of $2.5 million. Net cash used in operation activities for the year ended December 31, 2019 of $31.6 million resulted from cash outflows due to net loss of $38.4 million, adjusted for $7.3 million of non-cash items and cash outflows from changes in operating assets and liabilities of $0.5 million. The increase in net loss, net of non-cash items for the year ended December 31, 2020 compared to the year ended December 31, 2019 was mainly due to the higher operating expenses from the growth of the business, partly offset by higher revenue and decreases of certain expenses primarily due to the timing of accrual for litigation expense, and the result of actions taken to reduce discretionary spending in response to COVID-19. Cash outflows from changes in operating assets and liabilities for year ended December 31, 2020 were primarily due to timing of prepayments of certain expenses, higher accounts receivable due to the timing of collections, higher inventory due to the timing of inventory build-up and cash outflows due to increases in operating liabilities due to timing of payments. Cash outflows from changes in operating assets and liabilities for the year ended December 31, 2019 were primarily due to increases in inventories and accounts receivable as a result of increased case volumes and growth of the business, partly offset by increased operating liabilities due to the timing of payments and accrual of litigation expense related to a legal proceeding. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by (Used In) Investing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in the year ended December 31, 2020 was $62.9 million compared to net cash provided by investing activities of $13.5 million in the year ended December 31, 2019. Net cash used in investing activities for the year ended December 31, 2020 consisted of purchases of our marketable securities, net of maturities and sales, of $60.4 million, and by purchases of purchases of property and equipment of $2.6 million. Net cash provided by investing activities for the year ended December 31, 2019 consisted of maturities of our marketable securities, net of purchases of $15.9 million, partially offset by purchases of property and equipment of $2.4 million. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities in the year ended December 31, 2020 was $136.4 million compared to $3.5 million in the year ended December 31, 2019. The difference was primarily due to the receipt of the proceeds, net of underwriting discounts, commissions and offering costs of $134.6 million from our follow-on public offerings in January and October 2020. Cash provided by financing activities for the year ended December 31, 2020 also include proceeds from the issuance of common stock under our stock-based incentive compensation plans of $3.4 million, partly offset by debt payments associated with refinancing of our debt of $1.6 million. This compares to the cash provided by financing activities for the year ended December 31, 2019 which consisted of issuance of shares of common stock under our employee stock purchase plan of $3.7 million, partially offset by payments of additional IPO related costs of $0.2 million.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments, and Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. For more comprehensive discussion of our significant accounting policies, refer to &#8220;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Summary of Significant Account Policies&#8221; in the accompanying Notes to Consolidated Financial Statements in Item 8 of this Form 10-K. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) effective January 1, 2019. The adoption of ASC 606 did not have a material effect on our revenue recognition. We derive our revenue from the sale of our products to medical groups and hospitals through our direct sales force and distributors throughout the U.S. and Europe. In accordance with ASC 606, we recognize revenue when control is transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for the goods or services. To recognize revenue, we apply the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it relates to majority of our revenue consisting of product sales where our sales representative delivers the product at the point of implantation at hospital or medical facilities, we recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. We also generate a small portion of our revenue from sale of products through distributors and hospital or medical facilities where the product is ordered in advance of a procedure. The performance obligation is the delivery of the product and therefore, we recognize revenue upon shipment to the customers, net of rebates and price discounts. We account for rebates and price discounts as reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either customer contract, agreed price list, or purchase order, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, we have agreements in place consists of either a master services agreement or an approved price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. We also have agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor&#8217;s payment obligation. Our standard payment terms are generally net 30 to 90 days. We consider sales commissions and related expenses as incremental and recoverable costs of acquiring customer contracts. Our sales commissions paid to our sales representatives commensurate for each surgery performed. The period of benefit is concurrent when we recognize our revenue, as such, we also recognize sales commission as expense when incurred. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">         </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the grant date fair value of stock options and ESPP using the Black-Scholes option valuation model. The model requires us to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment.</span></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that we expect the share-based awards to be outstanding. We use the simplified method to determine the expected term as permitted by the guidance since we have no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we became public in October 2018 and have no sufficient trading history, we use stock price volatility using the average historical volatilities of publicly traded companies within our industry that we consider comparable to our business over a period approximately equal to the expected term of our stock options.</span></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the risk-free interest rate on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid any dividends and we have no current plans to pay dividends on our common stock. As such, we use expected dividend yield of zero.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense over the requisite service period using the straight-line method, which is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, we reduce our stock-based compensation for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that we expect to vest. To the extent actual forfeitures differ from the estimates, we record the difference as a cumulative adjustment in the period that the estimates are revised.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="ic5af433463274989b3f39da4377b2b55_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</span></div><div id="ic5af433463274989b3f39da4377b2b55_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is affected by seasonal variations. For instance, we have historically experienced lower sales in the summer months and higher sales in the last quarter of the fiscal year. However, taken as a whole, seasonality does not have a material impact on our financial results.</span></div><div id="ic5af433463274989b3f39da4377b2b55_130"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2012, the JOBS Act was enacted. Section&#160;107(b) of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, are not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div id="ic5af433463274989b3f39da4377b2b55_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 of Notes to Consolidated Financial Statements for related discussions on recently adopted accounting standards and updates on recently issued accounting standards not yet effective, which information is incorporated by reference here.</span></div><div id="ic5af433463274989b3f39da4377b2b55_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a &#8220;smaller reporting company&#8221;, we are not required to provide the information otherwise required by this Item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_139"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.277%"><tr><td style="width:1.0%"></td><td style="width:93.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_142">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_142">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_145">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_145">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_151">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_151">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_154">Consolidated Statements of Changes in Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_154">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_157">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_157">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_160">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_160">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_226">Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_226">107</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_142"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of SI-BONE, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of SI-BONE, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, of changes in stockholders' equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/PricewaterhouseCoopers LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;10, 2021 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2013.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMtMS0xLTEtMA_b073dcf8-0899-4bb9-91d9-f9b20ba1d3f0">53,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMtMy0xLTEtMA_98a11c07-f3fb-44eb-838b-65881a220363">10,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzQtMS0xLTEtMA_318b8456-f637-485a-83e2-7031473f9111">142,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzQtMy0xLTEtMA_72b426a3-ea4d-4028-b629-9674795fa867">81,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2RiNTg2ZDc3MzQ1MWViYzExMWFmYjgzOWI4ZGVkXzE2NDkyNjc0NDE4NzY_ae2ba10f-f971-435f-b613-e9a473a2f396">263</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2RiNTg2ZDc3MzQ1MWViYzExMWFmYjgzOWI4ZGVkXzE2NDkyNjc0NDE4ODI_691c4ca7-b856-4d2a-8519-97313d2cedb0">238</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMS0xLTEtMA_2c9efef0-ff58-42b9-aaad-9181c11d844f">13,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMy0xLTEtMA_fc5b5217-bfb6-49a7-8fa5-b565a617957c">11,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzYtMS0xLTEtMA_40209f7f-0527-4fc1-9304-742209368a0a">5,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzYtMy0xLTEtMA_fe863da0-fc86-4051-ba62-8bd587f0b378">5,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzctMS0xLTEtMA_9d7a9bc2-a7f0-4941-b10c-6a423b7c5ce5">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzctMy0xLTEtMA_edfc948f-4de9-42c3-a20e-bb2452e2ea4e">2,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzgtMS0xLTEtMA_89ac2be0-11b6-4dcb-b3ed-62baa1543348">218,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzgtMy0xLTEtMA_edb23767-05f2-45b9-9e43-e2f1c0f80e41">111,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzktMS0xLTEtMA_e410a5e5-062f-4805-a515-170aa6d29ec2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzktMy0xLTEtMA_2a34d73c-5eb9-4ed2-b2ac-0af05fc0e9a9">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEwLTEtMS0xLTA_bd0afd76-6aea-4382-a54d-2ecf10fa3930">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEwLTMtMS0xLTA_b34b63d8-568a-4252-ac46-3622ad0823a4">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzExLTEtMS0xLTA_da0d2c4b-cb54-4171-b58c-821dc3644510">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzExLTMtMS0xLTA_b5b97274-8c09-4eaa-88f8-f9ddad570be5">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL ASSETS </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEyLTEtMS0xLTA_9f8079a3-c4cc-4089-b619-407c9dcb4d11">223,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEyLTMtMS0xLTA_7b3e4e7d-96fd-4e5d-b115-75e7ee6d8bed">117,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT LIABILITIES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE2LTEtMS0xLTA_5750028a-46ab-4aa2-bc7b-cc17ff928666">3,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE2LTMtMS0xLTA_31f20bb3-a9c5-49a5-a912-409da6e69b33">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE3LTEtMS0xLTA_01230c1a-7aaa-43b5-b58d-83de57cb263e">10,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE3LTMtMS0xLTA_51bf3cc0-1dcd-4db5-b4b7-68bb20807e3f">11,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE4LTEtMS0xLTA_b49416eb-decb-4d33-a046-db0bfa7b8d4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE4LTMtMS0xLTA_4cdaf84d-7680-4d16-819c-3ef261b3001f">4,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE5LTEtMS0xLTA_83ae6ac9-4a8c-4df2-ba6a-ea5a33a4db71">13,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE5LTMtMS0xLTA_220e92eb-a037-469a-82ab-a9c48d51399f">18,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIwLTEtMS0xLTA_727adb47-bfc7-4ef9-9d90-7e3bd5fbebeb">39,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIwLTMtMS0xLTA_51c774cd-2940-41ac-85fc-894d93a276ef">34,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIxLTEtMS0xLTA_7b21633e-6abf-4e99-a7d0-f27e61b5de3c">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIxLTMtMS0xLTA_9c2e4f0e-09c7-4f31-9048-53869311c025">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIyLTEtMS0xLTA_b121ecf4-bbee-4fd4-8b7e-b033ec6eeacd">53,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIyLTMtMS0xLTA_66ac8fd8-1113-46e9-8611-1826ae29be7c">54,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI0LTEtMS0xLTA_68e16648-a80c-465f-ac1a-20704693ce23"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI0LTMtMS0xLTA_a56f7d81-8b0f-4a55-be60-89ed13498b30"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxNzcz_68e464a2-1ec4-42a9-a846-42bd6f640c86"><ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxNzcz_fb64fda6-463e-40b8-a100-6e20a54d27c5">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxODc3_fde9c6ba-69bf-4c7c-837b-edebee713994"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxODc3_fe736678-2095-4546-86f7-3d6689be731e">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_1cfb38c2-6fe4-453b-8b11-43ddf15e9ea5"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_2abaa248-ac65-4864-b7b0-ba242df08038"><ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_4213e4df-280b-4d7a-9ef1-d718c4f3eca4"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_5ac6ae06-5993-4cd9-b3b6-9570f1b39c9d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTEtMS0xLTA_f87c9635-e3a8-4581-bbbc-4ddc0cb0dcc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTMtMS0xLTA_e8e42b63-0037-40d0-8a35-a90154b996d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxODA5_2c7d54a6-5b3f-4aaf-a3d1-5c52fd453192"><ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxODA5_d1e62769-7774-491c-ac53-3133d9730de7">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTUx_51d68a71-1dd2-4187-8226-e3f4f5c48410"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTUx_a9d80cef-754a-4d09-9bcb-e82c539a7963">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTYz_97e898f8-63fb-4b48-b32c-ecf6ab171edc"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTYz_be43610b-b51a-4812-ae15-0c9a56117e4b">32,583,220</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTc1_c0b6af6b-7572-435e-9140-04f32d6e03aa"><ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTc1_cbedde50-5646-42b2-b194-6288c9f066ff">25,163,803</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTEtMS0xLTA_37d66e32-03a4-40af-9a0c-f9c97be27873">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTMtMS0xLTA_cab4e432-2817-4fcb-aba5-43b5376e090e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI5LTEtMS0xLTA_0a7d0ba4-ca16-409c-aac9-270f4b24c821">408,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI5LTMtMS0xLTA_1d60df64-e43a-41f6-96a2-55112b7def1d">258,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMwLTEtMS0xLTA_78a46e4f-2011-4095-9e36-fcaed5d5048c">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMwLTMtMS0xLTA_aee64011-8de9-4e69-9a43-439dc2378e4a">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMxLTEtMS0xLTA_063b5204-f68b-4502-857b-9ea33a586c10">239,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMxLTMtMS0xLTA_d4226e07-d9a9-474e-ac0f-14eed061aa17">195,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMyLTEtMS0xLTA_cb830294-9996-443d-b6d4-89e7db42e447">169,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMyLTMtMS0xLTA_e5db2ca4-f207-4346-a12e-e91992c874eb">63,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMzLTEtMS0xLTA_825ec427-96b7-4ba4-9f9c-3d92323de628">223,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMzLTMtMS0xLTA_7e705bdb-991a-42d9-9fff-30b2c406c1ff">117,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_151"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts) </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzItMi0xLTEtMA_b93b89fb-c892-4c38-b557-d62e1a32f2dd">73,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzItNC0xLTEtMA_9c11d514-9153-4403-b63c-918ce650aab0">67,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzMtMi0xLTEtMA_7b32be6c-721d-4635-a10d-04c5809db67c">8,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzMtNC0xLTEtMA_dccb4b8b-392d-468b-a3d1-5152ed572c90">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzQtMi0xLTEtMA_b421e82e-a580-43f2-8d16-da988485a06d">64,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzQtNC0xLTEtMA_8d72f00e-8914-4c3e-b0cd-f878318a2555">60,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzYtMi0xLTEtMA_4d636e27-1c84-483f-9d4a-8ea0e72a3b3d">73,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzYtNC0xLTEtMA_8b41b6c3-cbed-4051-a2de-3a5a079ef961">68,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzctMi0xLTEtMA_26bd79f7-349d-4f49-9a67-3bc7bf23f2df">9,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzctNC0xLTEtMA_25298f24-5324-436c-a35f-566371073c29">7,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzgtMi0xLTEtMA_6aa65e36-e7eb-4dbb-9169-27127ed10eaa">19,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzgtNC0xLTEtMA_caf94342-3df4-4655-bb38-533c1670c620">20,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzktMi0xLTEtMA_12c33f92-c435-4af6-b6b5-cff77655ff48">103,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzktNC0xLTEtMA_3d21c263-2aef-4e9f-92e0-4392ad7d3695">96,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEwLTItMS0xLTA_a71ba745-e36d-4298-ac7d-e5de48626ba4">38,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEwLTQtMS0xLTA_d52f0174-3ed1-4b4f-8e83-ea9a31fae339">36,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEyLTItMS0xLTA_6f5d62de-9e4f-4c69-b606-8e7cd7703717">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEyLTQtMS0xLTA_dc4a2d7c-f873-4003-9d0c-d8e02e22ea47">2,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEzLTItMS0xLTA_481baa0c-c00d-4e31-bd3b-65ed86d6d7a8">6,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEzLTQtMS0xLTA_a4996183-c3fd-42ca-8701-e544a5947ae4">4,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE0LTItMS0xLTA_73ae36d5-5609-46ab-ba84-4ea770314430">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE0LTQtMS0xLTA_f4fdf9db-e35b-41d1-a277-417c6bb81c37">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE1LTItMS0xLTA_15e8bbb3-ce1f-495b-b129-07dc4cbfb4f7">43,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE1LTQtMS0xLTA_b1ffa80e-4cb9-42e0-93a5-6db0796f8a36">38,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE3LTItMS0xLTA_1e41d443-5580-4bd4-b134-844778b9a8f9">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE3LTQtMS0xLTA_9619b3e5-35bf-46ac-9ba3-c0052d24ba31">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in foreign currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE4LTItMS0xLTA_c48647d3-b3ef-4774-8aca-234d886f7ef5">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE4LTQtMS0xLTA_f8828dce-1bcd-4d25-95bf-fbbddde2c05b">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE5LTItMS0xLTA_b02ce90a-13ae-44eb-887b-f3aedd79875b">43,637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE5LTQtMS0xLTA_7b390c5c-0d1b-4fc0-88dc-f9c5c04e8342">38,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIxLTItMS0xLTA_0325349d-0127-4825-addc-c7bd2cf7047a">1.50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIxLTQtMS0xLTA_8917c276-e324-4f13-91be-9309d9314992">1.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIzLTItMS0xLTA_d7610abc-9991-433a-87ae-f2905d6ce0cc">29,059,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIzLTQtMS0xLTA_61282f59-7e36-42ff-a33c-5d8fb0d907dd">24,705,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts) </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.145%"><tr><td style="width:1.0%"></td><td style="width:44.050%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.422%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated <br/>Other <br/>Comprehensive <br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total <br/>Stockholders&#8217; Equity </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie66d822de1dc49998b0d0dbd86b96408_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItNi0xLTEtMA_3152d186-a161-40ac-a7c4-275b6da33dfc">24,450,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d822de1dc49998b0d0dbd86b96408_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItOC0xLTEtMA_7f260b1e-d91d-4ee8-98e4-20fc6a491628">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dff6565556f4ea180e9d4dc002bcc73_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTAtMS0xLTA_02bcd563-454d-4ddd-97db-b8b0e4a2ac25">246,927</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b4c997fd0c473da8c08fde9e5c65d4_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTItMS0xLTA_7a323199-3be8-46e1-b732-a193a199b45b">439</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e5589745a4b4e59be2fa5da9fc96faa_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTQtMS0xLTA_f928b9b2-d173-4556-8bcf-a727e187a303">157,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTYtMS0xLTA_1360742d-74c6-428a-994c-aa95bbfb0d29">90,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options, net of shares withheld</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzMtNi0xLTEtMA_cb6aa02f-9e99-444c-9c8c-588141b77bfa">444,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzMtMTAtMS0xLTA_e6f4cb49-3736-4131-b7c1-12cd3fd71326">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzMtMTYtMS0xLTA_976df93e-560a-4a3e-82e5-b3083a241e09">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock related to employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzQtNi0xLTEtMA_d3169424-0e67-40e1-b25f-9bdb7ef93703">168,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzQtNi0xLTEtMzU_b3dc38cb-a607-4a1c-8879-b9a8f564c5f6">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzQtMTYtMS0xLTA_012f5598-4bc2-4a36-9159-6f213d2d5c0c">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="sibn:StockIssuedDuringPeriodSharesRestrictedStockUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzUtNi0xLTEtMA_0a0e37f2-8e23-4fba-ad79-88e300d2bf0d">108,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sibn:StockIssuedDuringPeriodAmountRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzUtMTYtMS0xLTA_6a35b441-833d-4253-862d-9bb3cfb53088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of unvested early exercised stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzYtMi0xLTEtMzU_86431696-1b11-42d3-b1d4-5fd17cac46a4">8,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzYtMTYtMS0xLTA_750ae728-245a-497a-b16b-bcd0453442e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzctNi0xLTEtMzU_ae1d9e9e-eece-4969-a5bb-2743a1430496">7,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzctMTYtMS0xLTA_b16b5a8f-42b3-4d27-8073-29b0cd4584c9">7,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231" decimals="-3" name="sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzgtMTAtMS0xLTA_2129ff35-c86a-4dc7-a27c-78250a4089ab">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzgtMTYtMS0xLTA_66ccef30-5a2d-4715-b424-ef76aaec826f">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional accrual of IPO related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzktNi0xLTEtMzU_70f0efae-4d9f-4132-a777-b591096e482a">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzktMTYtMS0xLTA_c39e122d-46c0-44e1-9538-1ea04f7adb22">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffbce40da8154d0ebfd353ebc4ecfc66_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEwLTgtMS0xLTM1_efa9b7e2-042b-4a65-8fdd-cd88e0e6894b">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEwLTE2LTEtMS0w_c07d5a23-1a4b-4e1c-8021-15c8639ffdf7">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbce40da8154d0ebfd353ebc4ecfc66_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzExLTgtMS0xLTM1_9ef40bd4-1738-44be-8326-a532e9248cc0">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzExLTE2LTEtMS0w_589431ad-e9ba-498a-a611-3efa116d79e9">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04fe10a38bbc4b9b992c2d00521e3926_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEyLTEwLTEtMS0zNQ_66593f0d-b650-48c1-b10f-38a3641f9984">38,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEyLTE2LTEtMS0w_f73dbe66-33da-4761-9502-6bd2e301dbf1">38,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances as of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i985109e7c07a47caa2b5f16db86a7f92_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTYtMS0xLTA_668a4e5c-4575-440f-bc32-7bc327b78a65">25,163,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985109e7c07a47caa2b5f16db86a7f92_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTgtMS0xLTA_dea616b7-ea44-4a93-89eb-d856637f0972">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b107ede87a64e409d8ea0d6c15db765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTEwLTEtMS0w_aa859a81-29f4-48da-b7db-a6e8db21c366">258,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26490e07c24473bb2dfc03fc2377ce8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTEyLTEtMS0w_490c5da8-4a2d-441a-98fd-a7c3a07dab9a">464</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d1708678a945beac3f5189fa6daf27_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTE0LTEtMS0w_1569e010-ea57-4d0a-b017-0d2dc46ab9c8">195,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTE2LTEtMS0w_3bfb1e1b-7642-47f5-a0ce-9f9d02b28801">63,008</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTItMS0xLTYwMg_7f28ba71-7d38-4af4-ab22-ec314b923cea">6,613,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTQtMS0xLTYwMg_383ef9a3-4181-490e-80e1-a75dddb9615d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTYtMS0xLTYwMg_2c1a3c59-57cc-4980-87c8-0f352e710186">134,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTEyLTEtMS02MDI_16485010-1008-4e12-ace1-a8dc36f6c855">134,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options, net of shares withheld</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE2LTYtMS0xLTA_aba59592-5c04-4838-83ef-2c1c5e569c4a">323,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE2LTEwLTEtMS0w_82ee2c04-a8c1-477f-b98e-9ca7b1bfec8a">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE2LTE2LTEtMS0w_0a8c3a6e-45fa-48b2-9ad0-914863439d8b">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock related to employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE3LTYtMS0xLTA_53bf1e14-2930-4095-a701-cc9b45fae991">137,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE3LTEwLTEtMS0w_0323586b-03ac-498c-b0cf-948dd5c5a9b6">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE3LTE2LTEtMS0w_55d5f692-25b7-412c-8eec-5568944c3ab7">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="sibn:StockIssuedDuringPeriodSharesRestrictedStockUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE4LTYtMS0xLTA_d64ed5b5-384b-47aa-8bce-91367e35bd90">344,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="sibn:StockIssuedDuringPeriodAmountRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE4LTE2LTEtMS0w_60c4efc1-99a1-47f6-89ac-1fdcea448d2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIwLTEwLTEtMS0w_39a3151d-8d53-403e-9901-376b15cd0743">11,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIwLTE2LTEtMS0w_b29a05ea-aa6c-47c2-92d8-dac5233700dc">11,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231" decimals="-3" name="sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIxLTEwLTEtMS0w_bc52ebd5-bcbb-4297-945d-7a2cf0f56c81">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIxLTE2LTEtMS0w_35653781-9bbc-4e53-9151-8269853cba96">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a1c74b555a4f0aba5275ea8e0f0cdc_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIzLTEyLTEtMS0w_0834de91-251d-4a54-ba5e-57bb4f96006a">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIzLTE2LTEtMS0w_39aaed8c-9e44-4214-ad45-550274cdca23">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6a1c74b555a4f0aba5275ea8e0f0cdc_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI0LTEyLTEtMS0w_c38227f0-0bd5-425e-ae44-04ef27d7eeb8">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI0LTE2LTEtMS0w_53489154-c33e-4c92-9cfa-fc6b2c1ceae7">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic95beb3614404efb8439b54564decf04_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI1LTE0LTEtMS0w_680d69a8-9de0-4b9b-9a5f-1deb4e08b771">43,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI1LTE2LTEtMS0w_1a899fe3-2603-431d-bdb6-80a5929a8de9">43,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances as of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida15542c93ec4747869dcb494008d0f3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTYtMS0xLTA_6b0f6944-3a3b-461e-8f3e-47d12e421913">32,583,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida15542c93ec4747869dcb494008d0f3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTgtMS0xLTA_23c656b3-9a1a-4b95-b94c-45b382c301c6">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a37168d69c463082d9d5b20b3a2f88_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTEwLTEtMS0w_cc7ce524-8741-4320-82f1-636e282b53ae">408,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f72f3efd8214401a36fbcad6478c88c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTEyLTEtMS0w_a2ff9c11-c3df-45e4-a816-35facc03753e">524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic23626475cd542f79e54023f0ce2273b_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTE0LTEtMS0w_8b95e5b0-5255-400d-a648-bc7da10caff7">239,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTE2LTEtMS0w_c8301df1-99e6-40e9-87b4-5f2ce0f2c4fe">169,363</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_157"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMtMS0xLTEtMA_b835daaf-64fa-4845-9e39-e073e61c9dff">43,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMtMy0xLTEtMA_75237591-660f-40a6-9241-96fb416d64ff">38,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzUtMS0xLTEtMA_df1e2895-1999-4448-9316-a0abdc2619f2">11,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzUtMy0xLTEtMA_f3b92b61-ed59-4af2-b1af-646a16adabba">7,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzYtMS0xLTEtMA_a9ecd7c8-fc90-4456-9094-4fcd12f30807">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzYtMy0xLTEtMA_379cfca2-0434-4434-a994-4c02f62135b8">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Bad debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMS0xLTEtMTAz_09e867bd-9708-4be8-9d86-1e6fe9d4afed">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMy0xLTEtMTAz_2a5b6d7f-ea72-48a7-8292-750530a1b212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMS0xLTEtMA_b4fdea36-e3c6-4ee0-b83c-0987cd5f7569">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMy0xLTEtMA_f3f00bfd-ca08-410d-b05b-ade25679c7da">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Realized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzktMS0xLTEtNjc0_35c21655-ac27-4e05-89e8-e54fae09ad10">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzktMy0xLTEtNjc0_a18f6d4e-44db-463f-a451-aa0bf5919075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzgtMS0xLTEtMA_bb4c179c-0037-45d1-a1de-7d0b6df89930">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzgtMy0xLTEtMA_4fb08505-3bab-4595-84f5-a5a83cf8a20f">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzExLTEtMS0xLTY3OA_2c7b99a3-6c42-441c-9c67-0351e7061ac9">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzExLTMtMS0xLTY3OA_b1900686-7139-4ead-b47b-f9c023bf513a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale and disposal of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEwLTEtMS0xLTA_5a7eef7e-d019-47ba-8b02-85fa35556b2d">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEwLTMtMS0xLTA_65800d2c-9bea-4781-84d7-75249336e41a">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEyLTEtMS0xLTA_622218a9-1676-4550-8106-3cbacec00f8e">2,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEyLTMtMS0xLTA_5db0a292-ab29-4cc9-a671-16a1b806796c">3,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEzLTEtMS0xLTA_aad98c72-aabc-4fe9-98e8-bbe5617b613e">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEzLTMtMS0xLTA_07978d60-1e4a-43e9-a652-14be7625a7bf">2,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE0LTEtMS0xLTA_c3623d54-50ca-4deb-8d2c-b7208e854ea7">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE0LTMtMS0xLTA_0188a171-55d9-4fd3-a105-1f19a9fbcbfa">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE1LTEtMS0xLTA_6fb5ffc8-978f-44b0-ac1d-c1040ec59fdb">835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE1LTMtMS0xLTA_362e464b-a4f1-4d6c-9dc4-03fc5132e7eb">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE2LTEtMS0xLTA_74eb1ef4-3abf-4d22-98a9-49e19d41f5dd">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE2LTMtMS0xLTA_65f0b43d-d3d7-4cb6-940a-8f4e83ab7ef1">4,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:60.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE3LTEtMS0xLTA_a89deea8-6c36-45aa-99ee-e214d9681516">30,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE3LTMtMS0xLTA_450d6673-6bde-4de9-96a7-30c011f51368">31,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:ProceedsFromMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE5LTEtMS0xLTA_ce9306ea-e762-4a96-a745-8409f2173233">104,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:ProceedsFromMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE5LTMtMS0xLTA_1f154853-9501-4458-acd5-93311a4fb733">159,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:ProceedsFromSaleOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTEtMS0xLTY5Mg_c12e4e2f-f1f6-42d6-b5d4-df174afb9c6b">14,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sibn:ProceedsFromSaleOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTMtMS0xLTY5Mg_76083ab2-c339-42c2-ac3e-4f44a3a29d47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIwLTEtMS0xLTA_bbee527e-4a31-45c0-bd47-c5bdd7b21725">179,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIwLTMtMS0xLTA_b66ee3d6-799d-4cd6-ac70-91edee8c81a5">143,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIxLTEtMS0xLTA_6db3d7aa-116f-4aea-81a7-e76487a24ea8">2,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIxLTMtMS0xLTA_3c94a5c3-fadd-49f0-84e5-3a51cd62b1b9">2,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTEtMS0xLTA_94935bac-6138-4a37-a5d0-74e57507a708">62,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTMtMS0xLTA_f88ed6fb-2670-4e74-9206-ba6ec2713934">13,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI0LTEtMS0xLTA_96a88a65-1e5d-48c3-80d9-1909cfc650ec">134,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI0LTMtMS0xLTA_a463891d-688b-4a79-aba5-d22486a6e871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTEtMS0xLTY5Ng_b08239a0-0fde-4e5c-b661-5ca5888a44b0">45,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTMtMS0xLTY5Ng_6831de64-e945-4c48-8eba-9bb095b573f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal repayments of debt financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTEtMS0xLTY5Ng_5c8a3447-2aa6-46a9-8fa4-5706d4560035">45,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTMtMS0xLTY5Ng_89582e26-9d2e-46cb-b667-a28dfc57c931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTEtMS0xLTY5Ng_d0dff60b-13a6-46d3-ab09-1e51eed44e3e">750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTMtMS0xLTY5Ng_752dc04b-77a7-44f2-a0a9-fc4173b072cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of prepayment penalty and lender fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTEtMS0xLTY5Ng_d600073d-e4e0-45a0-a469-55f319d6fe03">843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTMtMS0xLTY5Ng_7ff39e75-d1c1-4cda-bcfa-4bdb73658015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI1LTEtMS0xLTA_3f2e2007-c22d-4c9f-b126-b7d5c6f26916">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI1LTMtMS0xLTA_ae028849-a90a-4da1-86aa-de1af837c821">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI2LTEtMS0xLTA_b94411be-62c3-492b-b971-91332c2a401f">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI2LTMtMS0xLTA_fe1df3be-c6ac-4719-ac28-1ec4d58c35ea">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of unvested early exercised stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="sibn:PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI3LTEtMS0xLTA_9055be8e-94ec-4196-926e-914d21e3dfc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="sibn:PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI3LTMtMS0xLTA_5fde5d8d-eb69-4066-85f2-5fcc9d6c2191">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of initial public offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTEtMS0xLTA_f8bc45a8-27bf-4c9e-846b-13eccaef676d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTMtMS0xLTA_26882ac3-bc53-4c80-b6e0-0115cec621c4">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:60.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTEtMS0xLTA_019e3a62-eba3-4ddc-a05a-1aca83c3d622">136,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTMtMS0xLTA_1d7c54ca-da19-4187-8cab-86ed6bc95234">3,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTEtMS0xLTA_6164e273-4fc1-4a0f-94cf-302cd1526ce8">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTMtMS0xLTA_b873aaeb-f652-4e2e-9ab9-b8c6a39a1ef0">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTEtMS0xLTA_0c2865c1-a950-49d5-a4b1-ef596d382484">43,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTMtMS0xLTA_12a3fbac-a35f-4cfd-83f1-a30807b9d8ce">14,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMzLTEtMS0xLTA_7b211ce4-d782-4594-a1e9-b170e48e5851">10,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMzLTMtMS0xLTA_b04a5477-84c5-4574-81c3-54c2d71b5acf">25,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of year</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM0LTEtMS0xLTA_667f6242-256e-4bbc-9e1b-b4e9e97f791d">53,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM0LTMtMS0xLTA_9b7a0b6f-defd-449e-8bdc-ed236571ead4">10,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM2LTEtMS0xLTA_2bedbe56-ec98-441e-8547-172a955ca781">4,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM2LTMtMS0xLTA_ce234c6b-2983-4b8a-a85a-7b928daccdb0">4,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of early exercised stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="sibn:VestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQwLTEtMS0xLTA_5d7e90d6-8847-482e-8a5a-eaca24668cd6">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="sibn:VestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQwLTMtMS0xLTA_f78d79b7-89bc-4b31-904f-731e9ba972df">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQxLTEtMS0xLTA_b8eae387-b62b-4162-b95d-79c5014e65f7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQxLTMtMS0xLTA_6f7e046b-8395-40df-9836-cb58fc646726">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="margin-top:20pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ic5af433463274989b3f39da4377b2b55_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIyOTg_691c853a-fba1-44c4-a15c-31ce2075783e" continuedAt="i66418a3d532644818dff666f31c298f2" escape="true">The Company and Nature of Business</ix:nonNumeric></span></div><ix:continuation id="i66418a3d532644818dff666f31c298f2" continuedAt="i75ec8f6bfb404f7fae2f8fc6f526285e"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Public Offerings of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2018, the Company completed its initial public offering (&#8220;IPO&#8221;) by issuing <ix:nonFraction unitRef="shares" contextRef="ifd2d90a648464b458060488f94c81ad8_D20181001-20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzMyOTg1MzQ4OTI4NTM_e8b35cb2-3439-40c0-9ad6-22e752628fce">8,280,000</ix:nonFraction> shares of common stock, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iddc263e01aa24b63bfcb6b7c3ca255eb_I20181031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzMyOTg1MzQ4OTI4ODA_e698652b-6b06-47fc-9bc9-abaee5e2f1e5">15.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ifd2d90a648464b458060488f94c81ad8_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzMyOTg1MzQ4OTI4NjQ_977ac043-c146-49b8-88d3-90c1ab25d590">113.4</ix:nonFraction>&#160;million to the Company, net of underwriting discounts and commissions and offering costs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i181125cf82924e5b9581883ff443cf53_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTgxNjM_97391377-5a9c-42f3-92d4-ce8929e2ac0b">50.0</ix:nonFraction> million net proceeds, after deducting the underwriting discounts and commissions, from its public offering of <ix:nonFraction unitRef="shares" contextRef="ide3655a0a0a14ac1b122bcd81866b549_D20200101-20200131" decimals="INF" format="ixt:numdotdecimal" name="sibn:SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjI5NDI_9597b634-9ecd-41a9-9fb2-833cf9677fd8">4,300,000</ix:nonFraction> shares of the Company's common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f5bdb3241a241cab56395a180519bf7_I20200131" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjI5MDQ_4b541c16-3e2a-4813-a136-bdbee15ebe3b">21.50</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="i181125cf82924e5b9581883ff443cf53_D20200101-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjI1ODc_ac8ebc6b-385c-41d5-a5a7-8c2d2cdc8c3f">2,490,053</ix:nonFraction> shares were offered and sold by the Company. Further, in February 2020, the underwriters fully exercised its option to purchase <ix:nonFraction unitRef="shares" contextRef="if0448433af0a48b1a3ca65d600cf995e_D20200201-20200229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTg1MzI_ae9306c5-385b-4e3e-94ed-5d7de8ede9fb">645,000</ix:nonFraction> shares of the Company's common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i70eea66b474641c1ad7620f47edb01b0_I20200229" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTg2MTM_950c18d1-502c-485e-bbdb-d2da259bc39d">21.50</ix:nonFraction> per share for an additional net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if0448433af0a48b1a3ca65d600cf995e_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTg3ODc_2d75b8c2-2f23-443f-9f88-ff00c84c6353">13.0</ix:nonFraction> million to the Company, after deducting the underwriting discounts and commissions. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $<ix:nonFraction unitRef="usd" contextRef="i5492ced8113d48a1af6af8e02eeb934e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:AllocatedPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjM4MjY_548ecba1-7ad6-49a9-91dc-a4dcb325942f">0.4</ix:nonFraction>&#160;million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $<ix:nonFraction unitRef="usd" contextRef="i833840966f0446599fbe1ac28b5fc775_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:AllocatedPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjM4MTI_2b22aacf-0a9f-4d87-85f2-f559ec6b8918">0.2</ix:nonFraction>&#160;million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75ec8f6bfb404f7fae2f8fc6f526285e">In October 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="ie94283009e404d94a4b0dc42119c45bd_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMTA_758da82e-dfda-4620-9b7d-41479dbb1e88">71.6</ix:nonFraction> million of net proceeds from its second follow-on public offering of <ix:nonFraction unitRef="shares" contextRef="ie94283009e404d94a4b0dc42119c45bd_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMTc_2ea9b686-3697-42e7-8064-05fde5c5ac62">3,000,000</ix:nonFraction> shares of the Company's common stock, and the exercise of underwriter's option to purchase from the Company an additional <ix:nonFraction unitRef="shares" contextRef="i6bccb8eb33f2419aa52d19db5810f680_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMjE_1f8fb843-5272-48e9-bce3-01e26de51f52">478,507</ix:nonFraction> shares of the Company's common stock, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6592020c6d484bdca8308d69ae2e0cb8_I20201031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMjU_b0ec0c50-b992-4c41-96be-91a19a798ab6">22.00</ix:nonFraction> per share. In addition to the shares sold by the Company in the second follow-on offering, in October 2020, the selling stockholder sold <ix:nonFraction unitRef="shares" contextRef="ic82e690a259f4746a1c2de4c43841af5_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMjk_9d9db41e-5805-498f-a72d-cacc44aa6cbb">190,053</ix:nonFraction> shares of the Company's common stock previously held by the selling stockholder at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f59add943494c479a4150b168d4d73c_I20201031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMzM_c5e14085-68ce-4b9f-86b8-8b2a00de99af">22.00</ix:nonFraction> per share. The Company did not receive any proceeds from the sale by the selling stockholder.</ix:continuation>  </span></div><div id="ic5af433463274989b3f39da4377b2b55_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzU0OTc1NTgyMjE0NTE_44db66b6-f758-424f-9d12-f281c3c65f97" continuedAt="i6c5b31e1cd404d9799e9b9a0b4c45d64" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6c5b31e1cd404d9799e9b9a0b4c45d64" continuedAt="ia8ddfa7b53b9457794b20d48e303d968"><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDc4_b5b17f44-178d-4d6f-8853-bf2578af4b55" escape="true">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</ix:nonNumeric> <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDkx_a991453e-11b3-400e-b4f3-45831fd88c47" escape="true">The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDY4_79f9a930-7dd5-4bc5-bbb7-ceac33e06f89" continuedAt="iac2667f40a26410c8426aeae6138a216" escape="true">Use of Estimates </ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><ix:continuation id="iac2667f40a26410c8426aeae6138a216" continuedAt="i9169575202d84ef2b17717ad7a8757ad"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9169575202d84ef2b17717ad7a8757ad">Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="ia8ddfa7b53b9457794b20d48e303d968" continuedAt="i29a45872c3f5406b9a5409dd4f600273"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="sibn:EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzU0OTc1NTgyMjE0NTI_9fb91237-b503-4307-afa5-381ffc997958" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies. Those standards apply to companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the&#160;JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company continues to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if the Company's total annual gross revenues are $1.07 billion or more; or (ii) the Company has issued more than $1.0 billion in non-convertible debt in the past three years;&#160;or (iii) the Company becomes a &#8220;large accelerated filer,&#8221; as defined in Rule&#160;12b-2 of the Exchange Act.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDkz_dbca4568-18f1-4b0b-a3e9-64a115ae34a0" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are based on components of the Company that engage in business activities that earn revenue and incur expenses and (a)&#160;whose operating results are regularly reviewed by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), to make decisions about resource allocation and performance and (b)&#160;for which discrete financial information is available.&#160;The CODM for the Company are the Chief Executive Officer (&#8220;CEO&#8221;) and Chief Operating Officer &amp; Chief Financial Officer (&#8220;COO/CFO&#8221;). The CEO and the COO/CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives substantially all of its revenue from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. International revenue accounted for less than 10% of the total revenue during the periods presented. Long-lived assets held outside the U.S. are immaterial. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDY5_00d0720e-a2ec-4cbc-9427-695d5e8e1bdc" continuedAt="ided61d59a16e473d93c09307f44c9e92" escape="true">Following table summarizes the Company's revenue by geography:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><ix:continuation id="ided61d59a16e473d93c09307f44c9e92"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee17cf0cfb74aaeba258351d3587116_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzMtMS0xLTEtMA_470e8d51-1eac-4d33-8703-cb81ef4bd099">68,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c0e792c3dd245b38bfa934064b7a5f3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzMtMy0xLTEtMA_759ba855-6cdb-41fb-88d9-28fa62359962">61,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a304c056a549c6910518b3e4157eef_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzQtMS0xLTEtMA_59571223-3db1-4470-8471-a0efcdc8040c">5,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i682d696ec5a64a2d895607c7e0be6d52_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzQtMy0xLTEtMA_6a4c293a-b2b6-4ac0-9b7c-e0107f706cfe">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzUtMS0xLTEtMA_3708a2e3-e859-49a5-837d-56c662a13ff8">73,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzUtMy0xLTEtMA_d5795b64-9985-45b8-b278-0a28d3ad671e">67,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk0_27e83b49-0f22-402c-a56f-10be3ceb4aa9" escape="true"><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDcz_69970f61-8cb0-4f2f-a053-33601e21fa7c" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company&#8217;s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company&#8217;s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue and accounts receivable are spread across a large number of customers, primarily in the U.S., and no customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i29a45872c3f5406b9a5409dd4f600273" continuedAt="i861989c9cb4946b384131b873aaabe84"><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the response to the pandemic and the information surrounding the pandemic is rapidly evolving. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, excess and obsolete inventory, and the impact of any initiatives and programs that the Company may undertake to address financial and operations challenges faced by its customers. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors and uncertainty of market acceptance of products. The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had cash and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzY0NjY_d192a473-12b6-410d-9344-e2a617730521">196.4</ix:nonFraction> million compared to $<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzY0ODE_64e50a5d-6923-426f-b91f-2d0f46b5877d">93.1</ix:nonFraction> million as of December 31, 2019. The Company has financed its operations through our public offerings, debt financing arrangements, and the sale of its products. As of December 31, 2020 and 2019 the Company had $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE2NDkyNjc0OTQ0ODQ_20d48ac9-c387-4468-a9a1-be1e4d767d43">39.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE2NDkyNjc0OTQ0OTE_08a2dec0-6b74-48e3-ae2e-42ae67c664cb">39.2</ix:nonFraction> million outstanding debt, respectively. As of December 31, 2020, the Company's accumulated deficit was $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU4NzQ_edd0990b-49c4-4fcb-9f2c-619c7cbb6337">239.3</ix:nonFraction> million. During the years ended December 31, 2020 and 2019, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU4ODM_f78ea02c-14f8-455b-99f0-8b5afebead64">43.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU4OTI_20d7d7ea-55ba-40ee-ac28-6dc4fd5948db">38.4</ix:nonFraction> million, respectively. The Company has not achieved positive cash flow from operations to date. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company's current operating plan, the Company believes that its existing cash and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements through at least the next 12 months. However, the economic impact of the duration and severity of the COVID-19 pandemic, and the Company's responses thereto (including such actions that the Company had taken or may take in the future as disclosed elsewhere in this Report) poses risk and uncertainties in its future available capital resources. Further, the Company may face challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to, but not limited to, the following as a result of the COVID-19 pandemic or otherwise: (a)&#160;decreases in sales of its products and the uncertainty of future revenues from new products; (b)&#160;changes that the Company may make to the business that affect ongoing operating expenses; (c)&#160;changes that the Company may make in its business strategy; (d)&#160;regulatory developments affecting its existing products; (e)&#160;changes the Company may make in its research and development spending plans; and (f)&#160;other items affecting the Company's forecasted level of expenditures and use of cash resources. </span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg1_3f1b4702-2d33-4056-b70b-f9221d544a91" continuedAt="i24904272d8c948a295c9957dd6d566bb" escape="true"><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable.  The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i861989c9cb4946b384131b873aaabe84" continuedAt="i81138804596b4b51b1739ac23d711d00"><ix:continuation id="i24904272d8c948a295c9957dd6d566bb"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.</span></div></ix:continuation><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDYy_529d52de-ef82-4bcf-931b-9450f2049c98" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk2_3e1bc8c3-cf89-453b-92cf-a9d88a5ef140" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) (&#8220;OCI&#8221;) on the consolidated balance sheets. The Company evaluates its investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely the Company will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the consolidated statements of operations.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg2_a9381ea8-8b8b-4f26-bcf7-ac7210b3d9b2" continuedAt="i6adb5347ce994e93a816fcdae4087e30" escape="true">Accounts Receivable and Allowance for Doubtful Accounts</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6adb5347ce994e93a816fcdae4087e30">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#8217;s operating results or change in financial position. If circumstances related to such customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</ix:continuation></span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDc0_a5148861-d0b4-4084-9f17-0c7913d9b25b" continuedAt="ie5bfa9a1730e49db986a382da8de9290" escape="true">Inventory</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5bfa9a1730e49db986a382da8de9290">Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold.</ix:continuation> </span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTE1_03f84c18-d1b5-4625-a4de-9cc8513b03fc" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk3_ab015971-2918-4e08-a242-8616d5706b35" continuedAt="iffd3d8503ade44f38eb4deb9caa9f5d8" escape="true">All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><ix:continuation id="iffd3d8503ade44f38eb4deb9caa9f5d8" continuedAt="id36306a54b924df899d9792d99b04962"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:85.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id046e7c696d34711b1333b15ed30b43c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzAtMS0xLTEtMjIxOC90ZXh0cmVnaW9uOjQzZTZiNjFjOTc3ZjRiNWY5NGFhN2Q2N2IwYjkwMWYyXzMyOTg1MzQ4ODMzNDQ_0c0dee32-f406-4f54-a263-c6aa79e1b6ec">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i23e08d78c5ce4da8999df030e046372b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzAtMS0xLTEtMjIxOC90ZXh0cmVnaW9uOjQzZTZiNjFjOTc3ZjRiNWY5NGFhN2Q2N2IwYjkwMWYyXzMyOTg1MzQ4ODMzNDg_5e5db8f5-931e-4973-8538-4af6b7781a7b">5</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82073020dafa4bcc906a6b84e0f4ae90_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzEtMS0xLTEtMjIyNS90ZXh0cmVnaW9uOjVhNGRmYzk0YjU5ZDRhNTA5ZmQ2ZjNlZjFlMjFiOWE2XzMyOTg1MzQ4ODMzNDQ_a29b1f79-7cdc-4870-a733-a3178e36e388">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i08bbaa69d9864797b540f323ef6f6cbd_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzEtMS0xLTEtMjIyNS90ZXh0cmVnaW9uOjVhNGRmYzk0YjU5ZDRhNTA5ZmQ2ZjNlZjFlMjFiOWE2XzMyOTg1MzQ4ODMzNDk_00a8eda5-7af5-43a1-98a0-0b145b00d389">5</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab58f80617694d75bb76bca801a8396f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzItMS0xLTEtMjIzMA_e8d2167b-3ed3-4c7a-8ece-0684e5a278fb">7</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i81138804596b4b51b1739ac23d711d00" continuedAt="i6f941b6c741a42568218103ea1abc2d2"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDcw_40712a7e-b4c5-4b01-a797-217f457bb66a" continuedAt="i8f9750e041624f6395a5314ef25d6f26" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8f9750e041624f6395a5314ef25d6f26">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation.</ix:continuation> Through December 31, 2020 and 2019, the Company has <ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjI3ODk_981d4a74-da80-4cc7-a13b-c06019aac192"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjI3ODk_e1ed2f84-22e4-4cd8-bc14-fc123661a843">no</ix:nonFraction></ix:nonFraction>t experienced impairment losses on its long-lived assets.</span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTE2_97a9d190-1e24-48de-ac4e-c305bb773d12" continuedAt="i14d6b372962042cd8eed7dd9eff6bf01" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the new revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.  As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract, agreed price list, or purchase order, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor&#8217;s payment obligation. The Company's standard payment terms are generally net <ix:nonNumeric contextRef="i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231" format="ixt-sec:durday" name="sibn:RevenueRecognitionStandardPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE4MjQ3_3ab5b61c-600a-4609-a4b3-3ae40b2c0a6b">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i392839ad6d6e43ad9f50d6687b0aca2a_D20200101-20201231" format="ixt-sec:durday" name="sibn:RevenueRecognitionStandardPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE4MjUz_d5af6804-4851-4eda-a557-cd00da9b510c">90</ix:nonNumeric> days.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain Customer Contracts</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i14d6b372962042cd8eed7dd9eff6bf01">Sales commissions and related expenses are considered incremental and recoverable costs of acquiring customer contracts. The Company&#8217;s sales commissions paid to its sales representatives are generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. The period of benefit is concurrent with when the Company recognizes its revenue and as such, the Company recognizes sales commission as expense when incurred.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i6f941b6c741a42568218103ea1abc2d2" continuedAt="i7275629b986a444bba33cdadf8659085"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:StandardProductWarrantyPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDgz_d6c6a983-23f0-4585-a8cb-1a2ed42fe687" continuedAt="i6bfcf453d9cc448bbf934d633ca8a801" escape="true">Warranty </ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bfcf453d9cc448bbf934d633ca8a801">The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:durwordsen" name="sibn:StandardProductWarrantyTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU5MDI_06f5bb17-67ff-4343-ac22-e6d47af45c07">one-year</ix:nonNumeric> period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:durwordsen" name="sibn:SalesCreditReservePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU5MDM_f0763d76-709c-47f7-8794-6f84a3dafb2f">one-year</ix:nonNumeric> period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets.</ix:continuation> Sales and warranty reserves from the warranty program were immaterial as of December 31, 2020 and 2019.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="sibn:MedicalDeviceExciseTaxPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTAx_203f4c0b-8ca8-48a1-a246-29cf7ceaf06a" continuedAt="i06f32637695d40c6885806ebeabb5939" escape="true">Medical Device Excise Tax</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i06f32637695d40c6885806ebeabb5939">In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the U.S. The Company recorded the medical device excise tax within the cost of goods sold in the consolidated statements of operations and comprehensive loss when incurred. Effective January 1, 2016, the Consolidated Appropriations Act of 2016, which was signed into law in December 2015, included a two-year suspension on the medical device excise tax. In January 2018, the suspension on the tax on medical devices was further extended through January 1, 2020.</ix:continuation> In December 2019, the U.S. Senate passed a bipartisan legislation to permanently repeal the medical device excise tax. </span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDY1_a4269bcf-2428-4693-900d-4199c37df4c2" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#8217;s product which primarily include: (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2)&#160;external research and development expenses; and (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.</span></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTE3_ad8fb598-b1b6-4f0e-ae9f-f73c489a5295" continuedAt="i73c440ccc3dd4135ae9fe5c98feee2d6" escape="true">Advertising Expenditures</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73c440ccc3dd4135ae9fe5c98feee2d6">The cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations.</ix:continuation> Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzIxNTI3_45e3df04-99ca-4de5-a1e3-a0d6622d37bd">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzIxNTM0_785546dc-86f1-4b2d-810d-89a16fb81008">0.4</ix:nonFraction> million for the year ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg3_d3d86ce8-b725-4dda-b59f-76791ad16054" continuedAt="ia4bd953defb64b5fbbaf7c54eb5dc9d2" escape="true">Loss Contingency</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4bd953defb64b5fbbaf7c54eb5dc9d2">The Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.</ix:continuation> </span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDcx_06ee7ef7-7d58-4934-9fd7-de354f876d93" continuedAt="if2078db3081f4417b529db105ef0b3a7" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i7275629b986a444bba33cdadf8659085" continuedAt="i1e866dcc210944daa574d3fbb4ce611c"><ix:continuation id="if2078db3081f4417b529db105ef0b3a7"><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company became public in October 2018 and has no sufficient trading history, the Company uses stock price volatility using the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the restricted stock unit (&#8220;RSU&#8221;) grant is based on the market price of the Company&#8217;s common stock on the date of grant.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to IPO, the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.</span></div></ix:continuation><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDky_4b2cac30-cd26-48de-b4dd-aee79023e35f" continuedAt="ibf935bb45db74ac69c02c8354f5d0cca" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf935bb45db74ac69c02c8354f5d0cca">The Company recognizes uncertain tax positions when it meets a more-likely-than-not threshold. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDc2_59773f4e-97f7-4793-a3b8-bea081ad6a75" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share of Common Stock</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic and diluted net loss per common share attributable to shareholders i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n conformity with the two-class method required for companies with participating securities. The Company considers all ea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i1e866dcc210944daa574d3fbb4ce611c" continuedAt="i953ca5decbc24900a0796fe1b980b86b"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk4_da7d273b-42ae-49b2-bc74-fcd5672eb231" escape="true"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents all changes in the stockholders&#8217; equity except those resulting from distributions to stockholders. The Company&#8217;s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="sibn:WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg4_e6f25075-f44d-4b1b-87ad-3d7e046e3e72" continuedAt="i8911f3ef483e4bc98fa33c14f4135f7c" escape="true">Warrants</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8911f3ef483e4bc98fa33c14f4135f7c">The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. In connection with the IPO, all of the Company's redeemable convertible preferred stock warrants were automatically converted into common stock warrants.</ix:continuation> </span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTA2_0b5bb1cc-83d4-4c5f-9605-1f8b246a20c3" continuedAt="i9c775aae697c4049a4b8a465a1cae149" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of New Revenue Recognition Standard</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new revenue recognition standards (&#8220;ASC 606&#8221;) using the modified retrospective method effective for the year ended December 31, 2019. This approach was applied to all contracts that were not completed as of January 1, 2019. As an emerging growth company that elected to take advantage of the JOBS Act accounting election, the Company was not required to adopt the new revenue standard in the interim reporting periods on the year of adoption and is not required, and intends not, to revise its 2019 interim periods which were reported under previous revenue recognition standards (&#8220;ASC 605&#8221;). The adoption of ASC 606 did not result in a material impact on the Company&#8217;s consolidated financial statements and no adjustment was made to the opening balance of accumulated deficit at January 1, 2019.&#160;ASC 606's core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or medical facilities, which represents majority of the Company's revenue, the Company continues to recognize the revenue upon completion of the procedure&#160;and authorization by the customer, net of rebates and price discounts. As it relates to sale of products through distributors and hospitals where product is ordered in advance of the procedure, the Company continues to recognize the revenue upon shipments to the customers, net of rebates and price discounts. Additionally, ASC 606 requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company&#8217;s sales commissions paid to its sales representatives is generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. As such, the Company recognize sales commission as expense when incurred. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenues from contracts with customers into geographical regions. The Company determined that disaggregating revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by regional economic factors. For information revenue by geography, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in &#8220;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies&#8221; in the accompanying Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation-Stock Compensation, to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity-Based Payments to&#160;Non-Employees. The Company adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued&#160;ASU&#160;2018-13, Fair Value Measurements, which eliminates, adds or modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted to adopt either the entire standard or only the provisions that eliminate or modify the requirements. The Company has adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#8217;s consolidated financial statements. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i953ca5decbc24900a0796fe1b980b86b"><ix:continuation id="i9c775aae697c4049a4b8a465a1cae149"><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Effective</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet.&#160;A lease liability is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date.&#160;In July 2018, the FASB issued&#160;ASU&#160;2018-10 and&#160;ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. The new transition method allows an entity to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In March 2019, the FASB issued&#160;ASU 2019-01, which provides clarification on implementation issues associated with adopting&#160;ASU 2016-02.&#160;The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the &#8220;all other&#8221; categories. For public companies, the new guidance became effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the new guidance is now effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is still permitted for any interim or annual financial statements not yet issued. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company, the new leases standard is now effective for the Company for the fiscal year ending December 31, 2022 and interim periods within fiscal year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements including the timing of its adoption. The Company anticipates electing several practical expedients that permit the Company not to reassess (1) whether a contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. The Company expects that the adoption of this new standard will have a material impact on its balance sheet. The most significant impact would be the recognition of operating lease right-of-use assets and liability. The standard is not expected to have a material impact on the Company's consolidated statements of income and cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued&#160;ASU 2016-13,&#160;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. FASB issued ASU 2019-05 in May 2019 and ASU 2019-08 in November 2019 for codification improvements of Topic 326. The new standard revises the accounting requirements related to the measurement of credit losses and will require organizations to measure all expected credit losses for financial assets based on historical experience, current conditions and reasonable and supportable forecasts about collectability. Assets must be presented in the financial statements at the net amount expected to be collected.&#160;In November 2019, the FASB issued ASU 2019-10,&#160;which defers the effective date of&#160;ASU 2016-13&#160;for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&#160;In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. The Company is currently evaluating the impact of this standard on its consolidated financial statements but does not expect the adoption of the standard will have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_175"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90ZXh0cmVnaW9uOjRjOGRhNGZjYzk4NDQ0NzlhMTVmZWViYTA1OWEzNzFmXzE2MQ_38edf17d-d99a-44cf-92f7-00f4262967a0" continuedAt="i69e4ea15d1ea4535a2a07559376a755f" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="i69e4ea15d1ea4535a2a07559376a755f"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90ZXh0cmVnaW9uOjRjOGRhNGZjYzk4NDQ0NzlhMTVmZWViYTA1OWEzNzFmXzE2Mw_bbd852dc-e28c-4ba2-9fa4-1b7bff67a143" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the marketable securities:  </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9de17fd42404f5ab8f65ff659295c6e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzMtMS0xLTEtMA_fc91537e-54d9-48a7-9057-18ce83416954">45,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9de17fd42404f5ab8f65ff659295c6e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzMtNy0xLTEtMA_eff2e40e-63ce-4747-b547-b4fe57fdd793">45,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtMS0xLTEtNTE1Mw_0db6a327-1f99-44c7-bc06-6a5490c3a6a7">1,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtNy0xLTEtNTE2Mg_ba39f273-a32a-4f88-b367-9a0932e940b8">1,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtMS0xLTEtMA_5676fc73-9e1c-4210-9112-3138844d683e">47,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtNy0xLTEtMA_4fb81100-653b-4be3-a899-20c10e5b0fb2">47,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctMS0xLTEtMA_3ffe99d0-3a03-412a-8203-70f99b49246f">74,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctMy0xLTEtMA_3a952a7d-2aa4-46cf-9d00-e4725e44eaf3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctNS0xLTEtMA_669e9cfc-00ff-4297-a031-7b29de7b4a6a">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctNy0xLTEtMA_c4615209-5560-4b8e-91e2-cffa6e7ee874">74,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtMS0xLTEtMA_f1fd5136-aeec-4a7d-b556-d693a2933a13">8,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtMy0xLTEtMA_aa884599-104f-411d-aaad-e10f1ce337aa">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtNS0xLTEtMA_ced7e3f5-c610-4c0b-bf71-1e5a7f28fec9">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtNy0xLTEtMA_1fec76a5-5fec-4732-837d-073c92fa998e">8,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktMS0xLTEtMA_63bca986-6443-4c51-9a77-403aab0f8a95">59,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktMy0xLTEtMA_6ba2ba82-3e5a-4847-950d-9c124287e3a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktNS0xLTEtMA_fe63dd84-76dc-4283-9e90-1168e824a23c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktNy0xLTEtMA_8eb16e6f-fc65-4a73-8752-98649b7e3b01">59,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTEtMS0xLTA_740a9e72-efc5-4980-b314-380440c367ba">142,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTMtMS0xLTA_46afedf2-632a-4458-9f6d-e2e1c543ddc1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTUtMS0xLTA_0af84a96-7ee8-4788-8d27-f346dcb0f9fb">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTctMS0xLTA_b29edcd2-74ad-490b-8c75-1dd7b0cab1ce">142,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:MarketableSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTEtMS0xLTA_8f42f34f-ca38-47eb-bfee-4c946799094c">190,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTMtMS0xLTA_50d1241b-1954-4b11-af0d-33989b4a537e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTUtMS0xLTA_062f3fd5-7692-468e-9156-80a0ac391c37">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:MarketableSecuritiesFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTctMS0xLTA_e37ce799-c80e-4e44-9893-9a17338a991d">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica653fed6bb2408599a2f19e331e9a09_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzMtMS0xLTEtMA_99c406db-02eb-4496-83b1-fcc09d9d9727">3,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica653fed6bb2408599a2f19e331e9a09_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzMtNy0xLTEtMA_5cfcc35e-9a93-40da-8f34-b2afecaf7077">3,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzUtMS0xLTEtMA_4105dad7-9a6c-4680-bba9-ba6aa636e3d3">2,495</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzUtNy0xLTEtMA_f012401a-2b20-48c6-bad2-a630f1565016">2,495</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzYtMS0xLTEtMA_ce33522f-abf9-41c4-a95e-0150cb7ccdc5">5,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzYtNy0xLTEtMA_17fb20f7-0482-41ae-abbd-6585faadf824">5,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtMS0xLTEtMA_e29b9ff6-7c3e-4f76-bd58-d8559479dbce">67,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtMy0xLTEtMA_a58925c4-0756-41bf-b46e-425f5d546308">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtNS0xLTEtMA_1d825538-009c-477e-88ef-dda84a27c596">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtNy0xLTEtMA_2e1e5044-0440-4316-9c63-c62707986870">67,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktMS0xLTEtMA_9352f8f4-c822-474b-a527-4ad82bcdc7d7">9,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktMy0xLTEtMA_11f39a3f-a66e-4597-a334-d688eb8cf491">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktNS0xLTEtMA_32f44f05-bac6-4a15-a9e8-93aada4e64f8">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktNy0xLTEtMA_1012862e-5bf7-422d-a9c1-0c7eb0d96173">9,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTEtMS0xLTA_60288104-e2f5-4304-93f5-026c0d309367">5,165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTMtMS0xLTA_a82277b1-eb7e-47db-877b-754c9e1b7448">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTUtMS0xLTA_2fd75362-4732-4726-a1a6-db77bc1cea4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTctMS0xLTA_762170d9-a5b1-41db-9423-998e1297b5b8">5,165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTEtMS0xLTA_a080c29b-2be3-4995-bc15-4246f7fb39b0">81,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTMtMS0xLTA_79db0ceb-852b-4874-9a87-ca61c22b83d8">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTUtMS0xLTA_ce629fbe-e991-4827-b922-526a113cab00">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTctMS0xLTA_0cd66078-d3db-4f85-bf44-f6de7b9ded86">81,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTEtMS0xLTE4MQ_e7e7f5ad-30b5-47eb-bf2e-3a394aee109f">1,278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTMtMS0xLTE4MQ_c40ad726-851d-4db4-b2a2-7c7818b40912">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTUtMS0xLTE4MQ_5b7cbcd4-fd22-4c3a-9233-ebb8560b49e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTctMS0xLTE4MQ_dbbf0d9a-0e16-4a1a-8149-e656e67b0023">1,278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTEtMS0xLTE4MQ_5fc5f2eb-2b90-49a0-a60f-23e81e53d7e3">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTMtMS0xLTE4MQ_03201b34-e477-4c3d-b29c-67544ff75f63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:zerodash" name="sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTUtMS0xLTE4MQ_b422f6fa-c05d-41b3-b39a-21d9e925aeab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTctMS0xLTE4MQ_a1e8ff12-fdee-497c-8935-28011a29ad47">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:MarketableSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTEtMS0xLTA_cb458631-11d7-4bf7-a8dd-40521bea32fc">88,132</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTMtMS0xLTA_5cf6ad22-3c42-4504-adc3-8694962136f4">58</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTUtMS0xLTA_7ae1a70d-2029-4e97-8677-58ab53219af7">4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sibn:MarketableSecuritiesFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTctMS0xLTA_f29dfec3-0df5-49e9-ab82-8ea0a9fd5b72">88,186</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term investments outstanding as of December 31, 2019 matured in April 2020. The Company did not identify any of its marketable securities as other-than-temporarily impaired as of December 31, 2020 and 2019.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_178"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90ZXh0cmVnaW9uOmI3OWRkNGI5NTU4ODRlYTM5YmVlMDQ5YmY1MGMyY2YyXzgwNg_3f6f9727-dc60-412a-87cd-0d3ad38f0f14" continuedAt="ib93d01e065564bebbb7884880340054c" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="ib93d01e065564bebbb7884880340054c"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate. There were no other financial assets and liabilities that requires fair value hierarchy measurements and disclosures for the periods presented. </span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90ZXh0cmVnaW9uOmI3OWRkNGI5NTU4ODRlYTM5YmVlMDQ5YmY1MGMyY2YyXzgwOQ_3fed1fc5-5ad8-40a9-9ac5-d951b52f23df" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the fair value of the Company&#8217;s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:48.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2561190905814081bc53ffa2be1dab5b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtMS0xLTEtMA_5cd7f69c-c536-4a67-90db-bb5b85ef5425">45,948</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fdea8ce7124059abdb38fb9a56c535_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtMy0xLTEtMA_73ca2d8a-a77d-49a1-ba9b-1e93881c12f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c018ede41124dcb9546a1dc0d2be832_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtNS0xLTEtMA_5df877e9-3fa2-4835-9afe-1acec23d7a0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3540e490fa3e40728018f6cb6e927d47_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtNy0xLTEtMA_c80424d1-d4f0-4028-84c9-314427ccd8b4">45,948</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fc95b9ce164bc0840b48602420b3c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtMS0xLTEtMA_f1ed9dd8-5077-48bb-b75f-0c9a1ca554bd">74,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8bd8bffe9546e6a44571d468e8e8a2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtMy0xLTEtMA_be998dc5-619a-41de-88a9-e137821425e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21a7585b0b64bb1a4690ee991cf5d88_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtNS0xLTEtMA_025e48ce-bf2f-4282-86fc-669dbc67c85e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549ddb0f7656451894dc614cf8d2a488_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtNy0xLTEtMA_6baf5792-cc66-44ad-bc9d-be0e053fa990">74,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30be08150494e1ebf7f499accad38f5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtMS0xLTEtMA_f228c5e4-3573-406b-b736-55b85fa0c980">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a5a80e24444a2997770162f3127340_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtMy0xLTEtMA_0e7ee124-8380-4e37-afd1-942b2c621513">8,938</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6781f723ffcc40caaeb825c9755676eb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtNS0xLTEtMA_61e3e62c-8b1a-4d9c-b1dc-482252fd341d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60e4a56a8df4e8692eaec00e452ea3e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtNy0xLTEtMA_81230abc-0fef-41a5-8a30-bd8fa918a51c">8,938</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c39428374148bda44abdf22ebd5a95_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctMS0xLTEtMA_c0ed4752-0340-4770-a1b1-84c2f28eb889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c3186e6d7b427ebbbff1f0dbd4c8c4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctMy0xLTEtMA_b568c142-db8d-4729-98bf-5e3e47f83ab3">60,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b326db53886469788a4a2d43dfa03b4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctNS0xLTEtMA_42ac3bce-db59-45dd-a0fb-4c0be8e54880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21dfcac734f47f6957fcca7f72cdc88_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctNy0xLTEtMA_e67ce6f3-7372-47fe-8c3f-76353f09dcff">60,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29460ed74a94fa4ab322cb274b491e8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtMS0xLTEtMA_d6bd6379-02ce-4aee-9365-7695c548303b">120,724</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034bc01ef48b4d4a8bf1bb1de85b0868_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtMy0xLTEtMA_7f6964dd-1261-4ca8-92aa-83761503459b">69,475</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4613e4687843f8a379ce7c10a467e4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtNS0xLTEtMA_71c7ebf1-d802-4bc5-b2f7-f5ba9d3b9bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d4c9f2c6ba40f3828a4aa2b86a45a6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtNy0xLTEtMA_4625b3ff-80e4-4d15-9979-27a593956db9">190,199</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193aaa31e9c44a1e82bffc909a360749_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTEtMS0xLTA_7a125974-e3b3-4440-a911-8ef2130d2c1d">3,068</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657bb6e3a8a046f28bfa284cf457e36f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTMtMS0xLTA_08bfda64-dc33-4566-9c68-a937bc69b775">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ee32c33d8748298bb8a2da1f87d7ff_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTUtMS0xLTA_f1eff982-c3eb-4e1b-8012-6a8150894b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53b1d8bd84944b9a5118a390e4915d4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTctMS0xLTA_7be0b919-72de-4a24-a48d-cb76e6b379cd">3,068</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1873024e2f49b98f313c5e06a689bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTEtMS0xLTA_0044b168-776c-422b-970b-5074368d7dce">67,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7740378444747719a5eb6065629a5ea_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTMtMS0xLTA_9b3ac34c-8dab-4fe3-b1de-7f15e5627a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9109fa397bd4ab896aee4f1166409ff_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTUtMS0xLTA_8caf2b90-9aac-4c52-8c28-343d60073ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c36deb7f9274663a77e895314cda704_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTctMS0xLTA_77ad7fac-9dac-4dcf-ba40-1ca391b6957d">67,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if595c9553f034555b84ce4f3992ef574_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTEtMS0xLTA_0010df18-d2a6-48e0-af41-9983d874c621">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2978c44e2ebc42e5bfd593b3bd9ec954_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTMtMS0xLTA_76bd17a9-7b1d-42f2-8d9a-ae5ac3b3e81b">10,375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959e6655c905432b8c65682560f0dd19_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTUtMS0xLTA_b0496d1a-6e44-4d76-baef-fb8b1c506347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5dc8e414e04b1c913f494f9f5332ab_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTctMS0xLTA_3111a630-058f-4657-97fe-5e102b07b274">10,375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie229939d8dc74c648e87a676c60fecd4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTEtMS0xLTA_8bc0fa06-7029-4b6a-bff4-b397bf071f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if504c2f11d744b658048ae59b90b89ff_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTMtMS0xLTA_15166373-828d-4777-99cd-02ca74c122ba">7,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aa93fd86be47a69cae67136a4bf322_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTUtMS0xLTA_59b3b435-4ffc-4107-8734-f3b1a4f8e440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae975a338844ef786881ecd9e3b9cd1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTctMS0xLTA_87ed9eab-4431-46b9-a358-a90d6e8f3b36">7,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5e61b93a3f4b598884410e09cd44de_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTEtMS0xLTA_f18c5818-eaa9-4ab1-b866-3f5453f0c3dd">70,151</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3deabe50cd3e469793cfee5e9e7b0957_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTMtMS0xLTA_58be3677-1882-4943-abcc-fb913f220bc8">18,035</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64bda2b4edb482eb14a53a12c4bef2d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTUtMS0xLTA_4c45049f-f9e9-44c9-8aa7-790a932d5ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c484252700460b89333bc846225d68_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTctMS0xLTA_b554eae6-6bc8-47bb-88b4-839a0bc948e1">88,186</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic5af433463274989b3f39da4377b2b55_181"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzI1NQ_b5136816-e325-43e9-aad6-c569e0cc4a51" continuedAt="i49b091a2cdf146f8a8d3bb0044233fc2" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i49b091a2cdf146f8a8d3bb0044233fc2" continuedAt="i75681677c33645af924fbf9ba17fe8a3"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Inventory</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, inventory consisted entirely of finished goods.</span></div><ix:continuation id="id36306a54b924df899d9792d99b04962"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5113c368e6d84d078690ec4a2dcdac26_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzItMS0xLTEtMA_39a059d4-50fd-466b-87fa-cc88e8b9473a">6,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf10733689d841b993c15e2c32cb214e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzItMy0xLTEtMA_7708e141-c53c-4050-8821-2fe10049db4b">4,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebcd89814b67470fb88261e8811fe67c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzMtMS0xLTEtMA_eec2aac1-c46d-4686-8a6a-c20c96e9b95e">1,692</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7de72341f3240d6bca072b0cf1a49d4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzMtMy0xLTEtMA_3cb41183-6198-4698-bb54-773068df5120">1,854</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4199c211590a43da89a234cf0e6582df_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzQtMS0xLTEtMA_5fd6e3fd-8f09-454b-98e1-1e33eb9b1dc4">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7599f342c11d4e80a1f135e9a39b17ba_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzQtMy0xLTEtMA_4cb67382-1d49-40f9-8910-770b67488229">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cfa5d73e404d39a22111bbd6758462_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzUtMS0xLTEtMA_525edee8-fecc-40ef-bf4d-c0fe0f29bd38">503</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b43286347d44ef87b90ebfe3ab45f6_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzUtMy0xLTEtMA_0d8b6081-849e-49f4-93db-5ba1b46a0dfb">497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a04be12804c4f369306f503b36bee55_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzYtMS0xLTEtMA_c59f7e84-e9e8-48fb-9216-6eafb8cec241">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3566041ec40442cda4e388d38876c815_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzYtMy0xLTEtMA_cd33c654-7f87-40e7-b28e-4940dcd1c1da">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzctMS0xLTEtMA_cba194cf-4d84-4189-ad38-f6d1b7af1a9f">9,484</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzctMy0xLTEtMA_ed1e96ab-00a6-491e-9f6e-e0f330971e36">7,749</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzgtMS0xLTEtMA_5b4e63c5-f36f-44fd-ad8f-916cf06e6eef">4,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzgtMy0xLTEtMA_0fb2aa26-83cc-47e9-b465-b469862f116f">3,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzktMS0xLTEtMA_d2f61e7c-8446-4bcd-96ff-87a0c3ed7105">4,527</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzktMy0xLTEtMA_ffa8bca7-5819-4c65-845b-ce095ac6ddb4">3,954</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i75681677c33645af924fbf9ba17fe8a3"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress pertains to cost of individual components of a custom instrument set used for surgical placement of iFuse implants that have not yet been placed into service.  Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzE2NA_ffdc8586-b2d1-4b90-896d-a1f9f4eb689c">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzE3MQ_cdb87b3f-e698-42ef-aa1f-0513b06460b2">0.8</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzI1Mw_7ba9c560-7118-4aed-9ce6-5a9e662f7150" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzItMS0xLTEtMA_0186abc2-3b60-443a-a482-e68079e867cb">9,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzItMy0xLTEtMA_1f6b4716-f8f9-4349-8c23-86c1bf16431b">7,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accrued litigation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LitigationReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzMtMS0xLTEtMA_8292db1a-c934-488a-bca6-3d1eb8d54c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LitigationReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzMtMy0xLTEtMA_1a7170ac-1730-45ff-bab4-3842ade61cec">3,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzUtMS0xLTEtMA_89549374-f5ff-4ea0-8e4a-3ad364aacab6">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzUtMy0xLTEtMA_325eeb8a-0f4b-4ac4-9c1c-558ac912ad11">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzgtMS0xLTEtMA_ac47923f-df7b-4ad6-846b-f68891752bf4">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzgtMy0xLTEtMA_dbab24de-51a5-460d-a0e1-cd528eb47aea">739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzktMS0xLTEtMA_66454ab1-5632-4654-b4fe-2008fedadc56">10,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzktMy0xLTEtMA_6e621b1d-cde2-43d2-a615-b94e347f159c">11,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt"><span><br/></span></div><div id="ic5af433463274989b3f39da4377b2b55_184"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzUwMDk_72fcfccb-0fbf-4744-8d43-f408e09de738" continuedAt="i07160c40ca12442dac3db35726dc30ce" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i07160c40ca12442dac3db35726dc30ce" continuedAt="i459c31be4d12491895d2b9473253b508"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-cancelable operating lease for an office building space, located in Santa Clara, California which expires in May 2025. The Company also has non-cancelable operating leases for its office building spaces in Gallarate, Italy and Mannheim, Germany which both expire in November 2024, and in Knaresborough, United Kingdom, which expires in December 2025. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2021 to 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases totaled approximately $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzgwNg_11533d6e-ff36-4e09-b693-0f1180735444">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzgxMw_7d11075f-232a-4bc2-9d8e-a1adf77d8a3c">1.2</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzUwMTE_c541bd2e-47d3-4375-8d4e-5dc66680415a" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future minimum lease payments under all leases as of December 31, 2020 are as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"><tr><td style="width:1.0%"></td><td style="width:82.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzEtMS0xLTEtMA_b88e8391-36ca-439f-bf26-582ef4c199b3">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzItMS0xLTEtMA_f2710a64-f460-4a74-b6b4-f968d7cba0b1">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzMtMS0xLTEtMA_8f3b67a4-c8eb-44ae-94b9-47674c30790b">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzQtMS0xLTEtMA_40e96f61-0f02-4100-ad8d-f89b2d1e9f05">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzUtMS0xLTEtMA_05cbcaaa-c6fe-407d-a480-4a9e5703268c">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzYtMS0xLTEtMA_2ae46990-6ac9-42ac-829d-0e7bc4861672">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzctMS0xLTEtMA_5815bd97-8aa4-4726-a68c-2142483013de">4,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Obligations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has certain purchase commitments related to its inventory management with certain manufacturing suppliers wherein the Company is required to purchase the amounts forecasted in a blanket purchase order. The contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. These outstanding commitments amounted to $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzEyNDM_f342298c-215b-4994-968a-93adda874002">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzEyNTA_0c97900a-9b48-415d-b069-c298f425c0d5">0.4</ix:nonFraction> million as of December 31, 2020 and 2019, respectively. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i459c31be4d12491895d2b9473253b508"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. (&#8220;Plaintiff&#8221;) v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the U.S. District Court, Northern District of California (the &#8220;California Action&#8221;). The complaint alleges violations of the Telephone Consumer Protection Act (the &#8220;TCPA&#8221;) on behalf of an individual and a putative class of persons alleged to be similarly situated. The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission. The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship. The plaintiff sought various forms of relief, including statutory damages of $<ix:nonFraction unitRef="usd" contextRef="i6d2410d914e44ed9a27cd8b177231d10_D20190206-20190206" decimals="INF" name="us-gaap:LossContingencyDamagesSoughtValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzI0MzQ_52238a05-71b8-4abf-8ee7-24b14d360bb3">500</ix:nonFraction> for each violation of the TCPA or, in the alternative, treble damages of up to $<ix:nonFraction unitRef="usd" contextRef="id1f51810588c413195ac60a540302861_D20190206-20190206" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzI1MTY_3e9e46be-43a2-47ee-b718-9354ee4b68c9">1,500</ix:nonFraction> for each knowing and willful violation of the TCPA and a permanent injunction prohibiting the Company from sending or having sent advertisements by way of facsimile transmission. Subsequently on December 20, 2019, Plaintiff the filed a putative class action captioned Eric B. Fromer Chiropractic, Inc. v. SI-BONE, Inc. (Case No. 1922-CC12323), in the Circuit Court of the City of St. Louis, State of Missouri (the &#8220;Missouri Action&#8221;). The Missouri Action alleges the same TCPA violations as the California Action. On December 23, 2019 the parties filed a joint stipulation of dismissal of the California Action and on January 14, 2020, the parties executed a definitive settlement agreement (the &#8220;Settlement Agreement&#8221;) pursuant to which, the Company agreed to settle all disputes regarding the advertising faxes to the settlement class. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrued litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i9154de9e205d4bde873fb87f0044bdc1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzE2NDkyNjc0NTU4NjY_c34a3b57-f37b-42b3-837b-623dc5bd5682">3.2</ix:nonFraction>&#160;million during the year ended December 31, 2019 within general and administrative expenses in the consolidated financial statements, which was the Company's estimated cost to resolve the matter pursuant to the Settlement Agreement and based on the estimated class members' claim submission rate. Following the notice and claims submission process, on June 22, 2020, the Circuit Court of the City of St. Louis, State of Missouri, approved a final order to pay the approved claims submitted by class members, fees, expenses and incentive awards totaling $<ix:nonFraction unitRef="usd" contextRef="i59004ae255bc408fbcc9c0c0bfeb19e6_D20200622-20200622" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzE2NDkyNjc0NTEzNjc_3e2a54df-24b3-48d1-b57d-1fca7862a469">2.6</ix:nonFraction>&#160;million as final settlement. Accordingly, the Company recorded a reversal of accrued litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ie6ae02ed248d4976a0b8c92bb1c51665_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzE2NDkyNjc0NTEzOTQ_3001c86d-d979-4786-83c0-5e4a4c8f67cc">0.6</ix:nonFraction>&#160;million in year ended December 31, 2020 within general and administrative expenses in the consolidated financial statements. The Company made the final settlement payment on July 1, 2020. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="usd" contextRef="i95b018196eca491f8a64402c1d9c1b33_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LitigationSettlementExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzQ4MzM_54326089-a868-4b41-b981-c9c81689f6c2">no</ix:nonFraction>t incurred costs to defend lawsuits or settle claims related to these indemnification agreements. <ix:nonFraction unitRef="usd" contextRef="i1dc4cef314e248258972c3adbdc0456e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LitigationReserve" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzQ5MzI_108936f2-5d21-41ea-bdf3-8cce252931dd">No</ix:nonFraction> liability associated with such indemnifications has been recorded to date.</span></div></ix:continuation><div id="ic5af433463274989b3f39da4377b2b55_187"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzIxNDQ_ba7c3f97-82e3-4cc8-965d-56240594d0a2" continuedAt="ib1e52f39d1ca4784931ecd0e5295ce78" escape="true">Borrowings</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="ib1e52f39d1ca4784931ecd0e5295ce78" continuedAt="i08b2760026014be3b9d465088ca5d0e0"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzIxNDY_7beb4114-ad48-43cb-8eba-2d89c1fe8a74" continuedAt="i2d4a59abc6234a1aa5848eb869f57dc1" escape="true">The following table summarizes the outstanding borrowings from the term loan as of the periods presented:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i08b2760026014be3b9d465088ca5d0e0" continuedAt="ibf5309e17bde4c41ad6facc9b51f563e"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i2d4a59abc6234a1aa5848eb869f57dc1"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal outstanding and final fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzItMS0xLTEtMA_769d232a-2ff4-4436-8357-d84a5686fe1a">41,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzItMy0xLTEtMA_2cd74cd9-927a-4641-962b-d733b87b863e">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzMtMS0xLTEtMA_5e1124af-7627-44fd-818f-8dc0a738ea11">661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzMtMy0xLTEtMA_98002e23-988c-486c-8e2e-02688234b628">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMS0xLTEtMTIxNA_ee156eef-3924-4238-a1a4-e7909195c20d">884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMy0xLTEtMTIxNA_33d887c0-48d6-4ad2-a99f-7c41e0c13303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding debt, net of debt issuance costs and unaccreted value of final fee</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMS0xLTEtMA_8c41abb2-3e6c-4fd7-bac2-094e596e94e1">39,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMy0xLTEtMA_fb58dc59-5883-4933-a2b0-90efa18e6cfc">39,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term borrowings</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzYtMS0xLTEtMA_c1012261-3792-44f6-8025-bc5e77dcf9a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzYtMy0xLTEtMA_ca266e89-d224-4861-a01f-aad234e02a21">4,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzctMS0xLTEtMA_fdcedbfc-7cca-4bc3-ad0f-2aa4e7b594fe">39,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzctMy0xLTEtMA_fc16e3ad-92fc-430c-bd03-4d1efd0b4f53">34,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding debt as of December 31, 2019 related to a term loan entered by the Company with Biopharma Credit Investments IV Sub LP (&#8220;Pharmakon&#8221;) in October 2017 for total loan proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia4fc4f2f95ee4c97adad0fe62fb8956b_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NDA_5b813742-d73f-42fe-870c-8a3f59e60562">40.0</ix:nonFraction> million (the &#8220;Pharmakon Term Loan&#8221;). The Pharmakon Term Loan included an interest-only period for <ix:nonNumeric contextRef="ia4fc4f2f95ee4c97adad0fe62fb8956b_D20171001-20171031" format="ixt-sec:durmonth" name="sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NjQ_baff68e8-eb33-4701-a7e7-bed75e770f75">35</ix:nonNumeric> months through September 2020 and then equal quarterly principal payments plus interest through December 2022. The Pharmakon Term Loan carried a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="icc5dfa6f48e44ef7ad7fdc85379acfe1_I20171031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NzE_c79a63b7-461e-4050-b70e-2fe3e7cdad88">11.5</ix:nonFraction>% and allowed for early prepayment. The prepayment penalty fee was equal to the remaining interest due if prepaid within the first 30 months, a <ix:nonFraction unitRef="number" contextRef="i50c8f148cb4c45afa01a41eb83479fbc_I20171031" decimals="INF" name="sibn:DebtInstrumentPrepaymentPenaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NzU_796d874e-8fad-4941-b7cb-f3d9a13243ca">2</ix:nonFraction>% penalty for months 31-48, and a <ix:nonFraction unitRef="number" contextRef="i57f9e992b05a4a77b99d38cb277c0cc2_I20171031" decimals="INF" name="sibn:DebtInstrumentPrepaymentPenaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1Nzk_d5f9cc4d-7fe9-4b1b-8ded-d92d4ff7f694">1</ix:nonFraction>% penalty for months 49-60. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 29, 2020, the Company entered into a Loan and Security Agreement with Solar Capital Partners (&#8220;Solar&#8221;) providing for a term loan of an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1MDQ_caff3db4-ae7f-40ef-b6fa-5b28cae53ec3">40.0</ix:nonFraction>&#160;million to the Company (the &#8220;Solar Term Loan&#8221;). In accordance with the Loan and Security Agreement, the Company paid in full and terminated the Pharmakon Term Loan, which was accounted for as debt extinguishment in accordance with the accounting standards. The Company recognized the unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc2MzM_ce069085-c803-4eb7-9c96-8836c1588673">0.7</ix:nonFraction>&#160;million and the prepayment penalty and lender fees of $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1MTk_af065794-e958-4830-9592-aeb45a7933fa">0.8</ix:nonFraction>&#160;million related to Pharmakon Term Loan as a loss on debt extinguishment. The costs and fees are reflected as interest expense in the consolidated statement of operations for the year ended December 31, 2020. The total debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1MzM_1a52ded5-9824-47cd-995b-766a72f3e28e">0.8</ix:nonFraction>&#160;million associated with the Solar Term Loan were recorded in the consolidated balance sheet as a direct deduction from the carrying amount of the loan, and are amortized as a component of interest expense using straight-line method over the life of the term loan.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Solar Term Loan bears interest at a rate per annum equal to <ix:nonFraction unitRef="number" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NDc_fe637ea0-8bf3-4309-88af-d1308ebb108a">9.40</ix:nonFraction>% plus the greater London Interbank Offered Rate (&#8220;LIBOR&#8221;), payable monthly in arrears. LIBOR means the greater of (i) <ix:nonFraction unitRef="number" contextRef="i3171054c28c94e37a7274d5bfc3fb4de_D20200529-20200529" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NTQ_8c4cb232-f891-42d1-855e-ee169dcaff9f">0.33</ix:nonFraction>% or (ii) one-month LIBOR (or a comparable replacement rate to be determined by the collateral agent if the LIBOR is no longer available), which rate shall reset monthly. The Solar Term Loan matures in <ix:nonNumeric contextRef="i85a2c5d839d54923994ecdd79255d137_D20200529-20200529" format="ixt-sec:durmonth" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzU0OTc1NTgxNTEzNjM_ea23d236-9144-4a24-b819-710680d884c4">60</ix:nonNumeric> months on June 1, 2025 (&#8220;Maturity Date&#8221;), with an interest-only period of <ix:nonNumeric contextRef="i85a2c5d839d54923994ecdd79255d137_D20200529-20200529" format="ixt-sec:durmonth" name="sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzU0OTc1NTgxNTEzNzE_11a4d0bf-dc32-41e2-8dee-0fbcc63bc0d5">36</ix:nonNumeric> months through June 2023, and then repaid in equal monthly principal payments plus interest through maturity date. Pursuant to the Loan and Security Agreement, the Company may voluntarily prepay the Solar Term Loan, in full or in part, but only in increments of $<ix:nonFraction unitRef="usd" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NjE_78bc2dc4-96c7-463f-96eb-468bd3f7052f">10.0</ix:nonFraction>&#160;million, for a prepayment premium in an amount equal to <ix:nonFraction unitRef="number" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="2" name="sibn:DebtInstrumentPrepaymentPremiumYearOnePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1ODM_45855441-fd31-440e-8927-1526885860ce">3.00</ix:nonFraction>% of the principal if prepaid in year one, <ix:nonFraction unitRef="number" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="4" name="sibn:DebtInstrumentPrepaymentPremiumYearTwoPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NzY_02764642-6579-4ecc-ba8f-3f631d573982">1.25</ix:nonFraction>% of the principal if prepaid in year two, and <ix:nonFraction unitRef="number" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="3" name="sibn:DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5OTU_0c7be3ab-2c04-4973-995d-20649baa73e6">0.50</ix:nonFraction>% of the principal if prepaid in year three or later. The prepayment premium will be waived if the Company voluntarily prepays and refinances the outstanding balance with Solar. The Solar Term Loan is secured by substantially all of the Company&#8217;s assets.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is also obligated to pay a final fee equal to $<ix:nonFraction unitRef="usd" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc2NDc_9b4ec532-e36f-45e8-9fcb-2e606b69e0d0">1.0</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="number" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="3" name="sibn:DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc2NjE_9457ba80-73cf-40d5-a685-db3b6ab06979">2.5</ix:nonFraction>% of the aggregate principal amount of the Solar Term Loan, which was fully earned by Solar on the effective date of the Loan and Security Agreement. With respect to the Solar Term Loan, this final fee shall be due and payable on the earliest of (i) the maturity date, (ii) the acceleration of the loan balance or (iii) its full prepayment, refinancing, substitution or replacement. The final fee was included within the long-term borrowings and is accreted to interest expense using straight-line method over the life of the term loan.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective interest rate related to the Pharmakon Term Loan was <ix:nonFraction unitRef="number" contextRef="i91447b8f2dee4d7fb7da16614ef2b263_D20200101-20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzk2NTM_158d1c5b-3d40-438a-a2cf-1930179dbb94">12.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie6d91ea98cc44ed2ac071a60da01b6e0_D20190101-20191231" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzk1MzY_f6f0f03d-dd72-4b5f-927d-a9b95fc66037">12.3</ix:nonFraction>% for the term loan's outstanding periods for the years ended December 31, 2020 and 2019, respectively. The effective interest rate related to the Solar Term Loan was <ix:nonFraction unitRef="number" contextRef="i5cd440735cdc43f5a01ccd66c2e7e22a_D20200101-20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzk4ODg_f84f05fb-9019-4a06-90b1-c88495be0926">10.6</ix:nonFraction>% for the term loan's outstanding period for year ended December 31, 2020. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="ibf5309e17bde4c41ad6facc9b51f563e"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the future principal and final fee payments under the Solar Term Loan as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzIxNDg_6930998b-ca93-40b9-b19b-1a61ce507050" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"><tr><td style="width:1.0%"></td><td style="width:82.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzEtMS0xLTEtMA_7492f90b-8356-4549-ad39-0c02512bab36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzItMS0xLTEtMA_9e81acfb-a5e9-4c0b-a873-2b71c054faa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzMtMS0xLTEtMA_1229c7cb-902a-4aa3-b827-95da36fe69aa">11,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzQtMS0xLTEtMTc4OQ_f973fced-28de-406b-a15c-8a0222a12fde">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzUtMS0xLTEtMTc4OQ_72c0fd49-5039-4224-af63-fb46f51007ad">9,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and final fee payments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzQtMS0xLTEtMA_fee0b03b-c3a9-465d-aa7a-008916124e2b">41,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to other customary covenants set forth in the Loan and Security Agreement with Solar, the Company is required to maintain unrestricted cash and cash equivalents based on the trailing 12-month net products revenues tested on a monthly basis as follows: (a) $<ix:nonFraction unitRef="usd" contextRef="i37605fc017f54b699b34d502dfd83f5d_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentCovenantMinimumCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM4NzA_6f023e15-9627-4382-b2af-820e263042b6">15.0</ix:nonFraction>&#160;million if net product revenue is less than $<ix:nonFraction unitRef="usd" contextRef="i37605fc017f54b699b34d502dfd83f5d_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM4ODU_e02700c9-47b8-4fc7-bd7c-4a1a22e1707b">75.0</ix:nonFraction>&#160;million; or (b) $<ix:nonFraction unitRef="usd" contextRef="ia465af5919b8475cb3625c7d3c4c60b9_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentCovenantMinimumCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5MDA_1d12a797-2495-4f59-96f8-cca580545b90">7.5</ix:nonFraction>&#160;million if net product revenue is greater than or equal to $<ix:nonFraction unitRef="usd" contextRef="i0efb63d3047f421990b618ba7b240282_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5MTQ_d025d8c6-8929-4a47-83d9-d2f3e6357a14">75.0</ix:nonFraction>&#160;million, but less than $<ix:nonFraction unitRef="usd" contextRef="i7c56822bb4854a00aa2c71b72d285850_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5Mjk_621737de-4a3e-46cf-a79a-c4d157e3bbce">100.0</ix:nonFraction>&#160;million (the &#8220;minimum liquidity requirement&#8221;). The Company is <ix:nonFraction unitRef="usd" contextRef="i22adc896d58943239a8a55e36b35c2ff_I20200529" decimals="INF" format="ixt-sec:numwordsen" name="sibn:DebtInstrumentCovenantMinimumCashBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzU0OTc1NTgxNTEzNTY_1dfd7efb-b98a-461b-8b9e-ac0465a3ed4b">no</ix:nonFraction>t subject to minimum liquidity requirement when trailing twelve-month net product revenues exceeds $<ix:nonFraction unitRef="usd" contextRef="i0893e94d84ab4ef180a7082801b17e87_I20200529" decimals="-5" format="ixt:numdotdecimal" name="sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5NDY_c82a9f8e-1faf-4b5b-beda-c93fb78ae2a1">100.0</ix:nonFraction>&#160;million. Upon the occurrence of an event of default of certain customary covenants, including the minimum liquidity requirements, as specified in the Loan and Security Agreement, subject to specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is <ix:nonFraction unitRef="number" contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529" decimals="2" name="sibn:DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5NjQ_f84795c3-1573-4d52-a60c-dd4a7a564935">5.00</ix:nonFraction>% above the rate effective immediately before the event of default and may be declared immediately due and payable by Solar. As of December 31, 2020, the Company was in compliance with all debt covenants. Though there are uncertainties surrounding the impact of the COVID-19 pandemic that may impact our future revenue, the Company believes that it has sufficient cash and cash equivalents to meet the minimum liquidity requirements in the foreseeable succeeding periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CARES Act</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. federal government enacted the &#8220;Coronavirus Aid, Relief and Economic Security (CARES) Act,&#8221; and among other things, established the Paycheck Protection Program (&#8220;PPP&#8221;), administered by the Small Business Administration (&#8220;SBA&#8221;), whereby certain small businesses were eligible for a loan to fund payroll expenses, rent, and related costs. The loan may be forgiven if the funds are used for payroll and other qualified expenses. The Company met the requirements to apply for the PPP loan given that the Company has less than 500 employees and the business was negatively impacted by COVID-19. The Company submitted its application and was approved for the SBA program and received the proceeds from the PPP loan amounting to $<ix:nonFraction unitRef="usd" contextRef="i0029f543a0b44f28883347fcd2bda900_D20200421-20200421" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzMyOTg1MzQ4OTcwODE_64fce605-5cd8-4684-ae03-a41fca82afa1"><ix:nonFraction unitRef="usd" contextRef="ic1857c35e4ee46f3a5e3dd78d3069507_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzMyOTg1MzQ4OTcwODE_8dacb33c-7190-4d62-8ffd-4cf960e5cd57">5.3</ix:nonFraction></ix:nonFraction>&#160;million on April 21, 2020, pursuant to a Promissory Note with Silicon Valley Bank (&#8220;SVB&#8221;). In light of the subsequent clarifications from the U.S. government on the eligibility criteria, the Company determined it was appropriate to repay the entire amount of the PPP loan. Accordingly, on April 29, 2020, the Company repaid in full the PPP loan and correspondingly terminated the Promissory Note.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act allows employers to defer the deposit and payment of an employer's share of social security taxes through December 31, 2020. The Company recorded a total liability of $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzkzMTA_9220fc8a-14ed-4220-8626-3c33ef61e0fa">1.0</ix:nonFraction>&#160;million related to the deferral of the social security taxes of which $<ix:nonFraction unitRef="usd" contextRef="ib50689df2cf5465fbcc3d49d82ce6fe0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzkzMTY_4aa04468-ffc3-4165-a627-3fd01837363d"><ix:nonFraction unitRef="usd" contextRef="i5bb5133b5829435487b6826f9ee05e8d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzkzMTY_b7ec4be3-dd81-4e68-9f30-5fce9d71d4ea">0.5</ix:nonFraction></ix:nonFraction> million is included in each accrued liabilities and other and other long-term liabilities in the consolidated balance sheets as of December 31, 2020.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_190"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90ZXh0cmVnaW9uOjQ4ZTdmN2JhZmQ0ZjQxZTY4OWUzNWQyNzNmZTRlMzhkXzQ0OA_e7d79250-61a9-413f-a317-bafaf854d849" continuedAt="i1c95419040ee4fc0b88de6ca92555f59" escape="true">Warrants</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><ix:continuation id="i1c95419040ee4fc0b88de6ca92555f59"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90ZXh0cmVnaW9uOjQ4ZTdmN2JhZmQ0ZjQxZTY4OWUzNWQyNzNmZTRlMzhkXzQ0NQ_9fc0c309-7913-46c9-a432-3146673fdb65" escape="true"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes common stock warrants issued and outstanding at both December 31, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.916%"><tr><td style="width:1.0%"></td><td style="width:15.259%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.259%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.838%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of <br/>Shares <br/>Underlying <br/>Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price&#160;per <br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value<br/>(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4270a5f8e26b45ef92ae241f823a5c92_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNC0xLTEtMA_22e31c2b-9a3c-4dde-ba66-db80f41b0f4d"><ix:nonFraction unitRef="shares" contextRef="ia711fb7cbd244135958a45b84e252b9e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNC0xLTEtMA_8f639685-c047-426b-8cd0-7e14140434e5">1,388</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4270a5f8e26b45ef92ae241f823a5c92_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNi0xLTEtMA_29145448-002a-4b52-9c7e-69425d030667"><ix:nonFraction unitRef="usdPerShare" contextRef="ia711fb7cbd244135958a45b84e252b9e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNi0xLTEtMA_9b128dc2-27eb-4756-9f13-51531e6f91da">5.94</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia711fb7cbd244135958a45b84e252b9e_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItOC0xLTEtMA_f47d7495-91dd-4096-a3a1-9504ab5d0248"><ix:nonFraction unitRef="usd" contextRef="i4270a5f8e26b45ef92ae241f823a5c92_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItOC0xLTEtMA_f96cea1d-1bad-4a5b-a308-4f99e52a3819">5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc7925565e8c4323a6a9a220d817cd1e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNC0xLTEtMA_26b6c670-cadc-4af8-99de-83b81d98bdc3"><ix:nonFraction unitRef="shares" contextRef="i6ba592ea26314e52a133b56ede4ac0c3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNC0xLTEtMA_8393762d-b823-4c0f-a6f5-cb0ad7ed115b">32,983</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6ba592ea26314e52a133b56ede4ac0c3_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNi0xLTEtMA_d73ab411-701d-47d4-8121-f5b98941e43f"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc7925565e8c4323a6a9a220d817cd1e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNi0xLTEtMA_d87fad8a-88be-44dd-8538-6e014c17ac53">9.10</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba592ea26314e52a133b56ede4ac0c3_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtOC0xLTEtMA_74f741a7-ecec-46e9-9672-eeef684079f0"><ix:nonFraction unitRef="usd" contextRef="ibc7925565e8c4323a6a9a220d817cd1e_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtOC0xLTEtMA_9856eed9-3d53-449c-b32a-d8ff89f1d50e">122</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i774bf9ebb0d849c383fd489468d870df_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNC0xLTEtMA_0ec0b88c-dc63-499d-94d1-f7a900173824"><ix:nonFraction unitRef="shares" contextRef="i2d677b2975b845e383359e9465b1c838_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNC0xLTEtMA_742181e8-9816-4c20-8b4e-dab80d755967">6,680</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2d677b2975b845e383359e9465b1c838_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNi0xLTEtMA_36ebc7e5-28da-4b4d-856c-4d827920dfb0"><ix:nonFraction unitRef="usdPerShare" contextRef="i774bf9ebb0d849c383fd489468d870df_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNi0xLTEtMA_381ff911-823c-43b8-8420-a311d502b874">16.47</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d677b2975b845e383359e9465b1c838_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtOC0xLTEtMA_c62d1b00-7c0e-4e68-bec8-a9a9a9e87a20"><ix:nonFraction unitRef="usd" contextRef="i774bf9ebb0d849c383fd489468d870df_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtOC0xLTEtMA_d9c7ba77-fb3a-4b5b-9c8e-bf786ae05803">49</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7696c119674041ff8d5a58e5158f8c52_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNC0xLTEtMA_833688cc-a58a-4d3c-ab6b-50bbbfc60d58"><ix:nonFraction unitRef="shares" contextRef="i41018904b5854d86b3a31ec29a88bfb2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNC0xLTEtMA_d7ad0678-ecce-47ac-8ce9-b38eaf23ba98">41,650</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i41018904b5854d86b3a31ec29a88bfb2_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNi0xLTEtMA_b8051f08-3818-4400-82cc-1dad3a11915d"><ix:nonFraction unitRef="usdPerShare" contextRef="i7696c119674041ff8d5a58e5158f8c52_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNi0xLTEtMA_d74ea70b-c7c5-4727-a214-b6c54a3f9fff">16.47</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41018904b5854d86b3a31ec29a88bfb2_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtOC0xLTEtMA_1569aff7-3aa3-4f2e-8edc-b178824b6a5a"><ix:nonFraction unitRef="usd" contextRef="i7696c119674041ff8d5a58e5158f8c52_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtOC0xLTEtMA_8346e0d0-b850-49ef-b9d4-cf580f1f9442">396</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNC0xLTEtMA_35af318f-5c4e-4ee0-b224-3c76eeeb06b9"><ix:nonFraction unitRef="shares" contextRef="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNC0xLTEtMA_38ec614f-898f-45f6-b322-11ff884820f6">25,709</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNi0xLTEtMA_69dfc851-24f2-440d-ab07-4c70fef8c53d"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNi0xLTEtMA_75de8dc8-06c2-49b1-9e29-7c503187a478">16.47</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtOC0xLTEtMA_1a6e9f3e-7b36-4c42-84ca-441ff08c3678"><ix:nonFraction unitRef="usd" contextRef="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtOC0xLTEtMA_ad43a384-b281-4ed8-b184-a3f676311af6">244</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/22/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNC0xLTEtMA_0cd7db60-1e1a-49d1-afa7-40e1cdd32355"><ix:nonFraction unitRef="shares" contextRef="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNC0xLTEtMA_d15ce473-a243-44c2-bbfc-d5811dd5b7a8">9,712</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNi0xLTEtMA_284bd817-1e99-4a1d-afa7-9887fa6b8610"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNi0xLTEtMA_6c807033-6d4a-46e9-9ee5-d2b4046f23b6">10.03</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctOC0xLTEtMA_2d93fa20-b921-4fa7-9e5c-9a3c91c87668"><ix:nonFraction unitRef="usd" contextRef="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctOC0xLTEtMA_e5f797fe-c14a-478a-b4b0-a01fef36d5b3">45</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b01ed73e9446848e40e7b7b997079a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtNC0xLTEtMA_4a5e39d8-2a07-47f5-b7c1-ed7c98180239"><ix:nonFraction unitRef="shares" contextRef="ia6525e11de664dcc8219a14e1805fe4c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtNC0xLTEtMA_8fdce1e3-b26e-4cc0-9d03-7149afbdcc71">118,122</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6525e11de664dcc8219a14e1805fe4c_I20201231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtOC0xLTEtMA_d3407e0c-24f8-47e6-8704-469823ea5e4c"><ix:nonFraction unitRef="usd" contextRef="ib2b01ed73e9446848e40e7b7b997079a_I20191231" decimals="-3" name="sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtOC0xLTEtMA_e2e2f5ca-83fd-4e13-aa95-d745852f32df">861</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[a]&#160;&#160;&#160;&#160;Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[b]</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value at the date of issuance.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[c]     Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.</span></div></ix:nonNumeric></ix:continuation><div id="ic5af433463274989b3f39da4377b2b55_196"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzgwMQ_4fdab6a4-4c6e-493d-96d2-8900a9daebf9" continuedAt="id75e3db902e34d83a1bd5fac7a565b99" escape="true">Common and Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="id75e3db902e34d83a1bd5fac7a565b99"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's certificate of incorporate as amended and restated in October 2018, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzE0OQ_3a6f5a1b-2644-4242-a1f6-a5f20f689a41">100,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzE3OQ_d0b0565d-7a48-41a1-bb9b-3ef10b0f6e60">5,000,000</ix:nonFraction> shares of preferred stock, each having a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzIzNg_d1e7bb57-ec00-413a-81bd-4d3fc631a1e1"><ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzIzNg_f540e0c3-597a-4051-8de4-1a016093d662">0.0001</ix:nonFraction></ix:nonFraction>. Common stock issued and outstanding as of December 31, 2020 and 2019 were <ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzI5Nw_97e898f8-63fb-4b48-b32c-ecf6ab171edc"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzI5Nw_be43610b-b51a-4812-ae15-0c9a56117e4b">32,583,220</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzMxMQ_c0b6af6b-7572-435e-9140-04f32d6e03aa"><ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzMxMQ_cbedde50-5646-42b2-b194-6288c9f066ff">25,163,803</ix:nonFraction></ix:nonFraction> shares, respectively. As of December 31, 2020 and 2019, there was <ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_07818140-a8dd-4a66-b229-3b6721a710f6"><ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_2ea92dbf-d8be-4034-8565-88bcec49f032"><ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_a6ac8ddd-0286-4bb5-909e-8eda5a6f787a"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_da48fa5f-56ed-49fa-9479-1758df824e6f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been <ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzc3Mg_1f621408-73b5-464f-bcf9-3f11564e638b">no</ix:nonFraction> dividends declared to date.</span></div></ix:continuation><div id="ic5af433463274989b3f39da4377b2b55_202"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjc_bfda6d21-78eb-462e-adb5-9a59cebe7f6d" continuedAt="if72aefce6c0c43e5886d5bc7c3c13049" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><ix:continuation id="if72aefce6c0c43e5886d5bc7c3c13049" continuedAt="i9366ed3f7edf4df4a3e1114b1bc0ad71"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Stock Option Plan and 2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2008, the Company adopted the 2008 Stock Option Plan (the &#8220;2008 SOP&#8221;), as amended, under which the Board of Directors may issue incentive and non-qualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan (the &#8220;2018 EIP&#8221;), which serves as the successor to the 2008 SOP, under which the Board of Directors may issue incentive and non-qualified stock options and RSUs to employees, directors and consultants. No new options have been granted under the 2008 SOP since August 2018. Outstanding options under the 2008 SOP continue to be subject to the terms and conditions of that plan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2018 EIP will automatically increase on January 1 of each year, beginning January 1, 2019, and continuing through and including January 1, 2028, by <ix:nonFraction unitRef="number" contextRef="i139f7071f8c84f08bbe6dceaf889a5c2_I20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzk3Mg_ee13daec-ec6c-44b3-a564-72adcfcf118b">5</ix:nonFraction>% of the total number of shares of the Company's capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company's Board of Directors. On January 1, 2019 and 2020, the total number of shares of common stock reserved for issuance increased by <ix:nonFraction unitRef="shares" contextRef="i6bd0d0bfaa8049db933a2450c31775e0_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzEyNzA_acf3e324-95d8-4205-bb7e-f5169c6eb857">1,222,538</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibb403ea911274bf7b259455db756d709_D20190101-20190101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ5NDc4MDIzMzU1NDQ_46e84401-e1f1-4417-a5c0-514bb02a6f21">1,258,190</ix:nonFraction> shares respectively. As of&#160;December 31, 2020, a total of <ix:nonFraction unitRef="shares" contextRef="i139f7071f8c84f08bbe6dceaf889a5c2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzE0NTM_a4a36758-be37-4dfe-a36b-a8e1a847fb68">2,843,814</ix:nonFraction> shares of common stock are available for future grants under the 2018 EIP.  On January 1, 2021, the total number of shares of common stock reserved for issuance under the 2018 EIP automatically increased by <ix:nonFraction unitRef="shares" contextRef="ib2709796b037485da5c45a10ab0c0d2a_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ5NDc4MDIzMzU3MDA_7fa7e2f2-f96e-475a-9b70-80f41c70aeb7">1,629,161</ix:nonFraction> shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than <ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzE4Njg_4ae0f877-7af8-4273-bd82-6988d4744b99">10</ix:nonFraction>% of the outstanding shares, the price of each share shall be at least <ix:nonFraction unitRef="number" contextRef="i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzE5NDA_4f8a39c5-4fd2-45d5-abab-c963dc1efbb3">110</ix:nonFraction>% of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a non-qualified stock option shall not be less than <ix:nonFraction unitRef="number" contextRef="ifaca040e3897460d8726cb690a290765_D20200101-20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIxMTQ_d119b9c1-775a-4ddf-ba6c-39ed7633d39b">100</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i54ac410f45b545f6a9b196945613148b_D20200101-20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIxMjE_638ceca2-79b1-49d1-98a6-7aef420104b5">85</ix:nonFraction>%, respectively, of the fair market value on the date of grant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted have a term of <ix:nonNumeric contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIyMTg_62fc63c1-ae0f-4f13-8950-957beeac1c37">10</ix:nonNumeric> years, except, options granted to individuals holding more than <ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIyNzk_7c597ab5-63bb-4757-801a-976bf7322180">10</ix:nonFraction>% of the outstanding shares have a term of <ix:nonNumeric contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" format="ixt-sec:durwordsen" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIzMjM_d7ccbdae-7c4b-4b0f-91af-12fe95438dc7">five years</ix:nonNumeric>. Options generally vest over a <ix:nonNumeric contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTI0MTE_eec57d4e-89f3-4533-a314-10f7ae99efd0">four-year</ix:nonNumeric> period. Certain stock options are exercisable immediately, but are subject to a right of repurchase by the Company for any unvested shares. RSUs granted under the 2018 EIP generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1ODU_7bd59b98-57a3-4657-978b-3cc5ffa4e420">two</span> to <ix:nonNumeric contextRef="i3a3fc6a89c574e28830c17f1f39ec06b_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1OTE_426fdb5d-a86d-435d-841d-a9225fa596fa">four years</ix:nonNumeric> based upon continued services and are settled at vesting in shares of the Company's common stock. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i9366ed3f7edf4df4a3e1114b1bc0ad71" continuedAt="iffef70c897d749f3847bc7c918715a11"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjM_c38ef5e2-063f-4ce8-8c3c-889a0ca921b5" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.611%"><tr><td style="width:1.0%"></td><td style="width:51.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzItMS0xLTEtMA_05f0c004-a15a-4077-a6f5-ff17bf1a4214">2,641,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzItMy0xLTEtMA_f25c5839-d340-46ec-8a02-a12267964529">4.27</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzMtMS0xLTEtMA_07c3f6c9-a5fd-4a54-a234-a4ce1442f1a9">638,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzMtMy0xLTEtMA_f88594dc-5bf2-4ae7-a8c0-892758389f91">20.89</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzQtMS0xLTEtMA_50ff29c5-ce11-47d3-9d06-a57dbde2ff09">444,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzQtMy0xLTEtMA_a2353540-c1b0-45ad-9ef7-8fdb3571ce72">3.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzUtMS0xLTEtMA_49c384b8-7337-47e0-b8b7-098ccaf4d68d">116,286</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzUtMy0xLTEtMA_d9ee3c08-82de-42ad-8091-24d5cb6bd0c4">11.30</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzYtMS0xLTEtMA_4edc5c6a-3537-4829-84bf-75ca0fca7262">2,718,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzYtMy0xLTEtMA_8fd3a181-d5c6-4df1-9f65-2f90b640cdc9">8.02</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzctMS0xLTEtMA_413cd5ef-6e2b-4748-b14c-b01ba665b271">26,236</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzctMy0xLTEtMA_68a5891b-6bd1-4d48-9c23-96ed411955d2">17.31</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzgtMS0xLTEtMA_670b162e-e698-4814-a6b4-9d5c86fe565a">323,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzgtMy0xLTEtMA_fdcd2338-912a-4baa-b5e4-9fee0b846b4b">4.52</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzktMS0xLTEtMA_bd374a83-e2f1-4563-bd99-2a34acec8343">15,549</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzktMy0xLTEtMA_98e9d48b-f461-424a-b69a-89f16dd5c993">17.07</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTEtMS0xLTA_4998aeaf-1300-476c-ba87-5430bd643e68">2,405,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTMtMS0xLTA_38fbe270-7dd8-4072-a838-e07740550eff">8.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTUtMS0xLTA_ec54670e-f418-4690-9de3-6377bbda4f60">5.80</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTctMS0xLTA_c753413b-fab8-42bb-9abe-d383d9b27d07">51,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options vested and exercisable as of December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTEtMS0xLTA_f533a16f-09fd-4e1e-9e97-6f642086fe5a">2,069,020</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTMtMS0xLTA_3efd505c-d014-4f7a-bfd0-2e4050a40a48">6.85</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTUtMS0xLTA_c904d6db-844b-4235-b155-f1902d27a623">5.40</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTctMS0xLTA_b46d56fc-c794-49c6-8981-68d45acae175">47,689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options vested and expected to vest as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTEtMS0xLTA_fc8fa239-83ec-4e3e-a219-fd937dde2877">2,390,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTMtMS0xLTA_f5474222-ffaf-4e2a-833b-e38b89e1da94">8.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTUtMS0xLTA_ee6bb446-3a1e-4d5c-864e-75b2d3ab1e57">6.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTctMS0xLTA_73a1eacb-852c-4f20-a5b4-31c9f2e89520">51,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 amounted to $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI4OTE_fea0882b-e0fe-4b1c-9255-cb17818da977">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI4OTg_4ded0d66-2bc4-4076-b59d-e2784b6c911e">6.8</ix:nonFraction> million, respectively, representing the difference between the fair value of the Company's common stock at the date of exercise and the exercise price paid. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest as of December 31, 2020 represents the difference between the weighted average exercise price and the closing price of the Company&#8217;s common stock&#160;on the last trading day of the year. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMzQ_9cf1d51b-95e8-47b3-b089-87a473906507" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding options and exercisable options information by range of exercise prices as of&#160;December 31, 2020&#160;was as follows:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.166%"><tr><td style="width:1.0%"></td><td style="width:9.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.236%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested and Exercisable</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average <br/>Remaining <br/>Contractual <br/>Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMC0xLTEtMA_ab0e1e3e-df67-4cc8-bf24-491d4f23fffc">0.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMi0xLTEtMA_6915846a-f923-4469-90d2-082fac7d0277">3.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItNC0xLTEtMA_551cd304-af69-4db0-8604-fc382a6853ca">465,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItNi0xLTEtMA_4d1c3f7a-7d3f-49a3-9884-15311c89569c">3.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItOC0xLTEtMA_0d70bc2e-117f-496f-91ec-f9cd736bdc24">3.31</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMTAtMS0xLTA_cf819017-188b-479b-b2bb-0120f0affb12">465,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMTItMS0xLTA_4c8c042d-f4cf-4417-8c6f-bce33ec169ee">3.31</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMC0xLTEtMA_3013fb1a-94bf-4934-baad-654fbc15f28d">3.70</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMi0xLTEtMA_46fdf641-9c5f-41d6-89ff-4452aa5bf831">4.41</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtNC0xLTEtMA_e3363a4b-3ec5-4015-b279-8cab716ceced">689,903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtNi0xLTEtMA_5d3e6db5-b553-48f1-a29f-768503aba3c4">4.80</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtOC0xLTEtMA_15b98d1c-bb34-4bf0-8e59-ace2cfaf0a4e">4.29</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMTAtMS0xLTA_5cdb0c15-35a8-4622-9feb-cc82c5af878a">689,903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMTItMS0xLTA_4e98ba2c-cd11-49f8-8e7b-d0f453ed1514">4.29</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMC0xLTEtMA_a5a93116-5f90-405a-ad6b-be26dfe2c970">4.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMi0xLTEtMA_93225afb-9844-406b-881b-c616490c0677">5.31</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtNC0xLTEtMA_c7114886-7e8d-4494-8a6b-fa0ede523ec6">458,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtNi0xLTEtMA_636a29bc-d170-4529-be5f-95fe2389a0d8">6.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtOC0xLTEtMA_3dda1ade-f80e-414d-8323-e75a286eb982">4.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMTAtMS0xLTA_df623c51-e64e-4168-91ac-3f023af8eb02">422,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMTItMS0xLTA_1bd87059-70f8-43d9-901a-4d96ddaea2eb">4.67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMC0xLTEtMA_d7e49b56-c1cb-48e3-8014-49695c4d3ce3">5.32</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMi0xLTEtMA_40b224a4-77d3-4f2f-a52e-15dbe5fc95df">20.51</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtNC0xLTEtMA_c364b1f0-7327-4e77-9e07-de8965e01fd2">356,271</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtNi0xLTEtMA_d5d04103-b6f1-420d-9245-75a0dd630a66">7.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtOC0xLTEtMA_8580ab46-ea7e-4a48-bb4d-f24f687dba7f">12.08</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMTAtMS0xLTA_64060084-6d29-4949-81f7-56026c6d010a">282,203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMTItMS0xLTA_8e4d22c6-08d4-4504-b280-b66ea53deac6">11.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMC0xLTEtMA_83ddc57e-3b68-406d-89b3-30fe5df87aa5">20.52</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMi0xLTEtMA_64d5604a-9210-4e29-a45b-094f988c5aa7">22.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctNC0xLTEtMA_a121c4ab-cbd9-4ab5-8a05-4663d39dd01d">435,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctNi0xLTEtMA_9c00cb22-63f1-485e-994e-c069e414d090">8.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctOC0xLTEtMA_b9d55120-d068-4cad-b71f-b33b25161f1d">22.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMTAtMS0xLTA_250e1566-db63-4053-a2d9-efccb40d752b">208,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMTItMS0xLTA_d3c96ab8-9a80-44fc-a60c-88b1558a2f2b">22.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtNC0xLTEtMA_e6a99fa2-64b8-4e23-8d07-5760f9350b8b">2,405,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtNi0xLTEtMA_203af649-4203-4582-9a6d-7a449c2fa1b2">5.80</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtOC0xLTEtMA_9bcc02ea-0b73-4540-b48f-913080fd2d71">8.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtMTAtMS0xLTA_7a67414d-f9d2-4d06-95a9-f3ba67eef0a5">2,069,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtMTItMS0xLTA_346c6935-d1b1-44bf-bb54-b6aaaa452f4b">6.85</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the weighted average grant date fair value per share and the assumptions used to estimate the grant date fair value using the Black-Scholes option-pricing model of the stock options granted during the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMzM_463549ed-91ba-4c0f-9ffc-6dfd7a91eb5c" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.722%"><tr><td style="width:1.0%"></td><td style="width:59.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItMS0xLTEtMjk0MQ_7211cf37-b8ec-43bd-a433-dfce06d6399e">8.16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItNS0xLTEtMjkyOA_41a9e70b-9974-4b21-9119-e98964303b4d">9.78</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f6cd8ef95b04649a99031341fddf8ea_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItMS0xLTEtMA_a5f34b6a-673b-4290-b418-7e7c2b9ad19a">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1227fe8e7ba44a1bde242290ec79931_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItMy0xLTEtMA_26aae512-571e-4185-9709-b2b2e362f4be">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b3ffdb1efa44a3a807c3bb0733bd89f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItNS0xLTEtMA_0c239a05-c079-4990-9757-3d1ec2e11ab8">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d34965263684d8a827e3b511ef07bf7_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItNy0xLTEtMA_47e25fc2-e05b-4d3f-840f-39969bb78976">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtMS0xLTEtMA_32854539-e6c7-4cfd-af94-5ff09509e59f">46.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtMy0xLTEtMA_c3f85077-5c6f-4de7-bddd-bb3fc62f897a">47.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtNS0xLTEtMA_470067b6-f073-44eb-83a0-05123700227c">41.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtNy0xLTEtMA_6e29c9ce-30c4-4898-853d-ab16e614b9d1">47.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtMS0xLTEtMA_a4c3f2c0-4d81-428b-a581-e88e70ced594">1.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtMy0xLTEtMA_4851b59f-6492-410d-90e7-3036d7d7b5fd">1.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtNS0xLTEtMA_53268f58-e542-4410-82b6-56bac7132cc5">1.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtNy0xLTEtMA_3d93cc77-5941-4639-b986-4189a046b3c5">2.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzUtMS0xLTEtMA_fcfe5674-2753-42f2-9164-be0515e43cae">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzUtNS0xLTEtMA_784a2606-c092-45fc-b8ef-93b50f9634c5">&#8212;</ix:nonFraction>%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="iffef70c897d749f3847bc7c918715a11" continuedAt="i0e79daf0aa204a878992ce2c0a0f6fc0"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQwODQ_fbb90e5b-4b60-472d-9c72-61dd307a0e93">3.2</ix:nonFraction> million of unrecognized compensation cost related to stock options granted. These costs are expected to be recognized over a period of approximately <ix:nonNumeric contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQyMjg_bdb293cb-3827-4c32-99af-dca6b545d2f1">1.9</ix:nonNumeric> years.</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Unvested Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early exercises of stock options under the Company's 2008 SOP are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders&#8217; equity as the options vest. As of December 31, 2020 and 2019, the Company had a total of <ix:nonFraction unitRef="shares" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ3MzI_928f079e-77ed-43f1-922d-42ed6f1260e6">5,836</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt:numdotdecimal" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ3Mzk_0e58502d-01ba-47b3-91b3-3c3bf487f1b2">21,404</ix:nonFraction> shares of common stock, respectively, subject to repurchase under the 2008 SOP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMzA_494566de-21a3-46c1-a57e-e5b00bbd467c" escape="true"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock units activity for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Grant Date Fair  <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0283a6f15aee4e39bd5b62b008d5658f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzEtMi0xLTEtMA_b2d39505-fd98-481e-848f-91578fa3ca38">53,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0283a6f15aee4e39bd5b62b008d5658f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzEtNC0xLTEtMA_d8e9425a-1e60-4991-9aff-fd7c8d3b7e13">11.69</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzItMi0xLTEtMA_5147cb26-53e4-4dd6-a03d-4e8c8f69b1dd">639,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzItNC0xLTEtMA_e9ecb2ce-fd30-49c0-bf22-e85fae011756">20.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtMi0xLTEtMjQw_6b5da85b-daae-415a-9fb2-563b70219556">108,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtNC0xLTEtMjQw_e1ed2202-4c51-4ad5-aa53-e51f53896c17">19.10</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtMi0xLTEtMA_5ee6d9f1-8453-4537-afe9-05d7392bdd20">41,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtNC0xLTEtMA_dff26558-959e-456b-8485-bd3ec8601699">18.48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabe7e4f5c282479c9dd4b63577d53724_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzQtMi0xLTEtMA_af543cb2-d457-4686-9595-83ade35900df">543,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iabe7e4f5c282479c9dd4b63577d53724_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzQtNC0xLTEtMA_8afee3b3-6564-48d9-9ac6-13760379c52e">19.72</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzUtMi0xLTEtMA_8d62674b-ef52-43b3-befc-b6f7b94ff329">1,016,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzUtNC0xLTEtMA_6862075a-e997-435f-84ad-dc6843170621">20.17</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzYtMi0xLTEtMA_9d63cf57-3e2a-4871-8f68-5bf05a7ddb25">344,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzYtNC0xLTEtMA_08e4ef1b-58c5-47fd-b22d-a3f31a44a307">19.87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzctMi0xLTEtMA_19eed059-ec5e-422b-bf81-2b0200837c5f">49,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzctNC0xLTEtMA_651e5845-af01-42df-a807-79e85f6e9f03">19.73</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c1abe777aa459288707c7d8ba52b51_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzgtMi0xLTEtMA_f03593df-fbf7-4693-badf-c345a4a45e09">1,165,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i11c1abe777aa459288707c7d8ba52b51_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzgtNC0xLTEtMA_8348c444-b765-44d1-9b4f-eefb63168862">20.07</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was a total unrecognized compensation cost of $<ix:nonFraction unitRef="usd" contextRef="i11c1abe777aa459288707c7d8ba52b51_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzUwNzQ_9c4f00df-ee5b-49ae-8537-d15f3701a397">19.3</ix:nonFraction> million. These costs are expected to be recognized over a period of approximately <ix:nonNumeric contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzUxNTE_98979445-90e9-482e-bcb9-f1aca61d2790">2.9</ix:nonNumeric> years. </span></div><div style="margin-top:12pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to <ix:nonFraction unitRef="number" contextRef="i82add15eb7894a888a8e8a9ba05ff086_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU0MTk_3e64950a-1e87-40a7-a5e5-cab64f178485">85</ix:nonFraction>% of the lesser of the fair market value of the stock as of the first date or the ending date of each <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1MjI_0f5ed571-a69d-4bc7-b68e-654ed23d7077">six</span> month offering period. The offering period generally commences in May and November. On March 26, 2020, the Company's Compensation Committee approved the amendment of the terms of future offerings under the ESPP which, among other things, increased the maximum number of shares that may be purchased on any single purchase date, provided for automatic enrollment in a new offering, and provided that the offering which commenced in May 2020 be <ix:nonNumeric contextRef="i2931999815684f1992182b9f6d12780e_D20200501-20201231" format="ixt-sec:durwordsen" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM4MjM_0a1ad626-0597-4729-8cbe-75df6212fb07">twelve months</ix:nonNumeric> in duration and consist of <ix:nonFraction unitRef="purchase_period" contextRef="i2931999815684f1992182b9f6d12780e_D20200501-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM4MTg_3df558a3-6870-4455-8030-238062fe9ce9">two</ix:nonFraction> purchase periods. There were <ix:nonFraction unitRef="shares" contextRef="i7ce9444b0b5849639bc0b7f620058c77_I20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1NTk_6f0d9e7f-5ea9-4286-9a4f-67bfaa12d9e0">515,307</ix:nonFraction> shares of common stock originally reserved for issuance under the ESPP. Under the ESPP, the number of shares reserved for issuance under the ESPP automatically increases on January&#160;1st of each year, starting on January&#160;1, 2019, and continuing through January&#160;1, 2029, by an amount equal to (i) the lesser of <ix:nonFraction unitRef="number" contextRef="iadf669f97771460fb006978ac53fcd89_I20201231" decimals="INF" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU4NzA_6e034e03-aec7-401d-92a8-455bf043ffb0">1</ix:nonFraction>% of the total number of shares of the Registrant&#8217;s common stock outstanding on December&#160;31st of the preceding calendar year, and (ii) <ix:nonFraction unitRef="shares" contextRef="iadf669f97771460fb006978ac53fcd89_I20201231" decimals="INF" format="ixt:numdotdecimal" name="sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzYwMDY_f384ab2d-5d5c-4602-962c-33a35f6ff73e">555,555</ix:nonFraction> shares of common stock. As of&#160;December 31, 2020, a total of <ix:nonFraction unitRef="shares" contextRef="iadf669f97771460fb006978ac53fcd89_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzYyMDY_5708ab4d-835c-4985-a751-eb69b0f5bde0">705,618</ix:nonFraction> shares of common stock are available for future grants under the 2018 EIP. On January 1, 2021, the total number of shares of common stock reserved for issuance under the ESPP Plan increased by <ix:nonFraction unitRef="shares" contextRef="i474b61edbbc14b8d94e1ce0729536585_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY0MDI_8b0bda3f-915a-41d5-9f5d-2f4d3a933b71">325,832</ix:nonFraction> shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model, which is being amortized over the requisite service period. The Company issued <ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM3MTc_6872c038-cf5b-4372-adfa-02de508fa2a6">137,377</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM3MjY_6904d4d5-603a-4a3a-a87a-9a5513846588">168,457</ix:nonFraction> shares under the ESPP during the years ended December 31, 2020 and 2019, respectively, representing approximately $<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM3ODY_d8623768-95d9-497e-a7ea-1cc70038244b">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM4MDA_04a8e80c-36b3-4d99-8628-5d097c8dc7a8">2.2</ix:nonFraction>&#160;million in employee contributions. As of December 31, 2020 and 2019, total accumulated ESPP related employee payroll deductions amounted to $<ix:nonFraction unitRef="usd" contextRef="iadf669f97771460fb006978ac53fcd89_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY1MDI_5b29409d-5135-4201-9832-4736398f1771">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i297b39b995a14cdebf1cfa2c3d3fc236_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY1MDk_edfd8dfa-c2c4-474f-8fbe-8222ef7835db">0.2</ix:nonFraction> million, respectively, which were included within accrued compensation and related expenses in the consolidated balance sheets. For the years ended December 31, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i82add15eb7894a888a8e8a9ba05ff086_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY2ODU_cb098e06-b891-4213-aab4-54438880d7ff">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie584850230f64839b9c46ed2b0b8f3a3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY2OTI_b26f8331-6980-4d46-8c95-0a6128cb8387">0.8</ix:nonFraction> million, respectively, of stock-based compensation expense related to ESPP. As of December 31, 2020, the unrecognized compensation cost for the ESPP was $<ix:nonFraction unitRef="usd" contextRef="iadf669f97771460fb006978ac53fcd89_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY4MjU_43bf20e8-25c7-4d88-a08f-0048f21fb53e">0.2</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i0e79daf0aa204a878992ce2c0a0f6fc0"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjQ_88e52540-44b9-4211-9efc-5dd270ba2ade" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of&#160;ESPP purchase rights during the offering period&#160;using a Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.944%"><tr><td style="width:1.0%"></td><td style="width:57.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i79cb20fa436042dbb60426290872da75_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzItMS0xLTEtMA_cf6ed87f-9b29-4d71-b2f5-74847f1b1765">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibde4a023409a47be91b9ea5231045908_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzItMy0xLTEtNjE2Ng_f45082a2-30c9-4cc6-85a8-f9e4b4c33756">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzItNS0xLTEtMjg4_064917b7-a7b7-44b2-a992-ec4d5d91f2b9">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtMS0xLTEtMA_a6b4f718-311f-4568-9b6a-7d28848f647a">38.3</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtMy0xLTEtMA_5b1d3ed8-a547-41d4-a472-eace8ef1257a">79.4</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtNS0xLTEtMjky_57dcfa75-be4b-4381-8954-d0785650c351">38.3</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtNS0xLTEtMA_f9d3e973-cab5-4782-86a6-700eef08d9f9">58.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtMS0xLTEtMA_45ad586b-7f81-4c67-9693-c0c56574cb96">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtMy0xLTEtMA_fa53d01d-3794-4e33-b64f-f127a14c51ac">1.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtNS0xLTEtMjky_9d60d32e-4ffd-4a9e-9af6-9492bcc88e72">1.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtNS0xLTEtMA_eef525a3-e628-43eb-ac97-f727d7f27992">2.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzUtMS0xLTEtMA_b2f9dbaf-1611-428d-8aa0-f205be1d35d5">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzUtNS0xLTEtMzAw_c274824b-92e7-49f3-8404-cc2737590bb3">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjU_ae479742-ded8-4355-ac45-f9b279037ff0" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth stock-based compensation expense recognized for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i410806cbbdc746209446c410c6341047_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzMtMS0xLTEtMA_1c3c5c50-3b55-427d-b608-e210bc8a4e90">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a0c0dce9584a3eb98f59092edd33c5_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzMtMy0xLTEtMA_7d6398c6-0d51-485b-a4c8-0fbce9bb9b0a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4055a0636841d992ed275f0ce24c78_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzQtMS0xLTEtMA_d360da6a-c1fd-4370-a0f9-e663081d8001">5,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70af4b35e0d415a8450cc48c58a228a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzQtMy0xLTEtMA_1fb63852-a35c-4d22-bfc4-ef21e3207103">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfba54d8644e33a6243d800d6a11c0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzUtMS0xLTEtMA_a0162e25-2b0e-4b0a-bffc-279a655a9817">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00219ae7e63c44d783f827759951eaaa_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzUtMy0xLTEtMA_7a2ab3e8-73dc-42bc-97d9-5c402f2e809a">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ce6cefcf474ade882fc1adc72c8eb8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzYtMS0xLTEtMA_33e60aa9-41d0-4e60-ab59-7d6579bc38b7">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95838768b71a4d678805680c3b4e0eea_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzYtMy0xLTEtMA_c6b0fb63-1339-4a3b-8105-b1ab103bd363">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzctMS0xLTEtMA_fceacb1d-1975-4089-a39a-00ae847fd8dd">11,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzctMy0xLTEtMA_121f8256-bd76-43e6-aadf-b3b0f716ae08">7,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic5af433463274989b3f39da4377b2b55_208"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzg3MQ_37d16639-43fc-4418-9464-ba601def2591" continuedAt="ib7aaa8ddda2d46f29b5788bee2b21eb8" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7aaa8ddda2d46f29b5788bee2b21eb8">The Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. Effective January 1, 2019, the Company made a discretionary matching contribution equal to dollar for dollar employee contribution, up to <ix:nonFraction unitRef="number" contextRef="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzQzNw_4ef14167-f923-48fc-9ee9-89b26106de9b">3</ix:nonFraction>% eligible compensation of the employee, with a maximum annual contribution from the Company of <ix:nonFraction unitRef="usd" contextRef="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sibn:DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzUzNA_d7604a7d-3e9e-4210-a40a-766956ba63b9">one thousand</ix:nonFraction> dollars per employee. Further, in order for an employee to receive the matching contribution, the employee must be at least 21 years old, work at least 1,000 hours per year, and must be employed by the Company at the beginning through the end of the year. For the years ended December 31, 2020 and 2019, the Company made $<ix:nonFraction unitRef="usd" contextRef="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzE2NDkyNjc0NDI1Nzg_ad6aa8af-ef48-44ac-8844-86d879090aec">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3946e536ed904059b0b93a4cf16adf9c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzgzNQ_36845d40-3124-4a67-91aa-ae38894261c3">0.1</ix:nonFraction> million, respectively, contributions to the 401(k) plan.</ix:continuation> </span></div><div id="ic5af433463274989b3f39da4377b2b55_211"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90ZXh0cmVnaW9uOjcyMjhhZjE4NjYwZTQ1MTI5OWFlM2Q1YWJkY2E4Y2NkXzcwNg_201c5d7b-ef07-4151-8257-51acad477592" continuedAt="i3efee34e9e9642608eb6f43e86523df9" escape="true">Net Loss Per Share of Common Stock</ix:nonNumeric></span></div><ix:continuation id="i3efee34e9e9642608eb6f43e86523df9" continuedAt="i6dfb2c79cbbf49099b1e8186e56a707a"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90ZXh0cmVnaW9uOjcyMjhhZjE4NjYwZTQ1MTI5OWFlM2Q1YWJkY2E4Y2NkXzcwOA_3e0d069d-33bc-4e44-8ddb-9528ea9ca0df" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:74.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands, except share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzMtMS0xLTEtMA_2a19d98d-04c9-47d6-8faa-1bcda6b5052f">43,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzMtMy0xLTEtMA_0902914c-29f1-4abc-855d-b524bb0e3be2">38,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzUtMS0xLTEtMA_490558d8-1d51-4732-b939-9d0e92db058a">29,059,171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzUtMy0xLTEtMA_731476b1-ec21-46c9-bac4-c4ade01758f7">24,705,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzctMS0xLTEtMA_c45ad034-7f9a-4329-a17b-8c38a7a7c52d">1.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzctMy0xLTEtMA_66e656a8-91f4-407b-948c-8c0c27717063">1.55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i6dfb2c79cbbf49099b1e8186e56a707a"><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Company has reported a net loss in all periods presented, outstanding stock options, restricted stock units, shares subject to repurchase, ESPP purchase rights and common stock warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following anti-dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90ZXh0cmVnaW9uOjcyMjhhZjE4NjYwZTQ1MTI5OWFlM2Q1YWJkY2E4Y2NkXzcwNA_a02f3849-bc99-4a61-aa6b-6744fe535e25" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ea822832f34b5cae2305c150d8cd7a_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzItMS0xLTEtMA_1fe7a53b-7914-4b3f-abed-9fa0cb940fcd">2,405,957</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c4b044fdf884181b597402c0cfa5a59_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzItMy0xLTEtMA_eb70700a-95ed-4275-ae2a-9d1063c246b1">2,718,971</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6934a8f368ab4d9494b07c7ddfe7de0c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzMtMS0xLTEtMA_ebf31086-99f8-4656-85dd-666ee29060ff">1,165,295</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c03f872c9a9488c981785d7b2746aa4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzMtMy0xLTEtMA_e3dc7ba7-3824-464d-95a5-dd689c9f8eaf">543,041</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares subject to repurchase</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic58413a7253e4f4d8190a06a75631d77_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzQtMS0xLTEtMA_df2b77b3-1d89-4e63-ae99-1e552d67236c">5,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40b75f3d79804b4face844493077ae7d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzQtMy0xLTEtMA_fcd88a42-2424-4432-885c-4d0d3883e6e0">21,404</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP purchase rights</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc544ac398ba485a8fc4c71db95233b3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzUtMS0xLTEtMA_e1cea250-aebc-4e41-a757-0f2cd44bad70">83,040</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if06ea8c038f64be2b2835e0ef0d248f2_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzUtMy0xLTEtMA_18b20a6f-9c54-4596-90f7-76646434dfbe">65,442</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55d3b6b03018480f8f30f7f6f385c670_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzYtMS0xLTEtMA_008dc112-e2d8-4355-b220-05a05ee3e2c5">118,122</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696aeae988714665861bf927c6df4e88_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzYtMy0xLTEtMA_6c51ceda-289d-49c0-a9ab-83195ecf1cfa">118,122</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzctMS0xLTEtMA_cf6100e9-1752-4afe-a7ee-6909d3576986">3,778,250</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzctMy0xLTEtMA_85330d28-c947-4769-b8af-a432d4e1dc0a">3,466,980</ix:nonFraction></span></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="ic5af433463274989b3f39da4377b2b55_217"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MjI_d89ee5ca-12c0-4734-87ad-e1b4702afbb5" continuedAt="i05a6a102386543d4b0cf236a6296e89b" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i05a6a102386543d4b0cf236a6296e89b" continuedAt="i8e74faadab994ef6b43c4fa3599eb9cd"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTE_4416f70b-8ae4-44bb-bfbb-fa90e6c96603" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s loss before income taxes are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzMtMS0xLTEtMA_01d29a00-f65b-45e8-b2a0-518a6f8a9cbb">41,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzMtMy0xLTEtMA_f986be13-ef9e-462b-bdd4-33546ccc70e2">37,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzQtMS0xLTEtMA_3a035c6f-683a-45d7-8262-a0f6e063c5ea">1,989</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzQtMy0xLTEtMA_8dd0932c-b38c-46df-b8fa-b2caac8c67af">694</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzUtMS0xLTEtMA_7a5a53cb-e4bc-4144-91e3-aeed1f5aabfd">43,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzUtMy0xLTEtMA_b81189f5-07e3-4b59-bc59-8ef20ca70be2">38,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for income taxes recorded for the years ended December 31, 2020 and 2019. The Company continues to maintain a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The Company periodically evaluates the realizability of its net deferred tax assets based on the expected realization and is dependent on the Company's ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i8e74faadab994ef6b43c4fa3599eb9cd" continuedAt="i07eb2b2073354297b828f781b9ea64df"><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MDY_c6b85007-f7bd-4482-b76c-05f4540f7279" escape="true"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income taxes are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzMtMS0xLTEtMA_85f903c7-a6b7-4ed9-aa6f-58a0c51f062f">9,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzMtMy0xLTEtMA_e5ca4300-571b-48fa-bc8b-3b64de7daad7">8,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzQtMS0xLTEtMA_b25371fb-08f5-47a3-aa65-905a3e7c28b2">2,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzQtMy0xLTEtMA_21a91b81-3dc4-45a5-aaf3-202dbf2a48de">1,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzUtMS0xLTEtMA_dd1c60c6-f3e5-4ee3-ac00-3d1f710e177a">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzUtMy0xLTEtMA_1e25e3b3-d6d1-44c9-9ea8-d1a5ef916924">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzYtMS0xLTEtMA_505c852c-7766-468b-96f4-ef4b2acab45f">13,149</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzYtMy0xLTEtMA_e63b9670-407c-4d7a-8bc3-9b32da39cdb3">9,892</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzctMS0xLTEtMA_2eaf8bee-5840-46b9-97c8-1b2e8c25b794">13,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzctMy0xLTEtMA_8cbff8f9-8d5a-44e0-bcdf-d8d76194af7c">9,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzgtMS0xLTEtMA_32cea3cc-3c3e-4d31-9620-fbb3dff518f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzgtMy0xLTEtMA_257a7a82-0f8f-4a20-9e6a-9a3132208f72">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTI_cffaa5a3-ed46-473a-b726-adbc2b74bcb5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at statutory federal rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzItMS0xLTEtMA_896fefa6-1808-405f-8ede-e57b5d7923c3">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzItMy0xLTEtMA_f4cd3808-91a6-451e-aa73-24a0b9929d95">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzMtMS0xLTEtMA_02d0f85a-203e-4bc3-93a0-25bf300df8c0">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzMtMy0xLTEtMA_cd1f1cf1-d175-4674-a0fc-497bef85aa08">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzQtMS0xLTEtMA_fb771af1-117c-4331-9ca5-b13caa2ad625">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzQtMy0xLTEtMA_63483e03-ceae-431c-b0fd-884a39df8832">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzUtMS0xLTEtMA_c3c2e30f-2674-4432-80a0-3c8d51d7f3ec">30.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzUtMy0xLTEtMA_c1031fac-4f26-4728-a180-29c671cf9ae8">25.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMS0xLTEtNzQ2NQ_d0a7fd35-c443-4e2e-8d4c-3712bc95e86c">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMy0xLTEtNzQ2MA_af8acc9c-9a31-4c67-8e7c-e8357639d4c1">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMS0xLTEtNzc1NQ_fd8d7551-daf1-4dc0-8eb6-2f0f8240791b">1.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMy0xLTEtNzc1OQ_daf7e738-2c40-4fa7-84de-0ecea90795b7">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMS0xLTEtMA_4a9555bc-1b86-47ad-ba54-cfa9e0363e4a">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMy0xLTEtMA_23ebc1d4-4b88-4051-9fd9-e9213b6c923d">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMS0xLTEtMA_483c23dd-9e4a-4e4f-8af2-13c8abadeb13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMy0xLTEtMA_af238118-516e-48fa-be60-d8a641637092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTk_173d6917-af67-41ba-9b8a-a470555f2e01" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"></td><td style="width:74.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzMtMS0xLTEtMA_b4aee678-f4f5-4266-85cf-93db3c4ea7b5">52,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzMtMy0xLTEtMA_d570ab10-8bcb-4eb6-b692-df52405bbc21">42,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzQtMS0xLTEtMA_87b2255d-cc67-4012-8e8e-e5982a456ad2">3,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzQtMy0xLTEtMA_b892d67b-7a75-4bce-8d7e-802dbb210f58">2,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzUtMS0xLTEtMA_f6508853-f322-46fc-83f2-8958c963d533">5,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzUtMy0xLTEtMA_d69035a1-18bd-460e-8c24-12d246badce5">4,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzYtMS0xLTEtMA_8c365776-b22c-4823-8aa9-619076d863a7">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzYtMy0xLTEtMA_9d1c43a9-0044-4506-a567-47949600d7d1">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" name="sibn:DeferredTaxAssetsDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzctMS0xLTEtMA_f388f263-e472-422d-91a4-19a7099ffe10">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" name="sibn:DeferredTaxAssetsDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzctMy0xLTEtMA_f5346548-20ba-49c4-b5d4-979263e7bb78">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzgtMS0xLTEtMA_c130e5ce-98e8-4736-a1cb-e55794483f63">63,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzgtMy0xLTEtMA_bac3522c-3a34-46ad-8815-5f926e37eea8">50,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzktMS0xLTEtMA_d60dc48b-698c-41ca-982c-74d47974ecdf">63,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzktMy0xLTEtMA_63f8ee8c-671a-4863-bee3-19fa55d15faf">50,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax asset, net of valuation allowance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzEwLTEtMS0xLTA_524ee9d5-c5b8-47d6-9f0d-7de73a4d2940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzEwLTMtMS0xLTA_2cc697bb-ceca-4d8e-97a5-c2a4f747d276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MjA_ba7f7a03-2706-4023-9fe8-23d3eac2b19b" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in the valuation allowance for the years ended December 31, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:73.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzMtMS0xLTEtMA_635469a9-5f3a-4a12-8d14-cac90eb26dfa">50,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzMtMy0xLTEtMA_6397ca12-a037-4320-ac53-55600dcd3c27">40,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzQtMS0xLTEtMA_dfc4fdf6-7e65-472c-953c-1cac82bb6ce5">13,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzQtMy0xLTEtMA_6973db75-2e3e-4562-a663-954f4d950ee3">9,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzUtMS0xLTEtMA_68647e07-5828-48bd-8a3a-623c81f0d66a">63,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzUtMy0xLTEtMA_2068d22e-2e59-4e42-ad9f-051963a41d2f">50,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i07eb2b2073354297b828f781b9ea64df"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia344c14925fb435996aff0ac207bae68_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzE4MDg_963e8602-58f5-4964-a88a-4a003af41399">200.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bd326d4dba048b1a3b67d4854664c94_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzE4MTU_fb9bd770-b047-4a8a-a9b5-48d526378f12">165.0</ix:nonFraction> million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company&#8217;s federal NOL carryforward begins to expire in 2028, and the state NOL carryforward begins to expire in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia344c14925fb435996aff0ac207bae68_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzIxMjY_c9d953d2-3084-4d44-8841-f3a0519748ba">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bd326d4dba048b1a3b67d4854664c94_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzIxMzM_231dd6b8-cc3e-4749-b37c-06e7fd5f4342">2.5</ix:nonFraction> million available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in 2029, and the state credits have no expiration date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company updated its Section 382 ownership change analysis through December 31, 2020 a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd determined that the last ownership change was in February 2020 due to the follow-offering. The analysis concluded that no additional NOL carryforwards will expire due to the Section 382 limitation from the ownership change for both federal and state tax purposes. The Company maintains the reduction of $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sibn:OperatingLossCarryforwardsLimited" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzM0MTY_03204405-c5c8-4c99-94a3-e90d3dc2325c">1.4</ix:nonFraction> million of its NOL carryforwards from the previous ownership change. The Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pany will continually assess the need to update its Section 382 ownership change analysis, as the Company may experience ownership changes in the future that could materially limit its ability to use its NOL carryforwards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act includes provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the payment of an employer's share of social security taxes through December 31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sibn:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzMyOTg1MzQ4OTUwNDc_30f31884-5b85-4b5b-8ab8-46c12ce48b97">1.0</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 29, 2020, Governor Gavin Newsom signed California Assembly Bill 85 (AB 85) into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California Tax Credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1.0&#160;million. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $5.0&#160;million of California tax. Given the Company&#8217;s loss position for the year ended December 31, 2020, the new legislation did not impact the current year provision. The Company will continue to monitor the possible California net operating loss and credit limitations in future periods.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTA_ed428513-6072-454a-b20b-bf14b912dfde" continuedAt="iabb9abe342cb4a94b49f6c19b600d47e" escape="true">The changes in the Company&#8217;s uncertain income tax positions for the years ended December 31, 2020 and 2019 consisted of the following:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="iabb9abe342cb4a94b49f6c19b600d47e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.194%"><tr><td style="width:1.0%"></td><td style="width:73.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzMtMS0xLTEtMA_3eba3442-1e86-4ff1-9d64-8e80ff4ed194">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzMtMy0xLTEtMA_64caad2b-2dd1-4179-804d-ff90de42266e">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year's tax positions</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzQtMS0xLTEtMA_6aeca30a-db6b-467d-88ee-7174a5d2d837">226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzQtMy0xLTEtMA_6c3f00c9-e0fd-46c7-a0c9-962a38bcc387">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzUtMS0xLTEtMA_65b4f545-88e0-41c1-9837-02d128cf5c82">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzUtMy0xLTEtMA_72738a70-a2ab-44ab-bfad-7ba204fb81d8">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has <ix:nonFraction unitRef="usd" contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzQ3Nzc_05815183-868f-4cdc-82a6-48ed5fee1b46"><ix:nonFraction unitRef="usd" contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzQ3Nzc_bbb2e36f-6292-4eff-93d6-e0a336d44cea">no</ix:nonFraction></ix:nonFraction> accrued interest related to unrecognized tax benefits as of December 31, 2020 and 2019. None of the Company&#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rates for the years ended December 31, 2020 and 2019. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no federal, state or foreign tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company&#8217;s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_2259"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8zMjk4NTM0ODg5Mjc3_37a29393-5061-4cb8-9fc4-f586f9b62e35" continuedAt="i555986dccbe749b1b7ccf5ac95590c0b" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i555986dccbe749b1b7ccf5ac95590c0b" continuedAt="i6e24c3b6e4ba44119110badb14bceb25"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2020, the Company entered into a joint development agreement (the &#8220;Development Agreement&#8221;) with SeaSpine Orthopedics Corporation (&#8220;SeaSpine&#8221;) to develop a next generation device for sacropelvic fixation. Mr. Keith Valentine, who serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine, also serves as a member of the Company's Board of Directors since August 2015. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the development plan, SeaSpine shall use reasonable efforts to assist in the development of the potential product offering, including licensing certain existing intellectual property to be incorporated into such product. Under the terms of the&#160;Development Agreement, the Company agreed to make monthly payments to SeaSpine to reimburse for full time resources employed by SeaSpine responsible to conduct the development activities. For the year ended December 31, 2020, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="i8cd127df2c1c4983bc79d5cb10d32b12_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8xNjQ5MjY3NDQ3NjA3_32c8adc8-1980-46a9-989f-e7077bc90eec">118,000</ix:nonFraction> of the reimbursement charges from SeaSpine, which was recorded within research and development expense in the consolidated statement of operations. There was <ix:nonFraction unitRef="usd" contextRef="i193e00bc574d4629ac04368864c1127a_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DueToAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8zMjk4NTM0ODg5NDA4_a1d67577-26e2-41e3-beb9-874dc6f45091">no</ix:nonFraction> outstanding liabilities to SeaSpine as of December 31, 2020. </span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e24c3b6e4ba44119110badb14bceb25">Certain intellectual property developed pursuant to the project plan will be owned by the Company, certain intellectual property developed pursuant to the project plan will be owned by SeaSpine, and other intellectual property developed pursuant to the project plan will be jointly owned by SeaSpine and the Company. The Company also agreed to provide SeaSpine a royalty-free, worldwide, perpetual, non-exclusive license of certain of the Company's intellectual property incorporated into the product to be developed. The Company also agreed to pay SeaSpine a product royalty, in an amount specified in the Development Agreement, for each resulting product sold for a period of <ix:nonNumeric contextRef="id20be3b85bd54fcd9fcf877450d0dd25_D20200224-20200224" format="ixt-sec:duryear" name="sibn:RelatedPartyTransactionTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8yMTk5MDIzMjU3MjQz_e239eb6c-36af-4e43-b15b-a546526eaed2">10</ix:nonNumeric> years beginning on the initial market launch. The term of the Development Agreement shall continue until the expiration of all royalty terms, unless earlier terminated by either party, as provided for by the Development Agreement.</ix:continuation> </span></div><div id="ic5af433463274989b3f39da4377b2b55_223"></div><div style="margin-top:12pt"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_226"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplementary Data</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selected Quarterly Consolidated Financial Data (Unaudited)</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company&#8221;, we are not required to provide the information required by this Item.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Schedule&#160;II&#160;- Valuation and Qualifying Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.</span></div><div id="ic5af433463274989b3f39da4377b2b55_229"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">None.</span></div><div id="ic5af433463274989b3f39da4377b2b55_232"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As of December 31, 2020, our management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and our Chief Operating Officer &amp; Chief Financial Officer (&#8220;COO/CFO&#8221;), have evaluated our disclosure controls and procedures (as defined in Rules&#160;13a&#8209;15(e)&#160;and 15d&#8209;15(e)&#160;under the Securities Exchange Act of 1934, as amended). Based on that evaluation, our CEO and our COO/CFO have concluded that, as of December 31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Internal Control over Financial Reporting</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, our management used the criteria set forth in the Internal Control -Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on management's assessment, management has concluded that, as of December 31, 2020, our internal control over financial reporting was effective.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm because as an &#8220;emerging growth company&#8221; we are exempt from Section 404(b) of the Sarbanes-Oxley Act of 2002.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the&#160;fourth quarter of the year ended December 31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In response to the COVID-19 pandemic, certain of our employees still continued to work remotely during the quarter. Management took measures to ensure that our internal control over financial reporting remained unchanged during this period.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div><div><span><br/></span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_235"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic5af433463274989b3f39da4377b2b55_238"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ic5af433463274989b3f39da4377b2b55_241"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2021 Annual Meeting of Stockholders, or the 2021 Proxy Statement, which will be filed not later than 120&#160;days after the end of our fiscal&#160;year ended December 31, 2020, under the headings &#8220;Management,&#8221; &#8220;Proposal 1 - Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221;, and, if applicable, &#8220;Delinquent Section&#160;16(a)&#160;Reports&#8221;, and is incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees which is available on our website at www.si-bone.com. The Code of Business Conduct and Ethics is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section&#160;406 of the Sarbanes-Oxley Act of 2002 and Item&#160;406 of Regulation&#160;S-K. In addition, we intend to promptly disclose on our website in the future (1)&#160;the nature of any substantive amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2)&#160;the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver.</span></div><div id="ic5af433463274989b3f39da4377b2b55_244"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;11. Executive Compensation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The information required by this item regarding executive compensation will be incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; and &#8220;Compensation of Non-Employee Board Members&#8221; in our 2021 Proxy Statement.</span></div><div id="ic5af433463274989b3f39da4377b2b55_247"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The information required by this item regarding security ownership of certain beneficial owners and management will be incorporated by reference to the information set forth in the sections titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; in our 2021 Proxy Statement.</span></div><div id="ic5af433463274989b3f39da4377b2b55_250"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The information required by this item regarding certain relationships and related transactions and director independence will be incorporated by reference to the information set forth in the sections titled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221;, respectively, in our 2021 Proxy Statement.</span></div><div id="ic5af433463274989b3f39da4377b2b55_253"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;14. Principal Accounting Fees and Services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The information required by this item regarding principal accountant fees and services will be incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our 2021 Proxy Statement.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_256"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ic5af433463274989b3f39da4377b2b55_259"></div><div style="-sec-extract:summary;margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Item&#160;15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;The following documents are filed as part of this report:</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.&#160;Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Information in response to this Item&#160;is included in Part&#160;II, Item&#160;8 of this Annual Report on Form&#160;10&#8209;K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.&#160;Financial Statement Schedules</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.&#160;Exhibits</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits, as required by Item 601 of Regulation&#160;S-K&#160;are attached or incorporated by reference as stated below.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">EXHIBIT&#160;INDEX</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation By Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit <br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518303020/d641574dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38701</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex34.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex41.htm">Form&#160;of Common Stock Certificate of the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518303020/d641574dex31.htm">3.1</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex34.htm">3.2</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000145983920000047/exhibit43descriptionof.htm">Description of SI-BONE, Inc. Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38701</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex101.htm">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex102.htm">2008 Stock Plan and forms of agreements thereunder.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex103.htm">2018 Equity Incentive Plan</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex104.htm">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex105.htm">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex106.htm">2018 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex106.htm">Manufacturing, Quality and Supply Agreement, dated January 31, 2017, between the Registrant and rms Company and Addendum No. 1 dated July 7, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex107.htm">Offer Letter Agreement, dated December 15, 2009, between the Registrant and Jeffrey W. Dunn.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex108.htm">Offer Letter Agreement, dated February 19, 2015, between the Registrant and Michael A. Pisetsky</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex109.htm">Letter Regarding Change to Employment Terms, dated June 20, 2016, between the Registrant and Michael A. Pisetsky.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1010.htm">Offer Letter Agreement, dated April 27, 2015, between the Registrant and Laura Francis.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1011.htm">Severance and Change in Control Agreement dated March 15, 2016, between the Registrant and Laura Francis.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1012.htm">Amended and Restated Letter Agreement, dated March 1, 2017, between the Registrant and Laura Francis.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1018.htm">Offer Letter Agreement, dated June 19, 2016, between the Registrant and Anthony J. Recupero.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex1021.htm">Amended and Restated Investors&#8217; Rights Agreement, dated June 2, 2016, by and among the Registrant and the parties thereto, as amended on October 4, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh1016rmscompany-addendum.htm">Addendum No. 2 to Manufacturing, Quality and Supply Agreement, dated July 1, 2020, between the Registrant and rsm Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1021.htm">Office Lease Agreement, dated February 2, 2018, between the Registrant and Bixby SPE Finance 11, LLC, as amended on April 16, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1030.htm">Form of Restricted Stock Unit Grant Notice and Award Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-227445</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/20/2018</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000145983919000044/exhibit102amendmenttores.htm">Amendment to Restricted Stock Units of Chief Operating Officer &amp; Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38701</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2019</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000145983920000003/sibn8-k132020fy2020bonuspl.htm">Changes to Chief Executive Officer, Chief Operating Officer &amp; Chief Financial Officer, and Chief Commercial Officer Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38701</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.02</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2020</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000145983921000003/exh101_amendmenttoceooffer.htm">Amendment to Offer Letter with Jeffrey Dunn</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38701</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/7/2021</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh10222020-12proposedrevi.htm">2020 Non-Employee Directors' Compensation Policy</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1459839/000145983920000074/sibn-ex101loanandsecur.htm">Loan and Security Agreement, dated May 29, 2020, between SI-BONE, Inc. and Solar Capital Ltd., as collateral agent, and the lenders from time to time party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38701</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/4/2020</span></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024severancebenefi.htm">SI-BONE, Inc. Severance Benefit Plan and Form of Participation Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sibn-ex211_listxofxsubsidi.htm">List of Subsidiaries of Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sibn-ex231_pwcxconsent.htm">Consent of PricewaterhouseCoopers, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic5af433463274989b3f39da4377b2b55_265">Power of Attorney (contained in the signature page of this report)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sibn-ex311_12312010xk.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sibn-ex312_12312010xk.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sibn-ex321_12312010xk.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith. Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(b)&#160;We have filed, or incorporated into this Annual Report on Form&#160;10&#8209;K by reference, the exhibits listed on the Exhibit&#160;Index immediately above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(c)&#160;See Item&#160;15(a)2 above.</span></div><div id="ic5af433463274989b3f39da4377b2b55_262"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K Summary.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not provided.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="ic5af433463274989b3f39da4377b2b55_265"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in Santa Clara, California, on March&#160;10, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SI-BONE, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey W. Dunn </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey W. Dunn </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Executive Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">) </span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SI-BONE, Inc.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laura A. Francis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura A. Francis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer &amp; Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laura A. Francis, and Michael A. Pisetsky, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10&#8209;K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.000%"><tr><td style="width:1.0%"></td><td style="width:21.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.269%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.272%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey W. Dunn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey W. Dunn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer) and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laura A. Francis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer &amp; Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura A. Francis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy E. Davis, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director, Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy E. Davis, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark J. Foley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Foley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/John G. Freund, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John G. Freund, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeryl L. Hilleman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeryl L. Hilleman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gregory K. Hinckley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory K. Hinckley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karen A. Licitra</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen A. Licitra</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;/s/ Keith C. Valentine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith C. Valentine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mika Nishimura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mika Nishimura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>exh1016rmscompany-addendum.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if2aa27e35e3b49e4aed5a735b2a3b006_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONFIDENTIAL &#38; PROPRIETARY                                                                                                               Exhibit 10.16</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADDENDUM NO. 2 TO MANUFACTURING, QUALITY AND SUPPLY AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;THIS ADDENDUM NO. 2 TO MANUFACTURING, QUALITY AND SUPPLY AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Addendum No. 2</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), effective as of July 1, 2020 (&#8220;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Addendum Effective Date</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is by and between </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, Inc.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware corporation having a principal place of business at 471 El Camino Real, Suite 101, Santa Clara, California 95050 (&#8220;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SI-BONE</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and rms Company (&#8220;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a Minnesota corporation having a principal place of business at 8600 Evergreen Blvd., Coon Rapids, MN 55433, and amends that certain Manufacturing, Quality and Supply Agreement between the parties with an effective date of January 31, 2017 as amended by that certain addendum dated July 7, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Existing Agreement</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and together with this Addendum No. 1, the &#8220;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms used and not defined herein shall have the meaning given them in the Existing Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties agree as follows&#58;</font></div><div style="padding-left:21.6pt;text-align:justify"><font><br></font></div><div style="padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.02pt;text-decoration:underline">Schedule A to Addendum No. 1</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The parties hereby agree that Schedule A to Addendum No. 1 is amended and restated in its entirety with the Schedule A to Addendum No. 2 attached hereto. </font></div><div style="padding-left:21.6pt;text-align:justify"><font><br></font></div><div style="padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.02pt;text-decoration:underline">Pricing Addendum</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The parties hereby agree that the Exhibit A (Pricing Addendum) of the Agreement is amended and restated in its entirety with the Exhibit A (Pricing Addendum) attached hereto.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.02pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:21.6pt;text-align:justify"><font><br></font></div><div style="padding-left:50.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.87pt;text-decoration:underline">Ratification</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The parties take this opportunity to ratify the Existing Agreement and confirm all of their respective obligations set forth therein, including the representations and warranties made to one another.  </font></div><div style="padding-left:50.4pt;text-align:justify"><font><br></font></div><div style="padding-left:50.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.28pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If any provision of the Agreement will be declared invalid, illegal or unenforceable, such provision will be severed and all remaining provisions will continue in full force and effect.</font></div><div style="padding-left:50.4pt;text-align:justify"><font><br></font></div><div style="padding-left:50.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.35pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Agreement, including this Addendum No. 2, is the full, complete, and exclusive agreement between the parties and supersedes and cancels any and all previous or contemporaneous agreements of whatever nature, whether written or oral, between Customer and SI-BONE and SI-BONE&#8217;s subsidiaries and affiliates with respect to its subject matter.  The Agreement may only be modified or amended in a writing signed by both parties.  Subject headings are for convenience of reference only and will in no way affect interpretation of the Agreement.</font></div><div style="padding-left:50.4pt;text-align:justify"><font><br></font></div><div style="padding-left:50.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Addendum No. 2 may be executed in separate counterparts, and by facsimile, each of which will be deemed an original, and when executed separately or together, will constitute a single original instrument, effective in the same manner as if the parties had executed one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed this Addendum No. 2 as of the date set forth beneath such person&#8217;s name.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:700;line-height:120%">rms Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Michael Blanchard</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Richard S. Riddle</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Michael Blanchard</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Richard S. Riddle</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; VP, Operations</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Director of Sales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date Signed&#58; 7&#47;7&#47;2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date Signed&#58; 6-July-2020</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>exh10222020-12proposedrevi.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib3398733205d4906bfa3faf48eff924d_1"></div><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:98.8pt;padding-right:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.22</font></div><div style="margin-top:3.9pt;padding-left:98.8pt;padding-right:98.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SI-BONE, I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:98.87pt;padding-right:98.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ON</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">-E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MPLOYEE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IRECTORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8217; C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OMPENSATION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OLICY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PPROVED BY THE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OARD OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IRECTORS</font></div><div style="padding-left:98.77pt;padding-right:98.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">December 3, 2020</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each member of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) who is not also serving as an employee of SI-BONE, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or any of its subsidiaries (each such member, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will receive the compensation described in this Non-Employee Directors&#8217; Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for his or her Board service. The Director Compensation Policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Annual Cash Compensation</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Eligible Director shall receive the cash compensation described below. The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash retainer fees are vested upon payment.</font></div><div><font><br></font></div><div style="padding-left:42pt;padding-right:5.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Annual Board Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; payable in restricted stock units as further described under Equity Compensation below (&#8220;Annual Retainer RSU Grant&#8221;)</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.8pt;text-decoration:underline">Annual Committee Member &#47; Chair Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.05pt;padding-left:78pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.42pt">Member &#47; Chairperson of the Audit Committee&#58; $9,000 &#47; $20,000</font></div><div style="padding-left:78pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.8pt">Member &#47; Chairperson of the Compensation Committee&#58; $6,000 &#47; $15,000</font></div><div style="padding-left:78pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.42pt">Member &#47; Chairperson of the N&#38;CG Committee&#58; $5,000 &#47; $10,000</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.8pt;text-decoration:underline">Annual Lead Independent Director Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.05pt;padding-left:78pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.42pt">Lead Independent Director&#58; $27,500</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Compensation</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity compensation set forth below will be granted under the SI-BONE, Inc. 2018 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and will be documented on the applicable form of equity award agreement most recently approved for use by the Board (or a duly authorized committee thereof) for Eligible Directors. Any stock options granted under the Director Compensation Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan). Any RSU grant provided for by this Director Compensation Policy that vests quarterly shall have quarterly vesting dates of March 15, June 15, September 15 and December 15 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Vesting Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and any RSU Grant that vests annually shall vest on the earlier to occur of the one-year anniversary of the date of grant or the Company&#8217;s next Annual General Meeting of its stockholders.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.75pt;text-decoration:underline">Initial Share Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Upon first election to the Board, each Eligible Director will be granted, upon approval by the Board or Compensation Committee of the Board, restricted stock units having a value of</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$200,000 based on the share price then used by the Company for determination of the number of shares granted in RSU grants (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Initial RSU Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Initial RSU Grant will vest quarterly over three</font></div><div id="ib3398733205d4906bfa3faf48eff924d_4"></div><div style="margin-top:3.9pt;padding-left:6pt;padding-right:5.6pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">years beginning on the Quarterly Vesting Date that follows the date of grant, such that the Initial RSU Grant will be fully vested on the next Quarterly Vesting Date that follows the third anniversary of the Eligible Director&#8217;s first election to the Board, subject to the Eligible Director&#8217;s Continuous Service on each applicable vesting date. In addition, in the event of a Change in Control or a Corporate Transaction, any unvested portion of the Initial RSU Grant will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the Eligible Director&#8217;s Continuous Service on the effective date of such transaction.</font></div><div style="padding-right:5.6pt;text-align:justify"><font><br></font></div><div style="padding-left:0.78pt;padding-right:5.6pt;text-align:justify;text-indent:-0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Retainer RSU Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Each Eligible Director shall receive an annual RSU grant having an approximate value of $40,000 based on the most recent closing price of the Company&#8217;s shares, which will vest approximately one year from the grant date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Annual Retainer Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the Eligible Director&#8217;s Continuous Service on each applicable vesting date. In addition, in the event of a Change in Control or a Corporate Transaction, any unvested portion of the Annual Retainer Grant will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the Eligible Director&#8217;s Continuous Service on the effective date of such transaction.</font></div><div style="padding-right:5.6pt;text-align:justify"><font><br></font></div><div style="padding-left:0.78pt;padding-right:5.6pt;text-align:justify;text-indent:-0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Additional RSU Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; The Compensation Committee may review and approve additional equity grants to Eligible Directors on the date of each subsequent annual meeting. Each Eligible Director shall receive an annual RSU grant having an approximate value of $120,000 based on the share price then used by the Company for determination of the number of shares granted in RSU grants, which will vest approximately one year from the grant date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Additional Annual RSU Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the Eligible Director&#8217;s Continuous Service on each applicable vesting date. In addition, in the event of a Change in Control or a Corporate Transaction, any unvested portion of the Additional Annual RSU Grant will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the Eligible Director&#8217;s Continuous Service on the effective date of such transaction.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Philosophy</font></div><div style="margin-top:9.9pt;padding-left:6pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Director Compensation Policy is designed to attract and retain experienced, talented individuals to serve on the Board. The Board anticipates that the Board, or a duly authorized committee thereof, will generally review Eligible Director compensation on an annual basis on or about the date of the Company&#8217;s Annual General Meeting of its stockholders. The Director Compensation Policy, as amended from time to time, may take into account the time commitment expected of Eligible Directors, best practices and market rates in director compensation, the economic position of the Company, broader economic conditions, historical compensation structure, the advice of the compensation consultant that the Compensation Committee or the Board may retain from time to time, and the potential dilutive effect of equity awards on our stockholders.</font></div><div style="margin-top:9.85pt;padding-left:6pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the Director Compensation Policy, Eligible Directors receive cash compensation in the form of retainers to recognize their level of responsibility as well as the necessary time commitment involved in serving in a leadership role and&#47;or on Committees. Eligible Directors also receive equity compensation because we believe that stock ownership provides an incentive to act in ways that maximize long-term stockholder value. Further, we believe that stock-based awards are essential to attracting and retaining talented Board members. When stock options are granted, these stock options will have an exercise price at least equal to the Fair Market Value of Common Stock on the date of grant, so that stock options provide a return only if the Fair Market Value appreciates over the period in which the stock option vests and remains exercisable. We believe that the vesting acceleration provided in the case of a </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9.85pt;padding-left:6pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change in Control or other Corporate Transaction is consistent with market practices and is critical to attracting and retaining high quality directors.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>4
<FILENAME>exhibit1024severancebenefi.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9a0582ea3d75436b8a5b1c795c258cb4_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.24</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Severance Benefit Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1. INTRODUCTION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SI-BONE, Inc. Severance Benefit Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is hereby established by the Compensation Committee of the Board of Directors of SI-BONE, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) effective July 16, 2020. The purpose of the Plan is to provide for the payment of severance benefits to eligible employees of the Company in the event that such employees become subject to involuntary or constructive employment terminations.  This Plan document also is the Summary Plan Description for the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Plan, the following terms are defined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any corporation, limited liability company or other business entity (other than the Company) in an &#8220;unbroken chain&#8221; beginning with the Company, if each of the business entities other than the last such business entity in the unbroken chain owns stock or other equity interests possessing 50% or more of the total combined voting power of all classes of stock or other equity interests in one of the other business entities in such chain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means base pay (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect prior to any reduction that would give rise to an employee&#8217;s right to a resignation for Good Reason (if applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular employee, the meaning ascribed to such term in any written employment agreement, offer letter or similar agreement between such employee and the Company defining such term, and, in the absence of such agreement, means with respect to such employee, the term &#8220;Cause&#8221; as defined in the Equity Plan.  The determination whether a termination is for Cause shall be made by the Plan Administrator in its sole and exclusive judgment and discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in the Equity Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the period commencing three months prior to the Closing of a Change in Control and ending 12 months following the Closing of a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the initial closing of the Change in Control as defined in the definitive agreement executed in connection with the Change in Control.  In the case of a series of transactions constituting a Change in Control, &#8220;Closing&#8221; means the first closing that satisfies the threshold of the definition for a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors or the Compensation Committee of the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means SI-BONE, Inc. or, following a Change in Control, the surviving entity resulting from such event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s standard form of Employee Proprietary Information and Inventions Agreement or any similar or successor document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covered Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to an employee, a termination of employment that is due to (1) a termination by the Company without Cause (and other than as a result of the employee&#8217;s death or Disability) or (2) the employee&#8217;s resignation for Good Reason, and in either case of (1) or (2), results in such employee&#8217;s Separation from Service.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any physical or mental condition which renders an employee incapable of performing the work for which he or she was employed by the Company or similar work offered by the Company.&#160; The Disability of an employee shall be established if (i) the employee satisfies the requirements for benefits under the Company&#8217;s </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">long-term disability plan or (ii) in the absence of a Company-sponsored long-term disability plan, the employee satisfies the requirements for Social Security disability benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an employee of the Company that meets the requirements to be eligible to receive Plan benefits as set forth in Section 2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the SI-BONE, Inc. 2018 Equity Incentive Plan, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for an employee&#8217;s resignation means the occurrence of any one or more of the following are undertaken by the Company (or successor to the Company, if applicable) without the employee&#8217;s express written consent&#58; </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a material reduction in such employee&#8217;s annual base salary or total target cash compensation (i.e. the sum of such Covered Employee&#8217;s annual base salary and annual target bonus) representing, in either case, a reduction of an amount equal to more than ten percent (10%) of such employee&#8217;s then current base salary&#59; </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a material reduction or material adverse change in such employee&#8217;s job duties, responsibilities or authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any such reduction or change after a Change in Control (or similar corporate transaction that does not constitute a Change in Control) shall not constitute Good Reason by virtue of the fact that such employee is performing similar duties and responsibilities in a larger organization (e.g., the Chief Executive Officer continues to be the Chief Executive Officer of the successor or parent corporation)&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a material diminution in the authority, duties or responsibility of the supervisor to whom such employee is required to report including a requirement that such employee report to a corporate officer or employee instead of reporting directly to the board of directors of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a relocation of such employee&#8217;s principal place of employment with the Company (or successor to the Company, if applicable) to a place by more than 30 miles as compared to such employee&#8217;s then-current principal place of employment immediately prior to such relocation, except for required travel by the employee on the Company&#8217;s business to an extent substantially consistent with employee&#8217;s business travel obligations prior to the effective date of the Change in Control (or similar transaction)&#59; or </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a material breach by the Company of any provision of this Plan or any other material agreement between such employee and the Company concerning the terms and conditions of such employee&#8217;s employment or service with the Company, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in any case of (1), (2), (3) or (4) above, in order for the employee&#8217;s resignation to be deemed to have been for Good Reason, (i) the employee must first give the Company written notice of such employee&#8217;s intent to resign for Good Reason within 90&#160;days after the date on which the Company gives written notice to such employee of the Company&#8217;s affirmative decision to take an action set forth in clause (1), (2), (3), or (4) above (or such action or condition otherwise occurs), which notice shall describe such condition(s) employee believes constitute Good Reason&#59; (ii) the Company must fail to remedy such condition(s) within 30&#160;days after receipt of such written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (iii) the employee must resign from employment effective not later than 90&#160;days after the expiration of such Cure Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an agreement between an employee and the Company in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto, and which may include such other terms as the Committee deems necessary or advisable in the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Committee prior to the Closing and the Representative upon and following the Closing, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means one or more members of the Committee or other persons or entities designated by the Committee prior to or in connection with a Change in Control that will have authority to administer and interpret the Plan upon and following the Closing as provided in Section 8(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Section 409A of the Code and the treasury regulations and other guidance thereunder and any state law of similar effect.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a &#8220;separation from service&#8221; within the meaning of  Treasury Regulations Section 1.409A-1(h), without regard to any alternative definition thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2&#58; ELIGIBILITY FOR BENEFITS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  An employee of the Company is eligible to participate in the Plan if (i) the Plan Administrator has designated such employee as eligible to participate in the Plan by providing such employee a Participation Agreement&#59; (ii) such employee has signed and returned such Participation Agreement to the Company within the time period required therein&#59; and (iii) such employee meets the other Plan eligibility requirements set forth in this Section 2.  The determination of whether an employee is an Eligible Employee shall be made by the Plan Administrator, in its sole discretion, and such determination shall be binding and conclusive on all persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Release Requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except as otherwise provided in an individual Participation Agreement, in order to be eligible to receive benefits under the Plan, the employee also must execute a general waiver and release, in such a form as provided by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), within the applicable time period set forth therein, and such Release must become effective in accordance with its terms, which must occur in no event more than 60 days following the date of the applicable Covered Termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Plan Benefits Provided In Lieu of Any Previous Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  This Plan shall supersede any change in control or severance benefit plan, policy or practice previously maintained by the Company with respect to an Eligible Employee and any change in control or severance benefits in any individually negotiated employment contract, employment offer letter, or other agreement between the Company and an Eligible Employee.  Notwithstanding the foregoing, the Eligible Employee&#8217;s outstanding equity awards shall remain subject to the terms the Equity Plan or other applicable equity plan under which such awards were granted (including the award documentation governing such awards) that may apply upon a Change in Control and&#47;or termination of such employee&#8217;s service and no provision of this Plan shall be construed as to limit the actions that may be taken, or to violate the terms, thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Exceptions to Severance Benefit Entitlement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  An employee who otherwise is an Eligible Employee will not receive benefits under the Plan in the following circumstances, as determined by the Plan Administrator in its sole discretion&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The employee&#8217;s employment is terminated by the Company for any reason (including due to the employee&#8217;s death or Disability) or the employee voluntarily terminates employment with the Company in any manner, and in either case, such termination is not a Covered Termination. Voluntary terminations include, but are not limited to, resignation, retirement or failure to return from a leave of absence on the scheduled date.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The employee voluntarily terminates employment with the Company in order to accept employment with another entity that is wholly or partly owned (directly or indirectly) by the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The employee is offered an identical or substantially equivalent or comparable position with the Company or an Affiliate.  For purposes of the foregoing, a &#8220;substantially equivalent or comparable position&#8221; is one that provides the employee substantially the same level of responsibility and compensation and would not give rise to the employee&#8217;s right to a resignation for  Good Reason.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The employee is offered immediate reemployment by a successor to the Company or an Affiliate or by a purchaser of the Company&#8217;s assets, as the case may be, following a Change in Control and the terms of such reemployment would not give rise to the employee&#8217;s right to a resignation for Good Reason.  For purposes of the foregoing, &#8220;immediate reemployment&#8221; means that the employee&#8217;s employment with the successor to the Company or an Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the purchaser of its assets, as the case may be, results in uninterrupted employment such that the employee does not incur a lapse in pay or benefits as a result of the change in ownership of the Company or the sale of its assets. For the avoidance of doubt, an employee who becomes immediately reemployed as described in this Section 2(d)(4) by a successor to the Company or an Affiliate or by a purchaser of the Company&#8217;s assets, as the case may be, following a Change in Control shall continue to be an Eligible Employee following the date of such reemployment.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The employee is rehired by the Company or an Affiliate and recommences employment prior to the date severance benefits under the Plan are scheduled to commence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Termination of Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  An Eligible Employee&#8217;s right to receive severance benefits under this Plan shall terminate immediately if, at any time prior to or during the period for which the Eligible Employee is receiving severance benefits under the Plan, the Eligible Employee&#58; </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">willfully breaches any material statutory, common law, or contractual obligation to the Company or an Affiliate (including, without limitation, the contractual obligations set forth in the Confidentiality Agreement and any other confidentiality, non-disclosure and developments agreement, non-competition, non-solicitation, or similar type agreement between the Eligible Employee and the Company, as applicable)&#59; or </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">fails to enter into the terms of any Confidentiality Agreement reasonably requested by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3. AMOUNT OF BENEFITS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Benefits in Participation Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits under the Plan shall be provided to an Eligible Employee as set forth in the Participation Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Additional Benefits.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Committee may, in its sole discretion, provide benefits to individuals who are not Eligible Employees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) chosen by the Plan Administrator, in its sole discretion, and the provision of any such benefits to a Non-Eligible Employee shall in no way obligate the Company to provide such benefits to any other individual, even if similarly situated.  If benefits under the Plan are provided to a Non-Eligible Employee, references in the Plan to &#8220;Eligible Employee&#8221; (and similar references) shall be deemed to refer to such Non-Eligible Employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Certain Reductions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Section 2(e) above, the Company, in its sole discretion, shall have the authority to reduce an Eligible Employee&#8217;s severance benefits, in whole or in part, by any other severance benefits, pay and benefits provided during a period following written notice of a business closing or mass layoff, pay and benefits in lieu of such notice, or other similar benefits payable to the Eligible Employee by the Company or an Affiliate that become payable in connection with the Eligible Employee&#8217;s termination of employment pursuant to (i) any applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other similar state law or (ii) any Company policy or practice providing for the Eligible Employee to remain on the payroll for a limited period of time after being given notice of the termination of the Eligible Employee&#8217;s employment, and the Plan Administrator shall so construe and implement the terms of the Plan.  Any such reductions that the Company determines to make pursuant to this Section 3(c) shall be made such that any severance benefit under the Plan shall be reduced solely by any similar type of benefit under such legal requirement, agreement, policy or practice (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., any cash severance benefits under the Plan shall be reduced solely by any cash payments or severance benefits under such legal requirement, agreement, policy or practice).  The Company&#8217;s decision to apply such reductions to the severance benefits of one Eligible Employee and the amount of such reductions shall in no way obligate the Company to apply the same reductions in the same amounts to the severance benefits of any other Eligible Employee.  In the Company&#8217;s sole discretion, such reductions may be applied on a retroactive basis, with severance benefits previously paid being re-characterized as payments pursuant to the Company&#8217;s statutory obligation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Parachute Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If any payment or benefit an Eligible Employee will or may receive from the Company or otherwise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then any such Payment shall be equal to the Reduced Amount.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reduced Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Eligible Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reduction Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that results in the greatest economic benefit for the Eligible Employee.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro Rata Reduction Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions in this Section above to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and&#47;or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows&#58;  (A)&#160;as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for the Eligible Employee as determined on an after-tax basis&#59; (B)&#160;as a second priority, Payments that are contingent on future events (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events&#59; and (C)&#160;as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section.  The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.  If the Eligible Employee receives a Payment for which the Reduced Amount was determined pursuant to clause (x) above and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Eligible Employee agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) above) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) above, the Eligible Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4. RETURN OF COMPANY PROPERTY. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An Eligible Employee will not be entitled to any severance benefit under the Plan unless and until the Eligible Employee returns all Company Property.  For this purpose, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all paper and electronic Company documents and other Company property which the Eligible Employee had in his or her possession or control at any time, including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, research and development information, sales and marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones, servers), credit cards, entry cards, identification badges and keys&#59; and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part).  As a condition to receiving benefits under the Plan, an Eligible Employee must not make or retain copies, reproductions or summaries of any such Company documents, materials or property.  However, an Eligible Employee is not required to return his or her personal copies of documents evidencing the Eligible Employee&#8217;s hire, termination, compensation, benefits and stock options and any other documentation received as a stockholder of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5. TIME OF PAYMENT AND FORM OF BENEFITS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves the right in the Participation Agreement to specify whether payments under the Plan will be paid in a single sum, in installments, or in any other form and to determine the timing of such payments.  All such payments under the Plan will be subject to applicable withholding for federal, state, foreign, provincial and local taxes.  All benefits provided under the Plan are intended to satisfy the requirements for an exemption from application of Section 409A to the maximum extent that an exemption is available and any ambiguities herein shall be interpreted accordingly&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that to the extent such an exemption is not available, the benefits provided under the Plan are intended to comply with the requirements of Section 409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is intended that (i) each installment of any benefits payable under the Plan to an Eligible Employee be regarded as a separate &#8220;payment&#8221; for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), (ii) all payments of any such benefits under the Plan satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9)(iii), and (iii) any such benefits consisting of COBRA premiums also satisfy, to the greatest extent possible, the exemption from the application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(9)(v).  However, if the Company determines that any severance benefits payable under the Plan constitute &#8220;deferred compensation&#8221; under Section 409A and the Eligible Employee is a &#8220;specified employee&#8221; of the Company, as such term is defined in Section 409A(a)(2)(B)(i), then, solely to the extent necessary to avoid the imposition of the adverse personal tax consequences under Section 409A, (A) the timing of such severance benefit payments shall be delayed until the earlier of (1) the date that is six months and one day after the Eligible Employee&#8217;s Separation from Service and (2) the date of the Eligible Employee&#8217;s death (such applicable date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delayed Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (B) the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the severance benefit payments that the Eligible Employee would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the severance benefits had not been delayed pursuant to this paragraph and (2) commence paying the balance, if any, of the severance benefits in accordance with the applicable payment schedule.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall payment of any severance benefits under the Plan be made prior to an Eligible Employee&#8217;s Separation from Service or prior to the effective date of the Release.  If the Company determines that any severance payments or benefits provided under the Plan constitute &#8220;deferred compensation&#8221; under Section 409A, and the Eligible Employee&#8217;s Separation from Service occurs at a time during the calendar year when the Release could become effective in the calendar year following the calendar year in which the Eligible Employee&#8217;s Separation from Service occurs, then regardless of when the Release is returned to the Company and becomes effective, the Release will not be deemed effective, solely for purposes of the timing of payment of severance benefits under this Plan, any earlier than the latest permitted effective date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Release Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  If the Company determines that any severance payments or benefits provided under the Plan constitute &#8220;deferred compensation&#8221; under Section 409A, then except to the extent that severance payments may be delayed until the Delayed Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll date following the effective date of an Eligible Employee&#8217;s Release, the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the severance benefit payments that the Eligible Employee would otherwise have received through such payroll date but for the delay in payment related to the effectiveness of the Release and (2) commence paying the balance, if any, of the severance benefits in accordance with the applicable payment schedule.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6. TRANSFER AND ASSIGNMENT. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights and obligations of an Eligible Employee under this Plan may not be transferred or assigned without the prior written consent of the Company.  This Plan shall be binding upon any entity or person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company without regard to whether or not such entity or person actively assumes the obligations hereunder and without regard to whether or not a Change in Control occurs.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7. MITIGATION.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise specifically provided in the Plan, an Eligible Employee will not be required to mitigate damages or the amount of any payment provided under the Plan by seeking other employment or otherwise, nor will the amount of any payment provided for under the Plan be reduced by any compensation earned by an Eligible Employee as a result of employment by another employer or any retirement benefits received by such Eligible Employee after the date of the Eligible Employee&#8217;s termination of employment with the Company.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8. CLAWBACK&#59; RECOVERY. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments and severance benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9. RIGHT TO INTERPRET AND ADMINISTER PLAN&#59; AMENDMENT AND TERMINATION. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Interpretation and Administration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Prior to the Closing, the Committee shall be the Plan Administrator and shall have the exclusive discretion and authority to establish rules, forms, and procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the operation of the Plan, including, but not limited to, the eligibility to participate in the Plan and amount of benefits paid under the Plan.  The rules, interpretations, computations and other actions of the Committee shall be binding and conclusive on all persons.  Upon and after the Closing, the Plan will be interpreted and administered in good faith by the Representative who shall be the Plan Administrator during such period.  All actions taken by the Representative in interpreting the terms of the Plan and administering the Plan upon and after the Closing will be final and binding on all Eligible Employees.  Any references in this Plan to the &#8220;Committee&#8221; or &#8220;Plan Administrator&#8221; with respect to periods following the Closing shall mean the Representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Amendment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Plan Administrator reserves the right to amend this Plan at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that any amendment of the Plan will not be effective as to a particular employee who is or may be adversely impacted by such amendment or termination and has an effective Participation Agreement without the written consent of such employee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless otherwise extended by the Committee, the Plan will automatically terminate following satisfaction of all the Company&#8217;s obligations under the Plan.   </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.  NO IMPLIED EMPLOYMENT CONTRACT. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan shall not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company or (ii) to interfere with the right of the Company to discharge any employee or other person at any time, with or without cause, which right is hereby reserved.  This Plan does not modify the at-will employment status of any Eligible Employee.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11. LEGAL CONSTRUCTION. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Plan is intended to be governed by and shall be construed in accordance with the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;) and, to the extent not preempted by ERISA, the laws of the State of California.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 12. CLAIMS, INQUIRIES AND APPEALS. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Applications for Benefits and Inquiries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Any application for benefits, inquiries about the Plan or inquiries about present or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative).  The Plan Administrator is&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation Committee of the Board of Directors or Representative</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention to&#58; Corporate Secretary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471 El Camino Real, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Santa Clara, California, USA 95050</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Denial of Claims.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In the event that any application for benefits is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant&#8217;s right to review the denial.  Any electronic notice will comply with the regulations of the U.S. Department of Labor.  The notice of denial will be set forth in a manner designed to be understood by the applicant and will include the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">the specific reason or reasons for the denial&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">references to the specific Plan provisions upon which the denial is based&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a description of any additional information or material that the Plan Administrator needs to complete the review and an explanation of why such information or material is necessary&#59; and</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">an explanation of the Plan&#8217;s review procedures and the time limits applicable to such procedures, including a statement of the applicant&#8217;s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described in Section 10(d) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This notice of denial will be given to the applicant within 90 days after the Plan Administrator receives the application, unless special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional 90 days for processing the application.  If an extension of time for processing is required, written notice of the extension will be furnished to the applicant before the end of the initial 90 day period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Request for a Review.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Any person (or that person&#8217;s authorized representative) for whom an application for benefits is denied, in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within 60 days after the application is denied.  A request for a review shall be in writing and shall be addressed to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation Committee of the Board of Directors or Representative</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention to&#58; Corporate Secretary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471 El Camino Real, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Santa Clara, California, USA 95050</font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A request for review must set forth all of the grounds on which it is based, all facts in support of the request and any other matters that the applicant feels are pertinent.  The applicant (or his or her representative) shall have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and other information relating to his or her claim.  The applicant (or his or her representative) shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her claim.  The review shall take into account all comments, documents, records and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Decision on Review.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Plan Administrator will act on each request for review within 60 days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional 60 days), for processing the request for a review.  If an extension for review is required, written notice of the extension will be furnished to the applicant within the initial 60 day period.  This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the review.  The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor.  In the event that the Plan Administrator confirms the denial of the application for benefits in whole or in part, the notice will set forth, in a manner calculated to be understood by the applicant, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">the specific reason or reasons for the denial&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">references to the specific Plan provisions upon which the denial is based&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her claim&#59; and</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">a statement of the applicant&#8217;s right to bring a civil action under Section 502(a) of ERISA. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Rules and Procedures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Plan Administrator will establish rules and procedures, consistent with the Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims.  The Plan Administrator may require an applicant who wishes to submit additional information in connection with an appeal from the denial of benefits to do so at the applicant&#8217;s own expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.01pt">Exhaustion of Remedies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No legal action for benefits under the Plan may be brought until the applicant (i)&#160;has submitted a written application for benefits in accordance with the procedures described by Section 10(a) above, (ii)&#160;has been notified by the Plan Administrator that the application is denied, (iii)&#160;has filed a written request for a review of the application in accordance with the appeal procedure described in Section 10(c) above, and (iv)&#160;has been notified that the Plan Administrator has denied the appeal.  Notwithstanding the foregoing, if the Plan Administrator does not respond to an Eligible Employee&#8217;s claim or appeal within the relevant time limits specified in this Section 10, the Eligible Employee may bring legal action for benefits under the Plan pursuant to Section 502(a) of ERISA.  </font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13. BASIS OF PAYMENTS TO AND FROM PLAN. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan shall be unfunded, and all cash payments under the Plan shall be paid only from the general assets of the Company.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 14. OTHER PLAN INFORMATION. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Employer and Plan Identification Numbers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Employer Identification Number assigned to the Company (which is the &#8220;Plan Sponsor&#8221; as that term is used in ERISA) by the Internal Revenue Service is 26-2216351. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Ending Date for Plan&#8217;s Fiscal Year.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The date of the end of the fiscal year for the purpose of maintaining the Plan&#8217;s records is December 31.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Agent for the Service of Legal Process.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The agent for the service of legal process with respect to the Plan is&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention to&#58; Corporate Secretary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471 El Camino Real, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Santa Clara, California, USA 95050</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, service of legal process may be made upon the Plan Administrator. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Plan Sponsor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The &#8220;Plan Sponsor&#8221; is&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471 El Camino Real, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Santa Clara, California, USA 95050</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1 (408) 207-0700 </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Plan Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Plan Administrator is the Committee prior to the Closing and the Representative upon and following the Closing.  The Plan Administrator&#8217;s contact information is&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation Committee of the Board of Directors or Representative</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471 El Camino Real, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Santa Clara, California, USA 95050</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 15. STATEMENT OF ERISA RIGHTS. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:67.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants in this Plan (which is a welfare benefit plan sponsored by SI-BONE, Inc.) are entitled to certain rights and protections under ERISA.  If you are an Eligible Employee, you are considered a participant in the Plan and, under ERISA, you are entitled to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Receive Information About Your Plan and Benefits</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Examine, without charge, at the Plan Administrator&#8217;s office and at other specified locations, such as worksites, all documents governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the latest annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description.  The Administrator may make a reasonable charge for the copies&#59; and</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Receive a summary of the Plan&#8217;s annual financial report, if applicable.  The Plan Administrator is required by law to furnish each Eligible Employee with a copy of this summary annual report.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Prudent Actions by Plan Fiduciaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In addition to creating rights for Eligible Employees, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan.  The people who operate the Plan, called &#8220;fiduciaries&#8221; of the Plan, have a duty to do so prudently and in the interest of you and other Eligible Employees and beneficiaries.  No one, including your employer, your union or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a Plan benefit or exercising your rights under ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Enforce Your Rights.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If your claim for a Plan benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ERISA, there are steps you can take to enforce the above rights.  For instance, if you request a copy of Plan documents or the latest annual report from the Plan, if applicable, and do not receive them within 30 days, you may file suit in a Federal court.  In such a case, the court may require the Plan Administrator to provide the materials and pay </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you have a claim for benefits which is denied or ignored, in whole or in part, you may only file suit in a state or Federal court situated in Santa Clara County, California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a Federal court.  The court will decide who should pay court costs and legal fees.  If you are successful, the court may order the person you have sued to pay these costs and fees.  If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Assistance with Your Questions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you have any questions about the Plan, you should contact the Plan Administrator.  If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210.  You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i9a0582ea3d75436b8a5b1c795c258cb4_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appendix A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participation Agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name&#58; &#160;&#160;&#160;&#160; ___________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:0.06pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Section 1.&#160;&#160;&#160;&#160;ELIGIBILITY.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You have been designated as eligible to participate in the SI-BONE, Inc. Severance Benefit Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a copy of which is attached to this Participation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms not explicitly defined in this Participation Agreement but defined in the Plan shall have the same definitions as in the Plan.  You will receive the benefits set forth below if you meet all the eligibility requirements set forth in the Plan, including, without limitation, timely executing a Release for benefit of the Company and allowing such Release to become effective in accordance with its terms. Notwithstanding the schedule for provision of benefits set forth below, the schedule and timing of payment of any benefits under this Participant Agreement is subject to any delay in payment that may be required under Section 5 of the Plan. </font></div><div style="margin-bottom:0.06pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Section 2.&#160;&#160;&#160;&#160;CHANGE IN CONTROL SEVERANCE BENEFITS.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will receive the severance benefits set forth in this Section 2 in the event of either&#58; (i) a Covered Termination occurring during the Change in Control Period, or (ii) the Closing of a Change in Control, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that you agree to provide transition services for a period of up to six months (if the Company or its successor offers such transition services at a level of compensation no lower than the annual base salary you received prior to such Change in Control (pro-rated for any reduction in time commitment or work effort, based on a 40 hour work week, allowed by such transition consulting arrangement), without taking into account any prior reduction in compensation that would, itself, give rise to a Good Reason termination)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#91;If you are terminated in a Covered Termination that occurs during the Change in Control Period, you will receive the severance benefits set forth in this Section 2.&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All severance benefits described herein are subject to standard deductions and withholdings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Base Salary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  You shall receive a cash payment in an amount equal to &#91;______&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of payment of your Base Salary.  The Base Salary payment will be paid to you in a lump sum cash payment no later than the second regular payroll date following the later of (i)&#160;the effective date of the Release or (ii)&#160;the Closing, but in any event not later than March 15 of the year following the year in which your Separation from Service occurs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Bonus Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  You will be entitled to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one and one-half (1.5) times</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the annual target cash bonus established for you, if any, pursuant to the annual performance bonus or annual variable compensation plan established by the Board of Directors or Committee (or any authorized committee or designee thereof) for the year in which your Covered Termination occurs.  If at the time of the Covered Termination you are eligible for the annual target cash bonus for the year in which the Covered Termination occurs, but the target percentage (or target dollar amount, if specified as such in the applicable bonus plan) for such bonus has not yet been established for such year, the target percentage shall be the target percentage established for you for the preceding year (but adjusted, if necessary for your position for the year in which the Covered Termination occurs).  For the avoidance of doubt, the amount of the annual target bonus to which you are entitled under this Section&#160;2(b) will be calculated (1)&#160;assuming all articulated performance goals for such bonus (including, but not limited to, corporate and individual performance, if applicable), for the year of the Covered Termination were achieved at target levels&#59; (2)&#160;as if you had provided services for the entire year for which the bonus relates&#59; and (3)&#160;ignoring any reduction in your Base Salary that would give rise to your right to resignation for Good Reason (such bonus to which you are entitled under this Section 2(b), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Target Bonus Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The Annual Target Bonus Severance Payment shall be paid in a lump sum cash payment no later than the second regular payroll date following the later of (i)&#160;the effective date of the Release or (ii)&#160;the Closing, but in any event not later than March 15 of the year following the year in which your Separation from Service occurs.  </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Option 1 for chief executive officer only.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Option 2 for all other executive officers.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Insert 24 months for chief executive officer only, and 12 months for other executive officers.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5x target bonus is for the chief executive officer only.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Payment of Continued Group Health Plan Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If you timely elect continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) following your Covered Termination date, the Company shall pay directly to the carrier the full amount of your COBRA premiums on behalf of you for your continued coverage under the Company&#8217;s group health plans, including coverage for your eligible dependents, until the earliest of (i) the end of the Severance Period following the date of your Covered Termination, (ii) the expiration of your eligibility for the continuation coverage under COBRA, or (iii) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment  (such period from your termination date through the earliest of (i) through (iii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COBRA Payment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Upon the conclusion of such period of insurance premium payments made by the Company, you will be responsible for the entire payment of premiums (or payment for the cost of coverage) required under COBRA for the duration of your eligible COBRA coverage period, if any.  For purposes of this Section, (1) references to COBRA shall be deemed to refer also to analogous provisions of state law and (2) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are your sole responsibility.  You agree to promptly notify the Company as soon as you become eligible for health insurance coverage in connection with new employment or self-employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums directly to the carrier on your behalf, the Company will instead pay you on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the value of your monthly COBRA premium for the first month of COBRA coverage, subject to applicable tax withholding (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Special Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), such Special Severance Payment to be made without regard to your election of COBRA coverage or payment of COBRA premiums and without regard to your continued eligibility for COBRA coverage during the COBRA Payment Period.  Such Special Severance Payment shall end upon expiration of the COBRA Payment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Equity Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The vesting and exercisability of each outstanding unvested stock option and other stock award, as applicable, that you hold covering Company common stock (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall be accelerated in full and any reacquisition or repurchase rights held by the Company in respect of common stock issued pursuant to any Equity Award granted to you shall lapse in full.  For purposes of determining the number of shares that will vest pursuant to the foregoing provision with respect to any performance based vesting Equity Award for which the performance period has not ended and that has multiple vesting levels depending upon the level of performance, vesting acceleration with respect to any ongoing performance period(s) shall occur with respect to the number of shares subject to the award as if the applicable performance criteria had been attained at a 100% level or, if greater, based on actual performance as of the termination of your Continuous Service to the Company. Notwithstanding anything to the contrary set forth herein, your Equity Awards shall remain subject to the terms of the Equity Plan (or other applicable Company plan) and award documents under which such Equity Award was granted, including any provision for earlier termination of such Equity Awards.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.91pt">Extension of Post-Termination Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  All outstanding Equity Awards which carry a right to exercise that you hold as of the date of your Covered Termination will expire on the earlier of (A) the original term of such outstanding Equity Awards as set forth in the applicable award agreement or the equity incentive plan, subject to earlier termination in the event of a Change in Control as set forth in the terms of the applicable equity incentive plan and definitive agreement for such Change in Control transaction, and (B) the date which occurs on the second anniversary of termination of your Continuous Service to the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.&#160;&#160;&#160;&#160;NON-CHANGE IN CONTROL SEVERANCE BENEFITS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If your employment is terminated by the Company without Cause that occurs at a time that is not during the Change in Control Period, you will receive&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the base salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash payment described in Section 2(a) above, but the Severance Period for purposes of calculating such benefits shall be twelve (12) months&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">the COBRA benefits described in Section 2(c) above, but the Severance Period for purposes of calculating such benefits shall be twelve (12) months.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You shall not be eligible to receive any other benefits under the Plan except as described in Section 3(a) and Section 3(b) above.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, in no event shall you be entitled to benefits under both Section 2 and this Section 3.  If you are eligible for severance benefits under both Section 2 and this Section 3, you shall receive the benefits set forth in Section 2 and such benefits shall be reduced by any benefits previously provided to you under Section 3.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.&#160;&#160;&#160;&#160;ACKNOWLEDGEMENTS.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to participation in the Plan, you hereby acknowledge each of the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The benefits that may be provided to you under this Participation Agreement are subject to certain reductions and termination under Section 2 and Section 3 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Your eligibility for and receipt of any severance benefits to which you may become entitled as described in Section 2 or Section 3 above is expressly contingent upon your execution of and compliance with the terms and conditions of the Plan, the Release and the Confidentiality Agreement.  Severance benefits under this Participation Agreement shall immediately cease in the event of your violation of the provisions of Confidentiality Agreement or any other written agreement with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">As further described in Section 2(c) of the Plan, this Participation Agreement and the Plan supersede and replace any change in control or severance benefits previously provided to you and by executing below you expressly agree to such treatment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To accept the terms of this Participation Agreement and participate in the Plan, please sign and date this Agreement in the space provided below and return it to Timothy E. Davis no later than July ____, 2020.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SI-BONE, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Timothy E. Davis,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Lead Independent Director and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Compensation Committee Chairman&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligible Employee</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Insert Name&#93;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i9a0582ea3d75436b8a5b1c795c258cb4_56"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.102%"><tr><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Executive Officer</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Base Pay</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Bonus</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">COBRA Coverage</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity Awards</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Dunn</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24 months base salary</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5 times annual target cash bonus</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24 months</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full acceleration of vesting of all equity awards</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Laura Francis</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12 months base salary</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Then current annual target cash bonus</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12 months</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full acceleration of vesting of all equity awards</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anthony Recupero</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12 months base salary</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Then current annual target cash bonus</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12 months</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full acceleration of vesting of all equity awards</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Michael Pisetsky</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12 months base salary</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Then current annual target cash bonus</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12 months</font></div><div><font><br></font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full acceleration of vesting of all equity awards</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>sibn-ex211_listxofxsubsidi.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia6aa41cf8160438f8367639262860390_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of subsidiaries of the Registrant</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:473.25pt"><tr><td style="width:1.0pt"></td><td style="width:244.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:211.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SI-BONE S.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SI-BONE Deutschland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SI-BONE UK LTD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>sibn-ex231_pwcxconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4a7b5e17322842ae8b7296118a533b52_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-235714) and Form S-8 (Nos. 333-227907, 333-230473 and 333-237091) of SI-BONE, Inc. of our report dated March&#160;10, 2021&#160;relating to the financial statements, which appears in this Form 10-K.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;10, 2021 </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>sibn-ex311_12312010xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i71dc941c402141a297ec91610260b8e8_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey W. Dunn, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Form 10-K of SI-BONE, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey W. Dunn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey W. Dunn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>sibn-ex312_12312010xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i873f27d8ceb9423c9acc2880b107c239_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laura A. Francis, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Form 10-K of SI-BONE, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.083%"><tr><td style="width:1.0%"></td><td style="width:6.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laura A. Francis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura A. Francis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer &#38; Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>sibn-ex321_12312010xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i19fd32abb85047339a2a480e1c132987_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, Jeffrey W. Dunn, President and Chief Executive Officer of SI-Bone, Inc. (the &#8220;Company&#8221;), and Laura A. Francis, Chief Operating Officer &#38; Chief Financial Officer of the Company, each hereby certify that, to the best of his or her knowledge&#58; </font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.083%"><tr><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey W. Dunn </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey W. Dunn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laura A. Francis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura A. Francis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer &#38; Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the Securities and Exchange Commission as an exhibit to the Annual Report and shall not be deemed filed by the Company for purposes of &#167; 18 of the Securities Exchange Act of 1934, as amended.&#59; and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>sibn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84ec410f-3815-4763-9bc2-b77d68e36727,g:546a3c6e-3b19-4bdc-9aac-42f0e40439c5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sibn="http://si-bone.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://si-bone.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://si-bone.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandNatureofBusiness" roleURI="http://si-bone.com/role/TheCompanyandNatureofBusiness">
        <link:definition>2101101 - Disclosure - The Company and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandNatureofBusinessDetails" roleURI="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails">
        <link:definition>2402401 - Disclosure - The Company and Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentsDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLiquidityDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Warranty Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://si-bone.com/role/MarketableSecurities">
        <link:definition>2113103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://si-bone.com/role/MarketableSecuritiesTables">
        <link:definition>2314302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://si-bone.com/role/MarketableSecuritiesDetails">
        <link:definition>2415409 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://si-bone.com/role/FairValueMeasurement">
        <link:definition>2116104 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://si-bone.com/role/FairValueMeasurementTables">
        <link:definition>2317303 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2418410 - Disclosure - Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://si-bone.com/role/BalanceSheetComponents">
        <link:definition>2119105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://si-bone.com/role/BalanceSheetComponentsTables">
        <link:definition>2320304 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPropertyandEquipmentNetDetails" roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails">
        <link:definition>2421411 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails">
        <link:definition>2422412 - Disclosure - Balance Sheet Components - Accrued Liabilities and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://si-bone.com/role/CommitmentsandContingencies">
        <link:definition>2123106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://si-bone.com/role/CommitmentsandContingenciesTables">
        <link:definition>2324305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2425413 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" roleURI="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails">
        <link:definition>2426414 - Disclosure - Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://si-bone.com/role/Borrowings">
        <link:definition>2127107 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://si-bone.com/role/BorrowingsTables">
        <link:definition>2328306 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofBorrowingsDetails" roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails">
        <link:definition>2429415 - Disclosure - Borrowings - Summary of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofBorrowingsDetails_1" roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1">
        <link:definition>2429415 - Disclosure - Borrowings - Summary of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails">
        <link:definition>2430416 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails">
        <link:definition>2431417 - Disclosure - Borrowings - Annual Future Minimum Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://si-bone.com/role/Warrants">
        <link:definition>2132108 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://si-bone.com/role/WarrantsTables">
        <link:definition>2333307 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsIssuedandOutstandingDetails" roleURI="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails">
        <link:definition>2434418 - Disclosure - Warrants - Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStock" roleURI="http://si-bone.com/role/CommonandPreferredStock">
        <link:definition>2135109 - Disclosure - Common and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStockNarrativeDetails" roleURI="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails">
        <link:definition>2436419 - Disclosure - Common and Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://si-bone.com/role/StockBasedCompensation">
        <link:definition>2137110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://si-bone.com/role/StockBasedCompensationTables">
        <link:definition>2338308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://si-bone.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2439420 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2440421 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" roleURI="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails">
        <link:definition>2441422 - Disclosure - Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsforStockOptionsDetails" roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Valuation Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2443424 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails">
        <link:definition>2444425 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2445426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://si-bone.com/role/EmployeeBenefitPlan">
        <link:definition>2146111 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://si-bone.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2447427 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStock" roleURI="http://si-bone.com/role/NetLossPerShareofCommonStock">
        <link:definition>2148112 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockTables" roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockTables">
        <link:definition>2349309 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails">
        <link:definition>2450428 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails">
        <link:definition>2451429 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://si-bone.com/role/IncomeTaxes">
        <link:definition>2152113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://si-bone.com/role/IncomeTaxesTables">
        <link:definition>2353310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>2454430 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredIncomeTaxesDetails" roleURI="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails">
        <link:definition>2455431 - Disclosure - Income Taxes - Components of Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>2456432 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails">
        <link:definition>2457433 - Disclosure - Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesinValuationAllowanceDetails" roleURI="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails">
        <link:definition>2458434 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2459435 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUncertainIncomeTaxPositionsDetails" roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails">
        <link:definition>2460436 - Disclosure - Income Taxes - Uncertain Income Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://si-bone.com/role/RelatedPartyTransactions">
        <link:definition>2161114 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2462437 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" abstract="true" name="WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_OptionsTrancheFiveMember" abstract="true" name="OptionsTrancheFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_SecondaryOfferingMember" abstract="true" name="SecondaryOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DebtInstrumentPrepaymentPenaltyPercentage" abstract="false" name="DebtInstrumentPrepaymentPenaltyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" abstract="true" name="LitigationStatutoryDamagesPerViolationOfTCPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" abstract="true" name="WarrantsIssuedMarchFirstTwentySeventeenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_SecondFollowOnPublicOfferingMember" abstract="true" name="SecondFollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_NonqualifiedStockOptionMember" abstract="true" name="NonqualifiedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_OptionsTrancheTwoMember" abstract="true" name="OptionsTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" abstract="false" name="AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" abstract="false" name="PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ProceedsFromSaleOfMarketableSecurities" abstract="false" name="ProceedsFromSaleOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_EmployeeStockPurchasePlanSharesMember" abstract="true" name="EmployeeStockPurchasePlanSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_IncomeTaxesValuationAllowanceRollForward" abstract="true" name="IncomeTaxesValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sibn_PayrollProtectionProgramLoanCARESActMember" abstract="true" name="PayrollProtectionProgramLoanCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_MarketableSecuritiesFairValue" abstract="false" name="MarketableSecuritiesFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtPrepaymentPenaltyPeriodDomain" abstract="true" name="DebtPrepaymentPenaltyPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DebtPrepaymentPenaltyPeriodAxis" abstract="true" name="DebtPrepaymentPenaltyPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" abstract="false" name="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_StandardProductWarrantyTerm" abstract="false" name="StandardProductWarrantyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_A2018EquityIncentivePlanMember" abstract="true" name="A2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" abstract="false" name="StockIssuedDuringPeriodAmountRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" abstract="false" name="WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_FollowOnPublicOfferingMember" abstract="true" name="FollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumYearOnePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_DebtCovenantTrancheThreeMember" abstract="true" name="DebtCovenantTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_EricBFromerChiropracticIncClassActionMember" abstract="true" name="EricBFromerChiropracticIncClassActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_PharmakonTermLoanMember" abstract="true" name="PharmakonTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DebtCovenantTrancheOneMember" abstract="true" name="DebtCovenantTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_RevenueRecognitionStandardPaymentTerms" abstract="false" name="RevenueRecognitionStandardPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_ComputerAndOfficeEquipmentMember" abstract="true" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_VariableOptionOneMember" abstract="true" name="VariableOptionOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" abstract="true" name="WarrantsIssuedJulyTwentySecondTwentyThirteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" abstract="false" name="PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" abstract="false" name="EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sibn_ShareSubjectToRepurchaseMember" abstract="true" name="ShareSubjectToRepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" abstract="false" name="StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" abstract="false" name="WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_CommonStockWarrantsMember" abstract="true" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_SocialSecurityTaxEmployerDeferralCARESAct" abstract="false" name="SocialSecurityTaxEmployerDeferralCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" abstract="true" name="FollowOnPublicOfferingAndSecondaryOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_Company401KPlanMember" abstract="true" name="Company401KPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_PrepaymentPenalty3148MonthsMember" abstract="true" name="PrepaymentPenalty3148MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" abstract="false" name="MedicalDeviceExciseTaxPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sibn_RelatedPartyTransactionTermOfAgreement" abstract="false" name="RelatedPartyTransactionTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_OptionsTrancheOneMember" abstract="true" name="OptionsTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_OperatingLossCarryforwardsLimited" abstract="false" name="OperatingLossCarryforwardsLimited" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" abstract="false" name="AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" abstract="true" name="WarrantsIssuedDecemberTwentySecondTwentySixteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sibn_IncentiveStockOptionMember" abstract="true" name="IncentiveStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" abstract="false" name="DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" abstract="false" name="DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" abstract="false" name="DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" abstract="true" name="WarrantsIssuedOctoberTwentiethTwentyFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumYearTwoPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_DevelopmentAgreementMember" abstract="true" name="DevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" abstract="true" name="LitigationTrebleDamagesPerViolationOfTCPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_ESPPPurchaseRightsMember" abstract="true" name="ESPPPurchaseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DeferredTaxAssetsDepreciationAndAmortization" abstract="false" name="DeferredTaxAssetsDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtCovenantTrancheTwoMember" abstract="true" name="DebtCovenantTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sibn_PrepaymentPenalty4960MonthsMember" abstract="true" name="PrepaymentPenalty4960MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" abstract="false" name="DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" abstract="false" name="DebtInstrumentLiquidityCovenantProductRevenueThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ProceedsFromMaturityOfMarketableSecurities" abstract="false" name="ProceedsFromMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtCovenantThresholdDomain" abstract="true" name="DebtCovenantThresholdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_OptionsTrancheFourMember" abstract="true" name="OptionsTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_SolarLoanAndSecurityAgreementMember" abstract="true" name="SolarLoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_MarketableSecuritiesAmortizedCost" abstract="false" name="MarketableSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_SalesCreditReservePeriod" abstract="false" name="SalesCreditReservePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sibn_DebtCovenantThresholdAxis" abstract="true" name="DebtCovenantThresholdAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sibn_AllocatedPublicOfferingCosts" abstract="false" name="AllocatedPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" abstract="false" name="StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_A2018EmployeeStockPurchasePlanMember" abstract="true" name="A2018EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_OptionsTrancheThreeMember" abstract="true" name="OptionsTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" abstract="true" name="WarrantsIssuedNovemberNinthTwentyFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_VestingOfEarlyExercisedStockOptions" abstract="false" name="VestingOfEarlyExercisedStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sibn_DebtInstrumentCovenantMinimumCashBalance" abstract="false" name="DebtInstrumentCovenantMinimumCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" abstract="false" name="WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>sibn-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84ec410f-3815-4763-9bc2-b77d68e36727,g:546a3c6e-3b19-4bdc-9aac-42f0e40439c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://si-bone.com/role/Cover" xlink:type="simple" xlink:href="sibn-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6999145d-e327-4aa6-8a02-1b224c4257be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ec6a7f7c-d8cd-42dc-b0f1-117db39d948a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6999145d-e327-4aa6-8a02-1b224c4257be" xlink:to="loc_us-gaap_AccountsPayableCurrent_ec6a7f7c-d8cd-42dc-b0f1-117db39d948a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f969f1a0-ec58-4ac3-933b-5e49ffdc47be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6999145d-e327-4aa6-8a02-1b224c4257be" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f969f1a0-ec58-4ac3-933b-5e49ffdc47be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9a57054c-a416-4b93-b93d-3e0003cfcf22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6999145d-e327-4aa6-8a02-1b224c4257be" xlink:to="loc_us-gaap_LongTermDebtCurrent_9a57054c-a416-4b93-b93d-3e0003cfcf22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6711f62-0073-4a70-9b65-009a32c912c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a7c616e6-7d7f-45f3-bc10-ab2233cae82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6711f62-0073-4a70-9b65-009a32c912c9" xlink:to="loc_us-gaap_PreferredStockValue_a7c616e6-7d7f-45f3-bc10-ab2233cae82e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_863bf3ba-e297-4d92-9001-e28fdf736d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6711f62-0073-4a70-9b65-009a32c912c9" xlink:to="loc_us-gaap_CommonStockValue_863bf3ba-e297-4d92-9001-e28fdf736d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_873bb53a-4400-4b87-8e40-df941f848d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6711f62-0073-4a70-9b65-009a32c912c9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_873bb53a-4400-4b87-8e40-df941f848d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca77f768-cf42-43b0-b82d-809648662eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6711f62-0073-4a70-9b65-009a32c912c9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca77f768-cf42-43b0-b82d-809648662eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_72f7af6d-6a2d-4602-a5df-dbfb934f4320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6711f62-0073-4a70-9b65-009a32c912c9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_72f7af6d-6a2d-4602-a5df-dbfb934f4320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b197df75-d9ff-4ccf-aed8-bfa0d78949df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6137d981-8886-4056-8bc6-46857126d9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b197df75-d9ff-4ccf-aed8-bfa0d78949df" xlink:to="loc_us-gaap_Liabilities_6137d981-8886-4056-8bc6-46857126d9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9ab9043a-ebe1-448c-b928-5c58cc84fd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b197df75-d9ff-4ccf-aed8-bfa0d78949df" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9ab9043a-ebe1-448c-b928-5c58cc84fd75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d8563e2-3dde-4fa3-99e3-86eba1ab6003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b197df75-d9ff-4ccf-aed8-bfa0d78949df" xlink:to="loc_us-gaap_StockholdersEquity_1d8563e2-3dde-4fa3-99e3-86eba1ab6003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a2563f4c-e59f-46a7-8d75-72a061c9de3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4ed123f-25c5-4657-a9f5-9755335d5407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2563f4c-e59f-46a7-8d75-72a061c9de3d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4ed123f-25c5-4657-a9f5-9755335d5407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2c5345f5-d580-49e9-8f82-15346868d064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2563f4c-e59f-46a7-8d75-72a061c9de3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2c5345f5-d580-49e9-8f82-15346868d064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e71afad4-5980-4e2e-815c-6823213584a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2563f4c-e59f-46a7-8d75-72a061c9de3d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e71afad4-5980-4e2e-815c-6823213584a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b70ec34a-8de1-40ca-999f-9b698aa09a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2563f4c-e59f-46a7-8d75-72a061c9de3d" xlink:to="loc_us-gaap_InventoryNet_b70ec34a-8de1-40ca-999f-9b698aa09a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a03bad10-7b3b-4a0d-8288-22e1195631b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2563f4c-e59f-46a7-8d75-72a061c9de3d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a03bad10-7b3b-4a0d-8288-22e1195631b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6ca8298f-2e3d-4d54-9327-012a2fbef9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11084c9f-1acd-4c79-bb64-2e7c7bf6f4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ca8298f-2e3d-4d54-9327-012a2fbef9f6" xlink:to="loc_us-gaap_AssetsCurrent_11084c9f-1acd-4c79-bb64-2e7c7bf6f4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3be21383-6967-424f-88e7-958fe64c4a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ca8298f-2e3d-4d54-9327-012a2fbef9f6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3be21383-6967-424f-88e7-958fe64c4a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_809ff84e-cf4e-49cf-8231-f176b6c652c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ca8298f-2e3d-4d54-9327-012a2fbef9f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_809ff84e-cf4e-49cf-8231-f176b6c652c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_087754ba-80c1-47fe-8594-ffbd8ef9b7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ca8298f-2e3d-4d54-9327-012a2fbef9f6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_087754ba-80c1-47fe-8594-ffbd8ef9b7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7ca0b940-2e8b-4db2-8608-fc85c4143bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a7908b76-7753-4d04-bcf1-112a10711bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7ca0b940-2e8b-4db2-8608-fc85c4143bb7" xlink:to="loc_us-gaap_LiabilitiesCurrent_a7908b76-7753-4d04-bcf1-112a10711bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5017d822-1e61-4140-aacf-8b74528421fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7ca0b940-2e8b-4db2-8608-fc85c4143bb7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5017d822-1e61-4140-aacf-8b74528421fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89086d0c-1f6f-48a8-abe9-92301ffe9e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7ca0b940-2e8b-4db2-8608-fc85c4143bb7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89086d0c-1f6f-48a8-abe9-92301ffe9e33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6bd9686-1d8d-42d4-ac67-9db4cf80db4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c79ff0ac-326b-40d7-ba94-2fb8ab5dd547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6bd9686-1d8d-42d4-ac67-9db4cf80db4b" xlink:to="loc_us-gaap_NetIncomeLoss_c79ff0ac-326b-40d7-ba94-2fb8ab5dd547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_64bc6b15-86b6-4a84-ab01-4382c33eb6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6bd9686-1d8d-42d4-ac67-9db4cf80db4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_64bc6b15-86b6-4a84-ab01-4382c33eb6d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_555ab1d1-3734-4f3c-8f11-a7b699b46042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6bd9686-1d8d-42d4-ac67-9db4cf80db4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_555ab1d1-3734-4f3c-8f11-a7b699b46042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6f2aa962-040b-4f40-9765-fb252bda1b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6ce585cf-34d1-42f8-8ff1-ce75972847c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6f2aa962-040b-4f40-9765-fb252bda1b4c" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6ce585cf-34d1-42f8-8ff1-ce75972847c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e39446d7-0611-4a19-b46b-78cea9fdd61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6f2aa962-040b-4f40-9765-fb252bda1b4c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e39446d7-0611-4a19-b46b-78cea9fdd61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d6c54cfa-7e56-459f-a807-18f0d18bb501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6f2aa962-040b-4f40-9765-fb252bda1b4c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d6c54cfa-7e56-459f-a807-18f0d18bb501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c71025f8-4bc7-496a-a339-78d7c5ee11d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b086ded7-7122-459f-8a37-b9bcc642bd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c71025f8-4bc7-496a-a339-78d7c5ee11d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b086ded7-7122-459f-8a37-b9bcc642bd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fcb6277f-652c-4357-a067-7f1b34852deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c71025f8-4bc7-496a-a339-78d7c5ee11d9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fcb6277f-652c-4357-a067-7f1b34852deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fa2f819b-fa43-4d91-ab67-acc0c1c3dba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fb7e881c-0262-464a-a3df-be21b3a2d120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fa2f819b-fa43-4d91-ab67-acc0c1c3dba9" xlink:to="loc_us-gaap_GrossProfit_fb7e881c-0262-464a-a3df-be21b3a2d120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_04047258-c309-4c78-8518-3a54d4443045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fa2f819b-fa43-4d91-ab67-acc0c1c3dba9" xlink:to="loc_us-gaap_OperatingExpenses_04047258-c309-4c78-8518-3a54d4443045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7cacd5bf-249c-46a3-8e23-11ec374085e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_adf4d85e-450b-44bb-bfe8-76d531f023dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cacd5bf-249c-46a3-8e23-11ec374085e7" xlink:to="loc_us-gaap_OperatingIncomeLoss_adf4d85e-450b-44bb-bfe8-76d531f023dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_82299700-34a5-40ca-91d9-61e1b3dbb901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cacd5bf-249c-46a3-8e23-11ec374085e7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_82299700-34a5-40ca-91d9-61e1b3dbb901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_76e9ae7e-8aa9-47bf-98c6-b57e6266d48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cacd5bf-249c-46a3-8e23-11ec374085e7" xlink:to="loc_us-gaap_InterestExpense_76e9ae7e-8aa9-47bf-98c6-b57e6266d48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_173a7ab6-7ed8-4f3a-8c8e-fbe3fa439c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cacd5bf-249c-46a3-8e23-11ec374085e7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_173a7ab6-7ed8-4f3a-8c8e-fbe3fa439c6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_511d2724-c18c-4bbf-b494-004b4877395f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ProceedsFromMaturityOfMarketableSecurities_b68e4d21-844f-4a02-99d1-5cc93735d131" xlink:href="sibn-20201231.xsd#sibn_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_511d2724-c18c-4bbf-b494-004b4877395f" xlink:to="loc_sibn_ProceedsFromMaturityOfMarketableSecurities_b68e4d21-844f-4a02-99d1-5cc93735d131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ProceedsFromSaleOfMarketableSecurities_92da616c-9fa1-4ab5-a3f8-e61167ac6e52" xlink:href="sibn-20201231.xsd#sibn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_511d2724-c18c-4bbf-b494-004b4877395f" xlink:to="loc_sibn_ProceedsFromSaleOfMarketableSecurities_92da616c-9fa1-4ab5-a3f8-e61167ac6e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4fd483b1-b31a-483c-a74f-d5cd2172639b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_511d2724-c18c-4bbf-b494-004b4877395f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4fd483b1-b31a-483c-a74f-d5cd2172639b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18aa2f9e-4afa-44c2-83eb-baafc9fa1f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_511d2724-c18c-4bbf-b494-004b4877395f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18aa2f9e-4afa-44c2-83eb-baafc9fa1f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a3865f4-889c-422c-9a4f-27e4eaeb2428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_NetIncomeLoss_1a3865f4-889c-422c-9a4f-27e4eaeb2428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3e2f09c3-0d83-4753-b68a-2cc91d407c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_ShareBasedCompensation_3e2f09c3-0d83-4753-b68a-2cc91d407c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bfa25bcf-45b0-477f-bca5-5c359fa227aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bfa25bcf-45b0-477f-bca5-5c359fa227aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7216b5cb-2719-4855-ade4-443cf3bcacb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7216b5cb-2719-4855-ade4-443cf3bcacb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2f757e0c-1cc0-407b-a8ad-3f270a9fdc69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2f757e0c-1cc0-407b-a8ad-3f270a9fdc69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_d775fcc2-64c5-42d1-ab9a-2d6aec6e0250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_d775fcc2-64c5-42d1-ab9a-2d6aec6e0250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8fd47317-4f0b-4f78-a828-f69092b65126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8fd47317-4f0b-4f78-a828-f69092b65126" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2cc2c1bb-6f5b-400d-b2d3-165ed95a49ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2cc2c1bb-6f5b-400d-b2d3-165ed95a49ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f6a18fab-e08e-445b-ae43-9e599436f861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f6a18fab-e08e-445b-ae43-9e599436f861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f57de2ab-a93d-4fb4-aa99-34034f45d3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f57de2ab-a93d-4fb4-aa99-34034f45d3c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f35ab2e2-2013-4990-bb99-b8a9992267cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f35ab2e2-2013-4990-bb99-b8a9992267cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c895492a-3775-48ed-8828-70139cc2011d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c895492a-3775-48ed-8828-70139cc2011d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae25428f-c8eb-454c-8ea2-497fbd751144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae25428f-c8eb-454c-8ea2-497fbd751144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_999bcd9f-2661-4374-ac9a-f266454d381b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6fd3582-f247-4b77-a66f-b98e61801944" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_999bcd9f-2661-4374-ac9a-f266454d381b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d38af786-4e41-40c3-8d52-8d2235d07b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d38af786-4e41-40c3-8d52-8d2235d07b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_96376ab0-5c72-4265-8070-b67a18b21e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_96376ab0-5c72-4265-8070-b67a18b21e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_447c6e8f-ec32-4667-8a98-eec6eeab1237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_447c6e8f-ec32-4667-8a98-eec6eeab1237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_7c4b2d96-607b-4126-a111-02b8b2ceae77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_7c4b2d96-607b-4126-a111-02b8b2ceae77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_5ce936f1-bc73-4bdb-b279-b6acd5a37cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_5ce936f1-bc73-4bdb-b279-b6acd5a37cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4752cee8-726f-4b18-b502-0b0e912d228f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4752cee8-726f-4b18-b502-0b0e912d228f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d28a1dd7-2da1-48ee-9ed6-b56e6f720673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d28a1dd7-2da1-48ee-9ed6-b56e6f720673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_df8978e8-16fa-4ae4-b5ae-3a678c4806f5" xlink:href="sibn-20201231.xsd#sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_df8978e8-16fa-4ae4-b5ae-3a678c4806f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f8d0c695-5865-4be4-a6b4-3ce6213a891d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9f51ff5-5f17-43e4-9cd2-1c24f6427f85" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f8d0c695-5865-4be4-a6b4-3ce6213a891d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f6d3ce8-457c-4d3d-b4dc-bdd470063129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b198db0-ce09-40f4-82db-ade60c370496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f6d3ce8-457c-4d3d-b4dc-bdd470063129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b198db0-ce09-40f4-82db-ade60c370496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0ead6b7-e26b-4f4e-be93-ff11d431e295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f6d3ce8-457c-4d3d-b4dc-bdd470063129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0ead6b7-e26b-4f4e-be93-ff11d431e295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1c4701b-81a5-4290-97cf-c398ff3c6393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f6d3ce8-457c-4d3d-b4dc-bdd470063129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1c4701b-81a5-4290-97cf-c398ff3c6393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e99a24d-ff09-4e67-8398-006bab6d53d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f6d3ce8-457c-4d3d-b4dc-bdd470063129" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e99a24d-ff09-4e67-8398-006bab6d53d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/TheCompanyandNatureofBusiness" xlink:type="simple" xlink:href="sibn-20201231.xsd#TheCompanyandNatureofBusiness"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/TheCompanyandNatureofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#TheCompanyandNatureofBusinessDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesLiquidityDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesWarrantyProgramDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecurities" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_7c754d20-dd75-4882-85c4-9cf87ccd2718" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_6d5426a1-3c55-4128-b77c-b77da3937cd5" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_7c754d20-dd75-4882-85c4-9cf87ccd2718" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_6d5426a1-3c55-4128-b77c-b77da3937cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_0064b3a9-4819-4afa-801f-10ae80bcd14b" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_7c754d20-dd75-4882-85c4-9cf87ccd2718" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_0064b3a9-4819-4afa-801f-10ae80bcd14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7dad8efe-8e62-4e65-9ebe-22305a71f073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_7c754d20-dd75-4882-85c4-9cf87ccd2718" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7dad8efe-8e62-4e65-9ebe-22305a71f073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_49f354cc-46cf-403f-88e7-a551b90e6816" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_0cf03466-bde0-4347-bed6-88a3738832e8" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_49f354cc-46cf-403f-88e7-a551b90e6816" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_0cf03466-bde0-4347-bed6-88a3738832e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_855f52d6-14fa-4354-99b6-dae299c8d27c" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_49f354cc-46cf-403f-88e7-a551b90e6816" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_855f52d6-14fa-4354-99b6-dae299c8d27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f79131ed-c99b-4878-bb95-0a9f0a7158a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_49f354cc-46cf-403f-88e7-a551b90e6816" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f79131ed-c99b-4878-bb95-0a9f0a7158a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_fbe5b26a-599c-42e8-8671-61f03ee95ac0" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fce87e4d-9c07-49e7-8a2a-66559aa01da4" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_fbe5b26a-599c-42e8-8671-61f03ee95ac0" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fce87e4d-9c07-49e7-8a2a-66559aa01da4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_688a26c5-9240-4221-ad06-4fb7b7c91c53" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_fbe5b26a-599c-42e8-8671-61f03ee95ac0" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_688a26c5-9240-4221-ad06-4fb7b7c91c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesFairValue_462059ea-02c7-4def-89d9-106c52b1f1da" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_fbe5b26a-599c-42e8-8671-61f03ee95ac0" xlink:to="loc_sibn_MarketableSecuritiesFairValue_462059ea-02c7-4def-89d9-106c52b1f1da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0ca9d5f5-cc6f-4d2b-925f-ce08b60798f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_856811f2-1d83-4932-9849-f95682fd9b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0ca9d5f5-cc6f-4d2b-925f-ce08b60798f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_856811f2-1d83-4932-9849-f95682fd9b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_41057ff4-7744-456d-a883-2a49d503ad91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0ca9d5f5-cc6f-4d2b-925f-ce08b60798f2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_41057ff4-7744-456d-a883-2a49d503ad91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0343796e-ade2-4764-9f41-f3e8733d47be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_34c68465-69ec-490b-afa4-c3355452e732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0343796e-ade2-4764-9f41-f3e8733d47be" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_34c68465-69ec-490b-afa4-c3355452e732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_7f2792e2-0029-46cb-8e36-6e89712dd90d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0343796e-ade2-4764-9f41-f3e8733d47be" xlink:to="loc_us-gaap_LitigationReserveCurrent_7f2792e2-0029-46cb-8e36-6e89712dd90d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_97e03d28-0a93-4872-bd11-2842573314b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0343796e-ade2-4764-9f41-f3e8733d47be" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_97e03d28-0a93-4872-bd11-2842573314b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79bae5b1-29ea-48ae-a83d-deb5db5f0cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0343796e-ade2-4764-9f41-f3e8733d47be" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79bae5b1-29ea-48ae-a83d-deb5db5f0cfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_36c4ba54-aa12-47fd-bd20-b5a8075ee230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_36c4ba54-aa12-47fd-bd20-b5a8075ee230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_bf68b7a2-8afa-40b5-aa93-47452588fd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_bf68b7a2-8afa-40b5-aa93-47452588fd2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3fe5cba7-c719-49da-83b9-c34636c9dceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3fe5cba7-c719-49da-83b9-c34636c9dceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0f1f6d7e-74aa-40e7-b219-3fd0511e4d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0f1f6d7e-74aa-40e7-b219-3fd0511e4d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7bfd1641-ea4b-421f-8ccc-c73828bde5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7bfd1641-ea4b-421f-8ccc-c73828bde5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f4249564-19e6-4554-95d0-c75e7437cc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ad1a168b-371c-47ea-825d-ab68f2386106" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f4249564-19e6-4554-95d0-c75e7437cc73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/Borrowings" xlink:type="simple" xlink:href="sibn-20201231.xsd#Borrowings"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/Borrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsSummaryofBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b95b2a6a-9ff7-4ec3-aeae-4c3aa8e4704d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c7fb18af-8630-4402-8451-38812a273415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b95b2a6a-9ff7-4ec3-aeae-4c3aa8e4704d" xlink:to="loc_us-gaap_LongTermDebtCurrent_c7fb18af-8630-4402-8451-38812a273415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_48330508-9c3f-4c01-9f95-382bca28a19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b95b2a6a-9ff7-4ec3-aeae-4c3aa8e4704d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_48330508-9c3f-4c01-9f95-382bca28a19c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsSummaryofBorrowingsDetails_1"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c29bb1c-50c0-4f49-8aed-5377b5ed4ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2ddbf566-33e9-4b3d-8488-b3149051cd56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c29bb1c-50c0-4f49-8aed-5377b5ed4ae2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2ddbf566-33e9-4b3d-8488-b3149051cd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_39970a9e-b656-48ef-87a8-f0bdaff67ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c29bb1c-50c0-4f49-8aed-5377b5ed4ae2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_39970a9e-b656-48ef-87a8-f0bdaff67ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_e0ce9403-6b02-432c-809b-6e65d270e85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c29bb1c-50c0-4f49-8aed-5377b5ed4ae2" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_e0ce9403-6b02-432c-809b-6e65d270e85e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a23c5740-16dd-4439-af94-db4b7d102064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad40aa65-0e92-46a9-88b1-8b88958af042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a23c5740-16dd-4439-af94-db4b7d102064" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad40aa65-0e92-46a9-88b1-8b88958af042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_54d6a4e3-7ddb-4ed3-9511-813a35f29274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a23c5740-16dd-4439-af94-db4b7d102064" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_54d6a4e3-7ddb-4ed3-9511-813a35f29274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_451e7018-3c15-4f6c-8060-bbe2f1f13874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a23c5740-16dd-4439-af94-db4b7d102064" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_451e7018-3c15-4f6c-8060-bbe2f1f13874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9c63454d-48a8-4c8e-bdc3-8981c4aa3761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a23c5740-16dd-4439-af94-db4b7d102064" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9c63454d-48a8-4c8e-bdc3-8981c4aa3761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b7fec926-3648-4365-9e3c-f0ea54537e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a23c5740-16dd-4439-af94-db4b7d102064" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b7fec926-3648-4365-9e3c-f0ea54537e66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/Warrants" xlink:type="simple" xlink:href="sibn-20201231.xsd#Warrants"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/Warrants" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#WarrantsTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/WarrantsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#WarrantsIssuedandOutstandingDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommonandPreferredStock" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommonandPreferredStock"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommonandPreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommonandPreferredStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationValuationAssumptionsforStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sibn-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStock"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64ec3cbe-fbc2-491f-9f73-2a33002b1aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ee1f99ce-4213-43d7-a6c1-4c6095da53c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64ec3cbe-fbc2-491f-9f73-2a33002b1aa4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ee1f99ce-4213-43d7-a6c1-4c6095da53c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dfae980d-1fa2-4eba-85dc-940526802876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64ec3cbe-fbc2-491f-9f73-2a33002b1aa4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dfae980d-1fa2-4eba-85dc-940526802876" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_858e5c17-871e-4c3d-a466-9a13dcbf31a2" xlink:href="sibn-20201231.xsd#sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_380415a1-73d8-476c-ad72-8a6e4d5125ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_858e5c17-871e-4c3d-a466-9a13dcbf31a2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_380415a1-73d8-476c-ad72-8a6e4d5125ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f01a7a85-1b2d-4dd2-a8f0-6372d715979a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_858e5c17-871e-4c3d-a466-9a13dcbf31a2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f01a7a85-1b2d-4dd2-a8f0-6372d715979a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9ff26a2-cbe6-47b8-994a-5f4338dea0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_812fef9e-c177-4f6a-8968-50d7e9ccf708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9ff26a2-cbe6-47b8-994a-5f4338dea0a4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_812fef9e-c177-4f6a-8968-50d7e9ccf708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c4fe6351-a14c-4539-b255-825399175d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9ff26a2-cbe6-47b8-994a-5f4338dea0a4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c4fe6351-a14c-4539-b255-825399175d09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10a7345c-7f42-400b-a440-3b450eeaaf5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9ff26a2-cbe6-47b8-994a-5f4338dea0a4" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10a7345c-7f42-400b-a440-3b450eeaaf5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cbf77f74-38e4-4c09-b1ff-1d5ef1dc0bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cbf77f74-38e4-4c09-b1ff-1d5ef1dc0bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d490c3dd-8643-47b4-a174-e3bfbfad79b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d490c3dd-8643-47b4-a174-e3bfbfad79b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_61860a45-285c-4ace-9791-e8f8230f39b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_61860a45-285c-4ace-9791-e8f8230f39b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fe5d0062-190e-4a50-965c-22c1e2bac4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fe5d0062-190e-4a50-965c-22c1e2bac4c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8f7228f6-b651-4c27-acb5-d86edec03935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8f7228f6-b651-4c27-acb5-d86edec03935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6d4a43b9-90d9-4253-b73b-e7c6dc45b8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6d4a43b9-90d9-4253-b73b-e7c6dc45b8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0badb4e0-a749-4933-aca8-9b52b6c12847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44067d3e-fb12-4121-b2f0-d349b5db6156" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0badb4e0-a749-4933-aca8-9b52b6c12847" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3c350852-b7c3-462f-92f2-d3f2c09c1dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f1370d6a-dd72-405e-9fdb-af8df38eb48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3c350852-b7c3-462f-92f2-d3f2c09c1dc8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f1370d6a-dd72-405e-9fdb-af8df38eb48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c373903a-2c6c-48f1-a422-6cfece49e258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3c350852-b7c3-462f-92f2-d3f2c09c1dc8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c373903a-2c6c-48f1-a422-6cfece49e258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c9aca0b8-7186-49b4-b056-567906711370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_aa8cc6c5-bc0e-4a49-bb4b-3a1d8f8f20ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9aca0b8-7186-49b4-b056-567906711370" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_aa8cc6c5-bc0e-4a49-bb4b-3a1d8f8f20ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_201afe58-1150-463d-8ed1-a18e631af8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9aca0b8-7186-49b4-b056-567906711370" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_201afe58-1150-463d-8ed1-a18e631af8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_eea6eb2d-8b19-4028-9c3b-074575e77929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9aca0b8-7186-49b4-b056-567906711370" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_eea6eb2d-8b19-4028-9c3b-074575e77929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1d22dd34-2892-4a60-a7f0-9db645548895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9aca0b8-7186-49b4-b056-567906711370" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1d22dd34-2892-4a60-a7f0-9db645548895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_e73a2567-27af-4996-802f-71672f54c2db" xlink:href="sibn-20201231.xsd#sibn_DeferredTaxAssetsDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9aca0b8-7186-49b4-b056-567906711370" xlink:to="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_e73a2567-27af-4996-802f-71672f54c2db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesUncertainIncomeTaxPositionsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="sibn-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>sibn-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84ec410f-3815-4763-9bc2-b77d68e36727,g:546a3c6e-3b19-4bdc-9aac-42f0e40439c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://si-bone.com/role/Cover" xlink:type="simple" xlink:href="sibn-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/Cover" xlink:type="extended" id="if4ca16dcf44d4d38ba1699629241131f_Cover"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i4a0185d6c4ac4845bb27168529131967_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i56ba1e775f784a07ba258a7f1059e854_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i511fad0075df4936836c0864a5d7704d_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i6e0dd7bfe0cb4430bac0e79a537baf3e_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6c116a0c-5121-4b94-baaa-cb3599b8df82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6c116a0c-5121-4b94-baaa-cb3599b8df82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_91147c60-b105-42a8-8b87-3a2b1543ffa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_SharesOutstanding_91147c60-b105-42a8-8b87-3a2b1543ffa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbaa4eb3-71c4-4208-bcdf-2ab85761e171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockholdersEquity_bbaa4eb3-71c4-4208-bcdf-2ab85761e171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97e41510-ddde-4af4-a9dd-c54f6f7208d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97e41510-ddde-4af4-a9dd-c54f6f7208d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ce1cbc91-76f0-4086-b082-71b240c0f68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ce1cbc91-76f0-4086-b082-71b240c0f68b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f5b30d3-ba19-412f-8722-aa4d785e43a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f5b30d3-ba19-412f-8722-aa4d785e43a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58a8e8fd-f99d-43ec-a2f1-64755fcfb4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58a8e8fd-f99d-43ec-a2f1-64755fcfb4bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab86248e-5993-4f7a-9e14-c3245d440e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab86248e-5993-4f7a-9e14-c3245d440e95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_38b57f73-231e-4775-ad67-fc14d8d133e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_38b57f73-231e-4775-ad67-fc14d8d133e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_410bee5b-50b0-4ad1-be11-19117c3136de" xlink:href="sibn-20201231.xsd#sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_410bee5b-50b0-4ad1-be11-19117c3136de" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_16476e1b-cc8d-4790-9881-6ee21e219b66" xlink:href="sibn-20201231.xsd#sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_16476e1b-cc8d-4790-9881-6ee21e219b66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_898c8dfd-7bff-4f35-a48e-db8e6cbfad0e" xlink:href="sibn-20201231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_898c8dfd-7bff-4f35-a48e-db8e6cbfad0e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_37000aa8-f789-437c-849f-e2498c24b8e4" xlink:href="sibn-20201231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_37000aa8-f789-437c-849f-e2498c24b8e4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d62816dd-077d-4861-9952-8589153394bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d62816dd-077d-4861-9952-8589153394bb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_f7b38edd-6cf5-4863-8a14-b5421804be23" xlink:href="sibn-20201231.xsd#sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_f7b38edd-6cf5-4863-8a14-b5421804be23" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c11adb10-b5e1-432c-9716-3cd84f3e09d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c11adb10-b5e1-432c-9716-3cd84f3e09d6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_14b97aad-99c1-4df4-bf89-1bc63be98ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_14b97aad-99c1-4df4-bf89-1bc63be98ec3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_df37ca6f-15b3-467f-91d1-e5ead508afbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_df37ca6f-15b3-467f-91d1-e5ead508afbd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c232e2b-43b5-4fba-a6eb-652ed93fca1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_NetIncomeLoss_5c232e2b-43b5-4fba-a6eb-652ed93fca1f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_47f93dfa-ea7b-4ec6-ad84-32dd64c11068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04b950bb-5da8-49b3-8c0e-174c03e82ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6c116a0c-5121-4b94-baaa-cb3599b8df82" xlink:to="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e3e93f2-af95-4310-8321-f8e4a9df9ddd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:to="loc_us-gaap_EquityComponentDomain_5e3e93f2-af95-4310-8321-f8e4a9df9ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:to="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f5002eff-4278-4fd1-b3d8-aa968cc5848d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_CommonStockMember_f5002eff-4278-4fd1-b3d8-aa968cc5848d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3d0bc404-0697-4135-b083-d6947f0f93c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3d0bc404-0697-4135-b083-d6947f0f93c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_271194e0-4ec5-4b64-8e88-a489e2d18415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_271194e0-4ec5-4b64-8e88-a489e2d18415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8c122d4d-aba5-4047-8d4b-4f1abce9ea6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_RetainedEarningsMember_8c122d4d-aba5-4047-8d4b-4f1abce9ea6b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i7048766acfce4a6a9e243c003f7ec5b5_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://si-bone.com/role/TheCompanyandNatureofBusiness" xlink:type="simple" xlink:href="sibn-20201231.xsd#TheCompanyandNatureofBusiness"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/TheCompanyandNatureofBusiness" xlink:type="extended" id="i6c4a69fc094a4d188913f993abe0ad3b_TheCompanyandNatureofBusiness"/>
  <link:roleRef roleURI="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#TheCompanyandNatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails" xlink:type="extended" id="i0296f9008fa34bb28d5a2c81c4836bb4_TheCompanyandNatureofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f86c0011-0747-42e2-850b-849156edfa52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f86c0011-0747-42e2-850b-849156edfa52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7a64179c-6842-4456-89d9-ce0ace835364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7a64179c-6842-4456-89d9-ce0ace835364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_39fed3cb-e526-4905-8585-2dd23e23d3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_39fed3cb-e526-4905-8585-2dd23e23d3c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_0e4c5456-72d4-43d1-a1a9-d227c1588e6f" xlink:href="sibn-20201231.xsd#sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_0e4c5456-72d4-43d1-a1a9-d227c1588e6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AllocatedPublicOfferingCosts_6e718bda-297b-46bb-9d8f-2fa827027170" xlink:href="sibn-20201231.xsd#sibn_AllocatedPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_sibn_AllocatedPublicOfferingCosts_6e718bda-297b-46bb-9d8f-2fa827027170" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bc5272ae-26cb-41e0-b0ad-34f9410857ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bc5272ae-26cb-41e0-b0ad-34f9410857ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_015f1a59-b82a-425f-a8d3-e083b327b1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_us-gaap_IPOMember_015f1a59-b82a-425f-a8d3-e083b327b1c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_FollowOnPublicOfferingMember_c101812a-0520-478e-a856-b5202d382bb5" xlink:href="sibn-20201231.xsd#sibn_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_FollowOnPublicOfferingMember_c101812a-0520-478e-a856-b5202d382bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_d4de78fc-b540-4ff3-a616-1dedf198a665" xlink:href="sibn-20201231.xsd#sibn_FollowOnPublicOfferingAndSecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_d4de78fc-b540-4ff3-a616-1dedf198a665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_77ce0c0d-f4c9-4dc9-94eb-a4883afc0756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_us-gaap_OverAllotmentOptionMember_77ce0c0d-f4c9-4dc9-94eb-a4883afc0756" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SecondFollowOnPublicOfferingMember_765e2f28-4649-486c-95ef-c43e10ac309d" xlink:href="sibn-20201231.xsd#sibn_SecondFollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_SecondFollowOnPublicOfferingMember_765e2f28-4649-486c-95ef-c43e10ac309d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SecondaryOfferingMember_21a243f3-0606-4242-ab22-4b9e4157fdfe" xlink:href="sibn-20201231.xsd#sibn_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_SecondaryOfferingMember_21a243f3-0606-4242-ab22-4b9e4157fdfe" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i58de263465274a6ea4bde94455fdee64_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i1a04bcb0ad174ab5b8db1c5be85aa293_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="idb848ece301d4f99b6177155fc79e662_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" xlink:type="extended" id="i18dd57ebb1d047069b941a3df9608894_SummaryofSignificantAccountingPoliciesSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b068fb8-0f1f-479c-842b-ba2c69f1aa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b068fb8-0f1f-479c-842b-ba2c69f1aa03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_17624bd1-2e61-4e70-adb5-dda9024597c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:to="loc_us-gaap_Revenues_17624bd1-2e61-4e70-adb5-dda9024597c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:to="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5fa90a30-219d-49a0-a02a-e2b2c11275ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:to="loc_srt_SegmentGeographicalDomain_5fa90a30-219d-49a0-a02a-e2b2c11275ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:to="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6da75e3c-272a-4019-bb2a-b8c88e457e87" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:to="loc_country_US_6da75e3c-272a-4019-bb2a-b8c88e457e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e398f992-32f6-441a-a744-52f06140841f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:to="loc_us-gaap_NonUsMember_e398f992-32f6-441a-a744-52f06140841f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesLiquidityDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended" id="i377718d84c0e43bf98250642efe661e4_SummaryofSignificantAccountingPoliciesLiquidityDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i5ed6250c211c47eb95925bf5f51dd61b_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9caed9f4-fc5b-4f9e-91a7-115f762b4233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5f51d9bc-d582-4e16-9ec6-dacb9316b45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9caed9f4-fc5b-4f9e-91a7-115f762b4233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5f51d9bc-d582-4e16-9ec6-dacb9316b45e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9caed9f4-fc5b-4f9e-91a7-115f762b4233" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_064e0403-e32e-426a-81ee-b3edeadb6d72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_064e0403-e32e-426a-81ee-b3edeadb6d72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_9b475127-2fb4-4cae-a177-1f0834102b32" xlink:href="sibn-20201231.xsd#sibn_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_9b475127-2fb4-4cae-a177-1f0834102b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_73723d38-964c-47bc-b7fc-55d73bd31b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_73723d38-964c-47bc-b7fc-55d73bd31b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4e0702b6-28d0-4305-9f7f-98b3488ce5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4e0702b6-28d0-4305-9f7f-98b3488ce5ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:to="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_537cfa79-6476-469c-a7f9-3c36065cd3d7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:to="loc_srt_RangeMember_537cfa79-6476-469c-a7f9-3c36065cd3d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:to="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b059c00a-20d7-409f-b81d-8b04436b1950" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:to="loc_srt_MinimumMember_b059c00a-20d7-409f-b81d-8b04436b1950" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_818f6a7f-9b45-4a83-8718-c9f357b6714f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:to="loc_srt_MaximumMember_818f6a7f-9b45-4a83-8718-c9f357b6714f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended" id="i009a444d12544577814c858f77d09457_SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" id="i6657477914f9489991207bf7874f2666_SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_58e64233-bebf-478e-b752-9766fce8e2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_RevenueRecognitionStandardPaymentTerms_21150d6b-be71-4c3c-a186-7fc57672ae88" xlink:href="sibn-20201231.xsd#sibn_RevenueRecognitionStandardPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58e64233-bebf-478e-b752-9766fce8e2fb" xlink:to="loc_sibn_RevenueRecognitionStandardPaymentTerms_21150d6b-be71-4c3c-a186-7fc57672ae88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58e64233-bebf-478e-b752-9766fce8e2fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:to="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1308db84-51e9-405c-b195-4d6cf49a0b57_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:to="loc_srt_RangeMember_1308db84-51e9-405c-b195-4d6cf49a0b57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:to="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_844a1e1c-be58-4994-99eb-7c2a38f6c954" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:to="loc_srt_MinimumMember_844a1e1c-be58-4994-99eb-7c2a38f6c954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2db1fccb-8e25-461a-83bd-9fbf9b48bc91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:to="loc_srt_MaximumMember_2db1fccb-8e25-461a-83bd-9fbf9b48bc91" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesWarrantyProgramDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="extended" id="idc2c758b8f2c4a108902e6103fd0d206_SummaryofSignificantAccountingPoliciesWarrantyProgramDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="extended" id="i6668b052d6c743fc862381faa2b13a0e_SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecurities" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/MarketableSecurities" xlink:type="extended" id="i3df17ae6bc54492dbbe95b729370fa89_MarketableSecurities"/>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="extended" id="id14dc30cd39548b2910dcc078430bb08_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i9fd555a3010449b283b02d4b9b9458b2_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_cba2441b-0d36-49c5-9a89-5ec12aefedf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_cba2441b-0d36-49c5-9a89-5ec12aefedf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_3321f16d-6854-41f3-b0bf-1e9576b3964d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_cba2441b-0d36-49c5-9a89-5ec12aefedf5" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_3321f16d-6854-41f3-b0bf-1e9576b3964d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_5710b08b-d5b6-4d89-bad6-e2384ec8d564" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_5710b08b-d5b6-4d89-bad6-e2384ec8d564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_86d2f62a-034c-4be0-b5df-64234117b7c3" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_86d2f62a-034c-4be0-b5df-64234117b7c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_a8ce04c7-7091-42b2-837d-68edd890c592" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_a8ce04c7-7091-42b2-837d-68edd890c592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_97e80075-490f-48ad-907c-3bc264a3499a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_97e80075-490f-48ad-907c-3bc264a3499a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:href="sibn-20201231.xsd#sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_e2b78ab5-9281-4a78-b8fb-f92a51c61089" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_e2b78ab5-9281-4a78-b8fb-f92a51c61089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_7a172969-dd57-4068-b66e-a32178082882" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_7a172969-dd57-4068-b66e-a32178082882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_ea214c8c-c09d-4920-9b1e-64055a4b6bf5" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_ea214c8c-c09d-4920-9b1e-64055a4b6bf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b631a5b2-3921-48c9-8231-4c24f56978fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b631a5b2-3921-48c9-8231-4c24f56978fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_7257b0bd-996f-4fc0-82b6-92029987bf80" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesAmortizedCost_7257b0bd-996f-4fc0-82b6-92029987bf80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_02521eb2-ed94-426e-adb3-16d96bb3d889" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_02521eb2-ed94-426e-adb3-16d96bb3d889" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0123d24d-fea9-4659-83b6-92958d84b58c" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0123d24d-fea9-4659-83b6-92958d84b58c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesFairValue_8fcca066-a9f8-409a-a2a7-fd08726734f8" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesFairValue_8fcca066-a9f8-409a-a2a7-fd08726734f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b47a17c-4a5f-47fe-b103-fb3542559abb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b47a17c-4a5f-47fe-b103-fb3542559abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2474b399-d94d-4894-950a-08cc63f677ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2474b399-d94d-4894-950a-08cc63f677ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4b577f96-5e6c-487a-bd4a-0c483594d72c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4b577f96-5e6c-487a-bd4a-0c483594d72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_87f7741b-1c2c-4149-9e7e-0bba34c64099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_87f7741b-1c2c-4149-9e7e-0bba34c64099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03337bc1-b656-4de0-986a-7c0f07df429b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_CommercialPaperMember_03337bc1-b656-4de0-986a-7c0f07df429b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurement" xlink:type="extended" id="i7610dc74c1af4c63a29f5c7ea550dafc_FairValueMeasurement"/>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="extended" id="i58650a5aeddc4587b491dcc197c02cac_FairValueMeasurementTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="iefc707bb466046fea99e256b71f8cb43_FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e4077ab-969d-4f6d-a672-246c3b505abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0a79fbb6-f771-49e2-a694-312d63e4d92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e4077ab-969d-4f6d-a672-246c3b505abd" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0a79fbb6-f771-49e2-a694-312d63e4d92f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_028f7235-34b3-42f7-9375-d6163db1d8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0a79fbb6-f771-49e2-a694-312d63e4d92f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_028f7235-34b3-42f7-9375-d6163db1d8c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e4077ab-969d-4f6d-a672-246c3b505abd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3af6c565-3663-4787-9d49-8383a974e95c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3af6c565-3663-4787-9d49-8383a974e95c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab0a57b0-cd08-4ab4-a523-34e370d111cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab0a57b0-cd08-4ab4-a523-34e370d111cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bab01322-6be1-415a-98a8-6a4d0c9512fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab0a57b0-cd08-4ab4-a523-34e370d111cb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bab01322-6be1-415a-98a8-6a4d0c9512fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a82f625d-d435-4d22-b5a0-e3efb98643f3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a82f625d-d435-4d22-b5a0-e3efb98643f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c72d5f80-2051-4ee3-8e48-b25ceb1797d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c72d5f80-2051-4ee3-8e48-b25ceb1797d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6474665d-bbbe-4fd6-92f3-c7e07ef1846e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6474665d-bbbe-4fd6-92f3-c7e07ef1846e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e10b54e0-bf77-4a13-bb92-e2d922801407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e10b54e0-bf77-4a13-bb92-e2d922801407" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94a7a728-92f4-4f11-aaed-6a1bb715464d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94a7a728-92f4-4f11-aaed-6a1bb715464d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1cd8c72e-b6af-42b2-b37c-450118968348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1cd8c72e-b6af-42b2-b37c-450118968348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_02301eed-a7e0-44a7-b6fe-e9b8737fa101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_02301eed-a7e0-44a7-b6fe-e9b8737fa101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5810ceb2-f192-4006-9092-a922a808f074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5810ceb2-f192-4006-9092-a922a808f074" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_719e8fbc-b780-47e6-80f6-89321dcc2653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_CommercialPaperMember_719e8fbc-b780-47e6-80f6-89321dcc2653" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponents" xlink:type="extended" id="i4da3313189014be78bfe59ebaebc8579_BalanceSheetComponents"/>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="i876c23a28e9246e08a9db99d98d6213d_BalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended" id="idf792328fe1b4ee6965a2af86682a7cf_BalanceSheetComponentsPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0ab1fa6b-0e84-493c-a020-aad3e76965aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0ab1fa6b-0e84-493c-a020-aad3e76965aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_624bd60f-0574-4251-91d6-8ee1ccb221cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_624bd60f-0574-4251-91d6-8ee1ccb221cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_edc3e279-21d3-4bc4-b4cc-b2d162430b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_edc3e279-21d3-4bc4-b4cc-b2d162430b9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_33d8663f-b4b6-4af0-b3d2-796f4f45da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_Depreciation_33d8663f-b4b6-4af0-b3d2-796f4f45da9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_abeb45f3-a801-4fdc-8a7d-489316efc9fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_abeb45f3-a801-4fdc-8a7d-489316efc9fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_157766f5-a7d2-4e26-8f17-87443555046d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_157766f5-a7d2-4e26-8f17-87443555046d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6b42772c-26be-47c8-ad87-dabdc47dba54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_ConstructionInProgressMember_6b42772c-26be-47c8-ad87-dabdc47dba54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_dfc79877-4642-4d63-991d-84fd22bec903" xlink:href="sibn-20201231.xsd#sibn_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_dfc79877-4642-4d63-991d-84fd22bec903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b2d22a56-579a-4601-986f-2f21776f6a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b2d22a56-579a-4601-986f-2f21776f6a2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d69fc370-503a-4a3c-af13-91c3cbaceb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d69fc370-503a-4a3c-af13-91c3cbaceb25" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" xlink:type="extended" id="ice6ac7de848345fa825334f0a8a38c4d_BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsandContingencies" xlink:type="extended" id="i941922710f3a40269a3adaadd09a59ac_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="iffd9c3c0c8cc4dc6a72b7695bba4be13_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="id2641ee514124959837d352f75fdee12_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_3e0d80ef-b608-47a6-948d-6e4974798a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_3e0d80ef-b608-47a6-948d-6e4974798a7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b865a3f7-0eff-4077-abef-6ffad6420fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_PurchaseObligation_b865a3f7-0eff-4077-abef-6ffad6420fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_de73755e-9598-4380-b030-2ef9db013e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_de73755e-9598-4380-b030-2ef9db013e5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_25d0f58f-eff2-4fb0-beea-3743dfde7f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationReserveCurrent_25d0f58f-eff2-4fb0-beea-3743dfde7f6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17b602e3-dba5-49bc-87ee-0e2a6bb4a57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17b602e3-dba5-49bc-87ee-0e2a6bb4a57a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_704acfae-e407-4d14-8b5c-b66748db292c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_704acfae-e407-4d14-8b5c-b66748db292c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_27efe6fb-8418-489a-ae71-16a430e86a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationSettlementExpense_27efe6fb-8418-489a-ae71-16a430e86a55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_a09d5452-851c-4d19-88c8-595f50608377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationReserve_a09d5452-851c-4d19-88c8-595f50608377" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_94040272-90ac-4ef8-9594-fe1aa081d933" xlink:href="sibn-20201231.xsd#sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:to="loc_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_94040272-90ac-4ef8-9594-fe1aa081d933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_bebda192-cdbd-450e-9625-20ef76ee6350" xlink:href="sibn-20201231.xsd#sibn_LitigationTrebleDamagesPerViolationOfTCPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:to="loc_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_bebda192-cdbd-450e-9625-20ef76ee6350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_b65cb038-3548-4af0-a0c0-aff7d36ec032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_b65cb038-3548-4af0-a0c0-aff7d36ec032" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:to="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2110eb98-b53f-4d25-8d30-0a4d08e20a6b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:to="loc_srt_LitigationCaseTypeDomain_2110eb98-b53f-4d25-8d30-0a4d08e20a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_99a662b8-a830-4885-a59f-a7fe56411f9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:to="loc_srt_LitigationCaseTypeDomain_99a662b8-a830-4885-a59f-a7fe56411f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EricBFromerChiropracticIncClassActionMember_77450e79-02fd-4815-9496-60669a7c49ed" xlink:href="sibn-20201231.xsd#sibn_EricBFromerChiropracticIncClassActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_99a662b8-a830-4885-a59f-a7fe56411f9a" xlink:to="loc_sibn_EricBFromerChiropracticIncClassActionMember_77450e79-02fd-4815-9496-60669a7c49ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="i65f35742fbd243589cb5d4db003092b7_CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/Borrowings" xlink:type="simple" xlink:href="sibn-20201231.xsd#Borrowings"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/Borrowings" xlink:type="extended" id="i30931252454e41a48027f50275868677_Borrowings"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsTables" xlink:type="extended" id="i8ea74c6dafff4974ad3a6eea02403264_BorrowingsTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsSummaryofBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails" xlink:type="extended" id="i6fd519bf639447f28466761fea8d4ff4_BorrowingsSummaryofBorrowingsDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i2053a9d9d4aa4076baa3fcf1943df343_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6a58a90d-b9fa-4c60-94f4-bbc9bcea6931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6a58a90d-b9fa-4c60-94f4-bbc9bcea6931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_685d7ac0-af6a-40a3-b2b1-9ad102f1d4e2" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_685d7ac0-af6a-40a3-b2b1-9ad102f1d4e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5708bb7b-e931-4506-8d77-f8f690583030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5708bb7b-e931-4506-8d77-f8f690583030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_3abf7554-dc59-474e-b17e-3d33fb4d934c" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_3abf7554-dc59-474e-b17e-3d33fb4d934c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c8ce33d5-b30d-438a-a2cc-6709923cf3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c8ce33d5-b30d-438a-a2cc-6709923cf3c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_6c39e827-0ff2-4db3-ac24-7b9772a35e1b" xlink:href="sibn-20201231.xsd#sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_6c39e827-0ff2-4db3-ac24-7b9772a35e1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_70318e6f-7a7d-4ea0-9e04-13683f27bf91" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_70318e6f-7a7d-4ea0-9e04-13683f27bf91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c4e9cc99-374a-44dc-9557-6f2bcf997605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c4e9cc99-374a-44dc-9557-6f2bcf997605" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_04f6989a-0790-457e-b140-f0b4439adbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_04f6989a-0790-457e-b140-f0b4439adbf3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_575eb9b1-a5f3-4eb5-8216-3b5eb2110864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentTerm_575eb9b1-a5f3-4eb5-8216-3b5eb2110864" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_d3a0da85-ba97-4fcc-8d2e-1a7a679d970f" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_c7478402-3e3a-4167-b606-5d5cb10c5c25" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_c7478402-3e3a-4167-b606-5d5cb10c5c25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_553f4d18-a6e8-47d8-beff-eeb373d31db1" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_553f4d18-a6e8-47d8-beff-eeb373d31db1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_6725ca44-80ce-4b89-b32f-620424dabe50" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_6725ca44-80ce-4b89-b32f-620424dabe50" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_4e1db4ed-e664-4c66-a8e6-ae39fcc4e6d6" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_4e1db4ed-e664-4c66-a8e6-ae39fcc4e6d6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_28e85708-8104-4c80-9526-7956d99c1b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_28e85708-8104-4c80-9526-7956d99c1b3e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_41c771f2-3474-48a7-bad0-41de1c4a06d9" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_41c771f2-3474-48a7-bad0-41de1c4a06d9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_fd27f44d-b00e-41bb-ad68-a5f32528b529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_fd27f44d-b00e-41bb-ad68-a5f32528b529" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_ff88575b-50ff-408a-a03f-89e3872a272f" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_ff88575b-50ff-408a-a03f-89e3872a272f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_6dd829d1-703e-4c5a-b61b-da9f83842afc" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_6dd829d1-703e-4c5a-b61b-da9f83842afc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_d7521e83-8bd1-4982-b7d1-89325536a1b7" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_d7521e83-8bd1-4982-b7d1-89325536a1b7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_15abaabd-8889-4834-8d54-0d2bc38ac365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_15abaabd-8889-4834-8d54-0d2bc38ac365" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_b78a906c-a602-4397-bf98-859cd1e7dafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_b78a906c-a602-4397-bf98-859cd1e7dafa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_2fdf8389-ceda-45ad-b51e-901b0120e41d" xlink:href="sibn-20201231.xsd#sibn_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_2fdf8389-ceda-45ad-b51e-901b0120e41d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_789835d8-0617-4440-8b15-4c29991b566b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_789835d8-0617-4440-8b15-4c29991b566b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_291e596e-6ad8-4a92-98b0-804aa85dfebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_291e596e-6ad8-4a92-98b0-804aa85dfebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9d3b6ffa-3c18-42df-8503-2d90a8ddd8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_291e596e-6ad8-4a92-98b0-804aa85dfebb" xlink:to="loc_us-gaap_SecuredDebtMember_9d3b6ffa-3c18-42df-8503-2d90a8ddd8fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc5578eb-f9d1-4cb6-9c02-8a67de75b562_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc5578eb-f9d1-4cb6-9c02-8a67de75b562_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PharmakonTermLoanMember_609dae3f-3f5f-44d9-a6a5-536cfcf9373d" xlink:href="sibn-20201231.xsd#sibn_PharmakonTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:to="loc_sibn_PharmakonTermLoanMember_609dae3f-3f5f-44d9-a6a5-536cfcf9373d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SolarLoanAndSecurityAgreementMember_ad0152d7-fdb6-41e4-a5ca-c3ac6345f834" xlink:href="sibn-20201231.xsd#sibn_SolarLoanAndSecurityAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:to="loc_sibn_SolarLoanAndSecurityAgreementMember_ad0152d7-fdb6-41e4-a5ca-c3ac6345f834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PayrollProtectionProgramLoanCARESActMember_0ba0c0e7-cefc-463a-9e34-9272dcdcb153" xlink:href="sibn-20201231.xsd#sibn_PayrollProtectionProgramLoanCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:to="loc_sibn_PayrollProtectionProgramLoanCARESActMember_0ba0c0e7-cefc-463a-9e34-9272dcdcb153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdDomain_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b_default" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:to="loc_sibn_DebtCovenantThresholdDomain_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:to="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheOneMember_8a17bf3c-b95f-45d7-acda-44633b919818" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:to="loc_sibn_DebtCovenantTrancheOneMember_8a17bf3c-b95f-45d7-acda-44633b919818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheTwoMember_cca1d45f-b0ed-4b53-9b0e-483a6b002b67" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:to="loc_sibn_DebtCovenantTrancheTwoMember_cca1d45f-b0ed-4b53-9b0e-483a6b002b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheThreeMember_baa52722-00cb-4607-a474-3f8069fba6c5" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:to="loc_sibn_DebtCovenantTrancheThreeMember_baa52722-00cb-4607-a474-3f8069fba6c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:to="loc_srt_RangeMember_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:to="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_02225a5d-4d6b-44cf-ad99-a1cb5904b1ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:to="loc_srt_MinimumMember_02225a5d-4d6b-44cf-ad99-a1cb5904b1ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2292180-d56b-4180-8cf6-18e71b5e9583" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:to="loc_srt_MaximumMember_b2292180-d56b-4180-8cf6-18e71b5e9583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7e83db5f-5a21-41e3-8468-c1c63e736243_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:to="loc_us-gaap_VariableRateDomain_7e83db5f-5a21-41e3-8468-c1c63e736243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_80991bec-1b6e-4e4f-b168-855edc06c934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:to="loc_us-gaap_VariableRateDomain_80991bec-1b6e-4e4f-b168-855edc06c934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_VariableOptionOneMember_01f7e6d6-1099-442e-a72b-f286f7731319" xlink:href="sibn-20201231.xsd#sibn_VariableOptionOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_80991bec-1b6e-4e4f-b168-855edc06c934" xlink:to="loc_sibn_VariableOptionOneMember_01f7e6d6-1099-442e-a72b-f286f7731319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_b2a3646b-3548-44e0-92bf-9661f4295a77_default" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_b2a3646b-3548-44e0-92bf-9661f4295a77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenalty3148MonthsMember_fd7d8bb5-1f61-456f-a770-7822e72fd534" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenalty3148MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:to="loc_sibn_PrepaymentPenalty3148MonthsMember_fd7d8bb5-1f61-456f-a770-7822e72fd534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenalty4960MonthsMember_f0967e92-a387-40cc-9458-008b5e70cac0" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenalty4960MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:to="loc_sibn_PrepaymentPenalty4960MonthsMember_f0967e92-a387-40cc-9458-008b5e70cac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c249c3e3-f330-480d-83ce-b5d206146137_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c249c3e3-f330-480d-83ce-b5d206146137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_1b6a0aab-bcbb-48fc-9287-9f8b73479eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_1b6a0aab-bcbb-48fc-9287-9f8b73479eee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f6701260-8744-4e66-9faf-ee81ebe17d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f6701260-8744-4e66-9faf-ee81ebe17d86" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="extended" id="i2139adc1a25b4cfbb80b314fdbdc2c04_BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/Warrants" xlink:type="simple" xlink:href="sibn-20201231.xsd#Warrants"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/Warrants" xlink:type="extended" id="ifd7c6462fa8443a0bc499b1762cb4444_Warrants"/>
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#WarrantsTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/WarrantsTables" xlink:type="extended" id="id54cdeb3341a4fd2aa90248b5f1a5fa2_WarrantsTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#WarrantsIssuedandOutstandingDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails" xlink:type="extended" id="i8807df9a34fe443abb2035cda66ab499_WarrantsIssuedandOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa463e22-45ec-485e-b06c-9807dac49901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa463e22-45ec-485e-b06c-9807dac49901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_59491992-6aff-4ee2-aec3-c342e1048c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_59491992-6aff-4ee2-aec3-c342e1048c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_4a6a8f41-abfc-4c0f-9220-d0e343bca08b" xlink:href="sibn-20201231.xsd#sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_4a6a8f41-abfc-4c0f-9220-d0e343bca08b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_09833d83-13d5-4e24-a866-af118b4b3b83_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:to="loc_us-gaap_ClassOfStockDomain_09833d83-13d5-4e24-a866-af118b4b3b83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f2bf66c-0be3-4570-9eb3-311cae4bf4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:to="loc_us-gaap_ClassOfStockDomain_4f2bf66c-0be3-4570-9eb3-311cae4bf4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5d5248e3-98c4-4110-9e9e-97b04b2ae5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f2bf66c-0be3-4570-9eb3-311cae4bf4e8" xlink:to="loc_us-gaap_CommonClassAMember_5d5248e3-98c4-4110-9e9e-97b04b2ae5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_46899511-03c3-4cb6-8c92-b4a24e0f8ccc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_46899511-03c3-4cb6-8c92-b4a24e0f8ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_15785831-f7be-4b18-90c7-785145e6be6a" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedMarchFirstTwentySeventeenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_15785831-f7be-4b18-90c7-785145e6be6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_40a71897-8292-4f64-94ab-67d2ba0901d7" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_40a71897-8292-4f64-94ab-67d2ba0901d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_76eaff44-a6d1-4ee9-b29a-283e482980c9" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_76eaff44-a6d1-4ee9-b29a-283e482980c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_6e8507e2-40b8-4151-8143-e47e841e46ee" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_6e8507e2-40b8-4151-8143-e47e841e46ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_0d7a008b-ccaa-4102-a078-c8e1722b1dcb" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_0d7a008b-ccaa-4102-a078-c8e1722b1dcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_735932ec-4eaa-4a61-ba62-60bd248bac14" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_735932ec-4eaa-4a61-ba62-60bd248bac14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_CommonStockWarrantsMember_fe3dca4c-1e07-475e-99b7-df7ea1379a9f" xlink:href="sibn-20201231.xsd#sibn_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_CommonStockWarrantsMember_fe3dca4c-1e07-475e-99b7-df7ea1379a9f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommonandPreferredStock" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommonandPreferredStock"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommonandPreferredStock" xlink:type="extended" id="ia81516936cab44818e3f00bb1a135a54_CommonandPreferredStock"/>
  <link:roleRef roleURI="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommonandPreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="extended" id="i243387d1959d4eb7ad6ab8b1392fd2f2_CommonandPreferredStockNarrativeDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensation" xlink:type="extended" id="i4fd8e519209d442789fd84d4b319cecf_StockBasedCompensation"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationTables" xlink:type="extended" id="iebceba81482a494fac1b193c2914c974_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="icf4d861d1c69470bb1da1aaa183c0c46_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_23585843-51e1-486a-b960-e2faf07841ff" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_23585843-51e1-486a-b960-e2faf07841ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_63f0657e-217d-4e6d-875a-a1cf5a49c45d" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_63f0657e-217d-4e6d-875a-a1cf5a49c45d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_15c08dca-23a8-4732-ae6b-3364cabd1a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_15c08dca-23a8-4732-ae6b-3364cabd1a82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b951d05-0e62-4138-85f0-496a3b910de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b951d05-0e62-4138-85f0-496a3b910de5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_06bb4735-acf5-4cdb-9a24-398aeb722657" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_06bb4735-acf5-4cdb-9a24-398aeb722657" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_e9ceedb5-a3fe-4b4b-bb71-4ffae4bd4cc9" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_e9ceedb5-a3fe-4b4b-bb71-4ffae4bd4cc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_058d2adf-5ed1-49ea-a9f4-c91fd74c3201" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_058d2adf-5ed1-49ea-a9f4-c91fd74c3201" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_875c2d6e-8c6a-45c2-a341-cee4e373efdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_875c2d6e-8c6a-45c2-a341-cee4e373efdf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_54ba63ec-887c-4aa3-86bc-4d185ab6722f" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_54ba63ec-887c-4aa3-86bc-4d185ab6722f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1e9da7c8-8c8f-4101-8917-06343ecf9484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1e9da7c8-8c8f-4101-8917-06343ecf9484" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_694ec70c-367f-4e1e-989b-a1c780d9731d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_694ec70c-367f-4e1e-989b-a1c780d9731d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_92c32fba-38bb-492a-910d-9cc43bc2f02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_92c32fba-38bb-492a-910d-9cc43bc2f02d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7151dec-05a2-4293-913f-ac8071861c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7151dec-05a2-4293-913f-ac8071861c5b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_c2114e0f-c491-497f-b133-71a43f840485" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_c2114e0f-c491-497f-b133-71a43f840485" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dda6e996-a2a2-442d-841d-0cb687aee38c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dda6e996-a2a2-442d-841d-0cb687aee38c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c2cabd1f-5d46-4721-a728-82a92af3f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c2cabd1f-5d46-4721-a728-82a92af3f8e0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_5d086d9c-19d1-45bd-b153-df5744439bd3" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_5d086d9c-19d1-45bd-b153-df5744439bd3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_184cb850-fd61-45d0-ac85-20963eb79b85" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_184cb850-fd61-45d0-ac85-20963eb79b85" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2627180b-aee1-4ea9-8eca-2ca3aaef44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2627180b-aee1-4ea9-8eca-2ca3aaef44e7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_34c4936f-d162-484b-b064-24d262006aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_34c4936f-d162-484b-b064-24d262006aa5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2647c8ca-97bc-47d1-a67c-d385197cbbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2647c8ca-97bc-47d1-a67c-d385197cbbc7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_865af299-ef39-47cd-bfc1-b76d37aee612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_865af299-ef39-47cd-bfc1-b76d37aee612" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0855e826-818e-4684-b920-4be70a756cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0855e826-818e-4684-b920-4be70a756cc9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:to="loc_us-gaap_PlanNameDomain_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:to="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_A2018EquityIncentivePlanMember_5b011c9a-5118-469a-9647-17048b65f837" xlink:href="sibn-20201231.xsd#sibn_A2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:to="loc_sibn_A2018EquityIncentivePlanMember_5b011c9a-5118-469a-9647-17048b65f837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_A2018EmployeeStockPurchasePlanMember_b0143bf0-93b4-484d-b148-9a2d7c3b3cbc" xlink:href="sibn-20201231.xsd#sibn_A2018EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:to="loc_sibn_A2018EmployeeStockPurchasePlanMember_b0143bf0-93b4-484d-b148-9a2d7c3b3cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae0fd4ad-fa67-4316-b036-88741937a82a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae0fd4ad-fa67-4316-b036-88741937a82a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_IncentiveStockOptionMember_567547d5-2603-4bcb-8a6f-395503c72899" xlink:href="sibn-20201231.xsd#sibn_IncentiveStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:to="loc_sibn_IncentiveStockOptionMember_567547d5-2603-4bcb-8a6f-395503c72899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_NonqualifiedStockOptionMember_b2adfa61-a58d-4d27-8dae-c72d7ead6920" xlink:href="sibn-20201231.xsd#sibn_NonqualifiedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:to="loc_sibn_NonqualifiedStockOptionMember_b2adfa61-a58d-4d27-8dae-c72d7ead6920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4e77ec06-288a-4531-8683-3888885cb4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4e77ec06-288a-4531-8683-3888885cb4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e624478-20ec-40fa-ac6a-acea29265fd1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:to="loc_srt_RangeMember_7e624478-20ec-40fa-ac6a-acea29265fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:to="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_00c3cb70-e64e-44a8-a2fc-d60b27438b2a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:to="loc_srt_MinimumMember_00c3cb70-e64e-44a8-a2fc-d60b27438b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bdef4978-4036-43d2-80c0-995cd458d261" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:to="loc_srt_MaximumMember_bdef4978-4036-43d2-80c0-995cd458d261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f12e4b3f-6901-4c58-8917-fb982f43a5ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f12e4b3f-6901-4c58-8917-fb982f43a5ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58d6c4d0-1fb6-4db5-ae3c-4eac65eaddbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58d6c4d0-1fb6-4db5-ae3c-4eac65eaddbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_67f58b44-d091-4450-bd59-f6b6fbc359ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58d6c4d0-1fb6-4db5-ae3c-4eac65eaddbc" xlink:to="loc_us-gaap_SubsequentEventMember_67f58b44-d091-4450-bd59-f6b6fbc359ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="ic0033f88a8c54237bc3168312aff68fc_StockBasedCompensationStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" xlink:type="extended" id="i174b56a2b1c045c6b018312cf5c19295_StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a1084d22-9251-4556-97b8-e5221328da0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a1084d22-9251-4556-97b8-e5221328da0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e0b2e05-ce0b-4a2e-b92c-59f79d7e9dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e0b2e05-ce0b-4a2e-b92c-59f79d7e9dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f02e3ce6-9c33-49d7-80a6-70d1aa84a868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f02e3ce6-9c33-49d7-80a6-70d1aa84a868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_e6ea7ad2-86c3-4e26-bc19-746002939eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_e6ea7ad2-86c3-4e26-bc19-746002939eaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_b37431ee-31de-4469-9c53-2f733f50418a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_b37431ee-31de-4469-9c53-2f733f50418a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a4dad1bf-d18b-4770-9394-428f8ae9d1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a4dad1bf-d18b-4770-9394-428f8ae9d1c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d52b65ff-e5bb-458f-83a6-561d03353225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d52b65ff-e5bb-458f-83a6-561d03353225" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c4511f0-5de3-4f18-81b7-df86bdfc37bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c4511f0-5de3-4f18-81b7-df86bdfc37bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheOneMember_ff35c67e-5174-49c0-95f3-3cabcf5bdd9e" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheOneMember_ff35c67e-5174-49c0-95f3-3cabcf5bdd9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheTwoMember_f0c37703-e455-4458-9017-2009da47c6e0" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheTwoMember_f0c37703-e455-4458-9017-2009da47c6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheThreeMember_5bc2af1f-f804-4089-bf91-2d05935bad43" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheThreeMember_5bc2af1f-f804-4089-bf91-2d05935bad43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheFourMember_67a50ecc-c65f-41c3-b437-ff7a634dd87d" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheFourMember_67a50ecc-c65f-41c3-b437-ff7a634dd87d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheFiveMember_2db9b383-acc8-4e22-94f8-bdc7cf86f27c" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheFiveMember_2db9b383-acc8-4e22-94f8-bdc7cf86f27c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationValuationAssumptionsforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails" xlink:type="extended" id="i751e96a494744e87b84d63716f6de30a_StockBasedCompensationValuationAssumptionsforStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13ca4150-0500-4adf-ac94-621db8538444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13ca4150-0500-4adf-ac94-621db8538444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1a08ef6-ae63-4ddf-9f38-c2303576437d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1a08ef6-ae63-4ddf-9f38-c2303576437d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ff3419e-4fd8-4d6a-b223-c4767d308b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ff3419e-4fd8-4d6a-b223-c4767d308b02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1a3f1fe5-477d-4e8d-99b7-7fe5c9935c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1a3f1fe5-477d-4e8d-99b7-7fe5c9935c2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4530fafe-bfb3-4afb-adeb-ac8a6e6fbebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4530fafe-bfb3-4afb-adeb-ac8a6e6fbebf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_94769396-699b-4fea-99fe-c38c7454d51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_94769396-699b-4fea-99fe-c38c7454d51d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a14bc871-6293-44b1-8c40-63a21d4fdb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a14bc871-6293-44b1-8c40-63a21d4fdb07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e8eab3e-70e5-45c9-8dc8-01702b63e9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e8eab3e-70e5-45c9-8dc8-01702b63e9c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13ca4150-0500-4adf-ac94-621db8538444" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:to="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_149b8aa8-a136-46e8-8b64-c126c147db76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_149b8aa8-a136-46e8-8b64-c126c147db76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4256c1e8-d4ff-4cf6-94a0-bc0d13e0c672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4256c1e8-d4ff-4cf6-94a0-bc0d13e0c672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b91bdb2d-0b8d-4691-8269-9030960841f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4256c1e8-d4ff-4cf6-94a0-bc0d13e0c672" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b91bdb2d-0b8d-4691-8269-9030960841f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:to="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:to="loc_srt_RangeMember_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:to="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_15341b49-1f5c-47e7-8d3b-bae44a94ce83" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:to="loc_srt_MinimumMember_15341b49-1f5c-47e7-8d3b-bae44a94ce83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9eb29ba9-8c76-4c7d-b61e-22cf5e8a0420" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:to="loc_srt_MaximumMember_9eb29ba9-8c76-4c7d-b61e-22cf5e8a0420" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="i82a077088eee4c9d9dad3833396dc430_StockBasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64171527-4d5f-4149-88dc-9421bc99a4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64171527-4d5f-4149-88dc-9421bc99a4b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8a1462d0-46ae-4bb3-a0bf-1419dcb4ba8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8a1462d0-46ae-4bb3-a0bf-1419dcb4ba8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a88dd9be-7ee0-4c14-a8f2-d9545b5e463f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a88dd9be-7ee0-4c14-a8f2-d9545b5e463f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3825c06d-d539-46f4-bde1-9167c21d3b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3825c06d-d539-46f4-bde1-9167c21d3b11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_768f5694-b502-4b1b-8cae-3f552dc15ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2fe018a-c5b4-4f1c-a27e-d28f0890edaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2fe018a-c5b4-4f1c-a27e-d28f0890edaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b4d16fd-d31e-4d5c-ba5f-84ecbadda8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b4d16fd-d31e-4d5c-ba5f-84ecbadda8f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_08260552-6879-4473-917b-48cb9d25a661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_08260552-6879-4473-917b-48cb9d25a661" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_658e3f07-bf62-493b-8ca0-09b81661843d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_658e3f07-bf62-493b-8ca0-09b81661843d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef955074-f7d5-4c83-8542-0c0a2fd5e207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:to="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a537b13b-cf76-4ec2-bb73-7da500eda8ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a537b13b-cf76-4ec2-bb73-7da500eda8ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6acbaa03-43d9-43dc-a203-5946517110a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6acbaa03-43d9-43dc-a203-5946517110a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cd4d4f2f-ad94-4e65-813b-25a440e07779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6acbaa03-43d9-43dc-a203-5946517110a1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cd4d4f2f-ad94-4e65-813b-25a440e07779" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" xlink:type="extended" id="ice558ef0694f4a5fb524416d1d7ff3f9_StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e439c8ba-585b-463c-942d-17922e509d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e439c8ba-585b-463c-942d-17922e509d0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5317677d-4cc3-4907-9508-4594344887d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5317677d-4cc3-4907-9508-4594344887d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_76a62bd9-9134-4c39-a331-a052cb45980a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_76a62bd9-9134-4c39-a331-a052cb45980a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcea700d-bb32-4d45-8cc7-ffded044960e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcea700d-bb32-4d45-8cc7-ffded044960e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0c5c2452-2341-4fe1-9cdc-1ba101bac46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0c5c2452-2341-4fe1-9cdc-1ba101bac46a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87788eac-a1d7-4018-acd1-e22bd95d577e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87788eac-a1d7-4018-acd1-e22bd95d577e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:to="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aade97f3-1cc6-4003-ab0b-74fe8c811595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aade97f3-1cc6-4003-ab0b-74fe8c811595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ESPPPurchaseRightsMember_6cc7e202-20bc-4e7e-8cd1-f952722b253b" xlink:href="sibn-20201231.xsd#sibn_ESPPPurchaseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aade97f3-1cc6-4003-ab0b-74fe8c811595" xlink:to="loc_sibn_ESPPPurchaseRightsMember_6cc7e202-20bc-4e7e-8cd1-f952722b253b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:to="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17ee6e7d-d380-4d2a-8479-d0f76dbb8959_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:to="loc_srt_RangeMember_17ee6e7d-d380-4d2a-8479-d0f76dbb8959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:to="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a8e24159-4782-4ad5-836f-6b11762a06c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:to="loc_srt_MinimumMember_a8e24159-4782-4ad5-836f-6b11762a06c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eaf2b322-fc02-40b2-b151-87c3dbeb27ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:to="loc_srt_MaximumMember_eaf2b322-fc02-40b2-b151-87c3dbeb27ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i2a73b1d3565a4319b5d04d7604d7257f_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18115f77-85fb-4aa4-806b-33417377f6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fcc8fe5c-75af-4c9d-91b6-cda1098d5b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18115f77-85fb-4aa4-806b-33417377f6c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fcc8fe5c-75af-4c9d-91b6-cda1098d5b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18115f77-85fb-4aa4-806b-33417377f6c0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6086db67-89aa-48e3-9c6a-8409600f6aef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6086db67-89aa-48e3-9c6a-8409600f6aef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_334b4401-4970-41da-8bbe-15b0255e023d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_CostOfSalesMember_334b4401-4970-41da-8bbe-15b0255e023d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_008643a4-2436-4aec-a073-62b03c028cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_008643a4-2436-4aec-a073-62b03c028cbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_376b4ce8-35e2-4cff-bd96-2df93b86b0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_376b4ce8-35e2-4cff-bd96-2df93b86b0a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c507e480-9f1f-4e0c-8e3d-6b1eaf2c78b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c507e480-9f1f-4e0c-8e3d-6b1eaf2c78b8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sibn-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="extended" id="iab93681bb3704a578202ff2b6ea36b53_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" id="i5c7248382e364f1fb4dac580e676be12_EmployeeBenefitPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf1ba0af-b77f-4186-b9e0-56b8e637d2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf1ba0af-b77f-4186-b9e0-56b8e637d2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_3d61fcab-6665-40b3-a8c2-63b5a430a71f" xlink:href="sibn-20201231.xsd#sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_3d61fcab-6665-40b3-a8c2-63b5a430a71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3da3ef6d-33ba-430c-9d76-116ae3ba927c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3da3ef6d-33ba-430c-9d76-116ae3ba927c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:to="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_5e13426f-35d1-45ba-900e-a0835df73888_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:to="loc_us-gaap_RetirementPlanNameDomain_5e13426f-35d1-45ba-900e-a0835df73888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_df6f5ec4-8b25-41df-a424-6f3d3bed5e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:to="loc_us-gaap_RetirementPlanNameDomain_df6f5ec4-8b25-41df-a424-6f3d3bed5e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_Company401KPlanMember_8031ddd1-b091-4009-b009-2f00fbb4964a" xlink:href="sibn-20201231.xsd#sibn_Company401KPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_df6f5ec4-8b25-41df-a424-6f3d3bed5e1e" xlink:to="loc_sibn_Company401KPlanMember_8031ddd1-b091-4009-b009-2f00fbb4964a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStock"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStock" xlink:type="extended" id="i10c66052eacd4c0581d7623fc5b60c9d_NetLossPerShareofCommonStock"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended" id="i975cf51b859d4d5b8656fbd606bf9b5f_NetLossPerShareofCommonStockTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" xlink:type="extended" id="i294b4271c6694d9db8f229f610f57290_NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i66a4035a6e2948d8b411a11ef85f10dd_NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34dbd921-ba23-438c-bad7-7c8e5930138c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76e42915-814d-474b-af3f-2bcdf17dbf6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34dbd921-ba23-438c-bad7-7c8e5930138c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76e42915-814d-474b-af3f-2bcdf17dbf6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34dbd921-ba23-438c-bad7-7c8e5930138c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8053f96-8602-4072-80d5-d93ad90b5040_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8053f96-8602-4072-80d5-d93ad90b5040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_424286d2-e304-4276-ae30-39e6cfc45956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_424286d2-e304-4276-ae30-39e6cfc45956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9ab10d0b-eccc-45be-8123-f56eba2d7cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9ab10d0b-eccc-45be-8123-f56eba2d7cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareSubjectToRepurchaseMember_ebe42450-4267-4148-b121-628ba668a8b2" xlink:href="sibn-20201231.xsd#sibn_ShareSubjectToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_sibn_ShareSubjectToRepurchaseMember_ebe42450-4267-4148-b121-628ba668a8b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EmployeeStockPurchasePlanSharesMember_9fca7af8-2295-46c6-bc87-2d7583dff4b5" xlink:href="sibn-20201231.xsd#sibn_EmployeeStockPurchasePlanSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_sibn_EmployeeStockPurchasePlanSharesMember_9fca7af8-2295-46c6-bc87-2d7583dff4b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_CommonStockWarrantsMember_82f0be7c-0533-4af7-b0e9-d36d2a27cbf9" xlink:href="sibn-20201231.xsd#sibn_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_sibn_CommonStockWarrantsMember_82f0be7c-0533-4af7-b0e9-d36d2a27cbf9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxes" xlink:type="extended" id="i6254180e07a544d4a68a3ddb66bec795_IncomeTaxes"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesTables" xlink:type="extended" id="i449ff6925010420eadd31eb193e76984_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended" id="i1655b589477f493da8efee7cc975927e_IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="extended" id="i6fce2273ca4f411d967339bdd70718f7_IncomeTaxesComponentsofDeferredIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended" id="i1b34fb0c67c04823a8ee302fcc5c4112_IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" xlink:type="extended" id="ic7d2148dbb6640a9864e19fb0ee255a1_IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended" id="idc93d6bb898942618f5fe172e71e2567_IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i818dcb8cf604483cb6239d35bf10c402_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1b55ce47-4456-4285-9697-870e30257007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1b55ce47-4456-4285-9697-870e30257007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4e7ee76c-85a6-41cf-bedc-20f62f5eb463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4e7ee76c-85a6-41cf-bedc-20f62f5eb463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OperatingLossCarryforwardsLimited_fbd1c019-0826-4eb6-b1c0-df49f668f738" xlink:href="sibn-20201231.xsd#sibn_OperatingLossCarryforwardsLimited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_sibn_OperatingLossCarryforwardsLimited_fbd1c019-0826-4eb6-b1c0-df49f668f738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_02fea843-f0dd-4693-babf-8330c695bd54" xlink:href="sibn-20201231.xsd#sibn_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_02fea843-f0dd-4693-babf-8330c695bd54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_a2009f70-d498-4260-b5d8-72eb55382f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_a2009f70-d498-4260-b5d8-72eb55382f51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_92d312a2-cec6-4135-a420-30c8d7950195_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_92d312a2-cec6-4135-a420-30c8d7950195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_fb7b12f5-4f2f-4a14-a7de-01dcc4901ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:to="loc_us-gaap_DomesticCountryMember_fb7b12f5-4f2f-4a14-a7de-01dcc4901ec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_b0b683be-6edf-44e1-af36-eeeed3362edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_b0b683be-6edf-44e1-af36-eeeed3362edf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesUncertainIncomeTaxPositionsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="extended" id="i5b966d0efd4e4e1787fcce21584a7a2b_IncomeTaxesUncertainIncomeTaxPositionsDetails"/>
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="sibn-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="extended" id="ib00b185a0df744b98210b25cf5a9653a_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="id900d8cd32184d1882ebd2a3e5f3cbda_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4be24fca-f2c7-44f3-8097-1090622baade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4be24fca-f2c7-44f3-8097-1090622baade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_85c9a362-ea7e-486f-854c-d36e427c39ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_us-gaap_DueToAffiliateCurrent_85c9a362-ea7e-486f-854c-d36e427c39ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_RelatedPartyTransactionTermOfAgreement_0d4df277-7807-4ab3-b3cc-f032c577fb12" xlink:href="sibn-20201231.xsd#sibn_RelatedPartyTransactionTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_sibn_RelatedPartyTransactionTermOfAgreement_0d4df277-7807-4ab3-b3cc-f032c577fb12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5fc4b466-f22b-474e-8a16-6e0a0b4f8704_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:to="loc_us-gaap_RelatedPartyDomain_5fc4b466-f22b-474e-8a16-6e0a0b4f8704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_50474daf-ed81-498b-ba0f-60b63e78072f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:to="loc_us-gaap_RelatedPartyDomain_50474daf-ed81-498b-ba0f-60b63e78072f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5100ad4f-6b25-4d03-b026-4b0debbd24bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_50474daf-ed81-498b-ba0f-60b63e78072f" xlink:to="loc_srt_AffiliatedEntityMember_5100ad4f-6b25-4d03-b026-4b0debbd24bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bd893347-23c5-4cdd-b6bd-c9fa283cc666_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bd893347-23c5-4cdd-b6bd-c9fa283cc666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0697adef-b01d-4ece-acdb-f67c8605dd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0697adef-b01d-4ece-acdb-f67c8605dd54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DevelopmentAgreementMember_73c168c0-89c8-434d-9b31-ee59670f1f91" xlink:href="sibn-20201231.xsd#sibn_DevelopmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0697adef-b01d-4ece-acdb-f67c8605dd54" xlink:to="loc_sibn_DevelopmentAgreementMember_73c168c0-89c8-434d-9b31-ee59670f1f91" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>sibn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84ec410f-3815-4763-9bc2-b77d68e36727,g:546a3c6e-3b19-4bdc-9aac-42f0e40439c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d87753a-da55-4902-bc10-6bf7a294fb5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ed409144-c82b-448c-92e5-de8d45b88abd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_12bb2b40-f116-4444-a9f0-cc036dccc420_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2290b976-a2a7-4653-b038-ea1871533516_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_14d2ac69-ab42-4643-96dc-e9d72b895261_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_VestingOfEarlyExercisedStockOptions_da1b4872-1f0f-4814-ad16-42a9d228820e_terseLabel_en-US" xlink:label="lab_sibn_VestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised stock options</link:label>
    <link:label id="lab_sibn_VestingOfEarlyExercisedStockOptions_label_en-US" xlink:label="lab_sibn_VestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Of Early Exercised Stock Options</link:label>
    <link:label id="lab_sibn_VestingOfEarlyExercisedStockOptions_documentation_en-US" xlink:label="lab_sibn_VestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of Early Exercised Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_VestingOfEarlyExercisedStockOptions" xlink:href="sibn-20201231.xsd#sibn_VestingOfEarlyExercisedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_VestingOfEarlyExercisedStockOptions" xlink:to="lab_sibn_VestingOfEarlyExercisedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01888589-6114-4871-a4ae-f9755991bb8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_566b0cf6-aac3-4d75-8af7-39c65cd497e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5f9aedb6-4e47-4a71-9805-1eae9ad5cbf4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e14be301-392e-4f60-b9a0-7380768510fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_adf3bdf2-2e57-4031-aa4a-b8e6d57c11fa_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9740d37e-a8c9-42e9-8974-d06d4220aab0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_526dda87-adfa-41fb-8518-b4b3f9eaa600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6ccfc6e0-ca10-4bda-b75e-4aab2cbba4b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_e67e65de-cf10-4c66-8b6a-17571cb6a66d_negatedTerseLabel_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of unvested early exercised stock options</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_label_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_documentation_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:href="sibn-20201231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:to="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e970db96-ddee-4728-b26a-d816f8b424ff_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement charges expensed</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_621d6c53-a6e0-4d2b-8032-0a1497de79f2_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of option as percent of fair market value (percent)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f34fac2f-0b54-4c0b-916c-b71710c6cf4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_OptionsTrancheFourMember_6a4754df-a15d-4838-af5a-7af693b9a815_terseLabel_en-US" xlink:label="lab_sibn_OptionsTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$5.32-$20.51</link:label>
    <link:label id="lab_sibn_OptionsTrancheFourMember_label_en-US" xlink:label="lab_sibn_OptionsTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Four [Member]</link:label>
    <link:label id="lab_sibn_OptionsTrancheFourMember_documentation_en-US" xlink:label="lab_sibn_OptionsTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheFourMember" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OptionsTrancheFourMember" xlink:to="lab_sibn_OptionsTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c013b6d7-dde5-4901-99f1-9d57f67bf15b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16c807b-e0b6-413b-bf92-2c62d234367e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32e2c276-09e1-499a-8826-62814e7ece43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e278f9ec-f31b-461f-a3ca-73c3f9330206_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_88d1f5b9-4189-41c5-9b29-7923b35aabdd_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_06d7f093-fe3e-409b-91ad-e308f96afe83_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt financing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1a6d40dc-5948-43cb-92ef-852e3e36b59d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_9ede3850-1879-4ba3-ae90-558cac9afad6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_80bfacfa-0434-439a-bf8b-bb9655b031a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_535febdb-cae0-4321-82ab-fb962a8fc3e0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_8fa6d93d-5304-4719-b79a-76c6283dc6fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_ed8e4ee5-98ab-4cbb-b7d5-9e284bfa234a_terseLabel_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Prepayment Penalty, Period [Domain]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_label_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Prepayment Penalty, Period [Domain]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_documentation_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:to="lab_sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d10d874-22c0-46f9-8563-aa45bf184f86_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b535168a-a43f-4534-94ab-4352986ecc1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e2ac041f-7246-47a7-89f9-459fc8dfa248_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_3c577234-7133-47fe-9e6e-f8ffe7768a3d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_61d4d13f-b3b6-43b9-8c81-f5c82077be9d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_7de4b991-db78-4464-8b2a-8be378329f9f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8681dec6-0eb1-4301-98e1-25d7b53d3713_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3f75d244-69b6-486c-a144-db5d25f6eafd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax valuation allowance (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_15a292f6-d16e-463b-acc1-9f017832e777_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65c15bbd-be8c-452b-9fc8-145611b98d46_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5e9d22f1-3f2c-4a67-a8d0-6d106c2ae3ae_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_577a8719-27be-4bd8-ae25-5f2e8e0e92b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0b66eec8-fa6f-405e-873c-bca0085a1697_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2fcfb6d7-37a6-42c3-baed-c9cce32d28a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f40c9624-8cdb-45f0-9649-81fe477b0673_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fee88960-479c-48d6-b323-ee4152603b9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ed99248-c47d-49b3-b679-48744980847d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_82fbd05d-2205-45b5-b07c-b6b5ecbd285d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1a84e31c-1fa4-4221-96ea-2f2daee60bfb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_918c8131-27b1-44a3-90d4-93c6d2862f41_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_EmployeeStockPurchasePlanSharesMember_1a78e79d-8f3b-4ec0-bd17-1b17e58f4b3b_terseLabel_en-US" xlink:label="lab_sibn_EmployeeStockPurchasePlanSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase rights</link:label>
    <link:label id="lab_sibn_EmployeeStockPurchasePlanSharesMember_label_en-US" xlink:label="lab_sibn_EmployeeStockPurchasePlanSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Shares [Member]</link:label>
    <link:label id="lab_sibn_EmployeeStockPurchasePlanSharesMember_documentation_en-US" xlink:label="lab_sibn_EmployeeStockPurchasePlanSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EmployeeStockPurchasePlanSharesMember" xlink:href="sibn-20201231.xsd#sibn_EmployeeStockPurchasePlanSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_EmployeeStockPurchasePlanSharesMember" xlink:to="lab_sibn_EmployeeStockPurchasePlanSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtCovenantThresholdAxis_ee35af45-f0d0-4240-94f1-7516cf35f120_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Threshold [Axis]</link:label>
    <link:label id="lab_sibn_DebtCovenantThresholdAxis_label_en-US" xlink:label="lab_sibn_DebtCovenantThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Threshold [Axis]</link:label>
    <link:label id="lab_sibn_DebtCovenantThresholdAxis_documentation_en-US" xlink:label="lab_sibn_DebtCovenantThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdAxis" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantThresholdAxis" xlink:to="lab_sibn_DebtCovenantThresholdAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_455f4f22-c11f-44f0-9abf-a4abcfba5890_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2a474fda-e5dd-4b0f-b78b-7ba62fda88b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_2bb2ee2d-fc25-41b7-940a-7f6225da8560_totalLabel_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_label_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Noncurrent, Amortized Cost Basis</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_documentation_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Noncurrent, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" xlink:to="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b164e94f-1b10-4ae5-ae01-16ed6db3ab29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_554bb4bf-a2d2-4e8d-8791-c667f5eb5906_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ea0d129-d76d-45be-96b4-dcb05d40122b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ac4ea229-3522-4bdb-942e-5d9d156b8478_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_1562b63e-0d57-49ed-af0c-4638c1ab46d8_terseLabel_en-US" xlink:label="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Device Excise Tax</link:label>
    <link:label id="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Device Excise Tax Policy [Policy Text Block]</link:label>
    <link:label id="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Device Excise Tax Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:href="sibn-20201231.xsd#sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:to="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_2fb2f5e3-85b1-456a-9898-63dd001a489f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_62da3d78-8aff-455d-bd7f-0eb9e360c7a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_6599f4d1-3432-4e3e-bafc-234ff6f1c1bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_83f5ec4a-2946-4aa4-8894-6f2146ef80bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_47ee4695-2202-4b54-b8ab-db8ac13b07bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, lower limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_85c7e33e-87fd-492e-bc76-80637d42d753_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_fb4c5d6f-950a-4b07-83ad-809f99de8f4e_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in shares reserved as percentage of prior year-end shares outstanding (percent)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved As Percentage Of Prior Year Shares Outstanding</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Reserved As Percentage Of Prior Year Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_1f7a329d-acfa-4b97-bb92-a9a138fa46ad_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant minimum cash balance</link:label>
    <link:label id="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_label_en-US" xlink:label="lab_sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash Balance</link:label>
    <link:label id="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:to="lab_sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_c4b8666c-400e-4722-8ea8-7105c51cbefe_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in shares reserved, maximum (in shares)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved, Maximum Shares</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved, Maximum Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d3fb0d11-f8e7-477f-be6d-fe894f2354ed_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bacf046a-7a80-4266-bb13-c2d8ce575850_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_449fdefe-211e-4920-9299-add53a0acdca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of prepayment penalty and lender fees</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c4d95b78-1e46-4ae9-98e2-5951a9d1b98c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6689e53c-ba37-44db-83ce-11bb3f67cddb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c91e48b4-8913-487a-bd33-1527def44b38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled and forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_OperatingLossCarryforwardsLimited_b3583b44-716d-43e2-8682-3d0f58ac0b7c_terseLabel_en-US" xlink:label="lab_sibn_OperatingLossCarryforwardsLimited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited net operating loss carryforwards</link:label>
    <link:label id="lab_sibn_OperatingLossCarryforwardsLimited_label_en-US" xlink:label="lab_sibn_OperatingLossCarryforwardsLimited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Limited</link:label>
    <link:label id="lab_sibn_OperatingLossCarryforwardsLimited_documentation_en-US" xlink:label="lab_sibn_OperatingLossCarryforwardsLimited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OperatingLossCarryforwardsLimited" xlink:href="sibn-20201231.xsd#sibn_OperatingLossCarryforwardsLimited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OperatingLossCarryforwardsLimited" xlink:to="lab_sibn_OperatingLossCarryforwardsLimited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_711a01b1-8e47-48a8-97f9-80e00ccd1a76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_158929f8-036d-4edc-9938-39298f42ca31_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0a1112d2-28a4-41a6-9fdf-f06c97d17cf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_RevenueRecognitionStandardPaymentTerms_46f196bc-88b1-4be0-a4ce-3b3a9db40bd7_terseLabel_en-US" xlink:label="lab_sibn_RevenueRecognitionStandardPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard payment terms per agreements (in days)</link:label>
    <link:label id="lab_sibn_RevenueRecognitionStandardPaymentTerms_label_en-US" xlink:label="lab_sibn_RevenueRecognitionStandardPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Standard Payment Terms</link:label>
    <link:label id="lab_sibn_RevenueRecognitionStandardPaymentTerms_documentation_en-US" xlink:label="lab_sibn_RevenueRecognitionStandardPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Standard Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_RevenueRecognitionStandardPaymentTerms" xlink:href="sibn-20201231.xsd#sibn_RevenueRecognitionStandardPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_RevenueRecognitionStandardPaymentTerms" xlink:to="lab_sibn_RevenueRecognitionStandardPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9f38d1e5-3472-461f-b054-c6345a63e16c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9fa3b800-6677-4190-98bc-5ead83c0701d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_23d4e72e-834f-4966-8abb-2e8f5b9a53ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_250f65c7-1ede-4b90-8e47-3d027a3d424d_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_0f3b3d0a-cb28-415e-8e5d-ef421bec713b_totalLabel_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_label_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Current, Amortized Cost Basis</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_documentation_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Current, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" xlink:to="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_1aba36fd-de57-4310-b25a-cfcaade79c0e_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued 12/22/2016</link:label>
    <link:label id="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_label_en-US" xlink:label="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued December Twenty-Second Twenty Sixteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued December Twenty-Second Twenty Sixteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:to="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3f6f1c9a-0d4b-42e3-8b86-842d2d48d03b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_443053ca-4bc5-4a78-99af-8530158e45e9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct_a53e3dc4-f9c3-475f-ab58-4a88601f58ca_terseLabel_en-US" xlink:label="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred liability for social security taxes, CARES Act</link:label>
    <link:label id="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct_label_en-US" xlink:label="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:label id="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct_documentation_en-US" xlink:label="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct" xlink:href="sibn-20201231.xsd#sibn_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct" xlink:to="lab_sibn_SocialSecurityTaxEmployerDeferralCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ceaeef67-1d6b-4cb2-a600-ae83110da491_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f722ba2f-8041-482f-b0dd-c36ef97a744f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8c91caae-34a9-4b36-8637-197f01fbe175_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3c8beb7d-30c7-4fae-aa2a-3fd902fb83c3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a72b567d-7cfc-41cc-9ad6-b941dd945978_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_cdc95dad-04a8-411f-a18e-cca3190ffcff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt maturity term (in months)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_346090c8-bbdc-406c-8dab-f70262ac25b9_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5e0303e1-ae3f-4e8e-86b7-36c26e2200ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_fabfe879-1530-4a3c-ad69-6ae325e77595_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty Program</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtCovenantThresholdDomain_c05e2ea3-0578-418f-bfcd-5b15a694db44_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Threshold [Domain]</link:label>
    <link:label id="lab_sibn_DebtCovenantThresholdDomain_label_en-US" xlink:label="lab_sibn_DebtCovenantThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Threshold [Domain]</link:label>
    <link:label id="lab_sibn_DebtCovenantThresholdDomain_documentation_en-US" xlink:label="lab_sibn_DebtCovenantThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdDomain" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantThresholdDomain" xlink:to="lab_sibn_DebtCovenantThresholdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d567a998-1165-4935-a1a0-2a546d620b1c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3b3c6a5f-45d0-4a8e-a0c6-a8f34971d75b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_87d72182-4fd3-4a53-9fc1-8e5db98dc4b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b9a9fd68-9956-4fb2-92b7-4fe85c9f95eb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price&#160;per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtCovenantTrancheOneMember_171123ab-307b-44f4-b121-80f91ea83b7f_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche One</link:label>
    <link:label id="lab_sibn_DebtCovenantTrancheOneMember_label_en-US" xlink:label="lab_sibn_DebtCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche One [Member]</link:label>
    <link:label id="lab_sibn_DebtCovenantTrancheOneMember_documentation_en-US" xlink:label="lab_sibn_DebtCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheOneMember" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantTrancheOneMember" xlink:to="lab_sibn_DebtCovenantTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_ad64c796-7ae0-46b2-a051-67cfd806afff_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_9602cd83-c8b4-47e2-969f-995c40d8208d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_cb60d07a-56e1-4d29-8eb1-9adb904e4a84_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3ba09416-9d2b-43a6-bc69-1092824660d1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1499948b-832b-4f72-a432-6d52ecda0248_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6f02d094-2793-49c5-ab4f-b6a8296809ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0a91674b-74fc-40d2-b55c-64fda494ff07_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3d55aa56-97db-4000-a418-853497c88c08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d096b13-d95a-4029-9b0e-f06e6db903d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_PrepaymentPenalty3148MonthsMember_fb9010be-16d5-44cc-b1cd-c627df1d8e92_terseLabel_en-US" xlink:label="lab_sibn_PrepaymentPenalty3148MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty, 31-48 Months</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty3148MonthsMember_label_en-US" xlink:label="lab_sibn_PrepaymentPenalty3148MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty, 31-48 Months [Member]</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty3148MonthsMember_documentation_en-US" xlink:label="lab_sibn_PrepaymentPenalty3148MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty, 31-48 Months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenalty3148MonthsMember" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenalty3148MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PrepaymentPenalty3148MonthsMember" xlink:to="lab_sibn_PrepaymentPenalty3148MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_086362a6-1053-45b7-96e8-302336e04383_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_66983ead-3984-4b87-bda4-4bbaf1b1f324_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8e16ab24-39b1-4db5-b006-3f75b153b138_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c5082583-4b78-413e-a74e-1f2490ee98e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_c02dab18-ed16-4cf3-a9bb-4230df802347_negatedTerseLabel_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_34a83464-be34-4660-ac27-b60f16ba9594_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_80ae1091-0d3b-4880-a23d-820a9e8109d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes option-pricing model assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6156617d-9490-488b-b1d5-359fc3313f16_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1035a0e1-4829-45f5-85c5-7d4c1be5d05b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3a1c2482-badb-4f81-9733-82f767cd7e0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_2dc2ef53-bf1e-42c6-94f0-5acdb82b5523_totalLabel_en-US" xlink:label="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax</link:label>
    <link:label id="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_label_en-US" xlink:label="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance</link:label>
    <link:label id="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_documentation_en-US" xlink:label="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:href="sibn-20201231.xsd#sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:to="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_64860a3d-2dbb-4561-89dd-c7fff2b295bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_903f324d-91fd-4ab4-a3fb-dce86971c34c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd4729cf-942d-4975-8199-e7b8f965f715_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0ac6ba00-ac8c-4a3d-8c50-ac56ab51f2db_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_86ff7db1-29ae-4624-90e6-7dd57279b308_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_d974a7d4-727a-4839-8d25-245a1ba93d90_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs to defend lawsuits or settle claims</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3dbd5e4b-7b93-4c15-b76e-f68c01b0ef2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1c2dba10-1230-4379-8b40-0c6fcd3f9402_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_439e1148-09c7-4e32-871f-9b7d21fd2c4d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f690b0da-42e6-43a9-91e7-94f5e3d16dd8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_71d21013-c325-48f3-836d-60ff1d06bc66_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_EricBFromerChiropracticIncClassActionMember_23798db6-9ac2-49cc-99a0-d4d65d22b422_terseLabel_en-US" xlink:label="lab_sibn_EricBFromerChiropracticIncClassActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class action Eric B. Fromer Chiropractic Inc.</link:label>
    <link:label id="lab_sibn_EricBFromerChiropracticIncClassActionMember_label_en-US" xlink:label="lab_sibn_EricBFromerChiropracticIncClassActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric B Fromer Chiropractic Inc Class Action [Member]</link:label>
    <link:label id="lab_sibn_EricBFromerChiropracticIncClassActionMember_documentation_en-US" xlink:label="lab_sibn_EricBFromerChiropracticIncClassActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric B Fromer Chiropractic Inc Class Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EricBFromerChiropracticIncClassActionMember" xlink:href="sibn-20201231.xsd#sibn_EricBFromerChiropracticIncClassActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_EricBFromerChiropracticIncClassActionMember" xlink:to="lab_sibn_EricBFromerChiropracticIncClassActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50bfe97f-9d1a-4c89-b54e-379f41c15a38_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_42f687af-54be-4775-b305-f5cdd490431b_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued 3/1/2017</link:label>
    <link:label id="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_label_en-US" xlink:label="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued March First Twenty Seventeen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued March First Twenty Seventeen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedMarchFirstTwentySeventeenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:to="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_3940dc08-13d6-41f6-b24c-f80a47b972aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_9850f643-b50c-475d-a50d-f229783801e4_negatedTerseLabel_en-US" xlink:label="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of unvested early exercised stock options</link:label>
    <link:label id="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_label_en-US" xlink:label="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Unvested Early Exercised Stock Options</link:label>
    <link:label id="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_documentation_en-US" xlink:label="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Unvested Early Exercised Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:href="sibn-20201231.xsd#sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:to="lab_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_70205ab4-c91a-465f-bf81-5edd0bfeed8d_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_b2fd2b9b-cec2-4a7d-9558-f2c7d16d84df_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee as percentage of aggregate principal amount (percent)</link:label>
    <link:label id="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_label_en-US" xlink:label="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Amount As Percentage Of Aggregate Principal</link:label>
    <link:label id="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Amount As Percentage Of Aggregate Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" xlink:to="lab_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0e05a2b6-f9a3-407b-9dbd-60d958991c27_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_43be9cc0-0936-4c59-a3f2-20fd19b99e14_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_89d511f5-c280-41c9-a768-6514c8053c7a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of PPP loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_a814a68e-969f-4c7b-b016-b8398755634b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_76f9f14b-9be6-4361-bdda-0c7bf15e4c9e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_6ef3469c-cabe-4398-b307-20a77a2a4e55_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_deca9013-1e55-473f-a657-b2da3ffb2962_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_ec33c5b7-fa85-4b26-8fb7-ab480e96858f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f7f42038-d3c7-4a12-b239-3dd202e3ff1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5a8de30-3a67-400c-b783-4bcd0b6979f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_83abd30e-f680-4367-a703-c0fc8db3c7ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_beb9621c-5304-400b-ba22-e85d378fe003_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4427cc8c-779a-4680-a9ac-d9a2f35a8fe7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fae825db-6511-4c2c-a32e-83743f33566a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e3fa7082-aedc-4c35-bafc-47e9c10466eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtCovenantTrancheThreeMember_37db1dd2-b167-4219-8dbc-ed506bbae482_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche Three</link:label>
    <link:label id="lab_sibn_DebtCovenantTrancheThreeMember_label_en-US" xlink:label="lab_sibn_DebtCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche Three [Member]</link:label>
    <link:label id="lab_sibn_DebtCovenantTrancheThreeMember_documentation_en-US" xlink:label="lab_sibn_DebtCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheThreeMember" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantTrancheThreeMember" xlink:to="lab_sibn_DebtCovenantTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_e964ebaf-f5be-4ec4-8bef-77e3b13e745e_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2d52e1d8-0989-45a6-848a-d93a52633c58_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_68cdee0b-83c6-4277-b180-3fdbfadfff22_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_SecondFollowOnPublicOfferingMember_11bc2c82-2731-485c-a9a0-35e5200571c3_terseLabel_en-US" xlink:label="lab_sibn_SecondFollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second follow-on public offering</link:label>
    <link:label id="lab_sibn_SecondFollowOnPublicOfferingMember_label_en-US" xlink:label="lab_sibn_SecondFollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Follow On Public Offering [Member]</link:label>
    <link:label id="lab_sibn_SecondFollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_sibn_SecondFollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Follow On Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SecondFollowOnPublicOfferingMember" xlink:href="sibn-20201231.xsd#sibn_SecondFollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SecondFollowOnPublicOfferingMember" xlink:to="lab_sibn_SecondFollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_657ef403-06a8-4619-ae1e-8f8519ea8543_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_018e9664-67cf-4b10-9a7b-a4988f661429_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_A2018EquityIncentivePlanMember_3a950a91-53dd-4cf4-927a-5a71c1b7f8dd_terseLabel_en-US" xlink:label="lab_sibn_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_sibn_A2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_sibn_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_sibn_A2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_sibn_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2018 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_A2018EquityIncentivePlanMember" xlink:href="sibn-20201231.xsd#sibn_A2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_A2018EquityIncentivePlanMember" xlink:to="lab_sibn_A2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7a732080-f795-49d5-8121-1c2ba5e09dfd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b090b64f-fe6d-445d-8cd7-e530f3d958a3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_35c655bb-a733-4294-bed6-a30b5dc4b7b6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c5dea524-b64f-4074-81fd-52789887b0a9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b20c3524-730d-46eb-b449-c61ddc6ef14a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_2d9cdf8e-6647-4649-a4f3-867799287047_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued 11/9/2015</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_label_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued November Ninth Twenty Fifteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued November Ninth Twenty Fifteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:to="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_09f13338-5dac-4b3d-9f83-a5975514509a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce68df15-ebf6-4775-aa9e-87476f209663_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ef03a751-c1fa-4f98-a2f5-34b563900514_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6c44e30c-2377-429c-a0ba-bb6c5b2eaab7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities and Other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b202ce30-2208-4f9a-a6e7-51de0ba4089d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1037a75a-71e1-4ae7-bea2-f35661671f02_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_028c769f-ba01-458d-be47-186cc0774e4a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b0e9cfe5-3eb9-4c98-80f4-1165f4ac5c23_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6aa76b5c-d4b6-4220-857e-e4ba862f3421_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_0c908e30-3a86-4368-91eb-1a7abe302379_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_933718fd-b0af-42b6-8939-7b44b3639cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_849edf13-ab41-46bc-80ac-9ab0d05544df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_eed873bf-3c29-41a6-866a-f0b80c93e9d1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain income tax positions [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0e31f22a-59cc-49cf-a32d-8f748a8664fb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3710706e-f5c3-4191-8f0e-8caba6c370c1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6b05aff7-fcc7-48ad-9d10-918c6d600325_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_429b8bf4-a0cc-4163-8a73-13ac1377008a_terseLabel_en-US" xlink:label="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty and lender fees on debt extinguishment</link:label>
    <link:label id="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_label_en-US" xlink:label="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty And Lender Fees In Extinguishment Of Debt</link:label>
    <link:label id="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty And Lender Fees In Extinguishment Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" xlink:to="lab_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1be53921-775f-4f97-81d1-dc968394accb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_SalesCreditReservePeriod_ecd6a86c-2379-43a7-9309-9da0f962047b_terseLabel_en-US" xlink:label="lab_sibn_SalesCreditReservePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales credit reserve term (in years)</link:label>
    <link:label id="lab_sibn_SalesCreditReservePeriod_label_en-US" xlink:label="lab_sibn_SalesCreditReservePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Credit Reserve Period</link:label>
    <link:label id="lab_sibn_SalesCreditReservePeriod_documentation_en-US" xlink:label="lab_sibn_SalesCreditReservePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Credit Reserve Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SalesCreditReservePeriod" xlink:href="sibn-20201231.xsd#sibn_SalesCreditReservePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SalesCreditReservePeriod" xlink:to="lab_sibn_SalesCreditReservePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_67507fb3-9c5a-45e9-afe4-80ce5d36e544_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PPP loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_846bc1ee-f339-49b6-962c-1e3ebf73dff2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, expected period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_668391ea-e1b8-46f6-979c-ebb4877852b8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_1a361271-79c5-452a-a4c5-a123b4c1b85d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b4d68182-1765-4fbc-a776-db52448bd2fe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life, options vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dfe5a6e3-3f4e-4364-8f62-c85c9f192f95_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_Company401KPlanMember_241c5cce-c2be-4308-9770-13ab4b6bd5ae_terseLabel_en-US" xlink:label="lab_sibn_Company401KPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_sibn_Company401KPlanMember_label_en-US" xlink:label="lab_sibn_Company401KPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company 401K Plan [Member]</link:label>
    <link:label id="lab_sibn_Company401KPlanMember_documentation_en-US" xlink:label="lab_sibn_Company401KPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company 401K Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_Company401KPlanMember" xlink:href="sibn-20201231.xsd#sibn_Company401KPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_Company401KPlanMember" xlink:to="lab_sibn_Company401KPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6512d8e2-6197-4f21-bf13-57b2b389a1e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80d10ae2-a68b-4246-b03d-5788719153a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1d6b053b-ef62-4805-b8bc-05ad7943ffea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_93512f69-b0a7-40fa-9cbe-13b46b1e1061_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life, options vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fd88bb79-01b9-4c55-91a9-dbdf1b17d8b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8749f7ed-160f-4304-8b65-03b4d676c6ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3c55f99d-9180-49b3-b5f0-c6989e6a84e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_61fae16a-7242-4ccd-985d-af30d4fe47d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a2a5b2-a411-4173-b4de-5b7e9bcbd23d_terseLabel_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_label_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_documentation_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:to="lab_sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8e23d811-f7c3-47d1-bc40-d2e2e6985083_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ed5e4268-8d73-4384-be4a-8c0e0efd8108_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions during the period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b6e0afd8-df11-453a-8c43-a6f552750d25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7230cec4-ba75-4bdc-93b0-8fa1678be951_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_28ca8979-fb76-435a-9366-cc7b5be9a9a4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0ce05889-b5a6-4aec-858b-91e650c14791_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_MarketableSecuritiesFairValue_9a4748d3-f6a5-48ee-907c-e247aa352888_terseLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities, Aggregate Fair Value</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesFairValue_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Fair Value</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesFairValue_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate fair value for marketable securities included in cash equivalents and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesFairValue" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesFairValue" xlink:to="lab_sibn_MarketableSecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0b64c883-a82a-4dac-91bb-c9a542c5cb9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_71a55638-d770-44ba-99dc-c08399a1c184_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_94f4f8ec-e95c-4da4-ba76-280914576946_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c0b8fd74-0be8-441d-98ff-cb749d6a8d57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) of marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9188a6ab-1b4d-412a-a79d-d6cf2b383cf9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_f5af4436-edff-48a4-a362-cf3b2722180e_terseLabel_en-US" xlink:label="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, maximum amount per employee</link:label>
    <link:label id="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_label_en-US" xlink:label="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Maximum Amount Per Employee</link:label>
    <link:label id="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_documentation_en-US" xlink:label="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Maximum Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" xlink:href="sibn-20201231.xsd#sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" xlink:to="lab_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_464c8a23-194b-4365-b974-79ea44d6e6b5_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a9a6b501-5869-4eb2-abc6-194459473f14_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a7e2f731-3e7c-4035-88a2-3c6302b00a09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_fca59cc3-3db0-4c71-95d6-fd7b53376670_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase periods in offering interval</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dfd1e87d-5bd0-49f1-9e5b-f1b527834d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fe91fd8b-b7b1-4710-9369-6c0d6b8c81a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_31a88c0f-8cdf-4009-a8ca-e3efaa7d3bf0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b460f4e7-13aa-4639-9feb-c2b883787007_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cebca458-5d4b-41f3-9d31-45e39ebda471_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_10054a33-c2c5-4bac-8796-9c70aa88715d_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_86af6bbf-4c32-40c6-80e4-9ab65fbb5e09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_90e061e5-ecd0-4750-8397-c658005d1a8c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_1eb0669c-9605-4da9-96c9-001e1f859701_terseLabel_en-US" xlink:label="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Value</link:label>
    <link:label id="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_label_en-US" xlink:label="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion</link:label>
    <link:label id="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_documentation_en-US" xlink:label="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:href="sibn-20201231.xsd#sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:to="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dfdef3e5-85ef-4d4d-ba60-0d0b41509e6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fc6e456-9092-4ba0-9a4c-b09c4b475036_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_86bba79a-87e3-4bf2-b5ce-5057b50ac533_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_18af0ed4-4a13-47d2-9857-3a8619d0a1e6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_feed0ed8-e2fe-4810-9659-f6d6128b671c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_78e47eb8-d19b-4785-b906-677a69fabbba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_VariableOptionOneMember_68637e08-6134-4eec-8dcd-22d838a008ce_terseLabel_en-US" xlink:label="lab_sibn_VariableOptionOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Option One</link:label>
    <link:label id="lab_sibn_VariableOptionOneMember_label_en-US" xlink:label="lab_sibn_VariableOptionOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Option One [Member]</link:label>
    <link:label id="lab_sibn_VariableOptionOneMember_documentation_en-US" xlink:label="lab_sibn_VariableOptionOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Option One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_VariableOptionOneMember" xlink:href="sibn-20201231.xsd#sibn_VariableOptionOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_VariableOptionOneMember" xlink:to="lab_sibn_VariableOptionOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_845dcbb7-ffbb-4b87-90b4-9278f40d0dc4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_e89726f2-9ae0-4fe6-9656-c8cc8a567d4f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geography</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d68c6f4c-c1e4-4ac1-a374-08d7167c9997_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4f19ec31-ec98-4507-b2d2-7abb09ce96d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtCovenantTrancheTwoMember_594f2e48-362a-4a62-a428-e6b0458ea7d0_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche Two</link:label>
    <link:label id="lab_sibn_DebtCovenantTrancheTwoMember_label_en-US" xlink:label="lab_sibn_DebtCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche Two [Member]</link:label>
    <link:label id="lab_sibn_DebtCovenantTrancheTwoMember_documentation_en-US" xlink:label="lab_sibn_DebtCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheTwoMember" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantTrancheTwoMember" xlink:to="lab_sibn_DebtCovenantTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8ca75e75-70fa-467b-85c1-f290d14a5156_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses on long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f7d2e0d2-5ad0-4868-81f3-8dafb793d21d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_82e3e53b-aca3-4169-a77e-05b91a919d70_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11e4deef-d1ad-4b3d-a8f9-aff5d7ff8544_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_61cf3dd7-3eea-43c2-bd67-93003d873705_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_25dda473-c2df-4474-8f7d-3e0a2e8c18e0_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable prepayment increments per agreement</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_label_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment, Allowable Increments Per Agreement</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment, Allowable Increments Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" xlink:to="lab_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bb5df29e-9b36-4d84-bec7-2e986a7611ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a5a14421-2dde-4d15-afe1-69518e3b28b8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d63f46e2-db9d-4cd7-807c-038d7d889419_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b73a4718-d44b-4551-8a4b-ab8bf6fb96c3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0d87d7ad-dbda-42f5-88a6-1a8dafd0b2ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_91cc93f8-8e49-4a1e-83ef-fc2d1558930d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_46b31b2f-8558-4cbe-a621-40fb20083b8e_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued 7/22/2013</link:label>
    <link:label id="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_label_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued July Twenty-Second Twenty Thirteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued July Twenty-Second Twenty Thirteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" xlink:to="lab_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_15913938-2e5f-4f90-9186-70062c91e9e8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d131b7c9-0b56-48aa-9ef4-55cd06004286_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_78a78855-5ece-4140-9ec1-806506bec85c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_49e2caf6-f304-43fe-9837-aae78d8dc184_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_53b53aea-f5bc-4282-82c4-d7a57d8952c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4fc4b217-0365-405e-8f7d-0fe69a49cfe9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25440cad-ccd8-4145-8b73-05fd536791ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a38ce77c-27de-41bb-be5d-8e1c8f95fbfc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_c36f7064-93c1-4b34-aa62-806f50be92de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3ad23aab-ea5a-4b58-a195-3e607d23ad7d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6d667785-2eee-4130-aaf0-e4caaa9b8b25_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_0e1537c4-d7f6-4289-9127-f714c9e17bea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_46472bb0-a344-45ab-ace5-9c47e6f0f250_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_054d9451-747a-4550-a405-3154bf1a220a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_19ee38c0-a939-4525-8d75-67f7e818ecf3_terseLabel_en-US" xlink:label="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First follow-on public offering and secondary offering</link:label>
    <link:label id="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_label_en-US" xlink:label="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow On Public Offering And Secondary Offering [Member]</link:label>
    <link:label id="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_documentation_en-US" xlink:label="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow On Public Offering And Secondary Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" xlink:href="sibn-20201231.xsd#sibn_FollowOnPublicOfferingAndSecondaryOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" xlink:to="lab_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_60a04d50-5fb9-46e1-b748-3874cc897290_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued 11/26/2014</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_label_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued November Twenty-Sixth Twenty Fourteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued November Twenty-Sixth Twenty Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:to="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8c852ffe-e0d4-4011-b05f-b91c1e99584b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_fc9a0633-a011-411f-a51b-73e81cd3267f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_83e3bcf3-50e5-4a2e-9d52-50cede8a1081_terseLabel_en-US" xlink:label="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares in transaction, including shares in secondary offering (in shares)</link:label>
    <link:label id="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_label_en-US" xlink:label="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Including Shares In Secondary Offering</link:label>
    <link:label id="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_documentation_en-US" xlink:label="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Including Shares In Secondary Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" xlink:href="sibn-20201231.xsd#sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" xlink:to="lab_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_57bfb8cd-6320-4593-a454-22b3f0f7f523_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2237430d-8810-4318-b40c-586bc3fabbea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_3f44c082-3c81-41d9-bc3b-d390295f9f69_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f64907d5-bd23-4ec7-9615-2f7c926cfa5b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_000d1e13-d139-4e8a-a54b-e2a7aaa51de7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percentage of eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_53993b32-5295-4b0c-9c9f-341baa21eb48_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium in year two (percent)</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_label_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium Year Two Percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium Year Two Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" xlink:to="lab_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_67648fad-013f-4b0c-baf6-f0378496e6e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_fe174a73-36d4-429a-93f5-21d0232a6f6e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_888b42f7-3b00-4ede-aeb8-7df6ff5cf1ca_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SeaSpine</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_cab98935-d5e1-4ce0-83a9-24a80f99ae91_terseLabel_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ed8809c6-5070-4e8e-b55a-9938356b5c86_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ac3aa274-5ec5-403c-8520-170b3218712c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding debt, net of debt issuance costs and unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1f9c3e38-6154-47fd-b6ed-50e84c8a5d23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0b31f365-1751-4158-bbea-d8fba02a40e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_84fb4287-7243-4cda-b41f-11cc9db23db6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_70f7f76f-66cd-4d27-b326-f09c40d2d8aa_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_b2c71080-7c08-4823-a295-1a9138ff607f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_da2a2339-5748-4448-ad1a-4348f000f5e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4cb7a743-2039-494d-b72e-f8d93a65e467_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_f2a99116-b086-4cba-9916-e380fdeb4590_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue threshold for minimum liquidity covenant</link:label>
    <link:label id="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_label_en-US" xlink:label="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Liquidity Covenant Product Revenue Threshold</link:label>
    <link:label id="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Liquidity Covenant Product Revenue Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" xlink:to="lab_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c3e4b1b1-dd34-4900-a81a-2e8eb7809eaf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3085c8cb-6549-4b8f-9750-14d05dc6347c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c3f24f60-08cc-4043-a8ca-f54b6847aea3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_87581380-bfb3-4f59-89b5-7688afa5c319_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_55cca297-792a-45a5-a38a-6e71e9f75733_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_51794dfc-b361-48b5-b381-07db73aaa9a1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock_14f72560-d17e-4f9f-a588-b22dcd824090_terseLabel_en-US" xlink:label="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JOBS Act Accounting Election</link:label>
    <link:label id="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Extended Transition Period Policy [Policy Text Block]</link:label>
    <link:label id="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Extended Transition Period Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" xlink:href="sibn-20201231.xsd#sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" xlink:to="lab_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_c315f944-1998-439b-89b7-65ade19fc861_terseLabel_en-US" xlink:label="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_label_en-US" xlink:label="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Depreciation And Amortization</link:label>
    <link:label id="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_documentation_en-US" xlink:label="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:href="sibn-20201231.xsd#sibn_DeferredTaxAssetsDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5a955cd8-b19b-44e8-acc0-a0a6bade0080_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DevelopmentAgreementMember_09973d8b-b106-415c-8fb4-2a625a7ae704_terseLabel_en-US" xlink:label="lab_sibn_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint development agreement</link:label>
    <link:label id="lab_sibn_DevelopmentAgreementMember_label_en-US" xlink:label="lab_sibn_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement [Member]</link:label>
    <link:label id="lab_sibn_DevelopmentAgreementMember_documentation_en-US" xlink:label="lab_sibn_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DevelopmentAgreementMember" xlink:href="sibn-20201231.xsd#sibn_DevelopmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DevelopmentAgreementMember" xlink:to="lab_sibn_DevelopmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_db6fb322-bbfc-4b2e-b7ac-abad099d69a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_eb207583-3039-43f0-9671-6b5681a99647_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Related to Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a5ac670e-5b7a-46e3-ba06-eead9f77f3f8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_082183fc-d450-400e-81c6-94666537c490_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3095ca25-2261-4c89-a818-dfd163de1924_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_bc37fb8c-80a5-4f52-aada-14f6128ce26e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_883e9619-74c5-429a-8d85-cac04991bf9b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_IncentiveStockOptionMember_691256ed-cafc-44f8-812b-5e59557f5356_terseLabel_en-US" xlink:label="lab_sibn_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_sibn_IncentiveStockOptionMember_label_en-US" xlink:label="lab_sibn_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:label id="lab_sibn_IncentiveStockOptionMember_documentation_en-US" xlink:label="lab_sibn_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_IncentiveStockOptionMember" xlink:href="sibn-20201231.xsd#sibn_IncentiveStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_IncentiveStockOptionMember" xlink:to="lab_sibn_IncentiveStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_24da861e-c330-4746-a1d8-7a9249d0dc34_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4ab6c570-82cb-4b3d-ab08-bb178ecdc8c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_851edd77-f3b2-40f3-b8d8-a76e89161431_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments related to inventory</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_50070556-fc94-437b-8749-624fdc65495d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_3a49d03f-f624-4db2-b3bd-1d570b4ba068_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_def419e3-bad9-4c79-a83f-9f55edee4f59_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of approved claims by class members, fees, expenses and incentive awards</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5221dabb-3055-4db7-9520-3398f30add01_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7ceb1f1d-04ac-4836-8677-2c8e8a771ed7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_178394e9-1dd2-4c91-8482-308729efda64_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7e68c1cd-c1c8-40f0-bd6b-1c59e39970fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_bee6a00e-c20f-46b4-98fd-e921ef006bd5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_FollowOnPublicOfferingMember_b24a33f3-fe71-4b93-b2e7-c9a500ab2790_terseLabel_en-US" xlink:label="lab_sibn_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First follow-on public offering</link:label>
    <link:label id="lab_sibn_FollowOnPublicOfferingMember_label_en-US" xlink:label="lab_sibn_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow On Public Offering [Member]</link:label>
    <link:label id="lab_sibn_FollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_sibn_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow On Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_FollowOnPublicOfferingMember" xlink:href="sibn-20201231.xsd#sibn_FollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_FollowOnPublicOfferingMember" xlink:to="lab_sibn_FollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_3191da39-52b2-4384-8c7f-95b89e5ebf91_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment penalty percentage (percent)</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_label_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty Percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:to="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_efef9531-6cc0-4086-a421-79562b75f94c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_0706eca6-7b93-41c4-864f-a45d29b6fdbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_99dd6993-35b1-468d-b75f-1265d00822f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_61647fa6-688c-40a2-afbc-717378871909_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_008e91d1-d170-49e9-9bc0-a051aa58923b_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expenditures</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_e352ffd3-92c9-4a67-a6bf-65dba09a220f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77f49720-1795-456d-aa42-77c7e6964851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_db37aa47-fc64-43b9-b1de-b701c5f8986f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_08abd4ed-66dd-4621-ba45-f4abcfd6ff4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_09f7e77f-149a-48c2-93c5-31270b729b14_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_523eccbf-4cb3-48de-8b1b-8641a1aec543_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c7f04ac9-3de3-450b-a022-33473f39cb4f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a8784dd0-6a7f-4c3e-bdc8-eca549d06f61_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $263 and $238, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_1bb0b79e-a32c-4191-b3c2-f5071d7c5136_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt period payment, interest only period</link:label>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_label_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest Only Period</link:label>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest Only Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:to="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ProceedsFromMaturityOfMarketableSecurities_797c6959-cc19-4b56-a5a3-74d573d2728a_terseLabel_en-US" xlink:label="lab_sibn_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_sibn_ProceedsFromMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_sibn_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Marketable Securities</link:label>
    <link:label id="lab_sibn_ProceedsFromMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_sibn_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ProceedsFromMaturityOfMarketableSecurities" xlink:href="sibn-20201231.xsd#sibn_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ProceedsFromMaturityOfMarketableSecurities" xlink:to="lab_sibn_ProceedsFromMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4887a653-1f17-4ede-a8d0-e22bb52c85e8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_aa6f8c7c-d39d-4256-9c4d-ffd27cb6c8b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_5e1af364-06a7-4d0e-840b-4edbd5258a7c_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued 10/20/2015</link:label>
    <link:label id="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_label_en-US" xlink:label="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued October Twentieth Twenty Fifteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued October Twentieth Twenty Fifteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:to="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ea1090f9-6453-47fb-989d-5bbed003ad9e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_d7e9e8fb-6daf-4a81-846e-cc2c4f976ad6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_01ce5a11-2b2b-4d4c-a560-d0892108436d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_746aa31a-94c8-4ac1-b686-5315d9043430_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f5691533-d357-4286-8bd1-f215876bed8c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_bc0484ae-2ee1-44f3-a9b6-6717a2d97c6a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax asset, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_28e42206-43fd-4c7a-b9cd-491457b9b684_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock as a percent of fair market value (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_78345461-016b-4d7c-8975-ca9193e22ee7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_03881330-031c-4175-9c53-ffc6132b4b31_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_a7c4f611-20f9-4055-858e-f3a8435fbfc3_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding liability to SeaSpine</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c9b8171d-36b0-4c4f-a25d-592b46ce0c39_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_812e6052-6e79-4ee7-aacd-2e4f257b556a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Related to ESPP Purchase Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_705a47b4-5407-4b02-8a57-4b98566ec183_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_445b176d-ff1b-41bb-9138-e2d29a22be1a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_cbbb963d-cdbb-484b-8060-f25bb0aeb229_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_616716e4-feb0-41b2-a18d-d86a51d70f88_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d53a61f1-68cc-4036-8989-4fe957b5d1b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d5c459a1-d236-4ad5-b66b-45745ee108a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ead43bcc-067c-42f3-a289-918737e28d74_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c6105733-5883-4274-8da1-679ddcc3bc18_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_43c36cb0-d44f-4251-85bb-5ba80f7bc9de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional accrual of IPO related costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_9771822d-4759-4072-892e-9332bcc31f3c_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of option as percent of fair market value when individual owns more than 10% of shares outstanding (percent)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than Ten Percent Of Outstanding Shares</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than 10% Of Outstanding Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_310322c6-6dd9-4308-bcd1-6983a83009bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_3e222f6f-90e4-4fa5-a871-f1a1bbbab325_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_99eef56e-4e8c-45e9-9bc8-e20992b26bd2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_98dcfcf5-62c0-44fc-ad82-c7359fd56395_negatedTerseLabel_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of unvested early exercised stock options (in shares)</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_label_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_documentation_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:href="sibn-20201231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:to="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_2ef9da11-19e3-4c65-bbb4-5527bb17dd41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0a06ba02-d8a3-4907-92d5-f576dd24842d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1abf540-d8d0-4c73-a07f-0ff2bee45e48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_dc57b615-28bf-4ad7-bd0c-5cfaffddfcc2_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees stock purchase program offering period interval (in months)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_4be4edee-a1b4-4ba4-ab16-70e982c77f10_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_bb2ff0f7-69e5-46c2-8009-22a7db9375d7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_StandardProductWarrantyTerm_3ce54be2-cdb8-4592-8650-abb643560c43_terseLabel_en-US" xlink:label="lab_sibn_StandardProductWarrantyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty term (in years)</link:label>
    <link:label id="lab_sibn_StandardProductWarrantyTerm_label_en-US" xlink:label="lab_sibn_StandardProductWarrantyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Term</link:label>
    <link:label id="lab_sibn_StandardProductWarrantyTerm_documentation_en-US" xlink:label="lab_sibn_StandardProductWarrantyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StandardProductWarrantyTerm" xlink:href="sibn-20201231.xsd#sibn_StandardProductWarrantyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StandardProductWarrantyTerm" xlink:to="lab_sibn_StandardProductWarrantyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_7cf8e179-d2a6-4049-93be-4b45452b08a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9ddac0b4-305f-495c-ae8b-b53485b0686f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9c200a12-5c12-4efb-9c59-f5e512434b07_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8489f963-4efd-4561-b915-f5041cfb756d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9acaa891-e017-4fca-bfa9-b3acf1b6b3d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4bda5509-0d23-4eec-a007-698ba1ee221d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_A2018EmployeeStockPurchasePlanMember_42fbcbed-4472-42c3-ba15-e27d39b1308a_terseLabel_en-US" xlink:label="lab_sibn_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 ESPP</link:label>
    <link:label id="lab_sibn_A2018EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sibn_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sibn_A2018EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sibn_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_A2018EmployeeStockPurchasePlanMember" xlink:href="sibn-20201231.xsd#sibn_A2018EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_A2018EmployeeStockPurchasePlanMember" xlink:to="lab_sibn_A2018EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ComputerAndOfficeEquipmentMember_6658b2e7-a9ab-4e34-add9-e21c54b1fc22_terseLabel_en-US" xlink:label="lab_sibn_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_sibn_ComputerAndOfficeEquipmentMember_label_en-US" xlink:label="lab_sibn_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Office Equipment [Member]</link:label>
    <link:label id="lab_sibn_ComputerAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_sibn_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember" xlink:href="sibn-20201231.xsd#sibn_ComputerAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ComputerAndOfficeEquipmentMember" xlink:to="lab_sibn_ComputerAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_5ebe43c0-6756-4a87-87a3-7047307b1fc0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_IncomeTaxesValuationAllowanceRollForward_4fc011a1-6eb6-4a8c-aa26-0970f1c349e8_terseLabel_en-US" xlink:label="lab_sibn_IncomeTaxesValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Valuation Allowance</link:label>
    <link:label id="lab_sibn_IncomeTaxesValuationAllowanceRollForward_label_en-US" xlink:label="lab_sibn_IncomeTaxesValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_sibn_IncomeTaxesValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_sibn_IncomeTaxesValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Valuation Allowance [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_IncomeTaxesValuationAllowanceRollForward" xlink:href="sibn-20201231.xsd#sibn_IncomeTaxesValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward" xlink:to="lab_sibn_IncomeTaxesValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_SolarLoanAndSecurityAgreementMember_04c9f16d-2147-4cfb-991c-ad65e33c3ea0_terseLabel_en-US" xlink:label="lab_sibn_SolarLoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solar Loan And Security Agreement</link:label>
    <link:label id="lab_sibn_SolarLoanAndSecurityAgreementMember_label_en-US" xlink:label="lab_sibn_SolarLoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solar Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_sibn_SolarLoanAndSecurityAgreementMember_documentation_en-US" xlink:label="lab_sibn_SolarLoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solar Loan And Security Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SolarLoanAndSecurityAgreementMember" xlink:href="sibn-20201231.xsd#sibn_SolarLoanAndSecurityAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SolarLoanAndSecurityAgreementMember" xlink:to="lab_sibn_SolarLoanAndSecurityAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_18c2949f-f7a1-43d2-bd10-04921b62a813_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_6f289449-5b0a-4676-bc62-0f81ce33629b_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca067569-6e42-4843-961a-2c707420e23a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b9d9e8cb-62f3-4e79-a4a1-de8ffc173588_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayments of debt financing</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_72cdab42-1ce7-4893-83a1-515d1cf19c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Options by Range of Exercise Price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_580b27b7-03dd-4ff4-90bd-64481833465c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_839a4b37-aeb7-4469-974a-941b3e9dd4e9_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fd812c9f-d966-4022-b3de-f90584e2b8e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0e97f676-567f-4353-b507-326951bb333f_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_52b6892a-5137-4692-b972-e1cd46df87b1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9d07c7a7-10cd-43d7-8be8-df70c21fadc5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_PharmakonTermLoanMember_7f2a3693-1014-4dc1-877d-e37d78b7c9c2_terseLabel_en-US" xlink:label="lab_sibn_PharmakonTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loan</link:label>
    <link:label id="lab_sibn_PharmakonTermLoanMember_label_en-US" xlink:label="lab_sibn_PharmakonTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loan [Member]</link:label>
    <link:label id="lab_sibn_PharmakonTermLoanMember_documentation_en-US" xlink:label="lab_sibn_PharmakonTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PharmakonTermLoanMember" xlink:href="sibn-20201231.xsd#sibn_PharmakonTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PharmakonTermLoanMember" xlink:to="lab_sibn_PharmakonTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_53f5c406-1b0d-457e-93e5-d4460c3d3fc8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 100,000,000 shares authorized; 32,583,220 and 25,163,803 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5d705955-f6ec-4785-a0f9-8ba12ff9b33b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e748914c-0a96-4729-8d17-b5e41d0a95c6_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_95d8ef06-ea9d-4a36-ae33-722beccf4dd0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_650725d6-a6d0-4c3f-aa93-95d7ca063aa8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5681631c-d437-48fb-b593-cbeb86a48df5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_00239c0a-cbb8-4c01-b4a9-dd7b81353e53_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_db0c7e43-2a80-45cb-811d-03e864e8bc9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate during the period (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6c968f44-51cf-47c7-9960-3df591cd0fd6_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_1278914e-85bd-4191-8475-ce4f4bf4a5e5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_63b933e4-ff04-45ab-96bf-94937961f629_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a2440476-3726-43b6-9c85-be4177bcacc1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8a1ee88d-8475-4f81-9fc3-3df614c3fc51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e2ebb4a7-96c2-4b39-887d-14f50d1aa163_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_da397b9b-215d-4422-ae24-6ec7a3afe6f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc39aa05-ba17-46b0-b507-e0567acef1f2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8527f74d-204d-4abc-b8ca-ae3c8c852045_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3426f707-6f8f-46ec-bcbc-662a1bd0058a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_e3a8e86a-0b85-4e44-848b-1a1b732ca8e3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs accrued to defend lawsuits</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_OptionsTrancheTwoMember_63e58200-763d-438b-a094-d515964e99ed_terseLabel_en-US" xlink:label="lab_sibn_OptionsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.70-$4.41</link:label>
    <link:label id="lab_sibn_OptionsTrancheTwoMember_label_en-US" xlink:label="lab_sibn_OptionsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Two [Member]</link:label>
    <link:label id="lab_sibn_OptionsTrancheTwoMember_documentation_en-US" xlink:label="lab_sibn_OptionsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheTwoMember" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OptionsTrancheTwoMember" xlink:to="lab_sibn_OptionsTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_b58ab5a0-d4ef-4b2a-b80b-360a0e4e7e5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_79cf6253-da59-4eeb-9197-fcf105152610_terseLabel_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0e63641e-7728-481b-9b69-1efa50c82d75_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_95b1c23a-e617-47ce-a63b-1da170a6cb41_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium in year one (percent)</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_label_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium Year One Percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium Year One Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" xlink:to="lab_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_52efb0f1-c968-4653-b737-8a1faf4b63e9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_83cd5a90-abed-42c6-a5fc-a0104f187482_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise of stock options, share subject to repurchase (in shares)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b5a15b7f-322a-4ee8-9f69-a68968dfb2f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9ac253cb-7e5b-4881-9c2c-5bb4ae75b65e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b9255ee8-e923-40b9-b340-1a2378993937_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_269e568a-041d-4e90-bae2-7f309f63583e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_13dd6a65-518b-421e-a116-190db74061b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_MarketableSecuritiesAmortizedCost_f15ffa33-88ab-4929-99a6-94c24ba56d26_totalLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities, Amortized Cost</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortized cost for marketable securities included in cash equivalents and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost" xlink:to="lab_sibn_MarketableSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_f790c12f-55b8-4be9-87e8-8066030608da_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company and Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5526827c-22fa-4937-9a9c-5ffd3d247c31_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of initial public offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_5cb305ad-ee82-4237-af53-2ae299aedfc9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3cc44e23-90de-4ba7-b5dd-0a02f1d4c656_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_d3581583-f42e-40d5-b128-1c3868f07b2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related expenses for employee payroll deductions</link:label>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36cc59df-1f38-4c85-be4c-48b4ae739cb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7d1df971-039b-490f-9411-9d054d3704a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7df873e7-76af-4e34-92cf-4f2b1f8021ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_78351dd2-cea2-41b9-bb3d-94d836e5aefb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_08ab2b8b-2bc6-49b5-a552-daea44400e53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_65da094b-4a75-4678-b35d-55eb27955aa1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_15bc22b1-ff06-4b41-83b5-ae77614041b8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ProceedsFromSaleOfMarketableSecurities_f6f92f29-6738-463a-9a3a-31460c7c59fc_terseLabel_en-US" xlink:label="lab_sibn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_sibn_ProceedsFromSaleOfMarketableSecurities_label_en-US" xlink:label="lab_sibn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label id="lab_sibn_ProceedsFromSaleOfMarketableSecurities_documentation_en-US" xlink:label="lab_sibn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ProceedsFromSaleOfMarketableSecurities" xlink:href="sibn-20201231.xsd#sibn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_sibn_ProceedsFromSaleOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock_7c67be11-8904-4802-bfc9-1998c72dc0ed_terseLabel_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Classified As Equity And Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Classified As Equity And Liabilities [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" xlink:href="sibn-20201231.xsd#sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" xlink:to="lab_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e53d483d-94c4-4393-b937-8764ec9a61cb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_aae8da27-f965-46b6-a6e6-034b229690b1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b2906410-109a-47db-b5d7-6705ff5b029a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from the computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_bca8ce33-e337-4570-92a9-67d67dd67097_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_OptionsTrancheFiveMember_3bf45cda-a7c3-41ad-b79e-da7f430434f9_terseLabel_en-US" xlink:label="lab_sibn_OptionsTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$20.52-$22.00</link:label>
    <link:label id="lab_sibn_OptionsTrancheFiveMember_label_en-US" xlink:label="lab_sibn_OptionsTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Five [Member]</link:label>
    <link:label id="lab_sibn_OptionsTrancheFiveMember_documentation_en-US" xlink:label="lab_sibn_OptionsTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheFiveMember" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OptionsTrancheFiveMember" xlink:to="lab_sibn_OptionsTrancheFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_b4b72351-53f6-4a2b-b3b4-1dbdd4e6fd9d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_5ab796d5-b4bc-4a6e-8ae6-c183b1f97903_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_92634ea7-0ab9-4799-8fed-0253408cf904_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale and disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5bc580f9-65fe-483e-87ec-c2442d815569_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year's tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_e46ba4f4-e4a3-4f0f-93a3-9ed70b48d1d7_terseLabel_en-US" xlink:label="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of unamortized debt discount and issuance costs on debt extinguishment</link:label>
    <link:label id="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_label_en-US" xlink:label="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Deferred Debt Issuance Cost And Debt Discount</link:label>
    <link:label id="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_documentation_en-US" xlink:label="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Deferred Debt Issuance Cost And Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" xlink:href="sibn-20201231.xsd#sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" xlink:to="lab_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a2cbab1e-6edf-4da7-9607-39add8321270_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_f2c6df5b-ce1d-449e-b631-e0f59c8a19a3_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_505269a0-0a31-4ff4-9068-3167615a0de2_terseLabel_en-US" xlink:label="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory damages sought per violation of TCPA</link:label>
    <link:label id="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_label_en-US" xlink:label="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Statutory Damages Per Violation Of TCPA [Member]</link:label>
    <link:label id="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_documentation_en-US" xlink:label="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Statutory Damages Per Violation Of TCPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" xlink:href="sibn-20201231.xsd#sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" xlink:to="lab_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_dec7ab8c-c94b-4a6e-a206-4db49b6b9844_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_20364b0d-e82e-4652-a4cc-35941a6807cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_896d2744-b1d3-406d-995e-99f960e0675e_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, ending balance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_d12532c3-233f-4cee-9772-40c6c3392ac6_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_d395e36e-0b8e-41a5-8bae-207a0a35c15c_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership of outstanding shares for alternate terms</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Ownership Of Outstanding Shares Threshold For Alternate Terms</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Ownership Of Outstanding Shares Threshold For Alternate Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_df027c97-3171-4407-a463-a579571d78cd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5f8a0754-bcee-46dc-b1d6-84033b4348ef_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_43e249dd-01f9-4a30-b78f-7c2b116c4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1551a075-db5c-4589-912a-8df76705c4fa_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_821c5fff-9362-48b3-8bda-38e74417bd34_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_cec57ba0-e0c3-4acf-aaf6-00c4bd8eeb54_negatedTerseLabel_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9f328b9b-db32-4eae-88cd-4895ad38a18f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7f60bdb4-1b24-4764-af32-8d5c9638ec59_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_10009479-18d8-4aa3-9820-7806a6b092cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f467315a-1c3e-492d-bd24-060d875abda2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1639efd5-88d7-4944-841a-a2fd9436c422_terseLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities, Unrealized Gains</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_fba617e7-cd2c-4bb1-a9f9-19cf395e4ba2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_10b20041-840c-49c3-a9f5-f81b2a524859_terseLabel_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_label_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Amount Restricted Stock Units</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_documentation_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Amount Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" xlink:href="sibn-20201231.xsd#sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" xlink:to="lab_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4f731aa1-0dbc-45aa-9a96-933d15eeb9b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3cd487ca-c5bb-4ee9-a43b-e1464789857d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0fabbb3a-793e-4ca3-85c5-6a18bd14988e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_RelatedPartyTransactionTermOfAgreement_4245fa4b-faa2-492f-adec-12e76bf1b6d7_terseLabel_en-US" xlink:label="lab_sibn_RelatedPartyTransactionTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of product royalty sales period (in years)</link:label>
    <link:label id="lab_sibn_RelatedPartyTransactionTermOfAgreement_label_en-US" xlink:label="lab_sibn_RelatedPartyTransactionTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Term Of Agreement</link:label>
    <link:label id="lab_sibn_RelatedPartyTransactionTermOfAgreement_documentation_en-US" xlink:label="lab_sibn_RelatedPartyTransactionTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_RelatedPartyTransactionTermOfAgreement" xlink:href="sibn-20201231.xsd#sibn_RelatedPartyTransactionTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_RelatedPartyTransactionTermOfAgreement" xlink:to="lab_sibn_RelatedPartyTransactionTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3d4177b1-f24c-4f65-9fc4-fe1f2e4e62bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2d2a8d37-a4e9-4201-988c-48db27fe551c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6d1cc524-a03e-4a28-91c1-9e40bab9bfe5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d9d852d-de7b-48e5-875c-e587527b5948_negatedTerseLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities, Unrealized Losses</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_a12a2c76-229a-4726-b8e5-ba07d29739d6_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium in year three or later (percent)</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_label_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium Year Three Or Later Percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium Year Three Or Later Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" xlink:to="lab_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4294ff96-04e9-4277-95c7-a370107c5d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3ddd007-0a64-4e16-86ba-772843a0f9cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9c5a030b-510d-455e-b22e-ea5415611643_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal benefit (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d3469e1b-5e22-4203-addc-085dc262415e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d01cf995-823e-45b0-a491-8af57124e923_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares Underlying Warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_b528ae4b-db24-4bed-bfbe-279541bbd538_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c039d7a4-7a17-4ff1-9e33-0bae0c4b5c24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c7796e51-cc2f-4f23-9cfd-3cfeec613930_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_a543ad49-82fc-4534-8427-56973dd24739_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ESPPPurchaseRightsMember_006b65f9-7d96-486b-b0d8-73d617e18534_terseLabel_en-US" xlink:label="lab_sibn_ESPPPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Rights</link:label>
    <link:label id="lab_sibn_ESPPPurchaseRightsMember_label_en-US" xlink:label="lab_sibn_ESPPPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Rights [Member]</link:label>
    <link:label id="lab_sibn_ESPPPurchaseRightsMember_documentation_en-US" xlink:label="lab_sibn_ESPPPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ESPPPurchaseRightsMember" xlink:href="sibn-20201231.xsd#sibn_ESPPPurchaseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ESPPPurchaseRightsMember" xlink:to="lab_sibn_ESPPPurchaseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_130c5496-2766-4e6b-9692-9d86f0d9587d_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option term when grantee holds more than 10% of shares outstanding (in years)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than Ten Percent Of Outstanding Shares</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than 10% Of Outstanding Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_1caed1ac-5fa1-4b62-b391-41fe3e2b15f6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of accrued litigation expense</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ff3a7701-5c95-4fde-84bd-6da87fb076fc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_cb04e547-0218-4a5c-a827-f44d2f4cd64b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e70f71b2-6bca-42b7-9199-273a8118b4b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b4f2fda6-2c56-4140-9c41-25ef317cce7f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cdea1eb4-950e-4825-abc2-45af346f04a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_d98b0db7-8c30-41c9-9d8e-eb0478b6bba4_terseLabel_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_label_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Restricted Stock Units</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_documentation_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" xlink:href="sibn-20201231.xsd#sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" xlink:to="lab_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8c478896-ce07-44e9-88cc-a3da55d17ee8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_83b75abe-816d-43d1-94ce-0f1f1de943e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_bd26cb0d-fe03-48c0-b57c-f8ab13958d5d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_64953489-f3ff-4e8b-9fbe-089fa3b3dea4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e918b6b8-4679-4552-85bf-3d7d2478dd6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differences (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_f9058a85-b77d-4d41-ba4c-b0e05c0e1969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_OptionsTrancheThreeMember_730e4d93-4030-44a5-bb54-f7c256fa26b0_terseLabel_en-US" xlink:label="lab_sibn_OptionsTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$4.42-$5.31</link:label>
    <link:label id="lab_sibn_OptionsTrancheThreeMember_label_en-US" xlink:label="lab_sibn_OptionsTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Three [Member]</link:label>
    <link:label id="lab_sibn_OptionsTrancheThreeMember_documentation_en-US" xlink:label="lab_sibn_OptionsTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheThreeMember" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OptionsTrancheThreeMember" xlink:to="lab_sibn_OptionsTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a39a8a94-e941-476c-91a9-15ad043ad1a5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_18ff5a72-4e2a-4097-8745-8b34aa138b9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_2ad77d07-1bfb-44c2-b227-80d5a871ec49_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_abf47469-a62f-444b-88cb-0326c1eb39bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_bb685d83-d37d-44dc-96d7-b71acf4b2b14_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_c8705770-97ac-49b9-87b1-c2ead21f231d_terseLabel_en-US" xlink:label="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised stock options</link:label>
    <link:label id="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_label_en-US" xlink:label="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Vesting Of Early Exercised Stock Options</link:label>
    <link:label id="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_documentation_en-US" xlink:label="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Vesting Of Early Exercised Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" xlink:href="sibn-20201231.xsd#sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" xlink:to="lab_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f8778b9a-14c5-4ffc-8317-82e5adc33f0e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3d58a694-4d4b-4518-a329-f26aad8541d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_SecondaryOfferingMember_27a36705-e446-4d25-90e2-bf2de7944a85_terseLabel_en-US" xlink:label="lab_sibn_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary offering by selling shareholders</link:label>
    <link:label id="lab_sibn_SecondaryOfferingMember_label_en-US" xlink:label="lab_sibn_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering [Member]</link:label>
    <link:label id="lab_sibn_SecondaryOfferingMember_documentation_en-US" xlink:label="lab_sibn_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SecondaryOfferingMember" xlink:href="sibn-20201231.xsd#sibn_SecondaryOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SecondaryOfferingMember" xlink:to="lab_sibn_SecondaryOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_db58640e-0101-49f5-a9db-839b13571339_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b8f6dc45-7263-4dfb-8ea0-2d74556f06f2_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_2a6141fb-0618-40e0-817d-9705da357d89_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_6a3f1490-5e93-41dd-95a2-54e42926fd10_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d6a7e50d-e2ea-44bb-af74-6930c9cc2ed8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2c3fed9-954e-4de6-85ac-1403915ba27e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_NonqualifiedStockOptionMember_f6e7a235-f9f6-4830-a4de-3d5fbc3d8f81_terseLabel_en-US" xlink:label="lab_sibn_NonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Options</link:label>
    <link:label id="lab_sibn_NonqualifiedStockOptionMember_label_en-US" xlink:label="lab_sibn_NonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Option [Member]</link:label>
    <link:label id="lab_sibn_NonqualifiedStockOptionMember_documentation_en-US" xlink:label="lab_sibn_NonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_NonqualifiedStockOptionMember" xlink:href="sibn-20201231.xsd#sibn_NonqualifiedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_NonqualifiedStockOptionMember" xlink:to="lab_sibn_NonqualifiedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_d80400b8-95e1-438c-a065-eec7ff9b9b76_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash information</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_665978b5-5df3-491c-8a58-04239d4168a4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options, net of shares withheld (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b759adda-212e-4301-9a96-5d70735e0132_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_8009f774-bc2d-41c9-a550-37a6a7ff8457_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental interest rate increase upon default of minimum liquidity covenant (percent)</link:label>
    <link:label id="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_label_en-US" xlink:label="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate Incremental Increase Upon Default Of Covenant</link:label>
    <link:label id="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate Incremental Increase Upon Default Of Covenant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" xlink:to="lab_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_17ef5147-cfc3-4f66-bfa8-d984b9941dc2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_fe064ae7-d8a7-4b66-b994-d5b8b6de1a2c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_c8b1d849-d9ff-4a9a-ac32-78770f33ff70_terseLabel_en-US" xlink:label="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_label_en-US" xlink:label="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent [Abstract]</link:label>
    <link:label id="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_documentation_en-US" xlink:label="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:href="sibn-20201231.xsd#sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:to="lab_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_be342951-e452-40b9-b573-d961d4e8e20c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e2ff2344-f547-4b9e-a1be-7ddd04dfeb5d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7c4847a0-b17a-4671-a876-7bddf260d941_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_OptionsTrancheOneMember_55ca31e3-d8dc-4698-ab1f-57c079e6ebe4_terseLabel_en-US" xlink:label="lab_sibn_OptionsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.84-$3.69</link:label>
    <link:label id="lab_sibn_OptionsTrancheOneMember_label_en-US" xlink:label="lab_sibn_OptionsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche One [Member]</link:label>
    <link:label id="lab_sibn_OptionsTrancheOneMember_documentation_en-US" xlink:label="lab_sibn_OptionsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheOneMember" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OptionsTrancheOneMember" xlink:to="lab_sibn_OptionsTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_53155538-7f37-483b-9487-03674e91f7fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_bade92da-e980-4693-bace-cf322086246a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6dbfb3af-8528-4d17-8e5f-fbd4aae6ca8e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b351ea17-0a55-4bb5-b214-f19362f66a39_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_a31561f2-d453-42c7-acf1-ee08904ec2d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_decb5ac8-5c8c-47af-bd4f-1e1158027132_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3d3befeb-707f-4ec0-9e05-3d292a583213_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4c60666b-60e2-4b84-a91a-ec4f527fe683_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4d6874b0-f7e8-4ca1-aae6-19797873838c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6cc6590b-8ece-41d1-861f-f894b3939c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8a90520e-f357-40ca-b7d9-acb75228720f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_516bb79b-49f6-4dbd-ac34-fc1797d3e7f7_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c8a56748-b696-4d03-8aa6-cbde5253a6ec_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ab2d8fe6-a904-40fe-9e7d-8bc52bf93621_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_888ad80c-7c4e-4bd6-b2cb-b52446fd5163_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_f0e4ea5b-1bdf-4b09-84fe-773c1782efa0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_53854ec3-2661-4ab4-86e3-8f2cf3d79147_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_afc3bc87-0878-444d-89d4-8eb47fd80d54_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_CommonStockWarrantsMember_aeaa5b67-57b1-4d5e-9678-51e30dd74015_verboseLabel_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_sibn_CommonStockWarrantsMember_1f10f23d-e1de-4bb9-8365-80f5e5b07fd1_terseLabel_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_sibn_CommonStockWarrantsMember_label_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_sibn_CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_CommonStockWarrantsMember" xlink:href="sibn-20201231.xsd#sibn_CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_CommonStockWarrantsMember" xlink:to="lab_sibn_CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_964c02f6-e5a5-4e8a-a0a4-ca406bcafb24_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4902ea1c-2816-47c7-bc38-8a47484b040d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8b71e7b0-6176-408d-bf2d-586c14d212e6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1445e548-7d7b-4a50-8b97-7a752057696d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a27cc54c-c399-4cca-a066-e85ef960bae7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Annual Future Minimum Principal Payments Under Loan Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_ff5a2fc5-8efe-42dd-b383-91893fcbb9bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_29038a50-ab87-4835-8a56-89dd07056453_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5ba3a5a6-0c9d-4ec9-8c69-4d4d6bc3a5a6_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_adf4cbce-77ed-4fc6-bd1f-0200f1360085_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5953fae2-2d16-4af9-99c5-e24124021d1d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c5c3fcb9-0c39-479a-ac07-03ef3d0d1a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Uncertain Income Tax Positions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ae8c7d1f-c392-4f03-83c5-f84b32314758_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_61d8a622-e1d6-44fe-a5cf-fdfce2e9878e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, upper limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0261c8bf-c4e1-419b-8723-5dff063af56d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding and final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b2083b03-c249-40b6-8eba-9e5df9054f6c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal and final fee payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_80af6edd-465f-423a-9a2d-bec655dacb0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4e3134c0-bbf9-42e0-b0ba-68fc540e53b1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ceb8e14e-5510-41d1-bb4a-222a90973ce1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7b715d72-782b-4d2c-8a00-645c1c32b290_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_f5ad6872-4233-4325-a63d-3bb5000e83bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f8097309-fa9f-4119-9ba6-f24b9edbf2f4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_49f980dd-43a7-4498-a2c1-277444a6d935_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options, net of shares withheld</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_ShareSubjectToRepurchaseMember_087f046e-6641-4ad1-8bd2-04d17e717fef_terseLabel_en-US" xlink:label="lab_sibn_ShareSubjectToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares subject to repurchase</link:label>
    <link:label id="lab_sibn_ShareSubjectToRepurchaseMember_label_en-US" xlink:label="lab_sibn_ShareSubjectToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Subject To Repurchase [Member]</link:label>
    <link:label id="lab_sibn_ShareSubjectToRepurchaseMember_documentation_en-US" xlink:label="lab_sibn_ShareSubjectToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Subject To Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareSubjectToRepurchaseMember" xlink:href="sibn-20201231.xsd#sibn_ShareSubjectToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareSubjectToRepurchaseMember" xlink:to="lab_sibn_ShareSubjectToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e740a1ab-4ac7-48ae-84c7-d82d5ef2853b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_PayrollProtectionProgramLoanCARESActMember_662f3364-1893-42c2-bedc-b608bf5bec41_terseLabel_en-US" xlink:label="lab_sibn_PayrollProtectionProgramLoanCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan, CARES Act</link:label>
    <link:label id="lab_sibn_PayrollProtectionProgramLoanCARESActMember_label_en-US" xlink:label="lab_sibn_PayrollProtectionProgramLoanCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll Protection Program Loan, CARES Act [Member]</link:label>
    <link:label id="lab_sibn_PayrollProtectionProgramLoanCARESActMember_documentation_en-US" xlink:label="lab_sibn_PayrollProtectionProgramLoanCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll Protection Program Loan, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PayrollProtectionProgramLoanCARESActMember" xlink:href="sibn-20201231.xsd#sibn_PayrollProtectionProgramLoanCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PayrollProtectionProgramLoanCARESActMember" xlink:to="lab_sibn_PayrollProtectionProgramLoanCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_92de788d-4182-48e2-890c-17c3a516660e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_58c25648-4f95-48de-93e4-2a065579f495_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_72999956-a757-45c3-aac1-6667785b8fe2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_a75dc146-eaaf-43b0-a3da-d68636fd3a36_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_eaa04c36-de8b-4f84-b692-dbf354d65844_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0ab6c81f-9d41-4eb3-95b5-7c86b93cbc2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9f682987-bc59-4148-a560-6d08a5e33842_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6a6f6622-eb36-409c-b42f-bc60476d1191_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd8ede98-96b3-4bf3-8625-57ebd2d39002_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a64fbb72-b1a3-40d6-b9b4-8673bb17dd4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_88be98a2-5a5d-4c78-8f67-291da9e372c5_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a5f58f9e-5a89-49c3-87ca-934b082f7910_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35af5f52-7150-4811-9da9-2014fc60a717_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ea22956-b11d-4628-ae4c-bd1f5704dca8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life, options outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da288d38-658c-4623-811e-65674f690289_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef321b72-4a34-4b23-933f-2c0fc23df8a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_92fce96b-399b-459a-be0f-df17e32251eb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_46668a2e-c6a4-408c-afca-9dd70fa9ba94_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2df42e19-d9d5-4cab-8bc0-60d59745daed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_b3dc04a7-998a-405b-95fa-4eab2c8061dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_AllocatedPublicOfferingCosts_cea9b645-6489-4cdd-b95f-d783e31c7fd0_terseLabel_en-US" xlink:label="lab_sibn_AllocatedPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated public offering costs</link:label>
    <link:label id="lab_sibn_AllocatedPublicOfferingCosts_label_en-US" xlink:label="lab_sibn_AllocatedPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Public Offering Costs</link:label>
    <link:label id="lab_sibn_AllocatedPublicOfferingCosts_documentation_en-US" xlink:label="lab_sibn_AllocatedPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AllocatedPublicOfferingCosts" xlink:href="sibn-20201231.xsd#sibn_AllocatedPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AllocatedPublicOfferingCosts" xlink:to="lab_sibn_AllocatedPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_dbc95980-4e06-4082-b99e-bf008e39c382_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ac4b7951-7944-4605-892f-ea997460ec7a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e6f16bd-4274-4a58-ad09-796aa5b97a29_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_PrepaymentPenalty4960MonthsMember_8fcbd007-a72c-4bd3-9084-2712ce4b4640_terseLabel_en-US" xlink:label="lab_sibn_PrepaymentPenalty4960MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty, 49-60 Months</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty4960MonthsMember_label_en-US" xlink:label="lab_sibn_PrepaymentPenalty4960MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty, 49-60 Months [Member]</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty4960MonthsMember_documentation_en-US" xlink:label="lab_sibn_PrepaymentPenalty4960MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty, 49-60 Months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenalty4960MonthsMember" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenalty4960MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PrepaymentPenalty4960MonthsMember" xlink:to="lab_sibn_PrepaymentPenalty4960MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_284b9fec-af6b-44a7-aa2a-b2f080181210_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d8cf210f-4b15-4b8f-8e0b-68077bf6b440_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at statutory federal rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8a123b17-4ab0-40a6-9c6d-c7e613b10891_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_e5e05951-5484-4e96-8721-f57a381a4009_terseLabel_en-US" xlink:label="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treble damages sought per violation of TCPA</link:label>
    <link:label id="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_label_en-US" xlink:label="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Treble Damages Per Violation Of TCPA [Member]</link:label>
    <link:label id="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_documentation_en-US" xlink:label="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Treble Damages Per Violation Of TCPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" xlink:href="sibn-20201231.xsd#sibn_LitigationTrebleDamagesPerViolationOfTCPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" xlink:to="lab_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a6e9066a-048f-4cb1-8fbe-de4a3cee0c1c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a18ff4a3-53f3-413d-b969-59067be35938_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e756f3be-a68b-4c0d-8de0-7f2cef687203_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_cba8561a-17a6-421a-a730-f52298743a9d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4aff5beb-332c-4ab1-8301-ba8b2f2f45ac_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_237555b3-72fe-47cb-84ab-c67a4900945b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7b5cfb55-d637-4623-a35b-52c40e49e954_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>sibn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84ec410f-3815-4763-9bc2-b77d68e36727,g:546a3c6e-3b19-4bdc-9aac-42f0e40439c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://si-bone.com/role/Cover" xlink:type="simple" xlink:href="sibn-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eb90797a-55c3-40d5-be65-c07680ec1572" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentType_eb90797a-55c3-40d5-be65-c07680ec1572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_8cdf7bfa-7a60-4576-8aec-35c865130840" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentAnnualReport_8cdf7bfa-7a60-4576-8aec-35c865130840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3b7b2739-df51-41d5-a9d4-23e2ed38d2f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentPeriodEndDate_3b7b2739-df51-41d5-a9d4-23e2ed38d2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_09db75ee-aa3c-4e02-9964-f4d52d6405ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_CurrentFiscalYearEndDate_09db75ee-aa3c-4e02-9964-f4d52d6405ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_acb099ed-2e87-40d3-af96-1a4053acc5c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentTransitionReport_acb099ed-2e87-40d3-af96-1a4053acc5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_349f42fd-b2fa-4257-810e-d9ecac7f2661" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityFileNumber_349f42fd-b2fa-4257-810e-d9ecac7f2661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_566e0c64-7134-471d-abd1-a4ae87779c1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityRegistrantName_566e0c64-7134-471d-abd1-a4ae87779c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7e045a04-4867-4a4a-ba97-a8b8847f42e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityCentralIndexKey_7e045a04-4867-4a4a-ba97-a8b8847f42e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cf98103f-d85a-4514-a77c-67cbf80e3a5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentFiscalYearFocus_cf98103f-d85a-4514-a77c-67cbf80e3a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f6b2db63-683e-4352-b14e-b6fe6cbb8f4f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f6b2db63-683e-4352-b14e-b6fe6cbb8f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dd00f5d7-7cb4-437b-88eb-44add0f2091b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_AmendmentFlag_dd00f5d7-7cb4-437b-88eb-44add0f2091b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3d6f1673-80d7-4995-835e-7d173bdf85da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3d6f1673-80d7-4995-835e-7d173bdf85da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9a7d249f-d0b1-4f4b-b275-f9beb82630c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityTaxIdentificationNumber_9a7d249f-d0b1-4f4b-b275-f9beb82630c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c2f20449-69ee-42ff-a9a4-380fc785d0d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityAddressAddressLine1_c2f20449-69ee-42ff-a9a4-380fc785d0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ec1956b0-36f4-4a67-955b-ea9348e84128" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityAddressAddressLine2_ec1956b0-36f4-4a67-955b-ea9348e84128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d6c6ecdf-4eff-454a-82a4-fa811726c1c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityAddressCityOrTown_d6c6ecdf-4eff-454a-82a4-fa811726c1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b15ade12-41f3-4064-9fe4-d244e8b5b5bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityAddressStateOrProvince_b15ade12-41f3-4064-9fe4-d244e8b5b5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_daa49ba3-98ef-49cb-9749-b93c29bc6c30" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityAddressPostalZipCode_daa49ba3-98ef-49cb-9749-b93c29bc6c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_be575630-69cf-49cb-bf61-8d5db8bfbfa9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_CityAreaCode_be575630-69cf-49cb-bf61-8d5db8bfbfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_061cdcf4-42b4-4285-b8f9-9da0b354ffce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_LocalPhoneNumber_061cdcf4-42b4-4285-b8f9-9da0b354ffce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9a211d57-3b4a-488f-a837-85c4f3fc8673" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_Security12bTitle_9a211d57-3b4a-488f-a837-85c4f3fc8673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7df884fb-42d0-4de5-98d4-0782219e2249" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_TradingSymbol_7df884fb-42d0-4de5-98d4-0782219e2249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3f7d4a41-ec9d-4b79-ae1d-f2eb77bce8a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_SecurityExchangeName_3f7d4a41-ec9d-4b79-ae1d-f2eb77bce8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c8b9201a-9329-4b02-9aac-667ddfa6b480" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c8b9201a-9329-4b02-9aac-667ddfa6b480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_52bb62c0-3db3-492d-b9a0-168062220167" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityVoluntaryFilers_52bb62c0-3db3-492d-b9a0-168062220167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_eff6a3e4-3b16-413d-8ac2-d1517232adf4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityCurrentReportingStatus_eff6a3e4-3b16-413d-8ac2-d1517232adf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_800c3460-fbd4-45f4-8eed-ee9586a4b1ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityInteractiveDataCurrent_800c3460-fbd4-45f4-8eed-ee9586a4b1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_246d4369-0b73-48fd-a3d8-a94b807d0227" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityFilerCategory_246d4369-0b73-48fd-a3d8-a94b807d0227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_99672a2d-d65d-42e6-a1de-29b02aa17a91" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntitySmallBusiness_99672a2d-d65d-42e6-a1de-29b02aa17a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_99ccec34-defc-4f1f-a8f0-7338dffe33a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityEmergingGrowthCompany_99ccec34-defc-4f1f-a8f0-7338dffe33a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_3b3023d5-a6a8-4c79-8326-f487fe75016b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityExTransitionPeriod_3b3023d5-a6a8-4c79-8326-f487fe75016b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_39571aed-a48d-42af-9143-7c12b0de8e84" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_IcfrAuditorAttestationFlag_39571aed-a48d-42af-9143-7c12b0de8e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f849872f-a7db-4102-a730-553714afb6b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityShellCompany_f849872f-a7db-4102-a730-553714afb6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1df68d92-ce63-4ccc-8d6b-8ed4fe352001" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityPublicFloat_1df68d92-ce63-4ccc-8d6b-8ed4fe352001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6f9086c0-466d-4ee7-b2dd-411d72bc60b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6f9086c0-466d-4ee7-b2dd-411d72bc60b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d8bcdc3a-c63e-4297-b382-3c7643da10f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba3930ed-3fb2-4d2b-95b2-672273b95744" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d8bcdc3a-c63e-4297-b382-3c7643da10f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_33e68ad1-a94c-4690-91eb-784684a469aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33e68ad1-a94c-4690-91eb-784684a469aa" xlink:to="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e23ed24-9bc1-440e-8733-3d8ff367a14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e23ed24-9bc1-440e-8733-3d8ff367a14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5f7f04a7-1fb8-472d-b83a-484968af26e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5f7f04a7-1fb8-472d-b83a-484968af26e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2d71ec1b-1194-463c-82cc-1089179f0c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2d71ec1b-1194-463c-82cc-1089179f0c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_22e09ca8-367d-429d-8c6c-64761289e127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:to="loc_us-gaap_InventoryNet_22e09ca8-367d-429d-8c6c-64761289e127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59aea973-ba99-4200-991f-01268a6dbf34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59aea973-ba99-4200-991f-01268a6dbf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_419e6ffc-975a-483d-986c-545491c77e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c399631e-b615-49a5-b444-0b7614e73f23" xlink:to="loc_us-gaap_AssetsCurrent_419e6ffc-975a-483d-986c-545491c77e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fcfef6e5-f529-4fa0-b638-b52164437d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fcfef6e5-f529-4fa0-b638-b52164437d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17f74ddf-13ab-406f-a610-d87e62efaaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17f74ddf-13ab-406f-a610-d87e62efaaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c866f90f-1797-40e6-a9b2-3a99152e304e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c866f90f-1797-40e6-a9b2-3a99152e304e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2de49cba-c540-4e06-b2af-98ab693f3ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e53a5ab1-2617-4817-bda2-44fc91fbfc63" xlink:to="loc_us-gaap_Assets_2de49cba-c540-4e06-b2af-98ab693f3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33e68ad1-a94c-4690-91eb-784684a469aa" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0ad4a407-cbb6-492b-bc9b-8f5d26602d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0ad4a407-cbb6-492b-bc9b-8f5d26602d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3802a90a-d0e7-4276-87b2-d56b6a90ef30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ad4a407-cbb6-492b-bc9b-8f5d26602d1f" xlink:to="loc_us-gaap_AccountsPayableCurrent_3802a90a-d0e7-4276-87b2-d56b6a90ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eef23b92-0d7e-4d63-b520-348e815b08b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ad4a407-cbb6-492b-bc9b-8f5d26602d1f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eef23b92-0d7e-4d63-b520-348e815b08b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_16efd3fa-136a-44be-9c6c-7a47cf2ed9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ad4a407-cbb6-492b-bc9b-8f5d26602d1f" xlink:to="loc_us-gaap_LongTermDebtCurrent_16efd3fa-136a-44be-9c6c-7a47cf2ed9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c9bb854-d867-4b4e-b9fb-b7b9fc15d8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ad4a407-cbb6-492b-bc9b-8f5d26602d1f" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c9bb854-d867-4b4e-b9fb-b7b9fc15d8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_99abe551-f412-426e-ade1-cc0fec49ddea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_99abe551-f412-426e-ade1-cc0fec49ddea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c72597f9-e37a-4e48-8b96-82a2a8ad1a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c72597f9-e37a-4e48-8b96-82a2a8ad1a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b9f64de7-7297-4726-98a1-59b51a4f6fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_Liabilities_b9f64de7-7297-4726-98a1-59b51a4f6fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_69b26146-ca71-40c7-8274-3cb8af9f4489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_CommitmentsAndContingencies_69b26146-ca71-40c7-8274-3cb8af9f4489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7957508e-eea2-44d5-9a75-6a53147eeae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:to="loc_us-gaap_PreferredStockValue_7957508e-eea2-44d5-9a75-6a53147eeae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a8ba1663-11e1-44d2-ae71-7b64393c5f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:to="loc_us-gaap_CommonStockValue_a8ba1663-11e1-44d2-ae71-7b64393c5f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d94ec2e9-9f11-43e6-a6a7-81bfc22d04fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d94ec2e9-9f11-43e6-a6a7-81bfc22d04fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21afb8d7-b7d0-4a68-811c-9ae902f8b3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21afb8d7-b7d0-4a68-811c-9ae902f8b3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dda5e768-137f-4bc8-99d4-a75ac4c22c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dda5e768-137f-4bc8-99d4-a75ac4c22c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13e37a2e-b240-4391-94fa-3cd4757962dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2101494-bfdc-4238-b4ae-7acaeb855452" xlink:to="loc_us-gaap_StockholdersEquity_13e37a2e-b240-4391-94fa-3cd4757962dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_caf793ce-1a6d-4d54-afef-0034687652e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a077d3b-6214-4317-8e9a-8ef4fcd20024" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_caf793ce-1a6d-4d54-afef-0034687652e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d5d588e8-e56b-40a5-84ce-56e42a9204a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d5d588e8-e56b-40a5-84ce-56e42a9204a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_68ab5eb3-1d2b-4691-a825-2843d54cc201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_68ab5eb3-1d2b-4691-a825-2843d54cc201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2644c966-0a10-4848-baea-101c6d7a2c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2644c966-0a10-4848-baea-101c6d7a2c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_177dbf8c-5161-4de4-9f54-74b7e71f6f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_177dbf8c-5161-4de4-9f54-74b7e71f6f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ff8c3b37-316b-4c3a-9492-38ba0e2226b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ff8c3b37-316b-4c3a-9492-38ba0e2226b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c393e450-6784-49ab-b3cc-3ec833132eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c393e450-6784-49ab-b3cc-3ec833132eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_de7b358f-2749-4510-8b0f-2f1c4833ad00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_de7b358f-2749-4510-8b0f-2f1c4833ad00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5a126ab8-b09e-4be5-8a42-f9f0b81e832e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_CommonStockSharesIssued_5a126ab8-b09e-4be5-8a42-f9f0b81e832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_da97c392-ca7e-4de2-880a-8669a1810772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c1ee9bc3-6c9e-41d8-8575-d830d2e4ff8c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_da97c392-ca7e-4de2-880a-8669a1810772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10032220-d727-4051-a90c-267978e93e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10032220-d727-4051-a90c-267978e93e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9c703c55-60b5-4054-97fc-1bfbd82f9d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9c703c55-60b5-4054-97fc-1bfbd82f9d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f8ade563-c7ca-4a56-965d-5368c98a4a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_GrossProfit_f8ade563-c7ca-4a56-965d-5368c98a4a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_397f463e-b591-46a8-ba85-2f8a449aa028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_397f463e-b591-46a8-ba85-2f8a449aa028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_ca4714a0-2d8b-4829-b957-799af3eb1c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_397f463e-b591-46a8-ba85-2f8a449aa028" xlink:to="loc_us-gaap_SellingAndMarketingExpense_ca4714a0-2d8b-4829-b957-799af3eb1c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3616a288-402a-4697-90a6-a470c96d819e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_397f463e-b591-46a8-ba85-2f8a449aa028" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3616a288-402a-4697-90a6-a470c96d819e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1b60d8bb-0313-43a5-922a-2a876fb36be9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_397f463e-b591-46a8-ba85-2f8a449aa028" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1b60d8bb-0313-43a5-922a-2a876fb36be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9bd4d982-e799-4b22-9176-5ced019df834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_397f463e-b591-46a8-ba85-2f8a449aa028" xlink:to="loc_us-gaap_OperatingExpenses_9bd4d982-e799-4b22-9176-5ced019df834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5249b743-6afa-4943-82bc-f1a46357b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_OperatingIncomeLoss_5249b743-6afa-4943-82bc-f1a46357b7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bd95284-9e0d-463a-9c17-7cc62b8f7d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bd95284-9e0d-463a-9c17-7cc62b8f7d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_87d58b18-e622-4608-950b-ea4c158901fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bd95284-9e0d-463a-9c17-7cc62b8f7d95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_87d58b18-e622-4608-950b-ea4c158901fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e6eced8f-f8fc-4827-9d31-237e28844cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bd95284-9e0d-463a-9c17-7cc62b8f7d95" xlink:to="loc_us-gaap_InterestExpense_e6eced8f-f8fc-4827-9d31-237e28844cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_02bf4e9d-6e8a-4d32-9a0c-4c402b0e0a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bd95284-9e0d-463a-9c17-7cc62b8f7d95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_02bf4e9d-6e8a-4d32-9a0c-4c402b0e0a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a9671d4-aec6-409c-9d5e-9d68bb2d3433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_NetIncomeLoss_6a9671d4-aec6-409c-9d5e-9d68bb2d3433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b14addf9-6be2-461a-bed4-cbf758bb0527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b14addf9-6be2-461a-bed4-cbf758bb0527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fc3ac705-2028-4b20-afe0-77baf61a7723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b14addf9-6be2-461a-bed4-cbf758bb0527" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fc3ac705-2028-4b20-afe0-77baf61a7723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e287598d-a6a8-4ba9-9b1c-023653167afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b14addf9-6be2-461a-bed4-cbf758bb0527" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e287598d-a6a8-4ba9-9b1c-023653167afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9eae0917-d6f5-4a89-b5bf-ee547fb5ee8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9eae0917-d6f5-4a89-b5bf-ee547fb5ee8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_f465af32-c09e-437f-8359-df3aef849273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_f465af32-c09e-437f-8359-df3aef849273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5f1d8d4f-1ac6-4dc0-bc2e-a3850718788c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cabff0f-13e8-423d-9e5c-e4a36683c6bc" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5f1d8d4f-1ac6-4dc0-bc2e-a3850718788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_450e356a-30d8-4669-9728-bf79f267ab82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_450e356a-30d8-4669-9728-bf79f267ab82" xlink:to="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e3e93f2-af95-4310-8321-f8e4a9df9ddd" xlink:to="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f5002eff-4278-4fd1-b3d8-aa968cc5848d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_CommonStockMember_f5002eff-4278-4fd1-b3d8-aa968cc5848d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3d0bc404-0697-4135-b083-d6947f0f93c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3d0bc404-0697-4135-b083-d6947f0f93c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_271194e0-4ec5-4b64-8e88-a489e2d18415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_271194e0-4ec5-4b64-8e88-a489e2d18415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8c122d4d-aba5-4047-8d4b-4f1abce9ea6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbdc6785-668d-415f-b61d-6f8dc025cd5f" xlink:to="loc_us-gaap_RetainedEarningsMember_8c122d4d-aba5-4047-8d4b-4f1abce9ea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6c116a0c-5121-4b94-baaa-cb3599b8df82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0a7d0533-cb7b-45bd-bf1e-911e8fcc60a2" xlink:to="loc_us-gaap_StatementLineItems_6c116a0c-5121-4b94-baaa-cb3599b8df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6c116a0c-5121-4b94-baaa-cb3599b8df82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_91147c60-b105-42a8-8b87-3a2b1543ffa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_SharesOutstanding_91147c60-b105-42a8-8b87-3a2b1543ffa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbaa4eb3-71c4-4208-bcdf-2ab85761e171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockholdersEquity_bbaa4eb3-71c4-4208-bcdf-2ab85761e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97e41510-ddde-4af4-a9dd-c54f6f7208d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97e41510-ddde-4af4-a9dd-c54f6f7208d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ce1cbc91-76f0-4086-b082-71b240c0f68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ce1cbc91-76f0-4086-b082-71b240c0f68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f5b30d3-ba19-412f-8722-aa4d785e43a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f5b30d3-ba19-412f-8722-aa4d785e43a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58a8e8fd-f99d-43ec-a2f1-64755fcfb4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58a8e8fd-f99d-43ec-a2f1-64755fcfb4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab86248e-5993-4f7a-9e14-c3245d440e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab86248e-5993-4f7a-9e14-c3245d440e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_38b57f73-231e-4775-ad67-fc14d8d133e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_38b57f73-231e-4775-ad67-fc14d8d133e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_410bee5b-50b0-4ad1-be11-19117c3136de" xlink:href="sibn-20201231.xsd#sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits_410bee5b-50b0-4ad1-be11-19117c3136de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_16476e1b-cc8d-4790-9881-6ee21e219b66" xlink:href="sibn-20201231.xsd#sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits_16476e1b-cc8d-4790-9881-6ee21e219b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_898c8dfd-7bff-4f35-a48e-db8e6cbfad0e" xlink:href="sibn-20201231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_898c8dfd-7bff-4f35-a48e-db8e6cbfad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_37000aa8-f789-437c-849f-e2498c24b8e4" xlink:href="sibn-20201231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_37000aa8-f789-437c-849f-e2498c24b8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d62816dd-077d-4861-9952-8589153394bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d62816dd-077d-4861-9952-8589153394bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_f7b38edd-6cf5-4863-8a14-b5421804be23" xlink:href="sibn-20201231.xsd#sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions_f7b38edd-6cf5-4863-8a14-b5421804be23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c11adb10-b5e1-432c-9716-3cd84f3e09d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c11adb10-b5e1-432c-9716-3cd84f3e09d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_14b97aad-99c1-4df4-bf89-1bc63be98ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_14b97aad-99c1-4df4-bf89-1bc63be98ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_df37ca6f-15b3-467f-91d1-e5ead508afbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_df37ca6f-15b3-467f-91d1-e5ead508afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c232e2b-43b5-4fba-a6eb-652ed93fca1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_NetIncomeLoss_5c232e2b-43b5-4fba-a6eb-652ed93fca1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_47f93dfa-ea7b-4ec6-ad84-32dd64c11068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_SharesOutstanding_47f93dfa-ea7b-4ec6-ad84-32dd64c11068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04b950bb-5da8-49b3-8c0e-174c03e82ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5b224e7-2e9c-4110-86d6-914e9def25ab" xlink:to="loc_us-gaap_StockholdersEquity_04b950bb-5da8-49b3-8c0e-174c03e82ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sibn-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aa214347-bb3a-409f-9e67-8d61ac7d0f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aa214347-bb3a-409f-9e67-8d61ac7d0f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36169690-a992-4436-9a4e-633d28e581b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aa214347-bb3a-409f-9e67-8d61ac7d0f61" xlink:to="loc_us-gaap_NetIncomeLoss_36169690-a992-4436-9a4e-633d28e581b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aa214347-bb3a-409f-9e67-8d61ac7d0f61" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_afaf5cff-70b2-4f05-ae7e-601409c0a932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_ShareBasedCompensation_afaf5cff-70b2-4f05-ae7e-601409c0a932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ec3b579f-61bb-4fda-a9ac-02ec50a72347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ec3b579f-61bb-4fda-a9ac-02ec50a72347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d0590522-72d0-4d1c-9103-a1d6f056df34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d0590522-72d0-4d1c-9103-a1d6f056df34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7c94d06d-d090-4b55-a45c-0ecb56c301d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7c94d06d-d090-4b55-a45c-0ecb56c301d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_2a376de8-5ad9-47b8-9cc6-9795a54397dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_2a376de8-5ad9-47b8-9cc6-9795a54397dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8f5d78b4-b4c5-45d9-8937-418c4733213c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8f5d78b4-b4c5-45d9-8937-418c4733213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f2ea258a-8bfd-4e3e-8b2e-6acb344aaff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f2ea258a-8bfd-4e3e-8b2e-6acb344aaff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_771b6cfd-438d-4ce3-a2f9-aef0b2c44775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ab8a2a3-0a98-4eb4-a6fa-0ae129e19c09" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_771b6cfd-438d-4ce3-a2f9-aef0b2c44775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aa214347-bb3a-409f-9e67-8d61ac7d0f61" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e949502d-974a-4a75-8503-6d9044eabfd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e949502d-974a-4a75-8503-6d9044eabfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_84980928-7799-4c8d-a927-f9fc188d39c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_84980928-7799-4c8d-a927-f9fc188d39c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_62a1d666-05b8-4d61-970e-a0517ed06699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_62a1d666-05b8-4d61-970e-a0517ed06699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eca8ccb6-37e6-4b5e-90b2-f8811e648848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eca8ccb6-37e6-4b5e-90b2-f8811e648848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7bcb197e-7d20-4b3d-87b6-1b77781b3d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d4e3279-cabb-4f5b-926b-948212e3d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7bcb197e-7d20-4b3d-87b6-1b77781b3d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aafde4-45b7-4911-9681-71cb6703efb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aa214347-bb3a-409f-9e67-8d61ac7d0f61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aafde4-45b7-4911-9681-71cb6703efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ProceedsFromMaturityOfMarketableSecurities_a3024bcf-def9-46dd-b9e1-90695011cfbd" xlink:href="sibn-20201231.xsd#sibn_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:to="loc_sibn_ProceedsFromMaturityOfMarketableSecurities_a3024bcf-def9-46dd-b9e1-90695011cfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ProceedsFromSaleOfMarketableSecurities_756cdc21-de1a-457c-827a-0a053ab902bb" xlink:href="sibn-20201231.xsd#sibn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:to="loc_sibn_ProceedsFromSaleOfMarketableSecurities_756cdc21-de1a-457c-827a-0a053ab902bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9f013f99-cdda-48e7-9bf9-3c3a2bc5114b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9f013f99-cdda-48e7-9bf9-3c3a2bc5114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e29486b9-bb7e-45a3-a010-31199b10ffa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e29486b9-bb7e-45a3-a010-31199b10ffa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe9b6e0d-ac22-4619-a21c-43fba48bb90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb1027fa-1f41-4acd-a1be-167d353b5d65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe9b6e0d-ac22-4619-a21c-43fba48bb90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33fb8e9a-b4fd-467f-a216-f8c5a2056b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33fb8e9a-b4fd-467f-a216-f8c5a2056b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_797ac616-f531-4ed3-971a-ccfd8eb5827d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_797ac616-f531-4ed3-971a-ccfd8eb5827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4cccb9e1-8e89-4e10-b26b-ea08a0a80c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4cccb9e1-8e89-4e10-b26b-ea08a0a80c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_88a04c06-6717-443e-b979-bf8cebf17779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_88a04c06-6717-443e-b979-bf8cebf17779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_db7fd39b-89ae-484e-ad93-2b61b06f2f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_db7fd39b-89ae-484e-ad93-2b61b06f2f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4a4c464f-afee-4671-8b98-89f2ca14d51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4a4c464f-afee-4671-8b98-89f2ca14d51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_0bd48b05-6aa6-4d96-ae49-a82b0132bc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_ProceedsFromStockPlans_0bd48b05-6aa6-4d96-ae49-a82b0132bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_0275ffff-8598-47dd-a791-ec039419acb4" xlink:href="sibn-20201231.xsd#sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions_0275ffff-8598-47dd-a791-ec039419acb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_560017ea-5bde-43d5-ae12-5b704f605129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_560017ea-5bde-43d5-ae12-5b704f605129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8bcf9656-a89f-4ace-af21-1f7668c87440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c5ea7e1-4836-47fe-9fd6-0d75b2452442" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8bcf9656-a89f-4ace-af21-1f7668c87440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdead970-55ee-461a-931e-4dacbc865eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdead970-55ee-461a-931e-4dacbc865eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a63ec918-e0c1-4a85-aab8-0b5e077df298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a63ec918-e0c1-4a85-aab8-0b5e077df298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_3491d838-e78d-441e-b340-b4c754022b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_3491d838-e78d-441e-b340-b4c754022b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2403e91-98c7-478d-8f4b-eeb591c1228b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3491d838-e78d-441e-b340-b4c754022b33" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2403e91-98c7-478d-8f4b-eeb591c1228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9f187a2-cf62-4466-9433-edc66568cf4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3491d838-e78d-441e-b340-b4c754022b33" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9f187a2-cf62-4466-9433-edc66568cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd0de8c6-0861-4377-8905-c3cb9f771f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd0de8c6-0861-4377-8905-c3cb9f771f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ca1e2511-66f3-44b4-8dcf-027a779431d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd0de8c6-0861-4377-8905-c3cb9f771f19" xlink:to="loc_us-gaap_InterestPaidNet_ca1e2511-66f3-44b4-8dcf-027a779431d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b1d42a9b-4f3c-4b4f-850b-c62209ebe00a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99a4195e-72da-44ba-a173-9952d5630edf" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b1d42a9b-4f3c-4b4f-850b-c62209ebe00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_VestingOfEarlyExercisedStockOptions_5234e6f0-f7a7-479d-9a42-49f348319e18" xlink:href="sibn-20201231.xsd#sibn_VestingOfEarlyExercisedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b1d42a9b-4f3c-4b4f-850b-c62209ebe00a" xlink:to="loc_sibn_VestingOfEarlyExercisedStockOptions_5234e6f0-f7a7-479d-9a42-49f348319e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f157c6b9-d3cd-492c-92bd-efe2386219f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b1d42a9b-4f3c-4b4f-850b-c62209ebe00a" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f157c6b9-d3cd-492c-92bd-efe2386219f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/TheCompanyandNatureofBusiness" xlink:type="simple" xlink:href="sibn-20201231.xsd#TheCompanyandNatureofBusiness"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/TheCompanyandNatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8c8ef80-3acc-4a98-bbcb-a32c4c4943ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_7a7a87e7-b0d3-434c-ae4e-0def9f62e9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8c8ef80-3acc-4a98-bbcb-a32c4c4943ff" xlink:to="loc_us-gaap_NatureOfOperations_7a7a87e7-b0d3-434c-ae4e-0def9f62e9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#TheCompanyandNatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/TheCompanyandNatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2fd95adb-e833-4825-820c-0d0e34971445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2fd95adb-e833-4825-820c-0d0e34971445" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bc5272ae-26cb-41e0-b0ad-34f9410857ff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_015f1a59-b82a-425f-a8d3-e083b327b1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_us-gaap_IPOMember_015f1a59-b82a-425f-a8d3-e083b327b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_FollowOnPublicOfferingMember_c101812a-0520-478e-a856-b5202d382bb5" xlink:href="sibn-20201231.xsd#sibn_FollowOnPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_FollowOnPublicOfferingMember_c101812a-0520-478e-a856-b5202d382bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_d4de78fc-b540-4ff3-a616-1dedf198a665" xlink:href="sibn-20201231.xsd#sibn_FollowOnPublicOfferingAndSecondaryOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_FollowOnPublicOfferingAndSecondaryOfferingMember_d4de78fc-b540-4ff3-a616-1dedf198a665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_77ce0c0d-f4c9-4dc9-94eb-a4883afc0756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_us-gaap_OverAllotmentOptionMember_77ce0c0d-f4c9-4dc9-94eb-a4883afc0756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SecondFollowOnPublicOfferingMember_765e2f28-4649-486c-95ef-c43e10ac309d" xlink:href="sibn-20201231.xsd#sibn_SecondFollowOnPublicOfferingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_SecondFollowOnPublicOfferingMember_765e2f28-4649-486c-95ef-c43e10ac309d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SecondaryOfferingMember_21a243f3-0606-4242-ab22-4b9e4157fdfe" xlink:href="sibn-20201231.xsd#sibn_SecondaryOfferingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8de4ac8-5c93-4e13-bbc8-a7bdf39e79db" xlink:to="loc_sibn_SecondaryOfferingMember_21a243f3-0606-4242-ab22-4b9e4157fdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a148e0aa-d002-4045-a2a3-3acbdf413bbd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f86c0011-0747-42e2-850b-849156edfa52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f86c0011-0747-42e2-850b-849156edfa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7a64179c-6842-4456-89d9-ce0ace835364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7a64179c-6842-4456-89d9-ce0ace835364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_39fed3cb-e526-4905-8585-2dd23e23d3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_39fed3cb-e526-4905-8585-2dd23e23d3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_0e4c5456-72d4-43d1-a1a9-d227c1588e6f" xlink:href="sibn-20201231.xsd#sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering_0e4c5456-72d4-43d1-a1a9-d227c1588e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AllocatedPublicOfferingCosts_6e718bda-297b-46bb-9d8f-2fa827027170" xlink:href="sibn-20201231.xsd#sibn_AllocatedPublicOfferingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9b7f53d7-2e12-4711-8bb2-57565a42231e" xlink:to="loc_sibn_AllocatedPublicOfferingCosts_6e718bda-297b-46bb-9d8f-2fa827027170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85c4e2b0-60ad-4696-9484-7b64d993cb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7378afc7-1d18-42a2-8105-93767397012e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85c4e2b0-60ad-4696-9484-7b64d993cb4a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7378afc7-1d18-42a2-8105-93767397012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cda602b-4739-4400-8e4b-c7c8b7ab950b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cda602b-4739-4400-8e4b-c7c8b7ab950b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8949dacf-4847-4491-b1cf-b6e26d718012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8949dacf-4847-4491-b1cf-b6e26d718012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f3561590-fbb8-4e78-a13d-f2df70e4c8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_UseOfEstimates_f3561590-fbb8-4e78-a13d-f2df70e4c8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock_378ad9ad-8270-46c2-90c5-e5102962dca9" xlink:href="sibn-20201231.xsd#sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock_378ad9ad-8270-46c2-90c5-e5102962dca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_52e40697-b70a-4751-aea6-6d46c3591ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_52e40697-b70a-4751-aea6-6d46c3591ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a1d02926-5595-404c-ae1c-05161ded190b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a1d02926-5595-404c-ae1c-05161ded190b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_faf5aa09-b4d8-4168-9f61-a80f81cc5344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_faf5aa09-b4d8-4168-9f61-a80f81cc5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_40159e09-3d3b-49e1-b515-4a2a94c7879f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_40159e09-3d3b-49e1-b515-4a2a94c7879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_086c4a01-dd43-4f10-8dae-e329caa8f197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_086c4a01-dd43-4f10-8dae-e329caa8f197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_0771e0d8-cc73-4882-95a8-36b892022206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_0771e0d8-cc73-4882-95a8-36b892022206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_43307e69-5324-452e-a369-cc10e5ac01d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_43307e69-5324-452e-a369-cc10e5ac01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_009e46f0-d3ef-4e34-8320-f05378558236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_009e46f0-d3ef-4e34-8320-f05378558236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_46377046-10ff-466f-86e8-7a714a53876a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_46377046-10ff-466f-86e8-7a714a53876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bbea4d1a-dfb6-4d52-b56a-8efc92cf1068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bbea4d1a-dfb6-4d52-b56a-8efc92cf1068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c721c51d-bf4f-4a21-8121-312fa804a374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c721c51d-bf4f-4a21-8121-312fa804a374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_169ac5ce-0941-47d1-9ad7-410c71363791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_169ac5ce-0941-47d1-9ad7-410c71363791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_94a9baad-15df-4c03-86fc-349c1110a3d5" xlink:href="sibn-20201231.xsd#sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_94a9baad-15df-4c03-86fc-349c1110a3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fc9bb9df-26fb-4cf0-9e04-9e27840c041a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fc9bb9df-26fb-4cf0-9e04-9e27840c041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ba8f69df-126a-481b-bbe4-e6bd23d24da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ba8f69df-126a-481b-bbe4-e6bd23d24da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_c705a056-ac9a-4ada-80a0-32d41104e1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_c705a056-ac9a-4ada-80a0-32d41104e1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ff518c4b-abf5-465b-b1ed-ada3f2f4aa26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ff518c4b-abf5-465b-b1ed-ada3f2f4aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8dc3b3ec-7dec-45cb-857a-1a3783a162d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8dc3b3ec-7dec-45cb-857a-1a3783a162d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1f0ba39d-bdf1-4d40-a889-e8a402fe48cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1f0ba39d-bdf1-4d40-a889-e8a402fe48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a7faceea-2486-45d6-9235-8f8887dd508c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a7faceea-2486-45d6-9235-8f8887dd508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock_f8688acb-1e6f-4479-b49f-82192abc41a7" xlink:href="sibn-20201231.xsd#sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock_f8688acb-1e6f-4479-b49f-82192abc41a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0d4088c0-e2ff-4298-a3b4-0ad5ecd667ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a7487af-b03a-4d54-84d4-1a5c9ab1c4f6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0d4088c0-e2ff-4298-a3b4-0ad5ecd667ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2373e216-ebdb-402e-8760-160d30745ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_5062f2aa-1280-45b2-894a-fa78b85f4b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2373e216-ebdb-402e-8760-160d30745ca0" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_5062f2aa-1280-45b2-894a-fa78b85f4b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_df9b4a04-eab6-43d8-9b71-717ef6aa453a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2373e216-ebdb-402e-8760-160d30745ca0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_df9b4a04-eab6-43d8-9b71-717ef6aa453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c8b4d5db-e4de-41e5-b42f-f62aa2f6aa6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7d6ff860-19b5-4072-ad53-db3ff31fb14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8b4d5db-e4de-41e5-b42f-f62aa2f6aa6e" xlink:to="loc_us-gaap_NumberOfReportableSegments_7d6ff860-19b5-4072-ad53-db3ff31fb14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_282d2825-af6f-4eab-ada1-a2a9ba028945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8b4d5db-e4de-41e5-b42f-f62aa2f6aa6e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_282d2825-af6f-4eab-ada1-a2a9ba028945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8b4d5db-e4de-41e5-b42f-f62aa2f6aa6e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:to="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5fa90a30-219d-49a0-a02a-e2b2c11275ce" xlink:to="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6da75e3c-272a-4019-bb2a-b8c88e457e87" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:to="loc_country_US_6da75e3c-272a-4019-bb2a-b8c88e457e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e398f992-32f6-441a-a744-52f06140841f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a7fb56a-62be-4bff-8ebf-4210c3dad28f" xlink:to="loc_us-gaap_NonUsMember_e398f992-32f6-441a-a744-52f06140841f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5a7e582c-2fd7-4345-b90a-7af406089ca3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b068fb8-0f1f-479c-842b-ba2c69f1aa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b068fb8-0f1f-479c-842b-ba2c69f1aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_17624bd1-2e61-4e70-adb5-dda9024597c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd9e2600-4dc9-4c52-b12e-4e591b861205" xlink:to="loc_us-gaap_Revenues_17624bd1-2e61-4e70-adb5-dda9024597c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesLiquidityDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9f316e0b-b768-4ed8-b535-8072d0d072d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0c6b165f-d420-472e-bf93-f678eb089a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f316e0b-b768-4ed8-b535-8072d0d072d6" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0c6b165f-d420-472e-bf93-f678eb089a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_81ec25eb-c50f-484d-ac66-717f8a1850bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f316e0b-b768-4ed8-b535-8072d0d072d6" xlink:to="loc_us-gaap_LongTermDebt_81ec25eb-c50f-484d-ac66-717f8a1850bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f1447ed9-6a48-42af-8522-519cfe0d3259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f316e0b-b768-4ed8-b535-8072d0d072d6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f1447ed9-6a48-42af-8522-519cfe0d3259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2441d5e4-f35c-4b50-a090-35a1654c5dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f316e0b-b768-4ed8-b535-8072d0d072d6" xlink:to="loc_us-gaap_NetIncomeLoss_2441d5e4-f35c-4b50-a090-35a1654c5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_157a2d34-b46e-4c71-9946-ae01887afee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_157a2d34-b46e-4c71-9946-ae01887afee2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_064e0403-e32e-426a-81ee-b3edeadb6d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_9b475127-2fb4-4cae-a177-1f0834102b32" xlink:href="sibn-20201231.xsd#sibn_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_9b475127-2fb4-4cae-a177-1f0834102b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_73723d38-964c-47bc-b7fc-55d73bd31b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_73723d38-964c-47bc-b7fc-55d73bd31b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4e0702b6-28d0-4305-9f7f-98b3488ce5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1838d025-3f42-4383-92b1-8a99b25861be" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4e0702b6-28d0-4305-9f7f-98b3488ce5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:to="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_537cfa79-6476-469c-a7f9-3c36065cd3d7" xlink:to="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b059c00a-20d7-409f-b81d-8b04436b1950" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:to="loc_srt_MinimumMember_b059c00a-20d7-409f-b81d-8b04436b1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_818f6a7f-9b45-4a83-8718-c9f357b6714f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5eb8ed6-2fe7-4902-8c6c-7b2fd684b225" xlink:to="loc_srt_MaximumMember_818f6a7f-9b45-4a83-8718-c9f357b6714f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9caed9f4-fc5b-4f9e-91a7-115f762b4233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ae0abe1e-4245-415a-9c3b-6032910acb17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9caed9f4-fc5b-4f9e-91a7-115f762b4233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5f51d9bc-d582-4e16-9ec6-dacb9316b45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9caed9f4-fc5b-4f9e-91a7-115f762b4233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5f51d9bc-d582-4e16-9ec6-dacb9316b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bc7d16c-7151-4af5-95e4-faedf23379dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_905799f4-ab50-4ef7-b2f9-54289034750f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bc7d16c-7151-4af5-95e4-faedf23379dc" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_905799f4-ab50-4ef7-b2f9-54289034750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d3217da-b28b-4606-b66f-c93f7c3b7309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d3217da-b28b-4606-b66f-c93f7c3b7309" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:to="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1308db84-51e9-405c-b195-4d6cf49a0b57" xlink:to="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_844a1e1c-be58-4994-99eb-7c2a38f6c954" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:to="loc_srt_MinimumMember_844a1e1c-be58-4994-99eb-7c2a38f6c954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2db1fccb-8e25-461a-83bd-9fbf9b48bc91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32b55c96-6572-4580-9385-ba7ab2b3472b" xlink:to="loc_srt_MaximumMember_2db1fccb-8e25-461a-83bd-9fbf9b48bc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_58e64233-bebf-478e-b752-9766fce8e2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea99e238-09ac-4700-aa32-ab5965a1a4df" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_58e64233-bebf-478e-b752-9766fce8e2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_RevenueRecognitionStandardPaymentTerms_21150d6b-be71-4c3c-a186-7fc57672ae88" xlink:href="sibn-20201231.xsd#sibn_RevenueRecognitionStandardPaymentTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58e64233-bebf-478e-b752-9766fce8e2fb" xlink:to="loc_sibn_RevenueRecognitionStandardPaymentTerms_21150d6b-be71-4c3c-a186-7fc57672ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesWarrantyProgramDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b41586c8-ebd2-40bb-9ea6-82af4316e160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_StandardProductWarrantyTerm_961ba0d8-b671-414d-ba11-1db94eee014b" xlink:href="sibn-20201231.xsd#sibn_StandardProductWarrantyTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b41586c8-ebd2-40bb-9ea6-82af4316e160" xlink:to="loc_sibn_StandardProductWarrantyTerm_961ba0d8-b671-414d-ba11-1db94eee014b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SalesCreditReservePeriod_116c01fc-8765-4a5f-a7c9-111499866ded" xlink:href="sibn-20201231.xsd#sibn_SalesCreditReservePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b41586c8-ebd2-40bb-9ea6-82af4316e160" xlink:to="loc_sibn_SalesCreditReservePeriod_116c01fc-8765-4a5f-a7c9-111499866ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_63828e6f-d7e5-4d2b-b4cb-dfa35c72dd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_951ca379-5f7a-4649-a963-4f383da72f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63828e6f-d7e5-4d2b-b4cb-dfa35c72dd82" xlink:to="loc_us-gaap_AdvertisingExpense_951ca379-5f7a-4649-a963-4f383da72f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecurities" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_765e5523-dd67-4800-8ef7-b8536d6fe10f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_50441c30-ca78-4d52-94d3-58cb1daca46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_765e5523-dd67-4800-8ef7-b8536d6fe10f" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_50441c30-ca78-4d52-94d3-58cb1daca46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_947165cd-b98f-4735-9e74-f9e975c5166e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_139978b0-fe12-4eed-b751-bf5bd2e376d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_947165cd-b98f-4735-9e74-f9e975c5166e" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_139978b0-fe12-4eed-b751-bf5bd2e376d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4b98711c-9357-481b-b317-9514f57b3cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4b98711c-9357-481b-b317-9514f57b3cd2" xlink:to="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5b47a17c-4a5f-47fe-b103-fb3542559abb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2474b399-d94d-4894-950a-08cc63f677ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2474b399-d94d-4894-950a-08cc63f677ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4b577f96-5e6c-487a-bd4a-0c483594d72c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4b577f96-5e6c-487a-bd4a-0c483594d72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_87f7741b-1c2c-4149-9e7e-0bba34c64099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_87f7741b-1c2c-4149-9e7e-0bba34c64099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03337bc1-b656-4de0-986a-7c0f07df429b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06bb659d-f017-44eb-866f-3dff5913ef06" xlink:to="loc_us-gaap_CommercialPaperMember_03337bc1-b656-4de0-986a-7c0f07df429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_2d87813e-8029-43d4-bead-72606dd4382d" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_cba2441b-0d36-49c5-9a89-5ec12aefedf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_cba2441b-0d36-49c5-9a89-5ec12aefedf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_3321f16d-6854-41f3-b0bf-1e9576b3964d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_cba2441b-0d36-49c5-9a89-5ec12aefedf5" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_3321f16d-6854-41f3-b0bf-1e9576b3964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_5710b08b-d5b6-4d89-bad6-e2384ec8d564" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis_5710b08b-d5b6-4d89-bad6-e2384ec8d564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_86d2f62a-034c-4be0-b5df-64234117b7c3" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax_86d2f62a-034c-4be0-b5df-64234117b7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_a8ce04c7-7091-42b2-837d-68edd890c592" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax_a8ce04c7-7091-42b2-837d-68edd890c592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_97e80075-490f-48ad-907c-3bc264a3499a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_901f69db-49bc-4b3b-9263-d09cdb7fdc08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_97e80075-490f-48ad-907c-3bc264a3499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:href="sibn-20201231.xsd#sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_e2b78ab5-9281-4a78-b8fb-f92a51c61089" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis_e2b78ab5-9281-4a78-b8fb-f92a51c61089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_7a172969-dd57-4068-b66e-a32178082882" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax_7a172969-dd57-4068-b66e-a32178082882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_ea214c8c-c09d-4920-9b1e-64055a4b6bf5" xlink:href="sibn-20201231.xsd#sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax_ea214c8c-c09d-4920-9b1e-64055a4b6bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b631a5b2-3921-48c9-8231-4c24f56978fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract_4e00e0c6-f048-4a86-9a35-ce930b934285" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b631a5b2-3921-48c9-8231-4c24f56978fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_7257b0bd-996f-4fc0-82b6-92029987bf80" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesAmortizedCost_7257b0bd-996f-4fc0-82b6-92029987bf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_02521eb2-ed94-426e-adb3-16d96bb3d889" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_02521eb2-ed94-426e-adb3-16d96bb3d889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0123d24d-fea9-4659-83b6-92958d84b58c" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0123d24d-fea9-4659-83b6-92958d84b58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_MarketableSecuritiesFairValue_8fcca066-a9f8-409a-a2a7-fd08726734f8" xlink:href="sibn-20201231.xsd#sibn_MarketableSecuritiesFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_ca563eaf-06ce-4cda-960b-582ff47276fd" xlink:to="loc_sibn_MarketableSecuritiesFairValue_8fcca066-a9f8-409a-a2a7-fd08726734f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_807891fc-fb77-474b-8952-34f46a5d8856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6d8c2c69-bba7-4aa3-9c8b-675b3b177fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_807891fc-fb77-474b-8952-34f46a5d8856" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6d8c2c69-bba7-4aa3-9c8b-675b3b177fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d24dc597-4f72-49a3-a9d3-f80e2d7618b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_37e45e07-878a-4121-850d-1bac7efe8756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d24dc597-4f72-49a3-a9d3-f80e2d7618b1" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_37e45e07-878a-4121-850d-1bac7efe8756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_49addce3-ebef-485e-9e56-73a7a9cc81ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49addce3-ebef-485e-9e56-73a7a9cc81ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab0a57b0-cd08-4ab4-a523-34e370d111cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3af6c565-3663-4787-9d49-8383a974e95c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab0a57b0-cd08-4ab4-a523-34e370d111cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bab01322-6be1-415a-98a8-6a4d0c9512fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab0a57b0-cd08-4ab4-a523-34e370d111cb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bab01322-6be1-415a-98a8-6a4d0c9512fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a82f625d-d435-4d22-b5a0-e3efb98643f3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c72d5f80-2051-4ee3-8e48-b25ceb1797d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c72d5f80-2051-4ee3-8e48-b25ceb1797d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6474665d-bbbe-4fd6-92f3-c7e07ef1846e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6474665d-bbbe-4fd6-92f3-c7e07ef1846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e10b54e0-bf77-4a13-bb92-e2d922801407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b7c9662-1c1a-4030-a8ce-756fed0b079e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e10b54e0-bf77-4a13-bb92-e2d922801407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94a7a728-92f4-4f11-aaed-6a1bb715464d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1cd8c72e-b6af-42b2-b37c-450118968348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1cd8c72e-b6af-42b2-b37c-450118968348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_02301eed-a7e0-44a7-b6fe-e9b8737fa101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_02301eed-a7e0-44a7-b6fe-e9b8737fa101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5810ceb2-f192-4006-9092-a922a808f074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5810ceb2-f192-4006-9092-a922a808f074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_719e8fbc-b780-47e6-80f6-89321dcc2653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_318a1cd4-2c2a-4d61-89c7-5eedb014ece5" xlink:to="loc_us-gaap_CommercialPaperMember_719e8fbc-b780-47e6-80f6-89321dcc2653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e4077ab-969d-4f6d-a672-246c3b505abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c414f0ad-d236-4512-b029-23b9711b2670" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e4077ab-969d-4f6d-a672-246c3b505abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0a79fbb6-f771-49e2-a694-312d63e4d92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e4077ab-969d-4f6d-a672-246c3b505abd" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0a79fbb6-f771-49e2-a694-312d63e4d92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_028f7235-34b3-42f7-9375-d6163db1d8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0a79fbb6-f771-49e2-a694-312d63e4d92f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_028f7235-34b3-42f7-9375-d6163db1d8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce1ba7cf-0961-4837-83f0-73e17975941b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f4fb46a2-1609-40cd-83ed-8c6af4f326ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce1ba7cf-0961-4837-83f0-73e17975941b" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f4fb46a2-1609-40cd-83ed-8c6af4f326ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4cb29d8-9168-408b-943c-4bd889b8b343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3c68ad7e-c456-4c6a-b9f3-f824106de0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4cb29d8-9168-408b-943c-4bd889b8b343" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3c68ad7e-c456-4c6a-b9f3-f824106de0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7f80632b-2ded-4043-bbdc-16f973ffd2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4cb29d8-9168-408b-943c-4bd889b8b343" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7f80632b-2ded-4043-bbdc-16f973ffd2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d7c53cf-51ad-4290-88b9-a102cc053521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d7c53cf-51ad-4290-88b9-a102cc053521" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abeb45f3-a801-4fdc-8a7d-489316efc9fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_157766f5-a7d2-4e26-8f17-87443555046d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_157766f5-a7d2-4e26-8f17-87443555046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6b42772c-26be-47c8-ad87-dabdc47dba54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_ConstructionInProgressMember_6b42772c-26be-47c8-ad87-dabdc47dba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_dfc79877-4642-4d63-991d-84fd22bec903" xlink:href="sibn-20201231.xsd#sibn_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_dfc79877-4642-4d63-991d-84fd22bec903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b2d22a56-579a-4601-986f-2f21776f6a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b2d22a56-579a-4601-986f-2f21776f6a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d69fc370-503a-4a3c-af13-91c3cbaceb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f12e906-9f1d-48b9-b994-e87954e63564" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d69fc370-503a-4a3c-af13-91c3cbaceb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18ba76af-0fcf-4be6-bc0e-272633e6ca7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0ab1fa6b-0e84-493c-a020-aad3e76965aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0ab1fa6b-0e84-493c-a020-aad3e76965aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_624bd60f-0574-4251-91d6-8ee1ccb221cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_624bd60f-0574-4251-91d6-8ee1ccb221cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_edc3e279-21d3-4bc4-b4cc-b2d162430b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_edc3e279-21d3-4bc4-b4cc-b2d162430b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_33d8663f-b4b6-4af0-b3d2-796f4f45da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c8d86bd7-2c6d-4f03-9968-babf4e417d7a" xlink:to="loc_us-gaap_Depreciation_33d8663f-b4b6-4af0-b3d2-796f4f45da9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a319f37-2fb0-4cad-b8de-67c7d2a51840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a319f37-2fb0-4cad-b8de-67c7d2a51840" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6aea9f8c-d250-47ae-8f62-f3023c214b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6aea9f8c-d250-47ae-8f62-f3023c214b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_c71268ff-4325-4f1f-8356-5ae5aa3b0f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:to="loc_us-gaap_LitigationReserveCurrent_c71268ff-4325-4f1f-8356-5ae5aa3b0f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ca99dbf9-dd72-4a24-be5c-f5744b484592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ca99dbf9-dd72-4a24-be5c-f5744b484592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_54d07eda-7661-4613-8831-3fe908201353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_54d07eda-7661-4613-8831-3fe908201353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bfdfa5f8-2e3b-4172-a470-a3d67e2c4182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3ea37e79-2ce9-4f6e-830e-53c0df5fdb94" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bfdfa5f8-2e3b-4172-a470-a3d67e2c4182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d4ec5c4-5ae4-4c2b-82cc-fb76b3971057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a157b2cd-1551-4f3d-8be7-3911250fd157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d4ec5c4-5ae4-4c2b-82cc-fb76b3971057" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a157b2cd-1551-4f3d-8be7-3911250fd157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c416f7fa-4dc5-4430-9731-94a93d023bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_3f1ed2eb-497b-4711-be4a-85da8bbb7466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c416f7fa-4dc5-4430-9731-94a93d023bb3" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_3f1ed2eb-497b-4711-be4a-85da8bbb7466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72847828-3f8c-4d0f-8355-7d94fc28840f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72847828-3f8c-4d0f-8355-7d94fc28840f" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ee5fd53c-a461-49d0-bdaa-60fe7b4d53a2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_94040272-90ac-4ef8-9594-fe1aa081d933" xlink:href="sibn-20201231.xsd#sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:to="loc_sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember_94040272-90ac-4ef8-9594-fe1aa081d933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_bebda192-cdbd-450e-9625-20ef76ee6350" xlink:href="sibn-20201231.xsd#sibn_LitigationTrebleDamagesPerViolationOfTCPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:to="loc_sibn_LitigationTrebleDamagesPerViolationOfTCPAMember_bebda192-cdbd-450e-9625-20ef76ee6350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_b65cb038-3548-4af0-a0c0-aff7d36ec032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ab78713b-68bb-406e-be3c-ad6569797033" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_b65cb038-3548-4af0-a0c0-aff7d36ec032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:to="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_99a662b8-a830-4885-a59f-a7fe56411f9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2110eb98-b53f-4d25-8d30-0a4d08e20a6b" xlink:to="loc_srt_LitigationCaseTypeDomain_99a662b8-a830-4885-a59f-a7fe56411f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EricBFromerChiropracticIncClassActionMember_77450e79-02fd-4815-9496-60669a7c49ed" xlink:href="sibn-20201231.xsd#sibn_EricBFromerChiropracticIncClassActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_99a662b8-a830-4885-a59f-a7fe56411f9a" xlink:to="loc_sibn_EricBFromerChiropracticIncClassActionMember_77450e79-02fd-4815-9496-60669a7c49ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b812a43-7843-441e-9822-88ab470b9281" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_3e0d80ef-b608-47a6-948d-6e4974798a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_3e0d80ef-b608-47a6-948d-6e4974798a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b865a3f7-0eff-4077-abef-6ffad6420fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_PurchaseObligation_b865a3f7-0eff-4077-abef-6ffad6420fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_de73755e-9598-4380-b030-2ef9db013e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_de73755e-9598-4380-b030-2ef9db013e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_25d0f58f-eff2-4fb0-beea-3743dfde7f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationReserveCurrent_25d0f58f-eff2-4fb0-beea-3743dfde7f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17b602e3-dba5-49bc-87ee-0e2a6bb4a57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17b602e3-dba5-49bc-87ee-0e2a6bb4a57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_704acfae-e407-4d14-8b5c-b66748db292c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_704acfae-e407-4d14-8b5c-b66748db292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_27efe6fb-8418-489a-ae71-16a430e86a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationSettlementExpense_27efe6fb-8418-489a-ae71-16a430e86a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_a09d5452-851c-4d19-88c8-595f50608377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f138bc62-bfc0-4919-ae36-8517685d6bf1" xlink:to="loc_us-gaap_LitigationReserve_a09d5452-851c-4d19-88c8-595f50608377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa322752-dfe4-4378-9198-f39511a68eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa322752-dfe4-4378-9198-f39511a68eb2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_d6347a07-ce9e-481f-b6db-8c3dc12b412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_d6347a07-ce9e-481f-b6db-8c3dc12b412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7f52c514-3e49-4ede-9582-415570a6c29a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7f52c514-3e49-4ede-9582-415570a6c29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94335123-fec0-40ab-b07f-7e90bc2a9075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94335123-fec0-40ab-b07f-7e90bc2a9075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_85fab447-fe97-413f-9f6e-b4b3e273cfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_85fab447-fe97-413f-9f6e-b4b3e273cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_955d7f04-1912-46db-adf0-7d95be0375c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_955d7f04-1912-46db-adf0-7d95be0375c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_ab938fc5-b673-479e-828e-ad392897a649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_ab938fc5-b673-479e-828e-ad392897a649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3ec9a393-53c6-4e69-8258-9bafbcf6abad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_53a1c4b0-090d-4d0b-99da-c40aaf4b8b97" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3ec9a393-53c6-4e69-8258-9bafbcf6abad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/Borrowings" xlink:type="simple" xlink:href="sibn-20201231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_677975cc-6126-46a2-b430-c64bc4d63643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_813108df-ed3c-46f5-a4fa-55b3bb334314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_677975cc-6126-46a2-b430-c64bc4d63643" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_813108df-ed3c-46f5-a4fa-55b3bb334314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d2bf9b46-3726-4a52-8836-99e0b4661392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_22d777db-8724-4a91-bdd8-d03729a71392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d2bf9b46-3726-4a52-8836-99e0b4661392" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_22d777db-8724-4a91-bdd8-d03729a71392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f53a91d0-c8d1-4e9d-b5f9-cc90f0745eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d2bf9b46-3726-4a52-8836-99e0b4661392" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f53a91d0-c8d1-4e9d-b5f9-cc90f0745eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsSummaryofBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1ee2ff20-b200-4834-a389-1e529efce2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1ee2ff20-b200-4834-a389-1e529efce2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1368200e-94b4-44cd-95c8-a946e97c35c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1368200e-94b4-44cd-95c8-a946e97c35c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9ec22d27-4b96-4174-8ac4-a1d0a02c7e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9ec22d27-4b96-4174-8ac4-a1d0a02c7e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0297ab23-0a0d-49ee-b652-471bca02ba83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:to="loc_us-gaap_LongTermDebt_0297ab23-0a0d-49ee-b652-471bca02ba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1d29c11c-2f0d-44a5-b6a1-7d84618260ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:to="loc_us-gaap_LongTermDebtCurrent_1d29c11c-2f0d-44a5-b6a1-7d84618260ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b8f08692-75fc-453a-a331-2dbb69e7597e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_463b3cc0-d7c5-4c11-8c64-050b8c0d684d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b8f08692-75fc-453a-a331-2dbb69e7597e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsSummaryofBorrowingsDetails_1"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f63d4157-b59d-4d12-93ce-8d8304211b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f63d4157-b59d-4d12-93ce-8d8304211b02" xlink:to="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_291e596e-6ad8-4a92-98b0-804aa85dfebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_789835d8-0617-4440-8b15-4c29991b566b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_291e596e-6ad8-4a92-98b0-804aa85dfebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9d3b6ffa-3c18-42df-8503-2d90a8ddd8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_291e596e-6ad8-4a92-98b0-804aa85dfebb" xlink:to="loc_us-gaap_SecuredDebtMember_9d3b6ffa-3c18-42df-8503-2d90a8ddd8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dc5578eb-f9d1-4cb6-9c02-8a67de75b562" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PharmakonTermLoanMember_609dae3f-3f5f-44d9-a6a5-536cfcf9373d" xlink:href="sibn-20201231.xsd#sibn_PharmakonTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:to="loc_sibn_PharmakonTermLoanMember_609dae3f-3f5f-44d9-a6a5-536cfcf9373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SolarLoanAndSecurityAgreementMember_ad0152d7-fdb6-41e4-a5ca-c3ac6345f834" xlink:href="sibn-20201231.xsd#sibn_SolarLoanAndSecurityAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:to="loc_sibn_SolarLoanAndSecurityAgreementMember_ad0152d7-fdb6-41e4-a5ca-c3ac6345f834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PayrollProtectionProgramLoanCARESActMember_0ba0c0e7-cefc-463a-9e34-9272dcdcb153" xlink:href="sibn-20201231.xsd#sibn_PayrollProtectionProgramLoanCARESActMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dfbbc3fc-a007-412d-89cd-deaf093d8b92" xlink:to="loc_sibn_PayrollProtectionProgramLoanCARESActMember_0ba0c0e7-cefc-463a-9e34-9272dcdcb153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantThresholdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantThresholdAxis_3fd24df4-bda8-44a8-ba0d-b76d42bdef7b" xlink:to="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheOneMember_8a17bf3c-b95f-45d7-acda-44633b919818" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:to="loc_sibn_DebtCovenantTrancheOneMember_8a17bf3c-b95f-45d7-acda-44633b919818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheTwoMember_cca1d45f-b0ed-4b53-9b0e-483a6b002b67" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:to="loc_sibn_DebtCovenantTrancheTwoMember_cca1d45f-b0ed-4b53-9b0e-483a6b002b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtCovenantTrancheThreeMember_baa52722-00cb-4607-a474-3f8069fba6c5" xlink:href="sibn-20201231.xsd#sibn_DebtCovenantTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantThresholdDomain_0fc4d38b-0144-4162-9af5-88e5df58e8e7" xlink:to="loc_sibn_DebtCovenantTrancheThreeMember_baa52722-00cb-4607-a474-3f8069fba6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7bf34ea6-a6eb-4f1b-b90d-05b72e73acd8" xlink:to="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_02225a5d-4d6b-44cf-ad99-a1cb5904b1ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:to="loc_srt_MinimumMember_02225a5d-4d6b-44cf-ad99-a1cb5904b1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2292180-d56b-4180-8cf6-18e71b5e9583" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_391dd82d-9d16-42eb-a7d4-a88c91cae2b1" xlink:to="loc_srt_MaximumMember_b2292180-d56b-4180-8cf6-18e71b5e9583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_80991bec-1b6e-4e4f-b168-855edc06c934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7e83db5f-5a21-41e3-8468-c1c63e736243" xlink:to="loc_us-gaap_VariableRateDomain_80991bec-1b6e-4e4f-b168-855edc06c934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_VariableOptionOneMember_01f7e6d6-1099-442e-a72b-f286f7731319" xlink:href="sibn-20201231.xsd#sibn_VariableOptionOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_80991bec-1b6e-4e4f-b168-855edc06c934" xlink:to="loc_sibn_VariableOptionOneMember_01f7e6d6-1099-442e-a72b-f286f7731319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:href="sibn-20201231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_b2a3646b-3548-44e0-92bf-9661f4295a77" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenalty3148MonthsMember_fd7d8bb5-1f61-456f-a770-7822e72fd534" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenalty3148MonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:to="loc_sibn_PrepaymentPenalty3148MonthsMember_fd7d8bb5-1f61-456f-a770-7822e72fd534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenalty4960MonthsMember_f0967e92-a387-40cc-9458-008b5e70cac0" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenalty4960MonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_ae651c53-80af-4009-b5c9-a3f43799b7f9" xlink:to="loc_sibn_PrepaymentPenalty4960MonthsMember_f0967e92-a387-40cc-9458-008b5e70cac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c249c3e3-f330-480d-83ce-b5d206146137" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_1b6a0aab-bcbb-48fc-9287-9f8b73479eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_1b6a0aab-bcbb-48fc-9287-9f8b73479eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f6701260-8744-4e66-9faf-ee81ebe17d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_70311ce2-bfaa-42d8-b5cb-83e24d962230" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f6701260-8744-4e66-9faf-ee81ebe17d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e304c35d-0901-4527-b028-483f348c20df" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6a58a90d-b9fa-4c60-94f4-bbc9bcea6931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6a58a90d-b9fa-4c60-94f4-bbc9bcea6931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_685d7ac0-af6a-40a3-b2b1-9ad102f1d4e2" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_685d7ac0-af6a-40a3-b2b1-9ad102f1d4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5708bb7b-e931-4506-8d77-f8f690583030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5708bb7b-e931-4506-8d77-f8f690583030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_3abf7554-dc59-474e-b17e-3d33fb4d934c" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_3abf7554-dc59-474e-b17e-3d33fb4d934c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c8ce33d5-b30d-438a-a2cc-6709923cf3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c8ce33d5-b30d-438a-a2cc-6709923cf3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_6c39e827-0ff2-4db3-ac24-7b9772a35e1b" xlink:href="sibn-20201231.xsd#sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount_6c39e827-0ff2-4db3-ac24-7b9772a35e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_70318e6f-7a7d-4ea0-9e04-13683f27bf91" xlink:href="sibn-20201231.xsd#sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt_70318e6f-7a7d-4ea0-9e04-13683f27bf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c4e9cc99-374a-44dc-9557-6f2bcf997605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c4e9cc99-374a-44dc-9557-6f2bcf997605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_04f6989a-0790-457e-b140-f0b4439adbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_04f6989a-0790-457e-b140-f0b4439adbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_575eb9b1-a5f3-4eb5-8216-3b5eb2110864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentTerm_575eb9b1-a5f3-4eb5-8216-3b5eb2110864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_d3a0da85-ba97-4fcc-8d2e-1a7a679d970f" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_c7478402-3e3a-4167-b606-5d5cb10c5c25" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement_c7478402-3e3a-4167-b606-5d5cb10c5c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_553f4d18-a6e8-47d8-beff-eeb373d31db1" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage_553f4d18-a6e8-47d8-beff-eeb373d31db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_6725ca44-80ce-4b89-b32f-620424dabe50" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage_6725ca44-80ce-4b89-b32f-620424dabe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_4e1db4ed-e664-4c66-a8e6-ae39fcc4e6d6" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage_4e1db4ed-e664-4c66-a8e6-ae39fcc4e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_28e85708-8104-4c80-9526-7956d99c1b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_28e85708-8104-4c80-9526-7956d99c1b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_41c771f2-3474-48a7-bad0-41de1c4a06d9" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal_41c771f2-3474-48a7-bad0-41de1c4a06d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_fd27f44d-b00e-41bb-ad68-a5f32528b529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_fd27f44d-b00e-41bb-ad68-a5f32528b529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_ff88575b-50ff-408a-a03f-89e3872a272f" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_ff88575b-50ff-408a-a03f-89e3872a272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_6dd829d1-703e-4c5a-b61b-da9f83842afc" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold_6dd829d1-703e-4c5a-b61b-da9f83842afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_d7521e83-8bd1-4982-b7d1-89325536a1b7" xlink:href="sibn-20201231.xsd#sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant_d7521e83-8bd1-4982-b7d1-89325536a1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_15abaabd-8889-4834-8d54-0d2bc38ac365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_15abaabd-8889-4834-8d54-0d2bc38ac365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_b78a906c-a602-4397-bf98-859cd1e7dafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_b78a906c-a602-4397-bf98-859cd1e7dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_2fdf8389-ceda-45ad-b51e-901b0120e41d" xlink:href="sibn-20201231.xsd#sibn_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f9e82f22-1256-4619-bef3-de6cbe72ad51" xlink:to="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_2fdf8389-ceda-45ad-b51e-901b0120e41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fd5b70ff-14f8-4b51-ae01-41250e201d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd5b70ff-14f8-4b51-ae01-41250e201d36" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d6467202-3e55-49ce-a2f0-282d5f268e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d6467202-3e55-49ce-a2f0-282d5f268e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eee300f5-4858-4531-b05d-5da2a06315c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eee300f5-4858-4531-b05d-5da2a06315c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d99c9631-9ecf-4a34-bd8c-8a609cc5204f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d99c9631-9ecf-4a34-bd8c-8a609cc5204f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2bd4c81b-2fda-4ca2-9a2f-3bf64027b56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2bd4c81b-2fda-4ca2-9a2f-3bf64027b56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6e95b670-5d56-46d5-bbe1-8bfc94ed46f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6e95b670-5d56-46d5-bbe1-8bfc94ed46f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8f2453e3-2ee8-4af1-ab2b-5399fe1bcf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_67542588-b337-4e98-80a4-3cd35f968fc1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8f2453e3-2ee8-4af1-ab2b-5399fe1bcf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/Warrants" xlink:type="simple" xlink:href="sibn-20201231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e5c90a89-6680-48d9-8a4b-76cc70feeca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_f86797e3-e8a4-4bc7-9d2f-c1ae3d5bdafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e5c90a89-6680-48d9-8a4b-76cc70feeca0" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_f86797e3-e8a4-4bc7-9d2f-c1ae3d5bdafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_06b6425b-7c6c-4e43-9ac8-d8f558bdaf41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c659f4ba-e469-4ca8-bc92-922b2809b41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_06b6425b-7c6c-4e43-9ac8-d8f558bdaf41" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c659f4ba-e469-4ca8-bc92-922b2809b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#WarrantsIssuedandOutstandingDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/WarrantsIssuedandOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_80e25fd4-3ce0-4aed-a4c4-8a2d2048827d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_80e25fd4-3ce0-4aed-a4c4-8a2d2048827d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f2bf66c-0be3-4570-9eb3-311cae4bf4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09833d83-13d5-4e24-a866-af118b4b3b83" xlink:to="loc_us-gaap_ClassOfStockDomain_4f2bf66c-0be3-4570-9eb3-311cae4bf4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5d5248e3-98c4-4110-9e9e-97b04b2ae5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f2bf66c-0be3-4570-9eb3-311cae4bf4e8" xlink:to="loc_us-gaap_CommonClassAMember_5d5248e3-98c4-4110-9e9e-97b04b2ae5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_46899511-03c3-4cb6-8c92-b4a24e0f8ccc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_15785831-f7be-4b18-90c7-785145e6be6a" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedMarchFirstTwentySeventeenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_15785831-f7be-4b18-90c7-785145e6be6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_40a71897-8292-4f64-94ab-67d2ba0901d7" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember_40a71897-8292-4f64-94ab-67d2ba0901d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_76eaff44-a6d1-4ee9-b29a-283e482980c9" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_76eaff44-a6d1-4ee9-b29a-283e482980c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_6e8507e2-40b8-4151-8143-e47e841e46ee" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_6e8507e2-40b8-4151-8143-e47e841e46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_0d7a008b-ccaa-4102-a078-c8e1722b1dcb" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_0d7a008b-ccaa-4102-a078-c8e1722b1dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_735932ec-4eaa-4a61-ba62-60bd248bac14" xlink:href="sibn-20201231.xsd#sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_735932ec-4eaa-4a61-ba62-60bd248bac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_CommonStockWarrantsMember_fe3dca4c-1e07-475e-99b7-df7ea1379a9f" xlink:href="sibn-20201231.xsd#sibn_CommonStockWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_99da7db0-1a97-4323-907c-a39096b1e6c7" xlink:to="loc_sibn_CommonStockWarrantsMember_fe3dca4c-1e07-475e-99b7-df7ea1379a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_55d16e89-af39-4775-b83b-6269c37b2a8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa463e22-45ec-485e-b06c-9807dac49901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa463e22-45ec-485e-b06c-9807dac49901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_59491992-6aff-4ee2-aec3-c342e1048c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_59491992-6aff-4ee2-aec3-c342e1048c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_4a6a8f41-abfc-4c0f-9220-d0e343bca08b" xlink:href="sibn-20201231.xsd#sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_38a5d433-a743-4b85-8200-bc2248fc8d8b" xlink:to="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_4a6a8f41-abfc-4c0f-9220-d0e343bca08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommonandPreferredStock" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommonandPreferredStock"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommonandPreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_377e92c9-2609-437c-98c0-c1a25a50d2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2c938dde-4bc3-4a58-8b88-ecd5bbf5256f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_377e92c9-2609-437c-98c0-c1a25a50d2fe" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2c938dde-4bc3-4a58-8b88-ecd5bbf5256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#CommonandPreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2b9768c5-4a86-4b88-96fd-855089e7a8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2b9768c5-4a86-4b88-96fd-855089e7a8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_00a63883-ab68-4394-9c8b-0f8a60a38e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_00a63883-ab68-4394-9c8b-0f8a60a38e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_71bdbf4f-f212-45e1-bc49-273463932f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_CommonStockSharesIssued_71bdbf4f-f212-45e1-bc49-273463932f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1fd2c1a4-e6e9-42b8-bd24-be8a2d92661d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1fd2c1a4-e6e9-42b8-bd24-be8a2d92661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f18a4cd2-0efa-424b-b012-2b905dea831e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f18a4cd2-0efa-424b-b012-2b905dea831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75ee3279-13c9-4263-9a3f-8d925129a395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75ee3279-13c9-4263-9a3f-8d925129a395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9406104f-5880-4232-9f44-232ae403fd18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9406104f-5880-4232-9f44-232ae403fd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c524c23e-2488-4937-9d6a-02788af3cce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c524c23e-2488-4937-9d6a-02788af3cce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_cebdedfd-c246-4c70-93d1-ee705e1f2039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24787514-0353-4f52-83b3-dffe6ecd86be" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_cebdedfd-c246-4c70-93d1-ee705e1f2039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f66738f9-ec28-48b5-a372-585fe5571f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e2544f5f-afce-412a-bc75-455e38743d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f66738f9-ec28-48b5-a372-585fe5571f0f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e2544f5f-afce-412a-bc75-455e38743d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bb8054f7-814e-4f8b-b6c2-4254d6eff8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bb8054f7-814e-4f8b-b6c2-4254d6eff8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_d81d0d40-2e93-484e-80f0-cc651fa2e0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_d81d0d40-2e93-484e-80f0-cc651fa2e0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_450816c1-8cd8-4bcf-8243-16f37edee771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_450816c1-8cd8-4bcf-8243-16f37edee771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a8c6c778-3f2a-4f4c-92f9-5de10e440e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a8c6c778-3f2a-4f4c-92f9-5de10e440e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_c4f9412c-edb8-4c03-ad12-66b56931cca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_c4f9412c-edb8-4c03-ad12-66b56931cca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_574eb710-fa3f-438b-bcf6-f8bf659e9450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183f69e0-65ed-468f-9ff1-4f895600caaa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_574eb710-fa3f-438b-bcf6-f8bf659e9450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8f7dbff-5b1c-469e-816e-aa358b083ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8f7dbff-5b1c-469e-816e-aa358b083ff4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d8e7e6e5-88ac-4eb7-894f-5586c08bf9d8" xlink:to="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_A2018EquityIncentivePlanMember_5b011c9a-5118-469a-9647-17048b65f837" xlink:href="sibn-20201231.xsd#sibn_A2018EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:to="loc_sibn_A2018EquityIncentivePlanMember_5b011c9a-5118-469a-9647-17048b65f837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_A2018EmployeeStockPurchasePlanMember_b0143bf0-93b4-484d-b148-9a2d7c3b3cbc" xlink:href="sibn-20201231.xsd#sibn_A2018EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6acfc76e-6c7e-40ec-a064-ab54d4c7e248" xlink:to="loc_sibn_A2018EmployeeStockPurchasePlanMember_b0143bf0-93b4-484d-b148-9a2d7c3b3cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ae0fd4ad-fa67-4316-b036-88741937a82a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_IncentiveStockOptionMember_567547d5-2603-4bcb-8a6f-395503c72899" xlink:href="sibn-20201231.xsd#sibn_IncentiveStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:to="loc_sibn_IncentiveStockOptionMember_567547d5-2603-4bcb-8a6f-395503c72899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_NonqualifiedStockOptionMember_b2adfa61-a58d-4d27-8dae-c72d7ead6920" xlink:href="sibn-20201231.xsd#sibn_NonqualifiedStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0404c7eb-0005-4fa0-9e85-5e68b709050b" xlink:to="loc_sibn_NonqualifiedStockOptionMember_b2adfa61-a58d-4d27-8dae-c72d7ead6920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4e77ec06-288a-4531-8683-3888885cb4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_770c3449-f775-4bae-ae6d-e3c908a748e2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4e77ec06-288a-4531-8683-3888885cb4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7e624478-20ec-40fa-ac6a-acea29265fd1" xlink:to="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_00c3cb70-e64e-44a8-a2fc-d60b27438b2a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:to="loc_srt_MinimumMember_00c3cb70-e64e-44a8-a2fc-d60b27438b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bdef4978-4036-43d2-80c0-995cd458d261" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_169238bc-4d53-403a-bedd-a7f082cfc5c7" xlink:to="loc_srt_MaximumMember_bdef4978-4036-43d2-80c0-995cd458d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58d6c4d0-1fb6-4db5-ae3c-4eac65eaddbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f12e4b3f-6901-4c58-8917-fb982f43a5ec" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58d6c4d0-1fb6-4db5-ae3c-4eac65eaddbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_67f58b44-d091-4450-bd59-f6b6fbc359ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58d6c4d0-1fb6-4db5-ae3c-4eac65eaddbc" xlink:to="loc_us-gaap_SubsequentEventMember_67f58b44-d091-4450-bd59-f6b6fbc359ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68273276-8abb-4475-acc3-0bba02e0b277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_23585843-51e1-486a-b960-e2faf07841ff" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding_23585843-51e1-486a-b960-e2faf07841ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_63f0657e-217d-4e6d-875a-a1cf5a49c45d" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares_63f0657e-217d-4e6d-875a-a1cf5a49c45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_15c08dca-23a8-4732-ae6b-3364cabd1a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_15c08dca-23a8-4732-ae6b-3364cabd1a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b951d05-0e62-4138-85f0-496a3b910de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b951d05-0e62-4138-85f0-496a3b910de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_06bb4735-acf5-4cdb-9a24-398aeb722657" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms_06bb4735-acf5-4cdb-9a24-398aeb722657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_e9ceedb5-a3fe-4b4b-bb71-4ffae4bd4cc9" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_e9ceedb5-a3fe-4b4b-bb71-4ffae4bd4cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_058d2adf-5ed1-49ea-a9f4-c91fd74c3201" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_058d2adf-5ed1-49ea-a9f4-c91fd74c3201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_875c2d6e-8c6a-45c2-a341-cee4e373efdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_875c2d6e-8c6a-45c2-a341-cee4e373efdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_54ba63ec-887c-4aa3-86bc-4d185ab6722f" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_54ba63ec-887c-4aa3-86bc-4d185ab6722f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1e9da7c8-8c8f-4101-8917-06343ecf9484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1e9da7c8-8c8f-4101-8917-06343ecf9484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_694ec70c-367f-4e1e-989b-a1c780d9731d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_694ec70c-367f-4e1e-989b-a1c780d9731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_92c32fba-38bb-492a-910d-9cc43bc2f02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_92c32fba-38bb-492a-910d-9cc43bc2f02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7151dec-05a2-4293-913f-ac8071861c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7151dec-05a2-4293-913f-ac8071861c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_c2114e0f-c491-497f-b133-71a43f840485" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_c2114e0f-c491-497f-b133-71a43f840485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dda6e996-a2a2-442d-841d-0cb687aee38c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dda6e996-a2a2-442d-841d-0cb687aee38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c2cabd1f-5d46-4721-a728-82a92af3f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c2cabd1f-5d46-4721-a728-82a92af3f8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_5d086d9c-19d1-45bd-b153-df5744439bd3" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_5d086d9c-19d1-45bd-b153-df5744439bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_184cb850-fd61-45d0-ac85-20963eb79b85" xlink:href="sibn-20201231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_184cb850-fd61-45d0-ac85-20963eb79b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2627180b-aee1-4ea9-8eca-2ca3aaef44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2627180b-aee1-4ea9-8eca-2ca3aaef44e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_34c4936f-d162-484b-b064-24d262006aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_34c4936f-d162-484b-b064-24d262006aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2647c8ca-97bc-47d1-a67c-d385197cbbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2647c8ca-97bc-47d1-a67c-d385197cbbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_865af299-ef39-47cd-bfc1-b76d37aee612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_865af299-ef39-47cd-bfc1-b76d37aee612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0855e826-818e-4684-b920-4be70a756cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4346746b-35f9-4d1e-9aac-3283e068036d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0855e826-818e-4684-b920-4be70a756cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a116b9e-ed54-4d8c-94d8-78293bf5f115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a116b9e-ed54-4d8c-94d8-78293bf5f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1cbfa42a-9e0d-4801-b3bb-98a1f833c824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1cbfa42a-9e0d-4801-b3bb-98a1f833c824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc37b12b-7014-4da9-aa19-29b28fbdd273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc37b12b-7014-4da9-aa19-29b28fbdd273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bf2f6f9b-1195-40d0-8190-381d001773c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bf2f6f9b-1195-40d0-8190-381d001773c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6a62d6e-ca65-4ac6-8ff5-cd280a2635eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3e3d961-4ace-4731-9283-a8f2f68c2b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6a62d6e-ca65-4ac6-8ff5-cd280a2635eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a92ab378-2e9a-46db-b5b2-3ccc68a1f34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a92ab378-2e9a-46db-b5b2-3ccc68a1f34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11b29d9c-56b5-4e4d-a93d-ce404ac40d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11b29d9c-56b5-4e4d-a93d-ce404ac40d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c2817026-dd1c-4071-9bd1-4867be063248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c2817026-dd1c-4071-9bd1-4867be063248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d3862c89-2dfb-42dd-8603-fce62b93ebda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d3862c89-2dfb-42dd-8603-fce62b93ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_52ffda6f-d6a1-4d78-b826-64a666fdc1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_52ffda6f-d6a1-4d78-b826-64a666fdc1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_99e5ea29-fb27-4b11-bf66-d7c85c9bf58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_99e5ea29-fb27-4b11-bf66-d7c85c9bf58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_57229bf8-8c7b-40dd-8481-61609c9854c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e09d338-4717-4db9-9fa5-21c8ea233d50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_57229bf8-8c7b-40dd-8481-61609c9854c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_60248c71-8aa1-438d-958a-33cee56a269b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_60248c71-8aa1-438d-958a-33cee56a269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9348d3cc-315e-4301-bceb-293278258fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9348d3cc-315e-4301-bceb-293278258fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c40f51-c3f1-45dc-98fb-54ef0609a591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a51c0e6-be0c-4249-bba2-a018b1380e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a51c0e6-be0c-4249-bba2-a018b1380e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_195f80c8-8c0c-44ba-b5f8-8eea2598c917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_195f80c8-8c0c-44ba-b5f8-8eea2598c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fd4d385f-6a33-4d6a-b250-77e8387797cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fd4d385f-6a33-4d6a-b250-77e8387797cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fd721953-911a-4e75-be12-ebf7fb556a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fd721953-911a-4e75-be12-ebf7fb556a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_dac4265b-e43d-40e1-bb27-a6c7a5190a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_dac4265b-e43d-40e1-bb27-a6c7a5190a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f22caf18-f8c3-435e-aa64-8e9fed2042a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b555118-b6b9-48e8-841b-e104616db03f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f22caf18-f8c3-435e-aa64-8e9fed2042a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2490dc30-1787-49d4-9845-7e4847d8f23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2490dc30-1787-49d4-9845-7e4847d8f23a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4c4511f0-5de3-4f18-81b7-df86bdfc37bb" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheOneMember_ff35c67e-5174-49c0-95f3-3cabcf5bdd9e" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheOneMember_ff35c67e-5174-49c0-95f3-3cabcf5bdd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheTwoMember_f0c37703-e455-4458-9017-2009da47c6e0" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheTwoMember_f0c37703-e455-4458-9017-2009da47c6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheThreeMember_5bc2af1f-f804-4089-bf91-2d05935bad43" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheThreeMember_5bc2af1f-f804-4089-bf91-2d05935bad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheFourMember_67a50ecc-c65f-41c3-b437-ff7a634dd87d" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheFourMember_67a50ecc-c65f-41c3-b437-ff7a634dd87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OptionsTrancheFiveMember_2db9b383-acc8-4e22-94f8-bdc7cf86f27c" xlink:href="sibn-20201231.xsd#sibn_OptionsTrancheFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_59513d6b-c71f-41b7-96d4-16785b16fd74" xlink:to="loc_sibn_OptionsTrancheFiveMember_2db9b383-acc8-4e22-94f8-bdc7cf86f27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ad777293-ed1d-4f09-9988-5e84baf784ff" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a1084d22-9251-4556-97b8-e5221328da0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a1084d22-9251-4556-97b8-e5221328da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e0b2e05-ce0b-4a2e-b92c-59f79d7e9dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e0b2e05-ce0b-4a2e-b92c-59f79d7e9dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f02e3ce6-9c33-49d7-80a6-70d1aa84a868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f02e3ce6-9c33-49d7-80a6-70d1aa84a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_e6ea7ad2-86c3-4e26-bc19-746002939eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_e6ea7ad2-86c3-4e26-bc19-746002939eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_b37431ee-31de-4469-9c53-2f733f50418a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_b37431ee-31de-4469-9c53-2f733f50418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a4dad1bf-d18b-4770-9394-428f8ae9d1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a4dad1bf-d18b-4770-9394-428f8ae9d1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d52b65ff-e5bb-458f-83a6-561d03353225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1b109872-6617-4bee-b300-cd09ceb6fa2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d52b65ff-e5bb-458f-83a6-561d03353225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationValuationAssumptionsforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a40bde8-fa1e-4177-bb41-5aef243d87e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a40bde8-fa1e-4177-bb41-5aef243d87e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:to="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4256c1e8-d4ff-4cf6-94a0-bc0d13e0c672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_149b8aa8-a136-46e8-8b64-c126c147db76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4256c1e8-d4ff-4cf6-94a0-bc0d13e0c672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b91bdb2d-0b8d-4691-8269-9030960841f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4256c1e8-d4ff-4cf6-94a0-bc0d13e0c672" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b91bdb2d-0b8d-4691-8269-9030960841f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:to="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98a449a1-ed33-4f2d-87ad-1bfdfebbff0c" xlink:to="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_15341b49-1f5c-47e7-8d3b-bae44a94ce83" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:to="loc_srt_MinimumMember_15341b49-1f5c-47e7-8d3b-bae44a94ce83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9eb29ba9-8c76-4c7d-b61e-22cf5e8a0420" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b594770-dbc7-4d18-b228-72f92ad497e5" xlink:to="loc_srt_MaximumMember_9eb29ba9-8c76-4c7d-b61e-22cf5e8a0420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13ca4150-0500-4adf-ac94-621db8538444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4b20ff1-9da7-4aae-b1e4-0329755bc619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13ca4150-0500-4adf-ac94-621db8538444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13ca4150-0500-4adf-ac94-621db8538444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1a08ef6-ae63-4ddf-9f38-c2303576437d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1a08ef6-ae63-4ddf-9f38-c2303576437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ff3419e-4fd8-4d6a-b223-c4767d308b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ff3419e-4fd8-4d6a-b223-c4767d308b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1a3f1fe5-477d-4e8d-99b7-7fe5c9935c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1a3f1fe5-477d-4e8d-99b7-7fe5c9935c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4530fafe-bfb3-4afb-adeb-ac8a6e6fbebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4530fafe-bfb3-4afb-adeb-ac8a6e6fbebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_94769396-699b-4fea-99fe-c38c7454d51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_94769396-699b-4fea-99fe-c38c7454d51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a14bc871-6293-44b1-8c40-63a21d4fdb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a14bc871-6293-44b1-8c40-63a21d4fdb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e8eab3e-70e5-45c9-8dc8-01702b63e9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8cac3d9b-f6b5-41cc-8012-9396c0881ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e8eab3e-70e5-45c9-8dc8-01702b63e9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b178163-767f-4fc2-a798-65fb6bd3d7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b178163-767f-4fc2-a798-65fb6bd3d7b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:to="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6acbaa03-43d9-43dc-a203-5946517110a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a537b13b-cf76-4ec2-bb73-7da500eda8ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6acbaa03-43d9-43dc-a203-5946517110a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cd4d4f2f-ad94-4e65-813b-25a440e07779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6acbaa03-43d9-43dc-a203-5946517110a1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cd4d4f2f-ad94-4e65-813b-25a440e07779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_469ea4c4-28d0-4abf-85d4-22763822d76e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64171527-4d5f-4149-88dc-9421bc99a4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64171527-4d5f-4149-88dc-9421bc99a4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8a1462d0-46ae-4bb3-a0bf-1419dcb4ba8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8a1462d0-46ae-4bb3-a0bf-1419dcb4ba8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a88dd9be-7ee0-4c14-a8f2-d9545b5e463f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a88dd9be-7ee0-4c14-a8f2-d9545b5e463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3825c06d-d539-46f4-bde1-9167c21d3b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3825c06d-d539-46f4-bde1-9167c21d3b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_768f5694-b502-4b1b-8cae-3f552dc15ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6f8f0c2-aae1-4aa9-b57d-e80dbd97db2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_768f5694-b502-4b1b-8cae-3f552dc15ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5154be5-b9af-42ad-a00c-1af4cfebdafd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2fe018a-c5b4-4f1c-a27e-d28f0890edaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2fe018a-c5b4-4f1c-a27e-d28f0890edaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b4d16fd-d31e-4d5c-ba5f-84ecbadda8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b4d16fd-d31e-4d5c-ba5f-84ecbadda8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_08260552-6879-4473-917b-48cb9d25a661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_08260552-6879-4473-917b-48cb9d25a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_658e3f07-bf62-493b-8ca0-09b81661843d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_658e3f07-bf62-493b-8ca0-09b81661843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef955074-f7d5-4c83-8542-0c0a2fd5e207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3845910f-8ce4-404f-aba8-ff9bc0bbfd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef955074-f7d5-4c83-8542-0c0a2fd5e207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e6bb3e-4d60-4fb2-a743-146601a43e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e6bb3e-4d60-4fb2-a743-146601a43e6c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:to="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aade97f3-1cc6-4003-ab0b-74fe8c811595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fd2a7c1a-deb6-4a03-8f2f-07879a35a08e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aade97f3-1cc6-4003-ab0b-74fe8c811595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ESPPPurchaseRightsMember_6cc7e202-20bc-4e7e-8cd1-f952722b253b" xlink:href="sibn-20201231.xsd#sibn_ESPPPurchaseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aade97f3-1cc6-4003-ab0b-74fe8c811595" xlink:to="loc_sibn_ESPPPurchaseRightsMember_6cc7e202-20bc-4e7e-8cd1-f952722b253b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:to="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17ee6e7d-d380-4d2a-8479-d0f76dbb8959" xlink:to="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a8e24159-4782-4ad5-836f-6b11762a06c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:to="loc_srt_MinimumMember_a8e24159-4782-4ad5-836f-6b11762a06c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eaf2b322-fc02-40b2-b151-87c3dbeb27ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_abf03738-0c75-40f4-9e18-2a0abda781e9" xlink:to="loc_srt_MaximumMember_eaf2b322-fc02-40b2-b151-87c3dbeb27ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d369fce-ef59-424c-b90a-2cc9f662c53f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e439c8ba-585b-463c-942d-17922e509d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e439c8ba-585b-463c-942d-17922e509d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5317677d-4cc3-4907-9508-4594344887d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5317677d-4cc3-4907-9508-4594344887d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_76a62bd9-9134-4c39-a331-a052cb45980a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_76a62bd9-9134-4c39-a331-a052cb45980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcea700d-bb32-4d45-8cc7-ffded044960e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcea700d-bb32-4d45-8cc7-ffded044960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0c5c2452-2341-4fe1-9cdc-1ba101bac46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0c5c2452-2341-4fe1-9cdc-1ba101bac46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87788eac-a1d7-4018-acd1-e22bd95d577e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b6650e3-3e59-4552-8e89-f4e7209020f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87788eac-a1d7-4018-acd1-e22bd95d577e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac6fc42a-f6c6-4805-a015-b38bc1d28ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac6fc42a-f6c6-4805-a015-b38bc1d28ae9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6086db67-89aa-48e3-9c6a-8409600f6aef" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_334b4401-4970-41da-8bbe-15b0255e023d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_CostOfSalesMember_334b4401-4970-41da-8bbe-15b0255e023d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_008643a4-2436-4aec-a073-62b03c028cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_008643a4-2436-4aec-a073-62b03c028cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_376b4ce8-35e2-4cff-bd96-2df93b86b0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_376b4ce8-35e2-4cff-bd96-2df93b86b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c507e480-9f1f-4e0c-8e3d-6b1eaf2c78b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b00d4b5b-eb02-4f3e-b808-032f17ad5bd1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c507e480-9f1f-4e0c-8e3d-6b1eaf2c78b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18115f77-85fb-4aa4-806b-33417377f6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bdef24d-effe-4acc-b178-81f837950414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18115f77-85fb-4aa4-806b-33417377f6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fcc8fe5c-75af-4c9d-91b6-cda1098d5b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18115f77-85fb-4aa4-806b-33417377f6c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fcc8fe5c-75af-4c9d-91b6-cda1098d5b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sibn-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ebaab01a-2d44-4d6c-a365-5d0bb0978346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c63a8123-abdb-4760-970c-cf5d68f716d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ebaab01a-2d44-4d6c-a365-5d0bb0978346" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c63a8123-abdb-4760-970c-cf5d68f716d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_835aa931-05e2-4714-83de-63aa46c8b428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_835aa931-05e2-4714-83de-63aa46c8b428" xlink:to="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:to="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_df6f5ec4-8b25-41df-a424-6f3d3bed5e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_5e13426f-35d1-45ba-900e-a0835df73888" xlink:to="loc_us-gaap_RetirementPlanNameDomain_df6f5ec4-8b25-41df-a424-6f3d3bed5e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_Company401KPlanMember_8031ddd1-b091-4009-b009-2f00fbb4964a" xlink:href="sibn-20201231.xsd#sibn_Company401KPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_df6f5ec4-8b25-41df-a424-6f3d3bed5e1e" xlink:to="loc_sibn_Company401KPlanMember_8031ddd1-b091-4009-b009-2f00fbb4964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_7ef201b9-c0f5-4ecd-b100-1c5a4a56e5ab" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf1ba0af-b77f-4186-b9e0-56b8e637d2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf1ba0af-b77f-4186-b9e0-56b8e637d2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_3d61fcab-6665-40b3-a8c2-63b5a430a71f" xlink:href="sibn-20201231.xsd#sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee_3d61fcab-6665-40b3-a8c2-63b5a430a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3da3ef6d-33ba-430c-9d76-116ae3ba927c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_4fc529b1-fbe5-4dd9-8ca0-12fa5167ed6b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3da3ef6d-33ba-430c-9d76-116ae3ba927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStock"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b48a2daa-32ec-438b-b1f6-b9f251c45205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_302e7d0e-9e44-4b0e-9c74-51ead9f9a171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b48a2daa-32ec-438b-b1f6-b9f251c45205" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_302e7d0e-9e44-4b0e-9c74-51ead9f9a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7319b613-cd25-4b02-9713-94dfe0f1b84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_33b93629-a602-4863-b64d-623b555863cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7319b613-cd25-4b02-9713-94dfe0f1b84f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_33b93629-a602-4863-b64d-623b555863cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e269db5-fb92-4ec8-80c9-9e9ea2a370d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7319b613-cd25-4b02-9713-94dfe0f1b84f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e269db5-fb92-4ec8-80c9-9e9ea2a370d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3cffc48a-5e02-4f76-8923-272415091d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2fae8535-6855-4cf8-8a4e-8e294a8417d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3cffc48a-5e02-4f76-8923-272415091d58" xlink:to="loc_us-gaap_NetIncomeLoss_2fae8535-6855-4cf8-8a4e-8e294a8417d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_51cd9fd3-8644-4274-a5bc-f17648c1a151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3cffc48a-5e02-4f76-8923-272415091d58" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_51cd9fd3-8644-4274-a5bc-f17648c1a151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2f4423e4-585d-4f0c-8b67-2a47687158b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3cffc48a-5e02-4f76-8923-272415091d58" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2f4423e4-585d-4f0c-8b67-2a47687158b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_121d9557-3766-41ba-bc5f-8fd2e63d1c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_121d9557-3766-41ba-bc5f-8fd2e63d1c3f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8053f96-8602-4072-80d5-d93ad90b5040" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_424286d2-e304-4276-ae30-39e6cfc45956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_424286d2-e304-4276-ae30-39e6cfc45956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9ab10d0b-eccc-45be-8123-f56eba2d7cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9ab10d0b-eccc-45be-8123-f56eba2d7cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_ShareSubjectToRepurchaseMember_ebe42450-4267-4148-b121-628ba668a8b2" xlink:href="sibn-20201231.xsd#sibn_ShareSubjectToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_sibn_ShareSubjectToRepurchaseMember_ebe42450-4267-4148-b121-628ba668a8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_EmployeeStockPurchasePlanSharesMember_9fca7af8-2295-46c6-bc87-2d7583dff4b5" xlink:href="sibn-20201231.xsd#sibn_EmployeeStockPurchasePlanSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_sibn_EmployeeStockPurchasePlanSharesMember_9fca7af8-2295-46c6-bc87-2d7583dff4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_CommonStockWarrantsMember_82f0be7c-0533-4af7-b0e9-d36d2a27cbf9" xlink:href="sibn-20201231.xsd#sibn_CommonStockWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3409d203-86d5-46cc-88f5-49eae5f7c7bb" xlink:to="loc_sibn_CommonStockWarrantsMember_82f0be7c-0533-4af7-b0e9-d36d2a27cbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34dbd921-ba23-438c-bad7-7c8e5930138c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4775d2d-143d-4b2b-871b-88d58385d245" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34dbd921-ba23-438c-bad7-7c8e5930138c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76e42915-814d-474b-af3f-2bcdf17dbf6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34dbd921-ba23-438c-bad7-7c8e5930138c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76e42915-814d-474b-af3f-2bcdf17dbf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d319fb3d-67f4-4bb8-9333-afaf0e914f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3d113ce5-c2d1-4368-8493-c996f61b6a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d319fb3d-67f4-4bb8-9333-afaf0e914f7c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3d113ce5-c2d1-4368-8493-c996f61b6a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9cddd177-17d2-4976-8678-c47ad593aa83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9cddd177-17d2-4976-8678-c47ad593aa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_204bec5d-8f98-46cc-9cb9-54bbec9a9ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_204bec5d-8f98-46cc-9cb9-54bbec9a9ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_184911b4-7048-4cdb-a92e-823e2770f620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_184911b4-7048-4cdb-a92e-823e2770f620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_068c984c-3431-4ad8-a07e-61cb34bc3382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_068c984c-3431-4ad8-a07e-61cb34bc3382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_5f336d89-ec6d-4f87-9c0a-18e1978773f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_5f336d89-ec6d-4f87-9c0a-18e1978773f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_58e9c4a5-8570-49b4-a796-6ade7fef0dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b341770a-2cb0-40ab-af88-53696c1fd5a2" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_58e9c4a5-8570-49b4-a796-6ade7fef0dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_afb63655-7f9e-4b86-973d-412be1c60a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_18b2870f-42a9-492b-9cc2-49b36e2387e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afb63655-7f9e-4b86-973d-412be1c60a7e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_18b2870f-42a9-492b-9cc2-49b36e2387e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0f34d202-d027-4c5d-8527-98d0258f3a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_18b2870f-42a9-492b-9cc2-49b36e2387e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0f34d202-d027-4c5d-8527-98d0258f3a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b8daff9d-3a2a-453a-92ee-3645540545b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_18b2870f-42a9-492b-9cc2-49b36e2387e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b8daff9d-3a2a-453a-92ee-3645540545b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15525847-3fb0-41c5-b9d8-704704ea6641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_18b2870f-42a9-492b-9cc2-49b36e2387e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15525847-3fb0-41c5-b9d8-704704ea6641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_26e4c98d-16c0-4c46-bd72-4c3222b8a2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_26e4c98d-16c0-4c46-bd72-4c3222b8a2c7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_46607b0c-d0d2-45fa-8bb8-03fc6c0d7208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_46607b0c-d0d2-45fa-8bb8-03fc6c0d7208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_872273ce-337d-4f3b-807c-899e9edb758b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_872273ce-337d-4f3b-807c-899e9edb758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_969d377c-7693-4d98-a8da-59d33b7364e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_969d377c-7693-4d98-a8da-59d33b7364e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f6864dc7-bf5e-4ba8-8cf0-6e4190b00cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f6864dc7-bf5e-4ba8-8cf0-6e4190b00cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17d35c6a-05e7-4513-9633-96a5ddb42bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17d35c6a-05e7-4513-9633-96a5ddb42bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_91171e4f-dffe-4ab0-910f-88cb5d21bd95" xlink:href="sibn-20201231.xsd#sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7d8f51cf-16f3-4b79-9291-ed0356aeb893" xlink:to="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_91171e4f-dffe-4ab0-910f-88cb5d21bd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6b3e574e-9ef8-4086-b067-ee82845c5f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6b3e574e-9ef8-4086-b067-ee82845c5f24" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cda6a17a-f542-47cc-8373-c647d4492bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cda6a17a-f542-47cc-8373-c647d4492bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bced8c52-3ace-43bc-aea5-7a5a7638f6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bced8c52-3ace-43bc-aea5-7a5a7638f6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0066e3e9-2484-4589-a812-daebdc755d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0066e3e9-2484-4589-a812-daebdc755d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ed9b3c56-1010-4093-925d-44386d71532c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ed9b3c56-1010-4093-925d-44386d71532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_32c7c01a-600f-45b3-9867-6843a8bc8103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_32c7c01a-600f-45b3-9867-6843a8bc8103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_35ddec44-d723-48cd-b5e8-289d23e50af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_35ddec44-d723-48cd-b5e8-289d23e50af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9088494e-6492-4084-8d25-ed405f694b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9088494e-6492-4084-8d25-ed405f694b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_84c5024c-f466-4934-9a16-d6a299fc5e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fe8c648d-684e-4874-bdd5-e186ebdd3ba6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_84c5024c-f466-4934-9a16-d6a299fc5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0970101-0706-47d9-a75f-0c9a3ece2413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0970101-0706-47d9-a75f-0c9a3ece2413" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4efa426c-0977-4eb1-baa3-91a73ca6b4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4efa426c-0977-4eb1-baa3-91a73ca6b4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d765c9aa-eed0-4bbe-b8c7-3857834614cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d765c9aa-eed0-4bbe-b8c7-3857834614cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a001d263-86f7-41b2-b38f-855de24cb45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a001d263-86f7-41b2-b38f-855de24cb45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bddc3c8e-7728-4011-99a1-c45b740b6c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bddc3c8e-7728-4011-99a1-c45b740b6c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_4f3127ca-dd57-4cde-bbaa-705dc9acd561" xlink:href="sibn-20201231.xsd#sibn_DeferredTaxAssetsDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_4f3127ca-dd57-4cde-bbaa-705dc9acd561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7f8b0e0f-a26c-4490-a2fc-ee52511285d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7f8b0e0f-a26c-4490-a2fc-ee52511285d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_99655e41-fb9a-49c6-b95d-5bfe0cdf514b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_99655e41-fb9a-49c6-b95d-5bfe0cdf514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_560070aa-64c8-42a6-a30c-f9ccc4e3e389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f32ebe67-8fae-4fbd-a5f5-f8103a91c8ab" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_560070aa-64c8-42a6-a30c-f9ccc4e3e389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_869efe5b-ce0f-482c-a83f-3f637015552b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_IncomeTaxesValuationAllowanceRollForward_890ff82f-9927-4745-acb4-e7319f386776" xlink:href="sibn-20201231.xsd#sibn_IncomeTaxesValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_869efe5b-ce0f-482c-a83f-3f637015552b" xlink:to="loc_sibn_IncomeTaxesValuationAllowanceRollForward_890ff82f-9927-4745-acb4-e7319f386776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8b181614-3e05-4002-aad2-55d6d70e135a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_890ff82f-9927-4745-acb4-e7319f386776" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8b181614-3e05-4002-aad2-55d6d70e135a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_75593d0e-2fef-4d47-9080-5cb61b7d009d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_890ff82f-9927-4745-acb4-e7319f386776" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_75593d0e-2fef-4d47-9080-5cb61b7d009d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a0f9b424-c424-40b1-b66e-b4ceabb5930e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_890ff82f-9927-4745-acb4-e7319f386776" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a0f9b424-c424-40b1-b66e-b4ceabb5930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_19e4754b-ef2e-45ca-bfc3-45f5bb2bd8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e4754b-ef2e-45ca-bfc3-45f5bb2bd8f2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_92d312a2-cec6-4135-a420-30c8d7950195" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_fb7b12f5-4f2f-4a14-a7de-01dcc4901ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:to="loc_us-gaap_DomesticCountryMember_fb7b12f5-4f2f-4a14-a7de-01dcc4901ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_b0b683be-6edf-44e1-af36-eeeed3362edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b76c6668-d24f-47d6-b6aa-29ee1036b17d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_b0b683be-6edf-44e1-af36-eeeed3362edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3cff4d90-97f7-4606-bda1-30ce3ca78528" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1b55ce47-4456-4285-9697-870e30257007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1b55ce47-4456-4285-9697-870e30257007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4e7ee76c-85a6-41cf-bedc-20f62f5eb463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4e7ee76c-85a6-41cf-bedc-20f62f5eb463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_OperatingLossCarryforwardsLimited_fbd1c019-0826-4eb6-b1c0-df49f668f738" xlink:href="sibn-20201231.xsd#sibn_OperatingLossCarryforwardsLimited"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_sibn_OperatingLossCarryforwardsLimited_fbd1c019-0826-4eb6-b1c0-df49f668f738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_02fea843-f0dd-4693-babf-8330c695bd54" xlink:href="sibn-20201231.xsd#sibn_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_sibn_SocialSecurityTaxEmployerDeferralCARESAct_02fea843-f0dd-4693-babf-8330c695bd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_a2009f70-d498-4260-b5d8-72eb55382f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_29d1f6ab-8daa-484c-801c-63aa5849fce9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_a2009f70-d498-4260-b5d8-72eb55382f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#IncomeTaxesUncertainIncomeTaxPositionsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a47e178b-2187-4e26-9693-32e1ff10a091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7a73c752-5580-4d20-b01c-3304356cf8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a47e178b-2187-4e26-9693-32e1ff10a091" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7a73c752-5580-4d20-b01c-3304356cf8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_196db64f-7f56-4507-8322-96b3e83b0ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7a73c752-5580-4d20-b01c-3304356cf8b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_196db64f-7f56-4507-8322-96b3e83b0ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ce2e3524-56c0-4821-93c8-9f32cd763ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7a73c752-5580-4d20-b01c-3304356cf8b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ce2e3524-56c0-4821-93c8-9f32cd763ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_26a9d592-68cb-4c02-956d-586b292e182e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7a73c752-5580-4d20-b01c-3304356cf8b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_26a9d592-68cb-4c02-956d-586b292e182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="sibn-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_399e6215-3947-4e93-9d92-4c4e6088d4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a1523b5f-83f5-447b-938f-e9dc3060c7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_399e6215-3947-4e93-9d92-4c4e6088d4d1" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a1523b5f-83f5-447b-938f-e9dc3060c7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="sibn-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_54d32dfc-72db-4d0f-bd7f-d729ee5c8175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_54d32dfc-72db-4d0f-bd7f-d729ee5c8175" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_50474daf-ed81-498b-ba0f-60b63e78072f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5fc4b466-f22b-474e-8a16-6e0a0b4f8704" xlink:to="loc_us-gaap_RelatedPartyDomain_50474daf-ed81-498b-ba0f-60b63e78072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5100ad4f-6b25-4d03-b026-4b0debbd24bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_50474daf-ed81-498b-ba0f-60b63e78072f" xlink:to="loc_srt_AffiliatedEntityMember_5100ad4f-6b25-4d03-b026-4b0debbd24bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0697adef-b01d-4ece-acdb-f67c8605dd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_bd893347-23c5-4cdd-b6bd-c9fa283cc666" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0697adef-b01d-4ece-acdb-f67c8605dd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_DevelopmentAgreementMember_73c168c0-89c8-434d-9b31-ee59670f1f91" xlink:href="sibn-20201231.xsd#sibn_DevelopmentAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0697adef-b01d-4ece-acdb-f67c8605dd54" xlink:to="loc_sibn_DevelopmentAgreementMember_73c168c0-89c8-434d-9b31-ee59670f1f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b082434f-3349-406f-ac47-1028d17ef53e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4be24fca-f2c7-44f3-8097-1090622baade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4be24fca-f2c7-44f3-8097-1090622baade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_85c9a362-ea7e-486f-854c-d36e427c39ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_us-gaap_DueToAffiliateCurrent_85c9a362-ea7e-486f-854c-d36e427c39ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sibn_RelatedPartyTransactionTermOfAgreement_0d4df277-7807-4ab3-b3cc-f032c577fb12" xlink:href="sibn-20201231.xsd#sibn_RelatedPartyTransactionTermOfAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d070aac7-c2af-4ebc-80c1-477823e984d6" xlink:to="loc_sibn_RelatedPartyTransactionTermOfAgreement_0d4df277-7807-4ab3-b3cc-f032c577fb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sibn-20201231_g1.jpg
<TEXT>
begin 644 sibn-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=44&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      $-    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    5 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 X "  1P!/ $\
M1       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24T$"@       0  .$))32<0       *  $          3A"24T#
M]       $@ U     0 M    !@       3A"24T#]P      '   ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M ?8   7+          $                          0             %
MRP   ?8                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   ?8     4F=H=&QO;F<   7+    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   %RP    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
M A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R
M@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]/<_&Q*F,]M53 &U
ML:( :T0UK&-_-:H-ZCAN,"P ^8(_*%D]2>XYME;S[@1 [;"WV%O]H6_VT*EN
MY[8^"2GHMP>R6.!GAPU"PLMV:S.]-V8^PMK&YM8-8$GVRQCGM<]%H:&MMHR"
MX4VC782"UP/T@6G<J%U6S-)IR;'  !HL@E\?3<W:UJ2FTUV8<JC;DV5 N(.\
M.<TD@[6N8XL6Y6'LJ'JO#W-'N?&T'SC\U<QE6V5EEEEECSN:VNBN-[W._P '
M7ZFUC?WWOL_15U;WV(N0,HXOH,S!67.WOVM%@F-&E^0YOJ[7?GLIQF?\"DIW
M+.I85;MIM!/@T%W_ %(*3.HX3P3ZS6QJ0X[3_FOA<)U"[.JR13E7^I+2:[:C
MM8\"-[?3!_0W5[F[ZMUGL_25V?3],6&7"]I9_.%P#!XDG_J=F[>DI[NSK&"S
MZ+G6'^0T_P#5.VM53(Z^YC":J),AK YVKG..RNMK6_G6/=M^FLX\Z<+(^L9)
MJP:]^QC\H.<=9+JZ[;Z0-ON]MK/5_P"MI*3=5_QG8G1^IGIF=38^W'(;E65M
M:QH)8VW?CTWO;9?3[MG\XS?_ #E>]=ICY=5Y#08LVBS800=KOHNAT._\@O/+
MOK/U0AI-H/IZ,ML:PV:';+'-8'+3^K'4\N_K3*LAV\GU!ZA/N,-W;7P7I*>W
M22224I))"NR**!-KPR> >3_5;])R2DJ2YCJ?UNM#A5TC']9KGNJ.=:":6O;[
M'MKKK<RS)].W]%;^EQOTG\W9:^NVMF55F_6NLUW9>79G-S"TU,I;7BUT,+BR
MUV0WT[LE_I_3K_36;_\ ">E_.)*>\27E[O\ &E?T[J[\!XLS:*#Z#[7M;[[F
MO]-[JW5-H?70[_B<I_L_F[-Z[_HO7<#K5#[,1Q%E#O3R*'P'UO\ W71N:YCO
M\%=4Y]-O^#L24__0]*S\!F4T/: ,BL'TW>,_X-_\ARQL=P%X ^B[4+H,<O./
M4;/IEC=WQCW+G:=K\K,J -=E=[_3:[P+G.G^J]W\W_(24V,O.9C/+ W<]P#N
M%DY/K-<VYMD/OESJ@0=L>UNYO[VW^0M6OHOVG ;DV;OMKI<X$^T^[VU[/H^V
MOV,0K\2IF(:QLJ<7,+=K(<X@_G./N^C^ZDIR+V79-U%=UVUK_5:V3L!L=6?3
M;[#7L<]C;JV6?O\ ]=<LWT&6.J<ZFIK70=WJ6$>3C*[YN%CY&/=CW!E[;2TF
MM[>S1++&;2RVI[+/YJRO^;?^D^FJ]7U/>_&LN-M;K2'&@W5D%ICVV6OQ[:&O
M=^=_-?UTE/.'$%%6-7[=]MWJC:"! K>U[]KB=NUCZJ_^N+;P,-E31>=;7M]I
M_=:?#^4_\]96;CVX['V99<_+< WW -]G[E+&>QE?]3Z?^$WV+H=.P@=AX#P2
M4LLCZR &K":2!NR'#733T,C<M=97UA!->$T1+\AS03$:TW_O!W_4I*>?RLIV
M-Z ^SWW.R'&L?9VB6G\QEA>ZIS/:[<U=%]4*Q^W6EFT-;6[1D;>-FQOIC;[7
M?SOO_G%S^1D' R#>QU#791]2YF1=Z0<6-%&.S'KG;]%M5EUNQ_\ H5H_5;)?
M@]197BTLKQR+Z:227$.87OLV,VM;Z.ZNW9^DLL_FO6_X-*?3'.:T%SB !R3H
M%1OZQB5R*R;G?R/H_P">?;_FK&NNNO,W/=8>0#P/@SZ"@DIN7]5S+I#2*6GL
MSG_MQW_?=BQ.N9U&)ADY&4,/[435]I<Z'#VN?9L>9_3.:WTZ_P!SU/4_,5]<
MO]?,&G.Q<6JYSV!OJNK=6TO.X>CN_1L^G^AWI*:N3UYV:S#;T>_(9B;G4"G"
MJ#6M+A4UQR*KVV8KO1VTLJL8_P#PGZ/_  BT[\3J>76U^+8S"ZB\,^W7.9O+
M*: YM1;3+&M:ZSU?6]3_  OJK,ZA];\$8^!B8+/2>\6TUXV)M]2E[G55UMNK
MN8QE>UV]E%3_ /1_I/YQ&=AYGVW/;EW4T6YK*!7:6L'HY)/L<\6.L]UUFQ[7
M^K_IDE,,C#^J?47O?U#*8_*QG-];-9^AI'MWV8[[V[:+G^ZO93ONOI?[/TGZ
M57L3+ZCB?6JG/I:YF%C8E6,^L#:Q^,S=;?L:\N]9^"ZUO\SZ'O\ ^,L7(.Z+
MUKJ7V?'RZ/LVVRP7#TW,9:]KG-9L]%NVVW^<KWM_P:Z_K'6NF=+Z=>^S;D.P
M;/LC<8M)8,@UOQLJJO(LK;ZFRC[17ZO_ %O_ (Q*?__1]57.?6,#'S:<FO1[
MV$/ [AIT*Z-9?7^GOS,,/I;NOQSO8T:%PC;94/ZS?_!&,24UNG974[JA?54+
M&DPX!P!,?O-=M;_TU"WK&.'/9;4ZJ]I]]3YF?%NX>W][V/0Z/K'1C8#:ZV[K
MF2W:X%H9'YML_G,=^8I8?2W=4N.;GM>P.@P?87P(;#/ILK:DID>JX;;'UPZQ
MP=L8UDASY^CM]-I?[I^@K&7=U(T&ZRCTV- AA<.Y#6C:W?[OZZ'F=%;C$96&
MU[WM(<YHU=N&OJL;_P"BTU7UCK]"P9'Z.UH(#P#&X?OL/NK>U)32P:Z^I=28
MW+;/I;BT'D/;W:[^2Y6<SIUV++_YRG_2#D?\8W_OZ/\ 5[!+!9FV5FLW>VIK
MOI!GTB\_N^JY;22GE%D?6,C9@ S[LIS8&G-&0-7?FM779O1VNFS$ACN35PT_
MU/\ 1_\ 4+D_K&U[3@5EI;9]K+=I$$$T9!_L[H^FDIQ,DL^VL.71]K]_JXI%
M/J.I :!ZEA8[],W(R-UE=;?])^D6[]3L#'?U>T9&W*O;0X6Y#@W<X.>W8[<P
M;VN:W=2[Z%7Z/]'_ #2Y[/.']HH^V76853+C7C.;<:QDM#1<7/97_H\ES6>M
M]!=5]1S;^T+FW ,N%)-K&NW-:=[6[6O^G8WV_P ZY)3TEO1,=TFI[JSX?2'_
M $O=_P!-5+>C9C-6%MH\CM/^:[V_]-;B22GF+:;Z?YVMS/,C3_.'M6;UC%R<
MK"G!M-.72X64O#19/YMU7HO]MOJTN?[/])Z:[E5[<##MU?4V?WF^T_YS-KDE
M/D.7TWZO6FWK'6,T66_:W.RLS&:YM3K;&>I1A5>D'OI?C5UNL]+^<W_SURMW
M_6+I[NF9'5>E4M]7I;W._3$6.>VQWV6C]'ID4U[+:<C?9_A?59_@UUW7?\7O
M3NI"Y^.\TOR2'9%;I-=CV_S>1["ST<QN[T_M?Z7V/_2TWK*POJ)^SL;)QOV?
M9:,X&O)-%S'CTX_TV59BW.W_ /$_OI*>7=U[ZV]7_5.C55!];69!MH #V.<U
M^^G<]QK>[*^E_-?3]-=)TSI67U['Q,+JMN%U/==3F/R<4R6UUMFQ^4YOZ/U<
ME_ZI4UOI[_UBW^;H5GI_U"ZACMKJP+?V-06[<AX(MO<TZOJJ#?T#=W_<JRRR
MW_!^E96NMZ)T/IO0\%N#TZKTZP=SWG5]CS].Z^S_  EC_P#U'7LJ24__TO54
ME\JI)*?IF[]A?M%OK>A]OD;9V[Y_,W?R_P#1[UHKY5224_52S[_V)]O;]H]#
M[9I&^-T_X.9_/_T?YZ^94DE/U4DOE5))3]5+&^L;.A/9C-ZM8:K#;^IOKW&T
M6;+)]/TFV?X'U?YQGI?]<]-?-R22GUW)Z?@ORME75<6M@K8'6V4N-I;/M=Z=
M[';?\+Z7I_\ "?\ "+LOJS5T6JN]G3;CD7!S?M5KPYKBZ/;[7M8UM?\ Q7L_
MZ[O7S@DDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %^24DJ  @    ,   ! P !    T <   $! P !    _0(
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ >
M    M    #(! @ 4    T@   &F'!  !    Z    " !   (  @ " # QBT
M$"<  ,#&+0 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.#HP-SHS," Q,#HS.3HR,0    0  ) '  0    P,C(Q : #  $   #__P
M J $  $   #+!0   Z $  $   #V 0          !@ # 0,  0    8    :
M 04  0   &X!   ; 04  0   '8!   H 0,  0    (    ! @0  0   'X!
M   " @0  0              2     $   !(     0   #A"24T#_0
M"      !    _^$!@$E)*@ (    #    0,  0   - '   ! 0,  0   /T"
M   " 0,  P   )X    & 0,  0    (    2 0,  0         5 0,  0
M  ,    : 04  0   *0    ; 04  0   *P    H 0,  0    (    Q 0(
M'@   +0    R 0( %    -(   !IAP0  0   .@    @ 0  "  (  @ P ,
M  $   #  P   0   $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3@Z,#<Z,S @,3 Z,SDZ,C$    $  "0!P $    ,#(R,0&@ P !    __\
M  *@!  !    RP4   .@!  !    ]@$           8  P$#  $    &
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M @,              / !$2%1,4%AH;'_V@ , P$  A$#$0 _ -_C0- T#0-
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M:Y=Z9$;VPS$W9U!#6E)Z,ZDS]T4LD,9<:MSH6KU5H!=U@%Q5E1&UMH&.> 7
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MX3FE542LBJPK8IE.#@S;0"AL; ^\90P336$,[M!M+_2)S,K<[',BRLJNEBF
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M_<$3QYYYT%*W6QUX9-C.4XOLOC&7UN6=1VY\@\%([-[I[<'VDH;,N.M_U(W
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MC8_(L&S#:[;>OJ-N[(:=DM+7V@58D=U-<LK<BM+%@0,<$T-5ES[94JC?3E!
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M7_ZFI8TV)VF0 A#FV$M((#$T"*$MU8A=Q2.BI#PYD1CX:._PG#=N<;SBZ,M
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M!88C2HJQA"!&SI1^D-F&VV^L]7O'95>01V>*6T&/6.,K;C" NLF2UY=JI)T
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M=9T]5D@N6$3T[\/PLJGCR*Z&QA*KWF9Y+=X\]*X2AB'1X4;?3,Q3JRV_W<W
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MB2&5"F2>JP(IXYM3&Z)JSB,5%=S^4,4BJCD<O*/X5WR[SY7RG//'&@[Y@^U
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MV%&HJ_T0.'3X1%1$XT$=,HZ(<L"22;$LJJ+R-.58):CS4Q:I^F-FC<>)(_\
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MDHMSNJK'+[>_(+NDVSOA:'-@H]L[8PZXQ(_<O!$+'J+:TAE*BMCJ"V,(JY0
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MN)3N<,1QZH%A"B\(17F,3T285\<]CO4B<O9-''(BL0.EZ!H"^45/CG]I\_\
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M@\7-:]KF/:U['(J.:Y$<UR+\HYJ\HJ+^T5.-!BW*-DMJLP21;O":1Y$G/<:
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MK!>5...P:0->?97Z<V=X[OOE>)[S#7E'3[;TM7EC\JQV&-]:R5J4]O$::MF
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M#0- T#0- T#0- T#0- T#0- T#0=0S3_ .$2?[I_^=!P^W?_ ,-D_P#YM_\
IZ:#(^@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>sibn-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sibn="http://si-bone.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sibn-20201231.xsd" xlink:type="simple"/>
    <context id="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i723b611d0707480481c85096cc3174e1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3e43846424574f4d99b00787ea404847_I20210305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="i11ebde2211b84b37a9a25ed29b658cb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic35d9503efb0484a818b49ffdb765d03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie66d822de1dc49998b0d0dbd86b96408_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0dff6565556f4ea180e9d4dc002bcc73_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i81b4c997fd0c473da8c08fde9e5c65d4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6e5589745a4b4e59be2fa5da9fc96faa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ida53b01638da4d37aab2d0e74319d0d8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5678948a03bf48b99de61934b25d458e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffbce40da8154d0ebfd353ebc4ecfc66_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04fe10a38bbc4b9b992c2d00521e3926_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i985109e7c07a47caa2b5f16db86a7f92_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b107ede87a64e409d8ea0d6c15db765_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic26490e07c24473bb2dfc03fc2377ce8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9d1708678a945beac3f5189fa6daf27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic133b244626b43a18e2c5235832641ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6a1c74b555a4f0aba5275ea8e0f0cdc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic95beb3614404efb8439b54564decf04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida15542c93ec4747869dcb494008d0f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53a37168d69c463082d9d5b20b3a2f88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f72f3efd8214401a36fbcad6478c88c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic23626475cd542f79e54023f0ce2273b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd2d90a648464b458060488f94c81ad8_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="iddc263e01aa24b63bfcb6b7c3ca255eb_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i181125cf82924e5b9581883ff443cf53_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ide3655a0a0a14ac1b122bcd81866b549_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingAndSecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i7f5bdb3241a241cab56395a180519bf7_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="if0448433af0a48b1a3ca65d600cf995e_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i70eea66b474641c1ad7620f47edb01b0_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i5492ced8113d48a1af6af8e02eeb934e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i833840966f0446599fbe1ac28b5fc775_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie94283009e404d94a4b0dc42119c45bd_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondFollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i6bccb8eb33f2419aa52d19db5810f680_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i6592020c6d484bdca8308d69ae2e0cb8_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondFollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ic82e690a259f4746a1c2de4c43841af5_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i7f59add943494c479a4150b168d4d73c_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sibn:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i5ee17cf0cfb74aaeba258351d3587116_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c0e792c3dd245b38bfa934064b7a5f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77a304c056a549c6910518b3e4157eef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i682d696ec5a64a2d895607c7e0be6d52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id046e7c696d34711b1333b15ed30b43c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23e08d78c5ce4da8999df030e046372b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82073020dafa4bcc906a6b84e0f4ae90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08bbaa69d9864797b540f323ef6f6cbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab58f80617694d75bb76bca801a8396f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i392839ad6d6e43ad9f50d6687b0aca2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9de17fd42404f5ab8f65ff659295c6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4d2e8b5cf104e2a964925b3ce72d586_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id38adcbbef7041a5be7d1fff795cb320_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica653fed6bb2408599a2f19e331e9a09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia745aebd92ac40369a143cd547cfe75a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2561190905814081bc53ffa2be1dab5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18fdea8ce7124059abdb38fb9a56c535_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c018ede41124dcb9546a1dc0d2be832_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3540e490fa3e40728018f6cb6e927d47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25fc95b9ce164bc0840b48602420b3c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd8bd8bffe9546e6a44571d468e8e8a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if21a7585b0b64bb1a4690ee991cf5d88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i549ddb0f7656451894dc614cf8d2a488_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic30be08150494e1ebf7f499accad38f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56a5a80e24444a2997770162f3127340_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6781f723ffcc40caaeb825c9755676eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib60e4a56a8df4e8692eaec00e452ea3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46c39428374148bda44abdf22ebd5a95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0c3186e6d7b427ebbbff1f0dbd4c8c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b326db53886469788a4a2d43dfa03b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic21dfcac734f47f6957fcca7f72cdc88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id29460ed74a94fa4ab322cb274b491e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i034bc01ef48b4d4a8bf1bb1de85b0868_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a4613e4687843f8a379ce7c10a467e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01d4c9f2c6ba40f3828a4aa2b86a45a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i193aaa31e9c44a1e82bffc909a360749_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i657bb6e3a8a046f28bfa284cf457e36f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45ee32c33d8748298bb8a2da1f87d7ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib53b1d8bd84944b9a5118a390e4915d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a1873024e2f49b98f313c5e06a689bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7740378444747719a5eb6065629a5ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9109fa397bd4ab896aee4f1166409ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c36deb7f9274663a77e895314cda704_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if595c9553f034555b84ce4f3992ef574_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2978c44e2ebc42e5bfd593b3bd9ec954_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i959e6655c905432b8c65682560f0dd19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f5dc8e414e04b1c913f494f9f5332ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie229939d8dc74c648e87a676c60fecd4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if504c2f11d744b658048ae59b90b89ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60aa93fd86be47a69cae67136a4bf322_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ae975a338844ef786881ecd9e3b9cd1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac5e61b93a3f4b598884410e09cd44de_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3deabe50cd3e469793cfee5e9e7b0957_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib64bda2b4edb482eb14a53a12c4bef2d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9c484252700460b89333bc846225d68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5113c368e6d84d078690ec4a2dcdac26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf10733689d841b993c15e2c32cb214e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebcd89814b67470fb88261e8811fe67c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7de72341f3240d6bca072b0cf1a49d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4199c211590a43da89a234cf0e6582df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7599f342c11d4e80a1f135e9a39b17ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85cfa5d73e404d39a22111bbd6758462_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77b43286347d44ef87b90ebfe3ab45f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a04be12804c4f369306f503b36bee55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3566041ec40442cda4e388d38876c815_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d2410d914e44ed9a27cd8b177231d10_D20190206-20190206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">sibn:LitigationStatutoryDamagesPerViolationOfTCPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="id1f51810588c413195ac60a540302861_D20190206-20190206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">sibn:LitigationTrebleDamagesPerViolationOfTCPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="i9154de9e205d4bde873fb87f0044bdc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59004ae255bc408fbcc9c0c0bfeb19e6_D20200622-20200622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-22</startDate>
            <endDate>2020-06-22</endDate>
        </period>
    </context>
    <context id="ie6ae02ed248d4976a0b8c92bb1c51665_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sibn:EricBFromerChiropracticIncClassActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95b018196eca491f8a64402c1d9c1b33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1dc4cef314e248258972c3adbdc0456e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4fc4f2f95ee4c97adad0fe62fb8956b_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="icc5dfa6f48e44ef7ad7fdc85379acfe1_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i50c8f148cb4c45afa01a41eb83479fbc_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtPrepaymentPenaltyPeriodAxis">sibn:PrepaymentPenalty3148MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i57f9e992b05a4a77b99d38cb277c0cc2_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtPrepaymentPenaltyPeriodAxis">sibn:PrepaymentPenalty4960MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i3171054c28c94e37a7274d5bfc3fb4de_D20200529-20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">sibn:VariableOptionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="i85a2c5d839d54923994ecdd79255d137_D20200529-20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="i91447b8f2dee4d7fb7da16614ef2b263_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6d91ea98cc44ed2ac071a60da01b6e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5cd440735cdc43f5a01ccd66c2e7e22a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37605fc017f54b699b34d502dfd83f5d_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="ia465af5919b8475cb3625c7d3c4c60b9_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i0efb63d3047f421990b618ba7b240282_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i7c56822bb4854a00aa2c71b72d285850_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i22adc896d58943239a8a55e36b35c2ff_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i0893e94d84ab4ef180a7082801b17e87_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SolarLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sibn:DebtCovenantThresholdAxis">sibn:DebtCovenantTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i0029f543a0b44f28883347fcd2bda900_D20200421-20200421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PayrollProtectionProgramLoanCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-21</startDate>
            <endDate>2020-04-21</endDate>
        </period>
    </context>
    <context id="ic1857c35e4ee46f3a5e3dd78d3069507_D20200429-20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PayrollProtectionProgramLoanCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="ib50689df2cf5465fbcc3d49d82ce6fe0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bb5133b5829435487b6826f9ee05e8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4270a5f8e26b45ef92ae241f823a5c92_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia711fb7cbd244135958a45b84e252b9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc7925565e8c4323a6a9a220d817cd1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyTwentySecondTwentyThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ba592ea26314e52a133b56ede4ac0c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyTwentySecondTwentyThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i774bf9ebb0d849c383fd489468d870df_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d677b2975b845e383359e9465b1c838_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7696c119674041ff8d5a58e5158f8c52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41018904b5854d86b3a31ec29a88bfb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2b01ed73e9446848e40e7b7b997079a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6525e11de664dcc8219a14e1805fe4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i139f7071f8c84f08bbe6dceaf889a5c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bd0d0bfaa8049db933a2450c31775e0_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="ibb403ea911274bf7b259455db756d709_D20190101-20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="ib2709796b037485da5c45a10ab0c0d2a_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifaca040e3897460d8726cb690a290765_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54ac410f45b545f6a9b196945613148b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:NonqualifiedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e3d05c378a547599cd9b6952a3c1c80_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a3fc6a89c574e28830c17f1f39ec06b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic43d91cf37b340449447358d82ccd92a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i385b1bffbd6844aa86634798c26f1bcb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sibn:OptionsTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f6cd8ef95b04649a99031341fddf8ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1227fe8e7ba44a1bde242290ec79931_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b3ffdb1efa44a3a807c3bb0733bd89f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d34965263684d8a827e3b511ef07bf7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0283a6f15aee4e39bd5b62b008d5658f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iabe7e4f5c282479c9dd4b63577d53724_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11c1abe777aa459288707c7d8ba52b51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82add15eb7894a888a8e8a9ba05ff086_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fcd62c3950d4b03b74e4c0cf4d1a7cb_D20200101-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i2931999815684f1992182b9f6d12780e_D20200501-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ce9444b0b5849639bc0b7f620058c77_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="iadf669f97771460fb006978ac53fcd89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i474b61edbbc14b8d94e1ce0729536585_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i297b39b995a14cdebf1cfa2c3d3fc236_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie584850230f64839b9c46ed2b0b8f3a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79cb20fa436042dbb60426290872da75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibde4a023409a47be91b9ea5231045908_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:ESPPPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i410806cbbdc746209446c410c6341047_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73a0c0dce9584a3eb98f59092edd33c5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf4055a0636841d992ed275f0ce24c78_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie70af4b35e0d415a8450cc48c58a228a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5cfba54d8644e33a6243d800d6a11c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00219ae7e63c44d783f827759951eaaa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52ce6cefcf474ade882fc1adc72c8eb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95838768b71a4d678805680c3b4e0eea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sibn:Company401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3946e536ed904059b0b93a4cf16adf9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sibn:Company401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09ea822832f34b5cae2305c150d8cd7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c4b044fdf884181b597402c0cfa5a59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6934a8f368ab4d9494b07c7ddfe7de0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c03f872c9a9488c981785d7b2746aa4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic58413a7253e4f4d8190a06a75631d77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:ShareSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40b75f3d79804b4face844493077ae7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:ShareSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc544ac398ba485a8fc4c71db95233b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:EmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if06ea8c038f64be2b2835e0ef0d248f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:EmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i55d3b6b03018480f8f30f7f6f385c670_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i696aeae988714665861bf927c6df4e88_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia344c14925fb435996aff0ac207bae68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bd326d4dba048b1a3b67d4854664c94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8cd127df2c1c4983bc79d5cb10d32b12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:DevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i193e00bc574d4629ac04368864c1127a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:DevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id20be3b85bd54fcd9fcf877450d0dd25_D20200224-20200224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001459839</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:DevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-24</startDate>
            <endDate>2020-02-24</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>sibn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="purchase_period">
        <measure>sibn:purchase_period</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF84LTEtMS0xLTA_d7057714-94ff-4142-88e5-ea0693836023">0001459839</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF8xMC0xLTEtMS00MzI0_fc0bb83b-86a3-43ff-8178-a6e38f39dd81">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF8xMS0xLTEtMS00MzI0_dc277d22-f5ec-4be6-b077-157a223f598a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV80L2ZyYWc6NWUyN2NiM2NiYzIxNDk4YzgxODM3Mjc3MDkxNDZkMTcvdGFibGU6Zjc2ZmQxNmYxYWUzNDNmZmFmZjYyMmE2M2Q3OTljZjQvdGFibGVyYW5nZTpmNzZmZDE2ZjFhZTM0M2ZmYWZmNjIyYTYzZDc5OWNmNF8xMi0xLTEtMS00MzI0_30424d79-d8ba-4d4c-89d0-09ee3ddb628c">false</dei:AmendmentFlag>
    <us-gaap:NumberOfReportableSegments
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzIvZnJhZzowNzJiMmRmNTM3ZjU0ZTkwOGUxMWFmNmY3ZTAzY2I5OS90YWJsZTo3ODJiNzE0YzdhYTE0ZDVhOTNhODQ3ZTg3MTc3ZWQ3NC90YWJsZXJhbmdlOjc4MmI3MTRjN2FhMTRkNWE5M2E4NDdlODcxNzdlZDc0XzItMS0xLTEtMA_ad6ecbc7-6328-44ad-9f87-701728e1dd1e"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzIvZnJhZzowNzJiMmRmNTM3ZjU0ZTkwOGUxMWFmNmY3ZTAzY2I5OS90YWJsZTo3ODJiNzE0YzdhYTE0ZDVhOTNhODQ3ZTg3MTc3ZWQ3NC90YWJsZXJhbmdlOjc4MmI3MTRjN2FhMTRkNWE5M2E4NDdlODcxNzdlZDc0XzMtMS0xLTEtMA_e69ac7fe-921b-4695-9c75-f018ca5165e7"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0e3d05c378a547599cd9b6952a3c1c80_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1ODU_7bd59b98-57a3-4657-978b-3cc5ffa4e420">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval
      contextRef="i7fcd62c3950d4b03b74e4c0cf4d1a7cb_D20200101-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1MjI_0f5ed571-a69d-4bc7-b68e-654ed23d7077">P6M</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval>
    <dei:DocumentType
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MTIz_d16ec913-1826-493b-afcd-2969cacd0fd3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6OTE3NmNjNzNkMWQwNGU0NzlkMDFjYjFmOGQ4NGNjNTAvdGFibGVyYW5nZTo5MTc2Y2M3M2QxZDA0ZTQ3OWQwMWNiMWY4ZDg0Y2M1MF8wLTAtMS0xLTQwODc_44eee814-b6ea-478e-9b28-3e39525cc673">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MTQ0_3d97437e-5235-4143-9b4b-788d0f002a1b">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MTQ0_b841ca86-e206-4cbe-9d57-8221ac908439">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ZWYxMTI0ZjU5ZDNlNDJkMWExN2NjYTZmYzQ0MzdmZWEvdGFibGVyYW5nZTplZjExMjRmNTlkM2U0MmQxYTE3Y2NhNmZjNDQzN2ZlYV8wLTAtMS0xLTQwODk_fa4f7cd2-bfaa-4286-b861-edf197fc1b51">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcx_5912fd9f-a04e-43af-9130-af1fc4ca776e">001-38701</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcw_b9a93861-943e-4da4-b5c7-68e32b87504d">SI-BONE,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6YmE0MTY2YmUyNDNjNDlhYjk5ODgzMzRiOGQxODEyNDcvdGFibGVyYW5nZTpiYTQxNjZiZTI0M2M0OWFiOTk4ODMzNGI4ZDE4MTI0N18wLTAtMS0xLTQxMDM_1ba3f37e-ed63-49e0-ae54-41da5402f38b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6YmE0MTY2YmUyNDNjNDlhYjk5ODgzMzRiOGQxODEyNDcvdGFibGVyYW5nZTpiYTQxNjZiZTI0M2M0OWFiOTk4ODMzNGI4ZDE4MTI0N18wLTEtMS0xLTQxMDU_e3c5390b-bdff-4c65-b7be-c2ebf3f6c950">26-2216351</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcy_b16b02c1-2cb0-4b6d-9958-48ee89ae69e6">471 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTcz_f2181bff-cc93-42aa-9479-3de13c5122f7">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTc0_1c6e1bf3-866e-4d44-90f9-5b65620c4492">Santa Clara</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTc1_d5d1c2e6-c553-49b8-979a-31e90413b841">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTc3_e8399b90-2837-437b-99a7-53e8aafbf608">95050</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg2OTkx_fc126e39-a09d-4021-9ebc-5749fa363b40">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAw_baadd03b-8811-4498-b28d-3a4af39d0468">207-0700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ODdkZTRkYjczYzRkNGZlMDg4MTA2MTY0YjE0NDdmZGUvdGFibGVyYW5nZTo4N2RlNGRiNzNjNGQ0ZmUwODgxMDYxNjRiMTQ0N2ZkZV8xLTAtMS0xLTQxNTE_ced5497d-23ed-454c-be72-8bb012819da7">Common Stock, par value $0.0001&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ODdkZTRkYjczYzRkNGZlMDg4MTA2MTY0YjE0NDdmZGUvdGFibGVyYW5nZTo4N2RlNGRiNzNjNGQ0ZmUwODgxMDYxNjRiMTQ0N2ZkZV8xLTEtMS0xLTQxNTM_457bf2be-8ce7-410f-8cb8-94c2f6677428">SIBN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6ODdkZTRkYjczYzRkNGZlMDg4MTA2MTY0YjE0NDdmZGUvdGFibGVyYW5nZTo4N2RlNGRiNzNjNGQ0ZmUwODgxMDYxNjRiMTQ0N2ZkZV8xLTItMS0xLTQxNTU_5cb73e93-b2a5-4c03-8f42-f7b0d49a68ec">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAx_9fc6f937-a2e5-4e38-a1dc-e0c01e2516bb">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAy_4ba5fe28-1c0a-438b-ab43-5f9f90784c50">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDAz_a0a2cdee-fc4a-44c9-af1f-f91d1b97efe8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDA0_f3f76607-868b-4af5-b849-4783bc8d7a81">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6MTQ4ZmQ2ZGU4ZThhNGI2N2FkYTMwZmM2NjM5ZGFmMDQvdGFibGVyYW5nZToxNDhmZDZkZThlOGE0YjY3YWRhMzBmYzY2MzlkYWYwNF8wLTQtMS0xLTQyMzM_bbc1b623-9595-4c57-bce4-7fdd0ca927b8">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6MTQ4ZmQ2ZGU4ZThhNGI2N2FkYTMwZmM2NjM5ZGFmMDQvdGFibGVyYW5nZToxNDhmZDZkZThlOGE0YjY3YWRhMzBmYzY2MzlkYWYwNF8xLTEtMS0xLTQyMjk_4ec84c8e-f797-4f42-adaa-01ff4f5d666e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGFibGU6MTQ4ZmQ2ZGU4ZThhNGI2N2FkYTMwZmM2NjM5ZGFmMDQvdGFibGVyYW5nZToxNDhmZDZkZThlOGE0YjY3YWRhMzBmYzY2MzlkYWYwNF8xLTMtMS0xLTQyMzE_c44b8452-a692-4c6b-b885-91f40b862a12">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDcw_34aca053-5166-49cb-b95f-efcf844035ea">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDA5_d0de5862-4357-44a9-a37a-397aaf145d3b">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDA4_622b63f4-fa21-4bea-a488-63e5049c8806">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i723b611d0707480481c85096cc3174e1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDU0_e4b93e55-998c-46cd-b519-f423dca305ea"
      unitRef="usd">394100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3e43846424574f4d99b00787ea404847_I20210305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8yOTMw_041cc06b-a3a7-439d-b0c9-99d45035c781"
      unitRef="shares">32727666</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xL2ZyYWc6MjZmNTkzNmFlODk0NDM4YWE1OGQ1MWNhZTM5NmFlZWYvdGV4dHJlZ2lvbjoyNmY1OTM2YWU4OTQ0MzhhYTU4ZDUxY2FlMzk2YWVlZl8zMjk4NTM0ODg3MDE0_cbdf0eae-898f-44f6-9c19-96a78b974b77">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#x2019;s fiscal&#160;year ended December 31, 2020, are incorporated by reference into Part&#160;III of this Report&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMtMS0xLTEtMA_b073dcf8-0899-4bb9-91d9-f9b20ba1d3f0"
      unitRef="usd">53581000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMtMy0xLTEtMA_98a11c07-f3fb-44eb-838b-65881a220363"
      unitRef="usd">10435000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzQtMS0xLTEtMA_318b8456-f637-485a-83e2-7031473f9111"
      unitRef="usd">142851000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzQtMy0xLTEtMA_72b426a3-ea4d-4028-b629-9674795fa867"
      unitRef="usd">81345000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2RiNTg2ZDc3MzQ1MWViYzExMWFmYjgzOWI4ZGVkXzE2NDkyNjc0NDE4NzY_ae2ba10f-f971-435f-b613-e9a473a2f396"
      unitRef="usd">263000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2RiNTg2ZDc3MzQ1MWViYzExMWFmYjgzOWI4ZGVkXzE2NDkyNjc0NDE4ODI_691c4ca7-b856-4d2a-8519-97313d2cedb0"
      unitRef="usd">238000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMS0xLTEtMA_2c9efef0-ff58-42b9-aaad-9181c11d844f"
      unitRef="usd">13611000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzUtMy0xLTEtMA_fc5b5217-bfb6-49a7-8fa5-b565a617957c"
      unitRef="usd">11720000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzYtMS0xLTEtMA_40209f7f-0527-4fc1-9304-742209368a0a"
      unitRef="usd">5633000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzYtMy0xLTEtMA_fe863da0-fc86-4051-ba62-8bd587f0b378"
      unitRef="usd">5452000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzctMS0xLTEtMA_9d7a9bc2-a7f0-4941-b10c-6a423b7c5ce5"
      unitRef="usd">2565000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzctMy0xLTEtMA_edfc948f-4de9-42c3-a20e-bb2452e2ea4e"
      unitRef="usd">2510000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzgtMS0xLTEtMA_89ac2be0-11b6-4dcb-b3ed-62baa1543348"
      unitRef="usd">218241000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzgtMy0xLTEtMA_edb23767-05f2-45b9-9e43-e2f1c0f80e41"
      unitRef="usd">111462000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzktMS0xLTEtMA_e410a5e5-062f-4805-a515-170aa6d29ec2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzktMy0xLTEtMA_2a34d73c-5eb9-4ed2-b2ac-0af05fc0e9a9"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEwLTEtMS0xLTA_bd0afd76-6aea-4382-a54d-2ecf10fa3930"
      unitRef="usd">4527000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEwLTMtMS0xLTA_b34b63d8-568a-4252-ac46-3622ad0823a4"
      unitRef="usd">3954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzExLTEtMS0xLTA_da0d2c4b-cb54-4171-b58c-821dc3644510"
      unitRef="usd">374000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzExLTMtMS0xLTA_b5b97274-8c09-4eaa-88f8-f9ddad570be5"
      unitRef="usd">315000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEyLTEtMS0xLTA_9f8079a3-c4cc-4089-b619-407c9dcb4d11"
      unitRef="usd">223142000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzEyLTMtMS0xLTA_7b3e4e7d-96fd-4e5d-b115-75e7ee6d8bed"
      unitRef="usd">117009000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE2LTEtMS0xLTA_5750028a-46ab-4aa2-bc7b-cc17ff928666"
      unitRef="usd">3271000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE2LTMtMS0xLTA_31f20bb3-a9c5-49a5-a912-409da6e69b33"
      unitRef="usd">2811000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE3LTEtMS0xLTA_01230c1a-7aaa-43b5-b58d-83de57cb263e"
      unitRef="usd">10199000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE3LTMtMS0xLTA_51bf3cc0-1dcd-4db5-b4b7-68bb20807e3f"
      unitRef="usd">11605000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE4LTEtMS0xLTA_b49416eb-decb-4d33-a046-db0bfa7b8d4e"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE4LTMtMS0xLTA_4cdaf84d-7680-4d16-819c-3ef261b3001f"
      unitRef="usd">4358000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE5LTEtMS0xLTA_83ae6ac9-4a8c-4df2-ba6a-ea5a33a4db71"
      unitRef="usd">13470000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzE5LTMtMS0xLTA_220e92eb-a037-469a-82ab-a9c48d51399f"
      unitRef="usd">18774000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIwLTEtMS0xLTA_727adb47-bfc7-4ef9-9d90-7e3bd5fbebeb"
      unitRef="usd">39455000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIwLTMtMS0xLTA_51c774cd-2940-41ac-85fc-894d93a276ef"
      unitRef="usd">34865000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIxLTEtMS0xLTA_7b21633e-6abf-4e99-a7d0-f27e61b5de3c"
      unitRef="usd">854000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIxLTMtMS0xLTA_9c2e4f0e-09c7-4f31-9048-53869311c025"
      unitRef="usd">362000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIyLTEtMS0xLTA_b121ecf4-bbee-4fd4-8b7e-b033ec6eeacd"
      unitRef="usd">53779000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzIyLTMtMS0xLTA_66ac8fd8-1113-46e9-8611-1826ae29be7c"
      unitRef="usd">54001000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI0LTEtMS0xLTA_68e16648-a80c-465f-ac1a-20704693ce23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI0LTMtMS0xLTA_a56f7d81-8b0f-4a55-be60-89ed13498b30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxNzcz_68e464a2-1ec4-42a9-a846-42bd6f640c86"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxNzcz_fb64fda6-463e-40b8-a100-6e20a54d27c5"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxODc3_fde9c6ba-69bf-4c7c-837b-edebee713994"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8xNjQ5MjY3NDQxODc3_fe736678-2095-4546-86f7-3d6689be731e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_1cfb38c2-6fe4-453b-8b11-43ddf15e9ea5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_2abaa248-ac65-4864-b7b0-ba242df08038"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_4213e4df-280b-4d7a-9ef1-d718c4f3eca4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpmODI5ZTg2ZTQxZmI0MDUyODBiYzg1OTQzY2RjMjhlYl8zMjk4NTM0ODgzNTQ1_5ac6ae06-5993-4cd9-b3b6-9570f1b39c9d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTEtMS0xLTA_f87c9635-e3a8-4581-bbbc-4ddc0cb0dcc8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI3LTMtMS0xLTA_e8e42b63-0037-40d0-8a35-a90154b996d8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxODA5_2c7d54a6-5b3f-4aaf-a3d1-5c52fd453192"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxODA5_d1e62769-7774-491c-ac53-3133d9730de7"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTUx_51d68a71-1dd2-4187-8226-e3f4f5c48410"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTUx_a9d80cef-754a-4d09-9bcb-e82c539a7963"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTYz_97e898f8-63fb-4b48-b32c-ecf6ab171edc"
      unitRef="shares">32583220</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTYz_be43610b-b51a-4812-ae15-0c9a56117e4b"
      unitRef="shares">32583220</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTc1_c0b6af6b-7572-435e-9140-04f32d6e03aa"
      unitRef="shares">25163803</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDhhNDdhYjc2Yjg0YzBiODQ4ZGI2YTQ0ZTRhYmYzNl8xNjQ5MjY3NDQxOTc1_cbedde50-5646-42b2-b194-6288c9f066ff"
      unitRef="shares">25163803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTEtMS0xLTA_37d66e32-03a4-40af-9a0c-f9c97be27873"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI4LTMtMS0xLTA_cab4e432-2817-4fcb-aba5-43b5376e090e"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI5LTEtMS0xLTA_0a7d0ba4-ca16-409c-aac9-270f4b24c821"
      unitRef="usd">408113000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzI5LTMtMS0xLTA_1d60df64-e43a-41f6-96a2-55112b7def1d"
      unitRef="usd">258121000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMwLTEtMS0xLTA_78a46e4f-2011-4095-9e36-fcaed5d5048c"
      unitRef="usd">524000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMwLTMtMS0xLTA_aee64011-8de9-4e69-9a43-439dc2378e4a"
      unitRef="usd">464000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMxLTEtMS0xLTA_063b5204-f68b-4502-857b-9ea33a586c10"
      unitRef="usd">-239277000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMxLTMtMS0xLTA_d4226e07-d9a9-474e-ac0f-14eed061aa17"
      unitRef="usd">-195580000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMyLTEtMS0xLTA_cb830294-9996-443d-b6d4-89e7db42e447"
      unitRef="usd">169363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMyLTMtMS0xLTA_e5db2ca4-f207-4346-a12e-e91992c874eb"
      unitRef="usd">63008000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMzLTEtMS0xLTA_825ec427-96b7-4ba4-9f9c-3d92323de628"
      unitRef="usd">223142000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNDUvZnJhZzpiOWY5YTQ2ZDZhZGE0MTE5OTQwMzhjNGY1YTdlNTYxNS90YWJsZTozMzQ5MzUxYTc3MTM0NTQ2YjU1NGUwMGI4MDkzN2M5My90YWJsZXJhbmdlOjMzNDkzNTFhNzcxMzQ1NDZiNTU0ZTAwYjgwOTM3YzkzXzMzLTMtMS0xLTA_7e705bdb-991a-42d9-9fff-30b2c406c1ff"
      unitRef="usd">117009000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzItMi0xLTEtMA_b93b89fb-c892-4c38-b557-d62e1a32f2dd"
      unitRef="usd">73387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzItNC0xLTEtMA_9c11d514-9153-4403-b63c-918ce650aab0"
      unitRef="usd">67301000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzMtMi0xLTEtMA_7b32be6c-721d-4635-a10d-04c5809db67c"
      unitRef="usd">8902000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzMtNC0xLTEtMA_dccb4b8b-392d-468b-a3d1-5152ed572c90"
      unitRef="usd">6790000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzQtMi0xLTEtMA_b421e82e-a580-43f2-8d16-da988485a06d"
      unitRef="usd">64485000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzQtNC0xLTEtMA_8d72f00e-8914-4c3e-b0cd-f878318a2555"
      unitRef="usd">60511000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzYtMi0xLTEtMA_4d636e27-1c84-483f-9d4a-8ea0e72a3b3d"
      unitRef="usd">73790000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzYtNC0xLTEtMA_8b41b6c3-cbed-4051-a2de-3a5a079ef961"
      unitRef="usd">68251000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzctMi0xLTEtMA_26bd79f7-349d-4f49-9a67-3bc7bf23f2df"
      unitRef="usd">9459000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzctNC0xLTEtMA_25298f24-5324-436c-a35f-566371073c29"
      unitRef="usd">7279000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzgtMi0xLTEtMA_6aa65e36-e7eb-4dbb-9169-27127ed10eaa"
      unitRef="usd">19803000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzgtNC0xLTEtMA_caf94342-3df4-4655-bb38-533c1670c620"
      unitRef="usd">20984000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzktMi0xLTEtMA_12c33f92-c435-4af6-b6b5-cff77655ff48"
      unitRef="usd">103052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzktNC0xLTEtMA_3d21c263-2aef-4e9f-92e0-4392ad7d3695"
      unitRef="usd">96514000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEwLTItMS0xLTA_a71ba745-e36d-4298-ac7d-e5de48626ba4"
      unitRef="usd">-38567000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEwLTQtMS0xLTA_d52f0174-3ed1-4b4f-8e83-ea9a31fae339"
      unitRef="usd">-36003000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEyLTItMS0xLTA_6f5d62de-9e4f-4c69-b606-8e7cd7703717"
      unitRef="usd">1097000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEyLTQtMS0xLTA_dc4a2d7c-f873-4003-9d0c-d8e02e22ea47"
      unitRef="usd">2551000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEzLTItMS0xLTA_481baa0c-c00d-4e31-bd3b-65ed86d6d7a8"
      unitRef="usd">6101000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzEzLTQtMS0xLTA_a4996183-c3fd-42ca-8701-e544a5947ae4"
      unitRef="usd">4949000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE0LTItMS0xLTA_73ae36d5-5609-46ab-ba84-4ea770314430"
      unitRef="usd">-126000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE0LTQtMS0xLTA_f4fdf9db-e35b-41d1-a277-417c6bb81c37"
      unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE1LTItMS0xLTA_15e8bbb3-ce1f-495b-b129-07dc4cbfb4f7"
      unitRef="usd">-43697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE1LTQtMS0xLTA_b1ffa80e-4cb9-42e0-93a5-6db0796f8a36"
      unitRef="usd">-38403000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE3LTItMS0xLTA_1e41d443-5580-4bd4-b134-844778b9a8f9"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE3LTQtMS0xLTA_9619b3e5-35bf-46ac-9ba3-c0052d24ba31"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE4LTItMS0xLTA_c48647d3-b3ef-4774-8aca-234d886f7ef5"
      unitRef="usd">119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE4LTQtMS0xLTA_f8828dce-1bcd-4d25-95bf-fbbddde2c05b"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE5LTItMS0xLTA_b02ce90a-13ae-44eb-887b-f3aedd79875b"
      unitRef="usd">-43637000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzE5LTQtMS0xLTA_7b390c5c-0d1b-4fc0-88dc-f9c5c04e8342"
      unitRef="usd">-38378000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIxLTItMS0xLTA_0325349d-0127-4825-addc-c7bd2cf7047a"
      unitRef="usdPerShare">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIxLTQtMS0xLTA_8917c276-e324-4f13-91be-9309d9314992"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIzLTItMS0xLTA_d7610abc-9991-433a-87ae-f2905d6ce0cc"
      unitRef="shares">29059171</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTEvZnJhZzphZmQ0MzU4ZDIwZWI0MDFmOTg3NDk3M2RjODQzYjdkMi90YWJsZTplNzc4MzhlN2RkMDQ0YzdmYjk1Y2RjYmVlMDBkZGFmYS90YWJsZXJhbmdlOmU3NzgzOGU3ZGQwNDRjN2ZiOTVjZGNiZWUwMGRkYWZhXzIzLTQtMS0xLTA_61282f59-7e36-42ff-a33c-5d8fb0d907dd"
      unitRef="shares">24705980</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="ie66d822de1dc49998b0d0dbd86b96408_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItNi0xLTEtMA_3152d186-a161-40ac-a7c4-275b6da33dfc"
      unitRef="shares">24450757</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie66d822de1dc49998b0d0dbd86b96408_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItOC0xLTEtMA_7f260b1e-d91d-4ee8-98e4-20fc6a491628"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0dff6565556f4ea180e9d4dc002bcc73_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTAtMS0xLTA_02bcd563-454d-4ddd-97db-b8b0e4a2ac25"
      unitRef="usd">246927000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81b4c997fd0c473da8c08fde9e5c65d4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTItMS0xLTA_7a323199-3be8-46e1-b732-a193a199b45b"
      unitRef="usd">439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e5589745a4b4e59be2fa5da9fc96faa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTQtMS0xLTA_f928b9b2-d173-4556-8bcf-a727e187a303"
      unitRef="usd">-157177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzItMTYtMS0xLTA_1360742d-74c6-428a-994c-aa95bbfb0d29"
      unitRef="usd">90192000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzMtNi0xLTEtMA_cb6aa02f-9e99-444c-9c8c-588141b77bfa"
      unitRef="shares">444788</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzMtMTAtMS0xLTA_e6f4cb49-3736-4131-b7c1-12cd3fd71326"
      unitRef="usd">1490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzMtMTYtMS0xLTA_976df93e-560a-4a3e-82e5-b3083a241e09"
      unitRef="usd">1490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzQtNi0xLTEtMA_d3169424-0e67-40e1-b25f-9bdb7ef93703"
      unitRef="shares">168457</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzQtNi0xLTEtMzU_b3dc38cb-a607-4a1c-8879-b9a8f564c5f6"
      unitRef="usd">2203000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzQtMTYtMS0xLTA_012f5598-4bc2-4a36-9159-6f213d2d5c0c"
      unitRef="usd">2203000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sibn:StockIssuedDuringPeriodSharesRestrictedStockUnits
      contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzUtNi0xLTEtMA_0a0e37f2-8e23-4fba-ad79-88e300d2bf0d"
      unitRef="shares">108631</sibn:StockIssuedDuringPeriodSharesRestrictedStockUnits>
    <sibn:StockIssuedDuringPeriodAmountRestrictedStockUnits
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzUtMTYtMS0xLTA_6a35b441-833d-4253-862d-9bb3cfb53088"
      unitRef="usd">0</sibn:StockIssuedDuringPeriodAmountRestrictedStockUnits>
    <sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares
      contextRef="i165ffee2eb3a4ea1a0bc08ccd615a8d6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzYtMi0xLTEtMzU_86431696-1b11-42d3-b1d4-5fd17cac46a4"
      unitRef="shares">8830</sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares>
    <sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzYtMTYtMS0xLTA_750ae728-245a-497a-b16b-bcd0453442e5"
      unitRef="usd">0</sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzctNi0xLTEtMzU_ae1d9e9e-eece-4969-a5bb-2743a1430496"
      unitRef="usd">7464000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzctMTYtMS0xLTA_b16b5a8f-42b3-4d27-8073-29b0cd4584c9"
      unitRef="usd">7464000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
      contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzgtMTAtMS0xLTA_2129ff35-c86a-4dc7-a27c-78250a4089ab"
      unitRef="usd">197000</sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions>
    <sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzgtMTYtMS0xLTA_66ccef30-5a2d-4715-b424-ef76aaec826f"
      unitRef="usd">197000</sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i5678948a03bf48b99de61934b25d458e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzktNi0xLTEtMzU_70f0efae-4d9f-4132-a777-b591096e482a"
      unitRef="usd">160000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzktMTYtMS0xLTA_c39e122d-46c0-44e1-9538-1ea04f7adb22"
      unitRef="usd">160000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iffbce40da8154d0ebfd353ebc4ecfc66_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEwLTgtMS0xLTM1_efa9b7e2-042b-4a65-8fdd-cd88e0e6894b"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEwLTE2LTEtMS0w_c07d5a23-1a4b-4e1c-8021-15c8639ffdf7"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iffbce40da8154d0ebfd353ebc4ecfc66_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzExLTgtMS0xLTM1_9ef40bd4-1738-44be-8326-a532e9248cc0"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzExLTE2LTEtMS0w_589431ad-e9ba-498a-a611-3efa116d79e9"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i04fe10a38bbc4b9b992c2d00521e3926_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEyLTEwLTEtMS0zNQ_66593f0d-b650-48c1-b10f-38a3641f9984"
      unitRef="usd">-38403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzEyLTE2LTEtMS0w_f73dbe66-33da-4761-9502-6bd2e301dbf1"
      unitRef="usd">-38403000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i985109e7c07a47caa2b5f16db86a7f92_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTYtMS0xLTA_668a4e5c-4575-440f-bc32-7bc327b78a65"
      unitRef="shares">25163803</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i985109e7c07a47caa2b5f16db86a7f92_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTgtMS0xLTA_dea616b7-ea44-4a93-89eb-d856637f0972"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b107ede87a64e409d8ea0d6c15db765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTEwLTEtMS0w_aa859a81-29f4-48da-b7db-a6e8db21c366"
      unitRef="usd">258121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic26490e07c24473bb2dfc03fc2377ce8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTEyLTEtMS0w_490c5da8-4a2d-441a-98fd-a7c3a07dab9a"
      unitRef="usd">464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9d1708678a945beac3f5189fa6daf27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTE0LTEtMS0w_1569e010-ea57-4d0a-b017-0d2dc46ab9c8"
      unitRef="usd">-195580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE1LTE2LTEtMS0w_3bfb1e1b-7642-47f5-a0ce-9f9d02b28801"
      unitRef="usd">63008000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTItMS0xLTYwMg_7f28ba71-7d38-4af4-ab22-ec314b923cea"
      unitRef="shares">6613560</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTQtMS0xLTYwMg_383ef9a3-4181-490e-80e1-a75dddb9615d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTYtMS0xLTYwMg_2c1a3c59-57cc-4980-87c8-0f352e710186"
      unitRef="usd">134616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE0LTEyLTEtMS02MDI_16485010-1008-4e12-ace1-a8dc36f6c855"
      unitRef="usd">134616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE2LTYtMS0xLTA_aba59592-5c04-4838-83ef-2c1c5e569c4a"
      unitRef="shares">323701</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE2LTEwLTEtMS0w_82ee2c04-a8c1-477f-b98e-9ca7b1bfec8a"
      unitRef="usd">1463000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE2LTE2LTEtMS0w_0a8c3a6e-45fa-48b2-9ad0-914863439d8b"
      unitRef="usd">1463000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE3LTYtMS0xLTA_53bf1e14-2930-4095-a701-cc9b45fae991"
      unitRef="shares">137377</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE3LTEwLTEtMS0w_0323586b-03ac-498c-b0cf-948dd5c5a9b6"
      unitRef="usd">1915000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE3LTE2LTEtMS0w_55d5f692-25b7-412c-8eec-5568944c3ab7"
      unitRef="usd">1915000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sibn:StockIssuedDuringPeriodSharesRestrictedStockUnits
      contextRef="ic133b244626b43a18e2c5235832641ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE4LTYtMS0xLTA_d64ed5b5-384b-47aa-8bce-91367e35bd90"
      unitRef="shares">344779</sibn:StockIssuedDuringPeriodSharesRestrictedStockUnits>
    <sibn:StockIssuedDuringPeriodAmountRestrictedStockUnits
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzE4LTE2LTEtMS0w_60c4efc1-99a1-47f6-89ac-1fdcea448d2b"
      unitRef="usd">0</sibn:StockIssuedDuringPeriodAmountRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIwLTEwLTEtMS0w_39a3151d-8d53-403e-9901-376b15cd0743"
      unitRef="usd">11927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIwLTE2LTEtMS0w_b29a05ea-aa6c-47c2-92d8-dac5233700dc"
      unitRef="usd">11927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
      contextRef="i13198ff479454a829088c0ad4f3d367d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIxLTEwLTEtMS0w_bc52ebd5-bcbb-4297-945d-7a2cf0f56c81"
      unitRef="usd">71000</sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions>
    <sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIxLTE2LTEtMS0w_35653781-9bbc-4e53-9151-8269853cba96"
      unitRef="usd">71000</sibn:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id6a1c74b555a4f0aba5275ea8e0f0cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIzLTEyLTEtMS0w_0834de91-251d-4a54-ba5e-57bb4f96006a"
      unitRef="usd">119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzIzLTE2LTEtMS0w_39aaed8c-9e44-4214-ad45-550274cdca23"
      unitRef="usd">119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id6a1c74b555a4f0aba5275ea8e0f0cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI0LTEyLTEtMS0w_c38227f0-0bd5-425e-ae44-04ef27d7eeb8"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI0LTE2LTEtMS0w_53489154-c33e-4c92-9cfa-fc6b2c1ceae7"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ic95beb3614404efb8439b54564decf04_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI1LTE0LTEtMS0w_680d69a8-9de0-4b9b-9a5f-1deb4e08b771"
      unitRef="usd">-43697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI1LTE2LTEtMS0w_1a899fe3-2603-431d-bdb6-80a5929a8de9"
      unitRef="usd">-43697000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ida15542c93ec4747869dcb494008d0f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTYtMS0xLTA_6b0f6944-3a3b-461e-8f3e-47d12e421913"
      unitRef="shares">32583220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida15542c93ec4747869dcb494008d0f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTgtMS0xLTA_23c656b3-9a1a-4b95-b94c-45b382c301c6"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53a37168d69c463082d9d5b20b3a2f88_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTEwLTEtMS0w_cc7ce524-8741-4320-82f1-636e282b53ae"
      unitRef="usd">408113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f72f3efd8214401a36fbcad6478c88c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTEyLTEtMS0w_a2ff9c11-c3df-45e4-a816-35facc03753e"
      unitRef="usd">524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic23626475cd542f79e54023f0ce2273b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTE0LTEtMS0w_8b95e5b0-5255-400d-a648-bc7da10caff7"
      unitRef="usd">-239277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTQvZnJhZzowMWQyZTc3YmQ0ZDg0ZjRlYTBlMmFlZDk3YmQ1M2M3YS90YWJsZTo3Yjk2OGFlNGU0NjQ0YmJhOTZlMmFjNjRhYjYyYjQ2OC90YWJsZXJhbmdlOjdiOTY4YWU0ZTQ2NDRiYmE5NmUyYWM2NGFiNjJiNDY4XzI2LTE2LTEtMS0w_c8301df1-99e6-40e9-87b4-5f2ce0f2c4fe"
      unitRef="usd">169363000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMtMS0xLTEtMA_b835daaf-64fa-4845-9e39-e073e61c9dff"
      unitRef="usd">-43697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMtMy0xLTEtMA_75237591-660f-40a6-9241-96fb416d64ff"
      unitRef="usd">-38403000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzUtMS0xLTEtMA_df1e2895-1999-4448-9316-a0abdc2619f2"
      unitRef="usd">11927000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzUtMy0xLTEtMA_f3b92b61-ed59-4af2-b1af-646a16adabba"
      unitRef="usd">7464000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzYtMS0xLTEtMA_a9ecd7c8-fc90-4456-9094-4fcd12f30807"
      unitRef="usd">1130000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzYtMy0xLTEtMA_379cfca2-0434-4434-a994-4c02f62135b8"
      unitRef="usd">774000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMS0xLTEtMTAz_09e867bd-9708-4be8-9d86-1e6fe9d4afed"
      unitRef="usd">234000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMy0xLTEtMTAz_2a5b6d7f-ea72-48a7-8292-750530a1b212"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMS0xLTEtMA_b4fdea36-e3c6-4ee0-b83c-0987cd5f7569"
      unitRef="usd">-115000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzctMy0xLTEtMA_f3f00bfd-ca08-410d-b05b-ade25679c7da"
      unitRef="usd">1413000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzktMS0xLTEtNjc0_35c21655-ac27-4e05-89e8-e54fae09ad10"
      unitRef="usd">46000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzktMy0xLTEtNjc0_a18f6d4e-44db-463f-a451-aa0bf5919075"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzgtMS0xLTEtMA_bb4c179c-0037-45d1-a1de-7d0b6df89930"
      unitRef="usd">292000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzgtMy0xLTEtMA_4fb08505-3bab-4595-84f5-a5a83cf8a20f"
      unitRef="usd">259000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzExLTEtMS0xLTY3OA_2c7b99a3-6c42-441c-9c67-0351e7061ac9"
      unitRef="usd">-1534000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzExLTMtMS0xLTY3OA_b1900686-7139-4ead-b47b-f9c023bf513a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEwLTEtMS0xLTA_5a7eef7e-d019-47ba-8b02-85fa35556b2d"
      unitRef="usd">-376000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEwLTMtMS0xLTA_65800d2c-9bea-4781-84d7-75249336e41a"
      unitRef="usd">-171000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEyLTEtMS0xLTA_622218a9-1676-4550-8106-3cbacec00f8e"
      unitRef="usd">2186000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEyLTMtMS0xLTA_5db0a292-ab29-4cc9-a671-16a1b806796c"
      unitRef="usd">3236000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEzLTEtMS0xLTA_aad98c72-aabc-4fe9-98e8-bbe5617b613e"
      unitRef="usd">274000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzEzLTMtMS0xLTA_07978d60-1e4a-43e9-a652-14be7625a7bf"
      unitRef="usd">2105000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE0LTEtMS0xLTA_c3623d54-50ca-4deb-8d2c-b7208e854ea7"
      unitRef="usd">136000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE0LTMtMS0xLTA_0188a171-55d9-4fd3-a105-1f19a9fbcbfa"
      unitRef="usd">515000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE1LTEtMS0xLTA_6fb5ffc8-978f-44b0-ac1d-c1040ec59fdb"
      unitRef="usd">835000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE1LTMtMS0xLTA_362e464b-a4f1-4d6c-9dc4-03fc5132e7eb"
      unitRef="usd">383000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE2LTEtMS0xLTA_74eb1ef4-3abf-4d22-98a9-49e19d41f5dd"
      unitRef="usd">-766000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE2LTMtMS0xLTA_65f0b43d-d3d7-4cb6-940a-8f4e83ab7ef1"
      unitRef="usd">4994000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE3LTEtMS0xLTA_a89deea8-6c36-45aa-99ee-e214d9681516"
      unitRef="usd">-30662000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE3LTMtMS0xLTA_450d6673-6bde-4de9-96a7-30c011f51368"
      unitRef="usd">-31627000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sibn:ProceedsFromMaturityOfMarketableSecurities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE5LTEtMS0xLTA_ce9306ea-e762-4a96-a745-8409f2173233"
      unitRef="usd">104716000</sibn:ProceedsFromMaturityOfMarketableSecurities>
    <sibn:ProceedsFromMaturityOfMarketableSecurities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzE5LTMtMS0xLTA_1f154853-9501-4458-acd5-93311a4fb733"
      unitRef="usd">159800000</sibn:ProceedsFromMaturityOfMarketableSecurities>
    <sibn:ProceedsFromSaleOfMarketableSecurities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTEtMS0xLTY5Mg_c12e4e2f-f1f6-42d6-b5d4-df174afb9c6b"
      unitRef="usd">14095000</sibn:ProceedsFromSaleOfMarketableSecurities>
    <sibn:ProceedsFromSaleOfMarketableSecurities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTMtMS0xLTY5Mg_76083ab2-c339-42c2-ac3e-4f44a3a29d47"
      unitRef="usd">0</sibn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIwLTEtMS0xLTA_bbee527e-4a31-45c0-bd47-c5bdd7b21725"
      unitRef="usd">179166000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIwLTMtMS0xLTA_b66ee3d6-799d-4cd6-ac70-91edee8c81a5"
      unitRef="usd">143864000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIxLTEtMS0xLTA_6db3d7aa-116f-4aea-81a7-e76487a24ea8"
      unitRef="usd">2561000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIxLTMtMS0xLTA_3c94a5c3-fadd-49f0-84e5-3a51cd62b1b9"
      unitRef="usd">2445000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTEtMS0xLTA_94935bac-6138-4a37-a5d0-74e57507a708"
      unitRef="usd">-62916000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzIyLTMtMS0xLTA_f88ed6fb-2670-4e74-9206-ba6ec2713934"
      unitRef="usd">13491000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI0LTEtMS0xLTA_96a88a65-1e5d-48c3-80d9-1909cfc650ec"
      unitRef="usd">134616000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI0LTMtMS0xLTA_a463891d-688b-4a79-aba5-d22486a6e871"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTEtMS0xLTY5Ng_b08239a0-0fde-4e5c-b661-5ca5888a44b0"
      unitRef="usd">45297000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTMtMS0xLTY5Ng_6831de64-e945-4c48-8eba-9bb095b573f6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTEtMS0xLTY5Ng_5c8a3447-2aa6-46a9-8fa4-5706d4560035"
      unitRef="usd">45297000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTMtMS0xLTY5Ng_89582e26-9d2e-46cb-b667-a28dfc57c931"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTEtMS0xLTY5Ng_d0dff60b-13a6-46d3-ab09-1e51eed44e3e"
      unitRef="usd">750000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTMtMS0xLTY5Ng_752dc04b-77a7-44f2-a0a9-fc4173b072cd"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTEtMS0xLTY5Ng_d600073d-e4e0-45a0-a469-55f319d6fe03"
      unitRef="usd">843000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTMtMS0xLTY5Ng_7ff39e75-d1c1-4cda-bcfa-4bdb73658015"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI1LTEtMS0xLTA_3f2e2007-c22d-4c9f-b126-b7d5c6f26916"
      unitRef="usd">1463000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI1LTMtMS0xLTA_ae028849-a90a-4da1-86aa-de1af837c821"
      unitRef="usd">1490000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI2LTEtMS0xLTA_b94411be-62c3-492b-b971-91332c2a401f"
      unitRef="usd">1915000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI2LTMtMS0xLTA_fe1df3be-c6ac-4719-ac28-1ec4d58c35ea"
      unitRef="usd">2203000</us-gaap:ProceedsFromStockPlans>
    <sibn:PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI3LTEtMS0xLTA_9055be8e-94ec-4196-926e-914d21e3dfc3"
      unitRef="usd">0</sibn:PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions>
    <sibn:PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI3LTMtMS0xLTA_5fde5d8d-eb69-4066-85f2-5fcc9d6c2191"
      unitRef="usd">38000</sibn:PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTEtMS0xLTA_f8bc45a8-27bf-4c9e-846b-13eccaef676d"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI4LTMtMS0xLTA_26882ac3-bc53-4c80-b6e0-0115cec621c4"
      unitRef="usd">167000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTEtMS0xLTA_019e3a62-eba3-4ddc-a05a-1aca83c3d622"
      unitRef="usd">136401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzI5LTMtMS0xLTA_1d7c54ca-da19-4187-8cab-86ed6bc95234"
      unitRef="usd">3488000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTEtMS0xLTA_6164e273-4fc1-4a0f-94cf-302cd1526ce8"
      unitRef="usd">323000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMwLTMtMS0xLTA_b873aaeb-f652-4e2e-9ab9-b8c6a39a1ef0"
      unitRef="usd">-37000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTEtMS0xLTA_0c2865c1-a950-49d5-a4b1-ef596d382484"
      unitRef="usd">43146000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMxLTMtMS0xLTA_12a3fbac-a35f-4cfd-83f1-a30807b9d8ce"
      unitRef="usd">-14685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMzLTEtMS0xLTA_7b211ce4-d782-4594-a1e9-b170e48e5851"
      unitRef="usd">10435000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzMzLTMtMS0xLTA_b04a5477-84c5-4574-81c3-54c2d71b5acf"
      unitRef="usd">25120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM0LTEtMS0xLTA_667f6242-256e-4bbc-9e1b-b4e9e97f791d"
      unitRef="usd">53581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM0LTMtMS0xLTA_9b7a0b6f-defd-449e-8bdc-ed236571ead4"
      unitRef="usd">10435000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM2LTEtMS0xLTA_2bedbe56-ec98-441e-8547-172a955ca781"
      unitRef="usd">4276000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzM2LTMtMS0xLTA_ce234c6b-2983-4b8a-a85a-7b928daccdb0"
      unitRef="usd">4949000</us-gaap:InterestPaidNet>
    <sibn:VestingOfEarlyExercisedStockOptions
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQwLTEtMS0xLTA_5d7e90d6-8847-482e-8a5a-eaca24668cd6"
      unitRef="usd">71000</sibn:VestingOfEarlyExercisedStockOptions>
    <sibn:VestingOfEarlyExercisedStockOptions
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQwLTMtMS0xLTA_f78d79b7-89bc-4b31-904f-731e9ba972df"
      unitRef="usd">197000</sibn:VestingOfEarlyExercisedStockOptions>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQxLTEtMS0xLTA_b8eae387-b62b-4162-b95d-79c5014e65f7"
      unitRef="usd">26000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNTcvZnJhZzpkMmVkMTdlMWFhYTA0NDk4OGM2ZTdkZjFhYTEzMGUxYi90YWJsZTplNGUyMjg0YTU2YTc0NTQwOTUyODY0OGU2ZDI2NzJhMy90YWJsZXJhbmdlOmU0ZTIyODRhNTZhNzQ1NDA5NTI4NjQ4ZTZkMjY3MmEzXzQxLTMtMS0xLTA_6f7e046b-8395-40df-9836-cb58fc646726"
      unitRef="usd">375000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIyOTg_691c853a-fba1-44c4-a15c-31ce2075783e">The Company and Nature of Business&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SI-BONE, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware on March&#160;18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Public Offerings of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October&#160;2018, the Company completed its initial public offering (&#x201c;IPO&#x201d;) by issuing 8,280,000 shares of common stock, at an offering price of $15.00 per share for net proceeds of $113.4&#160;million to the Company, net of underwriting discounts and commissions and offering costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company received $50.0 million net proceeds, after deducting the underwriting discounts and commissions, from its public offering of 4,300,000 shares of the Company's common stock at a public offering price of $21.50 per share, of which 2,490,053 shares were offered and sold by the Company. Further, in February 2020, the underwriters fully exercised its option to purchase 645,000 shares of the Company's common stock at a public offering price of $21.50 per share for an additional net proceeds of $13.0 million to the Company, after deducting the underwriting discounts and commissions. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $0.4&#160;million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2&#160;million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;In October 2020, the Company received $71.6 million of net proceeds from its second follow-on public offering of 3,000,000 shares of the Company's common stock, and the exercise of underwriter's option to purchase from the Company an additional 478,507 shares of the Company's common stock, at a public offering price of $22.00 per share. In addition to the shares sold by the Company in the second follow-on offering, in October 2020, the selling stockholder sold 190,053 shares of the Company's common stock previously held by the selling stockholder at a price to the public of $22.00 per share. The Company did not receive any proceeds from the sale by the selling stockholder.</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ifd2d90a648464b458060488f94c81ad8_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzMyOTg1MzQ4OTI4NTM_e8b35cb2-3439-40c0-9ad6-22e752628fce"
      unitRef="shares">8280000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iddc263e01aa24b63bfcb6b7c3ca255eb_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzMyOTg1MzQ4OTI4ODA_e698652b-6b06-47fc-9bc9-abaee5e2f1e5"
      unitRef="usdPerShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ifd2d90a648464b458060488f94c81ad8_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzMyOTg1MzQ4OTI4NjQ_977ac043-c146-49b8-88d3-90c1ab25d590"
      unitRef="usd">113400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i181125cf82924e5b9581883ff443cf53_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTgxNjM_97391377-5a9c-42f3-92d4-ce8929e2ac0b"
      unitRef="usd">50000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sibn:SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering
      contextRef="ide3655a0a0a14ac1b122bcd81866b549_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjI5NDI_9597b634-9ecd-41a9-9fb2-833cf9677fd8"
      unitRef="shares">4300000</sibn:SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7f5bdb3241a241cab56395a180519bf7_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjI5MDQ_4b541c16-3e2a-4813-a136-bdbee15ebe3b"
      unitRef="usdPerShare">21.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i181125cf82924e5b9581883ff443cf53_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjI1ODc_ac8ebc6b-385c-41d5-a5a7-8c2d2cdc8c3f"
      unitRef="shares">2490053</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if0448433af0a48b1a3ca65d600cf995e_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTg1MzI_ae9306c5-385b-4e3e-94ed-5d7de8ede9fb"
      unitRef="shares">645000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i70eea66b474641c1ad7620f47edb01b0_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTg2MTM_950c18d1-502c-485e-bbdb-d2da259bc39d"
      unitRef="usdPerShare">21.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="if0448433af0a48b1a3ca65d600cf995e_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNTg3ODc_2d75b8c2-2f23-443f-9f88-ff00c84c6353"
      unitRef="usd">13000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sibn:AllocatedPublicOfferingCosts
      contextRef="i5492ced8113d48a1af6af8e02eeb934e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjM4MjY_548ecba1-7ad6-49a9-91dc-a4dcb325942f"
      unitRef="usd">400000</sibn:AllocatedPublicOfferingCosts>
    <sibn:AllocatedPublicOfferingCosts
      contextRef="i833840966f0446599fbe1ac28b5fc775_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzIxOTkwMjMyNjM4MTI_2b22aacf-0a9f-4d87-85f2-f559ec6b8918"
      unitRef="usd">200000</sibn:AllocatedPublicOfferingCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie94283009e404d94a4b0dc42119c45bd_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMTA_758da82e-dfda-4620-9b7d-41479dbb1e88"
      unitRef="usd">71600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie94283009e404d94a4b0dc42119c45bd_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMTc_2ea9b686-3697-42e7-8064-05fde5c5ac62"
      unitRef="shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6bccb8eb33f2419aa52d19db5810f680_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMjE_1f8fb843-5272-48e9-bce3-01e26de51f52"
      unitRef="shares">478507</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6592020c6d484bdca8308d69ae2e0cb8_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMjU_b0ec0c50-b992-4c41-96be-91a19a798ab6"
      unitRef="usdPerShare">22.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic82e690a259f4746a1c2de4c43841af5_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMjk_9d9db41e-5805-498f-a72d-cacc44aa6cbb"
      unitRef="shares">190053</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7f59add943494c479a4150b168d4d73c_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjMvZnJhZzo3OGMyMzIyMDdlYzA0YTlkYTBhYThhZjA1OTc0MzhhZC90ZXh0cmVnaW9uOjc4YzIzMjIwN2VjMDRhOWRhMGFhOGFmMDU5NzQzOGFkXzE2NDkyNjc0NTMzMzM_c5e14085-68ce-4b9f-86b8-8b2a00de99af"
      unitRef="usdPerShare">22.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzU0OTc1NTgyMjE0NTE_44db66b6-f758-424f-9d12-f281c3c65f97">Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;JOBS Act Accounting Election&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies. Those standards apply to companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the&#160;JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company continues to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if the Company's total annual gross revenues are $1.07 billion or more; or (ii) the Company has issued more than $1.0 billion in non-convertible debt in the past three years;&#160;or (iii) the Company becomes a &#x201c;large accelerated filer,&#x201d; as defined in Rule&#160;12b-2 of the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are based on components of the Company that engage in business activities that earn revenue and incur expenses and (a)&#160;whose operating results are regularly reviewed by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), to make decisions about resource allocation and performance and (b)&#160;for which discrete financial information is available.&#160;The CODM for the Company are the Chief Executive Officer (&#x201c;CEO&#x201d;) and Chief Operating Officer &amp;amp; Chief Financial Officer (&#x201c;COO/CFO&#x201d;). The CEO and the COO/CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives substantially all of its revenue from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. International revenue accounted for less than 10% of the total revenue during the periods presented. Long-lived assets held outside the U.S. are immaterial. Following table summarizes the Company's revenue by geography:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company&#x2019;s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company&#x2019;s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue and accounts receivable are spread across a large number of customers, primarily in the U.S., and no customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the response to the pandemic and the information surrounding the pandemic is rapidly evolving. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, excess and obsolete inventory, and the impact of any initiatives and programs that the Company may undertake to address financial and operations challenges faced by its customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors and uncertainty of market acceptance of products. The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company had cash and marketable securities of $196.4 million compared to $93.1 million as of December 31, 2019. The Company has financed its operations through our public offerings, debt financing arrangements, and the sale of its products. As of December 31, 2020 and 2019 the Company had $39.5 million and $39.2 million outstanding debt, respectively. As of December 31, 2020, the Company's accumulated deficit was $239.3 million. During the years ended December 31, 2020 and 2019, the Company incurred a net loss of $43.7 million and $38.4 million, respectively. The Company has not achieved positive cash flow from operations to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon the Company's current operating plan, the Company believes that its existing cash and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements through at least the next 12 months. However, the economic impact of the duration and severity of the COVID-19 pandemic, and the Company's responses thereto (including such actions that the Company had taken or may take in the future as disclosed elsewhere in this Report) poses risk and uncertainties in its future available capital resources. Further, the Company may face challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to, but not limited to, the following as a result of the COVID-19 pandemic or otherwise: (a)&#160;decreases in sales of its products and the uncertainty of future revenues from new products; (b)&#160;changes that the Company may make to the business that affect ongoing operating expenses; (c)&#160;changes that the Company may make in its business strategy; (d)&#160;regulatory developments affecting its existing products; (e)&#160;changes the Company may make in its research and development spending plans; and (f)&#160;other items affecting the Company's forecasted level of expenditures and use of cash resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable.  The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company&#x2019;s long-term debt also approximates fair value based on management&#x2019;s estimation that a current interest rate would not differ materially from the stated rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) (&#x201c;OCI&#x201d;) on the consolidated balance sheets. The Company evaluates its investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely the Company will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;          &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#x2019;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#x2019;s operating results or change in financial position. If circumstances related to such customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation. Through December 31, 2020 and 2019, the Company has not experienced impairment losses on its long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the new revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the new revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.  As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract, agreed price list, or purchase order, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor&#x2019;s payment obligation. The Company's standard payment terms are generally net 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs to Obtain Customer Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions and related expenses are considered incremental and recoverable costs of acquiring customer contracts. The Company&#x2019;s sales commissions paid to its sales representatives are generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. The period of benefit is concurrent with when the Company recognizes its revenue and as such, the Company recognizes sales commission as expense when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warranty &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a one-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the one-year period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets. Sales and warranty reserves from the warranty program were immaterial as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Device Excise Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the U.S. The Company recorded the medical device excise tax within the cost of goods sold in the consolidated statements of operations and comprehensive loss when incurred. Effective January 1, 2016, the Consolidated Appropriations Act of 2016, which was signed into law in December 2015, included a two-year suspension on the medical device excise tax. In January 2018, the suspension on the tax on medical devices was further extended through January 1, 2020. In December 2019, the U.S. Senate passed a bipartisan legislation to permanently repeal the medical device excise tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#x2019;s product which primarily include: (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2)&#160;external research and development expenses; and (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expenditures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations. Advertising expenses were $0.3 million and $0.4 million for the year ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#x2019;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company became public in October 2018 and has no sufficient trading history, the Company uses stock price volatility using the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividend Yield - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the restricted stock unit (&#x201c;RSU&#x201d;) grant is based on the market price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to IPO, the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes uncertain tax positions when it meets a more-likely-than-not threshold. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic and diluted net loss per common share attributable to shareholders i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n conformity with the two-class method required for companies with participating securities. The Company considers all ea&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents all changes in the stockholders&#x2019; equity except those resulting from distributions to stockholders. The Company&#x2019;s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#x2019;s own stock and (ii)&#160;classified in the stockholders&#x2019; equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. In connection with the IPO, all of the Company's redeemable convertible preferred stock warrants were automatically converted into common stock warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption of New Revenue Recognition Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the new revenue recognition standards (&#x201c;ASC 606&#x201d;) using the modified retrospective method effective for the year ended December 31, 2019. This approach was applied to all contracts that were not completed as of January 1, 2019. As an emerging growth company that elected to take advantage of the JOBS Act accounting election, the Company was not required to adopt the new revenue standard in the interim reporting periods on the year of adoption and is not required, and intends not, to revise its 2019 interim periods which were reported under previous revenue recognition standards (&#x201c;ASC 605&#x201d;). The adoption of ASC 606 did not result in a material impact on the Company&#x2019;s consolidated financial statements and no adjustment was made to the opening balance of accumulated deficit at January 1, 2019.&#160;ASC 606's core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or medical facilities, which represents majority of the Company's revenue, the Company continues to recognize the revenue upon completion of the procedure&#160;and authorization by the customer, net of rebates and price discounts. As it relates to sale of products through distributors and hospitals where product is ordered in advance of the procedure, the Company continues to recognize the revenue upon shipments to the customers, net of rebates and price discounts. Additionally, ASC 606 requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company&#x2019;s sales commissions paid to its sales representatives is generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. As such, the Company recognize sales commission as expense when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenues from contracts with customers into geographical regions. The Company determined that disaggregating revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by regional economic factors. For information revenue by geography, refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in &#x201c;Note 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Summary of Significant Accounting Policies&#x201d; in the accompanying Notes to Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07,&#160;Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation-Stock Compensation, to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity-Based Payments to&#160;Non-Employees. The Company adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued&#160;ASU&#160;2018-13, Fair Value Measurements, which eliminates, adds or modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted to adopt either the entire standard or only the provisions that eliminate or modify the requirements. The Company has adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet.&#160;A lease liability is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset is an asset that represents the lessee&#x2019;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date.&#160;In July 2018, the FASB issued&#160;ASU&#160;2018-10 and&#160;ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. The new transition method allows an entity to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In March 2019, the FASB issued&#160;ASU 2019-01, which provides clarification on implementation issues associated with adopting&#160;ASU 2016-02.&#160;The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the &#x201c;all other&#x201d; categories. For public companies, the new guidance became effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the new guidance is now effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is still permitted for any interim or annual financial statements not yet issued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As an emerging growth company, the new leases standard is now effective for the Company for the fiscal year ending December 31, 2022 and interim periods within fiscal year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements including the timing of its adoption. The Company anticipates electing several practical expedients that permit the Company not to reassess (1) whether a contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. The Company expects that the adoption of this new standard will have a material impact on its balance sheet. The most significant impact would be the recognition of operating lease right-of-use assets and liability. The standard is not expected to have a material impact on the Company's consolidated statements of income and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued&#160;ASU 2016-13,&#160;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. FASB issued ASU 2019-05 in May 2019 and ASU 2019-08 in November 2019 for codification improvements of Topic 326. The new standard revises the accounting requirements related to the measurement of credit losses and will require organizations to measure all expected credit losses for financial assets based on historical experience, current conditions and reasonable and supportable forecasts about collectability. Assets must be presented in the financial statements at the net amount expected to be collected.&#160;In November 2019, the FASB issued ASU 2019-10,&#160;which defers the effective date of&#160;ASU 2016-13&#160;for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&#160;In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. The Company is currently evaluating the impact of this standard on its consolidated financial statements but does not expect the adoption of the standard will have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDc4_b5b17f44-178d-4d6f-8853-bf2578af4b55">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDkx_a991453e-11b3-400e-b4f3-45831fd88c47">The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDY4_79f9a930-7dd5-4bc5-bbb7-ceac33e06f89">Use of Estimates &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. &lt;/span&gt;Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <sibn:EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzU0OTc1NTgyMjE0NTI_9fb91237-b503-4307-afa5-381ffc997958">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;JOBS Act Accounting Election&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies. Those standards apply to companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the&#160;JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company continues to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if the Company's total annual gross revenues are $1.07 billion or more; or (ii) the Company has issued more than $1.0 billion in non-convertible debt in the past three years;&#160;or (iii) the Company becomes a &#x201c;large accelerated filer,&#x201d; as defined in Rule&#160;12b-2 of the Exchange Act.&lt;/span&gt;&lt;/div&gt;</sibn:EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDkz_dbca4568-18f1-4b0b-a3e9-64a115ae34a0">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are based on components of the Company that engage in business activities that earn revenue and incur expenses and (a)&#160;whose operating results are regularly reviewed by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), to make decisions about resource allocation and performance and (b)&#160;for which discrete financial information is available.&#160;The CODM for the Company are the Chief Executive Officer (&#x201c;CEO&#x201d;) and Chief Operating Officer &amp;amp; Chief Financial Officer (&#x201c;COO/CFO&#x201d;). The CEO and the COO/CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDY5_00d0720e-a2ec-4cbc-9427-695d5e8e1bdc">Following table summarizes the Company's revenue by geography:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ee17cf0cfb74aaeba258351d3587116_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzMtMS0xLTEtMA_470e8d51-1eac-4d33-8703-cb81ef4bd099"
      unitRef="usd">68118000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i8c0e792c3dd245b38bfa934064b7a5f3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzMtMy0xLTEtMA_759ba855-6cdb-41fb-88d9-28fa62359962"
      unitRef="usd">61843000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a304c056a549c6910518b3e4157eef_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzQtMS0xLTEtMA_59571223-3db1-4470-8471-a0efcdc8040c"
      unitRef="usd">5269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i682d696ec5a64a2d895607c7e0be6d52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzQtMy0xLTEtMA_6a4c293a-b2b6-4ac0-9b7c-e0107f706cfe"
      unitRef="usd">5458000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzUtMS0xLTEtMA_3708a2e3-e859-49a5-837d-56c662a13ff8"
      unitRef="usd">73387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTo3YzhhYmUxMWRlNTM0OTM1OWY4ZTZjMGEwOWE0ODQ0Zi90YWJsZXJhbmdlOjdjOGFiZTExZGU1MzQ5MzU5ZjhlNmMwYTA5YTQ4NDRmXzUtMy0xLTEtMA_d5795b64-9985-45b8-b278-0a28d3ad671e"
      unitRef="usd">67301000</us-gaap:Revenues>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk0_27e83b49-0f22-402c-a56f-10be3ceb4aa9">&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDcz_69970f61-8cb0-4f2f-a053-33601e21fa7c">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company&#x2019;s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company&#x2019;s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzY0NjY_d192a473-12b6-410d-9344-e2a617730521"
      unitRef="usd">196400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzY0ODE_64e50a5d-6923-426f-b91f-2d0f46b5877d"
      unitRef="usd">93100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:LongTermDebt
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE2NDkyNjc0OTQ0ODQ_20d48ac9-c387-4468-a9a1-be1e4d767d43"
      unitRef="usd">39500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE2NDkyNjc0OTQ0OTE_08a2dec0-6b74-48e3-ae2e-42ae67c664cb"
      unitRef="usd">39200000</us-gaap:LongTermDebt>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU4NzQ_edd0990b-49c4-4fcb-9f2c-619c7cbb6337"
      unitRef="usd">-239300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU4ODM_f78ea02c-14f8-455b-99f0-8b5afebead64"
      unitRef="usd">-43700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU4OTI_20d7d7ea-55ba-40ee-ac28-6dc4fd5948db"
      unitRef="usd">-38400000</us-gaap:NetIncomeLoss>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg1_3f1b4702-2d33-4056-b70b-f9221d544a91">&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable.  The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company&#x2019;s long-term debt also approximates fair value based on management&#x2019;s estimation that a current interest rate would not differ materially from the stated rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDYy_529d52de-ef82-4bcf-931b-9450f2049c98">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk2_3e1bc8c3-cf89-453b-92cf-a9d88a5ef140">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) (&#x201c;OCI&#x201d;) on the consolidated balance sheets. The Company evaluates its investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely the Company will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg2_a9381ea8-8b8b-4f26-bcf7-ac7210b3d9b2">Accounts Receivable and Allowance for Doubtful AccountsAccounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#x2019;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#x2019;s operating results or change in financial position. If circumstances related to such customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDc0_a5148861-d0b4-4084-9f17-0c7913d9b25b">InventoryInventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTE1_03f84c18-d1b5-4625-a4de-9cc8513b03fc">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk3_ab015971-2918-4e08-a242-8616d5706b35">All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id046e7c696d34711b1333b15ed30b43c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzAtMS0xLTEtMjIxOC90ZXh0cmVnaW9uOjQzZTZiNjFjOTc3ZjRiNWY5NGFhN2Q2N2IwYjkwMWYyXzMyOTg1MzQ4ODMzNDQ_0c0dee32-f406-4f54-a263-c6aa79e1b6ec">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i23e08d78c5ce4da8999df030e046372b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzAtMS0xLTEtMjIxOC90ZXh0cmVnaW9uOjQzZTZiNjFjOTc3ZjRiNWY5NGFhN2Q2N2IwYjkwMWYyXzMyOTg1MzQ4ODMzNDg_5e5db8f5-931e-4973-8538-4af6b7781a7b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i82073020dafa4bcc906a6b84e0f4ae90_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzEtMS0xLTEtMjIyNS90ZXh0cmVnaW9uOjVhNGRmYzk0YjU5ZDRhNTA5ZmQ2ZjNlZjFlMjFiOWE2XzMyOTg1MzQ4ODMzNDQ_a29b1f79-7cdc-4870-a733-a3178e36e388">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i08bbaa69d9864797b540f323ef6f6cbd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzEtMS0xLTEtMjIyNS90ZXh0cmVnaW9uOjVhNGRmYzk0YjU5ZDRhNTA5ZmQ2ZjNlZjFlMjFiOWE2XzMyOTg1MzQ4ODMzNDk_00a8eda5-7af5-43a1-98a0-0b145b00d389">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iab58f80617694d75bb76bca801a8396f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90YWJsZTpmY2IyY2ZhYjFlMmY0OWJhYjQxYzc3YzA2MjUyZTNlMS90YWJsZXJhbmdlOmZjYjJjZmFiMWUyZjQ5YmFiNDFjNzdjMDYyNTJlM2UxXzItMS0xLTEtMjIzMA_e8d2167b-3ed3-4c7a-8ece-0684e5a278fb">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDcw_40712a7e-b4c5-4b01-a797-217f457bb66a">Impairment of Long-Lived AssetsThe Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjI3ODk_981d4a74-da80-4cc7-a13b-c06019aac192"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjI3ODk_e1ed2f84-22e4-4cd8-bc14-fc123661a843"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTE2_97a9d190-1e24-48de-ac4e-c305bb773d12">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the new revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the new revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.  As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract, agreed price list, or purchase order, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor&#x2019;s payment obligation. The Company's standard payment terms are generally net 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs to Obtain Customer Contracts&lt;/span&gt;&lt;/div&gt;Sales commissions and related expenses are considered incremental and recoverable costs of acquiring customer contracts. The Company&#x2019;s sales commissions paid to its sales representatives are generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. The period of benefit is concurrent with when the Company recognizes its revenue and as such, the Company recognizes sales commission as expense when incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sibn:RevenueRecognitionStandardPaymentTerms
      contextRef="i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE4MjQ3_3ab5b61c-600a-4609-a4b3-3ae40b2c0a6b">P30D</sibn:RevenueRecognitionStandardPaymentTerms>
    <sibn:RevenueRecognitionStandardPaymentTerms
      contextRef="i392839ad6d6e43ad9f50d6687b0aca2a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzE4MjUz_d5af6804-4851-4eda-a557-cd00da9b510c">P90D</sibn:RevenueRecognitionStandardPaymentTerms>
    <us-gaap:StandardProductWarrantyPolicy
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDgz_d6c6a983-23f0-4585-a8cb-1a2ed42fe687">Warranty The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a one-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the one-year period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets.</us-gaap:StandardProductWarrantyPolicy>
    <sibn:StandardProductWarrantyTerm
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU5MDI_06f5bb17-67ff-4343-ac22-e6d47af45c07">P1Y</sibn:StandardProductWarrantyTerm>
    <sibn:SalesCreditReservePeriod
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzMyOTg1MzQ5NjU5MDM_f0763d76-709c-47f7-8794-6f84a3dafb2f">P1Y</sibn:SalesCreditReservePeriod>
    <sibn:MedicalDeviceExciseTaxPolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTAx_203f4c0b-8ca8-48a1-a246-29cf7ceaf06a">Medical Device Excise TaxIn accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the U.S. The Company recorded the medical device excise tax within the cost of goods sold in the consolidated statements of operations and comprehensive loss when incurred. Effective January 1, 2016, the Consolidated Appropriations Act of 2016, which was signed into law in December 2015, included a two-year suspension on the medical device excise tax. In January 2018, the suspension on the tax on medical devices was further extended through January 1, 2020.</sibn:MedicalDeviceExciseTaxPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDY1_a4269bcf-2428-4693-900d-4199c37df4c2">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#x2019;s product which primarily include: (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2)&#160;external research and development expenses; and (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTE3_ad8fb598-b1b6-4f0e-ae9f-f73c489a5295">Advertising ExpendituresThe cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzIxNTI3_45e3df04-99ca-4de5-a1e3-a0d6622d37bd"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzIxNTM0_785546dc-86f1-4b2d-810d-89a16fb81008"
      unitRef="usd">400000</us-gaap:AdvertisingExpense>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg3_d3d86ce8-b725-4dda-b59f-76791ad16054">Loss ContingencyThe Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDcx_06ee7ef7-7d58-4934-9fd7-de354f876d93">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#x2019;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company became public in October 2018 and has no sufficient trading history, the Company uses stock price volatility using the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividend Yield - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the restricted stock unit (&#x201c;RSU&#x201d;) grant is based on the market price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to IPO, the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDky_4b2cac30-cd26-48de-b4dd-aee79023e35f">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;The Company recognizes uncertain tax positions when it meets a more-likely-than-not threshold. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDc2_59773f4e-97f7-4793-a3b8-bea081ad6a75">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic and diluted net loss per common share attributable to shareholders i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n conformity with the two-class method required for companies with participating securities. The Company considers all ea&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDk4_da7d273b-42ae-49b2-bc74-fcd5672eb231">&lt;div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents all changes in the stockholders&#x2019; equity except those resulting from distributions to stockholders. The Company&#x2019;s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <sibn:WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NDg4_e6f25075-f44d-4b1b-87ad-3d7e046e3e72">WarrantsThe Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#x2019;s own stock and (ii)&#160;classified in the stockholders&#x2019; equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. In connection with the IPO, all of the Company's redeemable convertible preferred stock warrants were automatically converted into common stock warrants.</sibn:WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNjkvZnJhZzoxM2QzYjEzMTEwMGQ0YzYzYjA1ZjAzZjg2ZjU5Y2JlYi90ZXh0cmVnaW9uOjEzZDNiMTMxMTAwZDRjNjNiMDVmMDNmODZmNTljYmViXzQ3NTA2_0b5bb1cc-83d4-4c5f-9605-1f8b246a20c3">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption of New Revenue Recognition Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the new revenue recognition standards (&#x201c;ASC 606&#x201d;) using the modified retrospective method effective for the year ended December 31, 2019. This approach was applied to all contracts that were not completed as of January 1, 2019. As an emerging growth company that elected to take advantage of the JOBS Act accounting election, the Company was not required to adopt the new revenue standard in the interim reporting periods on the year of adoption and is not required, and intends not, to revise its 2019 interim periods which were reported under previous revenue recognition standards (&#x201c;ASC 605&#x201d;). The adoption of ASC 606 did not result in a material impact on the Company&#x2019;s consolidated financial statements and no adjustment was made to the opening balance of accumulated deficit at January 1, 2019.&#160;ASC 606's core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or medical facilities, which represents majority of the Company's revenue, the Company continues to recognize the revenue upon completion of the procedure&#160;and authorization by the customer, net of rebates and price discounts. As it relates to sale of products through distributors and hospitals where product is ordered in advance of the procedure, the Company continues to recognize the revenue upon shipments to the customers, net of rebates and price discounts. Additionally, ASC 606 requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company&#x2019;s sales commissions paid to its sales representatives is generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. As such, the Company recognize sales commission as expense when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenues from contracts with customers into geographical regions. The Company determined that disaggregating revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by regional economic factors. For information revenue by geography, refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in &#x201c;Note 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Summary of Significant Accounting Policies&#x201d; in the accompanying Notes to Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07,&#160;Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation-Stock Compensation, to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity-Based Payments to&#160;Non-Employees. The Company adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued&#160;ASU&#160;2018-13, Fair Value Measurements, which eliminates, adds or modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted to adopt either the entire standard or only the provisions that eliminate or modify the requirements. The Company has adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet.&#160;A lease liability is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset is an asset that represents the lessee&#x2019;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date.&#160;In July 2018, the FASB issued&#160;ASU&#160;2018-10 and&#160;ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. The new transition method allows an entity to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In March 2019, the FASB issued&#160;ASU 2019-01, which provides clarification on implementation issues associated with adopting&#160;ASU 2016-02.&#160;The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the &#x201c;all other&#x201d; categories. For public companies, the new guidance became effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the new guidance is now effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is still permitted for any interim or annual financial statements not yet issued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As an emerging growth company, the new leases standard is now effective for the Company for the fiscal year ending December 31, 2022 and interim periods within fiscal year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements including the timing of its adoption. The Company anticipates electing several practical expedients that permit the Company not to reassess (1) whether a contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. The Company expects that the adoption of this new standard will have a material impact on its balance sheet. The most significant impact would be the recognition of operating lease right-of-use assets and liability. The standard is not expected to have a material impact on the Company's consolidated statements of income and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued&#160;ASU 2016-13,&#160;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. FASB issued ASU 2019-05 in May 2019 and ASU 2019-08 in November 2019 for codification improvements of Topic 326. The new standard revises the accounting requirements related to the measurement of credit losses and will require organizations to measure all expected credit losses for financial assets based on historical experience, current conditions and reasonable and supportable forecasts about collectability. Assets must be presented in the financial statements at the net amount expected to be collected.&#160;In November 2019, the FASB issued ASU 2019-10,&#160;which defers the effective date of&#160;ASU 2016-13&#160;for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&#160;In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. The Company is currently evaluating the impact of this standard on its consolidated financial statements but does not expect the adoption of the standard will have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90ZXh0cmVnaW9uOjRjOGRhNGZjYzk4NDQ0NzlhMTVmZWViYTA1OWEzNzFmXzE2MQ_38edf17d-d99a-44cf-92f7-00f4262967a0">Marketable Securities&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the marketable securities:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The long-term investments outstanding as of December 31, 2019 matured in April 2020. The Company did not identify any of its marketable securities as other-than-temporarily impaired as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90ZXh0cmVnaW9uOjRjOGRhNGZjYzk4NDQ0NzlhMTVmZWViYTA1OWEzNzFmXzE2Mw_bbd852dc-e28c-4ba2-9fa4-1b7bff67a143">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the marketable securities:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if9de17fd42404f5ab8f65ff659295c6e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzMtMS0xLTEtMA_fc91537e-54d9-48a7-9057-18ce83416954"
      unitRef="usd">45948000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if9de17fd42404f5ab8f65ff659295c6e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzMtNy0xLTEtMA_eff2e40e-63ce-4747-b547-b4fe57fdd793"
      unitRef="usd">45948000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtMS0xLTEtNTE1Mw_0db6a327-1f99-44c7-bc06-6a5490c3a6a7"
      unitRef="usd">1400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtNy0xLTEtNTE2Mg_ba39f273-a32a-4f88-b367-9a0932e940b8"
      unitRef="usd">1400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtMS0xLTEtMA_5676fc73-9e1c-4210-9112-3138844d683e"
      unitRef="usd">47348000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzUtNy0xLTEtMA_4fb81100-653b-4be3-a899-20c10e5b0fb2"
      unitRef="usd">47348000</us-gaap:CashEquivalentsAtCarryingValue>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctMS0xLTEtMA_3ffe99d0-3a03-412a-8203-70f99b49246f"
      unitRef="usd">74779000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctMy0xLTEtMA_3a952a7d-2aa4-46cf-9d00-e4725e44eaf3"
      unitRef="usd">4000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctNS0xLTEtMA_669e9cfc-00ff-4297-a031-7b29de7b4a6a"
      unitRef="usd">7000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i97f320ac1df14fd7ae7c8ee2aebebc1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzctNy0xLTEtMA_c4615209-5560-4b8e-91e2-cffa6e7ee874"
      unitRef="usd">74776000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtMS0xLTEtMA_f1fd5136-aeec-4a7d-b556-d693a2933a13"
      unitRef="usd">8940000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtMy0xLTEtMA_aa884599-104f-411d-aaad-e10f1ce337aa"
      unitRef="usd">4000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtNS0xLTEtMA_ced7e3f5-c610-4c0b-bf71-1e5a7f28fec9"
      unitRef="usd">6000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id38adcbbef7041a5be7d1fff795cb320_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzgtNy0xLTEtMA_1fec76a5-5fec-4732-837d-073c92fa998e"
      unitRef="usd">8938000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktMS0xLTEtMA_63bca986-6443-4c51-9a77-403aab0f8a95"
      unitRef="usd">59137000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktMy0xLTEtMA_6ba2ba82-3e5a-4847-950d-9c124287e3a7"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktNS0xLTEtMA_fe63dd84-76dc-4283-9e90-1168e824a23c"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id4d2e8b5cf104e2a964925b3ce72d586_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzktNy0xLTEtMA_8eb16e6f-fc65-4a73-8752-98649b7e3b01"
      unitRef="usd">59137000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTEtMS0xLTA_740a9e72-efc5-4980-b314-380440c367ba"
      unitRef="usd">142856000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTMtMS0xLTA_46afedf2-632a-4458-9f6d-e2e1c543ddc1"
      unitRef="usd">8000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTUtMS0xLTA_0af84a96-7ee8-4788-8d27-f346dcb0f9fb"
      unitRef="usd">13000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzEwLTctMS0xLTA_b29edcd2-74ad-490b-8c75-1dd7b0cab1ce"
      unitRef="usd">142851000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:MarketableSecuritiesAmortizedCost
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTEtMS0xLTA_8f42f34f-ca38-47eb-bfee-4c946799094c"
      unitRef="usd">190204000</sibn:MarketableSecuritiesAmortizedCost>
    <sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTMtMS0xLTA_50d1241b-1954-4b11-af0d-33989b4a537e"
      unitRef="usd">8000</sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTUtMS0xLTA_062f3fd5-7692-468e-9156-80a0ac391c37"
      unitRef="usd">13000</sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <sibn:MarketableSecuritiesFairValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo5ZTkwYzllN2M5NmU0MGU1YTg3MjIxMjVlYzViZmUwOS90YWJsZXJhbmdlOjllOTBjOWU3Yzk2ZTQwZTVhODcyMjEyNWVjNWJmZTA5XzE0LTctMS0xLTA_e37ce799-c80e-4e44-9893-9a17338a991d"
      unitRef="usd">190199000</sibn:MarketableSecuritiesFairValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ica653fed6bb2408599a2f19e331e9a09_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzMtMS0xLTEtMA_99c406db-02eb-4496-83b1-fcc09d9d9727"
      unitRef="usd">3068000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ica653fed6bb2408599a2f19e331e9a09_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzMtNy0xLTEtMA_5cfcc35e-9a93-40da-8f34-b2afecaf7077"
      unitRef="usd">3068000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzUtMS0xLTEtMA_4105dad7-9a6c-4680-bba9-ba6aa636e3d3"
      unitRef="usd">2495000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzUtNy0xLTEtMA_f012401a-2b20-48c6-bad2-a630f1565016"
      unitRef="usd">2495000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzYtMS0xLTEtMA_ce33522f-abf9-41c4-a95e-0150cb7ccdc5"
      unitRef="usd">5563000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzYtNy0xLTEtMA_17fb20f7-0482-41ae-abbd-6585faadf824"
      unitRef="usd">5563000</us-gaap:CashEquivalentsAtCarryingValue>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtMS0xLTEtMA_e29b9ff6-7c3e-4f76-bd58-d8559479dbce"
      unitRef="usd">67051000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtMy0xLTEtMA_a58925c4-0756-41bf-b46e-425f5d546308"
      unitRef="usd">34000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtNS0xLTEtMA_1d825538-009c-477e-88ef-dda84a27c596"
      unitRef="usd">2000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia745aebd92ac40369a143cd547cfe75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzgtNy0xLTEtMA_2e1e5044-0440-4316-9c63-c62707986870"
      unitRef="usd">67083000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktMS0xLTEtMA_9352f8f4-c822-474b-a527-4ad82bcdc7d7"
      unitRef="usd">9075000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktMy0xLTEtMA_11f39a3f-a66e-4597-a334-d688eb8cf491"
      unitRef="usd">24000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktNS0xLTEtMA_32f44f05-bac6-4a15-a9e8-93aada4e64f8"
      unitRef="usd">2000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzktNy0xLTEtMA_1012862e-5bf7-422d-a9c1-0c7eb0d96173"
      unitRef="usd">9097000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTEtMS0xLTA_60288104-e2f5-4304-93f5-026c0d309367"
      unitRef="usd">5165000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTMtMS0xLTA_a82277b1-eb7e-47db-877b-754c9e1b7448"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTUtMS0xLTA_2fd75362-4732-4726-a1a6-db77bc1cea4b"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i39bb6a8e8fab4251b82ddbf0d0a8590b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEwLTctMS0xLTA_762170d9-a5b1-41db-9423-998e1297b5b8"
      unitRef="usd">5165000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTEtMS0xLTA_a080c29b-2be3-4995-bc15-4246f7fb39b0"
      unitRef="usd">81291000</sibn:AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTMtMS0xLTA_79db0ceb-852b-4874-9a87-ca61c22b83d8"
      unitRef="usd">58000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTUtMS0xLTA_ce629fbe-e991-4827-b922-526a113cab00"
      unitRef="usd">4000</sibn:AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzExLTctMS0xLTA_0cd66078-d3db-4f85-bf44-f6de7b9ded86"
      unitRef="usd">81345000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sibn:AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTEtMS0xLTE4MQ_e7e7f5ad-30b5-47eb-bf2e-3a394aee109f"
      unitRef="usd">1278000</sibn:AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTMtMS0xLTE4MQ_c40ad726-851d-4db4-b2a2-7c7818b40912"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTUtMS0xLTE4MQ_5b7cbcd4-fd22-4c3a-9233-ebb8560b49e9"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i226a6c6f02614f6a86512ebde1b1ef9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEzLTctMS0xLTE4MQ_dbbf0d9a-0e16-4a1a-8149-e656e67b0023"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <sibn:AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTEtMS0xLTE4MQ_5fc5f2eb-2b90-49a0-a60f-23e81e53d7e3"
      unitRef="usd">1278000</sibn:AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis>
    <sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTMtMS0xLTE4MQ_03201b34-e477-4c3d-b29c-67544ff75f63"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTUtMS0xLTE4MQ_b422f6fa-c05d-41b3-b39a-21d9e925aeab"
      unitRef="usd">0</sibn:AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzE0LTctMS0xLTE4MQ_a1e8ff12-fdee-497c-8935-28011a29ad47"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <sibn:MarketableSecuritiesAmortizedCost
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTEtMS0xLTA_cb458631-11d7-4bf7-a8dd-40521bea32fc"
      unitRef="usd">88132000</sibn:MarketableSecuritiesAmortizedCost>
    <sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTMtMS0xLTA_5cf6ad22-3c42-4504-adc3-8694962136f4"
      unitRef="usd">58000</sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTUtMS0xLTA_7ae1a70d-2029-4e97-8677-58ab53219af7"
      unitRef="usd">4000</sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <sibn:MarketableSecuritiesFairValue
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzUvZnJhZzo0YzhkYTRmY2M5ODQ0NDc5YTE1ZmVlYmEwNTlhMzcxZi90YWJsZTo2MGQxZTMwNjUwNzE0MzQwYTIxZGVjYjJmMDM1MTdhOC90YWJsZXJhbmdlOjYwZDFlMzA2NTA3MTQzNDBhMjFkZWNiMmYwMzUxN2E4XzEyLTctMS0xLTA_f29dfec3-0df5-49e9-ab82-8ea0a9fd5b72"
      unitRef="usd">88186000</sibn:MarketableSecuritiesFairValue>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90ZXh0cmVnaW9uOmI3OWRkNGI5NTU4ODRlYTM5YmVlMDQ5YmY1MGMyY2YyXzgwNg_3f6f9727-dc60-412a-87cd-0d3ad38f0f14">Fair Value Measurement&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&#x2019;s long-term debt also approximates fair value based on management&#x2019;s estimation that a current interest rate would not differ materially from the stated rate. There were no other financial assets and liabilities that requires fair value hierarchy measurements and disclosures for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the fair value of the Company&#x2019;s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90ZXh0cmVnaW9uOmI3OWRkNGI5NTU4ODRlYTM5YmVlMDQ5YmY1MGMyY2YyXzgwOQ_3fed1fc5-5ad8-40a9-9ac5-d951b52f23df">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the fair value of the Company&#x2019;s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2561190905814081bc53ffa2be1dab5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtMS0xLTEtMA_5cd7f69c-c536-4a67-90db-bb5b85ef5425"
      unitRef="usd">45948000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i18fdea8ce7124059abdb38fb9a56c535_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtMy0xLTEtMA_73ca2d8a-a77d-49a1-ba9b-1e93881c12f2"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1c018ede41124dcb9546a1dc0d2be832_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtNS0xLTEtMA_5df877e9-3fa2-4835-9afe-1acec23d7a0b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3540e490fa3e40728018f6cb6e927d47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzQtNy0xLTEtMA_c80424d1-d4f0-4028-84c9-314427ccd8b4"
      unitRef="usd">45948000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i25fc95b9ce164bc0840b48602420b3c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtMS0xLTEtMA_f1ed9dd8-5077-48bb-b75f-0c9a1ca554bd"
      unitRef="usd">74776000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icd8bd8bffe9546e6a44571d468e8e8a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtMy0xLTEtMA_be998dc5-619a-41de-88a9-e137821425e2"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if21a7585b0b64bb1a4690ee991cf5d88_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtNS0xLTEtMA_025e48ce-bf2f-4282-86fc-669dbc67c85e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i549ddb0f7656451894dc614cf8d2a488_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzUtNy0xLTEtMA_6baf5792-cc66-44ad-bc9d-be0e053fa990"
      unitRef="usd">74776000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic30be08150494e1ebf7f499accad38f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtMS0xLTEtMA_f228c5e4-3573-406b-b736-55b85fa0c980"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i56a5a80e24444a2997770162f3127340_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtMy0xLTEtMA_0e7ee124-8380-4e37-afd1-942b2c621513"
      unitRef="usd">8938000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6781f723ffcc40caaeb825c9755676eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtNS0xLTEtMA_61e3e62c-8b1a-4d9c-b1dc-482252fd341d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib60e4a56a8df4e8692eaec00e452ea3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzYtNy0xLTEtMA_81230abc-0fef-41a5-8a30-bd8fa918a51c"
      unitRef="usd">8938000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i46c39428374148bda44abdf22ebd5a95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctMS0xLTEtMA_c0ed4752-0340-4770-a1b1-84c2f28eb889"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib0c3186e6d7b427ebbbff1f0dbd4c8c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctMy0xLTEtMA_b568c142-db8d-4729-98bf-5e3e47f83ab3"
      unitRef="usd">60537000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5b326db53886469788a4a2d43dfa03b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctNS0xLTEtMA_42ac3bce-db59-45dd-a0fb-4c0be8e54880"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic21dfcac734f47f6957fcca7f72cdc88_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzctNy0xLTEtMA_e67ce6f3-7372-47fe-8c3f-76353f09dcff"
      unitRef="usd">60537000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id29460ed74a94fa4ab322cb274b491e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtMS0xLTEtMA_d6bd6379-02ce-4aee-9365-7695c548303b"
      unitRef="usd">120724000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i034bc01ef48b4d4a8bf1bb1de85b0868_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtMy0xLTEtMA_7f6964dd-1261-4ca8-92aa-83761503459b"
      unitRef="usd">69475000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9a4613e4687843f8a379ce7c10a467e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtNS0xLTEtMA_71c7ebf1-d802-4bc5-b2f7-f5ba9d3b9bdf"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i01d4c9f2c6ba40f3828a4aa2b86a45a6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzgtNy0xLTEtMA_4625b3ff-80e4-4d15-9979-27a593956db9"
      unitRef="usd">190199000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i193aaa31e9c44a1e82bffc909a360749_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTEtMS0xLTA_7a125974-e3b3-4440-a911-8ef2130d2c1d"
      unitRef="usd">3068000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i657bb6e3a8a046f28bfa284cf457e36f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTMtMS0xLTA_08bfda64-dc33-4566-9c68-a937bc69b775"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i45ee32c33d8748298bb8a2da1f87d7ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTUtMS0xLTA_f1eff982-c3eb-4e1b-8012-6a8150894b0c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib53b1d8bd84944b9a5118a390e4915d4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE0LTctMS0xLTA_7be0b919-72de-4a24-a48d-cb76e6b379cd"
      unitRef="usd">3068000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7a1873024e2f49b98f313c5e06a689bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTEtMS0xLTA_0044b168-776c-422b-970b-5074368d7dce"
      unitRef="usd">67083000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib7740378444747719a5eb6065629a5ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTMtMS0xLTA_9b3ac34c-8dab-4fe3-b1de-7f15e5627a6c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id9109fa397bd4ab896aee4f1166409ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTUtMS0xLTA_8caf2b90-9aac-4c52-8c28-343d60073ff5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0c36deb7f9274663a77e895314cda704_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE1LTctMS0xLTA_77ad7fac-9dac-4dcf-ba40-1ca391b6957d"
      unitRef="usd">67083000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if595c9553f034555b84ce4f3992ef574_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTEtMS0xLTA_0010df18-d2a6-48e0-af41-9983d874c621"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2978c44e2ebc42e5bfd593b3bd9ec954_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTMtMS0xLTA_76bd17a9-7b1d-42f2-8d9a-ae5ac3b3e81b"
      unitRef="usd">10375000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i959e6655c905432b8c65682560f0dd19_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTUtMS0xLTA_b0496d1a-6e44-4d76-baef-fb8b1c506347"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1f5dc8e414e04b1c913f494f9f5332ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE2LTctMS0xLTA_3111a630-058f-4657-97fe-5e102b07b274"
      unitRef="usd">10375000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie229939d8dc74c648e87a676c60fecd4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTEtMS0xLTA_8bc0fa06-7029-4b6a-bff4-b397bf071f9c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if504c2f11d744b658048ae59b90b89ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTMtMS0xLTA_15166373-828d-4777-99cd-02ca74c122ba"
      unitRef="usd">7660000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i60aa93fd86be47a69cae67136a4bf322_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTUtMS0xLTA_59b3b435-4ffc-4107-8734-f3b1a4f8e440"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6ae975a338844ef786881ecd9e3b9cd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE3LTctMS0xLTA_87ed9eab-4431-46b9-a358-a90d6e8f3b36"
      unitRef="usd">7660000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iac5e61b93a3f4b598884410e09cd44de_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTEtMS0xLTA_f18c5818-eaa9-4ab1-b866-3f5453f0c3dd"
      unitRef="usd">70151000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3deabe50cd3e469793cfee5e9e7b0957_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTMtMS0xLTA_58be3677-1882-4943-abcc-fb913f220bc8"
      unitRef="usd">18035000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib64bda2b4edb482eb14a53a12c4bef2d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTUtMS0xLTA_4c45049f-f9e9-44c9-8aa7-790a932d5ac0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if9c484252700460b89333bc846225d68_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xNzgvZnJhZzpiNzlkZDRiOTU1ODg0ZWEzOWJlZTA0OWJmNTBjMmNmMi90YWJsZTpiNTczMjg5YzZmNWQ0N2YzOWRjNzk5ZGUxNzg4YWE1Ny90YWJsZXJhbmdlOmI1NzMyODljNmY1ZDQ3ZjM5ZGM3OTlkZTE3ODhhYTU3XzE4LTctMS0xLTA_b554eae6-6bc8-47bb-88b4-839a0bc948e1"
      unitRef="usd">88186000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzI1NQ_b5136816-e325-43e9-aad6-c569e0cc4a51">Balance Sheet Components&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, inventory consisted entirely of finished goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress pertains to cost of individual components of a custom instrument set used for surgical placement of iFuse implants that have not yet been placed into service.  Depreciation expense was $1.1 million and $0.8 million for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Accrued litigation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5113c368e6d84d078690ec4a2dcdac26_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzItMS0xLTEtMA_39a059d4-50fd-466b-87fa-cc88e8b9473a"
      unitRef="usd">6342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idf10733689d841b993c15e2c32cb214e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzItMy0xLTEtMA_7708e141-c53c-4050-8821-2fe10049db4b"
      unitRef="usd">4613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iebcd89814b67470fb88261e8811fe67c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzMtMS0xLTEtMA_eec2aac1-c46d-4686-8a6a-c20c96e9b95e"
      unitRef="usd">1692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id7de72341f3240d6bca072b0cf1a49d4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzMtMy0xLTEtMA_3cb41183-6198-4698-bb54-773068df5120"
      unitRef="usd">1854000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4199c211590a43da89a234cf0e6582df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzQtMS0xLTEtMA_5fd6e3fd-8f09-454b-98e1-1e33eb9b1dc4"
      unitRef="usd">714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7599f342c11d4e80a1f135e9a39b17ba_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzQtMy0xLTEtMA_4cb67382-1d49-40f9-8910-770b67488229"
      unitRef="usd">598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i85cfa5d73e404d39a22111bbd6758462_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzUtMS0xLTEtMA_525edee8-fecc-40ef-bf4d-c0fe0f29bd38"
      unitRef="usd">503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i77b43286347d44ef87b90ebfe3ab45f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzUtMy0xLTEtMA_0d8b6081-849e-49f4-93db-5ba1b46a0dfb"
      unitRef="usd">497000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a04be12804c4f369306f503b36bee55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzYtMS0xLTEtMA_c59f7e84-e9e8-48fb-9216-6eafb8cec241"
      unitRef="usd">233000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3566041ec40442cda4e388d38876c815_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzYtMy0xLTEtMA_cd33c654-7f87-40e7-b28e-4940dcd1c1da"
      unitRef="usd">187000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzctMS0xLTEtMA_cba194cf-4d84-4189-ad38-f6d1b7af1a9f"
      unitRef="usd">9484000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzctMy0xLTEtMA_ed1e96ab-00a6-491e-9f6e-e0f330971e36"
      unitRef="usd">7749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzgtMS0xLTEtMA_5b4e63c5-f36f-44fd-ad8f-916cf06e6eef"
      unitRef="usd">4957000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzgtMy0xLTEtMA_0fb2aa26-83cc-47e9-b465-b469862f116f"
      unitRef="usd">3795000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzktMS0xLTEtMA_d2f61e7c-8446-4bcd-96ff-87a0c3ed7105"
      unitRef="usd">4527000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTpkMmViOWVlMzgwODE0Y2U3YmM3NDNkNmI4NjJiNDVmZS90YWJsZXJhbmdlOmQyZWI5ZWUzODA4MTRjZTdiYzc0M2Q2Yjg2MmI0NWZlXzktMy0xLTEtMA_ffa8bca7-5819-4c65-845b-ce095ac6ddb4"
      unitRef="usd">3954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzE2NA_ffdc8586-b2d1-4b90-896d-a1f9f4eb689c"
      unitRef="usd">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzE3MQ_cdb87b3f-e698-42ef-aa1f-0513b06460b2"
      unitRef="usd">800000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90ZXh0cmVnaW9uOmVlNDIyYjY4Njk2MDRmNjU5MjA3NTlhZTc4NTA0NGJmXzI1Mw_7ba9c560-7118-4aed-9ce6-5a9e662f7150">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Accrued litigation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzItMS0xLTEtMA_0186abc2-3b60-443a-a482-e68079e867cb"
      unitRef="usd">9175000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzItMy0xLTEtMA_1f6b4716-f8f9-4349-8c23-86c1bf16431b"
      unitRef="usd">7274000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzMtMS0xLTEtMA_8292db1a-c934-488a-bca6-3d1eb8d54c60"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzMtMy0xLTEtMA_1a7170ac-1730-45ff-bab4-3842ade61cec"
      unitRef="usd">3200000</us-gaap:LitigationReserveCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzUtMS0xLTEtMA_89549374-f5ff-4ea0-8e4a-3ad364aacab6"
      unitRef="usd">511000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzUtMy0xLTEtMA_325eeb8a-0f4b-4ac4-9c1c-558ac912ad11"
      unitRef="usd">392000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzgtMS0xLTEtMA_ac47923f-df7b-4ad6-846b-f68891752bf4"
      unitRef="usd">513000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzgtMy0xLTEtMA_dbab24de-51a5-460d-a0e1-cd528eb47aea"
      unitRef="usd">739000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzktMS0xLTEtMA_66454ab1-5632-4654-b4fe-2008fedadc56"
      unitRef="usd">10199000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODEvZnJhZzplZTQyMmI2ODY5NjA0ZjY1OTIwNzU5YWU3ODUwNDRiZi90YWJsZTplN2VkYjI4NTUzODU0Y2RkYjk0MGI1ZjM5N2ViYTU1NC90YWJsZXJhbmdlOmU3ZWRiMjg1NTM4NTRjZGRiOTQwYjVmMzk3ZWJhNTU0XzktMy0xLTEtMA_6e621b1d-cde2-43d2-a615-b94e347f159c"
      unitRef="usd">11605000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzUwMDk_72fcfccb-0fbf-4744-8d43-f408e09de738">Commitments and Contingencies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a non-cancelable operating lease for an office building space, located in Santa Clara, California which expires in May 2025. The Company also has non-cancelable operating leases for its office building spaces in Gallarate, Italy and Mannheim, Germany which both expire in November 2024, and in Knaresborough, United Kingdom, which expires in December 2025. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2021 to 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases totaled approximately $1.2 million and $1.2 million for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate future minimum lease payments under all leases as of December 31, 2020 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:4.5pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has certain purchase commitments related to its inventory management with certain manufacturing suppliers wherein the Company is required to purchase the amounts forecasted in a blanket purchase order. The contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. These outstanding commitments amounted to $0.3 million and $0.4 million as of December 31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. (&#x201c;Plaintiff&#x201d;) v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the U.S. District Court, Northern District of California (the &#x201c;California Action&#x201d;). The complaint alleges violations of the Telephone Consumer Protection Act (the &#x201c;TCPA&#x201d;) on behalf of an individual and a putative class of persons alleged to be similarly situated. The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission. The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship. The plaintiff sought various forms of relief, including statutory damages of $500 for each violation of the TCPA or, in the alternative, treble damages of up to $1,500 for each knowing and willful violation of the TCPA and a permanent injunction prohibiting the Company from sending or having sent advertisements by way of facsimile transmission. Subsequently on December 20, 2019, Plaintiff the filed a putative class action captioned Eric B. Fromer Chiropractic, Inc. v. SI-BONE, Inc. (Case No. 1922-CC12323), in the Circuit Court of the City of St. Louis, State of Missouri (the &#x201c;Missouri Action&#x201d;). The Missouri Action alleges the same TCPA violations as the California Action. On December 23, 2019 the parties filed a joint stipulation of dismissal of the California Action and on January 14, 2020, the parties executed a definitive settlement agreement (the &#x201c;Settlement Agreement&#x201d;) pursuant to which, the Company agreed to settle all disputes regarding the advertising faxes to the settlement class. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrued litigation expense of $3.2&#160;million during the year ended December 31, 2019 within general and administrative expenses in the consolidated financial statements, which was the Company's estimated cost to resolve the matter pursuant to the Settlement Agreement and based on the estimated class members' claim submission rate. Following the notice and claims submission process, on June 22, 2020, the Circuit Court of the City of St. Louis, State of Missouri, approved a final order to pay the approved claims submitted by class members, fees, expenses and incentive awards totaling $2.6&#160;million as final settlement. Accordingly, the Company recorded a reversal of accrued litigation expense of $0.6&#160;million in year ended December 31, 2020 within general and administrative expenses in the consolidated financial statements. The Company made the final settlement payment on July 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&#x2019;s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzgwNg_11533d6e-ff36-4e09-b693-0f1180735444"
      unitRef="usd">1200000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzgxMw_7d11075f-232a-4bc2-9d8e-a1adf77d8a3c"
      unitRef="usd">1200000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzUwMTE_c541bd2e-47d3-4375-8d4e-5dc66680415a">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate future minimum lease payments under all leases as of December 31, 2020 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:4.5pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzEtMS0xLTEtMA_b88e8391-36ca-439f-bf26-582ef4c199b3"
      unitRef="usd">1081000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzItMS0xLTEtMA_f2710a64-f460-4a74-b6b4-f968d7cba0b1"
      unitRef="usd">1001000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzMtMS0xLTEtMA_8f3b67a4-c8eb-44ae-94b9-47674c30790b"
      unitRef="usd">908000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzQtMS0xLTEtMA_40e96f61-0f02-4100-ad8d-f89b2d1e9f05"
      unitRef="usd">893000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzUtMS0xLTEtMA_05cbcaaa-c6fe-407d-a480-4a9e5703268c"
      unitRef="usd">381000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzYtMS0xLTEtMA_2ae46990-6ac9-42ac-829d-0e7bc4861672"
      unitRef="usd">24000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90YWJsZTo2MDY3MzJlMmU0YmU0NjdjOWZiOGI3Mzg4MmZkMjdkOC90YWJsZXJhbmdlOjYwNjczMmUyZTRiZTQ2N2M5ZmI4YjczODgyZmQyN2Q4XzctMS0xLTEtMA_5815bd97-8aa4-4726-a68c-2142483013de"
      unitRef="usd">4288000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:PurchaseObligation
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzEyNDM_f342298c-215b-4994-968a-93adda874002"
      unitRef="usd">300000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzEyNTA_0c97900a-9b48-415d-b069-c298f425c0d5"
      unitRef="usd">400000</us-gaap:PurchaseObligation>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i6d2410d914e44ed9a27cd8b177231d10_D20190206-20190206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzI0MzQ_52238a05-71b8-4abf-8ee7-24b14d360bb3"
      unitRef="usd">500</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="id1f51810588c413195ac60a540302861_D20190206-20190206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzI1MTY_3e9e46be-43a2-47ee-b718-9354ee4b68c9"
      unitRef="usd">1500</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationReserveCurrent
      contextRef="i9154de9e205d4bde873fb87f0044bdc1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzE2NDkyNjc0NTU4NjY_c34a3b57-f37b-42b3-837b-623dc5bd5682"
      unitRef="usd">3200000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i59004ae255bc408fbcc9c0c0bfeb19e6_D20200622-20200622"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzE2NDkyNjc0NTEzNjc_3e2a54df-24b3-48d1-b57d-1fca7862a469"
      unitRef="usd">2600000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie6ae02ed248d4976a0b8c92bb1c51665_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzE2NDkyNjc0NTEzOTQ_3001c86d-d979-4786-83c0-5e4a4c8f67cc"
      unitRef="usd">600000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LitigationSettlementExpense
      contextRef="i95b018196eca491f8a64402c1d9c1b33_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzQ4MzM_54326089-a868-4b41-b981-c9c81689f6c2"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationReserve
      contextRef="i1dc4cef314e248258972c3adbdc0456e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODQvZnJhZzpjYzhiOTZiMTkwM2I0N2ExOTRkNjAxNzQ0MGYzMmNkYi90ZXh0cmVnaW9uOmNjOGI5NmIxOTAzYjQ3YTE5NGQ2MDE3NDQwZjMyY2RiXzQ5MzI_108936f2-5d21-41ea-bdf3-8cce252931dd"
      unitRef="usd">0</us-gaap:LitigationReserve>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzIxNDQ_ba7c3f97-82e3-4cc8-965d-56240594d0a2">Borrowings&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the outstanding borrowings from the term loan as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal outstanding and final fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding debt, net of debt issuance costs and unaccreted value of final fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding debt as of December 31, 2019 related to a term loan entered by the Company with Biopharma Credit Investments IV Sub LP (&#x201c;Pharmakon&#x201d;) in October 2017 for total loan proceeds of $40.0 million (the &#x201c;Pharmakon Term Loan&#x201d;). The Pharmakon Term Loan included an interest-only period for 35 months through September 2020 and then equal quarterly principal payments plus interest through December 2022. The Pharmakon Term Loan carried a fixed interest rate of 11.5% and allowed for early prepayment. The prepayment penalty fee was equal to the remaining interest due if prepaid within the first 30 months, a 2% penalty for months 31-48, and a 1% penalty for months 49-60. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 29, 2020, the Company entered into a Loan and Security Agreement with Solar Capital Partners (&#x201c;Solar&#x201d;) providing for a term loan of an aggregate principal amount of $40.0&#160;million to the Company (the &#x201c;Solar Term Loan&#x201d;). In accordance with the Loan and Security Agreement, the Company paid in full and terminated the Pharmakon Term Loan, which was accounted for as debt extinguishment in accordance with the accounting standards. The Company recognized the unamortized debt issuance costs of $0.7&#160;million and the prepayment penalty and lender fees of $0.8&#160;million related to Pharmakon Term Loan as a loss on debt extinguishment. The costs and fees are reflected as interest expense in the consolidated statement of operations for the year ended December 31, 2020. The total debt issuance costs of $0.8&#160;million associated with the Solar Term Loan were recorded in the consolidated balance sheet as a direct deduction from the carrying amount of the loan, and are amortized as a component of interest expense using straight-line method over the life of the term loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Solar Term Loan bears interest at a rate per annum equal to 9.40% plus the greater London Interbank Offered Rate (&#x201c;LIBOR&#x201d;), payable monthly in arrears. LIBOR means the greater of (i) 0.33% or (ii) one-month LIBOR (or a comparable replacement rate to be determined by the collateral agent if the LIBOR is no longer available), which rate shall reset monthly. The Solar Term Loan matures in 60 months on June 1, 2025 (&#x201c;Maturity Date&#x201d;), with an interest-only period of 36 months through June 2023, and then repaid in equal monthly principal payments plus interest through maturity date. Pursuant to the Loan and Security Agreement, the Company may voluntarily prepay the Solar Term Loan, in full or in part, but only in increments of $10.0&#160;million, for a prepayment premium in an amount equal to 3.00% of the principal if prepaid in year one, 1.25% of the principal if prepaid in year two, and 0.50% of the principal if prepaid in year three or later. The prepayment premium will be waived if the Company voluntarily prepays and refinances the outstanding balance with Solar. The Solar Term Loan is secured by substantially all of the Company&#x2019;s assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is also obligated to pay a final fee equal to $1.0&#160;million or 2.5% of the aggregate principal amount of the Solar Term Loan, which was fully earned by Solar on the effective date of the Loan and Security Agreement. With respect to the Solar Term Loan, this final fee shall be due and payable on the earliest of (i) the maturity date, (ii) the acceleration of the loan balance or (iii) its full prepayment, refinancing, substitution or replacement. The final fee was included within the long-term borrowings and is accreted to interest expense using straight-line method over the life of the term loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective interest rate related to the Pharmakon Term Loan was 12.4% and 12.3% for the term loan's outstanding periods for the years ended December 31, 2020 and 2019, respectively. The effective interest rate related to the Solar Term Loan was 10.6% for the term loan's outstanding period for year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the future principal and final fee payments under the Solar Term Loan as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal and final fee payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subject to other customary covenants set forth in the Loan and Security Agreement with Solar, the Company is required to maintain unrestricted cash and cash equivalents based on the trailing 12-month net products revenues tested on a monthly basis as follows: (a) $15.0&#160;million if net product revenue is less than $75.0&#160;million; or (b) $7.5&#160;million if net product revenue is greater than or equal to $75.0&#160;million, but less than $100.0&#160;million (the &#x201c;minimum liquidity requirement&#x201d;). The Company is not subject to minimum liquidity requirement when trailing twelve-month net product revenues exceeds $100.0&#160;million. Upon the occurrence of an event of default of certain customary covenants, including the minimum liquidity requirements, as specified in the Loan and Security Agreement, subject to specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 5.00% above the rate effective immediately before the event of default and may be declared immediately due and payable by Solar. As of December 31, 2020, the Company was in compliance with all debt covenants. Though there are uncertainties surrounding the impact of the COVID-19 pandemic that may impact our future revenue, the Company believes that it has sufficient cash and cash equivalents to meet the minimum liquidity requirements in the foreseeable succeeding periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;CARES Act&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the U.S. federal government enacted the &#x201c;Coronavirus Aid, Relief and Economic Security (CARES) Act,&#x201d; and among other things, established the Paycheck Protection Program (&#x201c;PPP&#x201d;), administered by the Small Business Administration (&#x201c;SBA&#x201d;), whereby certain small businesses were eligible for a loan to fund payroll expenses, rent, and related costs. The loan may be forgiven if the funds are used for payroll and other qualified expenses. The Company met the requirements to apply for the PPP loan given that the Company has less than 500 employees and the business was negatively impacted by COVID-19. The Company submitted its application and was approved for the SBA program and received the proceeds from the PPP loan amounting to $5.3&#160;million on April 21, 2020, pursuant to a Promissory Note with Silicon Valley Bank (&#x201c;SVB&#x201d;). In light of the subsequent clarifications from the U.S. government on the eligibility criteria, the Company determined it was appropriate to repay the entire amount of the PPP loan. Accordingly, on April 29, 2020, the Company repaid in full the PPP loan and correspondingly terminated the Promissory Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act allows employers to defer the deposit and payment of an employer's share of social security taxes through December 31, 2020. The Company recorded a total liability of $1.0&#160;million related to the deferral of the social security taxes of which $0.5 million is included in each accrued liabilities and other and other long-term liabilities in the consolidated balance sheets as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzIxNDY_7beb4114-ad48-43cb-8eba-2d89c1fe8a74">The following table summarizes the outstanding borrowings from the term loan as of the periods presented:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal outstanding and final fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding debt, net of debt issuance costs and unaccreted value of final fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzItMS0xLTEtMA_769d232a-2ff4-4436-8357-d84a5686fe1a"
      unitRef="usd">41000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzItMy0xLTEtMA_2cd74cd9-927a-4641-962b-d733b87b863e"
      unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzMtMS0xLTEtMA_5e1124af-7627-44fd-818f-8dc0a738ea11"
      unitRef="usd">661000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzMtMy0xLTEtMA_98002e23-988c-486c-8e2e-02688234b628"
      unitRef="usd">777000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMS0xLTEtMTIxNA_ee156eef-3924-4238-a1a4-e7909195c20d"
      unitRef="usd">884000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMy0xLTEtMTIxNA_33d887c0-48d6-4ad2-a99f-7c41e0c13303"
      unitRef="usd">0</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMS0xLTEtMA_8c41abb2-3e6c-4fd7-bac2-094e596e94e1"
      unitRef="usd">39455000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzQtMy0xLTEtMA_fb58dc59-5883-4933-a2b0-90efa18e6cfc"
      unitRef="usd">39223000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzYtMS0xLTEtMA_c1012261-3792-44f6-8025-bc5e77dcf9a3"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzYtMy0xLTEtMA_ca266e89-d224-4861-a01f-aad234e02a21"
      unitRef="usd">4358000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzctMS0xLTEtMA_fdcedbfc-7cca-4bc3-ad0f-2aa4e7b594fe"
      unitRef="usd">39455000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZToxZWQ0NGQxY2YxZDk0YTYzYmZiZGQxYWJhNWQ0NmUzNi90YWJsZXJhbmdlOjFlZDQ0ZDFjZjFkOTRhNjNiZmJkZDFhYmE1ZDQ2ZTM2XzctMy0xLTEtMA_fc16e3ad-92fc-430c-bd03-4d1efd0b4f53"
      unitRef="usd">34865000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia4fc4f2f95ee4c97adad0fe62fb8956b_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NDA_5b813742-d73f-42fe-870c-8a3f59e60562"
      unitRef="usd">40000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod
      contextRef="ia4fc4f2f95ee4c97adad0fe62fb8956b_D20171001-20171031"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NjQ_baff68e8-eb33-4701-a7e7-bed75e770f75">P35M</sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icc5dfa6f48e44ef7ad7fdc85379acfe1_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NzE_c79a63b7-461e-4050-b70e-2fe3e7cdad88"
      unitRef="number">0.115</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <sibn:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="i50c8f148cb4c45afa01a41eb83479fbc_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1NzU_796d874e-8fad-4941-b7cb-f3d9a13243ca"
      unitRef="number">0.02</sibn:DebtInstrumentPrepaymentPenaltyPercentage>
    <sibn:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="i57f9e992b05a4a77b99d38cb277c0cc2_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDQ1Nzk_d5f9cc4d-7fe9-4b1b-8ded-d92d4ff7f694"
      unitRef="number">0.01</sibn:DebtInstrumentPrepaymentPenaltyPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1MDQ_caff3db4-ae7f-40ef-b6fa-5b28cae53ec3"
      unitRef="usd">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <sibn:WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc2MzM_ce069085-c803-4eb7-9c96-8836c1588673"
      unitRef="usd">700000</sibn:WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount>
    <sibn:PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1MTk_af065794-e958-4830-9592-aeb45a7933fa"
      unitRef="usd">800000</sibn:PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1MzM_1a52ded5-9824-47cd-995b-766a72f3e28e"
      unitRef="usd">800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NDc_fe637ea0-8bf3-4309-88af-d1308ebb108a"
      unitRef="number">0.0940</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3171054c28c94e37a7274d5bfc3fb4de_D20200529-20200529"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NTQ_8c4cb232-f891-42d1-855e-ee169dcaff9f"
      unitRef="number">0.0033</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="i85a2c5d839d54923994ecdd79255d137_D20200529-20200529"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzU0OTc1NTgxNTEzNjM_ea23d236-9144-4a24-b819-710680d884c4">P60M</us-gaap:DebtInstrumentTerm>
    <sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod
      contextRef="i85a2c5d839d54923994ecdd79255d137_D20200529-20200529"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzU0OTc1NTgxNTEzNzE_11a4d0bf-dc32-41e2-8dee-0fbcc63bc0d5">P36M</sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
    <sibn:DebtInstrumentPrepaymentAllowableIncrementsPerAgreement
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NjE_78bc2dc4-96c7-463f-96eb-468bd3f7052f"
      unitRef="usd">10000000.0</sibn:DebtInstrumentPrepaymentAllowableIncrementsPerAgreement>
    <sibn:DebtInstrumentPrepaymentPremiumYearOnePercentage
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1ODM_45855441-fd31-440e-8927-1526885860ce"
      unitRef="number">0.0300</sibn:DebtInstrumentPrepaymentPremiumYearOnePercentage>
    <sibn:DebtInstrumentPrepaymentPremiumYearTwoPercentage
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc1NzY_02764642-6579-4ecc-ba8f-3f631d573982"
      unitRef="number">0.0125</sibn:DebtInstrumentPrepaymentPremiumYearTwoPercentage>
    <sibn:DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5OTU_0c7be3ab-2c04-4973-995d-20649baa73e6"
      unitRef="number">0.0050</sibn:DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc2NDc_9b4ec532-e36f-45e8-9fcb-2e606b69e0d0"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentFeeAmount>
    <sibn:DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NDc2NjE_9457ba80-73cf-40d5-a685-db3b6ab06979"
      unitRef="number">0.025</sibn:DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i91447b8f2dee4d7fb7da16614ef2b263_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzk2NTM_158d1c5b-3d40-438a-a2cf-1930179dbb94"
      unitRef="number">0.124</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ie6d91ea98cc44ed2ac071a60da01b6e0_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzk1MzY_f6f0f03d-dd72-4b5f-927d-a9b95fc66037"
      unitRef="number">0.123</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i5cd440735cdc43f5a01ccd66c2e7e22a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzk4ODg_f84f05fb-9019-4a06-90b1-c88495be0926"
      unitRef="number">0.106</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzIxNDg_6930998b-ca93-40b9-b19b-1a61ce507050">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal and final fee payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzEtMS0xLTEtMA_7492f90b-8356-4549-ad39-0c02512bab36"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzItMS0xLTEtMA_9e81acfb-a5e9-4c0b-a873-2b71c054faa9"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzMtMS0xLTEtMA_1229c7cb-902a-4aa3-b827-95da36fe69aa"
      unitRef="usd">11667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzQtMS0xLTEtMTc4OQ_f973fced-28de-406b-a15c-8a0222a12fde"
      unitRef="usd">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzUtMS0xLTEtMTc4OQ_72c0fd49-5039-4224-af63-fb46f51007ad"
      unitRef="usd">9333000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90YWJsZTo1NmNiMmUzMmE1ZDU0MGFlYmU1NzczM2FlNDE2NWUzOS90YWJsZXJhbmdlOjU2Y2IyZTMyYTVkNTQwYWViZTU3NzMzYWU0MTY1ZTM5XzQtMS0xLTEtMA_fee0b03b-c3a9-465d-aa7a-008916124e2b"
      unitRef="usd">41000000</us-gaap:DebtInstrumentCarryingAmount>
    <sibn:DebtInstrumentCovenantMinimumCashBalance
      contextRef="i37605fc017f54b699b34d502dfd83f5d_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM4NzA_6f023e15-9627-4382-b2af-820e263042b6"
      unitRef="usd">15000000.0</sibn:DebtInstrumentCovenantMinimumCashBalance>
    <sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold
      contextRef="i37605fc017f54b699b34d502dfd83f5d_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM4ODU_e02700c9-47b8-4fc7-bd7c-4a1a22e1707b"
      unitRef="usd">75000000.0</sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold>
    <sibn:DebtInstrumentCovenantMinimumCashBalance
      contextRef="ia465af5919b8475cb3625c7d3c4c60b9_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5MDA_1d12a797-2495-4f59-96f8-cca580545b90"
      unitRef="usd">7500000</sibn:DebtInstrumentCovenantMinimumCashBalance>
    <sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold
      contextRef="i0efb63d3047f421990b618ba7b240282_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5MTQ_d025d8c6-8929-4a47-83d9-d2f3e6357a14"
      unitRef="usd">75000000.0</sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold>
    <sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold
      contextRef="i7c56822bb4854a00aa2c71b72d285850_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5Mjk_621737de-4a3e-46cf-a79a-c4d157e3bbce"
      unitRef="usd">100000000.0</sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold>
    <sibn:DebtInstrumentCovenantMinimumCashBalance
      contextRef="i22adc896d58943239a8a55e36b35c2ff_I20200529"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzU0OTc1NTgxNTEzNTY_1dfd7efb-b98a-461b-8b9e-ac0465a3ed4b"
      unitRef="usd">0</sibn:DebtInstrumentCovenantMinimumCashBalance>
    <sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold
      contextRef="i0893e94d84ab4ef180a7082801b17e87_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5NDY_c82a9f8e-1faf-4b5b-beda-c93fb78ae2a1"
      unitRef="usd">100000000.0</sibn:DebtInstrumentLiquidityCovenantProductRevenueThreshold>
    <sibn:DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant
      contextRef="i85629cfe76bc4d9c8c1d726f5ab684ce_I20200529"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzE2NDkyNjc0NTM5NjQ_f84795c3-1573-4d52-a60c-dd4a7a564935"
      unitRef="number">0.0500</sibn:DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="i0029f543a0b44f28883347fcd2bda900_D20200421-20200421"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzMyOTg1MzQ4OTcwODE_64fce605-5cd8-4684-ae03-a41fca82afa1"
      unitRef="usd">5300000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="ic1857c35e4ee46f3a5e3dd78d3069507_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzMyOTg1MzQ4OTcwODE_8dacb33c-7190-4d62-8ffd-4cf960e5cd57"
      unitRef="usd">5300000</us-gaap:RepaymentsOfUnsecuredDebt>
    <sibn:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzkzMTA_9220fc8a-14ed-4220-8626-3c33ef61e0fa"
      unitRef="usd">1000000.0</sibn:SocialSecurityTaxEmployerDeferralCARESAct>
    <sibn:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="ib50689df2cf5465fbcc3d49d82ce6fe0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzkzMTY_4aa04468-ffc3-4165-a627-3fd01837363d"
      unitRef="usd">500000</sibn:SocialSecurityTaxEmployerDeferralCARESAct>
    <sibn:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i5bb5133b5829435487b6826f9ee05e8d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xODcvZnJhZzplMTE0YWZlODVjYWM0OTE1OWNhODI0MWJkNjczMTBlZS90ZXh0cmVnaW9uOmUxMTRhZmU4NWNhYzQ5MTU5Y2E4MjQxYmQ2NzMxMGVlXzQ5NDc4MDIzMzkzMTY_b7ec4be3-dd81-4e68-9f30-5fce9d71d4ea"
      unitRef="usd">500000</sibn:SocialSecurityTaxEmployerDeferralCARESAct>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90ZXh0cmVnaW9uOjQ4ZTdmN2JhZmQ0ZjQxZTY4OWUzNWQyNzNmZTRlMzhkXzQ0OA_e7d79250-61a9-413f-a317-bafaf854d849">Warrants&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes common stock warrants issued and outstanding at both December 31, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;Shares &lt;br/&gt;Underlying &lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price&#160;per &lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;br/&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3/1/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3/1/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[b]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7/22/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7/22/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,983&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[b]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/26/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/26/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,680&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[b]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/20/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/20/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[c]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/9/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,709&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[c]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/22/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/22/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,712&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[c]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.472%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;[a]&#160;&#160;&#160;&#160;Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;[b]&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value at the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;[c]     Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90ZXh0cmVnaW9uOjQ4ZTdmN2JhZmQ0ZjQxZTY4OWUzNWQyNzNmZTRlMzhkXzQ0NQ_9fc0c309-7913-46c9-a432-3146673fdb65">&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes common stock warrants issued and outstanding at both December 31, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;Shares &lt;br/&gt;Underlying &lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price&#160;per &lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;br/&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3/1/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3/1/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[b]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7/22/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7/22/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,983&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[b]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/26/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/26/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,680&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[b]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/20/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/20/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[c]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/9/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,709&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[c]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/22/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/22/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[a]&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,712&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;[c]&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.472%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;[a]&#160;&#160;&#160;&#160;Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;[b]&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value at the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;[c]     Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i4270a5f8e26b45ef92ae241f823a5c92_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNC0xLTEtMA_22e31c2b-9a3c-4dde-ba66-db80f41b0f4d"
      unitRef="shares">1388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia711fb7cbd244135958a45b84e252b9e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNC0xLTEtMA_8f639685-c047-426b-8cd0-7e14140434e5"
      unitRef="shares">1388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4270a5f8e26b45ef92ae241f823a5c92_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNi0xLTEtMA_29145448-002a-4b52-9c7e-69425d030667"
      unitRef="usdPerShare">5.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia711fb7cbd244135958a45b84e252b9e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItNi0xLTEtMA_9b128dc2-27eb-4756-9f13-51531e6f91da"
      unitRef="usdPerShare">5.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="ia711fb7cbd244135958a45b84e252b9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItOC0xLTEtMA_f47d7495-91dd-4096-a3a1-9504ab5d0248"
      unitRef="usd">5000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i4270a5f8e26b45ef92ae241f823a5c92_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzItOC0xLTEtMA_f96cea1d-1bad-4a5b-a308-4f99e52a3819"
      unitRef="usd">5000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibc7925565e8c4323a6a9a220d817cd1e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNC0xLTEtMA_26b6c670-cadc-4af8-99de-83b81d98bdc3"
      unitRef="shares">32983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6ba592ea26314e52a133b56ede4ac0c3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNC0xLTEtMA_8393762d-b823-4c0f-a6f5-cb0ad7ed115b"
      unitRef="shares">32983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6ba592ea26314e52a133b56ede4ac0c3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNi0xLTEtMA_d73ab411-701d-47d4-8121-f5b98941e43f"
      unitRef="usdPerShare">9.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibc7925565e8c4323a6a9a220d817cd1e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtNi0xLTEtMA_d87fad8a-88be-44dd-8538-6e014c17ac53"
      unitRef="usdPerShare">9.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i6ba592ea26314e52a133b56ede4ac0c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtOC0xLTEtMA_74f741a7-ecec-46e9-9672-eeef684079f0"
      unitRef="usd">122000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="ibc7925565e8c4323a6a9a220d817cd1e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzMtOC0xLTEtMA_9856eed9-3d53-449c-b32a-d8ff89f1d50e"
      unitRef="usd">122000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i774bf9ebb0d849c383fd489468d870df_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNC0xLTEtMA_0ec0b88c-dc63-499d-94d1-f7a900173824"
      unitRef="shares">6680</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i2d677b2975b845e383359e9465b1c838_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNC0xLTEtMA_742181e8-9816-4c20-8b4e-dab80d755967"
      unitRef="shares">6680</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2d677b2975b845e383359e9465b1c838_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNi0xLTEtMA_36ebc7e5-28da-4b4d-856c-4d827920dfb0"
      unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i774bf9ebb0d849c383fd489468d870df_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtNi0xLTEtMA_381ff911-823c-43b8-8420-a311d502b874"
      unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i2d677b2975b845e383359e9465b1c838_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtOC0xLTEtMA_c62d1b00-7c0e-4e68-bec8-a9a9a9e87a20"
      unitRef="usd">49000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i774bf9ebb0d849c383fd489468d870df_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzQtOC0xLTEtMA_d9c7ba77-fb3a-4b5b-9c8e-bf786ae05803"
      unitRef="usd">49000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7696c119674041ff8d5a58e5158f8c52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNC0xLTEtMA_833688cc-a58a-4d3c-ab6b-50bbbfc60d58"
      unitRef="shares">41650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i41018904b5854d86b3a31ec29a88bfb2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNC0xLTEtMA_d7ad0678-ecce-47ac-8ce9-b38eaf23ba98"
      unitRef="shares">41650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i41018904b5854d86b3a31ec29a88bfb2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNi0xLTEtMA_b8051f08-3818-4400-82cc-1dad3a11915d"
      unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7696c119674041ff8d5a58e5158f8c52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtNi0xLTEtMA_d74ea70b-c7c5-4727-a214-b6c54a3f9fff"
      unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i41018904b5854d86b3a31ec29a88bfb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtOC0xLTEtMA_1569aff7-3aa3-4f2e-8edc-b178824b6a5a"
      unitRef="usd">396000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i7696c119674041ff8d5a58e5158f8c52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzUtOC0xLTEtMA_8346e0d0-b850-49ef-b9d4-cf580f1f9442"
      unitRef="usd">396000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNC0xLTEtMA_35af318f-5c4e-4ee0-b224-3c76eeeb06b9"
      unitRef="shares">25709</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNC0xLTEtMA_38ec614f-898f-45f6-b322-11ff884820f6"
      unitRef="shares">25709</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNi0xLTEtMA_69dfc851-24f2-440d-ab07-4c70fef8c53d"
      unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtNi0xLTEtMA_75de8dc8-06c2-49b1-9e29-7c503187a478"
      unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i1ff142b8ab0a4a91a11e0d91e82bd468_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtOC0xLTEtMA_1a6e9f3e-7b36-4c42-84ca-441ff08c3678"
      unitRef="usd">244000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="i9f3e8fcdd93a46bbb6ebb9893e269ca8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzYtOC0xLTEtMA_ad43a384-b281-4ed8-b184-a3f676311af6"
      unitRef="usd">244000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNC0xLTEtMA_0cd7db60-1e1a-49d1-afa7-40e1cdd32355"
      unitRef="shares">9712</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNC0xLTEtMA_d15ce473-a243-44c2-bbfc-d5811dd5b7a8"
      unitRef="shares">9712</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNi0xLTEtMA_284bd817-1e99-4a1d-afa7-9887fa6b8610"
      unitRef="usdPerShare">10.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctNi0xLTEtMA_6c807033-6d4a-46e9-9ee5-d2b4046f23b6"
      unitRef="usdPerShare">10.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="ibd0ce3490812457ab1ebe6eb935a81d4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctOC0xLTEtMA_2d93fa20-b921-4fa7-9e5c-9a3c91c87668"
      unitRef="usd">45000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="ic5d9c3bdaa174753a35b02b7af41a58e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzctOC0xLTEtMA_e5f797fe-c14a-478a-b4b0-a01fef36d5b3"
      unitRef="usd">45000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ib2b01ed73e9446848e40e7b7b997079a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtNC0xLTEtMA_4a5e39d8-2a07-47f5-b7c1-ed7c98180239"
      unitRef="shares">118122</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia6525e11de664dcc8219a14e1805fe4c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtNC0xLTEtMA_8fdce1e3-b26e-4cc0-9d03-7149afbdcc71"
      unitRef="shares">118122</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="ia6525e11de664dcc8219a14e1805fe4c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtOC0xLTEtMA_d3407e0c-24f8-47e6-8704-469823ea5e4c"
      unitRef="usd">861000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion
      contextRef="ib2b01ed73e9446848e40e7b7b997079a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTAvZnJhZzo0OGU3ZjdiYWZkNGY0MWU2ODllMzVkMjczZmU0ZTM4ZC90YWJsZToyYzI4YjRjZDc4N2I0ODkwYThkYzdkZDM0ZDQ0N2QzZS90YWJsZXJhbmdlOjJjMjhiNGNkNzg3YjQ4OTBhOGRjN2RkMzRkNDQ3ZDNlXzgtOC0xLTEtMA_e2e2f5ca-83fd-4e13-aa95-d745852f32df"
      unitRef="usd">861000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzgwMQ_4fdab6a4-4c6e-493d-96d2-8900a9daebf9">Common and Preferred Stock&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's certificate of incorporate as amended and restated in October 2018, authorizes the Company to issue 100,000,000 shares of common stock and 5,000,000 shares of preferred stock, each having a par value of $0.0001. Common stock issued and outstanding as of December 31, 2020 and 2019 were 32,583,220 shares and 25,163,803 shares, respectively. As of December 31, 2020 and 2019, there was no preferred stock issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been no dividends declared to date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzE0OQ_3a6f5a1b-2644-4242-a1f6-a5f20f689a41"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzE3OQ_d0b0565d-7a48-41a1-bb9b-3ef10b0f6e60"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzIzNg_d1e7bb57-ec00-413a-81bd-4d3fc631a1e1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzIzNg_f540e0c3-597a-4051-8de4-1a016093d662"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzI5Nw_97e898f8-63fb-4b48-b32c-ecf6ab171edc"
      unitRef="shares">32583220</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzI5Nw_be43610b-b51a-4812-ae15-0c9a56117e4b"
      unitRef="shares">32583220</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzMxMQ_c0b6af6b-7572-435e-9140-04f32d6e03aa"
      unitRef="shares">25163803</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzMxMQ_cbedde50-5646-42b2-b194-6288c9f066ff"
      unitRef="shares">25163803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_07818140-a8dd-4a66-b229-3b6721a710f6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_2ea92dbf-d8be-4034-8565-88bcec49f032"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_a6ac8ddd-0286-4bb5-909e-8eda5a6f787a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzM2Mw_da48fa5f-56ed-49fa-9479-1758df824e6f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8xOTYvZnJhZzplMGI4MDgxNGJkY2Y0NGE0YjcwODU1ODNhNDhkZjNkZS90ZXh0cmVnaW9uOmUwYjgwODE0YmRjZjQ0YTRiNzA4NTU4M2E0OGRmM2RlXzc3Mg_1f621408-73b5-464f-bcf9-3f11564e638b"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjc_bfda6d21-78eb-462e-adb5-9a59cebe7f6d">Stock-Based Compensation &lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2008 Stock Option Plan and 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2008, the Company adopted the 2008 Stock Option Plan (the &#x201c;2008 SOP&#x201d;), as amended, under which the Board of Directors may issue incentive and non-qualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan (the &#x201c;2018 EIP&#x201d;), which serves as the successor to the 2008 SOP, under which the Board of Directors may issue incentive and non-qualified stock options and RSUs to employees, directors and consultants. No new options have been granted under the 2008 SOP since August 2018. Outstanding options under the 2008 SOP continue to be subject to the terms and conditions of that plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock reserved for issuance under the 2018 EIP will automatically increase on January 1 of each year, beginning January 1, 2019, and continuing through and including January 1, 2028, by 5% of the total number of shares of the Company's capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company's Board of Directors. On January 1, 2019 and 2020, the total number of shares of common stock reserved for issuance increased by 1,222,538 and 1,258,190 shares respectively. As of&#160;December 31, 2020, a total of 2,843,814 shares of common stock are available for future grants under the 2018 EIP.  On January 1, 2021, the total number of shares of common stock reserved for issuance under the 2018 EIP automatically increased by 1,629,161 shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than 10% of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a non-qualified stock option shall not be less than 100% and 85%, respectively, of the fair market value on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted have a term of 10 years, except, options granted to individuals holding more than 10% of the outstanding shares have a term of five years. Options generally vest over a four-year period. Certain stock options are exercisable immediately, but are subject to a right of repurchase by the Company for any unvested shares. RSUs granted under the 2018 EIP generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1ODU_7bd59b98-57a3-4657-978b-3cc5ffa4e420"&gt;two&lt;/span&gt; to four years based upon continued services and are settled at vesting in shares of the Company's common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Contractual Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options vested and exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options vested and expected to vest as of  December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,390,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 amounted to $5.6 million and $6.8 million, respectively, representing the difference between the fair value of the Company's common stock at the date of exercise and the exercise price paid. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest as of December 31, 2020 represents the difference between the weighted average exercise price and the closing price of the Company&#x2019;s common stock&#160;on the last trading day of the year. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding options and exercisable options information by range of exercise prices as of&#160;December 31, 2020&#160;was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.236%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Vested and Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the weighted average grant date fair value per share and the assumptions used to estimate the grant date fair value using the Black-Scholes option-pricing model of the stock options granted during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, there was $3.2 million of unrecognized compensation cost related to stock options granted. These costs are expected to be recognized over a period of approximately 1.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Early Exercise of Unvested Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early exercises of stock options under the Company's 2008 SOP are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders&#x2019; equity as the options vest. As of December 31, 2020 and 2019, the Company had a total of 5,836 and 21,404 shares of common stock, respectively, subject to repurchase under the 2008 SOP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock units activity for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.055%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Grant Date Fair  &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, there was a total unrecognized compensation cost of $19.3 million. These costs are expected to be recognized over a period of approximately 2.9 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to 85% of the lesser of the fair market value of the stock as of the first date or the ending date of each &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1MjI_0f5ed571-a69d-4bc7-b68e-654ed23d7077"&gt;six&lt;/span&gt; month offering period. The offering period generally commences in May and November. On March 26, 2020, the Company's Compensation Committee approved the amendment of the terms of future offerings under the ESPP which, among other things, increased the maximum number of shares that may be purchased on any single purchase date, provided for automatic enrollment in a new offering, and provided that the offering which commenced in May 2020 be twelve months in duration and consist of two purchase periods. There were 515,307 shares of common stock originally reserved for issuance under the ESPP. Under the ESPP, the number of shares reserved for issuance under the ESPP automatically increases on January&#160;1st of each year, starting on January&#160;1, 2019, and continuing through January&#160;1, 2029, by an amount equal to (i) the lesser of 1% of the total number of shares of the Registrant&#x2019;s common stock outstanding on December&#160;31st of the preceding calendar year, and (ii) 555,555 shares of common stock. As of&#160;December 31, 2020, a total of 705,618 shares of common stock are available for future grants under the 2018 EIP. On January 1, 2021, the total number of shares of common stock reserved for issuance under the ESPP Plan increased by 325,832 shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model, which is being amortized over the requisite service period. The Company issued 137,377 shares and 168,457 shares under the ESPP during the years ended December 31, 2020 and 2019, respectively, representing approximately $1.9&#160;million and $2.2&#160;million in employee contributions. As of December 31, 2020 and 2019, total accumulated ESPP related employee payroll deductions amounted to $0.4 million and $0.2 million, respectively, which were included within accrued compensation and related expenses in the consolidated balance sheets. For the years ended December 31, 2020 and 2019, the Company recognized $1.2 million and $0.8 million, respectively, of stock-based compensation expense related to ESPP. As of December 31, 2020, the unrecognized compensation cost for the ESPP was $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of&#160;ESPP purchase rights during the offering period&#160;using a Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.944%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth stock-based compensation expense recognized for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding
      contextRef="i139f7071f8c84f08bbe6dceaf889a5c2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzk3Mg_ee13daec-ec6c-44b3-a564-72adcfcf118b"
      unitRef="number">0.05</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i6bd0d0bfaa8049db933a2450c31775e0_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzEyNzA_acf3e324-95d8-4205-bb7e-f5169c6eb857"
      unitRef="shares">1222538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ibb403ea911274bf7b259455db756d709_D20190101-20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ5NDc4MDIzMzU1NDQ_46e84401-e1f1-4417-a5c0-514bb02a6f21"
      unitRef="shares">1258190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i139f7071f8c84f08bbe6dceaf889a5c2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzE0NTM_a4a36758-be37-4dfe-a36b-a8e1a847fb68"
      unitRef="shares">2843814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ib2709796b037485da5c45a10ab0c0d2a_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ5NDc4MDIzMzU3MDA_7fa7e2f2-f96e-475a-9b70-80f41c70aeb7"
      unitRef="shares">1629161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzE4Njg_4ae0f877-7af8-4273-bd82-6988d4744b99"
      unitRef="number">0.10</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares
      contextRef="i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzE5NDA_4f8a39c5-4fd2-45d5-abab-c963dc1efbb3"
      unitRef="number">1.10</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue
      contextRef="ifaca040e3897460d8726cb690a290765_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIxMTQ_d119b9c1-775a-4ddf-ba6c-39ed7633d39b"
      unitRef="number">1</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue
      contextRef="i54ac410f45b545f6a9b196945613148b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIxMjE_638ceca2-79b1-49d1-98a6-7aef420104b5"
      unitRef="number">0.85</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIyMTg_62fc63c1-ae0f-4f13-8950-957beeac1c37">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIyNzk_7c597ab5-63bb-4757-801a-976bf7322180"
      unitRef="number">0.10</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzIzMjM_d7ccbdae-7c4b-4b0f-91af-12fe95438dc7">P5Y</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTI0MTE_eec57d4e-89f3-4533-a314-10f7ae99efd0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3a3fc6a89c574e28830c17f1f39ec06b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1OTE_426fdb5d-a86d-435d-841d-a9225fa596fa">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjM_c38ef5e2-063f-4ce8-8c3c-889a0ca921b5">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Contractual Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options vested and exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options vested and expected to vest as of  December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,390,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzItMS0xLTEtMA_05f0c004-a15a-4077-a6f5-ff17bf1a4214"
      unitRef="shares">2641198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzItMy0xLTEtMA_f25c5839-d340-46ec-8a02-a12267964529"
      unitRef="usdPerShare">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzMtMS0xLTEtMA_07c3f6c9-a5fd-4a54-a234-a4ce1442f1a9"
      unitRef="shares">638983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzMtMy0xLTEtMA_f88594dc-5bf2-4ae7-a8c0-892758389f91"
      unitRef="usdPerShare">20.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzQtMS0xLTEtMA_50ff29c5-ce11-47d3-9d06-a57dbde2ff09"
      unitRef="shares">444924</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzQtMy0xLTEtMA_a2353540-c1b0-45ad-9ef7-8fdb3571ce72"
      unitRef="usdPerShare">3.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzUtMS0xLTEtMA_49c384b8-7337-47e0-b8b7-098ccaf4d68d"
      unitRef="shares">116286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzUtMy0xLTEtMA_d9ee3c08-82de-42ad-8091-24d5cb6bd0c4"
      unitRef="usdPerShare">11.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzYtMS0xLTEtMA_4edc5c6a-3537-4829-84bf-75ca0fca7262"
      unitRef="shares">2718971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzYtMy0xLTEtMA_8fd3a181-d5c6-4df1-9f65-2f90b640cdc9"
      unitRef="usdPerShare">8.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzctMS0xLTEtMA_413cd5ef-6e2b-4748-b14c-b01ba665b271"
      unitRef="shares">26236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzctMy0xLTEtMA_68a5891b-6bd1-4d48-9c23-96ed411955d2"
      unitRef="usdPerShare">17.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzgtMS0xLTEtMA_670b162e-e698-4814-a6b4-9d5c86fe565a"
      unitRef="shares">323701</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzgtMy0xLTEtMA_fdcd2338-912a-4baa-b5e4-9fee0b846b4b"
      unitRef="usdPerShare">4.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzktMS0xLTEtMA_bd374a83-e2f1-4563-bd99-2a34acec8343"
      unitRef="shares">15549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzktMy0xLTEtMA_98e9d48b-f461-424a-b69a-89f16dd5c993"
      unitRef="usdPerShare">17.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTEtMS0xLTA_4998aeaf-1300-476c-ba87-5430bd643e68"
      unitRef="shares">2405957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTMtMS0xLTA_38fbe270-7dd8-4072-a838-e07740550eff"
      unitRef="usdPerShare">8.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTUtMS0xLTA_ec54670e-f418-4690-9de3-6377bbda4f60">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEwLTctMS0xLTA_c753413b-fab8-42bb-9abe-d383d9b27d07"
      unitRef="usd">51402000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTEtMS0xLTA_f533a16f-09fd-4e1e-9e97-6f642086fe5a"
      unitRef="shares">2069020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTMtMS0xLTA_3efd505c-d014-4f7a-bfd0-2e4050a40a48"
      unitRef="usdPerShare">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTUtMS0xLTA_c904d6db-844b-4235-b155-f1902d27a623">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzExLTctMS0xLTA_b46d56fc-c794-49c6-8981-68d45acae175"
      unitRef="usd">47689000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTEtMS0xLTA_fc8fa239-83ec-4e3e-a219-fd937dde2877"
      unitRef="shares">2390755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTMtMS0xLTA_f5474222-ffaf-4e2a-833b-e38b89e1da94"
      unitRef="usdPerShare">8.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTUtMS0xLTA_ee6bb446-3a1e-4d5c-864e-75b2d3ab1e57">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTphYzVlZDc1MDZiYzA0NzhiYmE5Y2YxMTM0N2Y0NzM0YS90YWJsZXJhbmdlOmFjNWVkNzUwNmJjMDQ3OGJiYTljZjExMzQ3ZjQ3MzRhXzEyLTctMS0xLTA_73a1eacb-852c-4f20-a5b4-31c9f2e89520"
      unitRef="usd">51493000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI4OTE_fea0882b-e0fe-4b1c-9255-cb17818da977"
      unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI4OTg_4ded0d66-2bc4-4076-b59d-e2784b6c911e"
      unitRef="usd">6800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMzQ_9cf1d51b-95e8-47b3-b089-87a473906507">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding options and exercisable options information by range of exercise prices as of&#160;December 31, 2020&#160;was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.236%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Vested and Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMC0xLTEtMA_ab0e1e3e-df67-4cc8-bf24-491d4f23fffc"
      unitRef="usdPerShare">0.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMi0xLTEtMA_6915846a-f923-4469-90d2-082fac7d0277"
      unitRef="usdPerShare">3.69</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItNC0xLTEtMA_551cd304-af69-4db0-8604-fc382a6853ca"
      unitRef="shares">465071</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i598f4cb1b4724b229d7870132c124f31_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItNi0xLTEtMA_4d1c3f7a-7d3f-49a3-9884-15311c89569c">P3Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItOC0xLTEtMA_0d70bc2e-117f-496f-91ec-f9cd736bdc24"
      unitRef="usdPerShare">3.31</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMTAtMS0xLTA_cf819017-188b-479b-b2bb-0120f0affb12"
      unitRef="shares">465071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i69d1c0a6c41243298b07d03cb9f05aa8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzItMTItMS0xLTA_4c8c042d-f4cf-4417-8c6f-bce33ec169ee"
      unitRef="usdPerShare">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMC0xLTEtMA_3013fb1a-94bf-4934-baad-654fbc15f28d"
      unitRef="usdPerShare">3.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMi0xLTEtMA_46fdf641-9c5f-41d6-89ff-4452aa5bf831"
      unitRef="usdPerShare">4.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtNC0xLTEtMA_e3363a4b-3ec5-4015-b279-8cab716ceced"
      unitRef="shares">689903</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="icc85e799598c40ac832cb2ff1084bd25_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtNi0xLTEtMA_5d3e6db5-b553-48f1-a29f-768503aba3c4">P4Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtOC0xLTEtMA_15b98d1c-bb34-4bf0-8e59-ace2cfaf0a4e"
      unitRef="usdPerShare">4.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMTAtMS0xLTA_5cdb0c15-35a8-4622-9feb-cc82c5af878a"
      unitRef="shares">689903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i8dfa40eaff3d49f7924ec661d5efcf38_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzMtMTItMS0xLTA_4e98ba2c-cd11-49f8-8e7b-d0f453ed1514"
      unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMC0xLTEtMA_a5a93116-5f90-405a-ad6b-be26dfe2c970"
      unitRef="usdPerShare">4.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMi0xLTEtMA_93225afb-9844-406b-881b-c616490c0677"
      unitRef="usdPerShare">5.31</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtNC0xLTEtMA_c7114886-7e8d-4494-8a6b-fa0ede523ec6"
      unitRef="shares">458812</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ie79c2413427740f7a48c70c2d872ff6c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtNi0xLTEtMA_636a29bc-d170-4529-be5f-95fe2389a0d8">P6Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtOC0xLTEtMA_3dda1ade-f80e-414d-8323-e75a286eb982"
      unitRef="usdPerShare">4.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMTAtMS0xLTA_df623c51-e64e-4168-91ac-3f023af8eb02"
      unitRef="shares">422974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ic43d91cf37b340449447358d82ccd92a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzQtMTItMS0xLTA_1bd87059-70f8-43d9-901a-4d96ddaea2eb"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMC0xLTEtMA_d7e49b56-c1cb-48e3-8014-49695c4d3ce3"
      unitRef="usdPerShare">5.32</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMi0xLTEtMA_40b224a4-77d3-4f2f-a52e-15dbe5fc95df"
      unitRef="usdPerShare">20.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtNC0xLTEtMA_c364b1f0-7327-4e77-9e07-de8965e01fd2"
      unitRef="shares">356271</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibd6fdbf9c98047e5b6663ec0604a0c27_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtNi0xLTEtMA_d5d04103-b6f1-420d-9245-75a0dd630a66">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtOC0xLTEtMA_8580ab46-ea7e-4a48-bb4d-f24f687dba7f"
      unitRef="usdPerShare">12.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMTAtMS0xLTA_64060084-6d29-4949-81f7-56026c6d010a"
      unitRef="shares">282203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i385b1bffbd6844aa86634798c26f1bcb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzUtMTItMS0xLTA_8e4d22c6-08d4-4504-b280-b66ea53deac6"
      unitRef="usdPerShare">11.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMC0xLTEtMA_83ddc57e-3b68-406d-89b3-30fe5df87aa5"
      unitRef="usdPerShare">20.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMi0xLTEtMA_64d5604a-9210-4e29-a45b-094f988c5aa7"
      unitRef="usdPerShare">22.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctNC0xLTEtMA_a121c4ab-cbd9-4ab5-8a05-4663d39dd01d"
      unitRef="shares">435900</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1a57e483fbcf4fc6ac036076b31e515e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctNi0xLTEtMA_9c00cb22-63f1-485e-994e-c069e414d090">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctOC0xLTEtMA_b9d55120-d068-4cad-b71f-b33b25161f1d"
      unitRef="usdPerShare">22.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMTAtMS0xLTA_250e1566-db63-4053-a2d9-efccb40d752b"
      unitRef="shares">208869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i2a8a3d8e6b4c4bae8ba56718174f2b0f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzctMTItMS0xLTA_d3c96ab8-9a80-44fc-a60c-88b1558a2f2b"
      unitRef="usdPerShare">22.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtNC0xLTEtMA_e6a99fa2-64b8-4e23-8d07-5760f9350b8b"
      unitRef="shares">2405957</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtNi0xLTEtMA_203af649-4203-4582-9a6d-7a449c2fa1b2">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtOC0xLTEtMA_9bcc02ea-0b73-4540-b48f-913080fd2d71"
      unitRef="usdPerShare">8.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtMTAtMS0xLTA_7a67414d-f9d2-4d06-95a9-f3ba67eef0a5"
      unitRef="shares">2069020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo2ZmUxYzc1M2ZmMjA0YTFkOTdmZjEwNTYzZTM4MTdjNy90YWJsZXJhbmdlOjZmZTFjNzUzZmYyMDRhMWQ5N2ZmMTA1NjNlMzgxN2M3XzgtMTItMS0xLTA_346c6935-d1b1-44bf-bb54-b6aaaa452f4b"
      unitRef="usdPerShare">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMzM_463549ed-91ba-4c0f-9ffc-6dfd7a91eb5c">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItMS0xLTEtMjk0MQ_7211cf37-b8ec-43bd-a433-dfce06d6399e"
      unitRef="usdPerShare">8.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItNS0xLTEtMjkyOA_41a9e70b-9974-4b21-9119-e98964303b4d"
      unitRef="usdPerShare">9.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7f6cd8ef95b04649a99031341fddf8ea_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItMS0xLTEtMA_a5f34b6a-673b-4290-b418-7e7c2b9ad19a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie1227fe8e7ba44a1bde242290ec79931_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItMy0xLTEtMA_26aae512-571e-4185-9709-b2b2e362f4be">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4b3ffdb1efa44a3a807c3bb0733bd89f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItNS0xLTEtMA_0c239a05-c079-4990-9757-3d1ec2e11ab8">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5d34965263684d8a827e3b511ef07bf7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzItNy0xLTEtMA_47e25fc2-e05b-4d3f-840f-39969bb78976">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtMS0xLTEtMA_32854539-e6c7-4cfd-af94-5ff09509e59f"
      unitRef="number">0.467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtMy0xLTEtMA_c3f85077-5c6f-4de7-bddd-bb3fc62f897a"
      unitRef="number">0.472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtNS0xLTEtMA_470067b6-f073-44eb-83a0-05123700227c"
      unitRef="number">0.417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzMtNy0xLTEtMA_6e29c9ce-30c4-4898-853d-ab16e614b9d1"
      unitRef="number">0.473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtMS0xLTEtMA_a4c3f2c0-4d81-428b-a581-e88e70ced594"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtMy0xLTEtMA_4851b59f-6492-410d-90e7-3036d7d7b5fd"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtNS0xLTEtMA_53268f58-e542-4410-82b6-56bac7132cc5"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzQtNy0xLTEtMA_3d93cc77-5941-4639-b986-4189a046b3c5"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzUtMS0xLTEtMA_fcfe5674-2753-42f2-9164-be0515e43cae"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9f51879f87ee427c9e61db47ded9fcdd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjYTQzOTZkOTNlYzE0NDhmOGI0NjhjNTkwZmIyMjA0MC90YWJsZXJhbmdlOmNhNDM5NmQ5M2VjMTQ0OGY4YjQ2OGM1OTBmYjIyMDQwXzUtNS0xLTEtMA_784a2606-c092-45fc-b8ef-93b50f9634c5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQwODQ_fbb90e5b-4b60-472d-9c72-61dd307a0e93"
      unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i609981cb8c1e4f9797d95f94b7fa61f6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQyMjg_bdb293cb-3827-4c32-99af-dca6b545d2f1">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ3MzI_928f079e-77ed-43f1-922d-42ed6f1260e6"
      unitRef="shares">5836</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzQ3Mzk_0e58502d-01ba-47b3-91b3-3c3bf487f1b2"
      unitRef="shares">21404</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMzA_494566de-21a3-46c1-a57e-e5b00bbd467c">&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock units activity for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.055%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Grant Date Fair  &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0283a6f15aee4e39bd5b62b008d5658f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzEtMi0xLTEtMA_b2d39505-fd98-481e-848f-91578fa3ca38"
      unitRef="shares">53436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0283a6f15aee4e39bd5b62b008d5658f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzEtNC0xLTEtMA_d8e9425a-1e60-4991-9aff-fd7c8d3b7e13"
      unitRef="usdPerShare">11.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzItMi0xLTEtMA_5147cb26-53e4-4dd6-a03d-4e8c8f69b1dd"
      unitRef="shares">639726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzItNC0xLTEtMA_e9ecb2ce-fd30-49c0-bf22-e85fae011756"
      unitRef="usdPerShare">20.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtMi0xLTEtMjQw_6b5da85b-daae-415a-9fb2-563b70219556"
      unitRef="shares">108631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtNC0xLTEtMjQw_e1ed2202-4c51-4ad5-aa53-e51f53896c17"
      unitRef="usdPerShare">19.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtMi0xLTEtMA_5ee6d9f1-8453-4537-afe9-05d7392bdd20"
      unitRef="shares">41490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5929623007e944c68575d2d1e165eb7b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzMtNC0xLTEtMA_dff26558-959e-456b-8485-bd3ec8601699"
      unitRef="usdPerShare">18.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iabe7e4f5c282479c9dd4b63577d53724_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzQtMi0xLTEtMA_af543cb2-d457-4686-9595-83ade35900df"
      unitRef="shares">543041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iabe7e4f5c282479c9dd4b63577d53724_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzQtNC0xLTEtMA_8afee3b3-6564-48d9-9ac6-13760379c52e"
      unitRef="usdPerShare">19.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzUtMi0xLTEtMA_8d62674b-ef52-43b3-befc-b6f7b94ff329"
      unitRef="shares">1016432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzUtNC0xLTEtMA_6862075a-e997-435f-84ad-dc6843170621"
      unitRef="usdPerShare">20.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzYtMi0xLTEtMA_9d63cf57-3e2a-4871-8f68-5bf05a7ddb25"
      unitRef="shares">344779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzYtNC0xLTEtMA_08e4ef1b-58c5-47fd-b22d-a3f31a44a307"
      unitRef="usdPerShare">19.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzctMi0xLTEtMA_19eed059-ec5e-422b-bf81-2b0200837c5f"
      unitRef="shares">49399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzctNC0xLTEtMA_651e5845-af01-42df-a807-79e85f6e9f03"
      unitRef="usdPerShare">19.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i11c1abe777aa459288707c7d8ba52b51_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzgtMi0xLTEtMA_f03593df-fbf7-4693-badf-c345a4a45e09"
      unitRef="shares">1165295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i11c1abe777aa459288707c7d8ba52b51_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTo3NWJiZTBkNzcwMzY0ZWI4OTQ5ZTc5YzU3NTU4OTMwNi90YWJsZXJhbmdlOjc1YmJlMGQ3NzAzNjRlYjg5NDllNzljNTc1NTg5MzA2XzgtNC0xLTEtMA_8348c444-b765-44d1-9b4f-eefb63168862"
      unitRef="usdPerShare">20.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i11c1abe777aa459288707c7d8ba52b51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzUwNzQ_9c4f00df-ee5b-49ae-8537-d15f3701a397"
      unitRef="usd">19300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i67a20ec1e58641f3b989d65b6000cfb2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzUxNTE_98979445-90e9-482e-bcb9-f1aca61d2790">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i82add15eb7894a888a8e8a9ba05ff086_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU0MTk_3e64950a-1e87-40a7-a5e5-cab64f178485"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval
      contextRef="i2931999815684f1992182b9f6d12780e_D20200501-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM4MjM_0a1ad626-0597-4729-8cbe-75df6212fb07">P12M</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="i2931999815684f1992182b9f6d12780e_D20200501-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM4MTg_3df558a3-6870-4455-8030-238062fe9ce9"
      unitRef="purchase_period">2</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7ce9444b0b5849639bc0b7f620058c77_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1NTk_6f0d9e7f-5ea9-4286-9a4f-67bfaa12d9e0"
      unitRef="shares">515307</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding
      contextRef="iadf669f97771460fb006978ac53fcd89_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU4NzA_6e034e03-aec7-401d-92a8-455bf043ffb0"
      unitRef="number">0.01</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding>
    <sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares
      contextRef="iadf669f97771460fb006978ac53fcd89_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzYwMDY_f384ab2d-5d5c-4602-962c-33a35f6ff73e"
      unitRef="shares">555555</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iadf669f97771460fb006978ac53fcd89_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzYyMDY_5708ab4d-835c-4985-a751-eb69b0f5bde0"
      unitRef="shares">705618</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i474b61edbbc14b8d94e1ce0729536585_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY0MDI_8b0bda3f-915a-41d5-9f5d-2f4d3a933b71"
      unitRef="shares">325832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM3MTc_6872c038-cf5b-4372-adfa-02de508fa2a6"
      unitRef="shares">137377</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM3MjY_6904d4d5-603a-4a3a-a87a-9a5513846588"
      unitRef="shares">168457</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM3ODY_d8623768-95d9-497e-a7ea-1cc70038244b"
      unitRef="usd">1900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzMyOTg1MzQ4OTM4MDA_04a8e80c-36b3-4d99-8628-5d097c8dc7a8"
      unitRef="usd">2200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent
      contextRef="iadf669f97771460fb006978ac53fcd89_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY1MDI_5b29409d-5135-4201-9832-4736398f1771"
      unitRef="usd">400000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent
      contextRef="i297b39b995a14cdebf1cfa2c3d3fc236_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY1MDk_edfd8dfa-c2c4-474f-8fbe-8222ef7835db"
      unitRef="usd">200000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82add15eb7894a888a8e8a9ba05ff086_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY2ODU_cb098e06-b891-4213-aab4-54438880d7ff"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie584850230f64839b9c46ed2b0b8f3a3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY2OTI_b26f8331-6980-4d46-8c95-0a6128cb8387"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="iadf669f97771460fb006978ac53fcd89_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzY4MjU_43bf20e8-25c7-4d88-a08f-0048f21fb53e"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjQ_88e52540-44b9-4211-9efc-5dd270ba2ade">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of&#160;ESPP purchase rights during the offering period&#160;using a Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.944%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i79cb20fa436042dbb60426290872da75_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzItMS0xLTEtMA_cf6ed87f-9b29-4d71-b2f5-74847f1b1765">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibde4a023409a47be91b9ea5231045908_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzItMy0xLTEtNjE2Ng_f45082a2-30c9-4cc6-85a8-f9e4b4c33756">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzItNS0xLTEtMjg4_064917b7-a7b7-44b2-a992-ec4d5d91f2b9">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtMS0xLTEtMA_a6b4f718-311f-4568-9b6a-7d28848f647a"
      unitRef="number">0.383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtMy0xLTEtMA_5b1d3ed8-a547-41d4-a472-eace8ef1257a"
      unitRef="number">0.794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtNS0xLTEtMjky_57dcfa75-be4b-4381-8954-d0785650c351"
      unitRef="number">0.383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzMtNS0xLTEtMA_f9d3e973-cab5-4782-86a6-700eef08d9f9"
      unitRef="number">0.584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtMS0xLTEtMA_45ad586b-7f81-4c67-9693-c0c56574cb96"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtMy0xLTEtMA_fa53d01d-3794-4e33-b64f-f127a14c51ac"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtNS0xLTEtMjky_9d60d32e-4ffd-4a9e-9af6-9492bcc88e72"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzQtNS0xLTEtMA_eef525a3-e628-43eb-ac97-f727d7f27992"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i951c446b02ff4630b98290fdc11a812e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzUtMS0xLTEtMA_b2f9dbaf-1611-428d-8aa0-f205be1d35d5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTpjMjRlNDQ3MmM3ODU0YTBiODFkYTNjNzUxYjUyNTUxNi90YWJsZXJhbmdlOmMyNGU0NDcyYzc4NTRhMGI4MWRhM2M3NTFiNTI1NTE2XzUtNS0xLTEtMzAw_c274824b-92e7-49f3-8404-cc2737590bb3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzcxMjU_ae479742-ded8-4355-ac45-f9b279037ff0">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth stock-based compensation expense recognized for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i410806cbbdc746209446c410c6341047_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzMtMS0xLTEtMA_1c3c5c50-3b55-427d-b608-e210bc8a4e90"
      unitRef="usd">331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i73a0c0dce9584a3eb98f59092edd33c5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzMtMy0xLTEtMA_7d6398c6-0d51-485b-a4c8-0fbce9bb9b0a"
      unitRef="usd">185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf4055a0636841d992ed275f0ce24c78_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzQtMS0xLTEtMA_d360da6a-c1fd-4370-a0f9-e663081d8001"
      unitRef="usd">5527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie70af4b35e0d415a8450cc48c58a228a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzQtMy0xLTEtMA_1fb63852-a35c-4d22-bfc4-ef21e3207103"
      unitRef="usd">3335000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5cfba54d8644e33a6243d800d6a11c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzUtMS0xLTEtMA_a0162e25-2b0e-4b0a-bffc-279a655a9817"
      unitRef="usd">1139000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00219ae7e63c44d783f827759951eaaa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzUtMy0xLTEtMA_7a2ab3e8-73dc-42bc-97d9-5c402f2e809a"
      unitRef="usd">516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52ce6cefcf474ade882fc1adc72c8eb8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzYtMS0xLTEtMA_33e60aa9-41d0-4e60-ab59-7d6579bc38b7"
      unitRef="usd">4930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95838768b71a4d678805680c3b4e0eea_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzYtMy0xLTEtMA_c6b0fb63-1339-4a3b-8105-b1ab103bd363"
      unitRef="usd">3428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzctMS0xLTEtMA_fceacb1d-1975-4089-a39a-00ae847fd8dd"
      unitRef="usd">11927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90YWJsZTplOWQyNTY5NzI0ODQ0ZWNhOTVjYzRiMmZiODEzMWMwMy90YWJsZXJhbmdlOmU5ZDI1Njk3MjQ4NDRlY2E5NWNjNGIyZmI4MTMxYzAzXzctMy0xLTEtMA_121f8256-bd76-43e6-aadf-b3b0f716ae08"
      unitRef="usd">7464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzg3MQ_37d16639-43fc-4418-9464-ba601def2591">Employee Benefit PlanThe Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. Effective January 1, 2019, the Company made a discretionary matching contribution equal to dollar for dollar employee contribution, up to 3% eligible compensation of the employee, with a maximum annual contribution from the Company of one thousand dollars per employee. Further, in order for an employee to receive the matching contribution, the employee must be at least 21 years old, work at least 1,000 hours per year, and must be employed by the Company at the beginning through the end of the year. For the years ended December 31, 2020 and 2019, the Company made $0.2&#160;million and $0.1 million, respectively, contributions to the 401(k) plan.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzQzNw_4ef14167-f923-48fc-9ee9-89b26106de9b"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <sibn:DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee
      contextRef="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzUzNA_d7604a7d-3e9e-4210-a40a-766956ba63b9"
      unitRef="usd">1000</sibn:DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="if2a14c1464114e769cf73dfd2e130983_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzE2NDkyNjc0NDI1Nzg_ad6aa8af-ef48-44ac-8844-86d879090aec"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i3946e536ed904059b0b93a4cf16adf9c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDgvZnJhZzo0MTliZGRkMDJjNjM0MjUxOGMxOTczNGU0NzBlNTk3YS90ZXh0cmVnaW9uOjQxOWJkZGQwMmM2MzQyNTE4YzE5NzM0ZTQ3MGU1OTdhXzgzNQ_36845d40-3124-4a67-91aa-ae38894261c3"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90ZXh0cmVnaW9uOjcyMjhhZjE4NjYwZTQ1MTI5OWFlM2Q1YWJkY2E4Y2NkXzcwNg_201c5d7b-ef07-4151-8257-51acad477592">Net Loss Per Share of Common Stock&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,059,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,705,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because the Company has reported a net loss in all periods presented, outstanding stock options, restricted stock units, shares subject to repurchase, ESPP purchase rights and common stock warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following anti-dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718,971&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares subject to repurchase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,836&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,404&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP purchase rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466,980&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90ZXh0cmVnaW9uOjcyMjhhZjE4NjYwZTQ1MTI5OWFlM2Q1YWJkY2E4Y2NkXzcwOA_3e0d069d-33bc-4e44-8ddb-9528ea9ca0df">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,059,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,705,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzMtMS0xLTEtMA_2a19d98d-04c9-47d6-8faa-1bcda6b5052f"
      unitRef="usd">-43697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzMtMy0xLTEtMA_0902914c-29f1-4abc-855d-b524bb0e3be2"
      unitRef="usd">-38403000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzUtMS0xLTEtMA_490558d8-1d51-4732-b939-9d0e92db058a"
      unitRef="shares">29059171</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzUtMy0xLTEtMA_731476b1-ec21-46c9-bac4-c4ade01758f7"
      unitRef="shares">24705980</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzctMS0xLTEtMA_c45ad034-7f9a-4329-a17b-8c38a7a7c52d"
      unitRef="usdPerShare">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo3MjY1ZDZkN2ViMDI0YmQzOTkyMGU0ZjE5NGZhMjQ0NS90YWJsZXJhbmdlOjcyNjVkNmQ3ZWIwMjRiZDM5OTIwZTRmMTk0ZmEyNDQ1XzctMy0xLTEtMA_66e656a8-91f4-407b-948c-8c0c27717063"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90ZXh0cmVnaW9uOjcyMjhhZjE4NjYwZTQ1MTI5OWFlM2Q1YWJkY2E4Y2NkXzcwNA_a02f3849-bc99-4a61-aa6b-6744fe535e25">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718,971&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares subject to repurchase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,836&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,404&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP purchase rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466,980&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09ea822832f34b5cae2305c150d8cd7a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzItMS0xLTEtMA_1fe7a53b-7914-4b3f-abed-9fa0cb940fcd"
      unitRef="shares">2405957</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1c4b044fdf884181b597402c0cfa5a59_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzItMy0xLTEtMA_eb70700a-95ed-4275-ae2a-9d1063c246b1"
      unitRef="shares">2718971</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6934a8f368ab4d9494b07c7ddfe7de0c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzMtMS0xLTEtMA_ebf31086-99f8-4656-85dd-666ee29060ff"
      unitRef="shares">1165295</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3c03f872c9a9488c981785d7b2746aa4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzMtMy0xLTEtMA_e3dc7ba7-3824-464d-95a5-dd689c9f8eaf"
      unitRef="shares">543041</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic58413a7253e4f4d8190a06a75631d77_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzQtMS0xLTEtMA_df2b77b3-1d89-4e63-ae99-1e552d67236c"
      unitRef="shares">5836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i40b75f3d79804b4face844493077ae7d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzQtMy0xLTEtMA_fcd88a42-2424-4432-885c-4d0d3883e6e0"
      unitRef="shares">21404</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifc544ac398ba485a8fc4c71db95233b3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzUtMS0xLTEtMA_e1cea250-aebc-4e41-a757-0f2cd44bad70"
      unitRef="shares">83040</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if06ea8c038f64be2b2835e0ef0d248f2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzUtMy0xLTEtMA_18b20a6f-9c54-4596-90f7-76646434dfbe"
      unitRef="shares">65442</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i55d3b6b03018480f8f30f7f6f385c670_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzYtMS0xLTEtMA_008dc112-e2d8-4355-b220-05a05ee3e2c5"
      unitRef="shares">118122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i696aeae988714665861bf927c6df4e88_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzYtMy0xLTEtMA_6c51ceda-289d-49c0-a9ab-83195ecf1cfa"
      unitRef="shares">118122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzctMS0xLTEtMA_cf6100e9-1752-4afe-a7ee-6909d3576986"
      unitRef="shares">3778250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTEvZnJhZzo3MjI4YWYxODY2MGU0NTEyOTlhZTNkNWFiZGNhOGNjZC90YWJsZTo2NWJlMDk1NGM3NGU0ZjAzYjllY2Q5OGVmZGU4OWY1Mi90YWJsZXJhbmdlOjY1YmUwOTU0Yzc0ZTRmMDNiOWVjZDk4ZWZkZTg5ZjUyXzctMy0xLTEtMA_85330d28-c947-4769-b8af-a432d4e1dc0a"
      unitRef="shares">3466980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MjI_d89ee5ca-12c0-4734-87ad-e1b4702afbb5">Income Taxes&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no provision for income taxes recorded for the years ended December 31, 2020 and 2019. The Company continues to maintain a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The Company periodically evaluates the realizability of its net deferred tax assets based on the expected realization and is dependent on the Company's ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at statutory federal rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax asset, net of valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes changes in the valuation allowance for the years ended December 31, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company had net operating loss (&#x201c;NOL&#x201d;) carryforwards of approximately $200.5 million and $165.0 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company&#x2019;s federal NOL carryforward begins to expire in 2028, and the state NOL carryforward begins to expire in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company had credit carryforwards of approximately $2.5 million and $2.5 million available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in 2029, and the state credits have no expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company updated its Section 382 ownership change analysis through December 31, 2020 a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd determined that the last ownership change was in February 2020 due to the follow-offering. The analysis concluded that no additional NOL carryforwards will expire due to the Section 382 limitation from the ownership change for both federal and state tax purposes. The Company maintains the reduction of $1.4 million of its NOL carryforwards from the previous ownership change. The Com&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pany will continually assess the need to update its Section 382 ownership change analysis, as the Company may experience ownership changes in the future that could materially limit its ability to use its NOL carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act includes provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the payment of an employer's share of social security taxes through December 31, 2020 of $1.0&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 29, 2020, Governor Gavin Newsom signed California Assembly Bill 85 (AB 85) into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California Tax Credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1.0&#160;million. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $5.0&#160;million of California tax. Given the Company&#x2019;s loss position for the year ended December 31, 2020, the new legislation did not impact the current year provision. The Company will continue to monitor the possible California net operating loss and credit limitations in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company&#x2019;s uncertain income tax positions for the years ended December 31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year's tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has no accrued interest related to unrecognized tax benefits as of December 31, 2020 and 2019. None of the Company&#x2019;s unrecognized tax benefits that, if recognized, would affect its effective tax rates for the years ended December 31, 2020 and 2019. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has no federal, state or foreign tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company&#x2019;s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTE_4416f70b-8ae4-44bb-bfbb-fa90e6c96603">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzMtMS0xLTEtMA_01d29a00-f65b-45e8-b2a0-518a6f8a9cbb"
      unitRef="usd">-41708000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzMtMy0xLTEtMA_f986be13-ef9e-462b-bdd4-33546ccc70e2"
      unitRef="usd">-37709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzQtMS0xLTEtMA_3a035c6f-683a-45d7-8262-a0f6e063c5ea"
      unitRef="usd">-1989000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzQtMy0xLTEtMA_8dd0932c-b38c-46df-b8fa-b2caac8c67af"
      unitRef="usd">-694000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzUtMS0xLTEtMA_7a5a53cb-e4bc-4144-91e3-aeed1f5aabfd"
      unitRef="usd">-43697000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZToyOWI1NWE4ZDE3ZGU0Mzk0YWQwMjQxYWQ4YjVlYjFiYy90YWJsZXJhbmdlOjI5YjU1YThkMTdkZTQzOTRhZDAyNDFhZDhiNWViMWJjXzUtMy0xLTEtMA_b81189f5-07e3-4b59-bc59-8ef20ca70be2"
      unitRef="usd">-38403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MDY_c6b85007-f7bd-4482-b76c-05f4540f7279">&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzMtMS0xLTEtMA_85f903c7-a6b7-4ed9-aa6f-58a0c51f062f"
      unitRef="usd">9855000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzMtMy0xLTEtMA_e5ca4300-571b-48fa-bc8b-3b64de7daad7"
      unitRef="usd">8523000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzQtMS0xLTEtMA_b25371fb-08f5-47a3-aa65-905a3e7c28b2"
      unitRef="usd">2711000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzQtMy0xLTEtMA_21a91b81-3dc4-45a5-aaf3-202dbf2a48de"
      unitRef="usd">1569000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzUtMS0xLTEtMA_dd1c60c6-f3e5-4ee3-ac00-3d1f710e177a"
      unitRef="usd">583000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzUtMy0xLTEtMA_1e25e3b3-d6d1-44c9-9ea8-d1a5ef916924"
      unitRef="usd">-200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzYtMS0xLTEtMA_505c852c-7766-468b-96f4-ef4b2acab45f"
      unitRef="usd">13149000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzYtMy0xLTEtMA_e63b9670-407c-4d7a-8bc3-9b32da39cdb3"
      unitRef="usd">9892000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzctMS0xLTEtMA_2eaf8bee-5840-46b9-97c8-1b2e8c25b794"
      unitRef="usd">13149000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzctMy0xLTEtMA_8cbff8f9-8d5a-44e0-bcdf-d8d76194af7c"
      unitRef="usd">9892000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzgtMS0xLTEtMA_32cea3cc-3c3e-4d31-9620-fbb3dff518f2"
      unitRef="usd">0</sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance>
    <sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYzVjYzg0NmQxY2E0NDcwYjU2YmI5MWI4Njk1MDc5ZS90YWJsZXJhbmdlOjNjNWNjODQ2ZDFjYTQ0NzBiNTZiYjkxYjg2OTUwNzllXzgtMy0xLTEtMA_257a7a82-0f8f-4a20-9e6a-9a3132208f72"
      unitRef="usd">0</sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTI_cffaa5a3-ed46-473a-b726-adbc2b74bcb5">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at statutory federal rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzItMS0xLTEtMA_896fefa6-1808-405f-8ede-e57b5d7923c3"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzItMy0xLTEtMA_f4cd3808-91a6-451e-aa73-24a0b9929d95"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzMtMS0xLTEtMA_02d0f85a-203e-4bc3-93a0-25bf300df8c0"
      unitRef="number">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzMtMy0xLTEtMA_cd1f1cf1-d175-4674-a0fc-497bef85aa08"
      unitRef="number">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzQtMS0xLTEtMA_fb771af1-117c-4331-9ca5-b13caa2ad625"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzQtMy0xLTEtMA_63483e03-ceae-431c-b0fd-884a39df8832"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzUtMS0xLTEtMA_c3c2e30f-2674-4432-80a0-3c8d51d7f3ec"
      unitRef="number">-0.301</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzUtMy0xLTEtMA_c1031fac-4f26-4728-a180-29c671cf9ae8"
      unitRef="number">-0.258</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMS0xLTEtNzQ2NQ_d0a7fd35-c443-4e2e-8d4c-3712bc95e86c"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMy0xLTEtNzQ2MA_af8acc9c-9a31-4c67-8e7c-e8357639d4c1"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMS0xLTEtNzc1NQ_fd8d7551-daf1-4dc0-8eb6-2f0f8240791b"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMy0xLTEtNzc1OQ_daf7e738-2c40-4fa7-84de-0ecea90795b7"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMS0xLTEtMA_4a9555bc-1b86-47ad-ba54-cfa9e0363e4a"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzYtMy0xLTEtMA_23ebc1d4-4b88-4051-9fd9-e9213b6c923d"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMS0xLTEtMA_483c23dd-9e4a-4e4f-8af2-13c8abadeb13"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo5YTM0ZmMwYWRkZjM0Yzc4YTc1NGU2NjkyZjIyOGMwMy90YWJsZXJhbmdlOjlhMzRmYzBhZGRmMzRjNzhhNzU0ZTY2OTJmMjI4YzAzXzctMy0xLTEtMA_af238118-516e-48fa-be60-d8a641637092"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTk_173d6917-af67-41ba-9b8a-a470555f2e01">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax asset, net of valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzMtMS0xLTEtMA_b4aee678-f4f5-4266-85cf-93db3c4ea7b5"
      unitRef="usd">52331000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzMtMy0xLTEtMA_d570ab10-8bcb-4eb6-b692-df52405bbc21"
      unitRef="usd">42032000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzQtMS0xLTEtMA_87b2255d-cc67-4012-8e8e-e5982a456ad2"
      unitRef="usd">3160000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzQtMy0xLTEtMA_b892d67b-7a75-4bce-8d7e-802dbb210f58"
      unitRef="usd">2428000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzUtMS0xLTEtMA_f6508853-f322-46fc-83f2-8958c963d533"
      unitRef="usd">5450000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzUtMy0xLTEtMA_d69035a1-18bd-460e-8c24-12d246badce5"
      unitRef="usd">4222000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzYtMS0xLTEtMA_8c365776-b22c-4823-8aa9-619076d863a7"
      unitRef="usd">2395000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzYtMy0xLTEtMA_9d1c43a9-0044-4506-a567-47949600d7d1"
      unitRef="usd">1512000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <sibn:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzctMS0xLTEtMA_f388f263-e472-422d-91a4-19a7099ffe10"
      unitRef="usd">117000</sibn:DeferredTaxAssetsDepreciationAndAmortization>
    <sibn:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzctMy0xLTEtMA_f5346548-20ba-49c4-b5d4-979263e7bb78"
      unitRef="usd">110000</sibn:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzgtMS0xLTEtMA_c130e5ce-98e8-4736-a1cb-e55794483f63"
      unitRef="usd">63453000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzgtMy0xLTEtMA_bac3522c-3a34-46ad-8815-5f926e37eea8"
      unitRef="usd">50304000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzktMS0xLTEtMA_d60dc48b-698c-41ca-982c-74d47974ecdf"
      unitRef="usd">63453000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzktMy0xLTEtMA_63f8ee8c-671a-4863-bee3-19fa55d15faf"
      unitRef="usd">50304000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzEwLTEtMS0xLTA_524ee9d5-c5b8-47d6-9f0d-7de73a4d2940"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTo3ODM1YTAxMmE2NDM0ODEzYWExZDUwNjNlZDM1NmM3YS90YWJsZXJhbmdlOjc4MzVhMDEyYTY0MzQ4MTNhYTFkNTA2M2VkMzU2YzdhXzEwLTMtMS0xLTA_2cc697bb-ceca-4d8e-97a5-c2a4f747d276"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MjA_ba7f7a03-2706-4023-9fe8-23d3eac2b19b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes changes in the valuation allowance for the years ended December 31, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzMtMS0xLTEtMA_635469a9-5f3a-4a12-8d14-cac90eb26dfa"
      unitRef="usd">50304000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzMtMy0xLTEtMA_6397ca12-a037-4320-ac53-55600dcd3c27"
      unitRef="usd">40412000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzQtMS0xLTEtMA_dfc4fdf6-7e65-472c-953c-1cac82bb6ce5"
      unitRef="usd">13149000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzQtMy0xLTEtMA_6973db75-2e3e-4562-a663-954f4d950ee3"
      unitRef="usd">9892000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzUtMS0xLTEtMA_68647e07-5828-48bd-8a3a-623c81f0d66a"
      unitRef="usd">63453000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTpkYjQ0YTY0MjZkOGU0ZTRhODBhNDcwYjM0MjIzNzdjMy90YWJsZXJhbmdlOmRiNDRhNjQyNmQ4ZTRlNGE4MGE0NzBiMzQyMjM3N2MzXzUtMy0xLTEtMA_2068d22e-2e59-4e42-ad9f-051963a41d2f"
      unitRef="usd">50304000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia344c14925fb435996aff0ac207bae68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzE4MDg_963e8602-58f5-4964-a88a-4a003af41399"
      unitRef="usd">200500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0bd326d4dba048b1a3b67d4854664c94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzE4MTU_fb9bd770-b047-4a8a-a9b5-48d526378f12"
      unitRef="usd">165000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia344c14925fb435996aff0ac207bae68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzIxMjY_c9d953d2-3084-4d44-8841-f3a0519748ba"
      unitRef="usd">2500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0bd326d4dba048b1a3b67d4854664c94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzIxMzM_231dd6b8-cc3e-4749-b37c-06e7fd5f4342"
      unitRef="usd">2500000</us-gaap:TaxCreditCarryforwardAmount>
    <sibn:OperatingLossCarryforwardsLimited
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzM0MTY_03204405-c5c8-4c99-94a3-e90d3dc2325c"
      unitRef="usd">1400000</sibn:OperatingLossCarryforwardsLimited>
    <sibn:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzMyOTg1MzQ4OTUwNDc_30f31884-5b85-4b5b-8ab8-46c12ce48b97"
      unitRef="usd">1000000.0</sibn:SocialSecurityTaxEmployerDeferralCARESAct>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzU0MTA_ed428513-6072-454a-b20b-bf14b912dfde">The changes in the Company&#x2019;s uncertain income tax positions for the years ended December 31, 2020 and 2019 consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year's tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzMtMS0xLTEtMA_3eba3442-1e86-4ff1-9d64-8e80ff4ed194"
      unitRef="usd">1287000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ida53b01638da4d37aab2d0e74319d0d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzMtMy0xLTEtMA_64caad2b-2dd1-4179-804d-ff90de42266e"
      unitRef="usd">1084000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzQtMS0xLTEtMA_6aeca30a-db6b-467d-88ee-7174a5d2d837"
      unitRef="usd">226000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzQtMy0xLTEtMA_6c3f00c9-e0fd-46c7-a0c9-962a38bcc387"
      unitRef="usd">203000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzUtMS0xLTEtMA_65b4f545-88e0-41c1-9837-02d128cf5c82"
      unitRef="usd">1513000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90YWJsZTozYjczZjVlNjI4NmY0NGI5OTU5Y2NlYWI3MWJmNjNmZC90YWJsZXJhbmdlOjNiNzNmNWU2Mjg2ZjQ0Yjk5NTljY2VhYjcxYmY2M2ZkXzUtMy0xLTEtMA_72738a70-a2ab-44ab-bfad-7ba204fb81d8"
      unitRef="usd">1287000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i11ebde2211b84b37a9a25ed29b658cb1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzQ3Nzc_05815183-868f-4cdc-82a6-48ed5fee1b46"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="ic35d9503efb0484a818b49ffdb765d03_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMTcvZnJhZzphZGI3NjdhZmE1MTI0OWRiYWRkZGFlY2MzM2E5NDcyNC90ZXh0cmVnaW9uOmFkYjc2N2FmYTUxMjQ5ZGJhZGRkYWVjYzMzYTk0NzI0XzQ3Nzc_bbb2e36f-6292-4eff-93d6-e0a336d44cea"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8zMjk4NTM0ODg5Mjc3_37a29393-5061-4cb8-9fc4-f586f9b62e35">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 24, 2020, the Company entered into a joint development agreement (the &#x201c;Development Agreement&#x201d;) with SeaSpine Orthopedics Corporation (&#x201c;SeaSpine&#x201d;) to develop a next generation device for sacropelvic fixation. Mr. Keith Valentine, who serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine, also serves as a member of the Company's Board of Directors since August 2015. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the development plan, SeaSpine shall use reasonable efforts to assist in the development of the potential product offering, including licensing certain existing intellectual property to be incorporated into such product. Under the terms of the&#160;Development Agreement, the Company agreed to make monthly payments to SeaSpine to reimburse for full time resources employed by SeaSpine responsible to conduct the development activities. For the year ended December 31, 2020, the Company expensed $118,000 of the reimbursement charges from SeaSpine, which was recorded within research and development expense in the consolidated statement of operations. There was no outstanding liabilities to SeaSpine as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;Certain intellectual property developed pursuant to the project plan will be owned by the Company, certain intellectual property developed pursuant to the project plan will be owned by SeaSpine, and other intellectual property developed pursuant to the project plan will be jointly owned by SeaSpine and the Company. The Company also agreed to provide SeaSpine a royalty-free, worldwide, perpetual, non-exclusive license of certain of the Company's intellectual property incorporated into the product to be developed. The Company also agreed to pay SeaSpine a product royalty, in an amount specified in the Development Agreement, for each resulting product sold for a period of 10 years beginning on the initial market launch. The term of the Development Agreement shall continue until the expiration of all royalty terms, unless earlier terminated by either party, as provided for by the Development Agreement.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i8cd127df2c1c4983bc79d5cb10d32b12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8xNjQ5MjY3NDQ3NjA3_32c8adc8-1980-46a9-989f-e7077bc90eec"
      unitRef="usd">118000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i193e00bc574d4629ac04368864c1127a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8zMjk4NTM0ODg5NDA4_a1d67577-26e2-41e3-beb9-874dc6f45091"
      unitRef="usd">0</us-gaap:DueToAffiliateCurrent>
    <sibn:RelatedPartyTransactionTermOfAgreement
      contextRef="id20be3b85bd54fcd9fcf877450d0dd25_D20200224-20200224"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMjU5L2ZyYWc6NjRjMjVkMzYwYWU4NDU2Y2JiYmQ4YmQ1YjEyYTU2MWIvdGV4dHJlZ2lvbjo2NGMyNWQzNjBhZTg0NTZjYmJiZDhiZDViMTJhNTYxYl8yMTk5MDIzMjU3MjQz_e239eb6c-36af-4e43-b15b-a546526eaed2">P10Y</sibn:RelatedPartyTransactionTermOfAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532968216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SI-BONE,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001459839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2216351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">471 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Santa Clara<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">95050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">207-0700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SIBN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,727,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#8217;s fiscal&#160;year ended December 31, 2020, are incorporated by reference into Part&#160;III of this Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667539491224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,581<span></span>
</td>
<td class="nump">$ 10,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">142,851<span></span>
</td>
<td class="nump">81,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $263 and $238, respectively</a></td>
<td class="nump">13,611<span></span>
</td>
<td class="nump">11,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">5,633<span></span>
</td>
<td class="nump">5,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">2,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">218,241<span></span>
</td>
<td class="nump">111,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,527<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">223,142<span></span>
</td>
<td class="nump">117,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,271<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other</a></td>
<td class="nump">10,199<span></span>
</td>
<td class="nump">11,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,470<span></span>
</td>
<td class="nump">18,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term borrowings</a></td>
<td class="nump">39,455<span></span>
</td>
<td class="nump">34,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">53,779<span></span>
</td>
<td class="nump">54,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 32,583,220 and 25,163,803 shares issued and outstanding, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">408,113<span></span>
</td>
<td class="nump">258,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(239,277)<span></span>
</td>
<td class="num">(195,580)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">169,363<span></span>
</td>
<td class="nump">63,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 223,142<span></span>
</td>
<td class="nump">$ 117,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532853528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">32,583,220<span></span>
</td>
<td class="nump">25,163,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">32,583,220<span></span>
</td>
<td class="nump">25,163,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532478168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 73,387<span></span>
</td>
<td class="nump">$ 67,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">8,902<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">64,485<span></span>
</td>
<td class="nump">60,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">73,790<span></span>
</td>
<td class="nump">68,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,459<span></span>
</td>
<td class="nump">7,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">19,803<span></span>
</td>
<td class="nump">20,984<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">103,052<span></span>
</td>
<td class="nump">96,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,567)<span></span>
</td>
<td class="num">(36,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Interest and other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,101)<span></span>
</td>
<td class="num">(4,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,697)<span></span>
</td>
<td class="num">(38,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) of marketable securities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Changes in foreign currency translation</a></td>
<td class="nump">119<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (43,637)<span></span>
</td>
<td class="num">$ (38,378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">29,059,171<span></span>
</td>
<td class="nump">24,705,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667536053448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,450,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 90,192<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 246,927<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="num">$ (157,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, net of shares withheld (in shares)</a></td>
<td class="nump">444,924<span></span>
</td>
<td class="nump">444,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, net of shares withheld</a></td>
<td class="nump">$ 1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to employee stock purchase plan (in shares)</a></td>
<td class="nump">168,457<span></span>
</td>
<td class="nump">168,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to employee stock purchase plan</a></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares', window );">Repurchase of unvested early exercised stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue', window );">Repurchase of unvested early exercised stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Additional accrual of IPO related costs</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,403)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,163,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Dec. 31, 2019</a></td>
<td class="nump">63,008<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">258,121<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="num">(195,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,613,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">$ 134,616<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">134,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, net of shares withheld (in shares)</a></td>
<td class="nump">323,701<span></span>
</td>
<td class="nump">323,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, net of shares withheld</a></td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to employee stock purchase plan (in shares)</a></td>
<td class="nump">137,377<span></span>
</td>
<td class="nump">137,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to employee stock purchase plan</a></td>
<td class="nump">$ 1,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,583,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 169,363<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 408,113<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="num">$ (239,277)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Share-based Compensation, Vesting Of Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Amount Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535978184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,697)<span></span>
</td>
<td class="num">$ (38,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,927<span></span>
</td>
<td class="nump">7,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on marketable securities</a></td>
<td class="nump">115<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain on marketable securities</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale and disposal of property and equipment</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,186)<span></span>
</td>
<td class="num">(3,236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(2,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities and other</a></td>
<td class="num">(766)<span></span>
</td>
<td class="nump">4,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,662)<span></span>
</td>
<td class="num">(31,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ProceedsFromMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">104,716<span></span>
</td>
<td class="nump">159,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ProceedsFromSaleOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">14,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(179,166)<span></span>
</td>
<td class="num">(143,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,561)<span></span>
</td>
<td class="num">(2,445)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(62,916)<span></span>
</td>
<td class="nump">13,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">134,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt financing</a></td>
<td class="nump">45,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of debt financing</a></td>
<td class="num">(45,297)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(750)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payments of prepayment penalty and lender fees</a></td>
<td class="num">(843)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions', window );">Repurchase of unvested early exercised stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of initial public offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">136,401<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">323<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">43,146<span></span>
</td>
<td class="num">(14,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents at</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of year</a></td>
<td class="nump">10,435<span></span>
</td>
<td class="nump">25,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of year</a></td>
<td class="nump">53,581<span></span>
</td>
<td class="nump">10,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_VestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Repurchase Of Unvested Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_VestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_VestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529506200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company and Nature of Business</a></td>
<td class="text">The Company and Nature of Business<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Public Offerings of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2018, the Company completed its initial public offering (&#8220;IPO&#8221;) by issuing 8,280,000 shares of common stock, at an offering price of $15.00 per share for net proceeds of $113.4&#160;million to the Company, net of underwriting discounts and commissions and offering costs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company received $50.0 million net proceeds, after deducting the underwriting discounts and commissions, from its public offering of 4,300,000 shares of the Company's common stock at a public offering price of $21.50 per share, of which 2,490,053 shares were offered and sold by the Company. Further, in February 2020, the underwriters fully exercised its option to purchase 645,000 shares of the Company's common stock at a public offering price of $21.50 per share for an additional net proceeds of $13.0 million to the Company, after deducting the underwriting discounts and commissions. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $0.4&#160;million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2&#160;million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020. </span></div>In October 2020, the Company received $71.6 million of net proceeds from its second follow-on public offering of 3,000,000 shares of the Company's common stock, and the exercise of underwriter's option to purchase from the Company an additional 478,507 shares of the Company's common stock, at a public offering price of $22.00 per share. In addition to the shares sold by the Company in the second follow-on offering, in October 2020, the selling stockholder sold 190,053 shares of the Company's common stock previously held by the selling stockholder at a price to the public of $22.00 per share. The Company did not receive any proceeds from the sale by the selling stockholder.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529157352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates. </span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies. Those standards apply to companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the&#160;JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company continues to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if the Company's total annual gross revenues are $1.07 billion or more; or (ii) the Company has issued more than $1.0 billion in non-convertible debt in the past three years;&#160;or (iii) the Company becomes a &#8220;large accelerated filer,&#8221; as defined in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are based on components of the Company that engage in business activities that earn revenue and incur expenses and (a)&#160;whose operating results are regularly reviewed by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), to make decisions about resource allocation and performance and (b)&#160;for which discrete financial information is available.&#160;The CODM for the Company are the Chief Executive Officer (&#8220;CEO&#8221;) and Chief Operating Officer &amp; Chief Financial Officer (&#8220;COO/CFO&#8221;). The CEO and the COO/CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives substantially all of its revenue from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. International revenue accounted for less than 10% of the total revenue during the periods presented. Long-lived assets held outside the U.S. are immaterial. Following table summarizes the Company's revenue by geography:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company&#8217;s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company&#8217;s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue and accounts receivable are spread across a large number of customers, primarily in the U.S., and no customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the response to the pandemic and the information surrounding the pandemic is rapidly evolving. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, excess and obsolete inventory, and the impact of any initiatives and programs that the Company may undertake to address financial and operations challenges faced by its customers. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors and uncertainty of market acceptance of products. The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had cash and marketable securities of $196.4 million compared to $93.1 million as of December 31, 2019. The Company has financed its operations through our public offerings, debt financing arrangements, and the sale of its products. As of December 31, 2020 and 2019 the Company had $39.5 million and $39.2 million outstanding debt, respectively. As of December 31, 2020, the Company's accumulated deficit was $239.3 million. During the years ended December 31, 2020 and 2019, the Company incurred a net loss of $43.7 million and $38.4 million, respectively. The Company has not achieved positive cash flow from operations to date. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company's current operating plan, the Company believes that its existing cash and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements through at least the next 12 months. However, the economic impact of the duration and severity of the COVID-19 pandemic, and the Company's responses thereto (including such actions that the Company had taken or may take in the future as disclosed elsewhere in this Report) poses risk and uncertainties in its future available capital resources. Further, the Company may face challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to, but not limited to, the following as a result of the COVID-19 pandemic or otherwise: (a)&#160;decreases in sales of its products and the uncertainty of future revenues from new products; (b)&#160;changes that the Company may make to the business that affect ongoing operating expenses; (c)&#160;changes that the Company may make in its business strategy; (d)&#160;regulatory developments affecting its existing products; (e)&#160;changes the Company may make in its research and development spending plans; and (f)&#160;other items affecting the Company's forecasted level of expenditures and use of cash resources. </span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable.  The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) (&#8220;OCI&#8221;) on the consolidated balance sheets. The Company evaluates its investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely the Company will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#8217;s operating results or change in financial position. If circumstances related to such customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"><tr><td style="width:1.0%"/><td style="width:85.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation. Through December 31, 2020 and 2019, the Company has not experienced impairment losses on its long-lived assets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the new revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.  As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract, agreed price list, or purchase order, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor&#8217;s payment obligation. The Company's standard payment terms are generally net 30 to 90 days.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain Customer Contracts</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions and related expenses are considered incremental and recoverable costs of acquiring customer contracts. The Company&#8217;s sales commissions paid to its sales representatives are generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. The period of benefit is concurrent with when the Company recognizes its revenue and as such, the Company recognizes sales commission as expense when incurred. </span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a one-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the one-year period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets. Sales and warranty reserves from the warranty program were immaterial as of December 31, 2020 and 2019.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Device Excise Tax</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the U.S. The Company recorded the medical device excise tax within the cost of goods sold in the consolidated statements of operations and comprehensive loss when incurred. Effective January 1, 2016, the Consolidated Appropriations Act of 2016, which was signed into law in December 2015, included a two-year suspension on the medical device excise tax. In January 2018, the suspension on the tax on medical devices was further extended through January 1, 2020. In December 2019, the U.S. Senate passed a bipartisan legislation to permanently repeal the medical device excise tax. </span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#8217;s product which primarily include: (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2)&#160;external research and development expenses; and (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expenditures</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations. Advertising expenses were $0.3 million and $0.4 million for the year ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingency</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. </span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company became public in October 2018 and has no sufficient trading history, the Company uses stock price volatility using the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the restricted stock unit (&#8220;RSU&#8221;) grant is based on the market price of the Company&#8217;s common stock on the date of grant.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to IPO, the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes uncertain tax positions when it meets a more-likely-than-not threshold. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share of Common Stock</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic and diluted net loss per common share attributable to shareholders i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n conformity with the two-class method required for companies with participating securities. The Company considers all ea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents all changes in the stockholders&#8217; equity except those resulting from distributions to stockholders. The Company&#8217;s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. In connection with the IPO, all of the Company's redeemable convertible preferred stock warrants were automatically converted into common stock warrants. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of New Revenue Recognition Standard</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new revenue recognition standards (&#8220;ASC 606&#8221;) using the modified retrospective method effective for the year ended December 31, 2019. This approach was applied to all contracts that were not completed as of January 1, 2019. As an emerging growth company that elected to take advantage of the JOBS Act accounting election, the Company was not required to adopt the new revenue standard in the interim reporting periods on the year of adoption and is not required, and intends not, to revise its 2019 interim periods which were reported under previous revenue recognition standards (&#8220;ASC 605&#8221;). The adoption of ASC 606 did not result in a material impact on the Company&#8217;s consolidated financial statements and no adjustment was made to the opening balance of accumulated deficit at January 1, 2019.&#160;ASC 606's core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or medical facilities, which represents majority of the Company's revenue, the Company continues to recognize the revenue upon completion of the procedure&#160;and authorization by the customer, net of rebates and price discounts. As it relates to sale of products through distributors and hospitals where product is ordered in advance of the procedure, the Company continues to recognize the revenue upon shipments to the customers, net of rebates and price discounts. Additionally, ASC 606 requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company&#8217;s sales commissions paid to its sales representatives is generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. As such, the Company recognize sales commission as expense when incurred. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenues from contracts with customers into geographical regions. The Company determined that disaggregating revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by regional economic factors. For information revenue by geography, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in &#8220;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies&#8221; in the accompanying Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation-Stock Compensation, to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity-Based Payments to&#160;Non-Employees. The Company adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued&#160;ASU&#160;2018-13, Fair Value Measurements, which eliminates, adds or modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted to adopt either the entire standard or only the provisions that eliminate or modify the requirements. The Company has adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Effective</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet.&#160;A lease liability is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date.&#160;In July 2018, the FASB issued&#160;ASU&#160;2018-10 and&#160;ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. The new transition method allows an entity to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In March 2019, the FASB issued&#160;ASU 2019-01, which provides clarification on implementation issues associated with adopting&#160;ASU 2016-02.&#160;The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the &#8220;all other&#8221; categories. For public companies, the new guidance became effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the new guidance is now effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is still permitted for any interim or annual financial statements not yet issued. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company, the new leases standard is now effective for the Company for the fiscal year ending December 31, 2022 and interim periods within fiscal year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements including the timing of its adoption. The Company anticipates electing several practical expedients that permit the Company not to reassess (1) whether a contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. The Company expects that the adoption of this new standard will have a material impact on its balance sheet. The most significant impact would be the recognition of operating lease right-of-use assets and liability. The standard is not expected to have a material impact on the Company's consolidated statements of income and cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued&#160;ASU 2016-13,&#160;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. FASB issued ASU 2019-05 in May 2019 and ASU 2019-08 in November 2019 for codification improvements of Topic 326. The new standard revises the accounting requirements related to the measurement of credit losses and will require organizations to measure all expected credit losses for financial assets based on historical experience, current conditions and reasonable and supportable forecasts about collectability. Assets must be presented in the financial statements at the net amount expected to be collected.&#160;In November 2019, the FASB issued ASU 2019-10,&#160;which defers the effective date of&#160;ASU 2016-13&#160;for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&#160;In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. The Company is currently evaluating the impact of this standard on its consolidated financial statements but does not expect the adoption of the standard will have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667550023560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the marketable securities:  </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,856&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,132&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,186&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term investments outstanding as of December 31, 2019 matured in April 2020. The Company did not identify any of its marketable securities as other-than-temporarily impaired as of December 31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530746200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate. There were no other financial assets and liabilities that requires fair value hierarchy measurements and disclosures for the periods presented. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the fair value of the Company&#8217;s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"/><td style="width:48.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,724&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,475&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,151&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,186&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529522696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Inventory</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, inventory consisted entirely of finished goods.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,484&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,749&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress pertains to cost of individual components of a custom instrument set used for surgical placement of iFuse implants that have not yet been placed into service.  Depreciation expense was $1.1 million and $0.8 million for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accrued litigation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530775640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-cancelable operating lease for an office building space, located in Santa Clara, California which expires in May 2025. The Company also has non-cancelable operating leases for its office building spaces in Gallarate, Italy and Mannheim, Germany which both expire in November 2024, and in Knaresborough, United Kingdom, which expires in December 2025. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2021 to 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases totaled approximately $1.2 million and $1.2 million for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future minimum lease payments under all leases as of December 31, 2020 are as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"><tr><td style="width:1.0%"/><td style="width:82.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Obligations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has certain purchase commitments related to its inventory management with certain manufacturing suppliers wherein the Company is required to purchase the amounts forecasted in a blanket purchase order. The contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. These outstanding commitments amounted to $0.3 million and $0.4 million as of December 31, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. (&#8220;Plaintiff&#8221;) v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the U.S. District Court, Northern District of California (the &#8220;California Action&#8221;). The complaint alleges violations of the Telephone Consumer Protection Act (the &#8220;TCPA&#8221;) on behalf of an individual and a putative class of persons alleged to be similarly situated. The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission. The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship. The plaintiff sought various forms of relief, including statutory damages of $500 for each violation of the TCPA or, in the alternative, treble damages of up to $1,500 for each knowing and willful violation of the TCPA and a permanent injunction prohibiting the Company from sending or having sent advertisements by way of facsimile transmission. Subsequently on December 20, 2019, Plaintiff the filed a putative class action captioned Eric B. Fromer Chiropractic, Inc. v. SI-BONE, Inc. (Case No. 1922-CC12323), in the Circuit Court of the City of St. Louis, State of Missouri (the &#8220;Missouri Action&#8221;). The Missouri Action alleges the same TCPA violations as the California Action. On December 23, 2019 the parties filed a joint stipulation of dismissal of the California Action and on January 14, 2020, the parties executed a definitive settlement agreement (the &#8220;Settlement Agreement&#8221;) pursuant to which, the Company agreed to settle all disputes regarding the advertising faxes to the settlement class. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrued litigation expense of $3.2&#160;million during the year ended December 31, 2019 within general and administrative expenses in the consolidated financial statements, which was the Company's estimated cost to resolve the matter pursuant to the Settlement Agreement and based on the estimated class members' claim submission rate. Following the notice and claims submission process, on June 22, 2020, the Circuit Court of the City of St. Louis, State of Missouri, approved a final order to pay the approved claims submitted by class members, fees, expenses and incentive awards totaling $2.6&#160;million as final settlement. Accordingly, the Company recorded a reversal of accrued litigation expense of $0.6&#160;million in year ended December 31, 2020 within general and administrative expenses in the consolidated financial statements. The Company made the final settlement payment on July 1, 2020. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531426008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding borrowings from the term loan as of the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal outstanding and final fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding debt, net of debt issuance costs and unaccreted value of final fee</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term borrowings</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding debt as of December 31, 2019 related to a term loan entered by the Company with Biopharma Credit Investments IV Sub LP (&#8220;Pharmakon&#8221;) in October 2017 for total loan proceeds of $40.0 million (the &#8220;Pharmakon Term Loan&#8221;). The Pharmakon Term Loan included an interest-only period for 35 months through September 2020 and then equal quarterly principal payments plus interest through December 2022. The Pharmakon Term Loan carried a fixed interest rate of 11.5% and allowed for early prepayment. The prepayment penalty fee was equal to the remaining interest due if prepaid within the first 30 months, a 2% penalty for months 31-48, and a 1% penalty for months 49-60. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 29, 2020, the Company entered into a Loan and Security Agreement with Solar Capital Partners (&#8220;Solar&#8221;) providing for a term loan of an aggregate principal amount of $40.0&#160;million to the Company (the &#8220;Solar Term Loan&#8221;). In accordance with the Loan and Security Agreement, the Company paid in full and terminated the Pharmakon Term Loan, which was accounted for as debt extinguishment in accordance with the accounting standards. The Company recognized the unamortized debt issuance costs of $0.7&#160;million and the prepayment penalty and lender fees of $0.8&#160;million related to Pharmakon Term Loan as a loss on debt extinguishment. The costs and fees are reflected as interest expense in the consolidated statement of operations for the year ended December 31, 2020. The total debt issuance costs of $0.8&#160;million associated with the Solar Term Loan were recorded in the consolidated balance sheet as a direct deduction from the carrying amount of the loan, and are amortized as a component of interest expense using straight-line method over the life of the term loan.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Solar Term Loan bears interest at a rate per annum equal to 9.40% plus the greater London Interbank Offered Rate (&#8220;LIBOR&#8221;), payable monthly in arrears. LIBOR means the greater of (i) 0.33% or (ii) one-month LIBOR (or a comparable replacement rate to be determined by the collateral agent if the LIBOR is no longer available), which rate shall reset monthly. The Solar Term Loan matures in 60 months on June 1, 2025 (&#8220;Maturity Date&#8221;), with an interest-only period of 36 months through June 2023, and then repaid in equal monthly principal payments plus interest through maturity date. Pursuant to the Loan and Security Agreement, the Company may voluntarily prepay the Solar Term Loan, in full or in part, but only in increments of $10.0&#160;million, for a prepayment premium in an amount equal to 3.00% of the principal if prepaid in year one, 1.25% of the principal if prepaid in year two, and 0.50% of the principal if prepaid in year three or later. The prepayment premium will be waived if the Company voluntarily prepays and refinances the outstanding balance with Solar. The Solar Term Loan is secured by substantially all of the Company&#8217;s assets.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is also obligated to pay a final fee equal to $1.0&#160;million or 2.5% of the aggregate principal amount of the Solar Term Loan, which was fully earned by Solar on the effective date of the Loan and Security Agreement. With respect to the Solar Term Loan, this final fee shall be due and payable on the earliest of (i) the maturity date, (ii) the acceleration of the loan balance or (iii) its full prepayment, refinancing, substitution or replacement. The final fee was included within the long-term borrowings and is accreted to interest expense using straight-line method over the life of the term loan.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective interest rate related to the Pharmakon Term Loan was 12.4% and 12.3% for the term loan's outstanding periods for the years ended December 31, 2020 and 2019, respectively. The effective interest rate related to the Solar Term Loan was 10.6% for the term loan's outstanding period for year ended December 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the future principal and final fee payments under the Solar Term Loan as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"><tr><td style="width:1.0%"/><td style="width:82.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and final fee payments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to other customary covenants set forth in the Loan and Security Agreement with Solar, the Company is required to maintain unrestricted cash and cash equivalents based on the trailing 12-month net products revenues tested on a monthly basis as follows: (a) $15.0&#160;million if net product revenue is less than $75.0&#160;million; or (b) $7.5&#160;million if net product revenue is greater than or equal to $75.0&#160;million, but less than $100.0&#160;million (the &#8220;minimum liquidity requirement&#8221;). The Company is not subject to minimum liquidity requirement when trailing twelve-month net product revenues exceeds $100.0&#160;million. Upon the occurrence of an event of default of certain customary covenants, including the minimum liquidity requirements, as specified in the Loan and Security Agreement, subject to specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 5.00% above the rate effective immediately before the event of default and may be declared immediately due and payable by Solar. As of December 31, 2020, the Company was in compliance with all debt covenants. Though there are uncertainties surrounding the impact of the COVID-19 pandemic that may impact our future revenue, the Company believes that it has sufficient cash and cash equivalents to meet the minimum liquidity requirements in the foreseeable succeeding periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CARES Act</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. federal government enacted the &#8220;Coronavirus Aid, Relief and Economic Security (CARES) Act,&#8221; and among other things, established the Paycheck Protection Program (&#8220;PPP&#8221;), administered by the Small Business Administration (&#8220;SBA&#8221;), whereby certain small businesses were eligible for a loan to fund payroll expenses, rent, and related costs. The loan may be forgiven if the funds are used for payroll and other qualified expenses. The Company met the requirements to apply for the PPP loan given that the Company has less than 500 employees and the business was negatively impacted by COVID-19. The Company submitted its application and was approved for the SBA program and received the proceeds from the PPP loan amounting to $5.3&#160;million on April 21, 2020, pursuant to a Promissory Note with Silicon Valley Bank (&#8220;SVB&#8221;). In light of the subsequent clarifications from the U.S. government on the eligibility criteria, the Company determined it was appropriate to repay the entire amount of the PPP loan. Accordingly, on April 29, 2020, the Company repaid in full the PPP loan and correspondingly terminated the Promissory Note.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act allows employers to defer the deposit and payment of an employer's share of social security taxes through December 31, 2020. The Company recorded a total liability of $1.0&#160;million related to the deferral of the social security taxes of which $0.5 million is included in each accrued liabilities and other and other long-term liabilities in the consolidated balance sheets as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531030104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes common stock warrants issued and outstanding at both December 31, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.916%"><tr><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.838%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of <br/>Shares <br/>Underlying <br/>Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price&#160;per <br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value<br/>(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,983</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,680</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,650</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,709</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/22/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/22/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,712</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.03</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.472%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[a]&#160;&#160;&#160;&#160;Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[b]</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value at the date of issuance.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[c]     Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529452824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common and Preferred Stock</a></td>
<td class="text">Common and Preferred Stock<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's certificate of incorporate as amended and restated in October 2018, authorizes the Company to issue 100,000,000 shares of common stock and 5,000,000 shares of preferred stock, each having a par value of $0.0001. Common stock issued and outstanding as of December 31, 2020 and 2019 were 32,583,220 shares and 25,163,803 shares, respectively. As of December 31, 2020 and 2019, there was no preferred stock issued and outstanding. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been no dividends declared to date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530949896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Stock Option Plan and 2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2008, the Company adopted the 2008 Stock Option Plan (the &#8220;2008 SOP&#8221;), as amended, under which the Board of Directors may issue incentive and non-qualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan (the &#8220;2018 EIP&#8221;), which serves as the successor to the 2008 SOP, under which the Board of Directors may issue incentive and non-qualified stock options and RSUs to employees, directors and consultants. No new options have been granted under the 2008 SOP since August 2018. Outstanding options under the 2008 SOP continue to be subject to the terms and conditions of that plan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2018 EIP will automatically increase on January 1 of each year, beginning January 1, 2019, and continuing through and including January 1, 2028, by 5% of the total number of shares of the Company's capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company's Board of Directors. On January 1, 2019 and 2020, the total number of shares of common stock reserved for issuance increased by 1,222,538 and 1,258,190 shares respectively. As of&#160;December 31, 2020, a total of 2,843,814 shares of common stock are available for future grants under the 2018 EIP.  On January 1, 2021, the total number of shares of common stock reserved for issuance under the 2018 EIP automatically increased by 1,629,161 shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than 10% of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a non-qualified stock option shall not be less than 100% and 85%, respectively, of the fair market value on the date of grant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted have a term of 10 years, except, options granted to individuals holding more than 10% of the outstanding shares have a term of five years. Options generally vest over a four-year period. Certain stock options are exercisable immediately, but are subject to a right of repurchase by the Company for any unvested shares. RSUs granted under the 2018 EIP generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzI1ODU_7bd59b98-57a3-4657-978b-3cc5ffa4e420">two</span> to four years based upon continued services and are settled at vesting in shares of the Company's common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.611%"><tr><td style="width:1.0%"/><td style="width:51.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.89</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,549)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.07</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options vested and exercisable as of December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,020&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.85</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options vested and expected to vest as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,390,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 amounted to $5.6 million and $6.8 million, respectively, representing the difference between the fair value of the Company's common stock at the date of exercise and the exercise price paid. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest as of December 31, 2020 represents the difference between the weighted average exercise price and the closing price of the Company&#8217;s common stock&#160;on the last trading day of the year. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding options and exercisable options information by range of exercise prices as of&#160;December 31, 2020&#160;was as follows:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.166%"><tr><td style="width:1.0%"/><td style="width:9.491%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.236%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested and Exercisable</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average <br/>Remaining <br/>Contractual <br/>Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.84</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.70</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.42</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.67</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.51</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.08</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.52</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,020&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.85</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the weighted average grant date fair value per share and the assumptions used to estimate the grant date fair value using the Black-Scholes option-pricing model of the stock options granted during the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.722%"><tr><td style="width:1.0%"/><td style="width:59.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.78</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was $3.2 million of unrecognized compensation cost related to stock options granted. These costs are expected to be recognized over a period of approximately 1.9 years.</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Unvested Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early exercises of stock options under the Company's 2008 SOP are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders&#8217; equity as the options vest. As of December 31, 2020 and 2019, the Company had a total of 5,836 and 21,404 shares of common stock, respectively, subject to repurchase under the 2008 SOP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock units activity for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.055%"><tr><td style="width:1.0%"/><td style="width:73.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Grant Date Fair  <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.69</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.73</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.07</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was a total unrecognized compensation cost of $19.3 million. These costs are expected to be recognized over a period of approximately 2.9 years. </span></div><div style="margin-top:12pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to 85% of the lesser of the fair market value of the stock as of the first date or the ending date of each <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM1YWY0MzM0NjMyNzQ5ODliM2YzOWRhNDM3N2IyYjU1L3NlYzpjNWFmNDMzNDYzMjc0OTg5YjNmMzlkYTQzNzdiMmI1NV8yMDIvZnJhZzowNDkwYzQ2Y2FlMTg0NTllOGZiM2FhNmI2ZWI3MGQ1Mi90ZXh0cmVnaW9uOjA0OTBjNDZjYWUxODQ1OWU4ZmIzYWE2YjZlYjcwZDUyXzU1MjI_0f5ed571-a69d-4bc7-b68e-654ed23d7077">six</span> month offering period. The offering period generally commences in May and November. On March 26, 2020, the Company's Compensation Committee approved the amendment of the terms of future offerings under the ESPP which, among other things, increased the maximum number of shares that may be purchased on any single purchase date, provided for automatic enrollment in a new offering, and provided that the offering which commenced in May 2020 be twelve months in duration and consist of two purchase periods. There were 515,307 shares of common stock originally reserved for issuance under the ESPP. Under the ESPP, the number of shares reserved for issuance under the ESPP automatically increases on January&#160;1st of each year, starting on January&#160;1, 2019, and continuing through January&#160;1, 2029, by an amount equal to (i) the lesser of 1% of the total number of shares of the Registrant&#8217;s common stock outstanding on December&#160;31st of the preceding calendar year, and (ii) 555,555 shares of common stock. As of&#160;December 31, 2020, a total of 705,618 shares of common stock are available for future grants under the 2018 EIP. On January 1, 2021, the total number of shares of common stock reserved for issuance under the ESPP Plan increased by 325,832 shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model, which is being amortized over the requisite service period. The Company issued 137,377 shares and 168,457 shares under the ESPP during the years ended December 31, 2020 and 2019, respectively, representing approximately $1.9&#160;million and $2.2&#160;million in employee contributions. As of December 31, 2020 and 2019, total accumulated ESPP related employee payroll deductions amounted to $0.4 million and $0.2 million, respectively, which were included within accrued compensation and related expenses in the consolidated balance sheets. For the years ended December 31, 2020 and 2019, the Company recognized $1.2 million and $0.8 million, respectively, of stock-based compensation expense related to ESPP. As of December 31, 2020, the unrecognized compensation cost for the ESPP was $0.2 million.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of&#160;ESPP purchase rights during the offering period&#160;using a Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.944%"><tr><td style="width:1.0%"/><td style="width:57.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth stock-based compensation expense recognized for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531410904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanThe Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. Effective January 1, 2019, the Company made a discretionary matching contribution equal to dollar for dollar employee contribution, up to 3% eligible compensation of the employee, with a maximum annual contribution from the Company of one thousand dollars per employee. Further, in order for an employee to receive the matching contribution, the employee must be at least 21 years old, work at least 1,000 hours per year, and must be employed by the Company at the beginning through the end of the year. For the years ended December 31, 2020 and 2019, the Company made $0.2&#160;million and $0.1 million, respectively, contributions to the 401(k) plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529449240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text">Net Loss Per Share of Common Stock<div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"/><td style="width:74.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.931%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands, except share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,059,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,705,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Company has reported a net loss in all periods presented, outstanding stock options, restricted stock units, shares subject to repurchase, ESPP purchase rights and common stock warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following anti-dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405,957</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,971</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,295</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares subject to repurchase</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,836</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,404</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP purchase rights</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,040</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,122</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466,980</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529154360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s loss before income taxes are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,989)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,697)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,403)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for income taxes recorded for the years ended December 31, 2020 and 2019. The Company continues to maintain a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The Company periodically evaluates the realizability of its net deferred tax assets based on the expected realization and is dependent on the Company's ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income taxes are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,149&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,892&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,892)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at statutory federal rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax asset, net of valuation allowance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in the valuation allowance for the years ended December 31, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"/><td style="width:73.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.877%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,453&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $200.5 million and $165.0 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company&#8217;s federal NOL carryforward begins to expire in 2028, and the state NOL carryforward begins to expire in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had credit carryforwards of approximately $2.5 million and $2.5 million available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in 2029, and the state credits have no expiration date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company updated its Section 382 ownership change analysis through December 31, 2020 a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd determined that the last ownership change was in February 2020 due to the follow-offering. The analysis concluded that no additional NOL carryforwards will expire due to the Section 382 limitation from the ownership change for both federal and state tax purposes. The Company maintains the reduction of $1.4 million of its NOL carryforwards from the previous ownership change. The Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pany will continually assess the need to update its Section 382 ownership change analysis, as the Company may experience ownership changes in the future that could materially limit its ability to use its NOL carryforwards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act includes provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the payment of an employer's share of social security taxes through December 31, 2020 of $1.0&#160;million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 29, 2020, Governor Gavin Newsom signed California Assembly Bill 85 (AB 85) into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California Tax Credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1.0&#160;million. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $5.0&#160;million of California tax. Given the Company&#8217;s loss position for the year ended December 31, 2020, the new legislation did not impact the current year provision. The Company will continue to monitor the possible California net operating loss and credit limitations in future periods.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company&#8217;s uncertain income tax positions for the years ended December 31, 2020 and 2019 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.194%"><tr><td style="width:1.0%"/><td style="width:73.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year's tax positions</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has no accrued interest related to unrecognized tax benefits as of December 31, 2020 and 2019. None of the Company&#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rates for the years ended December 31, 2020 and 2019. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no federal, state or foreign tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company&#8217;s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530758488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2020, the Company entered into a joint development agreement (the &#8220;Development Agreement&#8221;) with SeaSpine Orthopedics Corporation (&#8220;SeaSpine&#8221;) to develop a next generation device for sacropelvic fixation. Mr. Keith Valentine, who serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine, also serves as a member of the Company's Board of Directors since August 2015. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the development plan, SeaSpine shall use reasonable efforts to assist in the development of the potential product offering, including licensing certain existing intellectual property to be incorporated into such product. Under the terms of the&#160;Development Agreement, the Company agreed to make monthly payments to SeaSpine to reimburse for full time resources employed by SeaSpine responsible to conduct the development activities. For the year ended December 31, 2020, the Company expensed $118,000 of the reimbursement charges from SeaSpine, which was recorded within research and development expense in the consolidated statement of operations. There was no outstanding liabilities to SeaSpine as of December 31, 2020. </span></div>Certain intellectual property developed pursuant to the project plan will be owned by the Company, certain intellectual property developed pursuant to the project plan will be owned by SeaSpine, and other intellectual property developed pursuant to the project plan will be jointly owned by SeaSpine and the Company. The Company also agreed to provide SeaSpine a royalty-free, worldwide, perpetual, non-exclusive license of certain of the Company's intellectual property incorporated into the product to be developed. The Company also agreed to pay SeaSpine a product royalty, in an amount specified in the Development Agreement, for each resulting product sold for a period of 10 years beginning on the initial market launch. The term of the Development Agreement shall continue until the expiration of all royalty terms, unless earlier terminated by either party, as provided for by the Development Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667539713976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. </span>Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock', window );">JOBS Act Accounting Election</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies. Those standards apply to companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the&#160;JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company continues to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if the Company's total annual gross revenues are $1.07 billion or more; or (ii) the Company has issued more than $1.0 billion in non-convertible debt in the past three years;&#160;or (iii) the Company becomes a &#8220;large accelerated filer,&#8221; as defined in Rule&#160;12b-2 of the Exchange Act.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are based on components of the Company that engage in business activities that earn revenue and incur expenses and (a)&#160;whose operating results are regularly reviewed by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), to make decisions about resource allocation and performance and (b)&#160;for which discrete financial information is available.&#160;The CODM for the Company are the Chief Executive Officer (&#8220;CEO&#8221;) and Chief Operating Officer &amp; Chief Financial Officer (&#8220;COO/CFO&#8221;). The CEO and the COO/CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company&#8217;s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company&#8217;s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable.  The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) (&#8220;OCI&#8221;) on the consolidated balance sheets. The Company evaluates its investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely the Company will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text">Accounts Receivable and Allowance for Doubtful AccountsAccounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#8217;s operating results or change in financial position. If circumstances related to such customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">InventoryInventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"><tr><td style="width:1.0%"/><td style="width:85.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the new revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.  As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract, agreed price list, or purchase order, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor&#8217;s payment obligation. The Company's standard payment terms are generally net 30 to 90 days.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain Customer Contracts</span></div>Sales commissions and related expenses are considered incremental and recoverable costs of acquiring customer contracts. The Company&#8217;s sales commissions paid to its sales representatives are generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. The period of benefit is concurrent with when the Company recognizes its revenue and as such, the Company recognizes sales commission as expense when incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Warranty Program</a></td>
<td class="text">Warranty The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a one-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the one-year period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock', window );">Medical Device Excise Tax</a></td>
<td class="text">Medical Device Excise TaxIn accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the U.S. The Company recorded the medical device excise tax within the cost of goods sold in the consolidated statements of operations and comprehensive loss when incurred. Effective January 1, 2016, the Consolidated Appropriations Act of 2016, which was signed into law in December 2015, included a two-year suspension on the medical device excise tax. In January 2018, the suspension on the tax on medical devices was further extended through January 1, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#8217;s product which primarily include: (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2)&#160;external research and development expenses; and (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenditures</a></td>
<td class="text">Advertising ExpendituresThe cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Loss Contingency</a></td>
<td class="text">Loss ContingencyThe Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company became public in October 2018 and has no sufficient trading history, the Company uses stock price volatility using the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the restricted stock unit (&#8220;RSU&#8221;) grant is based on the market price of the Company&#8217;s common stock on the date of grant.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to IPO, the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div>The Company recognizes uncertain tax positions when it meets a more-likely-than-not threshold. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share of Common Stock</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic and diluted net loss per common share attributable to shareholders i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n conformity with the two-class method required for companies with participating securities. The Company considers all ea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents all changes in the stockholders&#8217; equity except those resulting from distributions to stockholders. The Company&#8217;s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock', window );">Warrants</a></td>
<td class="text">WarrantsThe Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. In connection with the IPO, all of the Company's redeemable convertible preferred stock warrants were automatically converted into common stock warrants.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of New Revenue Recognition Standard</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new revenue recognition standards (&#8220;ASC 606&#8221;) using the modified retrospective method effective for the year ended December 31, 2019. This approach was applied to all contracts that were not completed as of January 1, 2019. As an emerging growth company that elected to take advantage of the JOBS Act accounting election, the Company was not required to adopt the new revenue standard in the interim reporting periods on the year of adoption and is not required, and intends not, to revise its 2019 interim periods which were reported under previous revenue recognition standards (&#8220;ASC 605&#8221;). The adoption of ASC 606 did not result in a material impact on the Company&#8217;s consolidated financial statements and no adjustment was made to the opening balance of accumulated deficit at January 1, 2019.&#160;ASC 606's core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or medical facilities, which represents majority of the Company's revenue, the Company continues to recognize the revenue upon completion of the procedure&#160;and authorization by the customer, net of rebates and price discounts. As it relates to sale of products through distributors and hospitals where product is ordered in advance of the procedure, the Company continues to recognize the revenue upon shipments to the customers, net of rebates and price discounts. Additionally, ASC 606 requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company&#8217;s sales commissions paid to its sales representatives is generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. As such, the Company recognize sales commission as expense when incurred. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenues from contracts with customers into geographical regions. The Company determined that disaggregating revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by regional economic factors. For information revenue by geography, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in &#8220;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies&#8221; in the accompanying Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation-Stock Compensation, to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity-Based Payments to&#160;Non-Employees. The Company adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued&#160;ASU&#160;2018-13, Fair Value Measurements, which eliminates, adds or modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted to adopt either the entire standard or only the provisions that eliminate or modify the requirements. The Company has adopted this standard effective for the year ended December 31, 2020, and the adoption did not have any material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Effective</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet.&#160;A lease liability is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date.&#160;In July 2018, the FASB issued&#160;ASU&#160;2018-10 and&#160;ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. The new transition method allows an entity to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In March 2019, the FASB issued&#160;ASU 2019-01, which provides clarification on implementation issues associated with adopting&#160;ASU 2016-02.&#160;The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the &#8220;all other&#8221; categories. For public companies, the new guidance became effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the new guidance is now effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is still permitted for any interim or annual financial statements not yet issued. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company, the new leases standard is now effective for the Company for the fiscal year ending December 31, 2022 and interim periods within fiscal year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements including the timing of its adoption. The Company anticipates electing several practical expedients that permit the Company not to reassess (1) whether a contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. The Company expects that the adoption of this new standard will have a material impact on its balance sheet. The most significant impact would be the recognition of operating lease right-of-use assets and liability. The standard is not expected to have a material impact on the Company's consolidated statements of income and cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued&#160;ASU 2016-13,&#160;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. FASB issued ASU 2019-05 in May 2019 and ASU 2019-08 in November 2019 for codification improvements of Topic 326. The new standard revises the accounting requirements related to the measurement of credit losses and will require organizations to measure all expected credit losses for financial assets based on historical experience, current conditions and reasonable and supportable forecasts about collectability. Assets must be presented in the financial statements at the net amount expected to be collected.&#160;In November 2019, the FASB issued ASU 2019-10,&#160;which defers the effective date of&#160;ASU 2016-13&#160;for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&#160;In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. The Company is currently evaluating the impact of this standard on its consolidated financial statements but does not expect the adoption of the standard will have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Extended Transition Period Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Device Excise Tax Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Classified As Equity And Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529250520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geography</a></td>
<td class="text">Following table summarizes the Company's revenue by geography:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"><tr><td style="width:1.0%"/><td style="width:85.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr></table><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,484&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,749&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530968520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the marketable securities:  </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,856&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,132&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,186&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529422840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the fair value of the Company&#8217;s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"/><td style="width:48.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,724&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,475&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,151&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,186&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530954360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"><tr><td style="width:1.0%"/><td style="width:85.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr></table><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,484&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,749&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities and Other</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accrued litigation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531006744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Aggregate Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future minimum lease payments under all leases as of December 31, 2020 are as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"><tr><td style="width:1.0%"/><td style="width:82.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529497448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Borrowings</a></td>
<td class="text">The following table summarizes the outstanding borrowings from the term loan as of the periods presented:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal outstanding and final fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding debt, net of debt issuance costs and unaccreted value of final fee</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term borrowings</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Annual Future Minimum Principal Payments Under Loan Agreements</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.777%"><tr><td style="width:1.0%"/><td style="width:82.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and final fee payments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529506760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Issued and Outstanding</a></td>
<td class="text"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes common stock warrants issued and outstanding at both December 31, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.916%"><tr><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.838%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of <br/>Shares <br/>Underlying <br/>Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price&#160;per <br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value<br/>(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,983</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,680</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[b]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,650</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,709</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/22/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/22/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[a]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,712</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.03</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[c]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.472%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[a]&#160;&#160;&#160;&#160;Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[b]</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value at the date of issuance.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">[c]     Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532548616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.611%"><tr><td style="width:1.0%"/><td style="width:51.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.89</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,549)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.07</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options vested and exercisable as of December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,020&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.85</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options vested and expected to vest as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,390,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Options by Range of Exercise Price</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding options and exercisable options information by range of exercise prices as of&#160;December 31, 2020&#160;was as follows:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.166%"><tr><td style="width:1.0%"/><td style="width:9.491%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.236%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested and Exercisable</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average <br/>Remaining <br/>Contractual <br/>Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.84</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.70</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.42</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.67</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.51</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.08</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.52</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,020&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.85</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Related to Stock Option Awards</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.722%"><tr><td style="width:1.0%"/><td style="width:59.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.78</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock units activity for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.055%"><tr><td style="width:1.0%"/><td style="width:73.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Grant Date Fair  <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.69</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.73</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.07</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Related to ESPP Purchase Rights</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of&#160;ESPP purchase rights during the offering period&#160;using a Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.944%"><tr><td style="width:1.0%"/><td style="width:57.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth stock-based compensation expense recognized for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532916520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"/><td style="width:74.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.931%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands, except share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,059,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,705,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405,957</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,971</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,295</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares subject to repurchase</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,836</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,404</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP purchase rights</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,040</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,122</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466,980</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535805784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s loss before income taxes are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,989)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,697)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,403)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income taxes are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,149&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,892&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,892)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at statutory federal rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.361%"><tr><td style="width:1.0%"/><td style="width:74.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax asset, net of valuation allowance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Changes in Valuation Allowance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in the valuation allowance for the years ended December 31, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.777%"><tr><td style="width:1.0%"/><td style="width:73.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.877%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,453&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Uncertain Income Tax Positions</a></td>
<td class="text">The changes in the Company&#8217;s uncertain income tax positions for the years ended December 31, 2020 and 2019 consisted of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.194%"><tr><td style="width:1.0%"/><td style="width:73.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year's tax positions</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531637672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Nature of Business (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_FollowOnPublicOfferingMember', window );">First follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AllocatedPublicOfferingCosts', window );">Allocated public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_FollowOnPublicOfferingAndSecondaryOfferingMember', window );">First follow-on public offering and secondary offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering', window );">Number of shares in transaction, including shares in secondary offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">478,507<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_SecondFollowOnPublicOfferingMember', window );">Second follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 71.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_SecondaryOfferingMember', window );">Secondary offering by selling shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">190,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AllocatedPublicOfferingCosts', window );">Allocated public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AllocatedPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AllocatedPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Issued In Transaction, Including Shares In Secondary Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sibn_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_FollowOnPublicOfferingAndSecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sibn_FollowOnPublicOfferingAndSecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_SecondFollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sibn_SecondFollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sibn_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sibn_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667544882840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 73,387<span></span>
</td>
<td class="nump">$ 67,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">68,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667533014664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and marketable securities</a></td>
<td class="nump">$ 196,400<span></span>
</td>
<td class="nump">$ 93,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">39,455<span></span>
</td>
<td class="nump">39,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">239,277<span></span>
</td>
<td class="nump">195,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,697)<span></span>
</td>
<td class="num">$ (38,403)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667539548328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532299464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530869400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_RevenueRecognitionStandardPaymentTerms', window );">Standard payment terms per agreements (in days)</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_RevenueRecognitionStandardPaymentTerms', window );">Standard payment terms per agreements (in days)</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_RevenueRecognitionStandardPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Standard Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_RevenueRecognitionStandardPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667529522136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Warranty Program (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StandardProductWarrantyTerm', window );">Warranty term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SalesCreditReservePeriod', window );">Sales credit reserve term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_SalesCreditReservePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Credit Reserve Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_SalesCreditReservePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StandardProductWarrantyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StandardProductWarrantyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530998040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Advertising Expenditures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531845384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">$ 47,348<span></span>
</td>
<td class="nump">$ 5,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">142,856<span></span>
</td>
<td class="nump">81,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Aggregate Fair Value</a></td>
<td class="nump">142,851<span></span>
</td>
<td class="nump">81,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Aggregate Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesAmortizedCost', window );">Total marketable securities, Amortized Cost</a></td>
<td class="nump">190,204<span></span>
</td>
<td class="nump">88,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total marketable securities, Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total marketable securities, Unrealized Losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesFairValue', window );">Total marketable securities, Aggregate Fair Value</a></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">88,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">45,948<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">74,779<span></span>
</td>
<td class="nump">67,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Aggregate Fair Value</a></td>
<td class="nump">74,776<span></span>
</td>
<td class="nump">67,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">9,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Aggregate Fair Value</a></td>
<td class="nump">8,938<span></span>
</td>
<td class="nump">9,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">59,137<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 59,137<span></span>
</td>
<td class="nump">$ 5,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Loss Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities, Current, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Loss Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities, Noncurrent, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Noncurrent [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amortized cost for marketable securities included in cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total aggregate fair value for marketable securities included in cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532769400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="nump">$ 88,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">45,948<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">74,776<span></span>
</td>
<td class="nump">67,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">8,938<span></span>
</td>
<td class="nump">10,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">60,537<span></span>
</td>
<td class="nump">7,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">120,724<span></span>
</td>
<td class="nump">70,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">45,948<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">74,776<span></span>
</td>
<td class="nump">67,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">69,475<span></span>
</td>
<td class="nump">18,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">8,938<span></span>
</td>
<td class="nump">10,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">60,537<span></span>
</td>
<td class="nump">7,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531571704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,484<span></span>
</td>
<td class="nump">$ 7,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(4,957)<span></span>
</td>
<td class="num">(3,795)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,527<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,342<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,692<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531944376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 9,175<span></span>
</td>
<td class="nump">$ 7,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other</a></td>
<td class="nump">$ 10,199<span></span>
</td>
<td class="nump">$ 11,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535241464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2020</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=sibn_EricBFromerChiropracticIncClassActionMember', window );">Class action Eric B. Fromer Chiropractic Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement of approved claims by class members, fees, expenses and incentive awards</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Reversal of accrued litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember', window );">Statutory damages sought per violation of TCPA | Class action Eric B. Fromer Chiropractic Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=sibn_LitigationTrebleDamagesPerViolationOfTCPAMember', window );">Treble damages sought per violation of TCPA | Class action Eric B. Fromer Chiropractic Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Costs to defend lawsuits or settle claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Costs accrued to defend lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sibn_EricBFromerChiropracticIncClassActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sibn_EricBFromerChiropracticIncClassActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=sibn_LitigationTrebleDamagesPerViolationOfTCPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=sibn_LitigationTrebleDamagesPerViolationOfTCPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535879016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Aggregate Future Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">1,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 4,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667536198376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Summary of Borrowings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding and final fee</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: Unamortized debt issuance costs</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted value of final fee</a></td>
<td class="num">(884)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding debt, net of debt issuance costs and unaccreted value of final fee</a></td>
<td class="nump">39,455<span></span>
</td>
<td class="nump">39,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term borrowings</a></td>
<td class="nump">$ 39,455<span></span>
</td>
<td class="nump">$ 34,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667455431000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Apr. 21, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,297,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount', window );">Recognition of unamortized debt discount and issuance costs on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt', window );">Prepayment penalty and lender fees on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Final fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred liability for social security taxes, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred liability for social security taxes, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred liability for social security taxes, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sibn_PayrollProtectionProgramLoanCARESActMember', window );">PPP Loan, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayment of PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Pharmakon Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Debt period payment, interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate during the period (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Pharmakon Term Loan | Prepayment Penalty, 31-48 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt prepayment penalty percentage (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Pharmakon Term Loan | Prepayment Penalty, 49-60 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt prepayment penalty percentage (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Debt period payment, interest only period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance cost</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt maturity term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement', window );">Allowable prepayment increments per agreement</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage', window );">Prepayment premium in year one (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage', window );">Prepayment premium in year two (percent)</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage', window );">Prepayment premium in year three or later (percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Final fee</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal', window );">Final fee as percentage of aggregate principal amount (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate during the period (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant', window );">Incremental interest rate increase upon default of minimum liquidity covenant (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Variable Option One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Debt Covenant Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentCovenantMinimumCashBalance', window );">Debt covenant minimum cash balance</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold', window );">Product revenue threshold for minimum liquidity covenant</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Debt Covenant Tranche One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold', window );">Product revenue threshold for minimum liquidity covenant</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Debt Covenant Tranche One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold', window );">Product revenue threshold for minimum liquidity covenant</a></td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Debt Covenant Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentCovenantMinimumCashBalance', window );">Debt covenant minimum cash balance</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Debt Covenant Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentCovenantMinimumCashBalance', window );">Debt covenant minimum cash balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Solar Loan And Security Agreement | Debt Covenant Tranche Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold', window );">Product revenue threshold for minimum liquidity covenant</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentCovenantMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentCovenantMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Fee Amount As Percentage Of Aggregate Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate Incremental Increase Upon Default Of Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Liquidity Covenant Product Revenue Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment, Allowable Increments Per Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPrepaymentPenaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPrepaymentPenaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Premium Year One Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Premium Year Three Or Later Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Premium Year Two Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment Penalty And Lender Fees In Extinguishment Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_SocialSecurityTaxEmployerDeferralCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Social Security Tax, Employer, Deferral, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_SocialSecurityTaxEmployerDeferralCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Deferred Debt Issuance Cost And Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sibn_PayrollProtectionProgramLoanCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sibn_PayrollProtectionProgramLoanCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sibn_PharmakonTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sibn_PharmakonTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty3148MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty3148MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty4960MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty4960MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sibn_SolarLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sibn_SolarLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=sibn_VariableOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=sibn_VariableOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantThresholdAxis=sibn_DebtCovenantTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantThresholdAxis=sibn_DebtCovenantTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantThresholdAxis=sibn_DebtCovenantTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantThresholdAxis=sibn_DebtCovenantTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantThresholdAxis=sibn_DebtCovenantTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantThresholdAxis=sibn_DebtCovenantTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535635048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Annual Future Minimum Principal Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">11,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">9,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal and final fee payments</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532715304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Issued and Outstanding (Details) - Common Stock - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Warrants Issued 3/1/2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price&#160;per Share (in dollars per share)</a></td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Warrants Issued 7/22/2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">32,983<span></span>
</td>
<td class="nump">32,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price&#160;per Share (in dollars per share)</a></td>
<td class="nump">$ 9.10<span></span>
</td>
<td class="nump">$ 9.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Warrants Issued 11/26/2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">6,680<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price&#160;per Share (in dollars per share)</a></td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Warrants Issued 10/20/2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">41,650<span></span>
</td>
<td class="nump">41,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price&#160;per Share (in dollars per share)</a></td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Warrants Issued 11/9/2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">25,709<span></span>
</td>
<td class="nump">25,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price&#160;per Share (in dollars per share)</a></td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Warrants Issued 12/22/2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">9,712<span></span>
</td>
<td class="nump">9,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price&#160;per Share (in dollars per share)</a></td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number&#160;of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">118,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair&#160;Value</a></td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedMarchFirstTwentySeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedMarchFirstTwentySeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535867688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">32,583,220<span></span>
</td>
<td class="nump">25,163,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">32,583,220<span></span>
</td>
<td class="nump">25,163,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667456410232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>purchase_period </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase', window );">Early exercise of stock options, share subject to repurchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,836<span></span>
</td>
<td class="nump">5,836<span></span>
</td>
<td class="nump">21,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to employee stock purchase plan (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,377<span></span>
</td>
<td class="nump">168,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to employee stock purchase plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,915<span></span>
</td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,927<span></span>
</td>
<td class="nump">7,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares', window );">Exercise price of option as percent of fair market value when individual owns more than 10% of shares outstanding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms', window );">Percentage of ownership of outstanding shares for alternate terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares', window );">Stock option term when grantee holds more than 10% of shares outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, expected period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sibn_IncentiveStockOptionMember', window );">Incentive Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue', window );">Exercise price of option as percent of fair market value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sibn_NonqualifiedStockOptionMember', window );">Nonqualified Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue', window );">Exercise price of option as percent of fair market value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, expected period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding', window );">Annual increase in shares reserved as percentage of prior year-end shares outstanding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222,538<span></span>
</td>
<td class="nump">1,258,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843,814<span></span>
</td>
<td class="nump">2,843,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember', window );">2018 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">1,629,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding', window );">Annual increase in shares reserved as percentage of prior year-end shares outstanding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares', window );">Annual increase in shares reserved, maximum (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as a percent of fair market value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval', window );">Employees stock purchase program offering period interval (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Number of purchase periods in offering interval | purchase_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,618<span></span>
</td>
<td class="nump">705,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses for employee payroll deductions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember', window );">2018 ESPP | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">325,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Reserved As Percentage Of Prior Year Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved, Maximum Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than 10% Of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Option, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than 10% Of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Ownership Of Outstanding Shares Threshold For Alternate Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sibn_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sibn_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sibn_NonqualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sibn_NonqualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667548462184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,718,971<span></span>
</td>
<td class="nump">2,641,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">26,236<span></span>
</td>
<td class="nump">638,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(323,701)<span></span>
</td>
<td class="num">(444,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled and forfeited (in shares)</a></td>
<td class="num">(15,549)<span></span>
</td>
<td class="num">(116,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,405,957<span></span>
</td>
<td class="nump">2,718,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable (in shares)</a></td>
<td class="nump">2,069,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (in shares)</a></td>
<td class="nump">2,390,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="nump">$ 4.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">17.31<span></span>
</td>
<td class="nump">20.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">4.52<span></span>
</td>
<td class="nump">3.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled and forfeited (in dollars per share)</a></td>
<td class="nump">17.07<span></span>
</td>
<td class="nump">11.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">8.54<span></span>
</td>
<td class="nump">$ 8.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per share)</a></td>
<td class="nump">6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life, options outstanding (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, options vested and exercisable (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, options vested and expected to vest (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 51,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, options vested and exercisable</a></td>
<td class="nump">47,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, options vested and expected to vest</a></td>
<td class="nump">$ 51,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531753864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of shares (in shares) | shares</a></td>
<td class="nump">2,405,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, average remaining contractual life (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of shares (in shares) | shares</a></td>
<td class="nump">2,069,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheOneMember', window );">$0.84-$3.69</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 3.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of shares (in shares) | shares</a></td>
<td class="nump">465,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, average remaining contractual life (years)</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of shares (in shares) | shares</a></td>
<td class="nump">465,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheTwoMember', window );">$3.70-$4.41</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">3.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 4.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of shares (in shares) | shares</a></td>
<td class="nump">689,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, average remaining contractual life (years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of shares (in shares) | shares</a></td>
<td class="nump">689,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheThreeMember', window );">$4.42-$5.31</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">4.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 5.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of shares (in shares) | shares</a></td>
<td class="nump">458,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, average remaining contractual life (years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of shares (in shares) | shares</a></td>
<td class="nump">422,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheFourMember', window );">$5.32-$20.51</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">5.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 20.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of shares (in shares) | shares</a></td>
<td class="nump">356,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, average remaining contractual life (years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of shares (in shares) | shares</a></td>
<td class="nump">282,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheFiveMember', window );">$20.52-$22.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">20.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 22.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of shares (in shares) | shares</a></td>
<td class="nump">435,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, average remaining contractual life (years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of shares (in shares) | shares</a></td>
<td class="nump">208,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sibn_OptionsTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532545032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions for Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 8.16<span></span>
</td>
<td class="nump">$ 9.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percent)</a></td>
<td class="nump">46.70%<span></span>
</td>
<td class="nump">41.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percent)</a></td>
<td class="nump">47.20%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (percent)</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667544979624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">543,041<span></span>
</td>
<td class="nump">53,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,016,432<span></span>
</td>
<td class="nump">639,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(344,779)<span></span>
</td>
<td class="num">(108,631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares)</a></td>
<td class="num">(49,399)<span></span>
</td>
<td class="num">(41,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,165,295<span></span>
</td>
<td class="nump">543,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 19.72<span></span>
</td>
<td class="nump">$ 11.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">20.17<span></span>
</td>
<td class="nump">20.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">19.87<span></span>
</td>
<td class="nump">19.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in dollars per share)</a></td>
<td class="nump">19.73<span></span>
</td>
<td class="nump">18.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 20.07<span></span>
</td>
<td class="nump">$ 19.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667539361000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details) - ESPP Purchase Rights<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percent)</a></td>
<td class="nump">38.30%<span></span>
</td>
<td class="nump">38.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percent)</a></td>
<td class="nump">79.40%<span></span>
</td>
<td class="nump">58.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (percent)</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sibn_ESPPPurchaseRightsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sibn_ESPPPurchaseRightsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sibn_ESPPPurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sibn_ESPPPurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667531717384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 11,927<span></span>
</td>
<td class="nump">$ 7,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,527<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,930<span></span>
</td>
<td class="nump">$ 3,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667530878520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - 401(k) Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percentage of eligible compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee', window );">Employer matching contribution, maximum amount per employee</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Matching Contribution, Maximum Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=sibn_Company401KPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=sibn_Company401KPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535765016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,697)<span></span>
</td>
<td class="num">$ (38,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">29,059,171<span></span>
</td>
<td class="nump">24,705,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532171416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">3,778,250<span></span>
</td>
<td class="nump">3,466,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">2,405,957<span></span>
</td>
<td class="nump">2,718,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">1,165,295<span></span>
</td>
<td class="nump">543,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_ShareSubjectToRepurchaseMember', window );">Shares subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">5,836<span></span>
</td>
<td class="nump">21,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_EmployeeStockPurchasePlanSharesMember', window );">ESPP purchase rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">83,040<span></span>
</td>
<td class="nump">65,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">118,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_ShareSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_ShareSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_EmployeeStockPurchasePlanSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_EmployeeStockPurchasePlanSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535501560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of loss before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (41,708)<span></span>
</td>
<td class="num">$ (37,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(1,989)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">$ (43,697)<span></span>
</td>
<td class="num">$ (38,403)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532401848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 9,855<span></span>
</td>
<td class="nump">$ 8,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">583<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income taxes</a></td>
<td class="nump">13,149<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in deferred tax valuation allowance</a></td>
<td class="num">(13,149)<span></span>
</td>
<td class="num">(9,892)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance', window );">Net deferred income tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535645960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate (percent)</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit (percent)</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits (percent)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax valuation allowance (percent)</a></td>
<td class="nump">30.10%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock compensation (percent)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differences (percent)</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532347736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 52,331<span></span>
</td>
<td class="nump">$ 42,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">3,160<span></span>
</td>
<td class="nump">2,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">5,450<span></span>
</td>
<td class="nump">4,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">2,395<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">63,453<span></span>
</td>
<td class="nump">50,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(63,453)<span></span>
</td>
<td class="num">(50,304)<span></span>
</td>
<td class="num">$ (40,412)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax asset, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667535305672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_IncomeTaxesValuationAllowanceRollForward', window );"><strong>Changes in Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, beginning balance</a></td>
<td class="nump">$ 50,304<span></span>
</td>
<td class="nump">$ 40,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Additions during the period</a></td>
<td class="nump">13,149<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, ending balance</a></td>
<td class="nump">$ 63,453<span></span>
</td>
<td class="nump">$ 50,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_IncomeTaxesValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Valuation Allowance [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_IncomeTaxesValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667536302792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_OperatingLossCarryforwardsLimited', window );">Limited net operating loss carryforwards</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred liability for social security taxes, CARES Act</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">200,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforwards</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforwards</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_OperatingLossCarryforwardsLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Limited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_OperatingLossCarryforwardsLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_SocialSecurityTaxEmployerDeferralCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Social Security Tax, Employer, Deferral, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_SocialSecurityTaxEmployerDeferralCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532963512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Uncertain Income Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Uncertain income tax positions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 1,287<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year's tax positions</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 1,513<span></span>
</td>
<td class="nump">$ 1,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140667532960776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - SeaSpine - Joint development agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Reimbursement charges expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Outstanding liability to SeaSpine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_RelatedPartyTransactionTermOfAgreement', window );">Term of product royalty sales period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_RelatedPartyTransactionTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_RelatedPartyTransactionTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sibn_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sibn_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%,>_BA7UH94Z<BNW"I H4+52UZ+2;@_3'DQBB%4G9K8#W3[]CITT2RB7H/%
M;.><__D=Y_C2VW#Q)B-"%'J/62+[5J34ZMJV91"1&,L&7Y$$WBRXB+&"KEC:
M<B4(#HU3S&S/<5IVC&EB#7IF;"H&/9XJ1A,R%4BF<8S%[QO"^*9ON=;'P#-=
M1DH/V(/>"B_)C*C7U51 SRY40AJ31%*>($$6?6OH7H]<XV LOE&RD:4VTJG,
M.7_3G?NP;SF:B# 2*"V!X;$F(\*85@*.7[FH5<34CN7VA_JM21Z2F6-)1IQ]
MIZ&*^E;'0B%9X)2I9[ZY(WE"3:T7<";-/]IDMJVNA8)4*A[GSD 0TR1[XO=\
M(DH.[M4>!R]W\.HZ^+F#;Q+-R$Q:8ZSPH"?X!@EM#6JZ8>;&>$,V--&?<:8$
MO*7@IP:CI\?9T\/]>/@R&:.;X</P<31!L[O)Y&6&SJ=8D$1%1-$ LPOT!;W.
MQNC\[ *=(9J@EXBG$B>A[-D*2+2>'>11;[*HWIZH8Q(TD.]>(L_QG!WNH]KN
M;K?J;D/^Q21XQ21X1L_?HS=36!&H387X MW2!"<!Q0Q-N:2FUGX,YU()J+B?
M!X+Y13#?!+O:$VS(8.E !()@$:*0IW.U2!G4<\#31.V<S$RP;03UNEP/O);?
ML]?E&=MAXW<*FPKI54%Z=9!T"BN*"$%"!&48O%VB%19HC5E*T#E\_Y SAH5$
M*P+;0@2E<K&+/0O1*7$Y#<=QW"W\HV:5#)I%!LU3,D X51$7] \,Z P,M=R)
MG>FV2CQ-Q_RVN(_;5<!;!7CK)' J97H<NO4)9AOWD$4%M%V MD\"A9-"*M@4
M:+(\1ML^2GO(HD+;*6@[!VE'/(YA/?]'.7?JE?-1LPI^M\#OUL8_H9:[GZ;1
M=9R=U5S'LD+N.O_.&:<^>[URSA7+.+[7[/B>M\V]P])KNBV_X_A[N$OGHUN?
M^X3JSF7KP'^VW -OE\YY?<GZBL62)A(QL@!7I]&&W4AD]Y:LH_C*'/USKN B
M89H1W/6(T ;P?L&Y^NCHVT1Q>QS\!5!+ P04    " !I@&I2-5M =!,%   U
M$0  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(V8W4_C.!# _Q6KVH=%
MVI+8^4:E$I3N+1)01&'WX70/H7&;B,3NV2[L[E]_$R<D)7&R]T*;=&;\F\E\
M9)B]<?$B4TH5^EGD3)Y/4J7V9Y8E-RDM8GG*]Y3!+ULNBEC!I=A9<B]HG&BE
M(K>(;?M6$6=L,I_I>_=B/N,'E6>,W@LD#T41BU^7-.=OYQ,\>;_QD.U25=ZP
MYK-]O*-KJI[V]P*NK,9*DA64R8PS).CV?'*!SQ;$*16TQ/>,OLFC[ZATY9GS
ME_+B.CF?V"41S>E&E29B^'BE"YKGI27@^+<V.FG.+!6/O[];_ZJ=!V>>8TD7
M//^1)2H]GX03E-!M?,C5 W_[1FN'O-+>AN=2_T5OM:P]09N#5+RHE8&@R%CU
M&?^L W&D@/T!!5(KD*Z".Z#@U HZ<E9%IMVZBE4\GPG^AD0I#=;*+SHV6AN\
MR5CY&-=*P*\9Z*GY8G6W7MU<7UT\+J_0^A$^;I=WCVNT^HI6]\N'B\=K$$ 7
M=U=HL;J]?UA^6]ZMK[\OT<UJO493]+2^0I\_G:!/*&/H,>4'&;-$SBP%:.4!
MUJ;&N*PPR  &)NB6,Y5*M&0)33X:L,"GQC'R[M@E&;5X13>GR,%?$+&);0!:
M_&]U'(W@.$V<'6W/&;!WS3:\H&BM8D6A"A3Z^^)9*@%9_,^(=;>Q[FKK[H#U
M!_I*V8&:XEXI!EJQK.G7>> X83"S7H^#T9?R \?&C=0'*J^A\D:I%EPJQ+=H
MQWDBD>1Y8@*L;/A'1X>133I\?2$_B&PSGM_@^:-X?PDN)=H+OLV4"<SOG^FZ
MH=<A,TC9'AZ(7-"@!:/9LMI3$:N,[1#]"0U;4GDVDB5A8S4<=7@=YU0B*%!H
M(.*%EO9-?H<]CP+G.-B5WWTI/R3>@-]10QC](8\EC<4FU9 ))'7.]V6UF#"C
M'D#D>E&'LB\4D" R0V*[[9GV>.90!L\GUY1Q ETY*TNYG$?&SF?W(' 4VDX'
MU2!&["AT!V"/&CP>A7WD"E!Y+Z.,J+B/:CNVURU'@USD>WB(E;2L9)3UIJS(
MK>#%.R]G9D[2.W_JA)[?;6M&.=\^BOU'T+:;XS^U<T4%A?96I@!7*14P '6'
M_US']^0+8E2-E2UNNSL>;^_-:=49QHBXAB<7]>+1ER+>4-'BML_C\4;?\-6^
M&P'[+7SJXZ,14Q,:Q-S('2K9MM?C\6:_TL^HYM./Q@C9[^933/PNHT&*# "V
M'1\'HX!W\,J>0_H;L0)#4!R__W@-<D[H#J9[.SAP.#Z/=/0@]V!52,MW^%?:
MY'L)?3*:YVWWQ^/M_XG!)I)GOVF"=K"!U+;+5XAJ8,7/.462;@XB4]E !^MW
M_&EO*AB$W('>1=JA0,:'PB*-V0[F*W##=@7K X/W=R$HV_Q",!V8S'4_,T$3
MPX3 76B#T!0/U 5IIP,9GPZ+#\]T* %K(T$G 9UN IKDG- )P@',=C"0\<'P
M7AT(Q@*2:2R@AF%[RS;5FT*6'Q0DS6>(?<+S/!9'@B=&AZKCH@_!/.V^VPU(
M>0/>M-.#.*/>_-#+)4VF\2M,N1U%[% \ R\D.M14 =NM)I?H(,$KQ77E@8<&
MEUDO,#H*E;[9=:<_ R+;BW#0[<4F23< T;#[YFT=+: %%3N]ETO /C!5K6S-
MW6;WO] ;;^?^)3Y;5!M\:Z;ZA\)M+'89DRBG6S!IGP8P*$2UHU<7BN_UFOO,
M%2S-^FM*XX2*4@!^WW*NWB_* YK_E,S_ U!+ P04    " !I@&I2K6?2(+(&
M   :(   &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+U:;7.;.!#^*QK/
MS;2=J6LD\>9.DIG$+]?,M4FN3GMS'PG(,1- +A))<[_^5M@%@P1VTS1?8C#/
M2L_N2GIV38X>>'XG5HQ)]#U-,G$\6$FY?C\:B7#%TD"\XVN6P9,ES]- PFU^
M.Q+KG 51:90F(V)9[B@-XFQP<E1^=Y6?'/%")G'&KG(DBC0-\L<SEO"'XP$>
M_/CB<WR[DNJ+T<G1.KAE"R:_K*]RN!M5HT1QRC(1\PSE;'D\.,7OY]15!B7B
M:\P>Q,XU4J[<<'ZG;LZCXX&E&+&$A5(-$<#'/9NP)%$C 8]OVT$'U9S*</?Z
MQ^CSTGEPYB80;,*3?^)(KHX'_@!%;!D4B?S,'SZPK4..&B_DB2C_HH<MUAJ@
ML!"2IUMC8)#&V>8S^+X-Q(X!IAT&9&M #C6@6P/:,B!>AX&]-;!;!G3<8>!L
M#9SV#%U.NUN#,IFC3;#*2$\#&9P<Y?P!Y0H-HZF+,EVE-00XSM3*6L@<GL9@
M)T\FEQ>+RX_GT]/KV10MKN'CT^SB>H$NYVCRX?3BS]D"G5_ @\O)7Q\N/TYG
MGQ>OT.SO+^?7_Z(A^K*8HM=_O$%_H#A#URM>B""+Q-%( C$U_"C<DCC;D" =
M)*ZY#!*#V:3?;,+3%!;G0O+PSF ][;<^C:)8+>X@05=!' W!A4FPCLU,9GO&
M"L,B+9) L@A=RA7+$7"#G;Y26_">H?,LY"DSC#L_?-PI6\9A+)N#C"#=5<Y)
ME7-2CFIWC%H&;,63B.7B%6+?BE@^OD4W[#;.LCB[A9V:!%G(T&L(B5@%.1-O
M4""!0/@.4?P6$0O[IFQM9G7+6=6)=G]";-NQ/,<[&MT;^-**+WT6O@=P/-O,
MY.UP'%MX3"J"&T]T%&TBICJ"V.Z8>$W83(?9=-S$S'7,$#L>]CJB9E=1LTM#
MVA$U6',@-0+2"$$IK]ZH;=H,YJP,9L^:<JK9G-X<G0M1E$G@2Q1N]J50,Z%B
M#9?L.\O#6)1/-U_SM=I[XBW*0#W5M^4Z@\-/KE8LB7;7GBF-CK;4;-L>$[N5
M1R/,\WUS9-W*5_<E?37YYVIK MMCJ[4&7<V[!JCAFU?YYCW-MYQMCB')$4O7
M"7]D;/MD7>3A2BVT-6S#?8GS=,ZN;SNM?3/9"VLXYU?.^;_5.9-#OGX0$*M]
M6OCZR;@+:C@SKIP9_\(JO&="JK,1'D(J9!Z'RK\M((NEV).HR5C/@.6[%)M)
M8ZNN-ZS?2=M87%@:UXY=@'?*(MQ+\S.K,@]<BDP1 R8LR)/':HM'S0V^+Z3;
M*7=Y#GV?=G&MY1SWZ_E3N!KCJ MX%[=:NO$!VCU4M7^DT@T-D0@4 >/\5)O?
ML]W6F3[=AVH2K=42V[U$O]8K[^<#9^N;9>RU>?>#FK1KV<7]NKM3Q09AF!?P
M"1Z<7UU69UK(1<>VT=5QB-VVR.Q#-7G7$HK[-13:0FCZ,FAQ\IQEX2.2>9")
MI'MMZ&(WQ*U*:K8'U*1:*R+NE\0+4.TB@PHJB?^#>-Y"NXY>)UQ 50PG%O3C
M=TP&-PDH!@-O(!O,'&Y=TVR[[4 OILF_%CW<KWJ*OZ)K)*4KTY#Z=EO YOMQ
M37*UB.%^%3/7]BR+#FQ$QL:#5A<OXF"7^EU\22U?I%^^#N)[ ,<SHHN62RW+
M;Q5"6UA?*V(8B3@^)KBUN PX[72=&T"PA1S'[]CQI%94@E^@'R$[36Z_*G86
M&LN<IU#7W21Q",^6+(?4U<5YD0&3![6-(:%1+$)>9!(>JR%B(4J=#[*HLMR<
MK_NDG^C2ZKJ8.ET'*:D%EO0+[(NZ:5S(>O^*J>UBM[V2=5Q;:X@N[:VAFD&J
MQ9WTB_L+=Z=$EWI*J&?A=DCVXIK^UE4!>=%NW.BC8VA17>ULTJN'!JKI7UT]
MD"=VX,_4I1)#:TT]ZK7;U/VXIH-US4%^;QMN=,K3,S;&3CMCAM9[%]5TJ"Y"
MR!-;[^?I5HE>GU#;]KR.XH_4]0GYK5VV,0]Z==*A K0N2^@!9<F!;1;5)1YC
M[:?+Z5Y8DVI=!]#^SOI7&BVJ=] >;O/NQ31)U\4$[2\F?K9=H;K>8ZU=V0-J
M4MWYL;R_('BF=H7J6CQT- _Z04T/:K6F_6K=U[!073*'-G7;W?9\/ZY)KI96
MVB^MO]BP$,MT?%%=)BG4\)20KI.AEDK:+Y5/:%B,',^HX3=I=TS;DC\QX+27
M)SK$MGR,:7MYZ3BG_1O_W  :$@H'53O5HYVWI.JM^:<@OXVAS$W8$BRM=QXD
M(=^\B-[<2+XN7YS><"EY6EZN6 "!5 !XON1<_KA1[V*K?P<X^1]02P,$%
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M<S5?*@K9_D5/O6PP0>E6-F+3#P8$F[SL_B?/O2$.!N#0,8#T \AX ',,H/T
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M-2'/"_!^[5S<#7B#X;/I^&]02P,$%     @ :8!J4I>8DGD"*@  HX4  !@
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ME\NFKSM7KXM/3>66SOI7CSO8#]]ZO)2UW_#:YQ-KGYT7OS1UM_'%N[JT9;[
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M'/  $1NX<\7@FQ8(L\V$ 8'A.KRYA^X18*RH&A F[5U4!% ]=/ P2#"'MAT
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M .&B %,(B8)LO4;I #LN5("2H\1JEQ\Q;9UI3M!-('"#_L0_/32/T!)" R7
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ME]SZ&IUKXB3[? (TS5X'_S%J9$+AD=HY%>F6N['DR[=".%6^+J>FH1TX2)0
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MHD(;X/Z6<W40=(#Q3;;\!U!+ P04    " !I@&I2WCYFK34$  !9"@  &0
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M>HKX;DEO/S2\@.8+K=U^P!L<7I.KOP%02P,$%     @ :8!J4L\]&O?Z P
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M:V> \ZU2]K1P%XS_0]9_ U!+ P04    " !I@&I2$;#7J,L*  #L&@  &0
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M$[@N3H&/D;@@-)Q,132)'0_X%7)DAP17PR-SA_^)1^21&_D"8>],O5!$C"X
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M+B<_M[Z0K=![1-B@PIH[N!),+1-'T-X@*0>830^3WP&3Y7"IE6LL7*@*JV.
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MVO@_J,'0=2[KIC7,O0A2IX+F.3!10,&KUF !@LQ4UDQ#9K0U<P5_(%. -I=
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M "[BR*=%6NLZ68UM.]Y2]7XA(;/8SUYW#; <GG>7_UXWR')3M>)/P.&YW"!
M"3RO^$T!TKKD03A?QK"T8Z<"@@@/= T=:V\GU,AR4-[+8,<RABR_6SR80/%(
MUO ]$*R>"P2J=?[]>^S8%*5'CNSS:::*?H;?U,\0:/%MH,5!@O_3HV:7>=.0
M*S9RUJ@M/D(&ZZ&C,A/'"7EU$6-HI8,&P+]Y3R P% -? PZC+_?Y0;ZI2'XW
M:$9$''^&UFM3WY+?)_;)%!U[$TB$-*94B]-M0:3"?K6>-/WVL8O2P&$D5CU#
MJRCX#A)Z^<9-$/JJS)VS:\N<\6=4!+)S5!WXH[<O(FA!SVOR9K4]Q$8)J1<\
M[4JWPCN<AK"/5O@<50HVG_+2U3%Z7#RC-QF"F\R/(WXT/%WL%A$QT,-0=E-W
MH%7AL6%W!*(53@]Q0Y(B""09V06]D!XY<3?*%GAQ,N1=LV1 #TI\$;81!IDQ
M@W3%+='Q;+7O6K*D1?7$M9G5MK)_=*Q_D MG9W+R?X;I3[,W 13+CK);2Q.L
M@"Q!16/M6;V5PH,(",;/T@AI\Q2.?.H5KX>4S-RR^P@E+&(Q]PL\4$ #[>O"
MH#D5"6$8MKU!+[G0[CX'RWEE ;/(VBX<,;M9C$<$7IZ>\^[+:MF[C ##X1"(
M(]744\J1JWE@:EDSZG.V(B31]D3+]6L33PU9&*06D2B$A9*&BZPZFA#..;L
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M)G!<NJ0\6TVWG/3LXKE/!J@*GOE:\HJ73%JX*4O52<OE&AZ5X"5' Q>_L:5
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M+3,&K0EA4_.R!J;="50^S6;J$]H1Q1Z#JJAZ\0!*"M]_-T[B^"?(84NI-?#
MRIH@Z*]!?RMYWVG*;>?\D63%7]W:0+&[/LYN")+FR/3(X_GJY-N7= H9/8\P
MS1+ZS<+K.*6();'9]3V=3% 6U@3,0!Q>3Q+ZCO/L/V@IX@SRR1A^16KGM1(K
MX V9>4%W:R ?I9!-BE,,)&D*,;W;29B-,RC"(IN0)4/)H";2-9WPJ1R>@!\]
MI,\:I2W_W!]<9.$D+R[A(@V+27[I@\L35PLI761'2R$Z:/(-ZK4?909\W^K[
M_7 Z3,N;?DA\$>]'[0/3:RX-"*Q(=7154 7H?GSU&ZM:/S*6RM( \LN:)CYJ
M)T#WE5)VOW$.AO\0BW\ 4$L#!!0    ( &F :E(X)=BXD ,  -P(   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;+U6W8^;1A#_5T:TJLX2-=\&KK8E
MGR])(R72*;Y+'ZH^K&%LT %+=I=SKG]]9P%S3K#]V!>8F9WYS><RS ]</,L,
M4<'WLJCDPLB4JF\M2R89EDQ.>8T5G>RX*)DB5NPM60MD:6M4%I9KVS.K9'EE
M+.>M[$$LY[Q115[A@P#9E"43KW=8\,/"<(RCX$N^SY066,MYS?:X0?54/PCB
MK $ES4NL9,XK$+A;&"OG]L[7^JW"UQP/\H0&G<F6\V?-?$P7AJT#P@(3I1$8
MO5YPC46A@2B,;SVF,;C4AJ?T$?U]FSOELF42U[SX*T]5MC B U+<L:907_CA
M3^SS"31>P@O9/N'0Z0;D,6FDXF5O3'R95]V;?>_K<&(0V1<,W-[ ;>/N'+51
MWC/%EG/!#R"T-J%IHDVUM:;@\DHW9:,$G>9DIY:?F7A&Q;8%P@:31N0J1PDW
MCUHB)W-+D0^M:24]WEV'YU[ <USXS"N527A7I9C^"&!1<$.$[C'"._<JXCTF
M4_ <$US;M:_@>4/&7HOG7<#[6+V@5#172IIPCUL%K$KAW;<F5Z^G-?A[M95*
MT-3\<\6I/SCU6Z?^!:<;NDQI0T7F.SA;\G.5O@JI;^NMK%F""X.NHT3Q@L;R
M,4/HH+?ZOO5W+?^7\E%T5+ZYEH/K6ZI"@N46Q5!F6)5<*#)+8<VE@J>*+GS1
M\A_HHLM3P2<N)<&O]GN!>Z80WK-<P%=6- @W>45^>2.IQ'*B)P-?^R!@UY ,
M?@4_,&,_(N*W7R+7<?_X@>H/U[PL420Y*Z!F-07JF+YM#WK'=R==,YD!4C]?
M6*&[#'YH>@3RLW8O?IINIJ H'=F(UY.R0.B;81B##S?AI&-F%(BHN=!9;KD.
M/Z+P;*TRFVC:.Q-J$)N.%XZ\]^)-1H7^7:$H(7\;3'!\UXR"&41PXWB3GG7@
MD2O"/=M%*I83VZ9K^T3I<K:&G=")XY][[,3_9X\]TYY=:G%W-BJ;:_IQ,*I:
M)QUU.#"#F3<N<2N]V-]9:-I44X^ZYTY:+O)&#8Y-.PS [72(B<,S'3:=V3C4
M3GJAOY%CNK$# ?77GVC.\X.1;]()QV/;23_Q:G]F;*Y87)^=**)Q=(D(VMGQ
M)[TLFL&YSY]ULG&H&/MVKTI(>%.I;OD,TF%UK[J-]:;>[7WZ'.[UN!6X(U-[
M&@8&B&Z7=HSB=;N_MES1-FS)C'X_4&@%.M]QKHZ,=C#\T"S_ U!+ P04
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M &2<P*V2MC'P7E98_1,@(GX3R61/\BHYBO@.RS-(XQ"263([@I=.3J<>+SV
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MC%P6.K[O=[$.!N>1Z9HXQYP3@DRRAKE0@K)&<K[5+SQOAC_W:2?=2=,T@*V
M1:X3N"'[2 I-_DM7WZP7HF_62[_KSJW.MDB[*NJ5735N^1SW\[D^I-L-U):W
M,O7]&,?)UH$N9O>J?I[9;<M#Z#B'-A>%[!ML)X\^&'IV)0($LM\>P!7U+"4-
MH(:6/\#<4UIE96G<6_"\R7V#,JCJ.B'(<Y*"D+:0TDIN^S[8GHET?X/%,7E?
M4T.;5F4/AO,6P_F+>])G6)$:E[3=G?%2J-K;+A![=?><@?:1>GHRK5H_=EKS
M9NO'*T%$$>-VJ$P[:OK6JW;-I_@V6*!/+EJH&[W&'V#C.7X\LT\W#DTF<0]6
M"%92SHT7Z*I)A>)%;S(2OZ@GX?G^%*:#75/P\#LCD1>TQKIX,-FY[Q4D5_96
MBR(QQX_ZZM>^;2_.)_5]\7%Y?>O^Q"5"Q8V!EA#%AHZCKZQOLO5$BXV]/2Z$
MQEW4#M>X_),T"_!]*83>3HR!]M\)Q_\"4$L#!!0    ( &F :E*/6L4ZF00
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M";MF?Q9+KTXT3_'Y'7Q?[KY;6/R:Q5<L7@?+JECS.(JE!UZ %4Y4HJX$#1_
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MIJ-3(8IIIE@HOK(#P9PK/5[8VZ6> $&8 _KY@G.U6QB":J8<_ =02P,$%
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MIXDMDZJ'H'IC9.D'CP=I[!CCEX4='$$Y _L^E])L-XZ@&44GOP%02P,$%
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MA6"'YD7"/1."%<W'/4TWE-<&\O<M8^+YHGXWT;V+6OX/4$L#!!0    ( &F
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M5VEZ9A(W::AL:RKH#!6(P"UG*I/@,TM)^A+ U76UQ:'GXK9H%G%/DBO@PX\
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M3O$-J+8MMQ,C&]?9UM)@GW3#"O]DH&P [F^D-"\3VRS[?V/^#U!+ P04
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MJCM+]6!DX0[E*VGPB.^:6[SG@;(#\/U:2O/\8,_YS<UQ]B]02P,$%     @
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M+.UG K0+L/L;I?!SXEI7^^')/@!02P,$%     @ :8!J4BETR+K1 @  $0@
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M)&%E[H\[S%_CYI<LW9IWMOYF;W/_^+'Y"-*URW*PRW)0^0M[_=UJ\K906I:
M$4W^?@<WD+>:Y>H?Q'VX<Q]6[J,>]U,I4L9FBLRER $$T-B<%[1(X;GJBMW&
MV[CR9EAY=Q;%P?'8\R!4=\THM6^T=SQ2&NV41JC2:Y:*1<$K"HHY*0N:"ZGY
MOVRVD3WC*A4E1(@6,\*5*J$3C*1":47 I+J'W6OH5\G5TL2RJW\;#4E#MNF;
MUZ,]WFF/'5%F*_I0Y0\F(IKIATIEQHH9DV3.V/=(C%L2CQ")R4YB@DI\#5G/
MC)2N)I-VDT=1.^?)OCD?[T2-45&7;,ZDA QGG-[RC$/<8 HG2J0<Q"J6EM)<
MT_2>J1?D8G)]=4,F:6?4QJTN^!X2MJ.=PB-4X21-9=D0R)E"1N7QSNOQ(0:]
M[]FIP_M5@:U;:D8V1@+K-Z8W']7X02]A<&2B6+S43.9[AMBW8/4/0E;?HM7'
MV?J406[C% VRA:J/4W4ZG9)W@A:][3_V:X'GQP<)KL65C_/J\<1ENI%!-SJ+
MC3:6XA +GJ63C^/I>D=UF) 0"1>UG_TE6/SX.'\^FI%A$DC^(],EA0K_"\PD
MNZM8J"V,_(/0*+ T"G :?6<1<E6[>U2%>!C- PN= (=.U=<5DUS,2)W<%X07
M ""F(,U%]E#_VJD+]QW&)!>%7F+X"AIU8>"8L.\!+3MI4/U#[0_:4I#<5?%?
M.?SY_C#V?L>D6? %./BNYG-6K5._D3<#X!4+ ES?AA@3_-K1BA\,HV\%;^H0
MMV&(]]3B,\#QZ1A^YJHM_::;TN\%+ ]>1D?DO?-9L+0-#D+;P-(VP&F[&1;M
M*K9.'UVXGCW<?3#T\(18) <XDG\L(='QR\3;(R$6R\'101)BF1P<'S8AN'O?
MD9#0LCW$V=X,_8W(J-Q\F<#RYV9; 4T6DK'V<N=QBQ;AH7^0%;,E;XB3\F?F
MB'.'[S!QSQ%A8W&/D^Y[YXASA[_C-G$?*[/@#'%P3A:0\X71LX(Y(>4KJ(AA
M05]V+GG/:V?[3_BA16>(+\T_[;^/T*DL;BG#5N.A)6ZX!W%SJNLU@AE%SWA1
M/QS=N<,= N#<3Y;E;(AS=I)E8DUO,]:$$"125N-8F0% :/>PKM6V2V(?3ZF%
M;XC7Q,W=%M##RQR4D0<&[!&%:P#@KD,7%RW 0YRPB$B]%@Z1+G@',28RLO".
M7(5YO\@E))? <C:#02QQO8Y6/$?A&5GT1WB%C6UBG=>V'4]<S\:DG1 B5RE>
M-TNH:L[ L"JDO9QSA QO,7"%S$X1T2^IU1VM^-XPP04WMH'QF>/M%C(0R<>2
M*_Q0Q4BYJG93JT,MDX2<%SPOS0[2UY+/#$]3<0<%DS,)N)+8 8/(3D(1/@E]
M5Y$$]WRFDE?P_;"J]L,_% S382>=*#E$Z139:2/"IXUSJK@BFZ-7L^5]M^V(
MNS1Q>/:&88@FPTX?T?Y;*OLDHPK:Q?:!^BBA7H!!XTB)G2>B@VR^Q);QL6LK
M&!K8C8?M4$FI6I);FIGBIRL;<7L+QH\QFL86XC$.\:D4LS*%,<U 4\FJF48M
M13:K=D_[QW*G3+]]GH/+M-"/<00_V6,"O[W?= K+IP5Z'![D@;$ CAU;QD^9
MGX[S-CP_C2.WIV4JFA]Z[\J/96Q\$,;&EK$Q3L(GS4_OL5EO@BQGXU_!V8]K
M@47-<C8^"&<3R]GD$)Q-VJ=K8^SD)[&837#,/E'XS3( BX_E:7*0X[C$@C%Q
M'<?]4 +"5@+Z0F\)FNR_:_R3H=]K\D@L-).#;"0GC;<,G,=V3P:GI'VPUP>G
M4>,U*_.>WGLJ%[Q0)&-SL/6&8PB+W+SZMOFBQ:IZ\^I6:"WRZN,2:E8FS0WP
M^UP(O?UB7N;:O8!X]C]02P,$%     @ :8!J4A'<.))] @  O 8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&ULC97;3N,P$(9?911Q =)"3CV!VDC0
M"NU*BU1QV+U8[86;3AJ+Q,[:#H6W9^R$J*NFE)O$IW^^F7%F,MU*]:QS1 .O
M92'TS,N-J:Y\7Z<YEDQ?R H%[612E<S05&U\72ED:R<J"S\*@I%?,BZ\9.K6
MEBJ9RMH47.!2@:[+DJFW&RSD=N:%WL?"/=_DQB[XR;1B&WQ \U0M%<W\SLJ:
MER@TEP(49C/O.KR:3^QY=^ 7QZW>&8.-9"7ELYW\6,^\P#J$!:;&6F#T>L$Y
M%H4U1&[\:VUZ'=(*=\<?UF]=[!3+BFF<R^(W7YM\YDT\6&/&ZL+<R^UW;.,9
M6GNI++1[PK8]&WB0UMK(LA63!R47S9N]MGG8$82# X*H%41?%<2M(':!-IZY
ML!;,L&2JY!:4/4W6[,#EQJDI&B[L+3X81;N<=":YD8H47&PTG,.U$#4KX+8V
MM4*XXX*7=0E+Q47**]I8LC>Z0*/A=(&&\4*?D>CI80&G)V=P ES 8RYKS<1:
M3WU#WEF&G[:>W#2>1 <\66!Z 7'X#:(@"GKD\R_+P\O_Y3Y%V"4FZA(3.7OQ
M 7MWC)+ #4<-,H.?4FS.#:H2%K@R\.=ZI8VB3_#O)Z2X(\6.-#A HGC#OG0U
MJK%3V6)\22@M+SV@00<:' -%?:!&-3H.&G:@X3%0W <:[H'"<#0:]\-&'6QT
M##;H@XWV8-39@@.1C3O8^!ALV <;[\$NXSCN9TTZUN13UJ,T5'-55WU45I!Q
M0:,,$:JV%ON\F>Q].8-P-_2FGGI.]23(W^DMMJ_?,;7A0D.!&>F"BS%=JFIZ
M93,QLG+M9B4--2\WS.GW@LH>H/U,2O,QL1VL^V$E[U!+ P04    " !I@&I2
MD95#!$L$   G%P  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R]F&]O
MFSH4QK^*Q9VF5MH-V"8D[":1ME33*MT_U;)N+Z;[PDV<!!5PKNTTV[>_-E",
M(85&$7G38/*<X^?8)[^")P?&'\664@E^)G$JILY6RMU[UQ7++4V(&+ =3=4W
M:\83(M60;URQXY2LLJ D=I'G!6Y"HM293;)[=WPV87L91RF]XT#LDX3P7Q]I
MS Y3!SK/-[Y$FZW4-]S99$<V=$'E_>Z.JY%;9EE%"4U%Q%+ Z7KJ?(#OYWBH
M S+%MX@>1.4:Z%(>&'O4@]O5U/&T(QK3I=0IB/IXHG,:QSJ3\O%?D=0IY]2!
MU>OG[)^RXE4Q#T30.8N_1RNYG3IC!ZSHFNQC^84=/M.BH,S@DL4B^PL.A=9S
MP'(O)$N*8.4@B=+\D_PL%J(2 /T7 E 1@%X;@(L G!6:.\O*NB&2S":<'0#7
M:I5-7V1KDT6K:J)4;^-"<O5MI.+D[#OAG*12@-_!K1![N@(D78%_]E)(=1&E
M&W!U0R6)8G&M)'.6)&KM%Y(M']7P?G$#KMY<@S? !6)+.!4@2L%]&DGQ3MU4
MUU^W;"]4(C%QI7*KYW27A;./N3/T@K,;NAP #-\!Y"'O2/C\U>$PM,-=M4;E
M0J%RH5"6S^]:J&*9L O5;P6.6E+C,C7.4N,74L]C(@1@:U#, 1@'V>\)_/A3
M2<&MI(GXMV4BOYS(;ZWA[WWR0/G;WV#@_:&F6^1;=I^N*(]_Z;TNB[Q2>Y?O
MZ/6QG<NG";)I-"B>9A"/QQ/WJ;H_'2*K@F%9P;"U@CL>+6E>P([RO(+,[(K%
M,>$"Z+N9\:.^\^1AQ=)P$/HUWQTBRW=0^@Y:?7\B4;'NWTB\I\>\Y0E&U6EK
MQMH4EJM1Z6IT4D^/7(1T4^.67AN7N<?]-G583A1>IJG#1K]B%(YQ;1.Z5%8-
MT#,8]OIL[")[M6G# :Q9[Q#9SBO_0."YK5UDJ'8N1*CNKEUDNS/4AJ=A&RIJ
M![K'_9;6@X;<L&=T0\-N>"%XPR:8@V#LU;>C0V578?@->P4X;,(9!@-_5#??
M);/=&XK#LS$.FY3VP[J]5HWMS; <G@9SZ*DVUYT^;&L_@W/8,\^A 3J\$-%A
M$]8^#(:-5N^2V0^,ANFH5Z:C)JZ/]7JGS'9ON([.YCIJ(AN'0=U?N\AV5WD:
M/YGK85>S(X-UU#/6D<$ZNA#641/8:#CRZNSIE-EU&+"C7L&.7@?V3IGMWH =
MG0UVU(0V\NOO#ATBVYU!.SH1[:AX4 _:6M"@'?6,=F30CBZ$=M1D=CB"]6?*
M+I7]NF[ CGL%.SY";&_@U=\T.F6V>P-V?#;8<9/9?OUMM%UC>S-8Q^U8MPZ8
MGGNA[8BE<L;2,]*Q03J^$-+QD2,4.&Z^.G7K[$H,U'$[U%_3*L-&&XR#^IMG
MARAWYU9.,?41\E^$;Z)4@)BN590W&*DD/#^5S0>2[;*#S0<F)4NRRRTE:I6U
M0'V_9DP^#_19:7DV/OL?4$L#!!0    ( &F :E)=?VUW!@,  *L*   9
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M0DG&ZG6B>D?0C5IJ>:%"T$)MK@E.":L,Y/DEI6*_4UV@7:V;_0-02P,$%
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M+4$ TK*V'!]$X8MI]KUJ+-[Y8]E+ER#1^# H<ICZK9QZH7^4)XG(:<MG1LY
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MIW)S0\*(4'$"_WZ5Y^RP(P)42X[F_P)02P,$%     @ :8!J4G4=!#68 P
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M38*K #)<L+4P]W+[%]:"+BU?*H5V_V%;SXT"2-?:R+P&DP4Y+ZI?]EP[8@]
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M9IA0Q]\-J5>O:8"[[2?VK]8\FIDR!6.1_>*)3OM>UR,)S-@BT[=B^0TVAJS
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M*JMRM^IH4=J*<2HTUI^VF>(G D@S 9_/A-!/';- _=$Q^ =02P,$%     @
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M@F$4!EYX15E\4KGP])=J"XB^@#S]H^\$2'%]K6A:D9>ZJD^ETA]?X,]*X[%
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M/ZS/]3KCN,IHRL-V$7J^[\[L[;ZYW:C <WROC?J$&[2XP2#N(RB@,LZJ=93
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ML?X)?3TCRU<(IMP3K?O8P$-%J[2H>[!14%/>O?%;[\,6($P/ *(>$.T"D@.
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M+AY@4U[.Y<3I57&_S;3#V[(8+O&#!HS?@._G6KOGB;\RZT^DT5]02P,$%
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M^0^H^#X)Q-H@^N@*7A8SN'AW.0Z)Q;D48=8*N6^$)">$/.!R ,GH/211$O7
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MD-"*WW2]'NQ"M+UZ^[N=GK]H$O9W[N@O4$L#!!0    ( &F :E*7BKL<P
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M\W^2ZN%\;[D^_K+\/HD2+BXXI]N*^O074$L#!!0    ( &F :E+A[%X1] $
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M15:#(JM!D=6@R&K^4]9[Y]9_'#\^R\XV_5L^&_^:MW@!4$L! A0#%     @
M:8!J4@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !I@&I2TTSP4NT    K @  $0
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M965T-"YX;6Q02P$"% ,4    " !I@&I2K6?2(+(&   :(   &
M    @(&A'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M:8!J4HXSAE7E!P  L"$  !@              ("!B20  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &F :E)%CDM\?04  $(-   8
M          " @:0L  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !I@&I2EYB2>0(J  "CA0  &               @(%7,@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ :8!J4M_3R1/, P  GPD
M !@              ("!CUP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( &F :E+>/F:M-00  %D*   9              " @9%@  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ :8!J4L\]&O?Z
M P  DP@  !D              ("!_60  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !I@&I2$;#7J,L*  #L&@  &0
M@($N:0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &F
M:E(HHBM#P0P  &HB   9              " @3!T  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ :8!J4JW8WT9@ P  2P<  !D
M         ("!*($  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !I@&I2J)[)Q \#  #C!@  &0              @(&_A   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &F :E*I==QNI P  "HE
M   9              " @06(  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ :8!J4IC79!!+ P  D0<  !D              ("!X)0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !I@&I2"!Y4
M_ZL#  # "   &0              @(%BF   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( &F :E+XS$L/_ H  %@>   9
M  " @42<  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M:8!J4H"8W@LD!   *@D  !D              ("!=Z<  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !I@&I2U;=IW"LL  "9EP  &0
M            @('2JP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( &F :E)NFJ%.N ,  $\(   9              " @338  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ :8!J4C@EV+B0 P
MW @  !D              ("!(]P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !I@&I2;#/Y.%8#   6"   &0              @('J
MWP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &F :E)C
M,$BTR@,  +T(   9              " @7?C  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ :8!J4D[L(Q20 @  >04  !D
M     ("!>.<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F :E(7O_O[Q04  %H0   9              "
M@2C\  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ :8!J
M4H]:Q3J9!   ;10  !D              ("!) (! 'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !I@&I2>G)SG1T#  !?"@  &0
M        @('T!@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( &F :E+I5EB*O@(  !0'   9              " @4@* 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ :8!J4AJ<9=G. @  E@H
M !D              ("!/0T! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !I@&I2PY!?'4H"  ! !0  &0              @(%"$ $
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &F :E+$FN:K
M50(  % &   9              " @<,2 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ :8!J4CVXK[PE @  ) 4  !D
M ("!3Q4! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !I
M@&I2F/KD%$<"   Y!0  &0              @(&K%P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &F :E)ZY4Q8* 4  )<:   9
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M970T-"YX;6Q02P$"% ,4    " !I@&I2P+^'#5T"  "$!@  &0
M    @(%<+P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M &F :E(I=,BZT0(  !$(   9              " @? Q 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ :8!J4E;/+0)'!P  C"@  !D
M             ("!^#0! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " !I@&I2$=PXDGT"  "\!@  &0              @(%V/ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &F :E*1E4,$2P0
M "<7   9              " @2H_ 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ :8!J4EU_;7<& P  JPH  !D              ("!
MK$,! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !I@&I2
M<Y%8?_<'   **P  &0              @('I1@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &F :E+MWOS9S@0  +D3   9
M      " @1=/ 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ :8!J4@"@4J;A!0  ?B0  !D              ("!'%0! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !I@&I2=1T$-9@#  #*#0
M&0              @($T6@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( &F :E*]2.:H>@,  .@+   9              " @0-> 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :8!J4CR^C9L[
M P  @ P  !D              ("!M&$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " !I@&I2ZF$-H"X#  #<"P  &0
M@($F90$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &F
M:E*AW ZAD0(  (0&   9              " @8MH 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ :8!J4O U0*C1 @  #@<  !D
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M=#8S+GAM;%!+ 0(4 Q0    ( &F :E(."K.Y-@,  .()   9
M  " @2Q[ 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
M:8!J4A'1+SJ& @  DP8  !D              ("!F7X! 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    " !I@&I2O7J"Q.8"   N"0  &0
M            @(%6@0$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    ( &F :E(%6B<=G (  *(&   9              " @7.$ 0!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ :8!J4C-17O-@ @
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M2P$"% ,4    " !I@&I2%MUK%"8"  !C*   &@              @ &ZD@$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !I@&I2X>Q>
M$?0!  "B)P  $P              @ $8E0$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     3 !, ,L4   ]EP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>437</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Company and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/TheCompanyandNatureofBusiness</Role>
      <ShortName>The Company and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Common and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommonandPreferredStock</Role>
      <ShortName>Common and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareofCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2161114 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://si-bone.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/MarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/FairValueMeasurement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/BalanceSheetComponents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/CommitmentsandContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/Borrowings</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/Warrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2349309 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareofCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/NetLossPerShareofCommonStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Company and Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/TheCompanyandNatureofBusinessDetails</Role>
      <ShortName>The Company and Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/TheCompanyandNatureofBusiness</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Warranty Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Warranty Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Advertising Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Balance Sheet Components - Accrued Liabilities and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Borrowings - Summary of Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails</Role>
      <ShortName>Borrowings - Summary of Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Borrowings - Annual Future Minimum Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails</Role>
      <ShortName>Borrowings - Annual Future Minimum Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Warrants - Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/WarrantsIssuedandOutstandingDetails</Role>
      <ShortName>Warrants - Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Common and Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommonandPreferredStockNarrativeDetails</Role>
      <ShortName>Common and Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails</Role>
      <ShortName>Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Valuation Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Income Taxes - Components of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Changes in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Income Taxes - Uncertain Income Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Uncertain Income Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sibn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/RelatedPartyTransactions</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sibn-20201231.htm">sibn-20201231.htm</File>
    <File>exh1016rmscompany-addendum.htm</File>
    <File>exh10222020-12proposedrevi.htm</File>
    <File>exhibit1024severancebenefi.htm</File>
    <File>sibn-20201231.xsd</File>
    <File>sibn-20201231_cal.xml</File>
    <File>sibn-20201231_def.xml</File>
    <File>sibn-20201231_lab.xml</File>
    <File>sibn-20201231_pre.xml</File>
    <File>sibn-ex211_listxofxsubsidi.htm</File>
    <File>sibn-ex231_pwcxconsent.htm</File>
    <File>sibn-ex311_12312010xk.htm</File>
    <File>sibn-ex312_12312010xk.htm</File>
    <File>sibn-ex321_12312010xk.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sibn-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sibn-20201231.htm": {
   "axisCustom": 2,
   "axisStandard": 26,
   "contextCount": 217,
   "dts": {
    "calculationLink": {
     "local": [
      "sibn-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sibn-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sibn-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sibn-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sibn-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sibn-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 592,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://si-bone.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 8
   },
   "keyCustom": 55,
   "keyStandard": 382,
   "memberCustom": 38,
   "memberStandard": 37,
   "nsprefix": "sibn",
   "nsuri": "http://si-bone.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://si-bone.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Fair Value Measurement",
     "role": "http://si-bone.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - Balance Sheet Components",
     "role": "http://si-bone.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Commitments and Contingencies",
     "role": "http://si-bone.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Borrowings",
     "role": "http://si-bone.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Warrants",
     "role": "http://si-bone.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Common and Preferred Stock",
     "role": "http://si-bone.com/role/CommonandPreferredStock",
     "shortName": "Common and Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Stock-Based Compensation",
     "role": "http://si-bone.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Employee Benefit Plan",
     "role": "http://si-bone.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Net Loss Per Share of Common Stock",
     "role": "http://si-bone.com/role/NetLossPerShareofCommonStock",
     "shortName": "Net Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Income Taxes",
     "role": "http://si-bone.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161114 - Disclosure - Related Party Transactions",
     "role": "http://si-bone.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://si-bone.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://si-bone.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://si-bone.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://si-bone.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Borrowings (Tables)",
     "role": "http://si-bone.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Warrants (Tables)",
     "role": "http://si-bone.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://si-bone.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349309 - Disclosure - Net Loss Per Share of Common Stock (Tables)",
     "role": "http://si-bone.com/role/NetLossPerShareofCommonStockTables",
     "shortName": "Net Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Income Taxes (Tables)",
     "role": "http://si-bone.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ifd2d90a648464b458060488f94c81ad8_D20181001-20181031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Company and Nature of Business (Details)",
     "role": "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails",
     "shortName": "The Company and Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ifd2d90a648464b458060488f94c81ad8_D20181001-20181031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "icbc273f09c6840ae989c360d9b4c07d1_D20190101-20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails",
     "shortName": "Summary of Significant Accounting Policies - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id046e7c696d34711b1333b15ed30b43c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id046e7c696d34711b1333b15ed30b43c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sibn:RevenueRecognitionStandardPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i1d2353dae8ad435392f4c1910cbd24e9_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sibn:RevenueRecognitionStandardPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sibn:StandardProductWarrantyTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Warranty Program (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails",
     "shortName": "Summary of Significant Accounting Policies - Warranty Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sibn:StandardProductWarrantyTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenditures (Details)",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails",
     "shortName": "Summary of Significant Accounting Policies - Advertising Expenditures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Marketable Securities (Details)",
     "role": "http://si-bone.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i01d4c9f2c6ba40f3828a4aa2b86a45a6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i01d4c9f2c6ba40f3828a4aa2b86a45a6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)",
     "role": "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Balance Sheet Components - Accrued Liabilities and Other (Details)",
     "role": "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails",
     "shortName": "Balance Sheet Components - Accrued Liabilities and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)",
     "role": "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Borrowings - Summary of Borrowings (Details)",
     "role": "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails",
     "shortName": "Borrowings - Summary of Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://si-bone.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sibn:WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Borrowings - Annual Future Minimum Principal Payments (Details)",
     "role": "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails",
     "shortName": "Borrowings - Annual Future Minimum Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ia711fb7cbd244135958a45b84e252b9e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Warrants - Issued and Outstanding (Details)",
     "role": "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails",
     "shortName": "Warrants - Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ia711fb7cbd244135958a45b84e252b9e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ie66d822de1dc49998b0d0dbd86b96408_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ie66d822de1dc49998b0d0dbd86b96408_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Common and Preferred Stock - Narrative (Details)",
     "role": "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails",
     "shortName": "Common and Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ic35d9503efb0484a818b49ffdb765d03_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ida53b01638da4d37aab2d0e74319d0d8_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails",
     "shortName": "Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Valuation Assumptions for Stock Options (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions for Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "iabe7e4f5c282479c9dd4b63577d53724_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i0283a6f15aee4e39bd5b62b008d5658f_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ia1ad172a765a4e7eb9caa3d8c5f8e870_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i410806cbbdc746209446c410c6341047_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "if2a14c1464114e769cf73dfd2e130983_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://si-bone.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "if2a14c1464114e769cf73dfd2e130983_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)",
     "role": "http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)",
     "role": "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Income Taxes - Components of Deferred Income Taxes (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ic35d9503efb0484a818b49ffdb765d03_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
     "shortName": "Income Taxes - Changes in Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sibn:OperatingLossCarryforwardsLimited",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i11ebde2211b84b37a9a25ed29b658cb1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sibn:OperatingLossCarryforwardsLimited",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ic35d9503efb0484a818b49ffdb765d03_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Income Taxes - Uncertain Income Tax Positions (Details)",
     "role": "http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails",
     "shortName": "Income Taxes - Uncertain Income Tax Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "ida53b01638da4d37aab2d0e74319d0d8_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i8cd127df2c1c4983bc79d5cb10d32b12_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Related Party Transactions (Details)",
     "role": "http://si-bone.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "i8cd127df2c1c4983bc79d5cb10d32b12_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Company and Nature of Business",
     "role": "http://si-bone.com/role/TheCompanyandNatureofBusiness",
     "shortName": "The Company and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://si-bone.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Marketable Securities",
     "role": "http://si-bone.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sibn-20201231.htm",
      "contextRef": "id0e4b4bdf79a4069b6056f2ce68fe2a3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sibn_A2018EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2018 Employee Stock Purchase Plan [Member]",
        "label": "A2018 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 ESPP"
       }
      }
     },
     "localname": "A2018EmployeeStockPurchasePlanMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_A2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2018 Equity Incentive Plan [Member]",
        "label": "A2018 Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2018EquityIncentivePlanMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Share-based Compensation, Vesting Of Early Exercised Stock Options",
        "label": "Adjustments To Additional Paid In Capital, Share-Based Compensation, Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AllocatedPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocated Public Offering Costs",
        "label": "Allocated Public Offering Costs",
        "terseLabel": "Allocated public offering costs"
       }
      }
     },
     "localname": "AllocatedPublicOfferingCosts",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Gain Before Tax",
        "label": "Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Loss Before Tax",
        "label": "Available For Sale Debt Securities, Current, Accumulated Gross Unrealized Loss Before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities, Current, Amortized Cost Basis",
        "label": "Available For Sale Debt Securities, Current, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Gain Before Tax",
        "label": "Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Loss Before Tax",
        "label": "Available For Sale Debt Securities, Noncurrent, Accumulated Gross Unrealized Loss Before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities, Noncurrent, Amortized Cost Basis",
        "label": "Available For Sale Debt Securities, Noncurrent, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common stock warrants",
        "verboseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails",
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_Company401KPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company 401K Plan [Member]",
        "label": "Company 401K Plan [Member]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "Company401KPlanMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer And Office Equipment [Member]",
        "label": "Computer And Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_DebtCovenantThresholdAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Threshold",
        "label": "Debt Covenant Threshold [Axis]",
        "terseLabel": "Debt Covenant Threshold [Axis]"
       }
      }
     },
     "localname": "DebtCovenantThresholdAxis",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sibn_DebtCovenantThresholdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Threshold",
        "label": "Debt Covenant Threshold [Domain]",
        "terseLabel": "Debt Covenant Threshold [Domain]"
       }
      }
     },
     "localname": "DebtCovenantThresholdDomain",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_DebtCovenantTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Tranche One",
        "label": "Debt Covenant Tranche One [Member]",
        "terseLabel": "Debt Covenant Tranche One"
       }
      }
     },
     "localname": "DebtCovenantTrancheOneMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_DebtCovenantTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Tranche Three",
        "label": "Debt Covenant Tranche Three [Member]",
        "terseLabel": "Debt Covenant Tranche Three"
       }
      }
     },
     "localname": "DebtCovenantTrancheThreeMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_DebtCovenantTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Tranche Two",
        "label": "Debt Covenant Tranche Two [Member]",
        "terseLabel": "Debt Covenant Tranche Two"
       }
      }
     },
     "localname": "DebtCovenantTrancheTwoMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_DebtInstrumentCovenantMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Minimum Cash Balance",
        "label": "Debt Instrument, Covenant, Minimum Cash Balance",
        "terseLabel": "Debt covenant minimum cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumCashBalance",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fee Amount As Percentage Of Aggregate Principal",
        "label": "Debt Instrument Fee Amount As Percentage Of Aggregate Principal",
        "terseLabel": "Final fee as percentage of aggregate principal amount (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmountAsPercentageOfAggregatePrincipal",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate Incremental Increase Upon Default Of Covenant",
        "label": "Debt Instrument Interest Rate Incremental Increase Upon Default Of Covenant",
        "terseLabel": "Incremental interest rate increase upon default of minimum liquidity covenant (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncrementalIncreaseUponDefaultOfCovenant",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_DebtInstrumentLiquidityCovenantProductRevenueThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Liquidity Covenant Product Revenue Threshold",
        "label": "Debt Instrument Liquidity Covenant Product Revenue Threshold",
        "terseLabel": "Product revenue threshold for minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtInstrumentLiquidityCovenantProductRevenueThreshold",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Interest Only Period",
        "label": "Debt Instrument, Periodic Payment, Interest Only Period",
        "terseLabel": "Debt period payment, interest only period"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentInterestOnlyPeriod",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_DebtInstrumentPrepaymentAllowableIncrementsPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment, Allowable Increments Per Agreement",
        "label": "Debt Instrument, Prepayment, Allowable Increments Per Agreement",
        "terseLabel": "Allowable prepayment increments per agreement"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentAllowableIncrementsPerAgreement",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_DebtInstrumentPrepaymentPenaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty Percentage",
        "label": "Debt Instrument, Prepayment Penalty Percentage",
        "terseLabel": "Debt prepayment penalty percentage (percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentage",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_DebtInstrumentPrepaymentPremiumYearOnePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Premium Year One Percentage",
        "label": "Debt Instrument Prepayment Premium Year One Percentage",
        "terseLabel": "Prepayment premium in year one (percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumYearOnePercentage",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Premium Year Three Or Later Percentage",
        "label": "Debt Instrument Prepayment Premium Year Three Or Later Percentage",
        "terseLabel": "Prepayment premium in year three or later (percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumYearThreeOrLaterPercentage",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_DebtInstrumentPrepaymentPremiumYearTwoPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Premium Year Two Percentage",
        "label": "Debt Instrument Prepayment Premium Year Two Percentage",
        "terseLabel": "Prepayment premium in year two (percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumYearTwoPercentage",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_DebtPrepaymentPenaltyPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt, Prepayment Penalty, Period [Axis]",
        "label": "Debt, Prepayment Penalty, Period [Axis]",
        "terseLabel": "Debt, Prepayment Penalty, Period [Axis]"
       }
      }
     },
     "localname": "DebtPrepaymentPenaltyPeriodAxis",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sibn_DebtPrepaymentPenaltyPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Debt, Prepayment Penalty, Period [Axis]",
        "label": "Debt, Prepayment Penalty, Period [Domain]",
        "terseLabel": "Debt, Prepayment Penalty, Period [Domain]"
       }
      }
     },
     "localname": "DebtPrepaymentPenaltyPeriodDomain",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_DebtSecuritiesAvailableForSaleNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Noncurrent [Abstract]",
        "label": "Debt Securities, Available For Sale, Noncurrent [Abstract]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNoncurrentAbstract",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance",
        "label": "Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance",
        "totalLabel": "Net deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_DeferredTaxAssetsDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Depreciation And Amortization",
        "label": "Deferred Tax Assets, Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Matching Contribution, Maximum Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Maximum Amount Per Employee",
        "terseLabel": "Employer matching contribution, maximum amount per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionMaximumAmountPerEmployee",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_DevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Agreement [Member]",
        "label": "Development Agreement [Member]",
        "terseLabel": "Joint development agreement"
       }
      }
     },
     "localname": "DevelopmentAgreementMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_ESPPPurchaseRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Purchase Rights [Member]",
        "label": "ESPP Purchase Rights [Member]",
        "terseLabel": "ESPP Purchase Rights"
       }
      }
     },
     "localname": "ESPPPurchaseRightsMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Growth Company Extended Transition Period Policy",
        "label": "Emerging Growth Company Extended Transition Period Policy [Policy Text Block]",
        "terseLabel": "JOBS Act Accounting Election"
       }
      }
     },
     "localname": "EmergingGrowthCompanyExtendedTransitionPeriodPolicyPolicyTextBlock",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sibn_EmployeeStockPurchasePlanSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Shares [Member]",
        "label": "Employee Stock Purchase Plan Shares [Member]",
        "terseLabel": "ESPP purchase rights"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanSharesMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_EricBFromerChiropracticIncClassActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eric B Fromer Chiropractic Inc Class Action [Member]",
        "label": "Eric B Fromer Chiropractic Inc Class Action [Member]",
        "terseLabel": "Class action Eric B. Fromer Chiropractic Inc."
       }
      }
     },
     "localname": "EricBFromerChiropracticIncClassActionMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_FollowOnPublicOfferingAndSecondaryOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow On Public Offering And Secondary Offering",
        "label": "Follow On Public Offering And Secondary Offering [Member]",
        "terseLabel": "First follow-on public offering and secondary offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingAndSecondaryOfferingMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow On Public Offering [Member]",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "First follow-on public offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_IncentiveStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Option [Member]",
        "label": "Incentive Stock Option [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_IncomeTaxesValuationAllowanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Valuation Allowance [Roll Forward]",
        "label": "Income Taxes Valuation Allowance [Roll Forward]",
        "terseLabel": "Changes in Valuation Allowance"
       }
      }
     },
     "localname": "IncomeTaxesValuationAllowanceRollForward",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sibn_LitigationStatutoryDamagesPerViolationOfTCPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation, Statutory Damages Per Violation Of TCPA [Member]",
        "label": "Litigation, Statutory Damages Per Violation Of TCPA [Member]",
        "terseLabel": "Statutory damages sought per violation of TCPA"
       }
      }
     },
     "localname": "LitigationStatutoryDamagesPerViolationOfTCPAMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_LitigationTrebleDamagesPerViolationOfTCPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation, Treble Damages Per Violation Of TCPA [Member]",
        "label": "Litigation, Treble Damages Per Violation Of TCPA [Member]",
        "terseLabel": "Treble damages sought per violation of TCPA"
       }
      }
     },
     "localname": "LitigationTrebleDamagesPerViolationOfTCPAMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "sibn_MarketableSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Total marketable securities, Unrealized Gains"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "sibn_MarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Total marketable securities, Unrealized Losses"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_MarketableSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amortized cost for marketable securities included in cash equivalents and investments.",
        "label": "Marketable Securities, Amortized Cost",
        "totalLabel": "Total marketable securities, Amortized Cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCost",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_MarketableSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "sibn_MarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total aggregate fair value for marketable securities included in cash equivalents and investments.",
        "label": "Marketable Securities, Fair Value",
        "terseLabel": "Total marketable securities, Aggregate Fair Value"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValue",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Device Excise Tax Policy [Policy Text Block]",
        "label": "Medical Device Excise Tax Policy [Policy Text Block]",
        "terseLabel": "Medical Device Excise Tax"
       }
      }
     },
     "localname": "MedicalDeviceExciseTaxPolicyPolicyTextBlock",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sibn_NonqualifiedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified Stock Option [Member]",
        "label": "Nonqualified Stock Option [Member]",
        "terseLabel": "Nonqualified Stock Options"
       }
      }
     },
     "localname": "NonqualifiedStockOptionMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_OperatingLossCarryforwardsLimited": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Limited",
        "label": "Operating Loss Carryforwards, Limited",
        "terseLabel": "Limited net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimited",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_OptionsTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Tranche Five [Member]",
        "label": "Options Tranche Five [Member]",
        "terseLabel": "$20.52-$22.00"
       }
      }
     },
     "localname": "OptionsTrancheFiveMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_OptionsTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Tranche Four [Member]",
        "label": "Options Tranche Four [Member]",
        "terseLabel": "$5.32-$20.51"
       }
      }
     },
     "localname": "OptionsTrancheFourMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_OptionsTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Tranche One [Member]",
        "label": "Options Tranche One [Member]",
        "terseLabel": "$0.84-$3.69"
       }
      }
     },
     "localname": "OptionsTrancheOneMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_OptionsTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Tranche Three [Member]",
        "label": "Options Tranche Three [Member]",
        "terseLabel": "$4.42-$5.31"
       }
      }
     },
     "localname": "OptionsTrancheThreeMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_OptionsTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Tranche Two [Member]",
        "label": "Options Tranche Two [Member]",
        "terseLabel": "$3.70-$4.41"
       }
      }
     },
     "localname": "OptionsTrancheTwoMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Repurchase Of Unvested Early Exercised Stock Options",
        "label": "Payments For Repurchase Of Unvested Early Exercised Stock Options",
        "negatedTerseLabel": "Repurchase of unvested early exercised stock options"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_PayrollProtectionProgramLoanCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll Protection Program Loan, CARES Act",
        "label": "Payroll Protection Program Loan, CARES Act [Member]",
        "terseLabel": "PPP Loan, CARES Act"
       }
      }
     },
     "localname": "PayrollProtectionProgramLoanCARESActMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_PharmakonTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loan [Member]",
        "label": "Pharmakon Term Loan [Member]",
        "terseLabel": "Pharmakon Term Loan"
       }
      }
     },
     "localname": "PharmakonTermLoanMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_PrepaymentPenalty3148MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Penalty, 31-48 Months [Member]",
        "label": "Prepayment Penalty, 31-48 Months [Member]",
        "terseLabel": "Prepayment Penalty, 31-48 Months"
       }
      }
     },
     "localname": "PrepaymentPenalty3148MonthsMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_PrepaymentPenalty4960MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Penalty, 49-60 Months [Member]",
        "label": "Prepayment Penalty, 49-60 Months [Member]",
        "terseLabel": "Prepayment Penalty, 49-60 Months"
       }
      }
     },
     "localname": "PrepaymentPenalty4960MonthsMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Penalty And Lender Fees In Extinguishment Of Debt",
        "label": "Prepayment Penalty And Lender Fees In Extinguishment Of Debt",
        "terseLabel": "Prepayment penalty and lender fees on debt extinguishment"
       }
      }
     },
     "localname": "PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_ProceedsFromMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Marketable Securities",
        "label": "Proceeds From Maturity Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Marketable Securities",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_RelatedPartyTransactionTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Term Of Agreement",
        "label": "Related Party Transaction, Term Of Agreement",
        "terseLabel": "Term of product royalty sales period (in years)"
       }
      }
     },
     "localname": "RelatedPartyTransactionTermOfAgreement",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_RevenueRecognitionStandardPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Standard Payment Terms",
        "label": "Revenue Recognition, Standard Payment Terms",
        "terseLabel": "Standard payment terms per agreements (in days)"
       }
      }
     },
     "localname": "RevenueRecognitionStandardPaymentTerms",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Shares Issued In Transaction, Including Shares In Secondary Offering",
        "label": "Sale Of Stock, Number Of Shares Issued In Transaction, Including Shares In Secondary Offering",
        "terseLabel": "Number of shares in transaction, including shares in secondary offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionIncludingSharesInSecondaryOffering",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sibn_SalesCreditReservePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Credit Reserve Period",
        "label": "Sales Credit Reserve Period",
        "terseLabel": "Sales credit reserve term (in years)"
       }
      }
     },
     "localname": "SalesCreditReservePeriod",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_SecondFollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Follow On Public Offering",
        "label": "Second Follow On Public Offering [Member]",
        "terseLabel": "Second follow-on public offering"
       }
      }
     },
     "localname": "SecondFollowOnPublicOfferingMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_SecondaryOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary Offering [Member]",
        "label": "Secondary Offering [Member]",
        "terseLabel": "Secondary offering by selling shareholders"
       }
      }
     },
     "localname": "SecondaryOfferingMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Reserved As Percentage Of Prior Year Shares Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved As Percentage Of Prior Year Shares Outstanding",
        "terseLabel": "Annual increase in shares reserved as percentage of prior year-end shares outstanding (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedAsPercentageOfPriorYearSharesOutstanding",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved, Maximum Shares",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved, Maximum Shares",
        "terseLabel": "Annual increase in shares reserved, maximum (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedMaximumShares",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than 10% Of Outstanding Shares",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than Ten Percent Of Outstanding Shares",
        "terseLabel": "Stock option term when grantee holds more than 10% of shares outstanding (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods",
        "terseLabel": "Number of purchase periods in offering interval"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval",
        "terseLabel": "Employees stock purchase program offering period interval (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase",
        "terseLabel": "Early exercise of stock options, share subject to repurchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value",
        "terseLabel": "Exercise price of option as percent of fair market value (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than 10% Of Outstanding Shares",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than Ten Percent Of Outstanding Shares",
        "terseLabel": "Exercise price of option as percent of fair market value when individual owns more than 10% of shares outstanding (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Ownership Of Outstanding Shares Threshold For Alternate Terms",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Ownership Of Outstanding Shares Threshold For Alternate Terms",
        "terseLabel": "Percentage of ownership of outstanding shares for alternate terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOwnershipOfOutstandingSharesThresholdForAlternateTerms",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sibn_ShareSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Subject To Repurchase [Member]",
        "label": "Share Subject To Repurchase [Member]",
        "terseLabel": "Shares subject to repurchase"
       }
      }
     },
     "localname": "ShareSubjectToRepurchaseMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_SocialSecurityTaxEmployerDeferralCARESAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Tax, Employer, Deferral, CARES Act",
        "label": "Social Security Tax, Employer, Deferral, CARES Act",
        "terseLabel": "Deferred liability for social security taxes, CARES Act"
       }
      }
     },
     "localname": "SocialSecurityTaxEmployerDeferralCARESAct",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_SolarLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solar Loan And Security Agreement",
        "label": "Solar Loan And Security Agreement [Member]",
        "terseLabel": "Solar Loan And Security Agreement"
       }
      }
     },
     "localname": "SolarLoanAndSecurityAgreementMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_StandardProductWarrantyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standard Product Warranty Term",
        "label": "Standard Product Warranty Term",
        "terseLabel": "Warranty term (in years)"
       }
      }
     },
     "localname": "StandardProductWarrantyTerm",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesWarrantyProgramDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sibn_StockIssuedDuringPeriodAmountRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Amount Restricted Stock Units",
        "label": "Stock Issued During Period Amount Restricted Stock Units",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAmountRestrictedStockUnits",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_StockIssuedDuringPeriodSharesRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Restricted Stock Units",
        "label": "Stock Issued During Period Shares Restricted Stock Units",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockUnits",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares",
        "label": "Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares",
        "negatedTerseLabel": "Repurchase of unvested early exercised stock options (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value",
        "label": "Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value",
        "negatedTerseLabel": "Repurchase of unvested early exercised stock options"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_VariableOptionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Option One",
        "label": "Variable Option One [Member]",
        "terseLabel": "Variable Option One"
       }
      }
     },
     "localname": "VariableOptionOneMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_VestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of Early Exercised Stock Options",
        "label": "Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "localname": "VestingOfEarlyExercisedStockOptions",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Classified As Equity And Liabilities [Policy Text Block]",
        "label": "Warrants, Classified As Equity And Liabilities [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsClassifiedAsEquityAndLiabilitiesPolicyTextBlock",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued December Twenty-Second Twenty Sixteen [Member]",
        "label": "Warrants Issued December Twenty-Second Twenty Sixteen [Member]",
        "terseLabel": "Warrants Issued 12/22/2016"
       }
      }
     },
     "localname": "WarrantsIssuedDecemberTwentySecondTwentySixteenMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_WarrantsIssuedJulyTwentySecondTwentyThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued July Twenty-Second Twenty Thirteen [Member]",
        "label": "Warrants Issued July Twenty-Second Twenty Thirteen [Member]",
        "terseLabel": "Warrants Issued 7/22/2013"
       }
      }
     },
     "localname": "WarrantsIssuedJulyTwentySecondTwentyThirteenMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_WarrantsIssuedMarchFirstTwentySeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued March First Twenty Seventeen [Member]",
        "label": "Warrants Issued March First Twenty Seventeen [Member]",
        "terseLabel": "Warrants Issued 3/1/2017"
       }
      }
     },
     "localname": "WarrantsIssuedMarchFirstTwentySeventeenMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued November Ninth Twenty Fifteen [Member]",
        "label": "Warrants Issued November Ninth Twenty Fifteen [Member]",
        "terseLabel": "Warrants Issued 11/9/2015"
       }
      }
     },
     "localname": "WarrantsIssuedNovemberNinthTwentyFifteenMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued November Twenty-Sixth Twenty Fourteen [Member]",
        "label": "Warrants Issued November Twenty-Sixth Twenty Fourteen [Member]",
        "terseLabel": "Warrants Issued 11/26/2014"
       }
      }
     },
     "localname": "WarrantsIssuedNovemberTwentySixthTwentyFourteenMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued October Twentieth Twenty Fifteen [Member]",
        "label": "Warrants Issued October Twentieth Twenty Fifteen [Member]",
        "terseLabel": "Warrants Issued 10/20/2015"
       }
      }
     },
     "localname": "WarrantsIssuedOctoberTwentiethTwentyFifteenMember",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion",
        "label": "Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion",
        "terseLabel": "Fair\u00a0Value"
       }
      }
     },
     "localname": "WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sibn_WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off Of Deferred Debt Issuance Cost And Debt Discount",
        "label": "Write Off Of Deferred Debt Issuance Cost And Debt Discount",
        "terseLabel": "Recognition of unamortized debt discount and issuance costs on debt extinguishment"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount",
     "nsuri": "http://si-bone.com/20201231",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r315",
      "r472",
      "r473",
      "r475",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "SeaSpine"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r341",
      "r347",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r509",
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r341",
      "r347",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r509",
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r288",
      "r341",
      "r347",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r509",
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r288",
      "r341",
      "r347",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r509",
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r258",
      "r260",
      "r549",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r258",
      "r260",
      "r549",
      "r560",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r174",
      "r175"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $263 and $238, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion of discount on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities and other",
        "totalLabel": "Accrued liabilities and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails",
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r38"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r208"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r53",
      "r54",
      "r55",
      "r541",
      "r555",
      "r556"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r108",
      "r109",
      "r110",
      "r438",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r386"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r349",
      "r351",
      "r389",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r241",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Additional accrual of IPO related costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expenditures"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpendituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r351",
      "r379",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r27",
      "r177",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r69",
      "r87",
      "r464"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common stock equivalents excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r152",
      "r161",
      "r167",
      "r187",
      "r434",
      "r439",
      "r451",
      "r524",
      "r539"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r50",
      "r100",
      "r187",
      "r434",
      "r439",
      "r451"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r183",
      "r196"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "sibn_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r183",
      "r196"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://si-bone.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "sibn_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r352",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "verboseLabel": "Cash and cash equivalents at"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r30",
      "r89"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r90",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r89",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r452"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r98",
      "r100",
      "r120",
      "r121",
      "r122",
      "r124",
      "r126",
      "r133",
      "r134",
      "r135",
      "r187",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r247",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price\u00a0per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number\u00a0of Shares Underlying Warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r247",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r216",
      "r528",
      "r545"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r230",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Loss Contingency"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 32,583,220 and 25,163,803 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r66",
      "r530",
      "r547"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r139",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r289",
      "r334",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r71",
      "r510"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r525",
      "r526",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r235",
      "r526",
      "r538"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal outstanding and final fee",
        "totalLabel": "Total principal and final fee payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails",
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r463",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedTerseLabel": "Less: Unaccreted value of final fee",
        "terseLabel": "Final fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate during the period (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Fixed interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r104",
      "r242",
      "r243",
      "r244",
      "r245",
      "r462",
      "r463",
      "r465",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt maturity term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r236",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt discount and issuance cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r417",
      "r423"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r34",
      "r464"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r417",
      "r423"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r101",
      "r417",
      "r423",
      "r424",
      "r425"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred tax expense:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r417",
      "r423"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax asset, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: Valuation allowance",
        "periodEndLabel": "Valuation allowance, ending balance",
        "periodStartLabel": "Valuation allowance, beginning balance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
      "http://si-bone.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsandDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percentage of eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r87",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r87",
      "r151"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r13",
      "r102",
      "r473",
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Outstanding liability to SeaSpine"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Total income tax expense (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r399",
      "r427"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "Tax at statutory federal rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r399",
      "r427"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Change in deferred tax valuation allowance (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r399",
      "r427"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign rate differences (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r399",
      "r427"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedTerseLabel": "Other (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r391",
      "r399"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "negatedTerseLabel": "Stock compensation (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r399",
      "r427"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State tax, net of federal benefit (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r399",
      "r427"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, expected period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r117",
      "r119",
      "r132",
      "r188",
      "r241",
      "r246",
      "r383",
      "r384",
      "r385",
      "r420",
      "r421",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r334",
      "r444",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r443",
      "r444",
      "r446",
      "r447",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r289",
      "r291",
      "r296",
      "r334",
      "r444",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r289",
      "r291",
      "r296",
      "r334",
      "r444",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r334",
      "r444",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r334",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on sale and disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Reversal of accrued litigation expense"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r87",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r70",
      "r100",
      "r152",
      "r160",
      "r163",
      "r166",
      "r168",
      "r187",
      "r451"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r87",
      "r205",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment losses on long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r204",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r105",
      "r426"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r105",
      "r426"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r105",
      "r152",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r400",
      "r406",
      "r412",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r96",
      "r397",
      "r398",
      "r406",
      "r407",
      "r411",
      "r418",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r227",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Agreement"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r150",
      "r461",
      "r464",
      "r531"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r82",
      "r84",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r48"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r49",
      "r96",
      "r131",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r73",
      "r149"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r523",
      "r535",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r100",
      "r162",
      "r187",
      "r435",
      "r439",
      "r440",
      "r451"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r100",
      "r187",
      "r451",
      "r527",
      "r543"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r100",
      "r187",
      "r435",
      "r439",
      "r440",
      "r451"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r45",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Costs accrued to defend lawsuits"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r45",
      "r216",
      "r225"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation expense"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails",
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement of approved claims by class members, fees, expenses and incentive awards"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Costs to defend lawsuits or settle claims"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r237",
      "r526",
      "r540"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Outstanding debt, net of debt issuance costs and unaccreted value of final fee"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails",
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r106",
      "r233"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r106",
      "r233"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r106",
      "r233"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r106",
      "r233"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r106",
      "r233"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsSummaryofBorrowingsDetails",
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r224",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r216",
      "r219",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r224",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "negatedTerseLabel": "Realized gain on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Maturities of Long-term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r136",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "The Company and Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r57",
      "r59",
      "r65",
      "r88",
      "r100",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r123",
      "r152",
      "r160",
      "r163",
      "r166",
      "r168",
      "r187",
      "r451",
      "r529",
      "r546"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash information"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r152",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Aggregate Future Minimum Lease Payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesAggregateFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r432",
      "r433",
      "r437"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) of marketable securities",
        "verboseLabel": "Net unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r432",
      "r433",
      "r437"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Changes in foreign currency translation",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related expenses for employee payroll deductions"
       }
      }
     },
     "localname": "OtherEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Interest and other income (expense), net:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Payments of prepayment penalty and lender fees"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of initial public offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r288",
      "r290",
      "r296",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r334",
      "r335",
      "r336",
      "r337",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r352",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://si-bone.com/role/CommonandPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from debt financing"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails",
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.",
        "label": "Proceeds from Issuance of Unsecured Debt",
        "terseLabel": "Proceeds from PPP loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r382"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r32",
      "r207"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r209",
      "r544"
     ],
     "calculation": {
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r96",
      "r209",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "verboseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsTables",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r68",
      "r191"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitments related to inventory"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r176",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Uncertain income tax positions [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r315",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r315",
      "r472",
      "r473",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Reimbursement charges expensed"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r315",
      "r472",
      "r475",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r470",
      "r471",
      "r473",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal repayments of debt financing"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayment of PPP loan"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r395",
      "r576"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r96",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r246",
      "r386",
      "r542",
      "r554",
      "r556"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r117",
      "r119",
      "r188",
      "r383",
      "r384",
      "r385",
      "r420",
      "r421",
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r159",
      "r164",
      "r165",
      "r169",
      "r170",
      "r173",
      "r257",
      "r258",
      "r510"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geography"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r64",
      "r100",
      "r147",
      "r148",
      "r159",
      "r164",
      "r165",
      "r169",
      "r170",
      "r173",
      "r187",
      "r451",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities and Other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockAntidilutiveSecuritiesExcludingfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r43",
      "r104",
      "r242",
      "r243",
      "r244",
      "r245",
      "r462",
      "r463",
      "r465",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r351",
      "r378",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Annual Future Minimum Principal Payments Under Loan Agreements"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r103",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r352",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of Options by Range of Exercise Price"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r357",
      "r367",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Related to ESPP Purchase Rights"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Related to Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r247",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r405",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Uncertain Income Tax Positions"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Black-Scholes option-pricing model assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://si-bone.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled and forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r359",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable (in shares)",
        "verboseLabel": "Options vested and exercisable, number of shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails",
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable (in dollars per share)",
        "verboseLabel": "Options vested and exercisable, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails",
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r350",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails",
      "http://si-bone.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r96",
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price, lower limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding, number of shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price, upper limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock option term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r375",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforESPPPurchaseRightsDetails",
      "http://si-bone.com/role/StockBasedCompensationValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life, options outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life, options vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life, options vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock as a percent of fair market value (percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options outstanding, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationOutstandingOptionsandExercisableOptionsInformationbyRangeofExercisePricesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Stockholders' equity, ending balance (in shares)",
        "periodStartLabel": "Stockholders' equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r96",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Warranty Program"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r98",
      "r100",
      "r120",
      "r121",
      "r122",
      "r124",
      "r126",
      "r133",
      "r134",
      "r135",
      "r187",
      "r241",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/WarrantsIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r108",
      "r109",
      "r110",
      "r112",
      "r117",
      "r119",
      "r132",
      "r188",
      "r241",
      "r246",
      "r383",
      "r384",
      "r385",
      "r420",
      "r421",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r132",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r241",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r241",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r241",
      "r246",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Issuance of common stock upon exercise of stock options, net of shares withheld (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://si-bone.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r241",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r241",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r241",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options, net of shares withheld"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r100",
      "r178",
      "r187",
      "r451"
     ],
     "calculation": {
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders' equity, ending balance",
        "periodStartLabel": "Stockholders' equity, beginning balance",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common and Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CommonandPreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r459",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r459",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r459",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/TheCompanyandNatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Changes in Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r289",
      "r334",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/FairValueMeasurementMarketableSecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://si-bone.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r396",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year's tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Accrued interest related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Change in deferred tax valuation allowance",
        "terseLabel": "Additions during the period"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
      "http://si-bone.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://si-bone.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://si-bone.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121548805&loc=d3e10037-110241"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e13051-110250"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r577": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r579": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r581": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r582": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r583": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r584": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r585": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r586": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001459839-21-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001459839-21-000012-xbrl.zip
M4$L#!!0    ( &F :E+S,6=4W@@  /DQ   >    97AH,3 Q-G)M<V-O;7!A
M;GDM861D96YD=6TN:'1M[5M;<]K($GX_OZ+7KI--JD!<?0DXKG(,V7#*QE[
MZ\K3J4%JF=D,(]7,",S^^M,SD@SXMD[B6"1G_8"%-)?NGJ^_[FD-![]TSHY'
MG\Z[,#%3 ><7[T]ZQ[!5KE0N&\>52F?4@8^CTQ-H>M4:C!23FAL>228JE6Y_
M"[8FQL2M2F4^GWOSAA>IJ\IH4+%#-2LBBC1Z@0FV#@_L'?I$%AS^Z^"7<ADZ
MD9],41KP%3*# 22:RRNX#%!_AG(Y:W4<Q0O%KR8&ZM5Z#2XC]9G/6/K<<"/P
M,!_GH))^/ZBX20[&4; X/ CX#'CP;HN'=<;J>]C8P<:X^1:;#(,=MM?8&==9
M8URM[OZW1D)6J'G:1YN%P'=;4R[+$[3SM_;JL6G/>6 FK5JU^N^MM78&KTV9
M"7XE6W\FVO!P0<_#B+3+&OB1B%1KN^K^VO9).613+A:M7X_9=*PX^[6DR;9E
MC8J':0/-_T*:BZ9U7^>9'-1?<(FY7+6Z%>;XK/^AU^GV1[VC$WBUW=AOP_G@
M['S0ZXZ.!I_@9?^ZUQ,^Y@9J5:^V>U"QTN>VO6/A%<OYM(JHGM]P;J06-S2+
M_P13'G7(CIV+4^B?>5"'T1F<'O4O/AP=CRX&O?YO)?C]XNBD-_H$1_T.#"_.
MST_H\K=!MWM*YE_7UGVD-\;J\,ZS M#3O%?E5]NUW6K[[N?H8V\(WV0/>/UJ
M>[]>K[9SY0M>VR! &213Z$>DRW>2Z6],3>:HM=^4 ,,0?<-G"$Q#%,)_$K&
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M,M$5DIE4NAQF0E%A+<;3$FR<%3?!>&\\(#:/G<Q_$? H\2;22C1=6K/*R$"
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MEUW86$>"<NP'NV3)+=FW=>METMJI^7ND7?M,?Q3A?IYQ^#]02P,$%     @
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MR?H3>;!'6^U:IM,WZ;.S]@=U ,HQ?+>,"Z#I)U0#2 ?',0TB)B:&XRQ&3$D
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MU[:4E41RKN;=X_&]<L8AL]"K%II2 T:_-@!5/2^)'X&-*NK$Z+MF5K4J3K<
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MKSFNWM@V&;$0F=L(9LW>2R77FD\DW[%).6+Y"=3#?AN Q?D!BYP*'9__!%9
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M#AAX4J@L0F>NOVZDU0KX4AI0F:A*,S:RE/'7GJ01<^/ 5@=G+M]V8/Q3U>+
M:2EBNN[80C,W6,9:#SV=U'T/BEY\W<N.I&>K-BAPZT[\.&,#@D&)OHK&<V<
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M,F9),:D^9^[T+F-D(FU5FFC+9<CV.XL?F305T416>K7%W& <5Z)JT2<Z4(H
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M[?(/_&<)2X)DB-A%;6_WJ\J[%QM6_<F-N)U UN MVR7R_9S9SU>HU6@N0CC
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M7R)\3X1WKR'L'0'+BI!&Y ',)QM$PR(I&YA+0PB-P+SFQ9N-_2?$=Q7 ]17
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M&F:=TT@8814+*#(3]*W=/N> >*8@><87;QG7RKNA&$Y>N(BD@Y2U)O6PU$J
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MW%$NY0P%IE$T-# DB0)"3@N;(F@B_6B;KWFAW"6Q/"ZQ$!Y3RS;M A8L[:'
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MT^DYZ&!=E0%MQR^F2.4#V\5.?MB:E):C$^5F60)"6ZGCXD9>E/V]4WC/<#>
M&=,/X<$J1U/Q<67ZC<:UV^^YXYN=B7O=NGSI49/I'K 'L,0X6NFL)XQARC57
MAJ5]S0+AQ.HYJ%!9DLD32!/KJL0D 8+>I6B&$2;UZT%>8>D\7C@R^=>@/1P3
M"$R$KW_OM?)B22O?HQ5A#=<D&")2W1LGIK(:1/"!&8<<733-\^QHY2'W;I?,
M@@5I+4@2IAU5-'JF-!/**XG\'&P0\V.TTDS=I.!)(WK)S_JM^N=&;[ DE^^2
M"_%"2DNT3!8*#T N8+$$(!=NL5-4+9H:>H[D\I!MZX06#F,M)$/@^D3EN>$J
M<,Q55([/08?!'R.7;=?OC:DE#Q>TDL<EJ7S77<8(*XV8Y8JSM.T3-10'1[11
MRD:[<.[R<R.5A]R"-M*@HO->4\.$M5: _:+3"AM)^X0MK!)JYMW%IY,'%"F@
M<# C5AF+##,:&XQ#:B(8%+&>S</>%$LZ>9)-<#QR@3*-%":,2V-QL %DBJ;<
M*#P/W>!_C$[6@ILT:B=\YF3@+LGE.^3BN ='V7ICL&22@YW"+2)6FLAPLFX7
M3?T\1W)YR,@ML0B'U&5=,U ZJ9D,"M*F_@T223T'+?&_1RXU*!5:8\I90))X
MR#4?P0D/&/L@!//.*8*UP2Q@A7@,; ZVBEF2Q$/;JE1'$ <X*J=81,J"!>)=
M,%$I;;B;@TA)ZD'>-)W)M@FK,&*5>I+WAYM=EU[Q+:3+Y@03 8:A1S8:HQ#3
M'NQ!:L! 1(YB*7E U^HLTX\E.+> \_.UCE<N_97\)LL0#> "8I+6.Z0E7#/.
MO95<>(GTM5KK)9(/7OO\8$@2@$MJ81&53'$/LI%Q@Q'X^ [Y4>TS'O,DGF4D
M=P>VK#:9[*^G%(A;DH^O7O!0"G1F*(C@^\L"_& 4))#6"CNK' XL BU)KWG4
MS,IH!(YBCJKG5T]-X6_2S7KGI-T;AE!91G7+HED2Z@]5P!Z-,PA\*:JT9 )Y
M)8EP5FADB$9R;OIS/VYQQ342J;C]@L47G$ X,XYA%!FW/&V29;3%6H#B%SCU
MF[1+ KF#0)J][G\&IIW&[!><1D!\>,0=E<IPEG8O=%Z##.'$4(>=NF[C+VED
M0L_LA+)?Y*X_(I+/W;Q?[NQ^7D0RH89&)XS2CDL6B%(4.2PCCE0'A\2\BI*'
M+9U>D@F %9FSV#))F"5$>ZDDPI0X3%BD> [(Y,+Y:)DBO#5E\&F?4SA;;P"6
MCI:K@WZK5^3GP7_N^E!,J(CD-)1OA^MGH7!Y&3X"[F&2Z))VJ:\L'[.@?/J4
M(+3'#AD!!@AAE&AED?2(.JLCXF8><A3FF@ >)1[HG.)!:@U3[1@R3@%?6Q(C
M1HI93^;!X7AJ<!^E\<_TN5OY:,#S-#&F,LDH-6'!"8$]#]'%>4B#G6L">!3N
M!LYVA&'*B)0,16F8<A(YDN(*,0JWY.Z;X#Y.:X+I\[=CU&L,G"PM39L#:\8D
MY2K50X-_2,R2OQ^9!!XG$\.+Z&W43BO$9.!6"$&3^X:8 4:72PZ_ 6\J<UA$
M!J>*@Y<6(Y"$8@SL<: $)L&N(R)BZ^R2P1^7 AXGA\)P&9BBT;K(4KC&(2J0
M%);B5'(2EOQ]$]W\VT(J<&*4H5X%D;;MLB8H:[B06&')(K$H+OG[<2G@<:K)
MP H'3&/:OY4)IHW6B(+!CJ/W485YZ'L^M5C],UD3#I@0&8,*TAK0Z]CZ0!@A
M&@4GM9Z+ .S4XO3/A$28I1'< !QBHA!J%)*.6HLDI=8K'>=@WXWG(T6FM,&&
MITP+3@0%[\ KHX@,U'(,-(.DC7).260QI<AT2$1'CI744<D0&)%.!X&]9=('
MKU-IZAR0R!+(*@&$*&K Z><&@ Q46\^M !<!*<\%5W4#%#6'^#W9LOM$B8QZ
MN&:'FFA!*$(RE4TYH;CDGG@<L.#!2CO__#65M(CI\)BQ0086N2.*,*F=]IY9
M0;F4GE-)YJ# =MH8/DH9FI"&@&.$ U<"G&B:>BAX >(/YM"EEANS[RS-"C[3
M=VLP=CCQF93&P/P2I20X-M*GR!<!VW7V(U[3QO!18E:*&.]Q4EE*,Z,4.!-!
M&6T-XC$B-4_5!G?6C4P:BA\'A6N9<N8JR1Z*S5(S>T$<U1R!#D/42A:8 W')
M/#;274\$18RB)9Z/41G(&A0]Q$*!IEBG@B .KGZ$GP0K8G44'A.IT,7>Y4O^
M_!D\^5/PYP T0@7FR>C;OM;77^#4":8<%*&>DFL7C9\YOF;\=WKH[0+ )8<$
M6-]RQ;0 A]$A*Z-(1**<E"-_$2WIY-XN(WJ@K@H^"J&C!A,(,X$B^/!"2V4<
MIR"TE9Y]"VBFD'G(WGX2W#T<O+4.,ZN\9@&[@"31G JN^+)H=QY(8_JENT1+
M"P)7:VXP<S[8B%TT8(UYX'!"Q>S'$68 QD<))010AHHC0E$43"6,'!/!$U"3
M*E)#YRA<-P,033]B)[6S!$7#J$",@.!._Q)$(R6)-W(>2AVF4SJ[OOOQXY@X
MJJ9(C[!=S?2]8)NV$@!N9T@;)FW0V.I@.% ! @"1FE/R>-0%TF=$'@8;CR4Q
M4G##@@R@#4Q*QW-I.R0ET1QI@UD <4HKW!P[QH1%)$8F*+):@?R/WF%L%";S
ME$T["R!.*=D)(X6$L]8[R01!J05EZHGA!(5_LGDJ>=CLNEXG7'3_NWW_N'>]
MLK\==TW[,;:)FSZ<DIK4YLH%#?:VH2!8501]JTGPGE+'YTBPSA:<TQ&Q+C+$
MN4%5GAGV.N%()(_(!<*<G <SZH?@W WM=MX]7.VF7>".0Q]^KY^EW/:%K$$(
M$IG(+.4!>8:Y4:EUI&-@!2E#B#*+QJS30G<ZO.NYB]946Y4P%B@U@C P<1'R
MPF#LYJ%QT ^ANQ/*D+9N!'C7PK?0[IVD:Q>8?1%*79G!>Q$4[& O%8V*R-0B
MBN-@S,*Q[Q0!GE*6=]K<VJ6&#4PRXX-2)#KP7)TD3@6[<-KW?>B&PK33GLJ^
MDW?SLE^8U 5P@7D8S&2JI%!68L.\D$HA+A1RU+* 0E@X'IXJQ-/AXDC26A!F
M@F',@A3:14E]]"1@B@"$.>+B';"9B@K=6]8@4A6HZ0X9PO^>M5R<!RO*UTP$
M3D7P&H%CI"VR:8<O%[$P/FHW1]PZ.U!.J:I"!Z/ R:$D4F:Y,X%0Q!WFR"OG
MY3R4ZEX$#^$)/F\/JH:YP0V*O)^'<OW,M0<^^(VBUTEX#OJ5.-Z.ZZ;H@N=3
M?@Q%7<(]O/T!S[+V$CMF$6/11Z485MAR+1DB*7_2<,.O]^%?DL7SJ,$2FC*C
M(A7*6.8UTT E*7?=QR!]0//4>NM)R.(9E350A\#O!H],&\V4<EIAJ;B7ED@F
MC&%+B3$#I#&EZ#D''4*-))P&%IE70 <&"2.YH-C+>5K;>E32J&S.ZKK=@3T*
MKK_7VPGC-.A%E!D,6<DC]3+U>;,L&A<48TQ3)*4!C;*4&5,GC"G%"AQGS#BJ
ME35,<3 Y'',2>ZLYH=3.4ZS@\0GCSGS'N@?5(@J.B 2XK6!QJ"B8#<2" \L#
M"A%YPE0D2\$Q*_0QI14#[JE-6X\AK)A"$5P6%&44D2KNA)RG-;_'IX\?WP)T
M+F6&T,($$[12J>I(<"6PC9I()WQD0:FES)@F34RIWP5E:4E"$QXMHUP#B<2(
MC"-(6A/$'+2'KU>;]LS9J-5D?WC5S5R#LV4_=^]Z@VZ_&,Y)'1JRGA+AF;<&
M,66Q 6DN/5B"P+C,:3;_N%3K@ZM=GY8'V_\"!BQ][AXG;/@X[1)<JKOVD3CL
M&$R>=5)[[BQ&@)S%\]229">T 0O_$03.,/5:+4T%1/EV.'GFLOI@-<:\G:<3
MZ]6'/%09PAWCF)#*$^D>JX=%J):M%E%58TT#0C9MX>69(-HXQ*A0"G@_;0P\
M!UW]ES3U!#+($V0#M8I;SUETJ9]?5%(RCCSRE]O\$,(:XQ]+>ID/>KDN@TB#
ML/O)H"N7WE<&O<K/7H,KW /G.)3UGZU@?#5XGW][\R?\8QS+-I%1R@0E$O2>
MMC12[0VC4EIB.?^:1-+E/65_V 9BZN3=1BNDXI77%*_PD_X?I[GOMUYCA/[_
M%]65;_XL3TSWS9^V> 7WU[_KQ]QX6!IRP[3SP^[KM#UL*%[4-X_/NUZ[5[S^
M!ZK^\T>$;VQ$T\G;P]?_9P\0+[-F.,UV>AW3_3\O2X"X4<*LQ/K",C\/KS&#
M 59_GM9CEO"<=MX-XV_ ) W[<W-S;WTMV]U;W5O?O3KF&1SM[OJ[SSN;>YOK
MN]EJ<RU;_Y]W_[W:?+^>O=O>VMK<W=W<;M[Y"1U3' * MM?O]SJO";SN\3\*
MW^NCOIBR!9Y=O]=]F:VMO%O)".),S]2'W ^=C>V=K?_Z!Q;HCS^!][J];G/0
M@2>Y;,2B.R$F@8\"L\SZ*+5A2&@K$!<Q98>J&(BY-2R<=4T2YS[DX NY09)
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MOYG??R.___;V][]-6IRZY#B[;.Q=;S(QEV+CH596W.E7RHPSB-,&QR)ML^5
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M,QB,=8YXW1RCHHSL@IW\R&F?N+9EOH4ZASR<I>9AM5U0V>=5WB*X_F7*]>D
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M,2A'W"44EA)]=H'3>"31Q5*B+RB\N^,.7QL7W7[2-B!+L;L8\"[%[LR,Y0>
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ML&^.0S=Q"=@7UMQU>Y+'6<LDN=$%TV220Y*YU+N@KY=9O"#'HB; ET U_QF
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M]8'*"B8JG Z@?85>,95 FW\=;5[7C6XD"6\I 5:<PRP!OT^+$H$%/1MB34>
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M\4:%4?.BMT\:@QCKMG Y@U>*";IITK\W58T+V6$S_6!?".CO0\V(@=B#KQ>
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M,Y2NI;$]:F@)&Z*+N_$QM@'Z85LV&3"G;L4AR2;$YE39I:&GM&COOF3:WKD
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M2Q" *US8O\.J(K@74&3?NC5".MY;F<YRPH/Z#GLS0VU4+6D2]TAE+8],7=0
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M[+V7^Z7R1H$9 G'MIJZ+Z@\7KSPZOE,8IM/0+OE9[9+[D3G[K3#>#\?+-+#
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M5+RC8PEJXG9;>QN.Y6X7ONXN&(\7]J%_C+K^.=+$-L<,C(^1.[\H5=AN\VY
M.PHPFW< MCQ7O9C>@W*,3 _:T=T>?5T#OBWG3"I%>P":Q?%"Q;N(MG8D*1(H
MBX.'7&T-2!PB2"\+<D]0CG1T</AD/_D)?.O<!Z\3B #Y-F =O!=8^Z ?\AOK
MAYSL&671V]EL[T? _!S#KX,*W@N9./']H>/VT$Q$UV^@7?J:9"EI#L V$0^!
MM#U71L;^QUI.]+[-\B)Y ;2"9RA2/N8H>LIY[3!,Z@.@6_L:J2(=MKM.I.Y6
M4C@>T]?%LZ?-"""?T@_6,(3&BR1 '6T (*%A]^!FR]LM8K[2)*&;*Q!G@XAP
M#_]<<#F[X1UYF%&H+V4441CK"V-\J;FYJ8;U$ 7D'*?7?+ZEP"DG)WDC%PUM
MTZ12")6$I;4T+)5-XZ>@)1*)^J8=4X)+YJK6>+= E=:NJGBP<>%V^644?A[#
M8UZU=4K$JKOG0N5!O>2PHX)F?7V)^VH8@'<-8I&E=0!C3C)4';>Q*><6_BGG
MDU7;%:Z^GQ>2R1ZXZF]J)$1A/B5 >01C=4/T R@^DH1($RAN\<E]A1$R%"XJ
M5\4G8))IQH2Y#9DA<PWRBI>V6"W#ACC@-,KFV9DF=+*\B?CE/2>'(U":(\CU
M)V^'VZ,?(Q8&7Y1JB_EC5I]G<RZZYYI)A=.)"H-(I)P= BM6TW9!D8&D@83D
M%E\MK=8X*B#- NTLDG3ULJHYR"M[A^[A4Z" :BNWC@F*0']R72*B3YO^[1&T
MMWSZ.O+DIN>I\8B)\JRC(F)W9&&+<14*G]PXPREDJ*[9\D*I&KIT<R6WSZHR
MTSCK/*FJY(O@=4A9J_674B5*:_6*%'$S+Z?)"?F8K@S[U:L3*\/F(5KY/7-7
MK]I6FCU$?'U!)I5?T"$75;) Q-5^4P7';.2R)#W$K2O4Z.AU27W)Q(68]H,7
MR$_3->C_]/SXNT='W[UZ]>)A6#S.)HP34) *\&CDDCTK.R^N,)4ORGQ%7WOU
M*XV0+6EE2 EVS9[I.S>]],U+Y$GC/#-1-KF0N[]34R*;S<J//.07KU@"N% 8
M\M&WY8RRT75V6H>-8]"[H 7+'7->V7Z_.MGQVD7PP:.[ 1^\<]KP?=P9?0P3
M,JX;V)#B&G6^K,\ D2=U 3($+>DKNDXP+%;39[8A2 9P0J=@L= +F!ESE/6Z
M!Z5QC7@B!LS]Y)708!O[[ACC;GKUH'PA9$;NM[+C_]#D:S5[&3LX^@SM:=_[
MD>OLDI$7H0P/4.=L\YH59W02[ZVO4?(:;0=,"5I=9+?NEL7<X8H#3%'0^BAH
M-B'U$ZF68@JE1%D/>H*$5X1V5H6?(R0/I,U>P!2:"6$H??V%FWS8E:CO'2W!
M [SMQV)YDX0CJ(KN.;C.7B "0H:<4\0O@I6&&3RF92-[.&(JOV((;H&WO9?!
M5AS()8,?<'&T?/*MDG+7.B+>>-UNLB"G J]RG.E3-QR]\G^B(5O0YZ"WIFB>
MS4]*^2'Q.Y1<+;;@WCDR-*:H,@KK8!%$"..%Z?HK8V.0V^U/[Y$!>&-QNS*\
M=U?5J/ KA.0?KO>[+HKZ=6.T"\&M[[5JA'4+2(LV@=T";^9OUUSEY_$B/]\<
MU]X%L;? E<O0D.R;R1SF]5;JJQ-OZE\W)[3;IL]0+]264\^5%82'1O9LMR]?
M;U]B>I&X@Q!3%X6U75N86P/BB-WV?;WM>UT659Z\DZJX%UH.<,'DQH,"2KT7
MM79#.A5KBCW36H[=SGVUG0.'0JM)#^U'=K[N2$G2>^ZME69%!L, 6#_8$^/\
MPPS+O,@Z!@1+3@[IE=I1G*Q<Q84$H_LI&0WF1V: $6A)F%HJ*10OG@4]:IA,
MV.4B\/A5)?V3]&#98>KCS#FJ.99J%_[.T;E)DD'0++77N4+; $,'Y2/9(IO"
M!_#D=R&@(C!JI74@X]W_O>)89&H/F0##!DRU^:HU-WRP -7]E41DCMZ0D!T]
M2<D-/#I,QX*G07#^P2]!71SYC4^_>_KH\4-IOTBW8*$]D!7QO#T2:U[PB?SS
M5*F D7'<^AM^F513V^;^2K]@ST38#=/D=%H(9?6/Y?0<$>]E4?[_[+WI<MQ6
MLBW\*A4=?>ZQ(T VJ<&6VO&="%J#K>Y66]>4CV_</U^@JE D6BB@#E @Q7[Z
MNW/EL',#* ZV9%$4^X=;)*LP["%W#BO7XDS$/YOV/&>ZN$O>L^RFA:B-\X52
MZ>HTA,"HKXE!>ZT$QWF+&A\+GO K,3-G1]'HL%MHU>;KXKP)$6N^"!NCLP4+
M\M:!)\_%<2BDYF!1C&I3KBU<.LA91E*X=IGMNV[.)'$%#<G8OW35U-.P3PW*
MM=N*KCHOB<?['K]TXR,TV.6B/MD2KP J%ST5!TB:)^S J8I)&O-+),+6-_5S
M5=*;11WRLW!JT3JY=BOR_7Q_W%B%P(1A[Y9;IHCH&#1?ISWIFN(-Q^F&X!9S
MQ7YI-I<)]/;ZC7H%DO7-J.T90A8:\RA'TLJ6TE06Z7YY?&*/>@T4C'+_+PJG
M;SXNGK:D54]5P:T*>$*,LS2AMG#:[?4=JURK#*U\C8^]X$J9[)?DECE+>+\0
M/O&Y$*P[I<YG5#%M109U#F'J2"JC<K_9 ":T*@#1RR5"=MPT"%7([V^+4T$2
M>'U75F44L1H],D;X@5]J:M6Y"6_"_2+YXYP'/1I<G=*+AX1+[J7$W::OP"Y\
MTJ;.ZC5-+,_6B:#Z:;%X1\$J-;F25+44 LWMF#IB/C0FZO;$8Y<'):DX9MZ?
M"&,== @&Y+0[(ZC(,V.EVT3[HILX*!)Q(F%P"%N;>[/4\W @'2=']N\HZJ%5
M;$^EG]Z:0Q ?A@'4 Z^F;NJ]$.?!BVE:UEMR+LV%,($W)>4Z6'N2PE 64N7$
MA9?0C9$CTKG!<(6_G)@-&T:4B/<XZ@+BB$OB!,(LNZTF<L(' %Z8?+D(T*0Y
M.S]EO8?3'#(.I6!#_]6'C;7D3BNGO%NV*;SS[FZ WQ"3RB*AI!7)14 4P] C
M<5;-*&EEDY8/Y9'*%?WJG!QJ40 U8GG4W76=J.V!TK!DR/B/_69""]BSC-@V
M>AUL&^T_?J]NT9*JW(7'KOE*NW?3MP;12&BL#53&R4-U['A<9$"B>M.\NKC'
M<R5XKH?W>*Z/DUCL6TH1\3K/+^LYV96L)2D6PXP.%-)\O#MUW'7QO,O<T??@
MX.";OQP>/OK+BV<)I+3LJB)?ZM.1]<@EU>V>?'"AQW]Y\)2NTU#GP2HO6P>A
MC,H_G/8&/O_!-YQH/7AP<(552Z&^R+09RL8C3]U@61;?'>]7COSHD.<" !H;
MR',#<Q S:G'[[PTG4R9+M9<E?F"DLMH\OHDZ'O6H$X3&\8P3%BP;LR-*^< 9
M^EN#DO\Y9HG)$>GO+!S^58)'.W@"!!*KPX?3;<0?D!9[6(6>%QIO#0B]23@2
MR1A?/C\BX2.Z@-U#^-7D1BXTH0ZS<<,UG<?$5$!UMK87"*K[EMZ3WEWD;%6A
M@)GC.^D$&@@RL4W@YY9*R.R8<9=P-Z3L )5XJA($GS=?S%;2 )3D\J3)30@K
M_^H__R^XQ\N+SCBBE8XRGRUAWK3<B'+"\'MEU_:;*+&P+'3(":4HGPYW-5?+
MO"3'GPF^S> _KS=AG5*\1WJ62]70*$ZH]G;!^@ILZ\-Z(N>W7^.?#>/75-6T
M(UH\IK&3#YG@'42,N_(]2=9M3[OOX-%QS!1F:=U0V."B$XH-XF_D6!D- ;60
MO2NJ$/ZP,#(E62V)HC$N$"/TS4U1!=,:EN=[N4\'/QX=:[.J7\_SE@4'FG!@
M-/(+GE-.CN2+GKKL*/:1?])OZ<=MF_>4<EE0]6C!W% AWFC"#<7V#Y]]?Z8+
M;]4S=O<<X34"NDW?DNBG6\B[EW[,[]!IR8M:C;T<V4X<@R49:5W?V2KJJP&6
M%B/+8FW0:;P2"PSHJG[4-W%,V@-:QQ"]\4T;L1F%35]LX-!9EPKX[#@<I/\N
M6BZ/RJ=W6QA>]KPF/8Y&;H(")*Q<>!XR!B<7;D%JTR!O ]KBT?S*,'%Q?[E,
M;6]B72\QJ?UF:<!BO,K>P^>,6.X*LCD[SX1,1UAA"\UJ!3'R+JKA 8&M&\3'
MA2C5PAT98Z/#G\,+-NVF02/#:+^,'KUDIR>%X/-FD\7 =5M[J&>RQ<"V8RXS
MZ6*R1SS8B<&H40<M^5(G;<$ BWFQ/2^*) /B5D5*3VY9#RH(BFWC.H'X>Q%8
M/ $Z]9>-IQ,EI*EX+^)M+FJ^/-P/?F,V.VW."X30)M_!,G)U,'!WU<+PIOE;
M7U$ <?@P[IQH93RCB-D @@6#?[6X:"2-GW@=L1.!,-]Q=Q_UA/:I2!#\65[G
MI ?^(]7]_]Y0(/2J:_.B(F%P6H&EB(7_W^":PZ8<4^? [*@-YVGX4WCTDWP#
M!=IPK[=Y>4XS)42R,<(+(UE1=(6U'LL)([98!YO@7J$3H$#^EH=9^;A!P#Q?
MO#MI0Z"UW)-I7^%_WWVZZ.!%?5:V38ULD.^A_:A1PI@-^8\8F:MHDIM^VX7U
M 0Q#DB4/8?28$'@0JL+Y;KGRH#N+&B/#AJ %FDA(,1TG):5]X_84D?$$5X+(
MIB;39G3ORP8WI>MSJ@.WG[ZW6'UZXJXH4&-CKVX_;%2QCS%_3/D#QW,8VX-M
M_Z]:Q<2Q1T>O%;^4/K![S\Z:?G A.L/"E)]8DQ6]CX"@I(6DOM!"TE9D;_BY
MC>>! 'VT 4"%; QD"0<JLIO2N&K=Q'2.MFC7WTG0O&/<O8+Q9V]!+K47/\;L
MR<L0/W H=30/A\5=/3B5>R8*7'."3-9 'OS#1:FHNK"2P@E*#I)RFGC0K.4@
MPW9Q::CPECW4BK%A"6J88/LTQ^]/5W["@HYM9F1)L+$>"5NLPK^W:6INP5VR
MJ@P>'CC8K]BJ$&G3=^31QIVMJ8C%7#)_&D<&_W.);T5<;-ZV%/5Q^?'<*6-Q
MCJ[IL(/#8T4PMW^N9BN-O"'J#-:FH[MR*K$(PU7.Z>>!A=XW%B$W]"M;PSFM
M8=G1\$W%)!NN%[([^<S(>L-DKM$6RS0;\)H(^$SQ%6MK860T.Z*].C CS K"
M7BJ%T?RO<IE%]G8Q_>%!B.RW6$Z1L# $%<\L&F4F3@BMN5C69#,8M8U_SV:]
M!TU\&%$9)80Y"BMY[^_EXAT9=\[1;JW#7.F!=H")W]4(AZH+@S5SCV_7 -:'
MH@-G)O%/#5$9BG7!5%SK7@/<3#)XU86JD_)/8.]8Y-VI)-5H/V=LK<+6*CC!
M?QX.\5E1RN.1!0OW:IF8-4]Z!\-.R6:2;]3]F\VJ O\GXCC./MCGP\-0NB*X
M"Q+K9=AMG=MN'/7*T.47W N0$X-E^+\ETY"<GS:5R*\BEZ8D/9>R'2D^)4:7
M$H[HUAUL2@HXE!#.#[%RPEE3+40T@$,/7PGF2W0 M7\B>#N8:QI%:H\O3+["
M'4/HN/!8\D06" #YJ35F?!XHAL%6Y] 9"M:3:9+!%$*&F?*(6YH[6G!5L3PI
M,/PL"!B<3?(N^>R"V\GWE]I[L$_7[62[MS=_@+UAA^$EN,:>,=?8T6)[38,3
MMW%G"P0@ RJ01&LDH!DV.BVD*"7,F1?Z1Q)(9L8SHH"C@[B'Y^3XSW0+F[@5
MVP.PW[N[K?-WN%/?3=^0MCX4N3JZ9RYW)7/20H,3;MU:UNX)M+8<%5MXBG(I
M2GKY64.G-)0NQ%QQ'1@.HD< 448\&)XPA,6%QE Z _%=]F='<I/HVXUM&A=4
MP!!'PSRQOR\]2Q*^PGSWF/.0]ZT IH0E<;!.]K4ETE&;#3^C)G<.D.]6.\G<
M%)+AH&?YR/MD9S)D>O,&[WVVS=>?;O/^Z;^<H \)OH5H EZ;G9WBL]?YNM 9
M<L.*HZ&9=:<<5NQ.9GZ12)U'GS%2YSJ'X"<:5TK(D)E303M:CA?[,W*#VB*2
MNHZI0KG0"MO-S*=Z9B1&BJ",6\@43YFLG9;UWN6X12X'9XUFKZ@0A*S?FZ;=
M:GB*#-("^"/]U1%C? ^?/OW&@ ""X[5E%$6FJE*_ATC!NRU&AKLK4"K>HXE8
MW(9\&\[>C69D^6_D<<^ZQ6EP$+B6H#F#"Q\IS(NZ6'$?%44!"5T &_'@0;7+
M/0HX+L@S +=GN.6N!Z,-$%89GDP\#'-N:)%S 9#D^C3K2?F76=Q1\2]RM2)S
MFRD;[*;H K'JD(&>*2I,MFDON"VYZ.R\Y40/J7<(KE1?2M)+ZT++GSDZ:"]^
M^Y-IV8^N5@L/F-&[+8NJ)-N#S$]T'LG*C&>JD^ Q\Y[6O=&X14;CC6;^9F]D
M)H_[NCNE,A[B%>/39-CSL]?'&J#_%(X8_5*G6U(-B;'DI3E+ZDEL>PIQK"=E
M7E(EHEQP:E$SGJ+C.)5I*'W#TJ4Y/G",G9;5LBUJ4Q8>6TDQ)N#[9M6'NNZQ
M;>3<"R^=)=5. W,W^E0^;RH)"728K^2MD570M 0B)?INS+I^%2NLP?:A4NSR
M$V'+,TTQ^O<ZL+T1+*O8MOS3IEF6.?\@:)^R;3:BEBELJ46^0([#I7VYJJ)\
MAK$ ,Z&6/!H86@G->1T^<%IN&-B!-@J>(_) H2IT2HPO8>$,,LS<+%&N:;[)
M;O/:%TY6R3+KR%JV]LJ!):^<4DAV,WG"_=GW1; BM2 T'AP\>)#M?E\X4JA=
M^;I5'(5T)9SD3$J9+(3Q(VHGWW+VU7SP+(=?)XN!VKE*5$;##-5$/"4X9;HA
MY"&M<87_BM10,(!8"7D=AOVTZ'A7==OD:D(M2'RY^*9\>*M?70X_L;<NE^?!
MW-^(;^?>;G\DNYT'CZPY(2>=2V0,UN$*6)6?N\(8UAUM> U?\SGU&JO19P)T
MS;92#7[OG:8S<%%/D<\?CHV"5KB92J$(51JV//D@(W_,U]<<$K\$>LEV/N,T
MOW-\[9PVE=VH!3&T -1E,5+[!497"GYF^:,@N*N,$\DS ;T<QL89AL$'\0\J
MU_75B5?.& =&9K3.2R3!!)AO1L(J29HX"R^0IL3)6+33Y3A+^C.2PL:)G:XP
MGO#>J&B 1^$)C)75G<.YR^Q?_^B;L'OI.1<_.OFV\(&U0NJQ!%0YK>%S\D)<
MEE1DX4P=KW-<=* <03D%:V0@( (WN:J_S 1%E#_O.YGJ!<,8W+QK:?>N5MY?
MH:U.Y*U"7%8U%X5PP:\( H&52<,FY08.RA*S@@4EY>6A2H9GI,JFRNB.I<IE
M9]<AH.L8 I+=4$%CMJ.H-%E0RL9*(UG,L\0D"G _T-N0#@!LZ=YP2BU!Y*C7
M5C/I*7XGX\BZG."/=YV/O%2;FC0I$(;&NVJA/.J [,] _9\SB-X:?9<HS6^F
MTM;1 OB!FBK.DQ0-[Q/TCZ_@1ZK[]6MAJB0 -0RZ=[LQ'^TO^\?[$T\Q?6<O
MJ--T18+>FK 9,SVXNO')-1)W<3H?WLKO&B#<2*QG[/2:@)]$"[L:4<:Q7$M=
MG&!TJ@0[H+ '\5\_59Y^&H3TL<L&EUHER<#_')9?-_LYGCFDQO$/](S3:+NN
M*P>Q)$RYKO]7!!0Y/#+&\2-$,.&+.-C"9\(>"A\XV/O['48E4ZD<>_"EK%>B
MWNPWVQ#Z2O\C<H$J#_+RV9NH#^+5<^ HS@'\N6"C/Q8D28OX F+^>]B_RV"Y
MOY?O^KO]\O?O[6Z9-B&BN,DE4N?DN<"1XDO$CJW5125Y!EZ=3=$Z7ZM)'+,5
M7"0F3/F+Q99<CH]]W%*A@RD'=EO,?%OH#[IY][$H-\""<,)CN4,: 1'78 @_
MFX;(2VW%\WR;A]44[.*"4ZS'13@/*5G\C_".=W5?_>H*+\[I(;T*"M)27/$P
M6A,7/"S6K:(523:"*9IR98)2,A>E=)*3VWGD"6FN?$JS:%Q\MT2/ZP[N.WZ@
M9=DMJJ83_/#NNU"D,^6QI]O]-U0@^-D(XI<H]SBL+P[??,U=3^$Q[";QX=X:
MH!G[UU2/H&.@R1+Y'MF>X-9!9C,6UX]"($H^8#@9N+0FYXO+:=$7'QP</#7+
M=?3SS]%.?J6-$73&9^HK_?CJS9&S;N5$0^EN W!+E_[A8T(HTXM%VA?GPX;I
MD)=7J0V%KV2:IG,9 .4JFEQ:L@RI9TC6L/L<&A[#-4[#5M,&?CX<A#"$FEWE
M22)M;-<U"THX=I8RI$U(.!,J04E[,06;)==1&HEIJ<,^ @0(2294:G @)_8+
M!(-;&HUY<9I7*^XE38;DPGN5_.CZ]V!-J)(C"5S6A#(B%,IRYJNP023SR$P+
ML+WDN(OAM32DJG@F EA7O\'^C.=8M$(E20Q81+--&%0B-UGD5Y?,.;R.YP5%
M;!H8R3:DQ_NQ#^LP'!62/=)]]>./QW'+1(?=':A.?9/)[\[DXOF,0 6<]NIK
MC$48S3=L8\._)FR'WO7-CZ_TKONJ7+1,WQ6!S=RE<A7:U]<$5&J8,!;]?I(0
M#]^7AT-S'_<Z?W,0(J^*$)9MB.XH0P$U$#+%C5;6Z*WX510XB=E(")XR$>B<
MA4>G[SP^.)AI4[5'D)6=.45AV@F>A3(B6W[":H4!%PIGZL^>F.,:!OJ\F(<(
M5K"1,=SW&7)\C7-B\,Z"R[F30_L>-Y/@9A[?5MS,;8# N#-GX[Q,,W:QOXG.
M\&D96<X]C7,[6,\,OI;3:%&VBWY-UT2%\OJIJKN;)/16APP:-VKPC"R;<"/*
MKG)E(.FL&*:=A4W&)LYY#I+0,BW+D=[;3GUJ"US?/HL'!V5B],O0-*;&VS!5
M]"C=MM@@+GQ7%!L -_NUX^#E6!!5B7A.\&&2H#R%4"A?<)'2V(2XQTT2/:[0
M ;1@@BH]EDS%XZ_RKPT+^O;9438[?(S#\UEP80Z_"<_TB#["J/?P 6D^1%\,
MPN-8Y2#VT#B^1M'/&%UW3"'OYL8D/%I%,VZ4&D0:BF8DWFM4/6$XI(Y7,CS!
M/SIMJJ5D1VEM&4E35;R7:(9.$?7%(L1^08<.'=Y6U=\V#>M(*TENXM6$LX;Z
M(<[ZBG(%2I2\;_WH&(&R,SHU:+#QRQ3\1ZZ^A*U "FS;MJE/J-5(?:H[G.N?
MHG>-LK"_Q-US7@P%:;%]QZVT'/2068##VE09:^MT1CS%]J#G7(IM+<S#5^5^
ML<__3-25Z]0YK=!8XWR:KYGR@>\SN&:I2LT,#T_S\,GW\'%)U5OA@X4GPO$1
M*^9Y(LK%G)#B^Q A2%4B.6D\$]J[ELK96'6_[R;:YNP(DC0 K9A+^3?5YV:+
MD(X 6+L$.1(7_G"48I/CV//'1?$Y/6V)H& =Z4I^28D5P\\_"'N89(+@<-,4
M>+HT2:W]\/S-SYD4W^C)PJ? N/:8I"T.GT2N@SW-*"6,;@_^\O@),;KIQR+G
MFAPP,8M0;O=G+R@<&-"$<AV;)-,]F4G"V>8OLQ7!EZBH 4H,LA[->1T?8&K$
MY"E;H\N-O&U2PYQ?)'2B&1@IM]CVSGVI6&BR+D33@MD^IO17F1N89&CHS1.F
M4N9TDKWM65;IM*(4D%6L_<9O6-^:7^LCY"QOCWU\*ZN33@]KTG.%(AW4P7(2
MKM'NE&(H;.,P6O6BA!L3G5$IU8D$R9!1)5D\W"'K1$9^X8W.#V=DNT5+><8\
M3:KY9 S'9K2&<7DQT55LY(4E;+C:;TF/W+IV5I*7D(=+[+IFO$-,NHT)@M%]
MV/%P<BO:/Z$!*/X-IX777!>.A9J%>!=E5["62Q7>J52W)3@Q!!9CVE?\E@;T
M:V*<D>>=].!*?1CN4-)A'# ;MI!ALH1)FF=%/Y(.J_15;_B(D+-KTQ7]LJDO
MUM#GQ@&7!3?S8F_1+(OEUWA3O!(LO]4+J(2%09#\11)_)[?CN(>0=6'ALGZY
MA#Z4<IH:?B_8#,]G2Z3=*2W-6=B12]9<$C"OGGRCJ;<.]1#< S<#OK&FWILR
M1EBPBJ5SYFP//35(NT&F-'@>#[]Y]%VP[[.PKZN2.R,?_0>:TJIF'J9RV[<U
MY4?<3I!$C*321US0?!#*2,]63'7J..[\ >U60>;H2_6MZ3'""1?<>R!6@;Q<
MX$23\Y/GE<$I7/(56LZT15P<ILP2\-Q%E!S. C^G:U"'73$D+2%_N1-XJ#3(
M4>,:P;TKS"OO4-/A"@L]CSI<L6RU^V2DE-_H>%3DCS\FZ0T,&%76]T?B9Y/%
M]P6L 6MOUV\H):M)8WY9-0/JUWG&#7B%9,G]R':7#NWDL+J3-HPI)G=9$ :,
MUJX7-0:JD'% ?/NAQV_$P^IH*T0Q2ZYCS;@3<81N%V3OP[/06L+R882QPD_.
MB:YFBV!8VB]::>).R#<&M/2PP$W-9>Z)FR>Y#Q ,U@PW,IA0.E8632?6O>M1
MZT;+K='6(21SRM\$(QQE"TJ6I<+9O.JK$.18;86-0)*W^54G6N%_PZ'LMQ2(
M1P*S<X*TATW-/283^[6HBC/*V>'KQ7N -?PIB+6!M YHVP=KTWM M#."DT0U
M.4!=+R) (-8^,\&4!?^^U0PU([LMT-6@3G-$.P*K;(SW4?,[D"_\BT#N/*+K
M@QB1J:3NA[W4M>[S12;QO]F=Q*?'+9?_WY_*Q>-\]>CAPT??/'SP[:.G3Y[.
M'ZX>/EWFCQY^^^W\P?SQX___T=,_?8#,/S#VO[]=]O9A35XG#'$ FS#/Y551
MZ6<1@O[*V R/FQ_!LC?BT>)@$"D?*3@:':N@DMK@%A*[%;=3M<PZJ5\APJ1U
M1YETRB!;'O#GUU9_C2R5>P^?4UXH1(DETE"F0D8(45AT>+0SBCMP;IT753".
MX'0&[&61=Q+ZD=G6TY+U+EAWA7-A]$^B^9^QOY?$I<MP!*"40$J:'0=H5%V%
M.&=XTF Z3B,?;WCD2#A+FAZ=(7/=0,E1"1I:&JJ4@% 'KM.BI_#+HH(>^66=
MFSSH)>H<RZV?B8[T=(<$B".ZPQB?N#]']::\34#[II9S38#)9[8O8-GQDN0K
M(N049'B8P,0J9+/_S>*(WCP<&:TNIBRL<B8D#9/9@J[U6U.><8 C^@C3N3XX
MV)^](?KMG"E,&/BD%\UP03<9G470@VE#*@C^771ZL$:$X2<?Q:98ULKAM)22
M6AC&"CD&6^MN741<25\O&GAL:[3_T>?U.?AE)0#H(J]DHV#;.5%!%<+<7[/O
M?CF%/YQ!DK)%<X ->!JG2T3@<0/Z<OR]-:6S.K,:/ OY;![N0$H"]F%AL9+K
M405R\II*'4WQWWLXVT2:3[/G[B WE7QZR^H\!=AE0-ABB7J"S(,$/(+'1B\J
MGGBY$JI+KIUUZ+-AY'NSGKBYTO_JPMF>AF4D537NT> U=H'W+%C0*GB:S9:O
M*@D./'U4,7B;/&&(VQKPT</HM&$>SSF#$P8$R0XDY(N]BR)OA<B_^\[>R[$Z
MIR\N]1!F ,;Z*>!*DV(<LY7A+,/2E(4>S95=9I]WI5>40?VFKMP1IMSI?LE?
M+;3UN1@Y8ATOSB1,I)<?$.*ZEA*.^!2D3!9$SY8LP=KXPH6@DZUS[>7SH\1<
M[-3G&90_-);;3PTOM8JH<*W"6^&JC,2-.:,55AKMFKS=#ICME]0T5,Y[SM$T
M;;7<.Z<0<I"NB _%*6FLUW(!R& MIK*OB=\VV$$L.(8&,J!5!L!5*9?!WG5;
M08X"9&Z9+,<5JFRD=V353<N<F,4[)^^(5L? 9L_'OL=4+!\&^#\[.X]%&L%7
M!1=AQF -PG)Y<#A[]O+GV1L2WWA" DR:4#V#ZPM865CRRXYA;&4=401NY>%O
M8"EAP@K*&89_T\P*T0<7JM>ISZ"4_YE**Q-<E(',E"!8O,M/\-<N+(*P!*2E
M\K3<;""8\*H>K!CN9.RRJ0./$^_2FRCNK>+&1W?'Q_2WX:%SH6Q<F%C%T&-@
MLU"&"_!6?_[B[S\?.7$+#/SW^_^]SR(,M4HCS)OEQ;Y\FL@3Y0K;1+,F?<OT
M(?YJ,_TZ/J=,^JOCGPX?/GKR^*_!U_J& ;(]4VV;53D.QCPGCK,6C/855<IJ
M8J>G$?@A'%DYJABOMGEU\=WL91^6I=[OR$8K>4UKZ.!E("-NR]9.$]%Q"88/
M'WOQ/L=!1E=8.$V0*))R-_;^K^.EZ<M%$NT,6F*'?-W.-":E*A^[<0T]72Q&
MQI.H=LP+L^.,4V:;S0MYMTUV^6@M7\5%H'Q[^S,3O#LOC/# .>DNWAL,2\)5
M3N9P]/[V2BKI<=(TR\'Y;1BQ_;!@J8Y'#TM7I$;:3$9)SZ3)ERU9PY65-2:X
M([V19+9Z+T,IX*Z138S!M[./$V8PVLC$('(P(G9ETCZ.B:*?W7Q!E9T__"T4
MAZA*V \8LTX[:,.TM>5)TR+[.U,M=',1HBM %6S?!)U&\(0CY%9F9+GIOE=/
M;_+8&;<><F*8T>$NUS&!!)+\1Z/]R%05H^2T5CMB0YK? "(L A@^[9SP#T]1
M[C#S!EVM_P5Y,7AW8=6OA&@3-6"P;Q:=(\O&7RA*1!W%E3H9N=2W8>Y9)BC2
M96D-LI"FUUJC26$HMV*LZ!>&EV1PE(-LW0E#^U.JY]!2?79+J[G94.D6<@K!
M@^&FD-RINRD+J@3Z9)[1248A)!QC^,7:W*4HAD)ZD;B^M$0^PNE,//OIOU\]
MWSM\&G9Q&!MJE1)E-T9^0I(I[/Y6JO.<_#C2HI1P5>_^+*RK:&!$$QML!]C;
M@[,=%L4IK7$N9>==5/ P'CKNT*+5<@(8#,E(EIQ!Y%_P[*,2U.7GBJZI":_!
MB1$WW#:XX]?4YAQZ;GJ2!:4,-&!GU3L$&@O&'OS*)7+(H)<%M#6D.Q:^$O:G
M*&7(H%P^\%/+^WIE@L</_O0YI>W?2!;F'Z5O"(RM@G=BE[]-%&P$X9%7Q<C*
M&]:I-R$P4"TD\@U4^.RD>4:36)&&D4D.-,_OTE,2&H6%N>VC:\T;"[@+UI'4
M^TF%%*=!"T[Z99%O3['4%WD++AF=).MR-HENRU? <>,R:2[I>-T9L8-;1-24
MFD?N ?D9.!G%[*+IK8S=^1LJALC5M!OV@S@WWDX("E7!3KBL8]RT=^1005(\
MS-89\V:;LRU\FV?%J-KOUD^<5617&9-8"Y Y/SFA CA"@##$Q$ "/%,<3)UX
M=$!K84:#.BMTJ^.=A5]M!<B47F_-[I H.?$RLNO1*J84=-*1\]M-YH.'CPX_
M*Z/)'9+/1&GIYT((GZYLG4/Q]\LHN7_[4?KF?F_U_!,!-O[HT7\M%H>I<)UM
MCABK[EVPW%0/,&HIQ>&Y/NUE;!'&V?2NH!-DT5NCQ"DV@DJ.F=S23RFZ,GAI
M;5]NP2Y:5,U&VH6XQ3P\-I41Y'&VS."#N_DN054QS".-DU1&]JGZ+5E&0&GY
M"OD6B"]$OH8=%NHF?@HN#U(:-;CH9Z*)_:Z8';_:^_ZG?[Y NTLM=4P*]A Q
M2?2<KPJ4F1F-Q;7"#<&A^CKF.E+F+J([:9MS_P3BK5.#>3#70MN RW!6A7N@
M<$X'EUW"^$CA&SOOI0I>56S<C6/+51#F%_9[/BOF?5DM'95P9[*F \8Q:P=;
MK_7MO-]"<E=RHM&(7(&XO#L;#;VO1]@)SXL%8W4?'F8QT"+AF =/'_L>IACC
M,T479SV%6,^R/>D"%>J= 6<;IT6YPP#?13%:ZR3L:0U3503,O>J!3<=\51)#
M+#]FXJD0-?F#!Y.0!MPRA&M.;?<Y!W9\#UI8"A>?(9%))?VJ0#=%F+S#@__X
M(Y;/QULK-Z3R>@Z;$F,NH=.[;7##3U#X,BG*MD#6@!. TE>,MM>2%;6EAD/&
MJ=P*/B(7NI=@A)$"#>N/+!-R;F+'33F\]JJ6:.WKJ[!$T:*B[(:2HR1&"3&$
MA,NRE?IAA^C!]912/B4)W*LZV@RT(T!Z?<=BGKVI<NHQQ.E9H+[+JM]<QQ&H
MX#-3_/X!E&!<,)))+;[<H98D HC03QI:E4F'"1T.M%'0?;4E)+E;WQ+4QZ6O
M*6SA!H<5)BQ+B.Z+O.7<<944ESC!01 3HE<D#P]G&>^5Q-^A;4<%HW"/,FK*
M1R]"*5DB?)N@C1MC@"$N@K[[M!/]26<ZR>(R9G_Q3N?7&2TN+5'ZE=NO:)A!
MYV/SS+6F#1$;A"#@A!6(HSL':E@^Y$E1F5P-M$X#056L\ZI0)E6O@X&VC.!=
MU(+="$]E'RB6B7,HQ83OFYQ;%9_+O:(K&5]'7/GT!3Y,T\YG? !2]9?E?5SO
MY[I\3\,519 I6J"H2;::)=$LG3?'# #/(Q2WX8J8.C0G2A2VJI3GCCJV++*3
M>(<VYKN"P&Z$C?UB[? S!;YE8C%EE&H2Y.!Q-HT$ZKFQG=+4]MGT8UU1K?:4
M3J% L>6H(R("I;S[1+O@UCC'S F6S8Y#K V$8AC-7R7$_=(-Q%O3T,Z0B]#Q
ML13 D#Z#$RJ;MFQ:<0VL4L"E8>3=A,Y" 'H,_',5?6X);Y2L V[!9*Z@;%DX
MI)2#7UK"<>H#3E4([TP=0D&A(%\1'<V\D@1+N.-947O2R\D,API[:TYDQM)_
M EATWHOOD'0$5=3!ZAZ?2*HP')N"TCJD]%WRPRR"3PKN^[-4)D"9^K=HH#TG
M5+(4@-\QK89\3IK-9&RLDD0OM#<O@%,[LEX%\0"@5^R2-L2S76TT0V2/+1PF
MX@J(,+L,&B=]P@BP,]?(6=%:PEHO&AYL;:P^8/N/^*#2FJG922/\PB)\GUR+
MHCY1-)G115Z@.?.L!$,B;"!>9'':,'H;I:YP)#%%0-=P$@E1',I4*!+3V5<4
M.F)\,AFSB)Y3Z5+[XMV&5P.JJ%%1.U-.2B"R8C['EM*E-B6LGW?DW,6>3)>A
MY7(5 Q)^+1)YJH3LC='O5JW2M"XA#(K6B&SF!*)7L:()+J"4H',Z-4D[B(7?
MLRD,K*.>=@@NH0PQ%AWIV@=X*_\7&T]5$:"D>K$W!P;$!3JT]6$$3H,3H#%5
MPEOCNI)XH&.#+Z6-G3UR,#^:,=KD3;U';(]F8O#_Q)4JG; .<$OZNC'A[RZK
MUW(.9BE119AH43,1F :!QX%&H@PQC*.>!MBD\77CF%R"&$6R7KF588G%FJ7W
MWA8AWA5/*;-#RB\J=RH,QY![/(1H:9V_+X-% 0A,&X+IF</^Y+9SRE\@(7M:
MKK8RFR1XN 0WP=8UUD'#[P3$'^BMBY;5KJS'S!GBY1(9W-E7;]Z\$,;44DCJ
MZ$N18*0C1!=SES/W@C"HR)3PH%X&N/HR',)GK@R"T?Q>3OV;O\QG;.2=[[48
M#HBY02.G0<_2-,8SD_#E!G:.01,@!TJJI?4V ;Q838U/ES,"T\PO1&#A(C.#
MPUI\(=BKF?]:$8#(<36+=\0SM25740C@9R_T\#W&G]]H>QSG31\=''[U[NO,
M,VR+(1&02"P'JI.&(TMD5\2IIMZNFOM5N60$JKJ2FWG)P&2J]%<5^9GXX/9E
MV'BSB0IO9N$G BY]P<OG2$"A&\+@[@03<I79*KMI5M28HICY,M)9R121(NX>
MYND\/Q&7/6Q>DN^-UR'65[C1\** VV+"3@V] .\USR 3AJ!P.H?3U&%!%\;>
MVBG%!DJ FZ()9^^7.\]$>5."=IS:.2M UBF^T[[*F8AOI>&P $P+U3V00)+"
MU!+'.QPG6R[J0'_I<<P+,F[<M5A*;2,X4UNL:&K\+;DI\:1E%U9HN(*?MA;X
MX?W99L6C"#F$3PVW:9R89Z")=/.2.RZ=$3JH7^X8^EHGX=)[@[]SQSVM1ZS.
M"^UVL0Y+57CE3!+01$R;A1Y!9K/%*B_;-;>#1XI;N9C<RN+SQ.-#3YB$SW0"
MH!F$[!"E:4J#@?CP>V-<;EPH" <\TGV*_(EY:_U__4NXB;9QT:^)Y,']*@1
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M#>0QFZU P<7'09J_J$]9J5N]UTCA39<@!Y'.JFZE,'VK>898I 'Y<Y%SV76
M7 N;3"H6*0;M%*V[',$0UGY[>DL 95_J\OK)6D1BR5E[+SN2>YSS.87@M&.>
M6I@J(D;K62\.9"03<P\K&'P^+K[,NB*FK=IBW8".4):/A63A9NU)(1'9*.^"
MMI6.-."6\;N;X'V3$\9)\WI/^KP9@]R"47A1A6W2-N%Q[%M%57)B""]%$#M\
MB:A:NK0G1/)S#O(_R[7L;2B(>TP<62H4 =MFWH.Q$FEV"3QA9V*8Q4>SZ(S3
M+S$E.NI.3LJ^"YN67\!N^9(DL_I($1)+CZ$21#_#3BXN;9HIX^?1)H]W2M9B
M'CKUKJ^)SE!Y@J2E9@</)_>)L/\-+FHFUM+;I5KHL0T>;$;V\B9'Y9J\VJ;Z
M5,OKUG@&SP1!<*%^]!=75$P([M ;Q@OVBO:P; #"$<2/I&3U9&8AUT[)(-9%
M3E9RU5>9T)@S=PT\V/I?S46N92?TUU%RC%EB<.L(.8I%N=1]H?AU0Y2@A3R=
M0DEX,YXV\WDIDE*UBD,W54^E$",O/F%QJ\3#<$](9;S_Z0N$"(52 7D,+LX<
M*:H)DN&+M^$_);/$$\E=[@X4&(5,F,U5$](TCZQYX%;6EQNY$D9\\:YNSH.W
M<B+;=F%6K*S#@CXKM'.7-'7:;3Y1'5'^Y'2<XWXQ[;/+FC^_W%EX0U@Z&E1U
M)AFMU""K+F#17 D6M,5ID:\W?=(-NFJ:93!'50.V,"%/#$9F28W)7_ B3[I'
MP02&1E170R=>(.I[K851A=BYB/]KGM?OA@8$X)>2H87+*,,,L-KL)<$I2.IY
M]GWPL(Z"49^T,U^JZ0:EB:)^00;3J,--B_O%\0^S8Y),XDZ1V3^*+8NOL-I4
M[.E[+K1WG8%4ISK_NB(A87L%6#J!'5GJ&IX]/(DED0A4X-6)F7+N,=,D7DI1
M8,@H1M&41-&,/3;[)V\^;5\R5>VX2W>_:$9Z44R$LR3*Y&5,V=(@V-9'5W];
M2/V-O7R46H\XG/D90NV_@WOJR6=%H_*"PG$:V1^0K#'%@V/@S.\,%Q#X&E?,
M(%?/1,VAT'?G1)77"WYP^!U]=EFLF!B^-CWBPX-#W3=_Z]>;;DNKC+RJ[Y78
MYYA^U6_"BEILF3[M\($I2/SMI^^/Z0\J(P&H]A31)R+&R>>;$=] -2(0>)B%
M/Z"17QJ>4FK:9K$([OA?9U^57X-]G7@ FBU:%K#NF3FNI0.3N-H(Y?;GP_V#
M;V?S*#I'^_T[^L=7)5_EW)ATURQ8%IZ:OF5?"@/'^G?!?+1;0-F6Q7RK5FE#
MRA>N__4[DG0^^([O8+<0LOU<YZT*:X\1NE7!6SJ$+\$"3$_<SWU5\&4/'\SW
M'NC(O'C/0'B:C-LG+_1';Q$>H*/N\F6GK/ZZB+G22#2 D!%?DC"5=+LBU?=>
MNX LJ2@DH[$0'W<6/\*W7^5??_7@ZZ^^-]'O8VX4(K>7-M1*^-&K"TLK4KE&
M\DP0@3!*#L/UH:F@9[#GKM>C]V *4I23 $KG\T^1>5,7ELW(K-+QM^=@-(U2
M;JS_CFZH\HR1[$+\!@. M!J(*84^@?2^:8]V)!4C!W5)2:7@=&GZ/HM2@9@(
M6!&"Q\W'NG7YNKC.,$&4A34)^GD%N)SRTR&Z43&)Z3&\G/?]UE3T>:%]EMOT
MT@UJ3!PH>/)2X12]GEV/#AY]-8\;*V^#BUYT>S^]KT(4::?5P0/6AM$#[]%1
MV)/XE?MR:CYO? ,3Q<W3E79AV=$\.'Q;#NSR[985/3)IG>/<<)TYQO?X/<H[
M=THE4HIZ0ELSHRZQ-W?VO-TU7BY+2OG!=]1W??K8'('GS7*Y1]'+._Z&MB2Z
MW4.(X4HT3<5O#?:R[*CYY*S9<L]^1 J.^@I.Z#MH_,H7I_TV_00XA2I"A",!
M/?!V+ELNWF;LHO1F)@+'-1W>^F.OJ'M\EN&SGGX(X;QO(KGCO7#>>)"/USEI
M0DOP1WOENG'0'2U%> NB;G<G@]3:(.T.F-A73%QO^M3!T^]V..!345#R$#OO
M'H($CFK (LR'R:IJ<F1=(['9GQ\\/M@W">T8Q4"%NE:N? Y^TB^&I1Z_:+65
M2^[TK?\";#-IJJH8=)8TW1H*:6"V+WE??MH*GY.QK"B.,F;996Z-$,+DO2JI
MIJZTVWBD2^Z )Z26^5YDQW8_BY3JHUXLW,KUNEFJ;/S**=K,CO?^SB?!WO]1
MAI00NK$Z@Q/TB]H-W5^ORD"(:2<A56=>H*M*L++Z9*\J5F*ZKMAT>X=//F$
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M6#O!YW2S/Q\^SIY\\\0LQ-1EJ 5@5R.5XF9WU 5PAP?9TV\?P0N;ASBR.)/
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M7X5RR;?YLFQ6=/(%*W%!J= DZ*_I.3JF/1''?_0LJ ]Q5MJ^6Q=]2QF!M0I
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M.U76R4#&SC=MB5MKK">M4ZV.77GK_ 0]%^1NGS@NWB;LS>"Y60T6XAF<5Y[
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M+LQ0%T*\,RZH8=A *Q\["_$&?=+Z)XV8"2A)\_IW-]WP:Z$D*'$O+T[S8![
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MPAR4G5@<\@XHN_VA!01NT?;X=5B.M@A=H[/EC0>2:Q^6I(\MJ\GX<N^I#C!
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M9.QZHLYK4J,RUI^LI>*@X>I_=I"D<8_";+)A15%+XL)U&>_/_/JUE;N*"Y$
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MB#<B"/NXQ_PM<NZ8T->.@QN/#"7!%%>*E?M,TZ%*TARE)8W#1B</UKUO23A
MKSN82VJU5[U4514TB3,FR\T8G+"]&#Y:E*N)C?%1D#+AZ5$:'CFN]F>OPRN'
M)Q744]F%EUI6S,_-Y?V^UF(696-)0X'7&=[V0B@C^59#<G7%W2(+_*46-QQM
M@76C)DL// W4#@"L*W^(,:Z&4K?PWF5B*&98YNWRB\U^P(. >JMY JSFJB$2
M_9.6X'TFS_Z+T!!0^#RX<A=;+8\S-BER;)!3$3]@W=!15&,@%$.E;35.:M&$
M"86AV]$&W<]&RNNYURTHW"XV)12Z.I$Q6?=43B&O7CSCSGJ/5-7K?B3MO\&]
M[EM P+N\8_G'*I]3.TW9;7K(*D28'4YY1N7EYP["QW) R/]EJ# 6 O86_0Y5
M/R9C+/S(4?(22N$<Q[3]1@6U#9KJ>])->H.[Z<PE:85P4;R(+SGY6+'(PK)@
MC(M0]1A96[X)\0RPI:NMQ[C @0*Z1 S/4CPC^7ID4\@EWF%5YLNJ"Z/626S#
MN^\OOUK-$NI*=N:TK45W3;A@-NSD5#J1H4IA3)(T3A4LQ([E]9AR[@&7'YSU
M;D0^-@74]HTF9ITRRX,!3<FD8GO,+L_=C?[/)!O+M&-5LS N+,J=$UINBN\2
M0-VZJ'UTHP#?9%VZ)[+NHP&FEY=C+]:<0AA5GI,@!BQEO*"[1+*.GZ3;[D4=
M.56QXQ6K7ZLF(O&/R)QXB^S$K\AU73#;W,1"86LQH%3D8>]V$?!%PM:7QEX[
M]]%M-@RXP[#X?IOAG.]86BQG'$GKPJ*HMSCHLZE0S$5?$I$)=JF$<&O3+N-G
M 7U?<@.%0IL,]6_)2E9 YAQLSJYT:AA])P!.-S0U4T.9#B(#I!9"I9,FIVUG
M<!:7_[K(D4N@HH]( 4,93;(/$;%/G$,$;47NW23?.<0"?#677'.D3WHER-9C
MUECF4IGN?'V<(0&BM)WG+-E;UI0:]/I]*H"L<RM:2E2,+!>@1(K3Y@*-M,']
MGO''\$B/#CX#/-+G9P>3.H)4*XB:<JL]MAU3.&Q38;W4CJ%A&,DTY $]VSB+
M0,0#RS,.R]&5#<S;_NS8KMR$2:P]081Q:W.!9$9A* 4E_<:('>A-3&G'!5 <
M&V6"G C;<IV:6?*:+\BI9GL[E1@P/M%!M8-KT$*.P5)R2ND6GWUI=0G)9W 5
M*!$"E[]8!W0<XVO:A<]]/?Y:1'9PE"2#(5[3&1L=NS@FUIH0>6IY+1DKLI[Q
M/[\^C@RK1((;V1C#YW\*IT2Y=!2L^E?F^E!7D_OWA29@['#&YZ(L'J4^V 5
M".*69"9,LAR"$ZGKR4?!T'^F21'OCJF7<$F^ 3M(J4O@^EQ<ZO8P].5=V)AM
M*Q*22>W)T]V/B?H89X*0F_:_NM>U,!4/:5&X_AK3ET3CLM:RL__P?5+L@\R_
M=9V>-,UR,*\.-^"*^D,K;R<#.FQM!:U*D! D8@@RN98Y4QM=MJ,[JVXD:Y#E
M2SDQ[U?%34"18NS]^DB7A<5HMBX&? :4#FMJC'Y?^Y8;[1$I(R:&=9 [HZ3A
M'V-[\S:< A0,A+A$:,CD^=(G$!^ J<P1XFL03R%#C<65Q/&I+W2_ B96 /62
MVQ!-S'@\_N<%FWOY?9-0SD^$RN1HY'2YA2"3)H^0^TGYG=LRA38CDS!;$?"H
MEV+#DB>)!,,7H!L=Y0\2'6YRW))%<3]%OW>*P$"2,Q,BA+A*+JH:C\8PVQDA
M62C3,OI.:THF_^. +"&6*M9SR5;J$6BQ)<O&WT_CC::1_1(73G)>:Q$F$_+C
MLJTHF5U=HW2;C6JW")[YZTV_19ZEX] G?,XJOAS>L"=$[%5@;HP2/=UI3_JK
M3'3/3VC\^6E"O4V6S/)^-0Q[1,:9 \XN,(1*^K2ON^UE=3A?2-##R$;T72Q4
M<.1JA;'[>8FP*7^*N1'T8IF&O+N^/8YUB%7LU4\AQXZ8AK@82N!=:S'?FIUS
M-00@OI.J$9>([B<SZ26ZR9EY7G:GPD5IKB:[*TIY*&/?1*9!F0>:5LH3>;HB
MIN*[WUTCJS>(ZB@V!]TO$8DX=LYTP*E_H%Z5)\")F8<A.=CI:'V\.51 (](%
MNYL(RB-$E@S)J8J/A87Y3*?OIOLIG&O$*.O%X0F$OV0RY+X>$-^PK4T90LOZ
MM)R7$\Q=J[Y:E4)D+*$]E@(USG /88SW[FZV7=$R-<?)33N"02>(F5)37RE;
M<T)U&]O]% ^>PFPPPNY83 OG4TR77=C.W<HS4 Z_+WMYO%]'(!]3F=#NP7-%
M\-#3EF *FFS,F>"/FF02EF*688:84"0\7KZ,U6B@ W2XC B7=L_AM]^YT8C\
M2<+1:3>&2SU-2LQ@ELXJ$A>W&(GTY56Q#^^KV!^[BNW!6:[=(SWE'6+$XU3"
MF);K?CWX,'GOMG?GE33BLT *A;ZL\$M?&A?'8R6X;MR7&69[ ?-[0A4DA8,,
MJN2Q149/QNEK@96_5X[I8<0 696I&Z4^DK,\7KYX")34H;!4=HID2:\YH5P\
ME#Z;\.F"KW9&XNY#0-:[Q*UCA6G-%JC7%4,; (?(^I(5EV)NZF+D5=<X/\.J
M/XC1/(>BE])4!)-_33_B3F*WA=C!%!K! QFRV3)?ASTO7::C I)!M[G906'=
MF8&&8L2A/#%&BAY+5TK33>IXX6E&TXS\#/6+Y1R*<*G+M5+*V]HAY.(<GLNZ
M0:*68"#I9  /-D7Z01/JF_J%+9;D+W"2*UFLKKET@;D:"NN[=D*+GSR9M'/J
MQ#-%>L=2+X9%(Q73L7S)5: MR)7$$J(/KB_S<Z8B"_I(S9SK'F:'X6.5F]A9
M>KUC?W9<+,384:>J\CWN=,%]6=5/LJQ3YHF<TBT?Q%V7U&JQW3P!#[&DGM2>
MHRV*[8E7AYG-VZ1DH(3FXSYO7[,!]R.V/AX1##Y:8N/^--_9F##(W5V7?Z"'
M@!:4H=1'-2J+I\#1G8A2'5GV?]4^;]JRV%*P'&_&O 'M=J<<7+CJXAV)@]4G
M9!@=91MB^;B:4S20/X*M9N&A96*'L! 'QH@*$AT?E+%#GM:W7]#BI'?7+!T:
M]=])7U(2KH[L)ZF$!72;BU&PY$Z5*PS(P)A;L!#.GCZJD2P]V VA6G9I$EGL
M7-JV*U3U\<Q*27<R(WN1J^;U%43C T)QZ>R+>A,1/#],(:3N@0;O=BRR^85:
MJ=A//M.G8E(O%+,.'UJK)4]:CZ7N=7,R];MK4?R6PIC8D7$A!RA3]X1;YTD*
MFE&.6/YN'M7<IX>@2 AG$V2?9G28C)WZJQS=6ZE* "H#*-;GQ8NCM!&NH(-H
MFC,N&C;7:3J"P'KP&1/&PWY)J+X+CF8U.RJX]IJMEUT8AV_'69;88NG\BMZF
M<)*&#;#E[D+=&,*:D<'?*&O31_9, O'375'^F^J'V6Q1GI55&(TEQ4F$##8U
MWF!LUU"&WA3AO]9TR(Y71[Q/N"3ITHF10)5B>[IL\_/_Q]Z[=KEM7%F@?X4?
MYJ[KK 5U+"5VQI-/LBS?:!*//)8<?P8)L!L6"'  LEO,K[]U]GG4J0+8W;*E
MJ$5JK7G(;!*/>IPZCWWV+JV%(N5E'E-B9EAO;]5DH((];6N6S5BQ@FBEYT;4
M14A\I;3%8$[K1\^=N5^E"CKLLM&DB$K.4Q6O<DV5O3?!RH-E=F38:"XHX\Y2
M'41@C^<:=>926R=.]Y[$^E[A<?Y<X!966HYA>C1X.O !FC5W20KZ2'=/@M>:
MP(_L#&O&JS#%A#\$]\85F'YWDE.U-C):RM([DR8+0#BYI?VY9^<!"=!UV.3E
M4"6Q7]SFY8KL"4,O!)]>B&X&J+[*U9M'^ZTN$,B!E%6_95:AJ 4IN-:PZW=]
MF$S9'.$QPG)D4IYUF"CP0(2E?UGK..QW< 9VY<7B;_T-R7(4A-Q)4 +8R (B
MT%:>:V*":)MQ S,T!%M+_X1ZG#9&FWW6#ND(20@++UC$W578X6\(@0_M30J/
MVS#TVN<F+@H$"H.YZ@]I*'V?:46GK<QJ=('8A_9-6,YH[X=$+26V[_IN0,(K
M-;!LSFGBR_(IP";..;YJ-E2 4N53(KR-2KQT=[J'U*\Z)E&BXY@.7])43+FC
MF$*Y%0 SGA#N$E$4V2UPZ3"21>;TY9!'36&[UO/,QD5MF1D!&=D1N1#OJ9+X
MB>,TDW[J![>>T'JC8*D9D+F!G\F+U7S-,7?#QQZNK_PW>N@G>\B\-D8TYCNC
MDYY#56K9E-F8B<EF,J+W[\CD8WZ'V8C.+T5IM&>UJ8I=A7);KE032I\&#E<]
M[M+'0B-B2G@,PKOK.H;[M>2WPO_&&#FNR])UN>0-6$WZ8 FJ;R=T;OJT[M Z
M5UXETW*=-)W]]>&6Z4Y]2B(1[JU-?^<Z0-R6GF"81 D:&*:$@N9<Q\@O(CL%
MK*D("K>U%:R$!O5<Q^J*@Y54FWI&P?"<J80XF60"?I"<"3YS75%KK"@PICDK
MA)4GZY#]-F!04D@2?/-44S/WG_[]J*'W"!KZC+4QK,V3T\':/)B8E?>A0&;J
M[JKLA#AI.?3AW.N2^DM/=2)IFQWZ_>655(I8UU!(6*-XGV0[Y\7756K5:5*?
ML+7K&)0J>:"(KO3:<)H;&,O5T =;5:X6O_8-*3;N1\UF*D26?S?&$/;^4\?J
MD<'M&V-["'Q!;91EFQL[PB"C>XTLYLA]1VQ8([,YAYCTOGG9-W(EM0==&X7"
M,'Y7U1_)P5O+"W1J%(SEP2!3Z3<%8M$ "4=*A#0EKP'K[S$G(-K7UIDD1;TM
M#Y"]OZ*^Y&:SW .LXVK8HNHDSB*Y1?2@X>+P"%+<[.O(HJS54O?X-IL@+>"9
M9RA(CSSJVX;C=/UZ1I,:@O]Z<.3>/O><GI3G&M6;?D!4SJ3 T3K,37'!R?N%
M":K/EP99]K9N95;(2+:<5SAR:_;?U;/T*0RB!IHL7+'3HB"9QK:MJ1$-A!9A
M:>YD15[W#21ZR1@P;5+/A\C\;P9ZEM'8%+F4<+Z!:SCI^@YE[]HSP:#>G%/!
M^*7\N0\H[0/BXSQMI/K]D+X[#_=[F9<3=BJ]Z^[M[_MPK][C#,"O%2XUU+3$
M']/^KE[;\!BM3%5*@^>Z^)\K[OYF_B9%6MZZ)3;G<NM=04N":BV3RC!S0RJ[
M =Y,-&P$LKL$JZ3F-YQ15Z^XJAFG4RO.2=,=UXWCY"O]Z!;1X3Y$KCV'>&JZ
M+DP<S>_%@BK"GF1SW;=M?\/(8:?-$6%U^>M'%&?-6$I^YV08XOL"41TVS@J#
MH]1MB1Z"L )(:9Z@2 UW-K3EOF/(AQ,]9>\\#N.^HX:^G0*0W*+P+-CTWBQ_
M3G):8>5OU*X?^8'*2N'5=GU/X(GK!@UP'HD>E;*\&#'MQR+1E,:8<#[)-3(L
MV*9$-INM^$;E@E,PUY2&@FZ>DM'%!9:!2P7INQ^FI5M^3 @CIG@ $*PVEFV[
M+3!+=ZWL;E7K0]23(T=%H_#NGR4=(WX4&*'9=,:IM)8],;*?XM>FS/]!DPF*
M*1Z(S8] OSVELBBI0)I1D[@VQ*]A>&HU=;L<_2[T"BX9ESQYO2$)*[HBO5\B
M[$5%^QI8Z%/&-M#R29L]A)S-ZB- FK :5MSJ&<PR6<]A=>PWM6:1Q)RP,<7J
MX-+X>$4HH)N[QY8&\NN'?FP[6+>!]NMW&E'9RJY_ MT/U./CORC;85S5(#C]
MP4&N70X;'56+L8ZV1I9R1E!= NM9\]%$[SN&(X;1O=A)8N.!=$$543;IZJH?
M:Y9FH5\M6*1-HA0)G0V$CQ :!LS29:K'[)_:Y0R9J0VLLG'TV/J">MLR-O1A
M>)0MK7CAB54@77(<1 >#L1$U%![PPD(22Q!%7);F8EW?@/23,!Z,+53HLO:2
M\2=CS2CH8, K@Q\S_;1A?.B,48.IOW%R$]&Z\<]@"DD*:\F7S0P_U!&S6#QA
M2?4LJZ;Q-)8;#A[#5JGHLB-=*,\HL>E?]&U59]V :XS"'DL;F-J8W;)Z",/M
MF)N3&H+Z_ WQ)G0#%HYE"'GB?,A03;&<?*71+N6:W.^'[Z\98RWI3[,]6FWB
M/B.EQI+F^''LPUF\TU0>GRSZ1%Q2P@$6SJ3ATKBVZ*?>GDH73/0!\/O?;O,>
MS-F!9";M?3AA"2>U$8EADT?"7A*9Y!PLT46/A)QBR*80/->KQG+BRD!'M,*Z
M%\/*5P^P(#]K;);(+JE,0K97W-<Q,6$;7'.=@V><N$;Z#6<&&&&[@@46SI&I
M1>>WL&QOM'HNZ:\A")H4L?3D$<P0D7EG@Y![M!A.3N.,7K(>_M@R^%[K9A?7
MF;Y.X9IB9 )D\&;"I,^%1RL\_NET"H\/R!$2EQ*J"S>EMH4MZ-E4"B9I =CM
M*^D+#HLM!,KP_%FP%;Z$]?AI48WV2#0I_9!N[;MW;2(1D6Y0/:'5JL6;TPWO
MLG$1RN 0Z)G9$==(3MH9HR/!L)HF(+K#V8LF+-K\^[&.?4X1[[FM^RVA4(U3
ME:-&-+/33\-A%[Y(KE%X!/#X]6(D8%1$3:/CY$HXU4P/P[\3CU^!!FZU?!YT
M:D!5?KYTDAMF*ARNZP/0]ELN(B,KJQ-PL?A%FX2683'4U[78/M6KQ6$?C&/X
M#\I+<$:=/,+*S@Q/'YLKM42AG5W?LQJ/W%O<EO#Y+BZU^4G-X&'N],BLLH31
MMKI<_ZP(@;FF.,'6CYJ5T*I=^G/NP&;T\4$D#)2P$<&5OD<X2ZM&E<;"JBA7
M3M4(B1>&+<G <FFRY+J"J&XS-B9;.''MR9>/]<[W0U9ECCL"+1_PP;W"D8DI
M^!.R62M<>;_9QC9==Z2BP"[#.4.(<7QOO_MNQ@PP)%NIB>W&J8_.0S.S*-3S
M^$W>!@O_VH#)$+*H!85C\'?>;OEYUGZ2)G8"NV'.)BADREF%(SO@G09SYO>*
M>6"/^<[Q"38G=P69M%LFN$)( $@6/'._E.HJ]8ZP8T4.6<.%5!;Y [4#/QC?
M77+EK,RZ]@*2PAS&O>/-#)R/J0\]#X%D22U+?Q;8G^=OPTU';N1%)MT/A>!X
MP-(2CIBV]J3)-DY<HKP\:+ZZ;Z_#\U'"1Y BI: =<]KEN(]6 _6I9?-@E/B4
M*B"^ _&D#**8D/\DV1%V,Y++2?ZNL,04-Z>$B:!NX;")?KYX=9$@72_):>E0
M+&@7X1TK<AF@[&6< RJDS,F#<<+#T)8WX4QZ-E6K'J><#?1=Z*<'0R(=+:FR
M2^QU1FVK[Q[%3I^+Q4O467 1-DOQZDRM0VLK(=*3QMZ]J8\CA]:#O6G7A&"A
M61*O+UW28W!H#C!6W\LX/>O!O+WX424O%D_#9;\0<IWOG_WX5'AU_A!/W9\[
M4#+]/5RP"E/UK=S+__#GOW^;_) >J3^LPD:31\)'FS#]!]1I*G83]6_I$'
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M7,;!?KJ!VB^RI<(^TMB'RD?-SE'[$DQ1T[3=P3LQ:>",_)=(2KSI0KS/Q$[
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M +Q-82ESZ7\WI)>YP/X2J5<VX<3VTIF(:]3O,4^1Q12&3>H6T<*F\&3FR'D
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M8%VAK@>.-J>'*-=S6"11GD2Y3I1VK:<EH_#//!]8=Y<$VPT_^XR;,MS4UY\
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M-G4M/+ZRSVPS/7XB&RG;1/1.FHT&<3FR>G2MFS+L_#")\E=Y;1T1TI2O]:1
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MOM[I!M=/A1%>\)M4F^UF0FNCQ1(!U8E54:N3HR1(IL9B;UYW=1I^-S.*>IH
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MLFP7,Q+W=FZ=-'1="67(KO24V>!*/L$-]-2-;2%(+P3;)DA24@((AI[ZPN
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M31B72[5B',7<!O29Z>#Z7(C_^(7XQP^Y$/^)\N<IDFTBL>U; (Y@:<+N%C%
MM"=0TJ20#*\C_Y+^5M**;AOJT" KE>=,^NX2M53EF871,OZG>/LTK^)3-6%
M(%&U[\AXH2^5Y7&7+3GF%I;'1,\NE6N=0^6GA F);J8!./D .%V/AN"5JNZ9
M-)T)"]U=\JWLT6=<LSG5K!K]69'L&O[V'-2L8." *<5FHEP2TE@/AX-UK<&8
M&UXD"I^2$E8Z_1'AG"Q!:NXK8M99D[A-7P5O++A!5,IAZ+/KGIF2G$:O/82:
M! 1=)>@ =\MESV*U+[I%E+)C]U+RMW%WW9:9# ]B4.3_W3.\X!4BU\3!TP+P
M_[[Z*1;CZ4ZIF- K2S*\=/*:1>(RK6-Z4GNT)K+8/GJ)O]24_'6M.F/!\$A"
MH^I7^X1,A<]]"OC"MJY'Z]X1@O-"/>=B\7_RVN4HK$B%Z0:&7Y2K-^4E_DG
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MO/>NMLK[U3X,OR(^=?#<(D_IJ>@YTWHS>-"2R"NX7.P>Z!18BQR0,>"BL@W
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MH9)L=7VZ1\ /:?2 =Y<"RU5#(&01I8IZ>Y7COHHCJ]1ZMT_*NB4:8#*E29Y
M+;#^V2'F.(JCB^$J5WU;U8Q*0M8>[M4@N155@+M]9DDE=^71U?$VR?U5^/'.
M%U/.8Z0;H-X1OO]?]UPQWTS[CK=T)G>7C]IZ'6;M&R(*3Q;,HX]*'DX!_9.O
M9[J1^?_"_5>N/*Y9+)Z]_.>+[QX]_B9,$[D5S0I$@YF?^]<3'["/QWB3CL]C
ML+>4?"PC'\89!>CU2CA%R=ML*QPEGCWU>3NVT/U@D$4(%V""I:@IQ#CM24U<
M4F+F2ISO"!J/9KG2]J,T@LB#^G0D/:GS!QO)XP?W@QY<\J$I:;M1]IX..>8U
ML*QCX3(4(ZN3S"1-7$W#\[M2[F$57/]1&9$-3H%$V<CB2=/I.MN%SJX#683@
M.9'ZR9R? 35$$B\19PG))TY&4<U.& [^>ERBX.R6N,_4IW2L+GT7QUX=.9D#
M M% GF=EK? *LM(\B,!EUPY5?D?.7<I\A*0MAW-=[K=YT7'PX=)?E8,8'NK[
M1C)5$J@LH+1N^W)WKN-HO/0\&&%MG^M(*/GB42<T;,AZ)RURY#MH$\6:">U4
M);!L#R,[$K'%%HN/0LGDE^P)G^MX)^5=*@73UMU+3DV-'<Y]P@8<'Z7SPU@]
M_@0P5J>V6ET<X4CW$Y*S8DH&<X_E>]K#U@8_\]%^2ZX]ZOJ,70$^E! >@)DL
M6Z0#9[)>'RB?<<\7H^<_TVG3@ITP/I&[N1]JP^[&1@,J7*!'B7SDB.G]*\WS
MF8Z=^/5SNCX2(M1$S7&RR?YI[YC%26MT$U@\)'4 ]<Q=3)H&2+$LL"@7:\8M
M&99<G2PCKZ!.V/OEU)/J"QZ."WP$M1EB4>M>0(E^F,=)O+Y?V0+-V* ,T<<!
MIP&GK-#D=AU!A K&SYJ1,YBE"5%SY58N( Q<C-2/P/Y]),:AQILBUAAH4S=]
MA1>^(P#NM06U[ Z6-HN^<>']Y%5;4@L&OY]S!9&T#_Y*Q_TMRX$9!F.GB'#5
MA%M8HP:/(3]#,[J*G%6G 7C&HJ 39Y?Y[!X2^&KNX[O[4+AWGF%Z/4OC',<F
M"H&#@%4-N1>;0E]?-5J:^L XGE,0=*,Z,[L4'/A',GH9 8AQ\;"D]4$H!PI+
MZ!#9H@YU.62-Z#S:N]L*PA_4HG]\(EE?FQ6.%Q,W<@;:<=\00X%"E\4V\331
MSUEI@,46>0O\WSYX&34:E>6?";DX9>V)G9:ZU.3O#"2/UYR/VHUMS$DN=6&9
M#,2>L.8JK8-[%B0[23@,9GZYHDSVAZBS/O!\Z,.J)/[^@N_'52#YO&X^SKK9
ME@=XAE3V$"5JTWZFP_D,:WD/:X*RS@.MPE++M[J8>B[,B'I4),>XB+I@EECP
M)=W/<_R1YSB;M!"ME<M695H<W9-C/&8F*BI_[6Q: 9S\/)D?VZ**P#;U=H_:
M]!;F*?)[NZI_[*'1L,6C8X^;9:,1_SS='WFZG4MMX"/JZB^'U95DLX!$$K=K
MVNDB<A'6U^.2YY\G]P$<OIOF;7Y@\NF[K!FN*B&::L(Q^3['2./N\T'[H.:S
M 3F9-N4*%X;#8Z6(*M_VQM&N![M\!)C5Y\E^Q\V;\6F.>W2K,W)=I&JFZBJ1
MHAO?/W C,:<7M2MUL^T[FO[/L_P 9KE6<,1D1\_@?C_/V .8,6)B[$ :48@#
MQ$YSOR[2DU8;6VXA-_L\H1]Y0M>^D0=MH;$80)'IM!T[ACTC-PP:F?YR7UUZ
MYD/M'/P\R1]YDBN*-G?-RB0/AJX44C.'_%FU(?!!N[;HI83#M6RY^OOL^>(9
M"7*LD;3 %#_KP?9G+6S66GY=6Q<,+R;CZ%$[()5+%O8R].!GZ_#@%@[6RK#?
MJA 6%\6[/5F-_:"T!/\_>V_>W#:2I ]_%837O3_Y#9##^VCO3(0L'^/>MN2Q
MW-/K^6<")(HB;!#@X)!,?_HWCZI" 00/R9)X"!.QVY9$ E5967GGDZH/6.*V
M5%[3'IT@F5@RFSXI180:8Q&*+JO(ANWD*@&K<]RS,//WN;*NKD1X%3GS*8AW
M#2J<ST9G^'(2LJXZS3VXE5Q90^XI)PDXDBR]5R]0Z$(JD%P85DJ^DF^4(,C/
M5V>[!V<KD:4\;1J/Y:3*+/@@;Z:,3%2GM@>GEJ5J%5R)ZRSB0J:V.JE=>ZQ9
M;UQN1"V!<(T19D.":B&&8_Q0M=K5D=W&C9C-'2_B>7IZ>@IVJ%.YYA2K5A^V
M9'QWYZ&F Y3YOS0VB =@TAA!Z9W3IT0!?97J_!2FUMO7IYFW;CKKU@C1Z<3R
MK*1\)X\,@Q<^H@8!9N$Z.;59+I_0[!BNT/>^"3_#^#) THUX0M73IGO:6@?0
MT[9SW/"U]Z@0CEH9B^)+!$96E!@#XT[!W)(%M#1Q1U7-9C.;LH$[>('&.)XC
MBW/+)H/L_G*N:6',3=?8OLOS+-3+9"67@D'+RK=Y&).(N2!8^7:%Z91C9\X&
M)<&\G6;3Q[))@%F=LI'JM!%TTP"HP<X2"12';Y!6#8__<(* (&V6"LLG#FW!
M#V]*.X1SK< E[<+V^MKR0JM* ==*0ODB-JA-1"];<AG63FE]/ ],32,X&JX
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M?0**6V^9?CLG3G//B(->4**-WPUWAUP@SLPHL:/@$FE.JG(<_$7F%*@/FNZ
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M+*0_ T'S"JC=^&4%[Q=768($5L"IDA!X\E7RJI603&-\R5BZ[\"KIQ*\H?"
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M&-XDAU0[%4;%-MC)C#<)K#/H_)+5J5-U/:%LUZUWP/$RR;Z7^,N>9'B;W,
M8ZQ<Q5XX(P5MB5BQJ%)PKQDES3R7!'#.Z):O@]@7 %U!.*LY_-S,TR[4^AL8
MQ45@K6+_ECEGPK%:O5^RM)T992FRR2[QF@\!.7BO[@SGPW11F^HQ9#VIX"&\
MY9D+:O!H69/N"FVM<I!;J8C!(;D0U#5])BWM=V'HQM9EZ+NV]8X8X&,43CQ9
M \"_^4 [/0Y=^:<NU\@U-F10EJJH374Q<:R[6*I [())= [X4+):D?2*2!H#
M257+ASG B-(),3NJRL#-O-BU[Z&\H_E2+&:+L-%%SA4;1\Y<?@?C=]@O$V*
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MJ %9(V<VX0NQ*+T$<6CB"=^5:5%P5'P];H/1:5'^D3!ST))981#RKDH<D95
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MCLGN:P[M0:,:(+KGI]1JV,/!'1L;JU-ZK%,Z:8*F;KZH#FAO#ZCWV(>S]S;
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MW\UFZ]G??AY@I].J][OWAK&SDRY7U@,H'\? BZ?L6>']^AB";",KXQ(.W9O
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M*5J8)VJSPY?MC>(#FH%2>VC1M'$F1(Z%,Y44&P,>=%!?!0@P?(*);)G9=VY
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MC4&ZS_1H!M/I+0QMNMBP8_O=/%AN2E[;(W$5&)L-QJY,*\&2.4$Q1U%JA[C
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MZKQ0=9XB+-Y&PQFGB(68"(L4 CG'=.(OS!.IL)<TMTW'3:/G'@!1/]_*HPI
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MHPO#_-9TT]#_FI.MNT>-T![XM S#]'+^BO9@D!M^-VPW7'YRCC[(3SM58+;
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MU;E]Z:9_YENK$-4+&SEC7#*JN-'&L<A,L)PIY:@3XB,1:N/B4\?]BQL\M4>
M7!_L9V1CNO_GMO/5G@\V?K^Z:FG)QM?+\K+=MKKWW "S?*P&VG@GB5Z%OB63
M@NH*#G;1GZW]G69C=__%LYG7?ME7^Z*U?]!ZM;N]=;BSW3@X3/_L[>P?'C1:
M+QLOM@[^W7CYJO7/0>WOXE^[W82KO;/T'6'PVZ^ <XQ?&?2F=K&X91./^\5<
M0%]U!*;[ZMC3 3R_>/!': ].._;\>;M;75WUH1\/N_17QBILZ#,F2=;B<1+C
M^.O'"OZL4O ?SNW1:XH_PUK=^C)^1FY][6=?2_ SPVY_^6=?^_/7A+C?)W]Y
ML?1.7_N+1-%?YD&:C1\D/]X[/^<__!E3-^VFY1@OYDZVRWNP_09T0Z(?TZFE
M5TCCO*O'?ER]7U/'=5BZNV;?WN6>G][:Y69H=]]CBZIS3JMWE3.-/X_RFY\3
M\HQ>XG\[*45W^!R92C K6*,7=G#<B)W>UT$C]GLGC=XI]&TU"2S;EE^N=BT;
ML;-[%+8L;'O>NW+F02YR2:4!]=Q/=RRSO[)GYFX&LCR'Y=UN=V9_91T\CG>[
MM5*5=4_WHQ^['T\_[YW\_7GO,'3V_GEY_/YP"^]O?^:MO_;HA\/P^<.G_-S.
M][V_WGU[W[YP/YYFM^/YWJ<C_/[P'7U_Z/'^X9NOK<-WYZWM][CUUSOZ87N7
M[G__G^.]\Q_<CR?9[;B;WI?NX?##<;HOLK^])?8/=_G^IS?\P^&'SWN?TDJ<
M['S_W^][XPS7G>'>UD>GF0C61B1YM(AK+I !9A!@Q4 2;T*,"ZC)JE^?H@)'
MCQ..O/-4L8B-EYIC"T8;SR0.QG&/52 9CH@9PQ$Q!8YJ $?GEW"D!&5*&(*D
MQ!$E^4ED*"?(R.@XD2&A5((CIIL<7P^%/.;^2>O$ Z=&?C6&O48?DH+Z=@<:
MW3%!S,_FQSX;(&=YSG"[^T#61UT,C/K:$$S69N-4D654C6=O^*E)<+_8!FO6
M:?!N:[%<!CY;*?"U47WER)OIR'LWS<!#)$"U$8@88Q#G7"/#B$066Q<\E<1$
MFGO[-PV]SL!+N]#'HL0+X*U%B9>LQ!/>&IDSU$F"((BDQ#92Y$AE54M+I W6
M.;NQJ9I<7D]F7_MIFM7?IN*N1&0%>CA:XFTX35RT76WVANV&ACW)/7"__WRR
MYIKU75IK=C$MH?2X ^.I0UM3@BHP-1-,O9_F&M: #\IK%+W!B6N(9%YCPQ&/
M/A :&=98):[1).QZUY'2#?&Q:/0"J$91VX=7VPF[8,KXZ"U%F+.DK/F'-5EM
M/:914L)$GO>@U-S<HGZMT]:%6_QI0U(1-VS MTRHX5YTXBG8.0L?8_BZW_O2
M'J2_^K+7W^Z=N6$\ZVQYG]9U6%SQLX&.GW"%PZWO'[$!+94+R"BL$7>0NZ]J
MB0C(""8D*P="+NRJDTE3W!*UXPK3[/\[]'O!#HZ+$C^D$I]/*3&UPLF@(@*K
M*.+:*J2IH4@)+!BVQ%%"+SN>UTB1%^F;^#%=L>(//X8\:D,HTK[O5PPZ5_&$
M]J#2@MG'BCYU*^?AIB]="FC:OFG%[;&H!LGR>=V'D_;9R6"W^P7&H= "8_?E
M(EL?'8\!+),(F)>( V#D-/,(&ZU\$%$):7*,1-3( "I>B_IE]MS9$5E4?+E,
M)4=0(L8NIBUML[%!<$ ."X=L "JD,KF91'9-\AL:MJUS;_AU<7"\O1AR?F1S
MLLXBV<C:VE%+3I.^"E%[E^L_F?)X(:2_DHQ**N+,@/3YDG/LI_OYR(2G1 J!
M;#IX$NO  FD#&H'@T0(V-A"\L<EE/1(1B^=C+3T?18T?0HW/I]38$AUEX( X
M#WG> HO(<D&0M8EO")-DJ,0C]H \FNS0:2I>N49RN*4]&)SE\35IA0;#7^4+
M/TH3:I4<Y*IU]'+47J9[]"++HH#63*!U=,7?D<X8DFP>A#%+S$.$A%8D %(!
M.QFB-H8EYD$-+?Z.1ZNL"\_2*,JZ2&6=>"YX=%B+9!PP9Q._$":9"3PFJT%8
MS7S4EN*8E/6&@>\E.V-)SHM,HK//(EUDNOJS]N X^^LN2,33<EK4O;0[&SV#
M+# 8M+H[5P36BMM)7 6K9L*JG6_C3I/IW_>LM?61>N6,L0Q)SVDRBHA'Z8Q1
M"#-!0&%)K,_!E*8HB1V/6+>7Y-XHVKQX;=Z;UF:7A(2EED@19A '&Y#CRJ%H
M/*;,14&8+=Z-^GLW+BC*("E#59R2._WUTF^9I9SV<W7T\+QZ ?YSUC[-"E2\
M'2M* +GPR[:Z!TE:K?AZ+)[7'=L=[ER(IR#;;,CV=<)3MCX*J](.58!".GQ0
M C2+M,,4:1$M$T)(1\/&)E/7@R_% _)8%'B1K5R* B]%@?<F4ZZ%QCC09%LX
ML$F!-4&:!X64H-PP)H&3G,^A2(T4N!;]..K5R^7%L>T>I6^[VJ ET?GAH"(C
MG;9U[<Z\S5KN:K2M\CL*8;V6IEREPN7^/M#^DB/83Y&0+CD'Z,YNM-VN[X,=
MP#:,_MWM7@CL[:6\R@$WVP%W/LU0):64:&L0D4HB+@1&FF")F$^[&SS&4</&
M)FT2/4^"4*&G]57G928D%W5^$'6>\%41'+:Y,,HZF@Q.[PVR4I&DW98XC:4R
MTB>#LTE93=2Y%F2U1GPDY^%WA[W^^5/L%K?23.3KV'0ABV05%%":#92^3W,,
M:X/17B50LLXC'L$@HT$CYT!(HIPD>4(RO:'Q0TE!?@RJNEJ&4;1X'BV>4 NL
MC-)!8D2 6\099&HA*"+<@9)46.5B92G@Z_6+3[>G<8VHQ>L^G-IVN.CM,O)\
M]8;'T!^[PHKC8^648RRC;8C0[T/8&8EJJQM:64Y;E9@*BLV&8GB:BZ2#A[(@
M.!+8)Q0+X)#._GVG*$Z<1'"PN7=<7<RCXNVH'Q<I.KP2'9YB(D1K2Q1!0@23
M[(G D$VL Y%(C#71>1?MQJ:XH8]"<7'4@(=<AEQ.[?F<\9:U-9_JQ3HN)/)Z
M)) "3K.!$[D24(E.Q.@U2M921)P[C*PG:<<2S#%X86)P&YN:S=WDI7@\:JNR
M2R 9167G5=D)GT@F 7#)';(\DF032(],\!QA%KT@C(("E\<U76_94A*/:T0J
M^F=P)9-GXM\HCHU5Y1C?"%Q94*\F<BK8-1MVT6FZH3@X I$C9EVB&X%29'(Z
M!S= 3. DBA V-I4L_HSU4=VU":T475Z +D\G&T?L. LHL* 0]TXBDX2*=.2@
MDWXKB&1CDS>->80M\N=C(A(_4_5)-]Y?P%3(.]A0=QKWOCZPMP[CNE\DJ59=
MO@.$/\_?)?'N=EL7PMVZE&V!P=E@D%U)%]$F %B-9#K*$!?6(F, $%#"@Y&:
M""*3.8:;4E[O'#-SI/G.2K1&SI4G# RK&IQ=@.&A@&'"C[C 04K%D'0!<NS6
M(".M0@Q[3$BN$9<Z 0-IRAMFC-8/&&KAPEE5G9:ZN4XKDZ;8Z7T=-&*_=Y*H
M4^Y*O>AIVG>2[*I';<]^D;4@XO6J^]NSPW$STMQ_X.>]GDOT<57%7H.VZ^;9
M.6GCA\'+I/=CL9VWXDU]9<L9.ML9*J[D/X%A6()%.6<3<6LDLHKG7F_81$H4
MHXQM;!+,FXK,W96@A"AKJ]?+<!P6O7YHO9YP8Q*)X%HP9$02&>="(^N#0(8Q
M0BR/3E5Z+4Q3X[FGXJYK''-EG1MS?XX[4) 2W:@!^1CU4BD -3= [4X5FK\7
M>T<?/:' @484292(TR"1$X&C$(GB-KIT%KF$4;R)31F!]7BU^H%[-A:%?DB%
MWIM6:"5QCDM2Y%GNVD@]3:2# >*1<\LL-8&KA75M?&PARWIY2EZ?]?VQ'11'
MR5JTQ7EMSZM1?8>]+?^?LW8?"KK-CVY7.C<Z!R"H2EAF6;*GA,?()31#7K@0
ME*-$49$;OYDFF2NWJKA(ZJO1RTRN*AK],!H]\9 X*0%8LCF4,0%QGQY9KS R
M! * ]IK8K-&<-;6L22>*)QTAO -/*0VEUXZH7.E1N]4-I4WM/;'MVY6BL^!8
M4-8B0F1,E 4L2G"F<I"':V4I!ZMS;PXAKS>J+7G@CT&I5\I5BE(O3JFGRM*\
MX59XEO962(3%1(PT!X&8%22Q%^J(,UFI.7]<A>[5WY9D*J%[BKK\R$)J$^BY
MS/G^USCI^[=,3ZI\P(8[_WDF4TGQ7-?<[]T+L984SP5$B;8^&FZ82)L>2<)T
M]KTH9$7 2"7@4P(KJW B,I(VS0W9*?5+\2RYW^L;5RIPL.H8T];'J#4$&1VB
M4F'$07%D*);(60E)V(09QG.WKB8W<T_@*&G?M4G[CA=3?4O:=\W2OE?2MG(4
MRA]OC5XG[1.43H+3,]=I^T8OQO2UW:-FHPO5+-QTI]#_FAWF:?^$]F#4)Z69
MUN;DI#T8)&08=X88?S"],!C.Q<4?]:FZ5&_A5-;&[F!PED  6O%%$ERO>S#L
M^<_E,)WM,+W2^M)(J[65 A$0 7'M&=*)':'$B8R/7@H,/A^FO"E+ZO<CUN@E
MS<PMRKQX99XP8\LETX8$)+5VR5!6!EEG!0J4<BT3/=:*//F!N2MG*P'<<,)F
M2YYW;3G&JU[WZ!#Z)V66]^RXQ*?3O/>//CJL*3,6(QQSF38(CYR4! EOA4X,
M)/?$W-CDHDG-]3+MDN;]6)1ZI32CZ/-<^KPWK<]2,Q) <@2&"\0]UTB#L\@X
MAXUP(@E9/ODL[Y50C7:B%:>VT\@-YT<A^>P 60#I6%LSJ*YY4&\O)52P:1YL
M$C]P#>&U99PK1*V5B$MKD(Z6(Z&P#%Q(C)FXE6N4+.VZJG']:$91X(4I\!5R
MH8W0%*A$)M!D+$COLK&@D*4Z1"^4-ZSX,59!+GXD%.TQMYXC7+*V5L]*AX2]
MOL2=C#<7)LZ++(4"/C.!S][7']A#P"%&B1TBK&(/>9!0LFER@(0DFY)SR(-)
ME;C>,*,D3==55^M''8H"+U*!K[ ')6CPF#NDE%6(\TB1Q<D&B)X3Q1Q6U(?B
MFE@M>SB]]$XT3J%K.^-RK0[D/(U&A/GRH-</H&I$)G:^Y229L_;@.#]9$.D>
MB/3M1THAT^91+"#@@'/S:HPLEP8)$1DQ04; ;&-3\^NSA(HWHJX:6W=*4=1X
M$6I\E5C$R PH@0+Q)!>+6^1\M"AAL5-,"HV)*&Z)5:=7#(^A =^@[]L#R%3#
M5\E%Z9)Z_G.C=YIE\<0\%34-?UQIQY6ETQH)9V<LO%#P:C8WZI61HRQ22))2
MR%.:.UN8B!RA$CD5A$\BE28/S"!-+N>>8%B\&;75YZ56@!=]7K@^3^5V J9:
M<X.LP8ER!$N0EM:B ,1&S91/K*/29S-W)]_BT[@G];@,A_Q(.ZKRDP:<G'9Z
MYP#C)T_'76L:IQW;?5KNCG5A)+EW13&;9H2M*Z-(G>&<$ =(4L\0-]0A9Q1!
MAC!&/4TB)3'#EB%E]OGC5>*5TI"BQ/=3XJF*:R ALJ3$7EJ/N"*)A7BJ$0'/
M@]">";"YZ0S%3W :^BI5\"U<DHBJR#4W&H#0 -OOG%\Z04+Q?:R":=S<@GSL
MHWW9ZT]DUXKOQI+;R8*[M)>FC:B"7[/AUY7AH08+X4 #,AP2?A$CD:$R_4IX
MH 18B)[5,2)<O"'U:XA7E'DERCPA(R(&$$$'!$X:E(!:(BTB12)Z;X+T-,EM
M8Y/I>J1G+<D!LDH%G,[K:"?=:]O.CWTX2CN-53*/ZP'B"HQ*TMEBZEMS1RKG
MN; :4>5BCK4 TESF#%+PWD*42BXNXZRX.9X OR@J^Z EK%L?J=2:6L^0\X(E
ME=48.0D884*$!R\I\;F)G*Q)@5@M^L-)/-5^=^5-_R][ZTYWU+U'D[@[&$5/
MMWWF,J,OM[3/?'DATM(^<P$%LEL?T[D#S$J:[">;D"\$CRP6%A'KK6:>!4EI
M[O@EFQS/W3]S5@5:(T_)TP6%&O34+:"PR*+;K8\D*"^XMRA88A G6B'MK4-:
M0I#.&T%S3UW6Y/JZ7Z6FD%#F.5[3\9T8P5?]4.&;/[;=(VCT[1 :H\>#1E+[
MBE'E4ISJ01Z?]"4I57>X@$F/3Q<P%UZQ,Q)D*^Z,Q?@V2;'5S4"9_]N92.TM
M#(;]MA]"R"]L=</5)Z;>6>#SWF7#6Q\ED1S2F8AXS)4!%D=DN(^(8>H#$51Z
MT D^Z:+"X[7A4POT##TR>%BRV^AR>$D!BOH!Q=2\2:V8M>!0E(*BA!F C'4&
M.>VE9<82B#@!Q0*\3O7C5S^)JJWE8*=VU_<AI][\*ZEB]>BW]-P=&%0Q-FOJ
M@9H+%U^GE>@ETW2T%;;'6R+]WCG+TIE&X!$J%R"]=U7UUD?LJ98BD2UK!$;<
M!($L=P1!%$8&IBG7R6#EK$GXW&WKBQ-K77!E5:2K(,QC09@IEU@Z7&*>.F>9
MR$']&)!F,0$.PQHK9X+VD$>#-Z5>P*C-^M&UQ^0.^\F$J9N86L/^:E[X(FSB
M57Y'+>+)]7*._@E'[6XWAXY[L7$.MO\41\;/<GXR$1+W8A =3F3+:J(=-S$&
MIZ0(F'W<G3OX4_P42SS\OD_3:^4H(1XX"DI3Q(7AR!(PR!&5[#$-0HM<;8R;
MG,U=MU<2YFNKX\$*YC"13 ?+ U/6.IH,<L5SVRH<=*7CNNCX&NGXE"\2<RNX
M4DAS+Y*.*XXT\0P)[FE0Q GKX\8F%4U"GVQ+@?6@+CO5Y,J?D):'C;W4K2#A
MOQ[,5S[#7JTWL!,"+@!-A[S3W"5@-Y8*"-0X*;1W) /[*IVI!=AG _8K,SVE
M5%%23A$5$A!WSB,#Q"''P8!141D2-C8%:PJ]-@.R%V0X%R L0%BLV,<-A!.&
M:YRRV,F( L2 .,]U62YXE XZ)H4B8 -?E!6[9F'W]:2_-_MQ#\Y.3SN0ZZ1L
MIQKNWND-SOJC+ES9LQL[O:^-=G>DL$FT<_AVKWOK69)CZ)VY#EP3\[V\MG=U
M33S,51;CZN8HP:E-:IPV4-I&0^@GL+Z?G?7X&<2C) G+S$'9'6^PUVG'[4,)
MX<YX_E]I/D<=! ="(O!&I_.?I/-?<(6(HM8(X:W29&.3-ZF:.T>D?E79!8L>
M)18ML_BJ8-&\6#2Q13Q0QKUTB!K-$'?:(JN%1<H9JH/U/E0#T)N&FQIA4;$V
M9K$VDLQ097$LU-BHBSE1#(:[@?G?"3'':21W:\1X[XJZQQU[7E317-6K;2R4
M5BQ=V19TO+VY4@$G@@*#@T1:)X+--4U4VZ;C#:RWE$NI?9 ;FVI1\88:\>RB
ML _27+$H[$,H[%1/9Z6#,DXA;9Q/?)019#"/2#$"QEFC:,B-V<WU4K3"1FM$
M-MYU*]?D1??1\7#-WFFZH]%(S9S6?)K9:DEG76Z-_@M[VDXFPLZW4^B&]C"9
M"(/=KC_K]R'\>3;<[PW?0V58%Q2;#<6NE($Y#1:85LA)ZA GDB)G1$#*>($)
M!RFBVMBDBRH!*SFJ]5/<A?=<+(K[8(H[H1\R*L"Y1ZIF1B".0T1&,XF\$SIZ
MR:6B,A?"URF[O*(?OP^MZ\#%,3I%$DYL_ZC='47^?ZAE]Y =J8O6)()_I4HT
MJ]+A,32L][V3]+?/LU^BVQNF;[?]]'2WBF<>]7/'9MNO.@,-CV$ 6<.JU 6;
MQTF,FRJF-PV&Z8FJ(>FSQE4^<?-"4/R3A=C\;]?_??/6KQG?!)/I*TY[@W86
M_O,^=.RP_07^^-H.P^,+L)CZU$ABS_'D(]:E.SD;WOZ1J>N5-9*;9M>6YO9U
MF_Z9;ZW"(R]LY(QQR:CB"18=B\P$RYE2CCHA/B9%VKCXU'%_PG:/ +D^V,_(
MQG3_SVWGJST?;/Q^==72DHVOE]-1]X;;%GCY*WK-<UNMZ,$N^K.UO]-L[.Z_
M^,G^K<OE[K<.=PX:AZW&B];^0>O5[O;6X<YVX^7N_M;^B]VM5XV#P_3$WL[^
MX<%->^$.-W2; MYU\["-7\ @7;Q5=,>U(TF^HW-C_^PD?85? -G_H3&AS<R@
M%5O)U+)C=\1J6<"GO3$+Z+%TXI_O?=\]W]L.Z7NVTLF>W_]G.OV/CS]\VB*M
M=,KO?4^/7QC\X7^/L3_YNVO_,6>M3YZ__[Z;_M;NUWWZ]Z>]=++G:]O[Z^5Q
MZZ^7)WO;[T2Z[N_I\>?_3=^?KN>C-,1KP2R*SA+$N<^E8L(C1CQ0K(32#$:4
MK=T]@["5 X]2<J(M"X)1R;DF.L0HI8SI,]3HF"@M)&YUFO=N_PQ&9]B+T0E6
M&;6CQ<_'U9]G@R3\P>"")HS%_<.N3J^-+Z 2U4A0O[Z(JQ>M!'@=I8N.8QY5
MM$!CYBI14$FU@+N>*I_.!L-V/+_B0*"\@M 5'3438.SZ9XU_Y0G:N5D]Q7^,
M%[WZC?SQ6^.K'>2^-[W^::]?<8-VMQJX71&#+(_M=$!_S=PBK?*>[?OC$5TC
MNME("J4KZ;4'C6.PX3]GB7) ?_0E![8[M(T7'=NWS<:+M%"QU^^V[;/&M.C3
M!VWC!$)F:(G"?VG[S%1&KPV/[;!QG"[O- D8JJ^UE2>DWX:A[9\WTH&5*7\G
M?4WWBQTD$M$8G"49Y>]JG^09G,/&X'R0^$UCV&O$L\2"JCNSOM]K=]K6-S[U
M$ENJLL"&Z70<9AXT9DR-D]Y@>#'R<WA^.O+#7/MH: ^JE+S!Z&J]S7^DT_L*
M_48FKCG+K/O#'7>'_5XX\WF1ANG>^ND6TKV<5D\.F]7?;K_,7[,[OH6#ZA::
MC9RKEE]HYM5-2V\N1/7NV<&S\9,$5PV+$N>U^=]$FX=IM087[]PYRXZDM!W?
M==.:-D>RJSXG?OJYG#)PL3!?>_U.>'87KI@-PRN.M@?7B>H;GV=;K^WO<*8T
M7H^&FK3&0TTJ&;\8R;QR2]_E+O.96&\PV.TV6G[8<] ?J6ZN\!QMM(M-F56N
M \/QGKQMY,N_QA"R^[IU"1_NO)J1FU^^U<(?'"?X&/Q@Y,= @\%6<LUE.KF%
MQA)SK:/A7A,;=&7DZT0]*R,_/;AJY._NOYPA[>4@6?7C@0OI.$D+D7ZI+BJ/
M7_B_['UY4QS'LN]7F5#<]ZX=07%ZJ=[L^Q2!)>0KAT&VA>PC_4/4UM!HF.%T
MSPBA3_\RLZIZF85%( G0G,4&9KJZEJS<\Y>(/GQ0P_[:>;=.@."[$_][*/[#
MO4]_\E=H\!_L'9I<QHF2$8MYC*V95, *H5,6128C(5DB9$J^%>7!%A#QDFD_
MLF>_V#X9.,\,;=66M( -VB;+_W69G^@/4].Q+3IZM8K2V 2A$!&7:2Q+)5.9
MJ5B)*$F,=#7-JRAH+9G\@1/JWK<A"2*)5\]W#DU:Y&D229;*(&4\*Q4KI"J8
MD,*8!#2HT"2@KB?;J\@!5&M+$B1T)V:&@L_VV[[J\.^6?[#D\]C',S +*NT,
MA+^,,J!UZ%<K^4?ZG1/+_LF?AT66"17PF*F0 [$4,F=YKF-6!"H4,DIT4@1
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M(+R# \0OOWO>3S1,)ZP:--R/*A3^&$)$C5OH#PC>=63U8@<*93X:KSZ0U/\
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MT2L)P]@417<@[9:W-\^1+$J+_]BSFRZ<4V.-336MZZF<VLYW\L(?(IR0N*+
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M)+.A8&+1TY&%Q2#?E,T#& JJ(S,!)HC1?STU-M3C'%(CZJH]PT_;3$ O12A
MC 7BJ%=9,,S%.6YWAVSE9PNRAD<.)U+!;W.$DEBQ/G*U#E-MD<7#0.<DBDO*
M;[#8$JVO;E#B3I7ME-G9YK=,)5"&KX?W!?=>2C@54XK)>P3?4!=;R[*7OKCX
MUB[#L$46J4<.BQ2>Z5[OM8GMT<MRI*H:5*)F9K>G)_!I7BULAAMHJU72&J^[
M.\'M5PQ_[;:OZ3( 2INS.O*1UN'A4[9)IZK(>BITZUN$R3LMRN<8-',$OZD(
MJ-1G1PPNLO87V9]I/X^(?+5F<@2*/ZX!KM9@RD0BF*ZL$1"V[[:=8B=W_#JF
MC>*85@<Z!]H[MFF9?60XHOMCL*= A58N3]J"]6U[_N(U1V<\'"/(G,:JTY$@
M1<?>IVYI%#4CU\VI 09 KX.[X5 VC@5HL#8)X..QH%UN\U];Z$?:GE;9JIIV
MUS'-QIQ.*=%F&2[[>FSOH1G^7UC4O_1(.!M!O_]<!8<B"7F>IR'3@>0,Y IG
M11EF+%!9$9*83^2BH#<)-LH481;#>11:%GDJXCS2(M>FB(HE0=_N^7<DNJ_<
MHVY7*!(U\V#9&+&R<)9H:V$HT:#415N+I)\SP0?V;)M?Y).)_,@VCXE0J:Q9
MY7FM-^0<K"E6OXI:>ZCM-L70?=U&'5MO"WW+)9&#_6Y_*JNZP1/9&MF?IO/6
M4K38:Y>@4N$.=)Z&=EJN(J '0>.\7;#=VAK?("_;0<Y!]S!,3\\G0]X]F[J]
M+$='TZENL+.!7L%1OVK&^A^$LC.[^ .$S6QGHC'"<=:EK7_7?.E@-SP,XC+G
M*LR9#F7">!HE3'!M6*%4GH2QA,\?,22VIPXB^I8T'@6['"S-^*59/V?+!.F^
M6@_NH*C^#+2DJJL[ V.FG@%?M)KSM[JQW_5=??X^/A0R"),B@ZTKX,)R$^1,
M1#QBH%:D.LF"5,;)H@Y1ECK6>1+$0AO.RS@W$JZW+)0019GHI= V.J[/5I..
MQ7BSE.&R$*D6"XF.(0$Z,8CJM2UI;$7-O#%HD8PI[\893S9A=*N')CE(O+V9
M!N-R#5'G[EW2D*])(ERI2ER]5<.MU7$:!]A@6!81UV5>%+K(BD@7A0PXM<C^
M'^?]]_F0U/>'+/JSQOSD?_A95\W96%S\5$WH&M-#BQU^8#DN%3 /MI,D087(
M-:9TP[M$P6W2E1::%;DGD^TP2-=^'&R':S^[;-@PVDX+?JUA;]M/\YI]UF"S
MAE)J8)R%X7;4&F>.5[/B6S#JP+9E.#V;DVT[(?L780/-:E%TF_9X-VU1]TUS
M-R_MT[9&\/#49"HM4AWS+ QE&,>Q#!.C8S"X8K52\/0P%6!.ZB<]KQ$LY-H2
MZ0VQM=^KTCQ0D60[LYV=OL5W1^^.WYZ\&.^=O@U>_?,;_/SGQ[>?5/SVTTZT
M=_+FXMW!_GCO]4)GMM-W)V]/?CMY=_JBVOL'OG/R9_(6?MY__N($YG>R]_SM
MQ?[!;^.]Z,W'?W_:Z5I;GKS\^.K9HDC\\].[@W?5_LF+DU<'*GYW\E>U_\_;
M9/_7%\?[T9\1[,_YVY/WYWO_O+WHH3L@N ?LT9^'@0JT,7'$2E \&"\3#M(Q
MC9E*A<@*$\K4J"=/XT7)8JTJ\B2&/[N.;Y?0612#V-59KA)E.%B9!7#],@#C
M$^@OSB*YH;/'36='AXE)M,S+!-,$#>-%%K,\B4$?$V4JLRP/12:?/$U6TQEA
M$:U@ZC<6C*N;7#\JP;B'0"H3=-4.]-!;B,3/V[2'*A+S*,ABX$%:E()+I0I0
M5E.9@]U0<F&*8,.JOCVKVNVSJHO]UXNLZN_C_5__.GW[Z7T ^Y" E7B\?["3
MO#O]$^:\/WZ'<SMY4;WZ9S=:)1)%5,@03'&6*:T8S[. B2R.F8C#+#=Q:N(\
MO[U(#'(IA4C!^LE3GA693'A0QB HR[1,E=0;.GO<=/;^, A$;K1(6"9 +O)8
MA*S(1< "&?)$!H&.\^++B\3OP%9\,:\G%FT*16()EP?18;ZHD6C%VWWLU[V2
M&0F9Y&4>I&&6%EQGB919*I7(@U#D<9&6&V;T[9G1RSXS^K2W<VAR'85I)ED,
MYCKC*A,L-\JP( 5M)1%1EI>@4F>+_&,T9!W7;GW]0#WZOR/>U_%TK#&=M9Y^
M,%WFLG/0HU?6.U_1JV\#G#:E=.B"==\!BO7N6(2IPY1C1.&S6-Z8*S%SB':+
M3MLVMFGA.UP+XK4Q!,J4.ITB"D:+;[(^C;C-W+#)/!@</2+PG-JF!%=-OR/O
MI2FF"QFFHSV$03,3FU%"4\?$X*4X9K\I4=."P6ZJZ&]719]MJN@W5?1KJ^BO
MJHI?S((M"Q[*5&4\%#Q*4C!6\C"(C0B%5)&.'E65UI=.UFK+(U[5SZL&.(T8
MORJQ4.9W1"ZRA>.;A(G]Y^K\D =9&(D,V!!78.M(V%8!1B^+PJSD229EFHHE
MQ(>RR!)T$8=IQ,LT+A*1Q"$W991H.*IT*9&K/0^47U2P1 <QLB?Q':5W7;ES
M@Q+?VGRHS+G#<QO3CCE8(DIW[G854YL12]=ELW;9PI1Q.\P+QBQIA85P+4*I
M&@+\#76CT0\># G[&,_/?B084=<7$32P\467-HP)VO_<8"K-_.C(-+-+9[*\
M]M[[>V\>(NAVJ<T]:-\6MKKIT&UM69%-6'<X0Y>MG;2]RB)NX=)HD9APKHG-
M=+G8-K7YU.]E^[[EJ6"=E4.:G:P_#JPFZRNK'8FT4'/P>(\D2+,<E$*Y5#HW
MHZ6W>$5[B%;7;<;VZ'4O?[J'*^'Q)*P>2VG^K19+VT:8N:M.DHQ^!Q7;]+!\
ME]/?6Q@ICW1&Y9S80VZ.#;-[B.2NL L&:\'Q5N7L'3A Z^LV4$!0MJ_7+.'E
M_HME*WXR/SV?UKHQDTODW:*4^U\SUB^F-5CT+71^\-V)NCYT_LOXU?/WAT4>
M:BXRSK3( [#05<9$&$NF@A2.7@@5%E&KIGR%U@B; __"!VY"HZ,RYRR*#(<#
MUSF3*N2L5' 4:1J*'/L[3:9+G1*6_C#K57_H18YK"YE10"QQN^VOF2;\ET5#
M?P'BZMG4M@_]IYH=/W,%+1O==_]@-SHL,E%HN)4L-!$V@=+80(,;IN( ':U9
MK,.E:L60ZU3&652D4< CH"-C=*9U8<HRE640/M[D8D=36':)*@=>AD>AJ:^"
MZ'+=!&R.:%T-''VK.@/V&S.3SN-*QJ8-]6#H&FC@0QHT)#5S70Z Z3O?':@S
ML[J2<RJ4<]^?SJUB3  =E-0]1Z?]]3I?A]$UMO[;M4D9% WJZ1FIX]16Y+S=
M_[;"Q (^@#3L6A7OO'XV.IB> ?=,@W1KY,F3SLDS/0<*\JPMY/,X$/@P/-9B
M01C;R>"#K3DD/;A"\4D^^=7-MK AY5\=G?1<N%1I2FV;IV/\R*,AN^:F_9+/
M+8>*W(=:KDV)=8!-ZP?&FCX/P]VS<<BF\  06!(X&]L78)7E1U<NZI=C2UBF
M6&U;8^/P!N$XM-/Y^UM>=]>[W?ZA+DQ@Z-ZT:KM_E+AYS<R<V3H@H8Y_&OT0
M_NB!%R[\:NA<[+&(WC;\$"U\%60L*40$B==5V?;\XS02/!G_V,$_T&=]:&F'
M;?T#_Y&*+YWEN^([_F2N_5[JBI'\V!U\NX5T_F+-2%2V!3\U""VS/4+@:,3>
MH)A#XQII4WMTRQ]L^YDALH[]I(7K)H<[; %J&[4]%C^&LZO/II4U)$%=P6"?
M"V/8#SV3HJ8XCH>50K7(^OVC][*0)MHMW 8W[.*I[Q&U%3>^L[>;$>A+/M0K
MYF"EU:X$PQO='3%@[1I5'TO:%'S"GI$W^:@ZK.KM@5WVJ3B9#AH*=:V7^N$4
M-]45=<O>$8!@WLTI5N=B-;I;1MWG,'U)T$D!Q^4'K)RB/].V9<+EV]T[[Z[Q
M#9K$M:WK16ZA/_1P(OVVVL6L)SDRF"V)7/3.9-!:IR8,EZV^].MQ-3K8YMA5
M3RSPL>:ZA];;<%^C;\N8US[E^PKA5(D'3OT$M\#N'RL7H1OX.I ;P%-'M;$<
MD=A-?[[;H_]MR[G'%UMV]=0@BJJN)]-!M?C2.E[3#708UU2#9'%F[ F9RF$
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M;//U(,"O94!&V_?)2?$:^/B9;=.B1_\+_QCC+\\(G^"A+/E2JWFPP&._0 ?
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MF2DSENDD9[R(L5FMSI@V<<++/$MU$2\UFHN"+-<R#O*PY#S,9!(56H9!8LI
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MN3XC.V-L7($LG.NP#TA!I2#8_P3XU!&I ?7T?';LPF^N$M",V^22&6%PZ _
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MJP,X;UA0XJ)E-/FUUUJO$W:9V.MZA+X?17F8M:<:X6J$^[DG'Q;"6)V]^DD
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MM\,>:-NP%TO\GUK?\NO;6_(7&E PB[F+A&K,/4],&H9E GOAF'0Q"E&;^$>
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M1!P+C)S"$0'4L:@\((76:Z\)V;CL1/VC*B&02?MB&%4\K$0NCF1M5'9U\C<
M5L>V!^=Y5VBI*U5)ZXB6OQ=/;*N3+?]$J,(P-EJI:J$5QN5#JOH>/?B<X9%>
MY/K(RTF>P%XGPK5WW'-AD\7$<A*=9ER9Y/R-DK<( "=/^D?UH+74+9*ZCX?*
MR* 5!VN:P(/G)A-T*^]08L%8PBAGWJZ]OEP<[1]3"0)Q&T$B(XCK43V+985
M)1.-H0X+RZU2SIC 0"2H4AY[3VLA^&E"\.4PB&2\YP&I% WBCCBDP<U!P=#
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M5P'FPE"FL_X9O/BMW"8T28X;M0D#3<D#V.4I-'PZ U_"<#L*"*N,=)@IKD4
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M]%YX:4KNZDA+]$QIHW>OP_T&%:[0/+ZIA?K!"N8PD4P'RP-3UCH*;K#BC)B
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M,D\&QS%$01DX2F#.A:YK\I)F@5=3*NZ1TEG*_E8IG=>(!&,[A)FTU#B/ E%
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MY(3)H()R(H5'Q(PW5U_P&GR#RGX_H"Z.!10$HU(GH5$4''01E!%IZB02$G1
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M#B6:JH!PYKHDHM0FMBML5VNFJ72QXUG0<.@LH-56_P.>J'E"8]96X#O<\]S
M<Z(XI+[T5,QU$-1*Q:8S827M2[J@KBM!:! JPD,):GLH(A(P)W2UC!T9BR69
M\-Y#1>^GQ^1SXLQ'K&]4<^;C<^9D GKL 8GHD#B^2PD7L08S6FOBA7:HF.M[
M8>"]>,,:OA\TZ)PL]/L]ZZY9\NDK&M4L^20L.1:6@<N8K6A 9,A]PH$%282-
MN@1G5''M*&D+9$E0FN;6-YH5EZ/\Y.G,Y%&^\JW;&#O^B\5);4_=98D]>)>E
MO*[JB?BUAJV*3V1!^9>M[Q\.6/-<M;YW]C%IS8;G)Z??OEQ\__ >*!E&@'W
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M[XE[*R<''HM"S[<)MWUL?.H+$D22D3!B5 D62A4Q<[H9KMA@[7&R3N[N;M@
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MON</AT^A<4W7VL4K]HI]Z2=8TJ9&P%404%:4+'CVYQ\Q%J!Q78<H/.?C2MJ
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M5XPK-^'9,-Q5PVRGDM5Z\ #,-A @8F1R:7*6,2^DU\<\YDX>! ^363QPDWB
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MJ&O&#WMU=;63)8!"(+; 4BZ3"FX>4Y(5!S.YVIOW=A_F>;K%YLOB,=K<,3+
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M6O]Z^^6C==#-^B9P8:\G!R9=B!BF3LK/5?FYZL$(NKV^)2XOM4A+Q]4!;C!
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MIP1W:"9_;TMTF^.4^S]]>-(=>#M\M<)9P2;,Z&7V<M3YX]N.:?YAS2.MQSU
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M]H*92QSZZ4S_T#S3,#4=B]#9I[.OX_O&]=E?/O_RRZ__TVC\X_:YK]TYIK_
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M3O17%J(*A)4#*:ECYVW39RLV+2 [0,,L[Z-%@+T+CQ_*C\RM*;&H 3%#C_H
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M8D3%Z(01*C'!GN+3EGT.S'%OP9G+&;RE-7JO]/? E9MR#P!S/'G-="0N^W(
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M_A0&A> =8ESU]/TQWSZ+),A^<C7N$/'C9W>*=WCM^UT*^-&C.T [?1"YANL
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MX\NEW3J1?(43X_MX%HEZ+1#5O%QZ#.DXETH=Z6SUDK*OP ]#!9EYR!JM;QI
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M_FXFT=$EO16W5LRJG6^^]SZ!_C!?%^8%B>\M'O/3-EPPIK%<F:@D-9&&L])
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MJ9DM*BO 3/B[N'>GU8@]><-3*L0A#&]]EZR68,39G>;BSQ75.H#HN1(Y$X7
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MQ43;CI'$O#T;#YT)LOZX?H%X@W_XK_\'4$L#!!0    ( &F :E+L];,K"IT
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MRS_Q%&'_+*>(L#4 N:!46/5@*, ?11%FR_2O^'I(&.J,K^,%DT>\_L7&]X"
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MY8<*R7]BX.0U@ 07[7P&)@8+X ()!B8)QLDDNJ/X)V\PY-!>7L0X*S_#B G
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M_X>.B8HAHZ'+FEZ:)/P=2 5!FOZ 39R @>R<],Y.#_$,V1[_[@ZW0O_43-,
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MEA50G0 ^IV>= '!?;KY9\7:O^%8I3)#[2GA]6#+YW;4,R0J*?AZHZ:J,E=G
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MZ-G^B/EL1P#ZL8-"[P<!"@!; !Q@ X  F  Z  =T'86^D&>UTZ-$LO^-!!-
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M2NV=D$"86G*(ZM.D=V=$4C;(54M[JTO*D7O!&'"0>#%9@=A69AT:Q8'7*"3
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MBZDXHJ,;.$XJN<6>1%_;<8NU8Y6!BXOW++T-9O2W:XE5[G!<*P37J.PABF=
M%IU<->\6FV]'F^<W'FU3BS77FGP$@;W6;5B]@5OU#0&WO1?30--X/?@IQ4&Y
M> ILK3Y^B&TM77*)H^-H;^#Q].Q#KYE:O-%^,<\;%!BBO)/5[G.&<^P1;':D
M'7&?Z48ZG%2&\[E$GS_MBNL,CQ#/62@R(:MFLU0+_#A:KN1A]@A,K:^(T,#<
MS./FT['GRNK]]&HF>#NZ,WA^>Y#F!(#_:HE+O-"4J'@B93<M&;N]-.DK9^M+
M_(.QM#+\9M@BA<?%*T*'8HJ2=^X*,P*RU=NU1FV>O*C!VI[X_#!@Z<7 ')>4
M>$41HI:C(G>*1')&4IO[2R='Q !H1A+H$20 -B"\;-B\4+-N?\]R &1@ )PQ
MS>LA.$#PSZ6XM<=]\-G\_)Q^8DZU+FYC[<@+J*S*+R<G%\E V?FU.^BARX?(
MRZ3&/<L5GWV0-5>A,5BV>JQ3H^3!D<:39 RCY(\FYW4;O"RP'3NE'F/FTN7Y
M^!SXHKZ4UR74F-W.ZM\X/MK@X^'QE]Q^"^71>2]#\F H<-QB<!+K@4.ARKBY
M1N_4%65"2PMOC=P;ZX2QTSG$F(_5+^:8'^EO-AJ,^@=F-M)53DP\M*GDH<RY
M1TL]\CZA[HU@DY.JDZ^'')?<-3[#G.\6]\KJ]17,)1_V/\Z8:#YTA= ^]Z\B
M+;O>$O/R;M-+FM?6E%LD++4/.J\;J@?RX)>+;"(B+0V!B*\9892,-W67CN:K
MU)/'JY.Y41RHIIG]HLGNK[#U*B?6)*((T103QA@=^9MU+.X1W(\#Y=T.8I3I
M5AF??PS9I;V;9E.3O"N>.T$ADSN5&,ATP$:X-[;>O=IW<>R>K:]NO#;@K3/5
M4J%_)9\?>.[;EHS.QX6[$?P*74:9;*GKGD2([UPE,F]G_!"O^!D;IF11!'B]
M=L8U,V1Q0'CZ&#]72,@@G'C_:"LXM/GZG9W\&K"R37Y!8U8/9_ZK'/03+R0_
MKWVS?0_TP2[_3F9FBWW*<&FY<?-.(+DE7?3G#3;#_,R*@G:D7X#ZWCY0^8-6
M:HASD$<"[F%RVO*TP?Y3-1+372,-1\2@H"[(Z'.A5SA<;BLK8%*)]_3@JUE[
MR7-V<O; &SVUVE.Q2T8,+[JG[T@.=CM=*67T6E_H5JGR:VVC:[IO$D,=:4BT
M$C6GVC86XB2F2N!72T)"W>)+RZ1!0$M'Z[S*]?:M"Z'CW&NH_*V=^.%X,0)U
MKFFK=FU=K6ND&BL'N1W2H[=(P1(T&(=I)E%A\C;S4[ Z09:'#*VY5627Y;P_
M:]Q9DY)\06BSR/-&^\T658>P]-M<ETCZQ'70I&:\I&8HP-:$<VAWZ%[72N!;
M:ODP0:Z-[N7D.R3)D7Q %B,7XHGVJ&AJ@ZCAV0NV"5X+/%J\EX=$1PJ%("\Z
M$*,FH 7 "WT^S(XW@<$T48^*O9"5%"]W1$P.E:9#'TQ]7)*5ZBI3*]A:52H-
MZWUB4KI8]9S:75:BMZ18G6WLL>#=^B':1\#+) ]4F)B;AG!LQC4WG"_.9\>;
M59A47QD(E)A%$'"MA!&P---KFCFYST@^ RD7AA1RVSS1(B8<E^>$P2Z]@A"2
M:5H3;GQPYM]^U-4YL89DZ>PLCK]VIY"ZW61<JWV23DNGLV4UZP:0[74RK@+
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M3\Z>3VRW2J8J,#_F^6"-RI)USAPYD$PACLA8X6NUGVQ?E$.>0GU(PX=JMM3
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M*VAV*:JB'_>VM_@.E"=&$'^"S%J2.S_H2Z/B](O;J?(FC*O^(H@](@=\BZ"
M[2HHNY<RVK8Z[AX7$[H^*;X:4\(I=G_WR4TSF2\(XR1>L^"B-K#X^J#ELR+>
M6>*;!(9)T, 5U*^#\N$RGG*:-T'N#V[Z&MU@U06QEPJ1Q&N1Q<%(ZM]>(W4-
M';]"&*/*?\^I.)!UT<+)AMSR1:*HX!,%QXDAX_1I?:UA;^7HZ/J(4M[<!E H
MX,;<\9-J PLLD6Z?>Y/FAX.!/6PL9<66VX<R..[RW+2O>/0E/ ];J-OO.][7
M&MS*'5@,Q[X"^EWF04:=^?G[(-"^!9;ER@D@+\7S&5'46W'U3U3K_'(TA)B4
M)@QOR[I6^JB/VW6FU<JT/F097RVOO4HUYX7*,"9MDS6>#9^AK34=T6Q\WK16
M%>!>TMWAN>C.S25.R3MU_>I+<[T)NC0WU6J;Q "GP4\2.C%#@Q_T[E+-&F&:
M7:ETOI]%0OI ]R#%7V6/[*ELR"YJPI0FM6N2X&BZ /8M&(<@OIN/7L;.6N13
MB]^573V#LJ6DSNKL%$Z>-6 1;%:>,VND&<4,VCX!F%M&[GVJ0ZQ//TRN&,U(
MI([1,=Q@=QQZ<G_*BUVY"FONVV3%A??!LNI]4 AVQ//MI)N2G?'7\,M%(QTZ
M*,4_:!W ./3-^#4'"@^?1C[OH;TYZ7P_L7.D#*-L#)OR8CQ[(IBY2V- DMZ4
MJ^'5Z-HCZX]OZ7/U$LS]B.7SM1YX5 5H=.X)YVLD^PACEODEN"/V5U]HSI84
M%V*Z.>6F?;=W86M:T[ZL.JMP/Q3T*3R$LE#'V#!;C-A'>3!=8?RK2Y5'HXLG
M&U/$!*$]R<N)5R'-N\UU7!/1I96?YLGM;;5T25"["FI,>TW&(K=L2X#/_;-=
M E^VJ#Z09'% T*[&H(Z2/I4^2JE\/5:G<E4(S]?$P>22C:U^ZRW!: EN:G A
M UE0(,+.X?%]*L'::QE@,T9F-0LC?\8J)>Z.)7@EIL@;<<2"QB4W(=\)P:)(
MLK>O(Z]X[6,!9@>+N#X1/.)[T\@>UQM3H??ZEG"PHN(BX2+6Q5'BQ^(ZLW.U
M-6W%&ZZ/@(>PA\,2^6.8O/DWV>_KO8/1CLG*?Z1G%E!?>/FP:V3AUC/E)HC-
M@Y5T#?IZS)SPV+;R*G#5]?NIY!<LB*(4<"N>@GKG]#0T1<T'Q9KJ6"43BPQZ
M]7"W(#NQN3G7:_$T'N"V@/P>YT8\NYTN9QJ^._'^&:D?F+-H^ONT,!G-';)K
M7[KJX&5U3_B-!5_V^Y#2ARQXU42)+3F,+5ONT]\29J[.P_N$L\.]M)=O4;\J
MGN-?O4+K_"Q&ROS3LW?.BN#DO3!A@?PD]:Y&O(9'N<,*;F%6A,[6]%U@]1 J
M'AQ5[%M;TFS==S-6G[BP1RQ*'$7PQX'"W52A^,VWE*MB+<GIKWR^,0C+HI .
MAS7'7Y]E<AQYFQ$=(U@LGSOQ#K-NS.(=AY.++<M0TEBE[V1-)VXXJ9EI(N-R
M@IK-KF!0PT82$ :4HBC%#50@NO%4L>\J-NO;6\9V"$ERNM2EHAD_MQEO+<K[
MJLB>=5DY4^*CJOBE126:NAG3UJU&7J0N6<\>>E?,'SGFP#Z)!>6YD3MG>&-
M>5[_/DB+7,ZQ'3_MMJ2E-,O5H/O=89<8&"@/UFVSL!5TCIV=KK%<(?DJ6:RL
M+0AJL1OZ[F6$* )98!-TB3O<RD*:*Q8,RAHJ PTL]6?H&N0:I1'!C5Q)N#6)
M<.E+L/>13WR3-D!+Z=OY_'@'^U8K&U\ZOX& \JNQ9EQV,[,X]J/82F8/P&_Q
M+C[X!"WD78?IR5JL- ,T(Y@?QBTME/8_H>LQ4,U8I4W:PU)-#7QZGUB0D(L*
M-QZW$Z:O0$T8 H3:10BQAGB('M6_AY66*0-G]/<RY@.S],CBD*:/ONRS9)X
M=A:/EWODY(IP.-?\P^#WC>H6(_R^'LMZ:W^=D:L-<'T]2;NVLD%QX+X:?M6
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MZ-6E1A.J@;P;@U'VA'_)YOWKU-&Y/.-)VC/5X?I2T&.^%IP<:(F*6E'7O)-
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MX'+/]\R( %?WEPWX^_Z,P1N.E>Q^X<<LR<X])5V8OD>34FJ]FI<S;(3RK;;
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M>JQNRU-26A6_T_[-^R<+C>$(,9FU$YC>G*NZ[_0OY.(RX <J"WH'9+;$:V;
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M:/:-:4QR3U7=.("XKK^)?+UQ=5E$61K? +?)-N[\K:#'^J=L/V%++J__%O&
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MI-]V*4WKG.;"HW6VBB*W:3V] FQH1OAI-Q/YO1P$S"3<P8AU[^'HWWU\3?J
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MNZF:E(J2S*W ZX7\AM L\^M;^Y?P;0Z&.27V/Y]56JT[!G"+;":_/D$YV#Z
MR\[1DO!>F=-8ZA,3QF^MK 6AH&#8"E!AP\[\7UXAJ8<_][H86H.G?QW8 UJ_
M]:RZ';P.4V\JE#7'GYETXKCBI[%8>OZ]3-#,5&T\%QXY&J/L_1FBU%M_BR/U
M1><-45EFYB#:+]=<+,KQI+"A=2B]7"#]8SBUS@W1 +#8;1UBILVCVCZM<HO!
M=+F?7E00ZC"WL8'K#S-1]BG;2DD&'PW_C+'EG?VVF(1CUK12]S/P&=KLY4'U
M;%%=K*WP\=KYX5]M\D,UMO8US:?!%:%^9?E;]2FN#=KE@#'+)%]!0P=4C1,8
MB=6Y="<N#FVR@2PC,"__E,<\DYX@+*2@PND<<DI5[5KC9A94[20E?^48HFE/
M,KJ7;3 ]\TZI"P-=H# 2TX>67;))=BL4W8H\40AARQTN]*"P,_(_]C65(A"(
M^-)_HJQ/1"(&"OU56G:830%O51$:V12V47U=JP,7#'JY;LH7SJZ4%;P1C$R8
M-W5,O"'ZT=[);"9QE _+6:45U1;H\J[F,-H^U"+LBI/XU;_023#?T%<AM/^4
M0BO'YX[JDZS'FEXX+.3YLS>GF%[=*Y?[F]ZUZ&AHLO#<+"[!>/[I+38GF+JJ
M- >@(F8DVO\;U'$2LVK>SML6%9:AYBXC6.R:_BL+;@$U-DQW:N(:M7A;_\%X
MLNMKM7M+RV@IR)PP4&L%J900INY58&\OHGMQ%?"$./-3[\ ;@+!<@T,HZ^Q>
M#=_ @9IL4\W.$0VN$,O/<D-4FH6\[6%*-CJFS20I_VRPH38@/JTV7</Q&76
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M?_D_OW[\PKZ)1P*S15&2!=,#%-E?"O/+CTM&2H/Y6;G T2OTOV!S&=2_@GX
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M[.Q\W^ML-6R?-/PU7Q;%S/,QQA%.8>PK-E?D[D."B( R3:(H37U*,1MSD^&
MC%-;!6I)P<.KG56?F,]Q=A$NG*4?:/]@]XQ9_T9I.YVM@Q-3,:5-@T-B_E#;
M!2=P[GNCX-10W58.)<=C5IKCY^N%DFJA5RJQ8)DHWF4%FR^+52[NQ??RC8+L
M]UD4Q]1C,H:$L! BGD00$YG ,&5QQ#A*$X%=%@6WX:?&]RWI 5EH2FG)[\;X
MCO-@1^;#H3LP3Y\$%FQD!U^U],"(___VQ[S=<.N35!TE&)4ONZ&S2X4=G]*-
MY3Z+N8GM)7GY<J\XM"#,\.F;E_9?KK]GQ2R2*1&<QA )E$!$E-F;8B^"OB B
M)3QB5"(7AK,?>FKL5LL'C(#@JQ;Q^#=V*>QVA#8,F .3F1..SESE#DF?/.4P
M^J@<Y8[*+C]U>$(W;OJP>!9%180?%N\$+14=_DKRWT5)Z%Q408)?!%OE6:FX
M47.ER$N2+910^L#HNBA$>=!&$#ZB(M1SE@8"(AE[D*;$@TF(O23&D>])JSW9
MH06=&N]M= (;==R(;[ YM:/)*<S4P*3:4E&[X%I)8RFV)J^.%=\H"GXRMF2E
M*ZB5!96V?Q[>JAQZ5OKD]<%D'745&!KQW35C\/&ZK3!W8J$3@M5XYI#P;EF4
MN2BSO-IQ$ LAL\-L0[@,*9<!#$2D;&$O])7?CPBD6,0\2ICO2^*R@G059&HK
MQ,WCTWSY(@2H909WZL]N*T3G.;%; <9 >G"SN9&W@;D8B)@O!:M/XNTLRZC$
M>BEBN\1Y\?-&/C8[F[JCC_P$;S9J_RYTS03!KY]%3AZ$V<5]IWR(]R3+JQ#/
M-$$>#Q,!"68I1(%((5:_@]R+.0H"CQ!JE14P.<VF1MV5^.9DCB_G<Y(7X$GD
MU2G=9!)*7=^>@8_V7O.=F/Z!H&5*:OWBM8X+&YQ #51UH@@T5$!C-9E0Y*'F
M?Q*GD+TK]V.<70XUI^-EQW85<&13X=/JD8K\5EYSGNE;R-Q<5URORF_+//LO
MP6=1$'-.< *5OT4@\B6%./(QI(B&,A6$Q-XXB_]Y6:>VG']8L%SHJDJ*5Q=&
M>AWB5L7< /7_(G]6!"N7.9"K4F_M9$6QTM6;7B$VQ^)-&'@A[W=^I[\T?UJ_
M$1N-J^L+L-%Y BNL_<1,8LVT$/?'6 7M<>]M77,8LMM*M5[Q/BR>5F7Q43R+
M>?BKT*/.8L8DBX4'&?$]77B/0)I$ B+E7P:,4H*H4^+HB;&FME(8V?[I'_S8
M^Y?0C?!/ 6I'V#W!-##A;GP.G0^I!;T"1E00@J^5M#UNNEE@TB?7G1IN5*ZR
MT'N7:VQNZ9#78^+//XLG]?Y\TRSU;I5GBX?*G+[-LX=,<=/\Y8,RF 1_O\R;
MN/5;^9LYYM@.8*\V(D2<B#CB C*I^87%,<0T)M!/HL1GZJ<XYK.]^H"G$R[Z
M%]/JF[.KF=COAG>CH[985K7TO>43#3#=I]GO-6=O)!/53$5+.U"IM][BV6@(
M*A6!TG&=>Z.SG!HUM]-PKL[L_8PRNPY)4:\[RR/E4+W:;+OE7@TW%R=3M088
M=KS,KN$PVTH$&W"87N-BZZ3AXKU"J1W[]O>L_-:^92;2Q.,TC2'G0GD128 A
M#=1ZS[$?2TQ1@*3L(5C65IZI^1R?1?9(5VH<LRFAYCQ_$$53<N#XOL,@4V7G
MJ8PX 8.'#[2C;EM"7X%&FZK$?5N?JO[]UJV#1^JZ8CM"^*ZU2%.(Z77%SS+0
MU_FQ73RP"]/!F@7B+L^8N"[40L+4%;=2.XQ5W%EER<6!SV,6A9#HO1_$ PJQ
M%P;0(SY*$RZ25 ;6U1E&$GIJ7+XVXYZTW-I#JUPP0$P$@=9!_U+J391'HT95
M60S\5/_5\IAAU!?#QH&;WG2/<O#PYO3!PYOFX.'-R23A]5MCU ?7!:@!T-Z
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M=[FNHU:^Z*2L\GIA(BJ>M-UC6@[.HB0A6*=]!@E5-B+E&!(11#"2@<#"$VE
MTVZ=-$\//+7/NY'VRJ0CENMN($]5QR CLVM? =LYL..%(9 =F#$N _6"3I=V
M" W3V/+,V*_4Q](.D>-M*RWO'SEDW_SG;\J1RQ8/54*3/_-H' NAW"M)8@F1
M%PF(DY!!RHCGX8CX<>KD]?8IW-18KVK$\5S)"*HH:Q/U_")(?J*TY/"S:,F)
MKS0W _-F#Y''U<S6&M;9E1.(&CZ!^R2B?P_)]V-$\9Y MK=HW%-C=(ZZ6Z[,
M,=O=<I[I@[:UMQ1()DW+SC A,40!"]6;+CAD*6,B#'B B>\8<7=DJ,FQ\EI2
MT(AJXW6Y FSICO8"V]"N:3?$NH38G0&CY_"Z8Z.-'5IW1NL#877G[NC&%^]7
M^2(K5[G.''V??=<_%75'$HD\EL8!@IAQ"E$D/9C&*(78EP(E"?7BQ"D*Y_A0
M4^.+M:3&P9*UK&X\<0)8.Y[H!ZZ!>6(;J4;, ;J[G$>C3Z(X,=JH1'%>ZUVB
ML+C#O<O;C6*>\N6:<_6P0C>!%K>Y\E^?,QU*(87 .(T]B)*4081Y#&D8A% (
MY$=![(4TM=JU/C?0U$BBDA74PEX!(ZZ"%#0"VS> .XGO:;;H$[6!N:([8$Z]
MX6S0N*!'W,G'C]8KSD;)=L\XJ^NG5A[B;R8/\<.B\HQF2/ T#1"&#"4<HI0J
M_R76;1UP@E"*/:Q^W2%$;RSY)QJ[5PEI]JA,-OYHFU2NTS_P!M80L_G#;&Y9
MIM77[XIZ52:S_]5QVB:Q-^8J^X^Q;]9Q1L;+<#\R_N7-#4V=<E.A?(8#2;D7
M<1@$7J1\9QI!ZB5,+5@T$HSR $=.V:V'AYF:2;S=A"]K->%CR\='Q4B%%AVL
M=%%W(!Z?YLL7(>I?/BDAOA'=7T,]LGO'P]8<V"T8ER,[_)EO"U0CHCG][;/_
MT$D,AFI?V!KIU5H6[FM[JDWA@:LOVJ4O%&_IT]XF5]LG&(G09]"7!$$4!#Y,
M8T%@( -.A(@]ZE8\_/ P4V.-1DKP5(G9:3]^%TJGO?@+ !IG'[X M83#9+F?
MP&" [??=D5YCZ_V(MD>VW8]=W;%=2*O%Z:^DK(-*/S?E9 L=&Z+\\NR)S#\L
M_D,09;OD0LQ27]?'"'T=6.9#A$@(4X\CF(8L5O9$'$CD='S738RID8=ZU4+'
M#B/=X+<CE.%!'9AP3$+'?=,M^0K42KQ< 2TM,.+VV+GD(KAZ[6[239)Q.Z!<
MA-9>EY3+GM:AY\!-;?%79E1M[VMSJNKZ5)^.^23!(DDYQ#*D$ GF0<K]!/K4
M3T2$):*AE1%D/^34..WFR]W=QA_*=1DVR\-'!YA/\]DPX U]P-!XE+63U"!H
M^J%4,I\_F>R*IT/7@=YQ':GS0"_XNG4<<(+J9-<!NR>-UWG 2;.M[@-N=W;L
M#?-V^2P69%%JTB^^+>?<% L2(HR(1!&4'O>4@XH\F"+IPR3R8R;#2/J!55O:
MT\-,C8]- F C*5B+ZE1_Z0RP%FS<"UP#,_ (2#EV=[D8L9&X]0AR/39N.8G$
MV88MA^\>MU'+20WV&K2<OKJ;Z_Y9E$0WY[HAN:Z-7UPS]7*LYOJL5K?M8EDY
M0U$DD0P"R'Q?*C==1\T1*B%!A#))2813I\[=YX><&EVV)-3U8+2(;AZZ!<H!
M00F2G$ 1<0X1]22D":8PH20.U.\QIEZ'6(">P![_%'\,S.UV0/I]7P=>KQIA
M02,M^*F-9"WP\8@(YPT/>W3ZW-RP&'74C0Q[%'8W+1SN[&#X[A8 .);V?_VX
MS$O=GOKMLBC?D$*9)0&E@1 !AY(%$40^391E[!&8R#@((D5(46S5\/E".9S6
M@A&Z0J\E!%I$!P/P@JFPL*7' 7CHLZ%&":"T %H-L%>J9*/*%=B>"V#4&6=&
M'&SV<69F)*-^T!ER\P NQ_6DBW#!X\?S(2['8,O)Z.%QW;R0OZHEL/BX+ I1
MW"YNONNLH%56?-,O]*W44LRH'R.1(JDWS3V(B(@@$<HN\&/!8TY#0H.T@WE\
M=N")6L=:9+!< +$ELHY+XDIH-T/Y//AV=G(_6(ZSTFA9P4]:V#]K&&_V8'QW
M"D9G(]D:FCYMY/.#CFHB6V.P:R';WSARN'\=?7F[*HN2F+9PGU;FY"2*$*5(
M;Y$$/(!(8 YQDOJ0Q7$B(T&CU(M';.UX3$Z7[_&U^S2.&\E_=&:1(![W@Q3R
M).8Z"E; -*8(<D:]B"-E0P1TM$Z+_<WKJ[1-G,B4VBUNKSI) R^&/:1;K!,J
M6GHJ3\!H.H&<BG.3,(GDB:-"_AA9$N<P[BT=XNQ E];#6_<#K.OM*7+,",WF
MQ@OZ59!BE0M^N_BL/:-<#6\\(%/DZE[9XV\4FK_/"%-+1: 6BC * ETTC\(4
M!0)&/.5^%%.,$MRM:%X/TDWM?*513AO>=0E)G7S?T@LTB@%2MHH!:]M]K:C+
M_L\PDVZYE+S65 Z]C+1F<3-%5V=G='\.Z[I_0&L)C)J#E #L$?YAZ@3V(> K
M%1/L$=OC%0?['*3#X<JO@F>,S-\)W>/PYCO+"MT!P)2S>:G^NZ$&Q?D!C4,!
M/1XE$*6"0R(]IDON8^83BF)NM1ZX#CPUJJ]%!Y7LH!)>]]]PV+=WP=WBZ&0@
M- =FVZ- 5N6M7L#7^G]M2/0RC!T.0P;">J33CUXQ=SOMZ #<R>,-E^>-=Y[1
M0<NM XPN]W?S%M1CWZK%)2O?DCQ_D<O<%#]\U+E5LT#20$8BA#C2>4U13&"*
M4PSCD'//\PG";CT\3XPU-7JOY 2L):BC17X*6#O[NB>X!N9OS1HU6FTYS9'I
MJL]L2 LX^K1>3PTWJBUJH?>N96ESRP5G#.TMBUD<<!+R!$-,I%0D$7%(>2)U
M@]!4A+''$A)V/"-HCS/-/7X3Z*\C6!4E_3,0IK[%%: ][_QOXQVEJ41<O:\H
MU&<RH=[)E P&(9(REC[S:;>=^\O0'G[G_3#6HL_]^"V@'?;3NT(WQG[X]EYV
MSWO8AQ3O?0]Z:Y#Q]Y /Z7AP#_C@A5UKU]1-]LQ+;[8&9CA4MAA#! 8IBB$B
M!$&,4P1C&?@H%A)[U*D$Q8$QIF:%K46L*M%<@7_T?O:4Y0F>2&YZF(I_ =&5
M^HW^__J[!V15?EOF.JKG7\!BV?Q6E[S1NZX+#I86GX/UK-BQQ(58#\P3&YB_
M5##7&YX?#&9]%K,YBD*_E6SVAQFYC,U1/?=KV!R_M,\HD(J@KM>?QF^ZT),9
MLSJ%,J5S;KZ+7+N:=[GR.C_KXZN/RS]$7OV4/>H4FD0(%*>1+IZE3X,B!"DF
M%'+U7^:'U$NHDT<XI+!3([-&8/"D);X"<RTNF&M1C=G"E_,YR0O=FJ0BK5XB
M"GJ:^$N""\:?SA'C#-;Q YOSWB:*X JLI]QH!8PR5\ H5OT#&-6&#BSH=P*&
MCS'H2=X)A!OTB[Q=Y$'/8W9;A=9]I'?WV''$$A&&NE&5U*6" _4AL22&V(O#
MA*. )Y%3ZX)C TV-_3?-W%W;%1R%THZ3^P!H8#[=8',UZ &$+21],MS1L49E
MIW,:[S++V>L[G#)W;\6T6*QTI2.6"_6G#S7!?1:%R)\%OR[N%)7I,[,'T[LO
M6^:Z)-+^?HZDB$4\EC"-/*(3DQ.(0\(5\Z0R3;G $EEU0YB",E-CMTHKD-5J
M@?4N',AKS0 QEFVMFPZM>=+:F>Y[4"BOO+Z^Y9R#G^H;+ WA*4R,S3G]#_3N
MC&)(OSD=L/NF"=A]<[#Y7_7F-:"H'YIZ1PTNX+H &V3 K00&FZIJ7GVMS0[I
M]-XUAWB%'^B=&RD&HH_&DZ.]>VXQ%A.9[)-Q&Z\MXWBQ(*^MZ:'XDJG(U+$$
MVJ:%0%-*Z-=LD3VN'M^2XMN;ZBAPYLN$A$'*(6%2VWMI BE- TA2XH=8$A03
MJT+_3J-.S3 S2>VL*5[U6,D+F!*X.3)U+/UE!;V%$30$H -;*P;+C<Q7ZZ)@
M5Z"6&VC!P9OA@'4LL=8WP&-67.L!:/=*;"Z G2W,9O6P<>NTN>BW5[;-Z>;I
M;!#\2KYK(:M?SABB.(YC!I'G"8B2((!8$ P3WXM8Y#,JY*OO FQ)/+45Y;RK
M?P4>*P7<HW'&>P]>ST_O/+O_'9QQ7;:^>C>J/TSMM7A]E[KSZS&JWSR5UV02
MCO'!*7L-[W=;D!_>Q3V(ZQA^[.&!NYV$WCZ)G.A:+S??M8":8T))/>[[4&*1
M*!,DD9"*F$,I<(ID$$9(<)N"A$='<#(91B@U>*_' ,M&3"!J.=W.0?>!M#L
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MC%JZO?=&+[UKJR,M?YKK@K%_<?2_>IH^2Z]M_$D9VM<S\[&E$J@C7ZL"OE=
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MHI#W>C/Q-O^</7PK;[XK8LT*<9=G3*S_6-1_+?P934DJ>:R+,46Q6N5H -.
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MD/JAU3'*WI.G9L:NA0-:.OOXV&VX3E/I12 ,3(&6^CL%PQ[4]8(PV.WGC18
M>U"-=NCKX0LZQFJL6S^?B8HW5>HW!W4L\G 08>6"4E,&.A20)$A 7P8H]81(
ML8B=PC:ZR3&US[K=R7TO\0/HQ)N/3>*-4<XQG*/C9-E97"-,P<"DTD;?*A6G
M[FPQ4#W[R_#L-?RCHRBOU.^^$U['F]IW>UR'<Y3K9Y+-]=/>+W,=DZ(/H#>I
MC;J]Y"K/=6$OQE:/J[EV!O^:*S[X;9$+,L_^2W#-#E47/V5CS9@7<$)]# 7W
M8XB8#"%)*84H"#TNL1>$*'%P@H>0<:+^[T9:0[BV*=*#S*+%@<YK3,I(=EZC
MF0X>!B8*S\3&M'.R-_I=@9:&P*@(=J825%IJS_@5Y]3A?.D5YW:DTZA7F6.W
M ZR!)N'D<5??8XYW.#806EM':4.-T<T-JGOH+AX^ZO#XXOVJ7.5-0<UZ@ZUX
MMQ*S$!$<HAA!*D($=?(N)"Q(((T]Z<>4I%&*9N6R)',[M\=R7"<W9SWZ<%_\
MO1[#S7>Q1=C.5QD MX$7PK7$H!+Y"E1"-R6(FWW< BBY^W-"'('JT^FP'7I4
M)\,1CUVGPO7V"52F5XY.U=][.5\^O#2=O6?8(\+W4A]Z/%0>!<:*R8*00QQX
M)!58_8D[U4 90>:I;?:\F1/V.U1^YM*D1AO1X5.>,?V5/RZYFEFRT>D5:](?
M>04LMX6F-;%#;R$-587>;#NU= =?&^W[W'(:;ZXF6W;^B-@_;KWYT_,P:*'Y
M,T-WK?I9"!VXK'?@Q+.8+Y^T#/4I=UV(+O:C./83#E.4>GIUHI#Z/()AE$H6
MAGZHK&VW J!GQYS:ZM*(7.U7;X1V+0-Z'FR[=:!G" ?F\6/H-=$4X]3D<,"L
MWS*BYX<=N:*H-0[[Q47M;QW9VM[.-6UO:/Q5%Y>?^5X8$4]7&,1!"E$D(X@C
M%L&$(^93$7'/K?/<4().C?GJE&RRWE:4RQS(REM^J/HU=,^('VJR!S:F>YS"
MZ5O0>]GYUUNO@M%X D:SY9Q,PE(^)^N/81Y;(MZ;36P[7L=-Y_*;R*\9RU>"
M?\P(U9V<,E&\K3:^9R'Q6:"6#O6-Z)("$OLP3<(0XD F<<)X(CRGNE"GAYO:
M(F"D==PT.0.HY=9R;S -O:.L!06UI* EZA6HA>UQ&]D*E%YWCT^/..ZFL97V
M>WO%=G=U:CA4=41=A^_6YG =E/M)E+=2N_(5S>D,*9WP,0LX"X2,0DBE+R *
M6*S<:^G!B#!.<4"C* AM#J\ND&%J!UDZ(H\W_7ZS*AB_=(HLZ#@7I[EH)(0'
M)JA&@7:6PX%D!CT'MQ*L50%K78:?!J=^2$-/QVB=DH::%M>.2I< >J;74J='
MC]F%Z1+==_HS7?2H_HK@5)LQNV5]8X1CCX0<!EQ'+D:Q#W'*.62)E#*@01I1
MITT0ZY&G9M"VCH648_L^6ZAIR,A<?85%F9OOWM':M9\#.\-W$&0'7F):H+:D
M'F=SUQFOH6O?'![\U>O>G,3$IN;-Z0=TW/1=/3W-S=/)_ V9:TK\\DV(5KVP
M8O/]I%ZH\XTY3'W)(2(401)*"CD3.$X3GX6(.6WD.@P^-1JKY05&8+/!MURX
M<Y<3_)9;JP.!.O1V:4MLL UN2_*!"@AVP:S7[4R7\<?=HNR S-ZV8Y=G=*,S
M9>6])<6WNWSYG''!W[S\5FB+<!VN=JW3?<WVPXQQE 0ID\KW#Q29I4D$L7I+
MH4@HEFD<R<2/7$)8[8>>HO//E.A@552E?Y?K&$VR%MJ-UQSFP8[5AD%W8$[3
MP&JI02.V/N_YZ;<*Y3^#32CL]7F8G3G-';$^&<UA]%'YS!V573;K\(2N#;3>
M*LK,R?S#@HOO_UN\S#S"8DIT266&F;*_=)@JB_0_HYC0R)?*MW1KH;4SPM2,
MK$I(4$L)C)A R>G:1VL7R-.<TPL\ U.+,S(=VFD=T?[BAEJ[SQVYI=81M?:;
M:AV[L&NXGTG>N2-YV93AQ;&4":<^#%(B((H#!%-/Q##A/$J")*6A6['T_2&F
M]D'7$@(C8N>.WGM VMD0E\$S\ ?MB$R'$+QCRO<;<;<WRL@!=L>TW(^G.WIE
MM^_[HUKS'ZJ20:(L*W^GWH*>\31!).$(JJ^:0(3#%&(>1#! $?$I24.>>BX?
M^HFQIO;%O]5E)$&Y-,>+"P[FY(]BE:E?+7-0&.$!FY/LT='!.(6V'1OTA.'
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M WBJE#"6S-RH :320SMA7,=3BBUU'(I5=IJIT_PZ"OX#LVH+^EI^H!0 E09
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M'RK^B""* @()4C\1/P@I8HI?(J=ZV:UG3XTT3)[8PE YF;MQ1ALQ.W;HB,/
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M2>84I-TYVMB^^JVPP$@+M7G9R.OVY7=#;$<"P8#KF0].8]9#2HD5*"%YHGO
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M49'A%*9599A419#D10QSEN4XIH3DR*DR3%CQQK9:[W9&WT@/=L0'32H.6"U
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M(48XT48 +A(BE:"Y4TA2QUACXXI*5+.I:835F()*7$^^Z(+9CC$"@=<S9UR
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M)$MCF)MNI2C".:0HB6%!LCQAA6F3S2=S>6\R/N[LM^4GAK/Z*DC]5;P:M,>
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M I1!A2CC2N1*(2>W80\RCHV?#@R?2DYM_FA)75/D>IC/2TSDP6:I9S[TF:!
MMFD0"/LW/B\3<P3691"<[<S',$,%K(3P95/T,"*JD$6A8(P(A0CS!)*49_H=
M2(J(%0EA\>7%$+Z,M<9D1U[_%]\JDV< MV/7<##V3)07(ABF.L(K8'HOD/#E
M;>I,VFEO52;A]5U^_/)-EE+?]' ]%Q_DLYPMGHR=^K$NAMBD9&5)*CEG"B+.
M4DTR>@^*6<Q,.&Y,8RIYAE(7DK$8<VQ,TXI<!:R(K=!NW&(#MAW!!(:P9Y;9
M0V]'7M ('# !S@.@D&QC,^R@E.. PR'ON-SJ6]'Q\YPOEGJ3W/0IH2OYWH04
M+U_>+X2<\$*9<G $ID)JXLDB!FF4)#!-49&JE'"&K#Q@EN.-C71JD<&>S%>@
MDMJLTXWDP(CN6@2R&_=N#NH!S;ZW@P& ]*@;:07/Q64DNT<9N*JDE<JOBTS:
MW>89-L>Y>5;Y37(Y?:ZB\>3J_7JYU&0VH;C 2(@(YK0P]DTJ(1,<0\EI9JKW
MYRIW.F'N&FQL]-+*"I8;8:_ 7-95LTTB=16_H?0'(A9KME+K&:#M+?J2?TKR
MM%K0_RE)\95^2&F"'Z=ZH7#L<-0Y07;F4"C8>^:A#>+?=A"G2D\VN-X#_/U2
MBND*?%F4Y15H] @8A6>!5M 0O*[QAHV_L]#\5?"=S3V7%Q60R^E"3'ES)OEY
MKE\*6:YNYK.7^D^3F+&(%41"FB8<HIC$D*4\@2J+BE@4/(M3^_[ECH./C;KJ
M @.5:*!) KX"TT9LL-!R-W_USX$_.Q_=S-0WRCTSU>O\]T;X-E3D"K3R Z-
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M)GI3F<8JM6_E-')E1V=1-NINZP(MGNK$Z;*['M!?#W*N&:V% "S^FI?@44,
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M**P,_8Y!QL8:.Y&G1E#P9RVF)5ETPGG&E@X$4L_DX(R/O;5C 4 '%^C;=WA
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M6(PZ*N?8HW!(/0YW]F.@]S0W]1"*QN]TOUK,^<NNZB6-$ I0FL XC1*(8I;
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M3H,P2#D6Q.I\_THYIK9T-6J8<_\3'8C=7#Y]Y\;.(S0"X@,O5!? +LN-M/0
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M>4.A>0/3"&(D491%B1)AX):M=CR(RW<P3G;:M35O]R"T(XKK8!F8'FH\2NG
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M]P'UP?"BQ\?IH>/Z=_KH>^3-Z?60?@;G^Z?GQ>I%RN,X5"9C%&4XA!+A"**
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M. HD5#%.(0HXA2P5&:2<I3B*2!H%RF4).S/.U-:;G9BE@0S+HH:EI(X]H<_
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M/\W.T:9&![6PH)06M,0%?U0".[:TZX;:SL3W!N# !'$%=CUZZEI@XK?1;M>
M(W??M=#]N"6OS4U]S8GW3S)_G"\?_Y:O?JR_F:,LNGR9*6(V#4$&%<V4WD^$
M&<P83:"*$,ND8"I25ET.+HPS-0ZI%\I&5E )"VII70V*T]#:FA17 S:.4>&*
M50^3HA.)JXV*TT\?V:SH5/'8L.B^O&]CW!7_Y\>BV$CQ;I/KAU<Q4F545.L
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MDL:]Z&^!L('$WP&0_K)<K%8?EHLR74^*"QFUD9!L"J""-N#KE%<MC4N>/,S
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M";R(&8AL(9T1W)=&EXB[$3AR#G=3\#55UF @'&YBZ^>O6&<XA?E)F.=WM8D
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MSZ,S7+ FP='/"!LW1AK<,6FBCP[P]9.ZMU<_3J>,U'I,^E_^''Y,7&3&E>B
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M$1T_N<X)Z5F>19R(9V^RCCYGD)X&Q+/%I)6J!,YQ:3Q!M&=1P[NT?59Z59Y
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M3JO[?I^[C=<GEF$JE[T#;DJ9EF4.RF4!V! $]X%EPJK8U%FXZV94KZVRH5T
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M,S%?<'=C>&-O;G-E;G0N:'1MU55M;]HP$/Z^7W%-M7:5"'F#A@)%6D/:L=&
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M* 6ITT,;@GDN7ZP'&B1WN"T8PAQ[Y:)64*/ O(ZV&"5%Y,X<3#XP(A)<"W)
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MI5,2!K5_([P_]VH?+\Y/JZ27Q77 R=X;79OHQ:W-1VI@12 %I1-RDZFQY&S
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MALTO@8T)_?4-;&M3_WH+GL U7.C-+0\,]1?/\O\+['\Z[/\+4$L! A0#%
M  @ :8!J4O,Q9U3>"   ^3$  !X              ( !     &5X:#$P,39R
M;7-C;VUP86YY+6%D9&5N9'5M+FAT;5!+ 0(4 Q0    ( &F :E)@4J461@T
M )Q5   >              "  1H)  !E>&@Q,#(R,C R,"TQ,G!R;W!O<V5D
M<F5V:2YH=&U02P$"% ,4    " !I@&I2$@;%^!U*   F+ ( '@
M    @ &<%@  97AH:6)I=#$P,C1S979E<F%N8V5B96YE9FDN:'1M4$L! A0#
M%     @ :8!J4H49>W 4UP, \[P@ !$              ( !]6   '-I8FXM
M,C R,#$R,S$N:'1M4$L! A0#%     @ :8!J4LEX%#>;%0  $^L  !$
M         ( !.#@$ '-I8FXM,C R,#$R,S$N>'-D4$L! A0#%     @ :8!J
M4I+YOU^K)0  I(@! !4              ( ! DX$ '-I8FXM,C R,#$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( &F :E+M9QT- 5X  (\"!  5
M  "  >!S! !S:6)N+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !I@&I2
M[/6S*PJ=   FY   %               @ $4T@0 <VEB;BTR,#(P,3(S,5]G
M,2YJ<&=02P$"% ,4    " !I@&I2<?:C95(= 0"A PP %0
M@ %0;P4 <VEB;BTR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ :8!J4M5!
M+4JBG@  SVT' !4              ( !U8P& '-I8FXM,C R,#$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( &F :E+IY[?3^@(  #81   >              "
M :HK!P!S:6)N+65X,C$Q7VQI<W1X;V9X<W5B<VED:2YH=&U02P$"% ,4
M" !I@&I2I4']8=T"   P"   &@              @ '@+@< <VEB;BUE>#(S
M,5]P=V-X8V]N<V5N="YH=&U02P$"% ,4    " !I@&I2;_9#87 (  "O,0
M&0              @ 'U,0< <VEB;BUE>#,Q,5\Q,C,Q,C Q,'AK+FAT;5!+
M 0(4 Q0    ( &F :E*X!&HGAP@  /XR   9              "  9PZ!P!S
M:6)N+65X,S$R7S$R,S$R,#$P>&LN:'1M4$L! A0#%     @ :8!J4NZ(,EPD
M!@  1"$  !D              ( !6D,' '-I8FXM97@S,C%?,3(S,3(P,3!X
;:RYH=&U02P4&      \ #P 9!   M4D'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
